FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Williams, BC Gerrity, MS AF Williams, BC Gerrity, MS TI Medical education and JGIM SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. Portland VA Med Ctr, Portland, OR USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. RP Williams, BC (reprint author), Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2005 VL 20 IS 5 BP 450 EP 451 DI 10.1111/j.1525-1497.2005.41009.x PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 935LE UT WOS:000229783000015 PM 15963171 ER PT J AU Fan, VS Reiber, GE Diehr, P Burman, M McDonell, MB Fihn, SD AF Fan, VS Reiber, GE Diehr, P Burman, M McDonell, MB Fihn, SD TI Functional status and patient satisfaction - A comparison of ischemic heart disease, obstructive lung disease, and diabetes mellitus SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE patient satisfaction; health services research; quality of care; questionnaire design; linear models ID QUALITY-OF-LIFE; CORONARY-ARTERY-DISEASE; HEALTH-STATUS; PRIMARY-CARE; MEDICAL-CARE; PHYSICIAN PERCEPTIONS; VETERANS-HEALTH; CHRONIC ILLNESS; MANAGEMENT; OLDER AB OBJECTIVE: To determine the extent to which chronic illness and disease severity affect patient satisfaction with their primary care provider in general internal medicine clinics. DESIGN: Cross-sectional mailed questionnaire study. SETTING: Primary care clinics at 7 Veterans Affairs medical centers. PATIENTS/PARTICIPANTS: Of 62,487 patients participating in the Ambulatory Care Quality Improvement Project, 35,383 (57%) returned an initial screening questionnaire and were subsequently sent a satisfaction questionnaire. Patients (N=21,689; 61%) who returned the Seattle Outpatient Satisfaction Survey (SOSQ) were included in the final analysis, representing 34% of the original sample. MEASUREMENTS AND MAIN RESULTS: The organizational score of the SOSQ measures satisfaction with health care services in the internal medicine clinic, and the humanistic scale measures patient satisfaction with the communication skills and humanistic qualities of the primary care physician. For ischemic heart disease (IHD), chronic obstructive pulmonary disease (COPD), and diabetes, patient ability to cope with their disease was more strongly associated with patient satisfaction than disease severity. Among IHD patients, improvement in ability to cope emotionally with their angina was associated with higher SOSQ organizational scores (standardized beta=0.18; P <.001) but self-reported physical limitation due to angina was not (beta=0.01; P=.65). Similarly, in COPD, improved ability to cope with dyspnea was associated with greater organizational scores (beta=0.11; P <.001) but physical function was not (beta=-0.03; P=.27). For diabetes, increased education was associated with improved organizational scores (beta=0.31; P <.001) but improvement in symptom burden was not (beta=0.03; P=.14). Similar results were seen with prediction of SOSQ humanistic scores. CONCLUSIONS: Patient education and ability to cope with chronic conditions are more strongly associated with satisfaction with their primary care provider than disease severity. Further improvements in patient education and self-management may lead to improved satisfaction and quality of care. C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98108 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Fan, VS (reprint author), Hlth Serv Res & Dev 152, 1660 S Columbian Way, Seattle, WA 98108 USA. EM vfan@u.washington.edu NR 47 TC 20 Z9 23 U1 0 U2 2 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAY PY 2005 VL 20 IS 5 BP 452 EP 459 DI 10.1111/j.1525-1497.2005.40057.x PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 935LE UT WOS:000229783000016 PM 15963172 ER PT J AU Dionysian, E Kabo, JM Dorey, FJ Meals, RA AF Dionysian, E Kabo, JM Dorey, FJ Meals, RA TI Proximal interphalangeal joint stiffness: Measurement and analysis SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE stiffness; proximal interphalangeal joint ID METACARPOPHALANGEAL JOINT; RHEUMATOID-ARTHRITIS AB Purpose: The purpose of this study was to quantify the stiffness of the human finger proximal interphalangeal (PIP) joint and to study its relationship to different common clinical parameters. Methods: Eighty-nine normal adult subjects had their PIP joints of the index, middle, and ring fingers evaluated using a computer-controlled moment-angle plotter. This device was used to measure stiffness and energy absorbed at the PIP joint during passive flexion and extension. Results: The average overall stiffness was 0.05 N-cm/degree. There was a weak correlation between stiffness and energy absorbed and the size of the finger: they both increased with the size of the finger. The men's fingers were stiffer and absorbed more energy than the corresponding women's fingers. No significant associations were found between the time of day when the test took place, occupation, hobbies, or age with stiffness or absorbed energy. No significant differences were associated with hand dominance. The finger on the dominant hand had a larger circumference for both genders. Heavier individuals had more stiffness and absorbed more energy than lighter individuals. Conclusions: The PIP joint stiffness was defined quantitatively and measured over a wide cross-section of a normal population. This may allow future studies to record the outcome of different treatments for finger joint stiffness objectively. The stiffness was greater in men and in larger fingers. C1 Univ Calif Los Angeles, Sch Med, Dept Orthopaed Surg, Los Angeles, CA USA. W Los Angeles Vet Affairs Med Ctr, Orthopaed Surg Serv, Los Angeles, CA 90073 USA. W Los Angeles Vet Affairs Med Ctr, Res Serv, Los Angeles, CA 90073 USA. RP Meals, RA (reprint author), 100 UCLA Med Plaza,305, Los Angeles, CA 90095 USA. EM rmeals@ucla.edu NR 13 TC 4 Z9 4 U1 0 U2 4 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0363-5023 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD MAY PY 2005 VL 30A IS 3 BP 573 EP 579 DI 10.1016/j.jhsa.2004.010.010 PG 7 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 932JC UT WOS:000229549000023 PM 15925170 ER PT J AU Boynton, JF Budoff, JF Clifford, JW AF Boynton, JF Budoff, JF Clifford, JW TI The effect of forearm bracing on radioulnar impingement SO JOURNAL OF HAND SURGERY-BRITISH AND EUROPEAN VOLUME LA English DT Article DE distal radioulnar joint; functional bracing; radioulnar impingement; distal ulna resection; wrist ID SAUVE-KAPANDJI PROCEDURE; CARPI ULNARIS TENODESIS; DARRACH PROCEDURE; DISTAL ULNA; FRACTURES; JOINT; RESECTION AB The purpose of this clinical study was to compare patients' symptoms and radioulnar convergence following distal radioulnar reconstruction with and without a functional brace on. Standardized radiographs were taken of the involved wrist at rest, while holding a weight, and during maximum power grip. All radiographs were then repeated while wearing a prefabricated functional brace (Maramed, Miami, FL). The functional brace did not decrease radioulnar convergence and, at rest, the brace actually increased radioulnar convergence. Despite this, all patients who experienced pain without the brace were pain free with the brace on. We conclude that forearm bracing may be a useful nonoperative treatment for residual pain following DRUJ salvage surgery, though its mechanism of action is unclear. C1 Baylor Coll Med, Dept Orthopaed Surg, Houston, TX USA. Houston Vet Adm Med Ctr, Houston, TX USA. Kaiser Permanente, San Diego, CA USA. RP Boynton, JF (reprint author), Baylor Coll Med, Dept Orthopaed Surg, 6550 Fannin, Houston, TX USA. EM jbudoff@houston.rr.com NR 17 TC 3 Z9 4 U1 1 U2 1 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0266-7681 J9 J HAND SURG-BRIT EUR JI J. Hand Surg.-Br. Eur. Vol. PD MAY PY 2005 VL 30B IS 2 BP 157 EP 161 DI 10.1016/j.jhsb.2004.10.002 PG 5 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 909GS UT WOS:000227849000007 PM 15757768 ER PT J AU Jackson, LA Benson, P Neuzil, KM Grandjean, M Marino, JL AF Jackson, LA Benson, P Neuzil, KM Grandjean, M Marino, JL TI Burden of community-onset Escherichia coli bacteremia in seniors SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID URINARY-TRACT-INFECTIONS; ANTIMICROBIAL SURVEILLANCE PROGRAM; BLOOD-STREAM INFECTIONS; ALPHA-HEMOLYSIN VACCINE; POSTMENOPAUSAL WOMEN; ACQUIRED BACTEREMIA; RISK-FACTORS; OLDER-ADULTS; INCONTINENCE; POPULATION AB Background. Although Escherichia coli is a well-recognized cause of urinary tract infection in seniors, little is known about the burden of invasive E. coli infection in this population. Methods. We conducted a population-based cohort study of 46,238 noninstitutionalized Group Health Cooperative members >= 65 years of age to ascertain incidences of community-onset E. coli bacteremia and, for comparison, pneumococcal bacteremia, and we then performed a case-control study to identify risk factors for community-onset E. coli bacteremia. Results. The overall rate of community-onset E. coli bacteremia in the study cohort was 150 cases/100,000 person-years, which was similar to 3 times higher than the rate of pneumococcal bacteremia. In the case-control study, urinary catheterization and urinary incontinence were the only factors associated with an increased risk of E. coli bacteremia in men (62 cases), whereas cancer, renal failure, congestive heart failure, coronary artery disease, and urinary incontinence were associated with an increased risk of E. coli bacteremia in women (119 cases). Conclusions. E. coli appears to be the leading cause of community-onset bacteremia in seniors, and, on the basis of these rates, we estimate that 53,476 cases occur in noninstitutionalized seniors each year in the United States. Community-onset E. coli bacteremia in seniors is, therefore, an infection of public health importance. C1 Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Jackson, LA (reprint author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Ste 1600, Seattle, WA 98101 USA. EM jackson.l@ghc.org OI Marino, Jennifer/0000-0001-6742-1940 NR 33 TC 35 Z9 35 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 1 PY 2005 VL 191 IS 9 BP 1523 EP 1529 DI 10.1086/429344 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 913CS UT WOS:000228128800020 PM 15809912 ER PT J AU Xie, Z Harris-White, ME Wals, PA Frautschy, SA Finch, CE Morgan, TE AF Xie, Z Harris-White, ME Wals, PA Frautschy, SA Finch, CE Morgan, TE TI Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE Alzheimer's; apoJ; clusterin; microglia; neurotoxicity; nitric oxide; tumor necrosis factor-alpha ID NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE SYNTHASE; A-BETA OLIGOMERS; ALZHEIMERS-DISEASE; AMYLOID-BETA; CELL-DEATH; OXIDATIVE STRESS; RAT-BRAIN; GENE-EXPRESSION; PROTEIN AB Apolipoprotein J (apoJ; also known as clusterin and sulfated glycoprotein (SGP)-2) is associated with senile plaques in degenerating regions of Alzheimer's disease brains, where activated microglia are also prominent. We show a functional link between apoJ and activated microglia by demonstrating that exogenous apoJ activates rodent microglia in vivo and in vitro. Intracerebroventricular infusion of purified human plasma apoJ (similar to 4 mu g over 28 days) activated parenchymal microglia to a phenotype characterized by enlarged cell bodies and processes (phosphotyrosine immunostaining). In vitro, primary rat microglia were also activated by apoJ, with changes in morphology and induction of major histocompatibility complex class II (MHCII) antigen. ApoJ increased the secretion of reactive nitrogen intermediates in a dose-dependent manner (EC50 112 nM), which was completely blocked by aminoguanidine (AG), a nitric oxide synthase inhibitor. However, AG did not block the increased secretion of tumor necrosis factor-alpha by apoJ (EC50 55 nM). Microglial activation by apoJ was also blocked by an anti-apoJ monoclonal antibody (G7), and by chemical cleavage of apoJ with 2-nitro-5-thiocyanobenzoate. The mitogen-activated protein kinase kinase and protein kinase C inhibitors PD98059 and H7 inhibited apoJ-mediated induction of reactive nitrogen intermediate secretion from cultured microglia. As a functional measure, apoJ-activated microglia secreted neurotoxic agents in a microglia-neuron co-culture model. We hypothesize that ApoJ contributes to chronic inflammation and neurotoxicity through direct effects on microglia. C1 Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA. Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA. VA Greater Los Angeles Healthcare Syst, GRECC, Sepulveda, CA USA. RP Xie, Z (reprint author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave, Los Angeles, CA 90089 USA. EM z-xie@north-western.edu RI Xie, Zhong/B-6829-2011 OI Xie, Zhong/0000-0002-8348-4455 FU NIA NIH HHS [AG10685, AG13499, P50 AG016570, R01 AG010685] NR 63 TC 19 Z9 19 U1 0 U2 7 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD MAY PY 2005 VL 93 IS 4 BP 1038 EP 1046 DI 10.1111/j.1471-4159.2005.03065.x PG 9 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA 920WB UT WOS:000228721200026 PM 15857407 ER PT J AU Vuletic, S Peskind, ER Marcovina, SM Quinn, JF Cheung, MC Kennedy, H Kaye, JA Jin, LW Albers, JJ AF Vuletic, S Peskind, ER Marcovina, SM Quinn, JF Cheung, MC Kennedy, H Kaye, JA Jin, LW Albers, JJ TI Reduced CSFPLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces apoE secretion in primary human astrocytes in vitro SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE Alzheimer's disease; cerebrospinal fluid; lipoproteins ID PHOSPHOLIPID TRANSFER PROTEIN; FLUID APOLIPOPROTEIN-E; CEREBROSPINAL-FLUID; HUMAN PLASMA; CHOLESTEROL EFFLUX; LIPOPROTEINS; CELLS; ONSET; BETA; HIPPOCAMPUS AB Phospholipid transfer protein (PLTP) plays a pivotal role in cellular lipid efflux and modulation of lipoprotein metabolism. PLTP is distributed widely in the central nervous system (CNS), is synthesized by glia and neurons, and is active in cerebrospinal fluid (CSF). The aims of this study were to test the hypothesis that patients with Alzheimer's disease (AD) have altered PLTP-mediated phospholipid transfer activity in CSF, and to examine the potential relationship between PLTP activity and apolipoprotein E (apoE) levels in CSF We assessed PLTP activity and apoE concentration in CSF of patients with probable AD (n = 50), multiple sclerosis (MS; n = 9), other neurologic diseases (n = 21), and neurologically healthy controls (n = 40). PLTP activity in AD was reduced compared to that in controls (P < 0.001), with approximately half of the AD patients with PLTP activity values below all controls. Patients with MS had lower PLTP activity than AD patients (P < 0.001). PLTP activity was highly correlated with PLTP mass, as estimated by Western blot (r = 0.006; P < 0.01). CSF PLTP activity positively correlated with apoE concentration in AD (P = 0.435; P = 0.002) and controls (R = 0.456; P = 0.003). Anti-apoE immunoaffinity chromatography and Western blot analyses indicated that some CSF PLTP is associated with apoE-containing lipoproteins. Exogenous addition of recombinant PLTP to primary human astrocytes significantly increased apoE secretion to the conditioned medium. The findings of reduced PLTP activity in AD CSF, and the observation that PLTP can influence apoE secretion in astrocytes suggest a potential link between alterations in the brain lipid metabolism and AD pathogenesis. (c) 2005 Wiley-Liss, Inc. C1 Univ Washington, Dept Med, NW Lipid Metab & Diabet Res Labs, Seattle, WA 98109 USA. Univ Washington, Sch Med, Mental Illness Res Educ & Clin Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98109 USA. Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98109 USA. VA Med Ctr, Dept Neurol, Portland, OR USA. Univ Calif Davis, Mind Inst, Dept Med, Davis, CA 95616 USA. RP Albers, JJ (reprint author), Univ Washington, Dept Med, NW Lipid Metab & Diabet Res Labs, 401 Queen Anne Ave N, Seattle, WA 98109 USA. EM jja@u.washington.edu OI Kaye, Jeffrey/0000-0002-9971-3478 FU NCRR NIH HHS [5 M01 RR000334]; NHLBI NIH HHS [HL30086]; NIA NIH HHS [AG05136, AG05136-18, AG08419, P30 AG08017] NR 46 TC 32 Z9 32 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD MAY 1 PY 2005 VL 80 IS 3 BP 406 EP 413 DI 10.1002/jnr.20458 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 918RT UT WOS:000228566000011 PM 15795933 ER PT J AU King, JT Moossy, JJ Tsevat, J Roberts, MS AF King, JT Moossy, JJ Tsevat, J Roberts, MS TI Multimodal assessment after surgery for cervical spondylotic myelopathy SO JOURNAL OF NEUROSURGERY-SPINE LA English DT Article DE cervical spine; spinal stenosis; surgery; health status; outcome assessment; quality of life ID QUALITY-OF-LIFE; POSTERIOR LONGITUDINAL LIGAMENT; SURGICAL-TREATMENT; MEDICAL OUTCOMES; CONTROLLED-TRIAL; SHORT FORM-36; FOLLOW-UP; ANTERIOR; FUSION; REHABILITATION AB Object. Investigators reporting decompressive surgery to treat patients with cervical spondylotic myelopathy (CSM) have described inconsistent benefits. In the present study the authors used three types of outcomes instruments to assess the results of CSM surgery. Methods. The authors collected prospective baseline and 6-month follow-up data in a cohort of 62 patients with CSM. Data collection included those pertaining to demographics; symptoms; physical findings; myelopathy severity; health status measured with the Short Form-36; and health values according to the standard gamble, time trade-off, visual analog scale, and willingness to pay. Rank-order methods were used to compare surgical and nonsurgical patients, and multivariate regression techniques adjusting for baseline characteristics were performed to examine the effects of surgery. During the study period, 28 patients underwent surgery, 34 did not, and there were no baseline differences between the two groups in demographics, symptoms, myelopathy scores, health status. or health values (p >= 0.120 in all domains); there was a greater prevalence of hand intrinsic muscle atrophy (p = 0.035) and Hoffmann sign (p = 0.006) in the surgery-treated group. Neither raw comparisons nor regression analyses showed a consistent surgery-related benefit. There were sporadic associations between worse outcomes and older patients, higher income, Babinski sign, longer duration of CSM symptoms, hand clumsiness, lower-extremity numbness, and multilevel surgery (p <= 0.049 for all). Conclusions. Analysis of results obtained in the 62 patients with CSM failed to show a surgery-related benefit despite the use of three classes of outcomes instruments. Patient demographics, symptoms, physical signs, and the surgical approach may explain some of the variation in outcomes in patients with CSM. C1 Vet Adm Connecticut Healthcare Syst, Neurosurg Sect, West Haven, CT 06516 USA. Yale Univ, Dept Neurosurg, New Haven, CT 06520 USA. Vet Affairs Pittsburgh Healthcare Syst, Neurosurg Sect, Surg Serv Line, Pittsburgh, PA USA. Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA 15260 USA. Univ Cincinnati, Med Ctr, Sect Outcomes Res & Decis Sci,Dept Internal Med, Div Gen Internal Med, Cincinnati, OH 45221 USA. Univ Cincinnati, Med Ctr, Inst Hlth Policy & Hlth Serv Res, Ctr Clin Effectiveness, Cincinnati, OH 45221 USA. Vet Affairs Med Ctr, Cincinnati, OH 45267 USA. RP King, JT (reprint author), Vet Adm Connecticut Healthcare Syst, Neurosurg Sect, 112-950 Campbell Ave, West Haven, CT 06516 USA. EM Joseph.KingJr@med.va.gov FU NINDS NIH HHS [1K23 NS02169-05] NR 44 TC 25 Z9 26 U1 0 U2 3 PU AMER ASSOC NEUROLOGICAL SURGEONS PI CHARLOTTESVILLE PA UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA SN 0022-3085 J9 J NEUROSURG-SPINE JI J. Neurosurg.-Spine PD MAY PY 2005 VL 2 IS 5 BP 526 EP 534 DI 10.3171/spi.2005.2.5.0526 PG 9 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 927EU UT WOS:000229176000005 PM 15948295 ER PT J AU Williams, DL Cummings, DE AF Williams, DL Cummings, DE TI Regulation of ghrelin in physiologic and pathophysiologic states SO JOURNAL OF NUTRITION LA English DT Article; Proceedings Paper CT Experimental Biology 2004 Annual Meeting CY APR 17-21, 2004 CL Washington, DC DE ghrelin; food intake; obesity ID GASTRIC BYPASS-SURGERY; GASTROINTESTINAL SATIETY SIGNALS; PLASMA GHRELIN; CIRCULATING GHRELIN; OBESE SUBJECTS; FOOD-INTAKE; WEIGHT-LOSS; BILIOPANCREATIC DIVERSION; BARIATRIC SURGERY; ACYLATED PEPTIDE AB Ghrelin, a ligand for the growth hormone secretagogue receptor, is an orexigenic hormone produced in the gastrointestinal tract. In humans and other animals, circulating ghrelin levels fluctuate over the course of the day in relation to food intake. If circulating ghrelin plays a role in determining food intake from meal to meal, it will be important to understand the factors that regulate plasma ghrelin levels in relation to feeding. Circulating ghrelin levels also appear to reflect body weight changes over the longer term, raising the possibility that ghrelin functions as an adiposity signal. This review discusses some of the factors known to affect ghrelin levels, including nutrient stimulation of the gastrointestinal tract, diet composition, and weight loss. We also consider potential hormonal and neural mediators of the effects of nutrients and weight change on ghrelin levels. C1 Univ Washington, Sch Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. Harborview Med Ctr, Seattle, WA 98104 USA. Univ Washington, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Williams, DL (reprint author), Univ Washington, Sch Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. EM dianalw@u.washington.edu RI Williams, Diana/C-1699-2014 OI Williams, Diana/0000-0002-3548-7440 NR 62 TC 81 Z9 89 U1 0 U2 3 PU AMER INST NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD MAY PY 2005 VL 135 IS 5 BP 1320 EP 1325 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 924BM UT WOS:000228953600068 PM 15867333 ER PT J AU Behnam, K Murray, SS Brochmann, EJ AF Behnam, K Murray, SS Brochmann, EJ TI Identification and characterization of valosin-containing protein (VCP/p97) in untransformed osteoblast-like cells SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE valosin-containing protein p97; osteoblast; proteomics ID PAGET-DISEASE; AAA-ATPASE; 2-DIMENSIONAL ELECTROPHORESIS; TYROSINE PHOSPHORYLATION; ENDOPLASMIC-RETICULUM; BINDING PROTEIN; BONE; VCP; LOCALIZATION; EXPRESSION AB A 97-kDa protein called valosin-containing protein (VCP) has been implicated in osteosarcoma metastasis and Paget's disease of gene expression is bone, two conditions that complicate the course and outcome of orthopaedic surgery. High VCP g.. associated with high metastatic potential in osteosarcoma cells, while loss-of-function VCP Mutations cause inclusion body myopathy associated with Paget's disease of bone and frontotemporal dementia (IBMPFD). VCP protein expression and regulation have not been examined in normal osteoblasts. The purpose of these studies was to characterize VCP protein expression in control and stressed untransformed osteoblasts. Proteins from confluent MC3T3-E1 mouse osteoblast-like cells were separated by 2D IEF/SDS-PAGE. An abundant spot with a M-r. of 94 kDa and a pI of 5.4 was identified as VCP by MALDI/ToF and peptide mass fingerprint analysis. High constitutive VCP protein expression in subconfluent and confluent resting and mildly physiologically stressed MC3T3-E1 I cells was confirmed by Western blotting. When assessed by indirect immunofluorescence in fixed cells or Western blotting of subcellular fractions, VCP was more abundant in the cytoplasm than in the nucleus. Induction of mild physiological stress sufficient to stimulate the ubiquitin-proteasome pathway, which is partially dependent on VCP-mediated targeting of polyubiquitinylated Substrates, did not affect steady-state VCP levels or distribution. Thus, VCP is a constitutively abundant protein in untransformed osteoblastic cells under all conditions tested. Such high levels of VCP protein expression in untransformed osteoblastic cells argue against a major causative role for it in metastasis, while the occurrence of Paget's disease in patients with missense VCP mutations supports a major role for VCP in normal osteoblast proliferation and regulation. (c) 2005 Orthopaedic Research Society. Published by Elsevier Ltd. All rights reserved. C1 VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP Brochmann, EJ (reprint author), VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, 16111 Plummer St, Sepulveda, CA 91343 USA. EM Elsa.Murray@ined.va.gov NR 31 TC 4 Z9 4 U1 1 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0736-0266 J9 J ORTHOP RES JI J. Orthop. Res. PD MAY PY 2005 VL 23 IS 3 BP 618 EP 624 DI 10.1016/j.orthres.2004.12.012 PG 7 WC Orthopedics SC Orthopedics GA 929VP UT WOS:000229375000016 PM 15885483 ER PT J AU Wang, WC Ledoux, WR Sangeorzan, BJ Reinhall, PG AF Wang, WC Ledoux, WR Sangeorzan, BJ Reinhall, PG TI A shear and plantar pressure sensor based on fiber-optic bend loss SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE anterior/posterior shear; biomechanics; biosensing techniques; diabetes mellitus; foot ulcers; gait; lower-limb complications; plantar pressure; plantar ulcers; ulcer ID FORCE DISTRIBUTION; FOOT PRESSURE; ULCERATION AB Lower-limb complications associated with diabetes include the development of plantar ulcers that can lead to infection and subsequent amputation. While we know from force-plate analyses that medial/lateral and anterior/posterior shear components of ground-reaction forces exist, little is known about the actual distribution of these stresses during daily activities or about the role that shear stresses play in causing plantar ulceration. Furthermore, one critical reason why these data have not been obtained previously is the lack of a validated, widely used, commercially available shear sensor, partly because of the various technical issues associated with measuring shear. In this study, we present a novel means of transducing plantar pressure and shear stress with a fiber-optic sensor. The pressure/shear sensor consists of an array of optical fibers lying in perpendicular rows and columns separated by elastomeric pads. We constructed a map of normal and shear stresses based on observed macrobending through the intensity attenuation from the physical deformation of two adjacent perpendicular fibers. Initial results show that this sensor exhibits low noise and responds to applied normal and shear loads with good repeatability. C1 Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. Ctr Excellence Limb Loss Prevent & Prosthet Engn, Dept Vet Affairs VA Rehabil Res & Dev, VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Wang, WC (reprint author), Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. EM abong@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 NR 18 TC 26 Z9 27 U1 0 U2 16 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD MAY-JUN PY 2005 VL 42 IS 3 BP 315 EP 325 DI 10.1682/JRRD.2004.07.0076 PG 11 WC Rehabilitation SC Rehabilitation GA 953MN UT WOS:000231080600006 PM 16187244 ER PT J AU Dvorznak, M Cooper, R Boninger, M AF Dvorznak, M Cooper, R Boninger, M TI Kinematic analysis for determination of bioequivalence of a modified Hybrid III test dummy and a wheelchair user SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE accident prevention; bioequivalence; electrically powered wheelchairs; Hybrid test dummy; injury assessment; injury biomechanics; kinematics; spinal cord injury; statistical measures; tips and falls; wheelchair safety ID BIOMECHANICS; ACCIDENTS; MOMENTS; FORCES; BELT AB We investigated whether a modified 50th-percentile Hybrid III test dummy (HTD) (First Technology Safety Systems, Plymouth, MI) would have motion similar to a wheelchair test pilot (TP) with T8 paraplegia. Test cases were seated in a Quickie P100 electrically powered wheelchair (Sunrise Medical, Inc., Phoenix, AZ) driven at three speeds (0.8, 1.4, and 2.0 m/s). Three braking conditions-joystick release, joystick full reverse, and emergency power-off-were used to stop the wheelchair. The subsequent upper-body motion was recorded for the creation of kinematic exposure profiles of the wheelchair riders. The maximum concentration (Cmax) and area under the trunk angular displacement, velocity, and acceleration curves (AUC(0-Cmax)) were calculated. Assessments of average, individual, and population bioequivalence were conducted after data were subjected to natural logarithmic transforms. Only the Cmax of the trunk angular acceleration of the HTD and TP was average bioequivalent (0.82-1.04). Both Cmax and AUC(0-Cmax) measures for all kinematic exposures between the TP and HTD were individual and population bioequivalent (95% upper-confidence bound < 0, linearized bioequivalence criteria). This indicates that the HTD is a suitable surrogate for a wheelchair user in low-speed, low-impact wheelchair studies. C1 Ctr Excellence Wheelchairs & Related Technol, Human Engn Res Labs, VA Pittsburgh Healthcare Syst, Dept Vet Affairs, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. RP Cooper, R (reprint author), Ctr Excellence Wheelchairs & Related Technol, Human Engn Res Labs, VA Pittsburgh Healthcare Syst, Dept Vet Affairs, 7180 Highland Dr,151R-1, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu OI Boninger, Michael/0000-0001-6966-919X NR 18 TC 2 Z9 2 U1 0 U2 0 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD MAY-JUN PY 2005 VL 42 IS 3 BP 343 EP 351 DI 10.1682/JRRD.2004.07.0082 PG 9 WC Rehabilitation SC Rehabilitation GA 953MN UT WOS:000231080600008 PM 16187246 ER PT J AU Gordon, JS Phillips, DS Helt, WJ Konrad-Martin, D Fausti, SA AF Gordon, JS Phillips, DS Helt, WJ Konrad-Martin, D Fausti, SA TI Evaluation of insert earphones for high-frequency bedside ototoxicity monitoring SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE circumaural earphones; early detection; hearing thresholds; high-frequency testing; insert earphones; instrumentation; intrasubject reliability; ototoxicity monitoring; test-retest reliability; threshold reliability ID HEARING THRESHOLDS; ADULTS; VARIABILITY; AUDIOMETRY; RANGE AB Ototoxic hearing loss is usually detected earliest through monitoring of the highest audible frequencies in individuals administered ototoxic medications. Conducting ototoxicity monitoring may require testing patients in the hospital room. This study evaluated the use of insert earphones for obtaining reliable threshold responses at bedside. Twenty adult subjects were tested during two different sessions in the sound booth and on the ward. Thresholds were obtained for frequencies from 5 to 16 kHz and at 2 kHz with the use of the KOSS Pro/4X Plus earphones and Etymotic ER-4B MicroPro insert earphones. Results indicate that ER-4B insert earphones are as reliable as KOSS earphones for testing on the ward for high-frequency ototoxicity monitoring. C1 Natl Ctr Rehabil Auditory Res, Dept Vet Affairs, VA Rehabil Res & Dev, Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR USA. RP Fausti, SA (reprint author), Natl Ctr Rehabil Auditory Res, Dept Vet Affairs, VA Rehabil Res & Dev, Portland VA Med Ctr, 3710 SW US Vet Hosp Rd,NCRAR, Portland, OR 97239 USA. EM stephen.fausti@med.va.gov NR 26 TC 9 Z9 9 U1 2 U2 4 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD MAY-JUN PY 2005 VL 42 IS 3 BP 353 EP 361 DI 10.1682/JRRD.2004.06.0093 PG 9 WC Rehabilitation SC Rehabilitation GA 953MN UT WOS:000231080600009 PM 16187247 ER PT J AU Monga, U Kerrigan, AJ Thornby, J Monga, TN Zimmermann, KP AF Monga, U Kerrigan, AJ Thornby, J Monga, TN Zimmermann, KP TI Longitudinal study of quality of life in patients with localized prostate cancer undergoing radiotherapy SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE depression; fatigue; Functional Assessment of Cancer Therapy; outcomes; physical well-being; Piper Fatigue Scale; prostate cancer; quality of life; radiotherapy; sleep disturbance ID EXTERNAL RADIATION-THERAPY; EPWORTH SLEEPINESS SCALE; RADICAL PROSTATECTOMY; FUNCTIONAL ASSESSMENT; MEN; FATIGUE; DIAGNOSIS; DISTRESS; OUTCOMES; CHEMOTHERAPY AB This study prospectively evaluated quality of life (QOL) in localized prostate cancer patients undergoing radiotherapy, and it examined the relationships between QOL, depression, fatigue, and sleep disturbance. Instruments that were used are Functional Assessment of Cancer Therapy for Prostate (FACT-P), Beck Depression Inventory (13131), Piper Fatigue Scale (PFS), and Epworth Sleepiness Scale (ESS). We evaluated patients at preradiotherapy (PRT), midway radiotherapy (MRT), completion of radiotherapy (CRT), follow-up radiotherapy (4 to 8 wk) (FRT), and long-term follow-up radiotherapy (FRT2) (12 mo or more). Forty participants with a mean age of 67.8 yr were studied. Duration of radiotherapy was 7-8 wk. Mean long-term follow-up period post-CRT was 16.2 mo (range 1224 mo). All patients had clinical T1c to T2b prostate cancer. Prostate Cancer Specific (PCS) and Physical Well-Being (PWB) subscales of FACT-P, scores at MRT and CRT were significantly lower than at PRT. At FRT2, PWB scores declined further, while PCS scores increased. PFS median scores were significantly higher at CRT and at FRT2 as compared with PRT. Patients scoring higher on PFS were more likely to report a poorer QOL and PWB as measured with FACT-P questionnaire. No significant changes were noted in the BDI and ESS scores during the study periods. The PWB declined during and at CRT and worsened at FRT2. Decline in PCS subscale scores during and at CRT reflects worsening of urinary symptoms and appearance of bowel problems. The scores improved at long-term follow-up. A relationship was found to exist between physical well-being and fatigue. C1 Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Kerrigan, AJ (reprint author), Michael E DeBakey Dept Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM KERRIGAN.ANTHONYJ@med.va.gov NR 44 TC 30 Z9 32 U1 0 U2 3 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD MAY-JUN PY 2005 VL 42 IS 3 BP 391 EP 399 DI 10.1682/JRRD.2004.06.0071 PG 9 WC Rehabilitation SC Rehabilitation GA 953MN UT WOS:000231080600013 PM 16187251 ER PT J AU Popa-Lisseanu, MGG Greisinger, A Richardson, M O'Malley, KJ Janssen, NM Marcus, DM Tagore, J Suarez-Almazor, ME AF Popa-Lisseanu, MGG Greisinger, A Richardson, M O'Malley, KJ Janssen, NM Marcus, DM Tagore, J Suarez-Almazor, ME TI Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE rheumatoid arthritis; treatment adherence; systemic lupus erythematosus; focus groups ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; FORMAL EDUCATION LEVEL; HEALTH BELIEF MODEL; SOCIOECONOMIC-STATUS; ARTHRITIS PATIENTS; REVISED CRITERIA; CLINICAL STATUS; AMERICAN; THERAPY; RACE AB Objective. To explore the determinants of adherence to medical recommendations, including drug therapy and appointment-keeping, among ethnically diverse and economically disadvantaged patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods. Patients with RA and SLE were identified through chart review and were invited to participate in focus groups to examine their attitudes and beliefs regarding adherence to treatment and medical appointments. Eight focus groups'(4 RA, 4 SLE) were conducted, with a total of 40 participants (22 SLE patients and 18 RA patients). Transcripts were analyzed using grounded theory techniques and qualitative analysis software to facilitate coding interpretation. Results. The majority of participants reported experiencing difficulty in adhering to their treatment at least occasionally. Both SLE and RA patients reported similar barriers to treatment adherence: fear of side effects, financial problems, difficulty in navigating the public health system, and perceived treatment inefficacy. RA and SLE patients also revealed barriers to appointment keeping, including difficulties in scheduling, financial costs, transportation, and functional impairment limiting their ability to attend the clinic. Conclusion. Patients' perceptions of and experiences with the health system, physicians, medication effectiveness, and side effects influence their adherence to treatment and other medical recommendations. Strategies to improve adherence could include the following: attempting to modify patients' beliefs and perceptions regarding medication effectiveness, promoting realistic expectations about risk/benefit ratios, and improving access to health care by reducing barriers that limit the interaction between patients and the health system. C1 Michael E DeBakey Vet Affairs Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Kelsey Res Fdn, Houston, TX USA. RP Suarez-Almazor, ME (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, Houston Ctr Qual Care & Utilizat Studies, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM mes@bcm.tmc.edu NR 43 TC 49 Z9 49 U1 0 U2 6 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO, ONTARIO M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD MAY PY 2005 VL 32 IS 5 BP 913 EP 919 PG 7 WC Rheumatology SC Rheumatology GA 926AH UT WOS:000229094600026 ER PT J AU Nicolaidis, C Curry, MA Gerrity, M AF Nicolaidis, C Curry, MA Gerrity, M TI Health care workers' expectations and empathy toward patients in abusive relationships SO JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE LA English DT Article; Proceedings Paper CT National Conference on Domestic Violence and Healthcare CY OCT 20-22, 2004 CL Boston, MA ID INTIMATE PARTNER VIOLENCE; DOMESTIC VIOLENCE; BARRIERS; INTERVENTION; EXPERIENCES; PHYSICIANS; SERVICES; WOMEN AB Purpose: To understand attitudes that may affect health care workers' ability to provide appropriate long-term care for patients who stay with abusive partners. Methods: We surveyed 278 health care workers in 31 primary care practices before their participation in an educational intervention. Results: More than half of participants (51% to 60%) found it easy to empathize with a patient who decided to remain in an abusive relationship if the patient was described as poor or disabled, but few (25% to 39%) could empathize if the patient was described as educated or financially secure. A majority (57% to 59%) agreed with a statement meant to assess unrealistic expectations. ("A provider's responsibility includes making sure a patient gets to a shelter right away if he or she discloses abuse.") Participants who agreed with this statement had more difficulty empathizing with patients who decided to stay with an abusive partner (P = .0045). Conclusions: Training efforts must focus on screening and on helping providers develop more realistic expectations about the complex nature of leaving an abusive relationship. Health care workers need a better understanding of the barriers patients face and why patients may choose to remain in abusive relationships, even in the absence of economic or health limitations. C1 Oregon Hlth & Sci Univ, Div Gen Internal Med, Portland, OR 97215 USA. Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97215 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Nicolaidis, C (reprint author), Oregon Hlth & Sci Univ, Div Gen Internal Med, L475, Portland, OR 97215 USA. EM nicolaid@ohsu.edu NR 21 TC 10 Z9 11 U1 1 U2 5 PU AMER BOARD FAMILY PRACTICE PI LEXINGTON PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA SN 0893-8652 J9 J AM BOARD FAM PRACT JI J. Am. Board Fam. Pract. PD MAY-JUN PY 2005 VL 18 IS 3 BP 159 EP 165 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 923TT UT WOS:000228932900001 PM 15879562 ER PT J AU Kaafarani, HM Itani, KMF Giobbie-Hurder, A Gleysteen, JJ McCarthy, M Gibbs, J Neumayer, L AF Kaafarani, HM Itani, KMF Giobbie-Hurder, A Gleysteen, JJ McCarthy, M Gibbs, J Neumayer, L TI Does surgeon frustration and satisfaction with the operation predict outcomes of open or laparoscopic inguinal hernia repair? SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID TOTAL HIP-ARTHROPLASTY; OF-VETERANS-AFFAIRS; SURGICAL CARE; HOSPITAL VOLUME; LEARNING-CURVE; QUALITY; PATIENT; IMPROVEMENT; PERFECT; PROGRAM AB BACKGROUND: A surgeon's level of frustration when performing an operation and level of satisfaction at completion may be correlated with patients' outcomes. We evaluated the relationship between the attending surgeons' frustration and satisfaction and recurrence and complications of open and laparoscopic inguinal hernia repair. STUDY DESIGN: Men with detectable inguinal hernias were randomized to undergo open or laparoscopic herniorrhaphy at 14 Veterans Affairs hospitals. After completion of the procedure, surgeons were asked to assess their level of frustration during the operation and their overall satisfaction with the operative result. Two subjective scales ranging from 1 (not frustrated/not satisfied) to 5 (very frustrated/very satisfied) were used to independently assess both parameters. Reasons for surgeon frustration were evaluated. Patients were followed for 2 years for recurrence and complications. RESULTS: Of 1,983 patients who underwent hernia repair, 1,622 were available for analysis; 808 had open repair and 813 had laparoscopic repair. Surgeons reported less frustration and more satisfaction with open than with laparoscopic repair (p = 0.0001 and 0.0001, respectively). Frustration was associated with a higher rate of hernia recurrence at 2 years (adjusted odds ratio, 2.01, 95% CI, 1.15-3.51) in open repair, and a higher overall rate of postoperative complications (adjusted odds ratio, 1.27, 95% CI, 1.03-1.56) in both open and laparoscopic hernia repair. Satisfaction was not correlated with recurrence or complications. CONCLUSIONS: The level of a surgeon's frustration during performance of an inguinal hermorrhaphy was a better predictor of outcomes of the operation than was satisfaction with the procedure. Sources of intraoperative frustration should be controlled to improve outcomes. (c) 2005 by the American College of Surgeons. C1 Univ Utah, Surg Serv, Salt Lake City, UT 84148 USA. Salt Lake City Vet Affairs Med Ctr, Dept Surg, Salt Lake City, UT 84148 USA. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Dept Surg, Houston, TX 77030 USA. Vet Affairs Boston Hlth Care Sst, Dept Surg, Boston, MA USA. Boston Med Ctr, Boston, MA USA. Vet Affairs Cooperat Studies Program Coordinating, Hines, IL USA. Univ Alabama, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Univ Alabama, Dept Surg, Birmingham, AL 35294 USA. Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Chicago, IL 60611 USA. RP Neumayer, L (reprint author), Univ Utah, Surg Serv, 500 Foothill Dr, Salt Lake City, UT 84148 USA. NR 22 TC 9 Z9 9 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD MAY PY 2005 VL 200 IS 5 BP 677 EP 683 DI 10.1016/j.jamcollsurg.2004.11.018 PG 7 WC Surgery SC Surgery GA 921PC UT WOS:000228775800005 PM 15848357 ER PT J AU Friedlander, AH Garrett, NR Chin, EE Baker, JD AF Friedlander, AH Garrett, NR Chin, EE Baker, JD TI Ultrasonographic confirmation of cartoid artery athermoas diagnosed via panoramic radiography SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article DE atherosclerosis; panoramic radiography; Doppler ultrasonography ID COMMON CAROTID ATHEROSCLEROSIS; ENDARTERECTOMY TRIAL; DUPLEX CRITERIA; STENOSIS; RISK; DISEASE; CALCIFICATION; ASSOCIATION; ULTRASOUND; STROKE AB Background. Studies have shown that panoramic radiographs can capture images of calcified atheromas in the internal carotid artery (ICA) in some neurologically asymptomatic patients receiving routine dental care. However, the prevalence of these hemodynamically significant lesions-that is, those causing greater than 50 percent vessel lumen occlusion with the consequent heightened risk of stroke-has been evaluated rarely. The purpose of this study was to use Doppler ultrasonography (DUS) to determine the prevalence of large occlusive lesions detected initially via panoramic radiography. Aggressive medical and surgical interventions directed toward these large lesions have been shown to moderate the risk of stroke. Study Design. The authors analyzed the panoramic radiographs of 1,548 consecutively treated, neurologically asymptomatic dental patients who were 50 years or older. Those with presumptive atheromas underwent DUS for confirmation of the diagnosis and for determination of the degree of stenosis. Results. The radiographs of 65 patients (4.2 percent) showed at least one ICA atheroma. Thirty-eight patients had bilateral opacities and 27 had unilateral opacities. DUS evaluation of the 103 sides of the neck with a radiographically identified atheroma revealed that none of the ICAs were normal, 81 (79 percent) had less than 50 percent stenosis, 18 (17 percent) had 50 to 69 percent stenosis and four (4 percent) had 70 percent or greater stenosis. Four of the ICAs on the 27 sides without calcifications were deemed normal and 23 had less than 50 percent stenosis. Conclusions. These results demonstrate that a subset of patients (15 [23 percent] of 65) with an occult atheroma discovered on panoramic radiography had significant (>= 50 percent) levels of ICA stenosis. Clinical Implications. Dentists should refer all patients with radiographically identified atheromas to a physician for confirmation of the diagnosis and a determination of the magnitude of,disease, because antiatherogenic interventions have been shown to prevent a stroke. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Med Ctr, Hosp Dent Serv, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Dent, Los Angeles, CA USA. RP Friedlander, AH (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@med.va.gov NR 23 TC 31 Z9 34 U1 0 U2 4 PU AMER DENTAL ASSN PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD MAY PY 2005 VL 136 IS 5 BP 635 EP 640 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 928AI UT WOS:000229243100021 PM 15966651 ER PT J AU Rickerson, E Harrold, J Kapo, J Carroll, JT Casarett, D AF Rickerson, E Harrold, J Kapo, J Carroll, JT Casarett, D TI Timing of hospice referral and families' perceptions of services: Are earlier hospice referrals better? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hospice; home care; caregiver burden ID ILL HOSPITALIZED ADULTS; OF-LIFE CARE; PALLIATIVE CARE; END; SATISFACTION; RELIABILITY; CANCER; SCALE; NEEDS AB OBJECTIVES: To determine whether families of patients who enroll in hospice near the end of life believe that they receive less benefit from hospice services than families of patients who enroll earlier. DESIGN: Semistructured interviews at the time of hospice enrollment and 1 month after the patient's death. SETTING: This study was conducted at the Hospice of Lancaster County, Lancaster, PA, over a 12-month period spanning 2003-2004. PARTICIPANTS: First-time hospice admissions. MEASUREMENTS: Interviews assessed the anticipated helpfulness of six hospice services (enrollment interviews) and the actual helpfulness of the same services (follow-up interviews). RESULTS: Length of stay in hospice was associated with families' reports of the number of services provided (Spearman rho=0.34, P <.001), and with the mean helpfulness ratings for the services that were provided (Spearman rho=0.34, P <.001), although even with short lengths of stay, most families reported that they received the services that they anticipated and that those services were helpful. CONCLUSION: These results indicate that families feel they receive greater benefits from longer lengths of stay in hospice. Future efforts to define an "optimal" length of stay in hospice should consider patients' and families' perceptions of the benefits that hospice offers. C1 Univ Penn, Div Geriatr Med, Philadelphia, PA 19104 USA. Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Hospice Lancaster Cty, Lancaster, PA USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Casarett, D (reprint author), Inst Aging, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM casarett@mail.med.upenn.edu NR 21 TC 63 Z9 63 U1 4 U2 8 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAY PY 2005 VL 53 IS 5 BP 819 EP 823 DI 10.1111/j.1532-5415.2005.53259.x PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 921GB UT WOS:000228751100010 PM 15877557 ER PT J AU Willrich, A Angirasa, AK Sage, RA AF Willrich, A Angirasa, AK Sage, RA TI Percutaneous tendo Achillis lengthening to promote healing of diabetic plantar foot ulceration SO JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION LA English DT Article ID EQUINUS DEFORMITY; PRESSURE; ANKLE; MELLITUS AB The etiology of ulcerations related to increased plantar pressure in patients with diabetes mellitus is complex but frequently includes a component of gastrocnemius soleus equinus. One viable treatment option is percutaneous tendo Achillis lengthening as a means of increasing dorsiflexory range of motion and decreasing forefoot shear forces. This article presents three case reports illustrating the importance of reducing plantar pressure as a crucial component of treatment of diabetic forefoot ulcerations. C1 Loyola Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, Maywood, IL 60152 USA. Loyola Univ, Med Ctr, Podiatry Sect, Maywood, IL 60152 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. RP Sage, RA (reprint author), Loyola Univ, Med Ctr, Dept Orthopaed Surg & Rehabil, 2160 S 1st Ave,Bldg 105,Ste 1700, Maywood, IL 60152 USA. NR 17 TC 4 Z9 4 U1 0 U2 0 PU AMER PODIATRIC MED ASSN PI BETHESDA PA 9312 OLD GEORGETOWN ROAD, BETHESDA, MD 20814-1621 USA SN 8750-7315 J9 J AM PODIAT MED ASSN JI J. Am. Podiatr. Med. Assoc. PD MAY-JUN PY 2005 VL 95 IS 3 BP 281 EP 284 PG 4 WC Orthopedics SC Orthopedics GA 928CT UT WOS:000229249400011 PM 15901817 ER PT J AU Horner, MD Ferguson, PL Selassie, AW Labbate, LA Kniele, K Corrigan, JD AF Horner, MD Ferguson, PL Selassie, AW Labbate, LA Kniele, K Corrigan, JD TI Patterns of alcohol use 1 year after traumatic brain injury: A population-based, epidemiological study SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE alcohol abuse; alcohol drinking; alcoholism; epidemiological studies; follow-up studies; substance abuse; traumatic brain injury ID NATIONAL PROBABILITY SAMPLE; AMERICAN DRINKING PRACTICES; SPINAL-CORD-INJURY; SUBSTANCE-ABUSE; PSYCHIATRIC-DISORDERS; HEAD-INJURY; AXIS-I; EXTENT AB This study delineated patterns of alcohol use 1 year after traumatic brain injury (TBI) in a large, population-based, epidemiological, nonclinical sample, and identified predictors of heavy alcohol use in these individuals. Participants were 1,606 adults identified by review of a South Carolina statewide hospital discharge data set, on the basis of satisfying the Centers for Disease Control case definition of TBI, and were interviewed by telephone 1 year after TBI-related discharge. Alcohol use in the month prior to interview was classified according to categories from the Quantity-Frequency-Variability Index; heavy drinking was defined as nearly daily use with &GE; 5 drinks at least occasionally, or at least three occasions with &GE; 5 drinks. A polychotomous logistic regression with 3 response levels (heavy, moderate, and abstinent/infrequent/light drinking) was used to identify predictors of heavy drinking. Heavy drinking in the month prior to interview was reported by 15.4% of participants, while 14.3% reported moderate drinking and 70.3% reported abstinence or light/infrequent drinking. Risk factors for heavy drinking included male gender, younger age, history of substance abuse prior to TBI, diagnosis of depression since TBI, fair/moderate mental health, and better physical functioning. There was no association between drinking patterns and TBI severity. C1 Ralph H Johnson Dept VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC USA. Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH USA. RP Horner, MD (reprint author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv, 109 Bee St, Charleston, SC 29401 USA. EM hornermd@musc.edu NR 38 TC 41 Z9 41 U1 2 U2 5 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA SN 1355-6177 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD MAY PY 2005 VL 11 IS 3 BP 322 EP 330 DI 10.1017/S135561770505037X PG 9 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA 924UL UT WOS:000229005900011 PM 15892908 ER PT J AU Hazzard, WR AF Hazzard, WR TI Preventive gerontology: Edging ever closer to the "barrier to immortality" SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Editorial Material C1 VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. RP Hazzard, WR (reprint author), VA Puget Sound Hlth Care Syst, S-GEC182,1660 S Columbian Way, Seattle, WA 98108 USA. EM william.hazzard@med.va.gov NR 5 TC 1 Z9 1 U1 0 U2 0 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD MAY PY 2005 VL 60 IS 5 BP 594 EP 595 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 937JU UT WOS:000229921200008 PM 15972607 ER PT J AU Baron, F Maris, MB Storer, BE Sandmaier, BM Panse, JP Chauncey, TR Sorror, M Little, MT Maloney, DG Storb, R Heimfeld, S AF Baron, F Maris, MB Storer, BE Sandmaier, BM Panse, JP Chauncey, TR Sorror, M Little, MT Maloney, DG Storb, R Heimfeld, S TI High doses of transplanted CD34(+) cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation SO LEUKEMIA LA English DT Article DE cell dose; CD34; T-cell; transplantation; nonmyeloablative ID BONE-MARROW-TRANSPLANTATION; IDENTICAL SIBLING TRANSPLANTATION; TOTAL-BODY IRRADIATION; HEMATOLOGIC MALIGNANCIES; LYMPHOCYTES-T; STEM-CELLS; INTENSITY; MORTALITY; DONORS; CHIMERISM AB This report examines the impact of graft composition on outcomes in 130 patients with hematological malignancies given unrelated donor granulocyte-colony-stimulating-factor-mobilized peripheral blood mononuclear cells (G-PBMC) ( n = 116) or marrow ( n = 14) transplantation after nonmyeloablative conditioning with 90 mg/m(2) fludarabine and 2Gy TBI. The median number of CD34(+) cells transplanted was 6.5 x 10(6)/ kg. Higher numbers of grafted CD14(+) ( P = 0.0008), CD3(+) ( P = 0.0007), CD4(+) ( P = 0.001), CD8(+) ( P = 0.004), CD3 - CD56(+) ( P = 0.003), and CD34(+) ( P = 0.0001) cells were associated with higher levels of day 28 donor T-cell chimerism. Higher numbers of CD14(+) ( P = 0.01) and CD34(+) ( P = 0.0003) cells were associated with rapid achievement of complete donor T-cell chimerism, while high numbers of CD8(+) ( P = 0.005) and CD34(+) ( P = 0.01) cells were associated with low probabilities of graft rejection. When analyses were restricted to G-PBMC recipients, higher numbers of grafted CD34(+) cells were associated with higher levels of day 28 donor T-cell chimerism ( P = 0.01), rapid achievement of complete donor T-cell chimerism ( P = 0.02), and a trend for lower risk for graft rejection ( P = 0.14). There were no associations between any cell subsets and acute or chronic GVHD nor relapse/progression. These data suggest more rapid engraftment of donor T cells and reduced rejection rates could be achieved by increasing the doses of CD34(+) cells in unrelated grafts administered after nonmyeloablative conditioning. C1 Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. Univ Washington, Sch Med, Seattle, WA USA. Univ Liege, Dept Hematol, B-4000 Liege, Belgium. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Maris, MB (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D1-100,POB 19024, Seattle, WA 98109 USA. EM mmaris@fhcrc.org FU NCI NIH HHS [CA18029, CA15704, CA78902, CA92058, P01 CA078902]; NHLBI NIH HHS [HL36444]; NICHD NIH HHS [HD44175]; NIDDK NIH HHS [DK56465] NR 32 TC 69 Z9 70 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD MAY PY 2005 VL 19 IS 5 BP 822 EP 828 DI 10.1038/sj.leu.2403718 PG 7 WC Oncology; Hematology SC Oncology; Hematology GA 920MA UT WOS:000228692500018 PM 15772701 ER PT J AU Bhidayasiri, R Bronstein, JM Sinha, S Krahl, SE Ahn, S Behnke, EJ Cohen, MS Frysinger, R Shellock, FG AF Bhidayasiri, R Bronstein, JM Sinha, S Krahl, SE Ahn, S Behnke, EJ Cohen, MS Frysinger, R Shellock, FG TI Bilateral neuro stimulation systems used for deep brain stimulation: in vitro study of MRI-related heating at 1.5 T and implications for clinical imaging of the brain SO MAGNETIC RESONANCE IMAGING LA English DT Article DE deep brain stimulation; magnetic resonance imaging safety; neurostimulation systems; implants; specific absorption rate; Parkinson's disease ID VARYING MAGNETIC-FIELDS; SUBTHALAMIC NUCLEUS; IMPLANTED NEUROSTIMULATORS; ELECTRODES; DEVICES; RECOMMENDATIONS; 1.5-TESLA; DYSTONIA; DISEASE AB Deep brain stimulation (DBS) is used increasingly in the field of movement disorders. The implanted electrodes create not only a prior risk to patient safety during MRI, but also a unique opportunity in the collection of functional MRI data conditioned by direct neural stimulation. We evaluated MRI-related heating for bilateral neurostimulation systems used for DBS with an emphasis on assessing clinically relevant imaging parameters. Magnetic resonance imaging was performed using transmit body radiofrequency (RF) coil and receive-only head RF coil at various specific absorption rates (SARs) of RF power. In vitro testing was performed using a gel-filled phantom with temperatures recorded at the electrode tips. Each DBS electrode was positioned with a single extension loop around each pulse generator and a single loop at the "head" end of the phantom. Various pulse sequences were used for MRI including fast spin-echo, echo-planar imaging, magnetization transfer contrast and gradient-echo techniques. The MRI sequences had calculated whole-body averaged SARs and local head SARs ranging from 0.1 to 1.6 W/kg and 0.1 to 3.2 W/kg, respectively. Temperature elevations of less than 1.0&DEG; C were found with the fast spin-echo, magnetization transfer contrast, gradient-echo and echo-planar clinical imaging sequences. Using the highest SAR levels, wholebody averaged, 1.6 W/kg, local exposed-body, 3.2 W/kg, and local head, 2.9 W/kg, the temperature increase was 2.1&DEG; C. These results showed that temperature elevations associated with clinical sequences were within an acceptable physiologically safe range for the MR conditions used in this evaluation, especially for the use of relatively low SAR levels. Notably, these findings are highly specific to the neurostimulation systems, device positioning technique, MR system and imaging conditions used in this investigation. © 2005 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, Med Ctr, Reed Neurol Res Ctr, Dept Neurol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Med Ctr, Dept Radiol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Med Ctr, Dept Psychiat, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Med Ctr, Dept Biomed Engn, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Med Ctr, Div Neurosurg, Los Angeles, CA 90095 USA. Univ So Calif, Parkinsons Dis Res Educ & Clin Ctr, W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. Univ So Calif, Keck Sch Med, Los Angeles, CA 90073 USA. RP Bhidayasiri, R (reprint author), Univ Calif Los Angeles, Med Ctr, Reed Neurol Res Ctr, Dept Neurol, Los Angeles, CA 90095 USA. EM rbh@ucla.edu OI Bhidayasiri, Roongroj/0000-0002-6901-2064 FU NIDA NIH HHS [DA15549]; NINDS NIH HHS [NS44575-01] NR 29 TC 35 Z9 35 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0730-725X J9 MAGN RESON IMAGING JI Magn. Reson. Imaging PD MAY PY 2005 VL 23 IS 4 BP 549 EP 555 DI 10.1016/j.mri.2005.02.007 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 933DA UT WOS:000229603200004 PM 15919600 ER PT J AU Palmer, AA Verbitsky, M Suresh, R Kamens, HM Reed, CL Li, N Burkhart-Kasch, S McKinnon, CS Belknap, JK Gilliam, TC Phillips, TJ AF Palmer, AA Verbitsky, M Suresh, R Kamens, HM Reed, CL Li, N Burkhart-Kasch, S McKinnon, CS Belknap, JK Gilliam, TC Phillips, TJ TI Gene expression differences in mice divergently selected for methamphetamine sensitivity SO MAMMALIAN GENOME LA English DT Article ID QUANTITATIVE-TRAIT LOCI; FUNCTIONAL GENOMICS APPROACH; NUCLEUS-ACCUMBENS; CANDIDATE GENES; LOCOMOTOR STIMULATION; DOPAMINE RELEASE; DRUG-ADDICTION; COMPLEX TRAITS; ALCOHOL; COCAINE AB In an effort to identify genes that may be important for drug-abuse liability, we mapped behavioral quantitative trait loci (bQTL) for sensitivity to the locomotor stimulant effect of methamphetamine (MA) using two mouse lines that were selectively bred for high MA-induced activity (HMACT) or low MA-induced activity (LMACT). We then examined gene expression differences between these lines in the nucleus accumbens, using 20 U74Av2 Affymetrix microarrays and quantitative polymerase chain reaction (qPCR). Expression differences were detected for several genes, including Casein Kinase I Epsilon (Csnkle), glutamate receptor, ionotropic, AMPA1 (GluR1), GABA B1 receptor (Gabbr1), and dopamine- and cAMP-regulated phosphoprotein of 32 kDa (Darpp-32). We used the www.WebQTL.org database to identify QTL that regulate the expression of the genes identified by the microarrays (expression QTL; eQTL). This approach identified an eQTL for Csnkle on Chromosome 15 (LOD = 3.8) that comapped with a bQTL for the MA stimulation phenotype (LOD = 4.5), suggesting that a single allele may cause both traits. The chromosomal region containing this QTL has previously been associated with sensitivity to the stimulant effects of cocaine. These results suggest that selection was associated with (and likely caused) altered gene expression that is partially attributable to different frequencies of gene expression polymorphisms. Combining classical genetics with analysis of whole-genome gene expression and bioinformatic resources provides a powerful method for provisionally identifying genes that influence complex traits. The identified genes provide excellent candidates for future hypothesis driven studies, translational genetic studies, and pharmacological interventions. C1 Columbia Univ, Columbia Genome Ctr, New York, NY 10032 USA. Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA. Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Portland Alcohol Res Ctr, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Res Serv, Portland, OR 97239 USA. Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA. RP Palmer, AA (reprint author), Columbia Univ, Columbia Genome Ctr, 1150 St Nicholas Ave, New York, NY 10032 USA. EM aap20l0@columbia.edu RI Palmer, Abraham/L-2158-2014 OI Palmer, Abraham/0000-0003-3634-0747; Kamens, Helen/0000-0001-5085-8847 FU NIAAA NIH HHS [AA07468]; NIDA NIH HHS [DA10913]; NIMH NIH HHS [MH70933] NR 57 TC 67 Z9 69 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0938-8990 J9 MAMM GENOME JI Mamm. Genome PD MAY PY 2005 VL 16 IS 5 BP 291 EP 305 DI 10.1007/s00335-004-2451-8 PG 15 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA 933NS UT WOS:000229640800001 PM 16104378 ER PT J AU Pickard, AS Knight, SJ AF Pickard, AS Knight, SJ TI Proxy evaluation of health-related quality of life - A Conceptual framework for understanding multiple proxy perspectives SO MEDICAL CARE LA English DT Article DE proxy; health status; caregiving; quality of life; provider/patient communication ID METASTATIC PROSTATE-CANCER; SIGNIFICANT OTHERS; RESPONSE COMPARABILITY; DECISION-MAKING; CLINICAL-TRIALS; UTILITIES INDEX; CHRONIC DISEASE; CARE PROVIDERS; FAMILY-MEMBERS; PATIENT HEALTH AB Proxy assessment of health-related quality of life (HRQL) may be sought to substitute for, or to complement, patient self-assessment. The viewpoint from which the proxy is asked to assess the patient is a subtle yet important aspect of proxy assessment. Proxy assessments can be elicited by asking a proxy to assess the patient as they think the patient would respond (ie, proxy-patient perspective) or for the proxy to provide their own perspective on the patient's HRQL (ie, proxy-proxy perspective). In this article, we introduce a framework for differentiating between and understanding HRQL assessments according to rater viewpoint. The difference between patient self-assessment and the proxy-patient perspective is defined as the inter-rater gap, whereas the difference between the proxy-patient and proxy-proxy perspective is described as the intra-proxy gap. The inter-rater gap represents the difference between patient self-assessed HRQL and the proxy ability to comprehend the patient view. The extent to which the proxy-proxy perspective is informative will depend upon the proxy's ability to provide reinforcing or complementary information, ie, represented by the intraproxy gap, on the HRQL of the patient. We refer to the framework to emphasize the importance of delineating between proxy perspectives in study design and HRQL measurement and to guide inquiries into the validity and interpretation of the meaningfulness of the proxy HRQL assessments from each viewpoint. Future research and use of proxy raters of HRQL in clinical trials, population health monitoring, resource allocation, and clinical management can be informed by explicit consideration of the suggested framework. C1 Univ Illinois, Coll Pharm, Ctr Pharmacoecon Res, Chicago, IL 60612 USA. Univ Illinois, Coll Pharm, Dept Pharm, Chicago, IL 60612 USA. San Francisco Vet Affairs Med Ctr, Hlth & Urol Serv, Dept Vet Affairs,Res Enhancement Award Program Hl, Interdisciplinary Res Program Improve Care Older, San Francisco, CA USA. Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. RP Pickard, AS (reprint author), Univ Illinois, Coll Pharm, Ctr Pharmacoecon Res, Room 164,MC 886,833 S Wood St, Chicago, IL 60612 USA. EM pickardl@uic.edu FU NCI NIH HHS [R03 CA10839-01, R03 CA108395-01] NR 66 TC 75 Z9 77 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD MAY PY 2005 VL 43 IS 5 BP 493 EP 499 DI 10.1097/01.mlr.0000160419.27642.a8 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 921XE UT WOS:000228798100011 PM 15838415 ER PT J AU Atherly, A Hebert, PL Maciejewski, ML AF Atherly, A Hebert, PL Maciejewski, ML TI An analysis of disenrollment from Medicare managed care plans by medicare beneficiaries with diabetes SO MEDICAL CARE LA English DT Article DE medicare; managed care; diabetes; disenrollment ID FEE-FOR-SERVICE; HEALTH-MAINTENANCE-ORGANIZATIONS; PREPAID GROUP-PRACTICE; RHEUMATOID-ARTHRITIS; CHRONICALLY ILL; OUTCOMES; HMOS; SYSTEMS; HYPERTENSION; SPECIALTIES AB Research Objective: The purpose of this work is to determine whether high-cost high-risk Medicare patients with diabetes in managed care plans disenroll more quickly than lower-cost lower-risk Medicare patients with diabetes, If high-cost high-risk patients with diabetes do disenroll more quickly, Medicare managed care plans benefit financially from favorable disenrollment. Study Design: Time in a health maintenance organization (HMO) was modeled using a duration model with the number of months in the HMO as the dependent variable, controlling for censoring. Data were drawn from a representative sample of Medicare patients with diabetes in the FFS sector in 1994. The panel was followed for 4 years, 1995-1998. The sample included all 6839 individuals who enrolled in a Medicare HMO for at least 1 month during the 48-month observation window. Principal Findings: We found a statistically significant negative association between the time in an HMO and pre-enrollment Part B expenditures (beta = -0.00001, t = -4.39) and any Part A expenditures (beta = -0.465, t = -1.98), and 2 of 4 diabetic complications (heart complications: beta = -0.0773 t = -4.61, vision complications beta = -0.2474, t = -1.94). Of the plan characteristics, only the drug benefit variable (beta = 0.151, t = 5.64) had a statistically significant coefficient. C1 Emory Univ, Dept Hlth Policy & Management, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. Mt Sinai Sch Med, Dept Hlth Policy, New York, NY 10029 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, NE Ctr Outcomes Res Older Adults, Seattle, WA 98195 USA. RP Atherly, A (reprint author), Emory Univ, Dept Hlth Policy & Management, Rollins Sch Publ Hlth, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. EM aatherl@sph.emory.edu FU AHRQ HHS [HS500-92-0014] NR 28 TC 6 Z9 6 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD MAY PY 2005 VL 43 IS 5 BP 500 EP 506 DI 10.1097/01.mlr.0000160420.82977.ae PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 921XE UT WOS:000228798100012 PM 15838416 ER PT J AU Gonzalez, GM Fothergill, AW Sutton, DA Rinaldi, MG Loebenberg, D AF Gonzalez, GM Fothergill, AW Sutton, DA Rinaldi, MG Loebenberg, D TI In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi SO MEDICAL MYCOLOGY LA English DT Article DE fluconazole; itraconazole; posaconazole; ravuconazole; voriconazole ID AMPHOTERICIN-B; ORAL TRIAZOLE; ITRACONAZOLE; VORICONAZOLE; SUSCEPTIBILITIES; SCEDOSPORIUM; ASPERGILLUS; INFECTION; EFFICACY; ER-30346 AB The in vitro activities of three new triazoles were determined and compared to those of itraconazole and fluconazole against 306 clinical isolates of Blastomyces dermatitidis, Cladophialophora carrionii, Coccidioides immitis, Fonsecaea pedrosoi, Fusarium spp., Histoplasma capsulatum, Paecilomyces lilacinus, Pseudallescheria boydii and Sporothrix schenckii. Minimum inhibitory concentrations ( MIC) were determined by a broth macrodilution method of the National Committee for Clinical Laboratory Standards M38-A procedure. Itraconazole ( geometric mean MIC, 0.16-0.65 mu g/ml), voriconazole ( geometric mean MIC, 0.18-1.44 mu g/ml), ravuconazole ( geometric mean MIC, 0.18-1.09 mu g/ml), and posaconazole ( geometric mean MIC, 0.18-1.38 mu g/ml), had relatively uniform values showing potent in vitro inhibitory activity against B. dermatitidis, C. carrionii, C. immitis, F. pedrosoi, H. capsulatum, and S. schenckii. The in vitro activity was variable with strains of P. boydii, P. lilacinus and Fusarium spp. C1 Univ Autonoma Nuevo Leon, Dept Microbiol, Fac Med, Colonia Mitras Ctr, Monterrey 64460, NL, Mexico. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Schering Plough Res Inst, Kenilworth, NJ USA. RP Gonzalez, GM (reprint author), Univ Autonoma Nuevo Leon, Dept Microbiol, Fac Med, Colonia Mitras Ctr, Madero & Dr Eduardo A Pequeno S-N, Monterrey 64460, NL, Mexico. EM gmglez@yahoo.com.mx NR 22 TC 60 Z9 65 U1 0 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1369-3786 J9 MED MYCOL JI Med. Mycol. PD MAY PY 2005 VL 43 IS 3 BP 281 EP 284 DI 10.1080/13693780500088416 PG 4 WC Infectious Diseases; Mycology; Veterinary Sciences SC Infectious Diseases; Mycology; Veterinary Sciences GA 938HT UT WOS:000229991200010 PM 16010855 ER PT J AU Zemlin, M Ippolito, GC Zemlin, C Link, J Monestier, M Schroeder, HW AF Zemlin, M Ippolito, GC Zemlin, C Link, J Monestier, M Schroeder, HW TI Adult lupus-prone MRL/MpJ(2+) mice express a primary antibody repertoire that differs in CDR-H3 length distribution and hydrophobicity from that expressed in the C3H parental strain SO MOLECULAR IMMUNOLOGY LA English DT Article; Proceedings Paper CT 2nd International Con ference on B Cells and Autoimmunity - New Concepts and Therapeutiv Perspective CY JUL 15-18, 2004 CL Quebec City, CANADA DE MRL; auto-antibodies; immunoglobulin heavy chain complernentarity determining region hydrophobicity; B-cell repertoire ID COMPLEMENTARITY-DETERMINING REGION; B-CELL DEVELOPMENT; AMINO-ACID-COMPOSITION; IG HEAVY-CHAINS; V-H; SOMATIC MUTATION; MRL MICE; AUTOIMMUNE ANTIBODIES; COMBINING SITE; CDR3 REGIONS AB Anti-dsDNA antibodies tend to be enriched for heavy chain complementarity determining region 3 (CDR-H3) intervals of above average length that contain an increased frequency of charged amino acids. It is unclear whether these types of CDR-H3s are more common in the primary B-cell repertoire of auto-immune prone strains or whether their increased prevalence in affected individuals reflects positive selection and expansion of atypical CDR-H3s in the pathogenic response to self-antigen. Here, we present evidence that when compared to C3H, a MRL/MpJ(2+) parental strain, CDR-H3 intervals from pre-B cells of adult lupus-prone MRL/MpJ(2+) mice are longer on average and are enriched for charged amino acids. The predicted prevalence of deformed loops per Shirai H3 criteria is also higher. In contrast, the frequency of charge, the distribution of length, and the pattern of predicted deformed loop structures did not differ in sequences obtained from neonates of the same two strains. These observations suggest that the mechanisms that serve to shape the initial CDR-H3 repertoire in adults, but not neonates, are being regulated differently in C3H versus MRL/MpJ(2+). Dysregulation of the adult pre-B CDR-H3 antibody repertoire could be a contributing factor for the development of florid auto-immune disease in MRL/MpJ(2+) mice. (c) 2004 Elsevier Ltd. All rights reserved. C1 Univ Alabama, Div Dev & Clin Immunol, Birmingham, AL 35294 USA. Univ Alabama, Dept Med, Birmingham, AL 35294 USA. Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA. Portland Vet Affairs Med Ctr, Portland, OR 97207 USA. Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA. Univ Texas, Inst Cellular & Mol Biol Mol Genet & Microbiol, Austin, TX 78712 USA. Univ Marburg, Dept Gynecol Gynecol Oncol & Endocrinol, D-35037 Marburg, Germany. Univ Marburg, Clin Neonatol & Neuropediat, D-35037 Marburg, Germany. RP Schroeder, HW (reprint author), Univ Alabama, Div Dev & Clin Immunol, WTI 378,1530 3rd Ave S, Birmingham, AL 35294 USA. EM harry.schroeder@ccc.uab.edu OI Link, Jason/0000-0002-6892-0431 FU NIAID NIH HHS [R01 AI047322, AI48115, AI42732, R01 AI048115]; NIAMS NIH HHS [AR050777, R21 AR050777] NR 48 TC 9 Z9 9 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD MAY PY 2005 VL 42 IS 7 BP 789 EP 798 DI 10.1016/j.molimm.2004.07.049 PG 10 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA 923DG UT WOS:000228888600006 PM 15829267 ER PT J AU Kochi, Y Yamada, R Suzuki, A Harley, JB Shirasawa, S Sawada, T Bae, SC Tokuhiro, S Chang, XT Sekine, A Takahashi, A Tsunoda, T Ohnishi, Y Kaufman, KM Kang, CSP Kang, CW Otsubo, S Yumura, W Mimori, A Koike, T Nakamura, Y Sasazuki, T Yamamoto, K AF Kochi, Y Yamada, R Suzuki, A Harley, JB Shirasawa, S Sawada, T Bae, SC Tokuhiro, S Chang, XT Sekine, A Takahashi, A Tsunoda, T Ohnishi, Y Kaufman, KM Kang, CSP Kang, CW Otsubo, S Yumura, W Mimori, A Koike, T Nakamura, Y Sasazuki, T Yamamoto, K TI A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities SO NATURE GENETICS LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENETIC SUSCEPTIBILITY; REVISED CRITERIA; CHROMOSOME 1Q21; B-CELLS; FAMILY; POLYMORPHISMS; IDENTIFICATION; POPULATION; PSORIASIS AB Rheumatoid arthritis is a common autoimmune disease with a complex genetic etiology. Here we identify a SNP in the promoter region of FCRL3, a member of the Fc receptor-like family, that is associated with susceptibility to rheumatoid arthritis ( odds ratio = 2.15, P = 0.00000085). This polymorphism alters the binding affinity of nuclear factor-κ B and regulates FCRL3 expression. We observed high FCRL3 expression on B cells and augmented autoantibody production in individuals with the disease-susceptible genotype. We also found associations between the SNP and susceptibility to autoimmune thyroid disease and systemic lupus erythematosus. FCRL3 may therefore have a pivotal role in autoimmunity. C1 RIKEN, SNP Res Ctr, Lab Rheumat Dis, Yokohama, Kanagawa 2300045, Japan. Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo 1130033, Japan. Univ Oklahoma, Oklahoma City, OK 73104 USA. US Dept Vet Affairs, Oklahoma City, OK 73104 USA. Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA. Int Med Ctr Japan, Tokyo 1628655, Japan. Hanyang Univ, Hosp Rheumat Dis, Div Rheumatol, Dept Internal Med, Seoul 133792, South Korea. RIKEN, SNP Res Ctr, Lab SNP Anal, Yokohama, Kanagawa 2300045, Japan. RIKEN, SNP Res Ctr, Lab Genotyping, Yokohama, Kanagawa 2300045, Japan. RIKEN, SNP Res Ctr, Lab Med Informat, Yokohama, Kanagawa 2300045, Japan. Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea. Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo 1088639, Japan. Tokyo Womens Med Univ, Kidney Ctr, Dept Med, Tokyo 1628666, Japan. Hokkaido Univ, Sch Med, Dept Med 2, Sapporo, Hokkaido 0608638, Japan. RIKEN, SNP Res Ctr, Res Grp Personalized Med, Yokohama, Kanagawa 2300045, Japan. RP Yamada, R (reprint author), RIKEN, SNP Res Ctr, Lab Rheumat Dis, Yokohama, Kanagawa 2300045, Japan. EM ryamada@src.riken.go.jp RI Kang, Changwon/C-1938-2011; Tsunoda, Tatsuhiko/K-2061-2014; Yamamoto, Kazuhiko/N-5096-2015 FU NCRR NIH HHS [P20 RR020143]; NIAID NIH HHS [R01 AI024717]; NIAMS NIH HHS [P01 AR049084, R01 AR042460]; NIDCR NIH HHS [R01 DE015223] NR 50 TC 239 Z9 262 U1 0 U2 12 PU NATURE PUBLISHING GROUP PI NEW YORK PA 345 PARK AVENUE SOUTH, NEW YORK, NY 10010-1707 USA SN 1061-4036 J9 NAT GENET JI Nature Genet. PD MAY PY 2005 VL 37 IS 5 BP 478 EP 485 DI 10.1038/ng1540 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 922TU UT WOS:000228862300016 PM 15838509 ER PT J AU Walker, M Meekins, G Hu, SC AF Walker, M Meekins, G Hu, SC TI Yoga neuropathy - A snoozer SO NEUROLOGIST LA English DT Article DE sciatic nerve; yoga; compression neuropathy ID SATURDAY NIGHT PALSY; SCIATIC NEUROPATHY AB Sciatic nerve compression very rarely occurs bilaterally. The authors present a woman with profound lower extremity weakness and sensory abnormality after falling asleep in the head-to-knees yoga position (also called "Paschimottanasana"). Clinical and electrodiagnostic findings are discussed in detail and a brief review of the literature is presented. C1 Univ Washington, Dept Neurol, Med Ctr, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Walker, M (reprint author), Univ Washington, Dept Neurol, Med Ctr, 1959 NE Pacif,Box 356465, Seattle, WA 98195 USA. EM MWalkerMD@aol.com NR 5 TC 15 Z9 15 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1074-7931 J9 NEUROLOGIST JI Neurologist PD MAY PY 2005 VL 11 IS 3 BP 176 EP 178 DI 10.1097/01.nrl.0000159986.75426.d5 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 925KY UT WOS:000229053200005 PM 15860140 ER PT J AU Dackis, CA O'Brien, CP AF Dackis, CA O'Brien, CP TI Clinical implications of cocaine-induced cortical depression SO NEUROPSYCHOPHARMACOLOGY LA English DT Letter ID DEPENDENCE C1 Univ Penn, Sch Med, Treatment Res Ctr, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Dackis, CA (reprint author), Univ Penn, Sch Med, Treatment Res Ctr, 3900 Chestnut St, Philadelphia, PA 19104 USA. EM dackis@mail.med.upenn.edu NR 8 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD MAY PY 2005 VL 30 IS 5 BP 1033 EP 1033 DI 10.1038/sj.npp.1300701 PG 1 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 917HX UT WOS:000228452800019 PM 15841088 ER PT J AU Patel, V Shrager, JB AF Patel, V Shrager, JB TI Which patients with stage III non-small cell lung cancer should undergo surgical resection? SO ONCOLOGIST LA English DT Article DE non-small cell lung carcinoma; neoadjuvant therapy; pulmonary surgical procedures; neoplasm staging ID COMPARING PERIOPERATIVE CHEMOTHERAPY; SATELLITE NODULES; PLEURAL SPREAD; SURGERY; TRIAL; SURVIVAL; CARCINOMA; METASTASES; PROGNOSIS; REVISIONS AB The treatment of patients with stage III NSCLC remains controversial. Stage III NSCLC comprises a fairly heterogeneous group of tumors, and furthermore only sparse data from randomized clinical trials exist to guide therapy decisions. This review article proposes a management algorithm for patients with stage III NSCLC that is based upon the currently available data on surgical therapy, chemotherapy, and radiation therapy. By necessity, given the paucity of strong data, a good deal of opinion is offered. The choice to proceed with aggressive, combined modality treatment is presented in light of extent of local disease as well as patient performance status. C1 Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. RP Shrager, JB (reprint author), Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA. EM jshrag@mail.med.upenn.edu NR 36 TC 11 Z9 12 U1 0 U2 1 PU ALPHAMED PRESS PI MIAMISBURG PA ONE PRESTIGE PLACE, STE 290, MIAMISBURG, OH 45342-3758 USA SN 1083-7159 J9 ONCOLOGIST JI Oncologist PD MAY PY 2005 VL 10 IS 5 BP 335 EP 344 DI 10.1634/theoncologist.10-5-335 PG 10 WC Oncology SC Oncology GA 925BH UT WOS:000229026000014 PM 15851792 ER PT J AU Woodard, LD Hernandez, MT Lees, E Petersen, LA AF Woodard, LD Hernandez, MT Lees, E Petersen, LA TI Racial differences in attitudes regarding cardiovascular disease prevention and treatment: a qualitative study SO PATIENT EDUCATION AND COUNSELING LA English DT Article; Proceedings Paper CT 25th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 01-05, 2002 CL ATLANTA, GA SP Soc Gen Internal Med DE coronary heart disease; racial disparities; physician-patient relationship ID ACUTE MYOCARDIAL-INFARCTION; CORONARY HEART-DISEASE; NUTRITION EXAMINATION SURVEY; AFRICAN-AMERICANS; MEDICAL-RESEARCH; SECONDARY PREVENTION; EDUCATION-PROGRAM; NATIONAL-HEALTH; MENTAL STRESS; UNITED-STATES AB The objective of this study was to explore coronary heart disease (CHD) health care experiences and beliefs of African-American and white patients to elicit potential causes of racial disparities in CHD outcomes. Twenty-four patients (14 white, 10 African-American) with established CHD participated in one of four focus groups. Using qualitative methods, verbatim transcripts of the groups were analyzed by independent investigators to identify key themes. We identified four themes: risk factor knowledge, physician-patient relationship, medical system access, and treatment beliefs. Racial differences were apparent in the experience of racism as a stress, knowledge of specifics of CHD risk factors, and assertiveness in the physician-patient relationship. These findings suggest that strategies to improve risk factor knowledge and to enable African-American patients to become active partners in their medical care may lead to improved CHD morbidity and mortality in this population. The efficacy of such interventions would need to be tested in further work. (c) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Houston Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Dept Vet Affairs, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. Houston Baptist Univ, Houston, TX USA. RP Woodard, LD (reprint author), Houston Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence, Dept Vet Affairs, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. EM lwoodard@bcm.tmc.edu FU AHRQ HHS [P01 HS10876]; BHP HRSA HHS [1 T32 PE 10031-01] NR 44 TC 14 Z9 14 U1 1 U2 3 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD MAY PY 2005 VL 57 IS 2 BP 225 EP 231 DI 10.1016/j.pec.2004.06.004 PG 7 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 935UM UT WOS:000229808900012 PM 15911197 ER PT J AU Anselmi, L Lakhter, A Hirano, AA Tonini, M Sternini, C AF Anselmi, L Lakhter, A Hirano, AA Tonini, M Sternini, C TI Expression of galanin receptor messenger RNAs in different regions of the rat gastrointestinal tract SO PEPTIDES LA English DT Article DE real-time RT-PCR; intestine; stomach; enteric nervous system ID PIG SMALL-INTESTINE; FEEDING-BEHAVIOR; GUT; TRANSMISSION; PHARMACOLOGY; CONTRACTION; PROJECTIONS; ACTIVATION; MOTILITY; SUBTYPES AB Galanin effects are mediated by three G-protein-coupled receptors: galanin receptor 1 (GalR1), GalR2 and GalR3. We quantified mRNA levels of GalR1, GalR2 and GalR3 in the rat stomach, small and large intestine using real-time RT-PCR. All three GalR mRNAs were detected throughout the gut at different levels. GalR1 and GalR2 mRNA levels were higher in the large than in the small intestine. GalR2 mRNA was most abundant in the stomach. GalR3 mRNA levels were generally quite low. The differential regional distribution of GalRs suggests that the complex effects of galanin in the gut are the result of activating multiple receptor subtypes, whose density, subtype and signaling vary along the gastrointestinal tract. (c) 2005 Elsevier Inc. All rights reserved. C1 VAGLAHS, CURE Digest Dis Res Ctr, Div Digest Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Pavia, Dept Physiol & Pharmacol Sci, I-27100 Pavia, Italy. RP Anselmi, L (reprint author), VAGLAHS, CURE Digest Dis Res Ctr, Div Digest Dis, Bldg 115,Room 224,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM lanselmi@mednet.ucla.edu FU NIDDK NIH HHS [DK41301, DK57037, P30 DK041301, R01 DK057037] NR 28 TC 17 Z9 17 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD MAY PY 2005 VL 26 IS 5 BP 815 EP 819 DI 10.1016/j.peptides.2004.12.011 PG 5 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 919BZ UT WOS:000228594600013 PM 15808911 ER PT J AU Siegel, JM AF Siegel, JM TI Functional implications of sleep development SO PLOS BIOLOGY LA English DT Editorial Material ID RETICULAR-FORMATION NEURONS; IN-VIVO MICRODIALYSIS; REM-SLEEP; LOCUS-COERULEUS; DEPRIVATION; PONTINE; CYCLE; ACTIVATION; DISCHARGE; RELEASE C1 Vet Adm Greater Los Angeles Hlth Care Syst, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90024 USA. RP Siegel, JM (reprint author), Vet Adm Greater Los Angeles Hlth Care Syst, Sepulveda, CA 91343 USA. EM jsiegel@ucla.edu FU NHLBI NIH HHS [R01 HL041370, R37 HL041370, P50 HL060296, HL060296, HL41370]; NIMH NIH HHS [MH64109, R01 MH064109]; NINDS NIH HHS [NS14610, R01 NS014610, R37 NS014610] NR 32 TC 9 Z9 9 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1544-9173 J9 PLOS BIOL JI PLoS. Biol. PD MAY PY 2005 VL 3 IS 5 BP 756 EP 758 AR e178 DI 10.1371/journal.pbio.0030178 PG 3 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA 926LT UT WOS:000229125400004 PM 15884980 ER PT J AU Mackin, RS Horner, MD Harvey, RT Stevens, LA AF Mackin, RS Horner, MD Harvey, RT Stevens, LA TI The relationship between neuropsychological measures and employment problems in outpatients with substance abuse SO REHABILITATION PSYCHOLOGY LA English DT Article ID ADDICTION SEVERITY INDEX; TRAUMATIC BRAIN-INJURY; DEPENDENT PATIENTS; COCAINE ABUSERS; ALCOHOL; TESTS AB Objective: To determine the relation between standard clinical neuropsychological tests and employment problems in persons with substance abuse. Participants: Sixty-four patients enrolled in an intensive outpatient substance abuse treatment program. Measures: Employment Problem Severity Score (EPSS) of the Addiction Severity Index and a comprehensive neuropsychological evaluation, including standard measures of attention, executive function, and memory. Results: Multiple regression analyses showed that response latency on the Vigilance trial of the Gordon Diagnostic System and scores on list acquisition and long-delay free recall of the California Verbal Learning Test were significant predictors of EPSS. Performance on measures of executive function did not predict EPSS. Conclusions: Neuropsychological tests may help to identify individuals at risk for employment problems, thereby improving outcomes for patients with substance abuse problems and cognitive deficits. C1 Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Mackin, RS (reprint author), Univ Calif San Francisco, Dept Psychiat, 401 Parnassus Ave,Box OVS-0984, San Francisco, CA 94143 USA. EM scottm@lppi.ucsf.edu NR 31 TC 4 Z9 4 U1 0 U2 0 PU EDUCATIONAL PUBLISHING FOUNDATION PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 0090-5550 J9 REHABIL PSYCHOL JI Rehabil. Psychol. PD MAY PY 2005 VL 50 IS 2 BP 158 EP 163 DI 10.1037/0090-5550.50.2.158 PG 6 WC Psychology, Clinical; Rehabilitation SC Psychology; Rehabilitation GA 931ND UT WOS:000229491100009 ER PT J AU Vilaichone, RK Mahachai, V Tumwasorn, S Wu, JY Graham, DY Yamaoka, Y AF Vilaichone, RK Mahachai, V Tumwasorn, S Wu, JY Graham, DY Yamaoka, Y TI Gastric mucosal cytokine levels in relation to host interleukin-1 polymorphisms and Helicobacter pylori cagA genotype SO SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY LA English DT Article DE cytokines; gastric diseases; Helicobacter pylori; interleukin-1; interleukin-8; polymorphisms ID NECROSIS-FACTOR-ALPHA; ATROPHIC GASTRITIS; VIRULENCE FACTORS; INCREASED RISK; INFECTION; GENE; CARCINOMA; DISEASE; CANCER; EXPRESSION AB Objective. The outcome of a Helicobacter pylori infection is related in part to interrelationships among H. pylori virulence factors and the H. pylori-induced mucosal response. The host inflammatory response is partly governed by polymorphisms in pro-inflammatory genes. Material and methods. Cytokine levels ( interleukin (IL)-1 beta, IL-6 and IL-8) were examined in H. pylori - infected and uninfected normal-appearing mucosa from patients with non-ulcer dyspepsia (NUD), margins of gastric ulcers and cancer tissues. Cytokine levels were compared with cagA genotypes and host interleukin ( IL)- 1 polymorphisms. Results. The study comprised 168 Thai patients. All infected patients possessed anti-CagA antibody. Gastric mucosal IL-8 levels were significantly higher in H. pylori - positive cases than in - negative cases in all three tissue types ( e. g. 1115 versus 217 pg/mg protein for NUD) ( p< 0.001). Normal-appearing but H. pylori - infected antral mucosa of patients with cagA type 1a strains had higher IL-8 levels than those with type 2a strains ( 2632 versus 1036 pg/mg protein) (p< 0.005). IL-1B-511T/ T carriers had higher antral mucosal IL-1 beta levels versus non-carriers (pg/mg protein) (T/T = 221, T/C = 178, C/C = 70) ( p = 0.005). IL-1B-511T/ T carriers also had higher IL-1 beta levels versus non-carriers in H. pylori negative patients. Conclusions. It was found that both the host factors (IL-1 polymorphisms) and bacterial factors ( cagA type 1a versus type 2a) influenced gastric mucosal cytokine levels. Future studies should concentrate on interactions among host factors ( e. g. genetics and tissue responses) and bacterial and environmental factors. C1 Thammasat Univ Hosp, Dept Med, Gastroenterol Unit, Pathum Thani, Thailand. Michael E Debakey Vet Affairs Med Ctr, Dept Med, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Chulalongkorn Univ Hosp, Dept Med, Bangkok, Thailand. Chulalongkorn Univ Hosp, Dept Microbiol, Bangkok, Thailand. RP Yamaoka, Y (reprint author), Michael E Debakey Vet Affairs Med Ctr 111D, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu NR 39 TC 24 Z9 29 U1 0 U2 2 PU TAYLOR & FRANCIS AS PI OSLO PA PO BOX 12 POSTHUSET, NO-0051 OSLO, NORWAY SN 0036-5521 J9 SCAND J GASTROENTERO JI Scand. J. Gastroenterol. PD MAY PY 2005 VL 40 IS 5 BP 530 EP 539 DI 10.1080/00365520510012299 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 920IT UT WOS:000228683300006 PM 16036505 ER PT J AU Green, MF Barnes, TR Danion, JM Gallhofer, B Meltzer, HY Pantelis, C AF Green, MF Barnes, TR Danion, JM Gallhofer, B Meltzer, HY Pantelis, C TI The FOCIS international survey on psychiatrists' opinions on cognition in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE cognitive deficit; schizophrenia; survey; functional outcome ID QUALITY-OF-LIFE; NEUROCOGNITIVE DEFICITS; CLOZAPINE; RISPERIDONE; OLANZAPINE; SYMPTOMS AB Background: The goal of this project was to develop an interview to evaluate psychiatrists' views on the nature of cognitive dysfunction in schizophrenia, its importance as a potential treatment target, and its relative importance as a treatment target across different phases of schizophrenia. Materials and methods: A survey (available in paper or on-line) consisting of 27 questions, was developed by the Focus on Cognition in Schizophrenia (FOCIS) group, and distributed in a single wave mailing to 63,295 psychiatrists in 21 countries worldwide. Results: The overall response rate was 4.7% (n=2975). The surveyed psychiatrists perceived cognition as a high treatment priority in stabilized schizophrenia patients, but less so for first episode or acute schizophrenia patients. The potential of atypical antipsychotics to improve cognitive dysfunction in schizophrenia was identified by 81% of the respondent psychiatrists. Conclusions: Cognitive deficits in people with schizophrenia are seen by clinical psychiatrists as relevant to treatment and rehabilitation plans. They were, however, regarded as a higher treatment priority in stabilized chronic rather than in first episode patients. The results suggest clinical psychiatrists need additional education regarding the nature of cognitive dysftinction in schizophrenia and its importance for psychosocial rehabilitation and community re-entry. (C) 2004 Elsevier B.V. All rights reserved. C1 Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ London Imperial Coll Sci & Technol, Div Neurosci & Psychol Med, London, England. Hop Univ, Strasbourg, France. Univ Giessen, Sch Med, Giessen, Germany. Vanderbilt Univ, Nashville, TN USA. Univ Melbourne, Neuropsychiat Ctr, Melbourne, Vic, Australia. RP Green, MF (reprint author), Univ Calif Los Angeles, Inst Neuropsychiat, Med Plaza Bldg 300,Rm 2263, Los Angeles, CA 90095 USA. EM mgreen@ucla.edu RI Meltzer, Herbert/E-8131-2013; Pantelis, Christos/H-7722-2014 OI Pantelis, Christos/0000-0002-9565-0238 NR 26 TC 13 Z9 13 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD MAY 1 PY 2005 VL 74 IS 2-3 BP 253 EP 261 DI 10.1016/j.schres.2004.05.023 PG 9 WC Psychiatry SC Psychiatry GA 904FP UT WOS:000227481800012 PM 15722004 ER PT J AU Myaskovsky, L Unikel, E Dew, MA AF Myaskovsky, L Unikel, E Dew, MA TI Effects of gender diversity on performance and interpersonal behavior in small work groups SO SEX ROLES LA English DT Article DE gender composition; group performance; interpersonal behavior ID MIXED-SEX GROUPS; JURY DELIBERATIONS; TRANSACTIVE MEMORY; SOCIAL-INTERACTION; TEAM PERFORMANCE; TOKEN STATUS; MALE-FEMALE; WOMEN; MEN; PERCEPTIONS AB We examined the separate and combined impact of gender composition and training method on both the performance and interpersonal behaviors exhibited in small work groups. Participants were scheduled in groups of three for two 1-h sessions that occurred 1 week apart. In Session 1, groups were trained to assemble the AM portion of a radio. In Session 2, groups were tested on their training. Analyses indicated that groups whose members were trained together took longer to assemble their radios and made more errors than groups whose members were trained apart. No performance differences were found between mixedgender and same-gender groups. However, women were less task-oriented in mixed-gender than in same-gender groups, but men were more task-oriented in mixed-gender than in same-gender groups. Further, solo women were less talkative than women in the majority, whereas men were more talkative when they were solos rather than in the majority. Implications for the nature of training and gender composition in groups in the workplace are discussed. C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. RP Myaskovsky, L (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr C 151-C, Pittsburgh, PA 15240 USA. EM Larissa.Myaskovsky@med.va.gov NR 74 TC 27 Z9 27 U1 6 U2 33 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0360-0025 J9 SEX ROLES JI Sex Roles PD MAY PY 2005 VL 52 IS 9-10 BP 645 EP 657 DI 10.1007/s11199-005-3732-8 PG 13 WC Psychology, Developmental; Psychology, Social; Women's Studies SC Psychology; Women's Studies GA 946IV UT WOS:000230566500008 ER PT J AU Skatrud, JB Morgan, BJ AF Skatrud, JB Morgan, BJ TI Probing the link between sleep apnea and cardiovascular disease - Comment on Phillips C; Hedner J; Berend N et al. Diurnal and obstructive sleep apnea influences on arterial stiffness and central blood pressure in men. SLEEP 2005;28(5): 604-609 SO SLEEP LA English DT Editorial Material ID POSITIVE AIRWAY PRESSURE; ENDOTHELIAL GROWTH-FACTOR; CORONARY HEART-DISEASE; SMOOTH-MUSCLE-CELLS; C-REACTIVE PROTEIN; ANGIOTENSIN-II; VASCULAR WALL; HYPERTENSION; EXPRESSION; HYPOXIA C1 William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. Univ Wisconsin, Dept Med, Madison, WI 53706 USA. Univ Wisconsin, Dept Orthoped & Rehabil, Madison, WI 53706 USA. RP Skatrud, JB (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. EM james.skatrud2@med.va.gov NR 30 TC 1 Z9 1 U1 0 U2 0 PU AMER ACADEMY SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CENTER STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD MAY 1 PY 2005 VL 28 IS 5 BP 545 EP 547 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 926PX UT WOS:000229136200003 PM 16171266 ER PT J AU Myaskovsky, L Dew, MA Switzer, GE McNulty, ML DiMartini, AF McCurry, KR AF Myaskovsky, L Dew, MA Switzer, GE McNulty, ML DiMartini, AF McCurry, KR TI Quality of life and coping strategies among lung transplant candidates and their family caregivers SO SOCIAL SCIENCE & MEDICINE LA English DT Article; Proceedings Paper CT 25th Annual Meeting of the Society-of-Behavioral-Medicine CY MAR, 2004 CL Baltimore, MD SP Soc Behav Med DE transplant candidates; caregivers; coping; quality of life (QOL); USA ID CARDIOVASCULAR HEALTH; RECIPIENTS; DEPRESSION; SIMILARITY; DEMENTIA; DISEASE; RISK AB Although numerous studies have examined coping strategies and quality of life (QOL) among patients with chronic diseases and their family caregivers, no studies have examined the reciprocal effects of patient and caregiver coping strategies on their dyad partner's QOL. Because most people who cope with stressful health experiences do so within the context of interpersonal relation ships, it is important to understand the ways in which the two partners' coping strategies may reciprocally affect each other's QOL. Adult lung transplant candidates and their caregivers (N = 114 pairs) participated in semi-structured interviews that included measures of QOL and coping with patients' health-related problems. Multivariate, canonical correlation analyses were performed to examine unique patterns of associations between coping and QOL in patient-caregiver dyads. Better patient QOL, across multiple domains, was associated with better caregiver QOL. Multiple elements of patients' coping, including greater use of active coping and emotionally oriented coping were related to generally poorer patient QOL in psychosocial and physical domains. Similarly, caregivers who used more emotionally oriented coping had poorer QOL. There was no statistically reliable relationship between either (a) patient and caregiver use of coping strategies, or (b) caregiver coping and patient QOL. However, patients' coping strategies were important correlates of caregivers' QOL. These findings belie common clinical beliefs that family members' coping responses to patients' health are likely to affect patient well-being. instead, patients' coping and QOL may be critical for understanding caregiver well-being, especially in the current era in which caregivers are assuming increased responsibility for providing patient care. (c) 2004 Elsevier Ltd. All rights reserved. C1 Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA. Dept Psychol, Pittsburgh, PA 15213 USA. Dept Med, Pittsburgh, PA 15213 USA. VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. UPMC Presbyterian, Dept Surg, Pittsburgh, PA 15213 USA. RP Myaskovsky, L (reprint author), Univ Pittsburgh, Dept Psychiat, Suite 502 Iroquois Bldg,3600 Forbes Ave, Pittsburgh, PA 15213 USA. EM myaskovskyl@uipmc.edu NR 44 TC 31 Z9 31 U1 3 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD MAY PY 2005 VL 60 IS 10 BP 2321 EP 2332 DI 10.1016/j.socscimed.2004.10.001 PG 12 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 908HX UT WOS:000227779200015 PM 15748679 ER PT J AU Rehman, SU Cope, DW Senseney, AD Brzezinski, W AF Rehman, SU Cope, DW Senseney, AD Brzezinski, W TI Thyroid disorders in elderly patients SO SOUTHERN MEDICAL JOURNAL LA English DT Review DE elderly; hyperthyroidism; hypothyroidism; thyroid disease ID HYPERTHYROIDISM; DISEASE; AGE; HYPOTHYROIDISM; DYSFUNCTION; MANAGEMENT AB Thyroid disorders are common in the elderly and are associated with significant morbidity if left untreated. Typical symptoms may be absent and may be erroneously attributed to normal aging or coexisting disease. Physical examination of the thyroid gland may not be helpful, as the gland is often shrunken and difficult to palpate. Usually only myxedema coma requires levothyroxine parenterally; all other forms of hypothyroidism can be treated with oral levothyroxine. Low-dose levothyroxine should be initiated and increased gradually over several months. In unstable elderly patients with hyperthyroidism, antithyroid medication can quickly produce a euthyroid state. Radioactive iodine therapy is more definitive and is well tolerated, effective, and preferred. Surgical thyroid ablation may be necessary in patients who fail to respond to radioactive iodine therapy and in patients with multinodular goiter. If there is a suspicion of malignant disease, early biopsy or fine needle aspiration for cytology should be considered. C1 Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Primary Care Serv Line, Charleston, SC 29425 USA. Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Geriatr Serv Line, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Olive View UCLA Med Ctr, Dept Med, Sylmar, CA 91342 USA. RP Rehman, SU (reprint author), 214 Hist Dr, Mt Pleasant, SC 29464 USA. EM Shakaib.rehman@med.va.gov NR 46 TC 14 Z9 20 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 J9 SOUTH MED J JI South.Med.J. PD MAY PY 2005 VL 98 IS 5 BP 543 EP 549 DI 10.1097/01.SMJ.0000152364.57566.6D PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 928IE UT WOS:000229264100009 PM 15954511 ER PT J AU Shifrin, AL Chirmule, N Zhang, Y Raper, SE AF Shifrin, AL Chirmule, N Zhang, Y Raper, SE TI Macrophage ablation attenuates adenoviral vector-induced pancreatitis SO SURGERY LA English DT Article ID MEDIATED GENE-TRANSFER; IN-VIVO; RECOMBINANT ADENOVIRUS; DEPLETION; EXPRESSION; MURINE; INTERLEUKIN-6; CONSEQUENCES; CYTOKINES; RESPONSES AB Background. The objective of these studies is to determine the effects of macrophage ablation on the course of acute viral pancreatitis. Macrophages secrete poinflammatory cytokines triggering local pancreatic and systemic inflammation in the acute phase of virus-induced pancreatitis. We hypothesized that ablation of macrophages should attenuate the host inflammatory response in a mouse model of adenovirus-induced pancreatitis. Methods. Liposome encapsulated dichloromethylene diphosphonate, a macrophage-depleting agent, was used before direct pancreatic injection of a recombinant adenovirus expressing a marker gene in C57Bl/6 and IL-6 knockout (KO) mice. Results. C57Bl/6 mice depleted of macrophages had diminished pancreatic inflammation in the first 24 hours after vector administration. IL-6 KO mice depleted of macrophages had more severe inflammation than similarly treated C57Bl/6 mice. C57Bl/6 mice depleted of macrophages, and IL-6 KO mice had prolonged transgene expression and diminished cytotoxic T lymphocyte responses to adenoviral vector. Mortality was highest in IL-6 KO mice depleted of macrophages. Depletion of macrophages also prevented delectable serum IL-6, IL-10, or IL-12 levels in C57Bl/6 mice. Conclusions. The data suggest that macrophages play a role in the acute inflammatory response to viral vector-induced pancreatitis and that IL-6 may be protective. Understanding of the mechanisms that initiate the host immune cascade will allow more effective use of adenoviral vector-based pancreatic gene delivery. C1 Univ Penn, Dept Surg, Hlth Syst, Philadelphia, PA 19104 USA. Merck Res Labs, Wayne, NJ USA. Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Raper, SE (reprint author), Univ Penn, Dept Surg, Hlth Syst, 4 Silverstein Pavil 3400 Spruce St, Philadelphia, PA 19104 USA. EM rapers@uphs.upenn.edu FU NIDDK NIH HHS [DK 54207, DK 47757] NR 25 TC 20 Z9 23 U1 0 U2 1 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0039-6060 J9 SURGERY JI Surgery PD MAY PY 2005 VL 137 IS 5 BP 545 EP 551 DI 10.1016/j.surg.2005.01.004 PG 7 WC Surgery SC Surgery GA 924BF UT WOS:000228952900009 PM 15855927 ER PT J AU Hershman, JM AF Hershman, JM TI In my view ... Perchlorate and thyroid function: What are the environmental issues? SO THYROID LA English DT Article ID LOW-DOSE PERCHLORATE; DRINKING-WATER; SUBCLINICAL HYPOTHYROIDISM; POTASSIUM PERCHLORATE; ARIZONA PERCHLORATE; IODINE; EXPOSURE; NEWBORNS; THYROTOXICOSIS; CONTAMINATION AB Ammonium Perchlorate, used in the solid-propellant of rocket engines, has contaminated some water supplies and represents a potential public health hazard. Its toxicity is the result of the inhibition of the sodium iodide symporter resulting in reduced iodide uptake, possibly leading to reduced production of thyroid hormone. The fetus is the most vulnerable subject. Studies of newborn screening for thyroid function have yielded conflicting results and have not measured Perchlorate or iodine intake. Based on short-term clinical studies in adults, less than 0.5 mg Perchlorate per 70-kg adult will not lower thyroid uptake of radioiodine, while 1.6 mg/kg per day will lower thyroid uptake by 20%. To avoid interference with thyroid function, the California Office of Environmental Health Hazard Assessment recommended a public health goal of 6 μ g Perchlorate per liter of drinking water, but approximately three times that concentration is likely to be safe. C1 Univ Calif Los Angeles, Sch Med, VA Greater Los Angeles Healthcare Syst, Endocrinol & Diabet Div, Los Angeles, CA 90073 USA. RP Hershman, JM (reprint author), Univ Calif Los Angeles, Sch Med, VA Greater Los Angeles Healthcare Syst, Endocrinol & Diabet Div, 111D,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jhershmn@ucla.edu NR 34 TC 16 Z9 17 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 J9 THYROID JI Thyroid PD MAY PY 2005 VL 15 IS 5 BP 427 EP 431 DI 10.1089/thy.2005.15.427 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 932JO UT WOS:000229550200005 PM 15929663 ER PT J AU Bloom, MA Barghout, V Kahler, KH Bentkover, JD Kurth, H Gralnek, IM Spiegel, B AF Bloom, MA Barghout, V Kahler, KH Bentkover, JD Kurth, H Gralnek, IM Spiegel, B TI The budget impact of tegaserod on a managed care organization formulary SO VALUE IN HEALTH LA English DT Meeting Abstract C1 Innovat Hlth Solut, Brookline, MA USA. Novartis Pharmaceut Corp, E Hanover, NJ USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, David Geffen Sch Med, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol & Hepatol, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 1098-3015 J9 VALUE HEALTH JI Value Health PD MAY-JUN PY 2005 VL 8 IS 3 BP 370 EP 370 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 918PE UT WOS:000228559300428 ER PT J AU Taha, TA Kitatani, K Bielawski, J Cho, W Hannun, YA Obeid, LM AF Taha, TA Kitatani, K Bielawski, J Cho, W Hannun, YA Obeid, LM TI Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID MEDIATED HEPATOCYTE APOPTOSIS; CELL-DEATH; TNF-ALPHA; LYSOSOMAL PERMEABILIZATION; PROTEASE PATHWAYS; SPHINGOSINE-1-PHOSPHATE; ACTIVATION; RELEASE; CASPASE AB Sphingosine kinase-1 (SK1) has emerged as a key component of cytokine responses, including roles in apoptosis, yet the specific mechanisms by which cytokines regulate SK1 in the apoptotic responses have not been studied. In this study, we show that prolonged treatment of MCF-7 cells with tumor necrosis factor (TNF) induces a dose- and time-dependent decrease in SK1 protein. Inhibition of the upstream caspase 8 by IETD significantly rescued TNF effects on SK1, yet the caspase 7 inhibitor DEVD failed to have any effect, suggesting that the decline in SK1 occurs downstream of the initiator caspase but upstream of the effector caspase. In addition to caspase activation, TNF caused disruption of lysosomes with relocation of the cysteine protease cathepsin B into the cytosol. Down-regulation of cathepsin B using small interfering RNA significantly restored SK1 levels following exposure to TNF, suggesting that SK1 loss was dependent on cathepsin B activity. The regulation of SK1 by the lysosomal protease was further supported by the colocalization of SK1 with the lysosome and cathepsin B in cells and the loss of the colocalization following exposure to TNF. The ability of cathepsin B to regulate SK1 was further corroborated by an in vitro approach where recombinant cathepsin B cleaved SK1 at multiple sites to produce several cleavage fragments. Therefore, these studies show that SK1 down-regulation by TNF is dependent on the "lysosomal pathway" of apoptosis and specifically on cathepsin B, which functions as an SK1 protease in cells. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Hosp, Div Gen Internal Med, Charleston, SC 29401 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Univ Illinois, Dept Chem, Chicago, IL 60607 USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA. EM obeidl@musc.edu OI Kitatani, Kazuyuki/0000-0002-8516-6135; obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [P01 CA097132]; NIDDK NIH HHS [DK59340] NR 21 TC 58 Z9 60 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 29 PY 2005 VL 280 IS 17 BP 17196 EP 17202 DI 10.1074/jbc.M413744200 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 919JY UT WOS:000228615500081 PM 15710602 ER PT J AU Szot, P White, SS Shen, DD Anderson, GD AF Szot, P White, SS Shen, DD Anderson, GD TI Valproic acid, but not lamotrigine, suppresses seizure-induced c-fos and c-Jun mRNA expression SO MOLECULAR BRAIN RESEARCH LA English DT Article DE valproic acid; lamotrigine; c-fos; c-Jun; flurothyl; bipolar disorder; seizure ID CEREBELLAR GRANULE CELLS; CENTRAL-NERVOUS-SYSTEM; PRIMARY CULTURES; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; BIPOLAR DISORDER; CHRONIC LITHIUM; CALCIUM INFLUX; RAT-BRAIN; IN-VITRO AB Seizure-induced activity has been shown to increase the expression of immediate early genes (IEGs) c-fos and c-Jun in the CNS. Anti-epileptic drugs (AEDs) can suppress the induction of a seizure, but it is unknown if AEDs affect the expression of seizure-induced IEGs. We found that valproic acid (VPA), but not lamotrigine (LTG), was capable of suppressing seizure-induced c-fos and c-Jun mRNA expression in rats despite a similar anticonvulsant effect. LTG in some regions of the CM enhanced seizure-induced IEG expression. These studies indicate that the older AED (VPA), as compared to the newer AED (LTG), can suppress seizure-induced IEG expression. The consequence of this suppression of IEGs following a generalized seizure may be viewed either as a neuroprotective or detrimental effect upon the brain. Published by Elsevier B.V. C1 VA Puget Sound Hlth Care Syst, MIRECC, Seattle, WA 98108 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Pharm, Seattle, WA 98195 USA. RP Szot, P (reprint author), VA Puget Sound Hlth Care Syst, MIRECC, 1660 S Columbian Way, Seattle, WA 98108 USA. EM szot@u.washington.edu NR 35 TC 7 Z9 7 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0169-328X J9 MOL BRAIN RES JI Mol. Brain Res. PD APR 27 PY 2005 VL 135 IS 1-2 BP 285 EP 289 DI 10.1016/j.molbrainres.2004.11.011 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 927PN UT WOS:000229206100029 ER PT J AU van Gorp, WG Hinkin, CH AF van Gorp, WG Hinkin, CH TI Triple trouble - Cognitive deficits from hepatitis C, HIV, and methamphetamine SO NEUROLOGY LA English DT Editorial Material ID NEUROPSYCHOLOGICAL IMPAIRMENT; DYSFUNCTION; IMPACT; VIRUS C1 Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10022 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP van Gorp, WG (reprint author), Columbia Univ, Coll Phys & Surg, Dept Psychiat, 16 E 60th St,Suite 400, New York, NY 10022 USA. EM wvangorp@aol.com NR 10 TC 6 Z9 7 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR 26 PY 2005 VL 64 IS 8 BP 1328 EP 1329 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 920AY UT WOS:000228660600002 PM 15851716 ER PT J AU Ostrem, JL Kang, GA Subramanian, I Guarnieri, M Hubble, J Rabinowicz, AL Bronstein, J AF Ostrem, JL Kang, GA Subramanian, I Guarnieri, M Hubble, J Rabinowicz, AL Bronstein, J TI The effect of entacapone on homocysteine levels in Parkinson disease SO NEUROLOGY LA English DT Editorial Material ID LEVODOPA C1 Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. San Francisco Vet Affairs Med Ctr, San Francisco, CA USA. Parkinsons Dis Res Educ & Clin Ctr, San Francisco, CA USA. Novartis Pharmaceut Corp, E Hanover, NJ USA. RP Bronstein, J (reprint author), Univ Calif Los Angeles, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90095 USA. EM jbronste@ucla.edu NR 6 TC 17 Z9 18 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR 26 PY 2005 VL 64 IS 8 BP 1482 EP 1482 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 920AY UT WOS:000228660600044 PM 15851757 ER PT J AU Colston, JT de la Rosa, SD Strader, JR Anderson, MA Freeman, GL AF Colston, JT de la Rosa, SD Strader, JR Anderson, MA Freeman, GL TI H2O2 activates Nox4 through PLA(2)-dependent arachidonic acid production in adult cardiac fibroblasts SO FEBS LETTERS LA English DT Article DE Nox4; NADPH oxidase; reactive oxygen species; cardiac fibroblasts; arachidonic acid ID SMOOTH-MUSCLE-CELLS; NADPH OXIDASE; NAD(P)H OXIDASE; SIGNALING CASCADE; PHORBOL ESTER; SUPEROXIDE; EXPRESSION; SYSTEM; KINASE; ALPHA AB Stimulated production of reactive oxygen species (ROS) by plasma membrane-associated nicotinamide adenine dinucleotide phosphate oxidases (Nox) in non-phagocytic cells regulates a number of biological processes including growth, vessel tone, and oxygen sensing. The purpose of this study was to investigate H2O2-stimulated ROS production in primary adult cardiac fibroblasts (CF). Results demonstrate that CF express an H2O2-inducible oxidant generating system that is inhibitable by diphenylene iodonium (DPI) and sensitive to antioxidants. In addition to H2O2, generation of ROS was stimulated potently by 1-oleoyl-2-acetyl-sn-glycerol (OAG) and arachidonic acid (AA) in a protein kinase C-independent manner. Pretreatment with arachidonyl trifluoromethyl ketone was nearly as effective as DPI at reducing H2O2- and OAG-stimulated oxidant generation indicating a central role for phospholipase A(2) (PLA(2)) in this signaling pathway. Co-stimulation with H2O2 and OAG did not increase ROS generation as compared to OAG alone suggesting both agonists signal through a shared, rate-limited enzymatic pathway involving PLA(2). Co-stimulation with H2O2 and AA had additive effects indicating these two agonists stimulate oxidant production through a parallel activation pathway. Reverse transcriptase-coupled polymerase chain reaction and Western blotting demonstrate primary cardiac fibroblasts express transcripts and protein for Nox4, p22, p47, and p67 phox. Transfections with Nox4 small inhibitory ribonucleic acid oligonucleotides or p22 phox antisense oligonucleotides significantly downregulated stimulated Nox activity. Inhibitors of nitric oxide synthases were without effect. We conclude adult CF express Nox4/p22 phox-containing oxidant generating complex activated by H2O2, OAG, and AA through a pathway that requires activation of PLA(2). (c) 2005 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Janey Briscoe Ctr Excellence Cardiovasc Dis,Div C, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Colston, JT (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Janey Briscoe Ctr Excellence Cardiovasc Dis,Div C, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA. EM colstonj@uthscsa.edu NR 41 TC 56 Z9 59 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-5793 J9 FEBS LETT JI FEBS Lett. PD APR 25 PY 2005 VL 579 IS 11 BP 2533 EP 2540 DI 10.1016/j.febslet.2005.03.057 PG 8 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 921IA UT WOS:000228756400048 PM 15848200 ER PT J AU Soares, JC Kochunov, P Monkul, ES Nicoletti, MA Brambilla, P Sassi, RB Mallinger, AG Frank, E Kupfer, DJ Lancaster, J Fox, P AF Soares, JC Kochunov, P Monkul, ES Nicoletti, MA Brambilla, P Sassi, RB Mallinger, AG Frank, E Kupfer, DJ Lancaster, J Fox, P TI Structural brain changes in bipolar disorder using deformation field morphometry SO NEUROREPORT LA English DT Article DE bipolar disorder; mood disorders; magnetic resonance imaging; morphometry; neuroimaging; structural ID REGIONAL SPATIAL NORMALIZATION; VENTRICULAR ENLARGEMENT; MOOD DISORDERS; SCHIZOPHRENIA; ABNORMALITIES; TARGET; MRI AB The objective of this study was to investigate anatomical brain abnormalities in adult bipolar patients using a deformation field morphometry technique. Our sample consisted of 32 right-handed bipolar I patients (men/women=16/16) and 32 right-handed, age and gender matched healthy controls. Deformation field morphometry analysis was performed on three-dimensional spoiled gradient recalled acquisition images. We found genderspecific structural differences between bipolar patients and healthy individuals. Bipolar men had significantly larger lateral ventricles (especially pronounced in the left hemisphere) and smaller left dorsolateral prefrontal cortex than healthy male controls. Our results are complementary to the findings of functional imaging and post-mortem studies that demonstrate abnormalities in the dorsolateral prefrontal cortex in bipolar patients.© 2005 Lippincott Williams & Wilkins. C1 Audie L Murpy Div, S Texas Vet Hlth Care Syst, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX USA. Audie L Murpy Div, S Texas Vet Hlth Care Syst, Dept Radiol, San Antonio, TX USA. Univ Texas, Ctr Hlth Sci, Res Imaging Ctr, San Antonio, TX 78285 USA. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. Univ Udine, Dept Pathol & Expt & Clin Med, Sect Psychiat, I-33100 Udine, Italy. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. RP Soares, JC (reprint author), Audie L Murpy Div, S Texas Vet Hlth Care Syst, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX USA. EM soares@uthscsa.edu RI Lancaster, Jack/F-2994-2010; Kochunov, Peter/E-4711-2010; brambilla, paolo/B-4184-2010; Fox, Peter/B-4725-2010 OI brambilla, paolo/0000-0002-4021-8456; Fox, Peter/0000-0002-0465-2028 FU NCRR NIH HHS [M01-RR-01346]; NIMH NIH HHS [MH 068662, MH 01736, MH 29618, MH 30915] NR 25 TC 31 Z9 32 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0959-4965 J9 NEUROREPORT JI Neuroreport PD APR 25 PY 2005 VL 16 IS 6 BP 541 EP 544 DI 10.1097/00001756-200504250-00004 PG 4 WC Neurosciences SC Neurosciences & Neurology GA 925XK UT WOS:000229086700004 PM 15812303 ER PT J AU Novgorodov, SA Szulc, ZM Luberto, C Jones, JA Bielawski, J Bielawska, A Hannun, YA Obeid, LM AF Novgorodov, SA Szulc, ZM Luberto, C Jones, JA Bielawski, J Bielawska, A Hannun, YA Obeid, LM TI Positively charged ceramide is a potent inducer of mitochondrial permeabilization SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID RAT-LIVER MITOCHONDRIA; TRANSITION PORE; RESPIRATORY-CHAIN; CALCIUM SIGNALS; GOLGI-APPARATUS; CELL-DEATH; APOPTOSIS; MEMBRANE; PHOSPHORYLATION; MECHANISM AB Ceramide-induced cell death is thought to be mediated by change in mitochondrial function, although the precise mechanism is unclear. Proposed models suggest that ceramide induces cell death through interaction with latent binding sites on the outer or inner mitochondrial membranes, followed by an increase in membrane permeability, as an intermediate step in ceramide signal propagation. To investigate these models, we developed a new generation of positively charged ceramides that readily accumulate in isolated and in situ mitochondria. Accumulated, positively charged ceramides increased inner membrane permeability and triggered release of mitochondrial cytochrome c. Furthermore, the positively charged ceramide-induced permeability increase was suppressed by cyclosporin A (60%) and 1,3-dicyclohexylcarbodiimide (90%). These observations suggest that the inner membrane permeability increase is due to activation of specific ion transporters, not the generalized loss of lipid bilayer barrier functions. The difference in sensitivity of ceramide-induced ion fluxes to inhibitors of mitochondrial transporters suggests activation of at least two transport systems: the permeability transition pore and the electrogenic H+ channel. Our results indicate the presence of specific ceramide targets in the mitochondrial matrix, the occupation of which triggers permeability alterations of the inner and outer mitochondrial membranes. These findings also suggest a novel therapeutic role for positively charged ceramides. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Obeid, LM (reprint author), Med Univ S Carolina, Dept Med, 114 Doughty St,POB 250779, Charleston, SC 29425 USA. EM obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [IPO1CA097132]; NIA NIH HHS [AG16583]; NIDDK NIH HHS [DK59340] NR 44 TC 72 Z9 74 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 22 PY 2005 VL 280 IS 16 BP 16096 EP 16105 DI 10.1074/jbc.M411707200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 917GO UT WOS:000228444800077 PM 15722351 ER PT J AU Romero-Gallo, J Sozmen, EG Chytil, A Russell, WE Whitehead, R Parks, WT Holdren, MS Her, MF Gautam, S Magnuson, M Moses, HL Grady, WM AF Romero-Gallo, J Sozmen, EG Chytil, A Russell, WE Whitehead, R Parks, WT Holdren, MS Her, MF Gautam, S Magnuson, M Moses, HL Grady, WM TI Inactivation of TGF-beta signaling in hepatocytes results in an increased proliferative response after partial hepatectomy SO ONCOGENE LA English DT Article DE TGF-beta; liver regeneration ID TRANSFORMING-GROWTH-FACTOR; CELL-CYCLE ARREST; LIVER EPITHELIAL-CELLS; RAT-LIVER; DNA-SYNTHESIS; II RECEPTOR; C-MYC; HEPATOCELLULAR-CARCINOMA; NUCLEAR-LOCALIZATION; GENE-EXPRESSION AB The transforming growth factor beta (TGF-beta) signaling pathway, which is activated by the TGF-beta receptor complex consisting of type I and type II TGF-beta receptors (TGFBR1 and TGFBR2), regulates cell growth and death. TGF-beta and components of its signaling pathway, particularly TGFBR2, have been implicated as tumor suppressor genes and important antimitogenic factors in the gastrointestinal tract and liver. An in vivo approach to study these effects has been hindered by the embryonic lethality of Tgfbr2(-/-) mice and poor viability of the Tgfb1(-/-) mice. Consequently, we have developed a hepatocyte-specific Tgfbr2 knockout mouse, the Alb-cre Tgfbr2(flx/flx) mouse, to study the physiologically relevant effects of TGF-beta signaling on epithelial cell proliferation in vivo. After 70% hepatectomy, we observed increased proliferation and an increased liver mass : body weight ratio in the Alb-cre Tgfbr2(flx/flx) mice compared to Tgfbr2(flx/flx) mice. We also observed decreased expression and increased phosphorylation of p130 in the livers from the Alb-cre Tgfbr2(flx/flx) mice as well as increased expression of cyclin E, which is transcriptionally regulated, in part, by p130:E2F4. Consistent with these results, in a hepatocyte cell line derived from the Tgfbr2(flx/flx) mice, we found that TGF-beta increases the nuclear localization of E2F4, and presumably the transcriptional repression of the p130: E2F4 complex. Thus, we have demonstrated that TGF-beta signaling in vivo regulates the mitogenic response in the regenerating liver, affecting the liver mass : body weight ratio after partial hepatectomy, and that these mitogenic responses are accompanied by alterations in p130 expression and phosphorylation, implicating p130 as one of the proteins regulated in vivo by TGF-beta during liver regeneration. C1 Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. Vanderbilt Univ, Dept Med, Nashville, TN USA. Vanderbilt Univ, Dept Canc Biol, Nashville, TN USA. Vanderbilt Univ, Dept Pediat, Nashville, TN USA. Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN USA. Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. Beth Israel Deaconess Med Ctr, Dept Biostat, Boston, MA 02215 USA. Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. RP Grady, WM (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D4-100,POB 19024, Seattle, WA 98104 USA. EM wgrady@fhcrc.org RI Russell, William/A-7307-2009; Magnuson, Mark/B-1335-2009 OI Magnuson, Mark/0000-0002-8824-6499 FU NCI NIH HHS [R01 CA102162, R01CA85492]; NIDDK NIH HHS [R01 DK53804, R01 DK60669-01] NR 84 TC 62 Z9 68 U1 2 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-9232 J9 ONCOGENE JI Oncogene PD APR 21 PY 2005 VL 24 IS 18 BP 3028 EP 3041 DI 10.1038/sj.onc.1208475 PG 14 WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity GA 919WY UT WOS:000228649500012 PM 15735717 ER PT J AU Nihal, M Ahmad, N Mukhtar, H Wood, GS AF Nihal, M Ahmad, N Mukhtar, H Wood, GS TI Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: Possible implications for the chemoprevention of melanoma SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE green tea; EGCG; melanoma; apoptosis; Bcl-2 family; caspase; cell cycle ID MALIGNANT-MELANOMA; CELL-SURVIVAL; BCL-2 FAMILY; APOPTOSIS; CANCER; TEA; THERAPY; TUMOR AB Melanoma accounts for only about 4% of all skin cancer cases but most of skin cancer-related deaths. Standard systemic therapies such as interferon (IFN) have not been adequately effective in the management of melanoma. Therefore, novel approaches are needed for prevention and treatment of this disease. Chemoprevention by naturally occurring agents present in food and beverages has shown benefits in certain cancers including nonmelanoma skin cancers. Here, employing 2 human melanoma cell lines (A375 amelanotic malignant melanoma and Hs-294T metastatic melanoma) and normal human epidermal melanocytes (NHEM), we studied the antiproliferative effects of epigallocatechin-3-gallate (EGCG), the major polyphenolic antioxidant present,in green tea. EGCG treatment was found to result in a dose-dependent decrease in the viability and growth of both melanoma cell lines. Interestingly, at similar, EGCG concentrations, the normal melanocytes were not affected. EGCG treatment of the melanoma cell lines resulted in decreased cell proliferation (as assessed by Ki-67 and PCNA protein levels) and induction of apoptosis (as assessed cleavage of PARP, TUNEL assay and JC-1 assay). EGCG also significantly inhibited the colony formation ability of the melanoma cells studied. EGCG treatment of melanoma cells resulted in a downmodulation of anti-apoptotic protein Bcl2, upregulation of proapoptotic Bax and activation of caspases -3, -7 and -9. Furthermore, our data demonstrated that EGCG treatment resulted in a significant, dose-dependent decrease in cyclin D1 and cdk2 protein levels and induction of cyclin kinase inhibitors (ckis) p16(INK4a), p21(WAF1/CIP1) and p27(KIP1). Our data suggest that EGCG causes significant induction of cell cycle arrest and apoptosis of melanoma cells that is mediated via modulations in the cki-cyclin-cdk network and Bcl2 family proteins. Thus, EGCG, alone or in conjunction with current therapies, could be useful for the management of melanoma. (C) 2004 Wiley-Liss, Inc. C1 Univ Wisconsin, Dept Dermatol, Madison, WI 53706 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Wood, GS (reprint author), Univ Wisconsin, Dept Dermatol, 1300 Univ Ave,MSC 25B, Madison, WI 53706 USA. EM gwood@dermatology.wisc.edu FU NIAMS NIH HHS [AR002136-06] NR 33 TC 132 Z9 141 U1 1 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD APR 20 PY 2005 VL 114 IS 4 BP 513 EP 521 DI 10.1002/ijc.20785 PG 9 WC Oncology SC Oncology GA 904YV UT WOS:000227535400002 PM 15609335 ER PT J AU Huppenbauer, CB Tanzer, L DonCarlos, LL Jones, KJ AF Huppenbauer, CB Tanzer, L DonCarlos, LL Jones, KJ TI Gonadal steroid attenuation of developing hamster facial motoneuron loss by axotomy: Equal efficacy of testosterone, dihydrotestosterone, and 17-beta estradiol SO JOURNAL OF NEUROSCIENCE LA English DT Article DE androgen receptor; testosterone; estrogen; dihydrotestosterone; motoneuron; development; peripheral nerve injury ID ANDROGEN RECEPTOR IMMUNOREACTIVITY; NUCLEAR HORMONE-RECEPTORS; MALE SYRIAN-HAMSTER; ESTROGEN-RECEPTOR; NERVE TRANSECTION; RAT PROSTATE; MEDIATED NEUROPROTECTION; RUBROSPINAL MOTONEURONS; IMMUNODEFICIENT MICE; INDUCED ACCELERATION AB In the hamster facial nerve injury paradigm, we have established that androgens enhance both functional recovery from facial nerve paralysis and the rate of regeneration in the adult, through intrinsic effects on the nerve cell body response to injury and via an androgen receptor (AR)-mediated mechanism. Whether these therapeutic effects of gonadal steroids encompass neuroprotection from axotomy-induced cell death is the focus of the present study. Virtually 100% of adult hamster facial motoneurons (FMNs) survive axotomy at the stylomastoid foramen (SMF), whereas, before postnatal day 15 (P15), developing FMNs undergo substantial axotomy-induced cell death. The first part of the present study focuses on determining when ARs are first expressed in developing hamster FMNs. Using AR immunocytochemistry, it was found that males express ARs by P2 and females by P4, which is the earliest demonstration of AR expression in mammalian motoneurons reported thus far in the literature. The second half examines the neuroprotective effects of testosterone propionate, 17-beta estradiol, and dihydrotestosterone on FMNs of P7 hamsters after facial nerve transection at the SMF. The results demonstrate that androgens and estrogens are equally able to rescue similar to 20% of FMNs from axotomy-induced cell death, with the effects permanent. This study is the first to investigate the effects of both androgens and estrogens on axotomy-induced cell death in one system and, with our previously published work, to validate the hamster FMN injury paradigm as a model of choice in the investigation of both neurotherapeutic and neuroprotective actions of gonadal steroids. C1 Loyola Univ, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60153 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Res & Dev Serv, Hines, IL 60141 USA. RP Jones, KJ (reprint author), Loyola Univ, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, 5th Floor,2160 S 1st Ave, Maywood, IL 60153 USA. EM kjones1@lumc.edu FU NIMH NIH HHS [MH48794, MH62588]; NINDS NIH HHS [NS-28238] NR 80 TC 42 Z9 42 U1 0 U2 0 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD APR 20 PY 2005 VL 25 IS 16 BP 4004 EP 4013 DI 10.1523/JNEUROSCI.5279-04.2005 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 918LF UT WOS:000228542600002 PM 15843602 ER PT J AU Zahid, M Sonel, AF Kelley, ME Wall, L Whittle, J Fine, MJ Good, CB AF Zahid, M Sonel, AF Kelley, ME Wall, L Whittle, J Fine, MJ Good, CB TI Effect of both elevated troponin-I and peripheral white blood cell count on prognosis in patients with suspected myocardial injury SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ACUTE CORONARY SYNDROMES; UNSTABLE ANGINA; TISSUE FACTOR; MORTALITY; ASSOCIATION; INFARCTION; REVASCULARIZATION; EXPRESSION; MONOCYTES AB We found a high white blood cell count (> 11,000/mu l) to be of additive prognostic value to high troponin-l levels in predicting risk of recurrent nonfatal myocardial infarctions and all-cause mortality in patients who present with acute coronary syndromes and non-ST-elevation myocardial infarctions. A high troponin-I level or white blood cell count increased the odds ratio of an event to 2.2 (95% confidence interval 1.0 to 4.73, p = 0.05), but high values for the 2 markers increased the odds ratio to 4.5 (95% confidence interval 1.42 to 14.21, p = 0.01). (c) 2005 by Excerpta Medica Inc. C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. Univ Pittsburgh, Cardiovasc Inst, Pittsburgh, PA 15260 USA. Univ Kansas, Kansas City, MO USA. RP Zahid, M (reprint author), 111C-U Univ Dr, Pittsburgh, PA 15240 USA. EM ali.sonel@med.va.gov NR 14 TC 4 Z9 4 U1 0 U2 3 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD APR 15 PY 2005 VL 95 IS 8 BP 970 EP 972 DI 10.1016/j.amjcard.2004.12.037 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 915WX UT WOS:000228343200010 PM 15820165 ER PT J AU Spiegel, BMR Chiou, CF Ofman, JJ AF Spiegel, BMR Chiou, CF Ofman, JJ TI Minimizing complications from nonsteroidal antiinflammatory drugs: Cost-effectiveness of competing strategies in varying risk groups SO ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH LA English DT Article DE cost-effectiveness; nonsteroidal antiinflammatory drugs; cox-2 inhibitors; proton pump inhibitors ID RANDOMIZED CONTROLLED-TRIAL; LOW-DOSE ASPIRIN; RHEUMATOID-ARTHRITIS; PEPTIC-ULCER; DOUBLE-BLIND; HELICOBACTER-PYLORI; CYCLOOXYGENASE-2 INHIBITOR; GASTROINTESTINAL ENDOSCOPY; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION AB Objective. To appraise the cost-effectiveness of competing therapeutic strategies in patient cohorts eligible for aspirin prophylaxis with varying degrees of gastrointestinal (GI) and cardiovascular risk. Methods. Cost-effectiveness and cost-utility analyses were performed to evaluate 3 competing strategies for the management of chronic arthritis: 1) a generic nonselective nonsteroidal antiinflammatory drug (NSAID(NS)) alone; 2) NSAID(NS) plus a proton pump inhibitor (PPI); and 3) a cyclooxygenase 2-selective inhibitor (coxib) alone. Cost estimates were from a third-party payer perspective. The outcomes were incremental cost per ulcer complication avoided and incremental cost per quality-adjusted life year (QALY) gained. Sensitivity analysis was performed to evaluate the impact of varying patient GI risks and aspirin use. Results. In average-risk patients, the NSAID(NS) + PPI strategy costs an incremental $45,350 per additional ulcer complication avoided and $309,666 per QALY gained compared with the NSAID(NS) strategy. The coxib strategy was less effective and more expensive than the NSAID(NS) + PPI strategy. Sensitivity analysis revealed that the NSAID(NS) + PPI strategy became the dominant approach in patients at high risk for an NSAID adverse event (i.e., patients taking aspirin with >= 1 risk factor for a GI complication). Conclusion. Generic nonselective NSAIDs are most cost-effective in patients at low risk for an adverse event. However, the addition of a PPI to a nonselective NSAID may be the preferred strategy in patients taking aspirin or otherwise at high risk for a GI or cardiovascular adverse event. C1 Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Ctr Study Digest Healthcare Qual & Outcomes, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Spiegel, BMR (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Ctr Study Digest Healthcare Qual & Outcomes, 11301 Wilshire Blvd,Bldg 115 Room 215E, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu NR 73 TC 45 Z9 47 U1 0 U2 4 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRIT RHEUM-ARTHR JI Arthritis Rheum-Arthritis Care Res. PD APR 15 PY 2005 VL 53 IS 2 BP 185 EP 197 DI 10.1002/art.21065 PG 13 WC Rheumatology SC Rheumatology GA 916CK UT WOS:000228362800006 PM 15818647 ER PT J AU Short, EB Kose, S Newberg, A George, MS Kozel, FA AF Short, EB Kose, S Newberg, A George, MS Kozel, FA TI FMRI investigation of meditation SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Med Univ S Carolina, Brain Stimulat Lab, Charleston, SC 29425 USA. Med Univ S Carolina, Ctr Adv Imaging Res, Charleston, SC 29425 USA. Univ Penn, Med Ctr, Div Nucl Med, Philadelphia, PA 19104 USA. Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. RI Kozel, Frank/I-5366-2012 NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 157 BP 45S EP 45S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338600159 ER PT J AU Nery, FG Borba, EF Soares, JC Bonfa, E Neto, FL AF Nery, FG Borba, EF Soares, JC Bonfa, E Neto, FL TI Associations of depressive disorder, psychosocial stress and disease activity in systemic lupus erythematosus SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div mood & Anxiety Disorders, San Antonio, TX 78284 USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo, Brazil. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. S Texas Vet Hlth Care Syst, Psychiat, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Dept Internal Med, Div Rheumatol, Sao Paulo, Brazil. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 198 BP 56S EP 56S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338600198 ER PT J AU Nery, FG Borba, EF Soares, JC Bonfa, E Neto, FL AF Nery, FG Borba, EF Soares, JC Bonfa, E Neto, FL TI Prevalence of psychiatric manifestations in patients with systemic lupus erythematosus and association with anti-ribosomal P autoantibodies SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo, Brazil. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. Univ Sao Paulo, Sch Med, Dept Internal Med, Div Rheumatol, Sao Paulo, Brazil. S Texas Vet Hlth Care Syst, Psychiat, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 199 BP 56S EP 56S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338600199 ER PT J AU Radant, AD Olincy, A Calkins, ME Dobie, DJ Meichle, S Tsuang, DW David, AC AF Radant, AD Olincy, A Calkins, ME Dobie, DJ Meichle, S Tsuang, DW David, AC TI Saccadic latencies are related to diagnosis and overall antisaccade task performance: Analysis of antisaccade data from the consortium on the genetics of schizophrenia (COGS) data set SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. VA Puget Sound Healthcare Syst, NW Network Mental Illness res Educ & Clin Ctr VIS, Seattle, WA USA. Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO USA. Univ Penn, Sch Med, Schizophrenia Res Ctr, Neuropsychiat Sect, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 243 BP 68S EP 68S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338600242 ER PT J AU Brody, A Mandelkern, MA London, ED Olmestead, R Scheibal, D Jou, J Allen, V Tiongson, N Chefer, S Mukhin, A AF Brody, A Mandelkern, MA London, ED Olmestead, R Scheibal, D Jou, J Allen, V Tiongson, N Chefer, S Mukhin, A TI Effect of variable levels of cigarette smoking on nicotinic acetylcholine receptor availability during early smoking abstinence SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Univ Calif Los Angeles, Los Angeles, CA USA. Greater Los Angeles VA Healthcare Syst, Psychiat, Los Angeles, CA USA. Greater Los Angeles VA Healthcare Syst, Nucl Med, Los Angeles, CA USA. Univ Calif Irvine, Irvine, CA USA. NIDA, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 357 BP 98S EP 98S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338600349 ER PT J AU Kose, S Lorberbaum, JP Dubno, JR Horwitz, AR Newman, JD Sullivan, LK Hamner, MB Bohning, DE Arana, GW George, MS AF Kose, S Lorberbaum, JP Dubno, JR Horwitz, AR Newman, JD Sullivan, LK Hamner, MB Bohning, DE Arana, GW George, MS TI Regional brain activity in mothers and fathers listening to infant cries SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Mental Hlth Clin, Charleston, SC USA. Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. NICHHD, NIH, Poolesville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 369 BP 102S EP 102S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338600361 ER PT J AU Kose, S Lorberbaum, JP Johnson, MR Arana, GW Sullivan, LK Hamner, MB Ballenger, JC Lydiard, RB Brodrick, PS Bohning, DE George, MS AF Kose, S Lorberbaum, JP Johnson, MR Arana, GW Sullivan, LK Hamner, MB Ballenger, JC Lydiard, RB Brodrick, PS Bohning, DE George, MS TI The functional neuroanatomy of speech anticipatory anxiety in generalized social phobia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Mental Hlth Clin, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 368 BP 102S EP 102S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338600360 ER PT J AU Najib, A Lorberbaum, JP Kose, S Bohning, DE George, MS AF Najib, A Lorberbaum, JP Kose, S Bohning, DE George, MS TI Regional brain activity in women grieving the loss of a romantic relationship SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Med Univ S Carolina, Charleston, SC 29425 USA. Univ Tubingen, Med Ctr, Sch Med, Tubingen, Germany. Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 370 BP 102S EP 102S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338600362 ER PT J AU Dracheva, S Chin, B Woo, DA Davis, KL Gorman, JM Haroutunian, V AF Dracheva, S Chin, B Woo, DA Davis, KL Gorman, JM Haroutunian, V TI Differential expression of myelin-related genes in schizophrenic brain SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Bronx Vet Adm Med Ctr, Bronx, NY USA. Mt Sinai Sch Med, New York, NY USA. NR 0 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 443 BP 121S EP 121S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601041 ER PT J AU Kozel, FA Nahas, Z Ramsey, D Molnar, C Johnson, K Grenesko, E Kose, S George, MS AF Kozel, FA Nahas, Z Ramsey, D Molnar, C Johnson, K Grenesko, E Kose, S George, MS TI Measuring scalp to cortex distances in order to adjust TMS stimulation parameters SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 MUSC, Ctr Adv Imaging Res, Charleston, SC USA. Ralph H Johnson VA Med Ctr, Ctr Adv Imaging Res, Mental Hlth Serv, Charleston, SC USA. S Carolina Res Author, Bioinformat Res, Charleston, SC USA. RI Kozel, Frank/I-5366-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 442 BP 121S EP 121S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601040 ER PT J AU Fonseca, M Caetano, SC Kaur, S Nicoletti, M Olvera, RL Hunter, K Ortiz, O Hatch, JP Bowden, C Pliska, S Soares, JC AF Fonseca, M Caetano, SC Kaur, S Nicoletti, M Olvera, RL Hunter, K Ortiz, O Hatch, JP Bowden, C Pliska, S Soares, JC TI MRI study of the cingulate cortex in children and adolescents with bipolar disorder: A replication study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, Psychiat Serv, San Antonio, TX USA. Univ Fed Rio Grande Sul, Sch Med, Psychiat Res Unit, Porto Alegre, RS, Brazil. Univ Sao Paulo, Sch Med, Inst Psychiat, Dept Psychiat, Sao Paulo, Brazil. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 458 BP 125S EP 126S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601056 ER PT J AU Fonseca, M Soares, JC Hatch, JP Santin, AP Kapczinski, F AF Fonseca, M Soares, JC Hatch, JP Santin, AP Kapczinski, F TI An open trial of escitalopram in bipolar depression SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Univ Fed Rio Grande Sul, Psychiat Res Unit, Sch Med, Porto Alegre, RS, Brazil. Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audies L Murphy Div, Psychiat Serv, San Antonio, TX USA. Univ Fed Rio Grande Sul, Sch Med, Clin Hosp Porto Alegre, Psychiat Serv, Porto Alegre, RS, Brazil. RI Cloninger, Claude/F-5357-2012; Kapczinski, Flavio/D-3175-2013; Caetano, Sheila/H-5010-2012; Kapczinski, Flavio/J-5803-2014 OI Cloninger, Claude/0000-0003-3096-4807; Caetano, Sheila/0000-0001-8403-7078; NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 459 BP 126S EP 126S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601057 ER PT J AU Fonseca, M Caetano, SC Olvera, RL Hatch, JP Hunter, K Nicoletti, M Pliszka, S Bowden, C Cloninger, CR Soares, JC AF Fonseca, M Caetano, SC Olvera, RL Hatch, JP Hunter, K Nicoletti, M Pliszka, S Bowden, C Cloninger, CR Soares, JC TI Assessment of personality traits in pediatric bipolar disorder using the junior temperament and character inventory SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78284 USA. S Texas Vet Hlth Care syst, Audie L Murphy Div, Psychiat Serv, San Antonio, TX USA. Univ Fed Rio Grande Sul, Sch Med, Psychiat Res Unit, Porto Alegre, RS, Brazil. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. RI Cloninger, Claude/F-5357-2012; Kapczinski, Flavio/D-3175-2013; Caetano, Sheila/H-5010-2012; Kapczinski, Flavio/J-5803-2014 OI Cloninger, Claude/0000-0003-3096-4807; Caetano, Sheila/0000-0001-8403-7078; NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 460 BP 126S EP 126S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601058 ER PT J AU Caetano, SC Olvera, RL Hunter, K Fonseca, M Hatch, JP Bowden, C Pliszka, S Soares, JC AF Caetano, SC Olvera, RL Hunter, K Fonseca, M Hatch, JP Bowden, C Pliszka, S Soares, JC TI Comorbid bipolar disorder and anxiety in pediatric patients SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, Dept Psychiat, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Dept Psychiat, Sao Paulo, Brazil. Univ Fed Rio Grande Sul, Sch Med, Psychiat Res Unit, Porto Alegre, RS, Brazil. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 463 BP 127S EP 127S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601061 ER PT J AU Najt, P Nicoletti, M Chen, HH Hatch, JP Sassi, R Axelson, D Brambilla, P Keshavan, MS Ryan, ND Birmaher, B Soares, JC AF Najt, P Nicoletti, M Chen, HH Hatch, JP Sassi, R Axelson, D Brambilla, P Keshavan, MS Ryan, ND Birmaher, B Soares, JC TI Anatomical measurements of the orbitofrontal cortex in child and adolescent patients with bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Orthodont, San Antonio, TX 78284 USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Dept Psychiat, Sao Paulo, Brazil. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. Univ Udine, Dept Pathol & Expt & Clin Med, Sect Psychiat, I-33100 Udine, Italy. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 461 BP 127S EP 127S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601059 ER PT J AU Pekary, AE Sattin, A Stevens, SA AF Pekary, AE Sattin, A Stevens, SA TI Kinetics of TRH and TRH-LIKE peptide response to corticosterone in rat brain SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Ctr Ulcer Res & Educ, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Psychiat Serv, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 496 BP 136S EP 137S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601094 ER PT J AU Glahn, DC Beardene, CE Caetano, SC Fonseca, M Najt, P Hunter, K Pliszka, S Olvera, RL Soares, JC AF Glahn, DC Beardene, CE Caetano, SC Fonseca, M Najt, P Hunter, K Pliszka, S Olvera, RL Soares, JC TI Declarative memory impairment in pediatric bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 UTHSCSA, Psychiat, San Antonio, TX USA. Univ Calif Los Angeles, Los Angeles, CA USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo, Brazil. Univ Fed Rio Grande Sul, Sch Med, Psychiat Res Unit, Porto Alegre, RS, Brazil. RI Caetano, Sheila/H-5010-2012 OI Caetano, Sheila/0000-0001-8403-7078 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 498 BP 137S EP 137S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601096 ER PT J AU Griffith, JM Gasper, JJ Waldo, M Nagamoto, HT Adler, LE AF Griffith, JM Gasper, JJ Waldo, M Nagamoto, HT Adler, LE TI Metabolic risks associated with typical and atypical antipsychotic medications SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Denver VAMC, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 591 BP 162S EP 162S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601188 ER PT J AU Byne, WM Buchsbaum, MS Haroutunian, V AF Byne, WM Buchsbaum, MS Haroutunian, V TI The pulvinar in schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Bronx Vet Affairs Med Ctr, Bronx, NY USA. CUNY Mt Sinai Sch Med, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 601 BP 165S EP 165S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601198 ER PT J AU Olincy, A Ellis, J Freedman, R AF Olincy, A Ellis, J Freedman, R TI The Consortium on the Genetics of Schizophrenia (COGS): Utility of the P50 auditory evoked potential to explore the genetics of schizophrenia in a multisite study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 657 BP 181S EP 181S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601254 ER PT J AU Nery, FG Hatch, JP Glahn, DC Nicoletti, M Monkul, S Najt, P Kaur, S Fonseca, M Bowden, C Cloninger, CR Soares, JC AF Nery, FG Hatch, JP Glahn, DC Nicoletti, M Monkul, S Najt, P Kaur, S Fonseca, M Bowden, C Cloninger, CR Soares, JC TI Personality traits in bipolar disorder with alcohol or anxiety co-morbidity SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo, Brazil. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. RI Cloninger, Claude/F-5357-2012 OI Cloninger, Claude/0000-0003-3096-4807 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 669 BP 184S EP 184S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601266 ER PT J AU Nery, FG Hatch, JP Glahn, DC Nicoletti, M Monkul, S Najt, P Kaur, S Fonseca, M Bowden, C Cloninger, CR Soares, JC AF Nery, FG Hatch, JP Glahn, DC Nicoletti, M Monkul, S Najt, P Kaur, S Fonseca, M Bowden, C Cloninger, CR Soares, JC TI Temperament and character in symptomatic bipolar patients SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo, Brazil. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. RI Cloninger, Claude/F-5357-2012 OI Cloninger, Claude/0000-0003-3096-4807 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 668 BP 184S EP 184S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601265 ER PT J AU Bearden, CE Glahn, DC Monkul, S Barrette, J Najit, P Sanches, M Villarreal, V Bowden, C Soares, JC AF Bearden, CE Glahn, DC Monkul, S Barrette, J Najit, P Sanches, M Villarreal, V Bowden, C Soares, JC TI Sources of declarative memory impairment in bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Univ Calif Los Angeles, Los Angeles, CA USA. Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. Dokuz Eylul Univ, Sch Med, Dept Psychiat, Izmir, Turkey. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 716 BP 197S EP 198S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601313 ER PT J AU Peluso, MAM Glahn, DC Monkul, S Najt, P Zamarripa, F Li, J Lancaster, J Fox, P Gao, JH Soares, JC AF Peluso, MAM Glahn, DC Monkul, S Najt, P Zamarripa, F Li, J Lancaster, J Fox, P Gao, JH Soares, JC TI Right amygdala hyperactivation in untreated depressed individuals SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 UTHSCSA, RIC, San Antonio, TX USA. Univ Sao Paulo, Sao Paulo, Brazil. Dokuz Eylul Univ, Sch Med, Izmir, Turkey. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RI Lancaster, Jack/F-2994-2010 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 723 BP 199S EP 199S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601320 ER PT J AU Peluso, MAM Hatch, JP Glahn, D Monkul, S Sanches, M Najt, P Kaur, S Bowden, C Barratt, ES Soares, JC AF Peluso, MAM Hatch, JP Glahn, D Monkul, S Sanches, M Najt, P Kaur, S Bowden, C Barratt, ES Soares, JC TI Impulsivity and hostility in mood disorders SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 UTHSCSA, San Antonio, TX USA. Univ Sao Paulo, Sao Paulo, Brazil. Dokuz Eylul Univ, Sch Med, Izmir, Turkey. Univ Texas, Med Branch, Galveston, TX 77550 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 724 BP 200S EP 200S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601321 ER PT J AU Koenigsber, HW Siever, LJ Guo, XD New, AS Goodman, M Cheng, H Prohovnik, I AF Koenigsber, HW Siever, LJ Guo, XD New, AS Goodman, M Cheng, H Prohovnik, I TI Cerebral processing of negative emotion in borderline personality disorder: An fMRI perspective SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Mt Sinai Sch Med, Bronx, NY USA. Bronx Vet Affairs Med Ctr, Mirrec, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 731 BP 201S EP 202S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601328 ER PT J AU Solomon, BD Nicoletti, M Hatch, JP Monkul, S Villarreal, V Bowden, C Soares, JC AF Solomon, BD Nicoletti, M Hatch, JP Monkul, S Villarreal, V Bowden, C Soares, JC TI Anatomical examination of sub-genual prefrontal cortex in adult bipolar patients: A non-replication study SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Sch Med, San Antonio, TX USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Dokuz Eylul Univ, Sch Med, Izmir, Turkey. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 737 BP 203S EP 204S PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601334 ER PT J AU Soares, JC Bearden, CE Dalwani, M Hayashi, KM Lee, AD Glahn, DC Nicoletti, M Trahkenbroit, M Brambilla, P Sassi, RB Mallinger, AG Frank, E Kupfer, D Thompson, PM AF Soares, JC Bearden, CE Dalwani, M Hayashi, KM Lee, AD Glahn, DC Nicoletti, M Trahkenbroit, M Brambilla, P Sassi, RB Mallinger, AG Frank, E Kupfer, D Thompson, PM TI Cortical gray matter abnormalities mapped in patients with bipolar disorder SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract CT 60th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 19-21, 2005 CL Atlanta, GA SP Soc Biol Psychiat C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Neurol, Lab Neuro Imaging, Los Angeles, CA 90024 USA. Univ Udine, Sect Psychiat, Dept Pathol, I-33100 Udine, Italy. Univ Udine, Sect Psychiat, Dept Expt & Clin Med, I-33100 Udine, Italy. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2005 VL 57 IS 8 SU S MA 747 BP 207S EP 207S PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 915VE UT WOS:000228338601344 ER PT J AU Klyushnenkova, EN Link, J Oberle, WT Kodak, J Rich, C Vandenbark, AA Alexander, RB AF Klyushnenkova, EN Link, J Oberle, WT Kodak, J Rich, C Vandenbark, AA Alexander, RB TI Identification of HLA-DRB1*1501-Restricted T-cell epitopes from prostate-specific antigen SO CLINICAL CANCER RESEARCH LA English DT Article ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GRANULOMATOUS PROSTATITIS; TRANSGENIC MICE; CANCER-PATIENTS; PEPTIDE; RECOGNITION; GENERATION; RESPONSES; MELANOMA; HLA-DR2 AB The development of immunotherapy for prostate cancer based on the induction of autoimmunity to prostate tissue is very attractive because prostate is not a vital organ beyond the reproductive years. CD4 Tcells play an important role in the development of antitumor immune responses, yet the identification of naturally processed MHC Class II - restricted epitopes derived from prostate differentiation antigens has not been described. To facilitate the search for prostate-specific antigen (PSA) -derived VIHC class II -restricted peptides, we immunized mice transgenic for HLA-DRB1* 1501 with human PSA and showed a robust dose-dependent immune response to the antigen. Screening a library of overlapping 20-mer peptides that span the entire PSA sequence identified two 20-mer peptides, PSA(171-190) and PSA(221-240), which were responsible for this reactivity. Immunization of DR2b transgenic mice with these peptides induced specific responses to the peptide and whole PSA. Identified peptides were used to stimulate CD4 T cells from HLA-DRB1*1501+ patients with a rare condition, granulomatous prostatitis, and who seem to have a preexisting immune response directed against the prostate gland. We previously showed a linkage of granulomatous prostatitis to HLA-DRB1*1501, suggesting that this disease may have an autoimmune etiology. Peptide-specific CD4 T-cell lines were generated from the peripheral blood of these patients as well as one patient with prostate cancer, These lines also recognized whole, processed PSA in the context of HLA-DRB1*1501. This study will be instrumental in understanding the interaction between circulating self-reactiveT cells, organ-specific autoimmunity, and antitumor immune response. The use of these peptides for the immunotherapy of prostate cancer is under investigation. C1 Univ Maryland, Sch Med, Urol Sect, VA Maryland Hlth Care Syst, Baltimore, MD 21201 USA. Univ Maryland, Sch Med, Div Urol, Baltimore, MD 21201 USA. Oregon Hlth Sci Univ, Dept Neuroimmunol, Portland VA Med Ctr, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. RP Klyushnenkova, EN (reprint author), Univ Maryland, Sch Med, Dept Surg, Med Sch Teaching Facil, 10 S Pine St,Room 4-00A, Baltimore, MD 21201 USA. EM eklyustinenkova@smail.umaryland.edu OI Link, Jason/0000-0002-6892-0431 NR 23 TC 21 Z9 21 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD APR 15 PY 2005 VL 11 IS 8 BP 2853 EP 2861 DI 10.1158/1078-0432.CCR-04-1927 PG 9 WC Oncology SC Oncology GA 916SM UT WOS:000228406300006 PM 15837732 ER PT J AU Wu, JD Odman, A Higgins, LM Haugk, K Vessella, R Ludwig, DL Plymate, SR AF Wu, JD Odman, A Higgins, LM Haugk, K Vessella, R Ludwig, DL Plymate, SR TI In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors SO CLINICAL CANCER RESEARCH LA English DT Article ID IGF-BINDING PROTEIN-3; BREAST-CANCER CELLS; FACTOR SYSTEM; MONOCLONAL-ANTIBODY; EXPRESSION; APOPTOSIS; INHIBITION; PROGRESSION; TRANSFORMATION; PROLIFERATION AB Purpose: The type I insulin-like growth factor receptor (IGF-IR) and its ligands have been shown to play a critical role in prostate carcinoma development, growth, and metastasis. Targeting the IGF-IR may be a potential treatment for prostate cancer. A fully human monoclonal antibody, A12, specific to IGF-IR, has shown potent antitumor effects in breast, colon, and pancreatic cancers in vitro and in vivo. In this study, we tested the in vivo effects of A12 on androgen-dependent and androgen-independent prostate tumor growth. Experimental Design: Androgen-dependent LuCaP 35 and androgen-independent LuCaP 35V prostate tumors were implanted s.c. into intact and castrated severe combined immuno-deficient mice, respectively. When tumor volume reached about 150 to 200 mm(3), A12 was injected at 40 mg/kg body weight thrice a week for up to 5 weeks. Results: We find that A12 significantly inhibits growth of androgen-dependent LuCaP 35 and androgen-independent LuCaP 35V prostate xenografts, however, by different mechanisms, In LuCaP 35 xenografts, A12 treatment induces tumor cell apoptosis or G, cycle arrest. In LuCaP 35V xenografts, A12 treatment induces tumor cell G(2)-M cycle arrest. Moreover, we find that blocking the function of IGF-IR down-regulates androgen-regulated gene expression in androgen-independent LuCaP 35V tumor cells. Conclusions: Our findings suggest that A12 is a therapeutic candidate for both androgen-dependent and androgen-independent prostate cancer. Our findings also suggest an IGF-IR-dependent activity of the androgen receptor in androgen-independent prostate cancer cells. C1 Univ Washington, Dept Med, Seattle, WA 98104 USA. Univ Washington, Dept Gerontol & Geriatr Med, Seattle, WA 98104 USA. Univ Washington, Dept Urol & Immunol, Seattle, WA 98104 USA. Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res & Educ Clin Ctr, Seattle, WA USA. ImClone Syst, New York, NY USA. RP Wu, JD (reprint author), Univ Washington, Dept Med, Box 359625, Seattle, WA 98104 USA. EM wuj@u.washington.edu FU NCI NIH HHS [K01 CA116002, P01-CA85859]; NIDDK NIH HHS [R01DK52683] NR 46 TC 121 Z9 125 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD APR 15 PY 2005 VL 11 IS 8 BP 3065 EP 3074 DI 10.1158/1078-0432.CCR-04-1586 PG 10 WC Oncology SC Oncology GA 916SM UT WOS:000228406300036 PM 15837762 ER PT J AU Fireman, M Indest, DW Blackwell, A Whitehead, AJ Hauser, P AF Fireman, M Indest, DW Blackwell, A Whitehead, AJ Hauser, P TI Addressing tri-morbidity (Hepatitis C, psychiatric disorders, and substance use): The importance of routine mental health screening as a component of a comanagement model of care SO CLINICAL INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT Conference on Hepatitis C Virus Infection and Substance Abuse CY NOV 11-13, 2003 CL Washington, DC SP Off AIDS Res, NIAID, Natl Inst Diabetes & Dugest & Kidney Dus, Dept Vet Affairs, Hlth Resources & Serv Adm ID INTERFERON-ALPHA; PLUS RIBAVIRIN; UNITED-STATES; DEPRESSION; VETERANS; THERAPY; VIRUS; INFECTION AB Background. Recent studies suggest that most patients with hepatitis C virus (HCV) infection commonly present to medical clinics with active psychiatric and substance use disorders. However, routine screening for these disorders is generally not done. Objectives. The purpose of our study was to assess prospectively the frequency of psychiatric and substance use disorders in patients presenting for initial assessment of a positive HCV antibody test result. Methods. A sample of 293 patients represented the majority of patients scheduled for their initial hepatology clinic visit at the Portland Veterans Affairs Medical Center between September 2002 and September 2003. The patient screening questionnaire, Alcohol Use Disorders Identification Test-Consumption (AUDIT-C), and the Beck Depression Inventory (BDI-II) were administered to all patients. Results. At screening, 93% of the patients had a current or past history of at least 1 psychiatric disorder, and 73% had >= 2 disorders. The most common disorders included depression (81%), posttraumatic stress disorder (62%), any substance use disorder (58%), bipolar disorder (20%), and other psychotic disorders (17%). One hundred two patients (35%) had baseline BDI-II scores in the moderate-to-severe range of depression (> 19), and 61 (21%) had AUDIT-C scores indicating current heavy alcohol use (>= 4). Conclusions. Psychiatric and substance use disorders are highly prevalent among veterans with chronic hepatitis C. Thirty-five percent have significant symptoms of depression before the initiation of treatment with interferon (IFN). Routine screening for underlying psychiatric and substance use disorders and early treatment intervention before initiating antiviral therapy is essential to prevent worsening of depression and to optimize the outcome of treatment with IFN. Comanagement treatment models involving mental health care may expand the pool of patients eligible to receive treatment with IFN, as well as enhance treatment outcomes. C1 Portland VA Med Ctr, NW Hepatitis C Resource Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA. Portland VA Med Ctr, Div Neurosci, Portland, OR 97239 USA. Portland VA Med Ctr, JENS Lab, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. RP Hauser, P (reprint author), Portland VA Med Ctr, NW Hepatitis C Resource Ctr, Behav Hlth & Clin Neurosci Div, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM peter.hauser2@med.va.gov RI Blackwell, Aaron/B-5258-2008 OI Blackwell, Aaron/0000-0002-5871-9865 NR 26 TC 60 Z9 61 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 15 PY 2005 VL 40 SU 5 BP S286 EP S291 DI 10.1086/427442 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 908WM UT WOS:000227820900005 PM 15768336 ER PT J AU Jackson, LA Drevets, DA Dong, ZM Greenfield, RA Murphy, JW AF Jackson, LA Drevets, DA Dong, ZM Greenfield, RA Murphy, JW TI Levels of L-selectin (CD62L) on human leukocytes in disseminated cryptococcosis with and without associated HIV-1 infection SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID IMMUNODEFICIENCY-VIRUS-INFECTION; TRANSENDOTHELIAL MIGRATION; OXIDATIVE BURST; T-LYMPHOCYTES; CELL-SURFACE; IN-VITRO; GLUCURONOXYLOMANNAN; NEOFORMANS; NEUTROPHILS; MENINGITIS AB Patients with disseminated cryptococcosis typically have measurable levels of cryptococcal polysaccharide in serum samples but minimal leukocyte infiltration into infected tissues. In vitro data have shown that cryptococcal polysaccharide induces L-selectin (CD62L) shedding from leukocytes. To assess shedding in vivo, we compared leukocyte L-selectin levels in human immunodeficiency virus (HIV) type 1-negative and -positive subjects with and without circulating cryptococcal polysaccharide. Results showed that subjects with cryptococcal polysaccharide in serum samples have significantly lower percentages of neutrophils, monocytes, and CD3(+) T cells with L-selectin on their surfaces than do healthy subjects, regardless of HIV status. There was significantly more soluble L-selectin in serum samples from subjects with cryptococcosis than in those from uninfected subjects. Reduced L-selectin levels on leukocytes in subjects with circulating cryptococcal polysaccharide and increased serum levels of soluble L-selectin indicates that surface L-selectin shedding is a mechanism that likely explains reduced leukocyte extravasation into infected tissues of patients with disseminated cryptococcosis. C1 Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA. Vet Affairs Med Ctr, Oklahoma City, OK 73104 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. RP Murphy, JW (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73104 USA. EM juneann-murphy@ouhsc.edu FU NHLBI NIH HHS [HL-59852]; NIAID NIH HHS [AI-15716] NR 25 TC 8 Z9 9 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD APR 15 PY 2005 VL 191 IS 8 BP 1361 EP 1367 DI 10.1086/428949 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 908QR UT WOS:000227804500022 PM 15776384 ER PT J AU Armstrong, K Micco, E Carney, A Stopfer, J Putt, M AF Armstrong, K Micco, E Carney, A Stopfer, J Putt, M TI Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID AFRICAN-AMERICAN FAMILIES; GENERAL-POPULATION; ETHNIC-DIFFERENCES; HEREDITARY BREAST; INCREASED RISK; HEALTH-CARE; MUTATIONS; DECISIONS; ATTITUDES; RACE AB Context Given the current context of racial disparities in health and health care and the historical context of eugenics, racial disparities in the use of genetic susceptibility testing have been widely anticipated. However, to our knowledge there are no published studies examining the magnitude and determinants of racial differences in the use of genetic susceptibility testing. Objectives To investigate the relationship between race and the use of BRCA1/2 counseling among women with a family history of breast or ovarian cancer and to determine the contribution of socioeconomic characteristics, cancer risk perception and worry, attitudes about genetic testing, and interactions with primary care physicians to racial differences in utilization. Design, Setting, and Participants Case-control study (December 1999-August 2003) of 408 women with a family history of breast or ovarian cancer, of whom 217 underwent genetic counseling for BRCA1/2 testing (cases) and 191 women did not (controls). Participants received primary care within a large health system in greater Philadelphia, Pa. Main Outcome Measures Probability of carrying a BRCA1/2 mutation, socioeconomic characteristics, perception of breast and ovarian cancer risk, worry about breast and ovarian cancer, attitudes about BRCA1/2 testing, and primary care physician discussion of BRCA1/2 testing were measured prior to undergoing BRCA1/2 counseling for cases and at the time of enrollment for controls. Results African American women with a family history of breast or ovarian cancer were significantly less likely to undergo genetic counseling for BRCA1/2 testing than were white women with a family history of breast or ovarian cancer (odds ratio, 0.22; 95% confidence interval, 0.12-0.40). This association persisted after adjustment for probability of BRCA1/2 mutation, socioeconomic characteristics, breast and ovarian cancer risk perception and worry, attitudes about the risks and benefits of BRCA1/2 testing, and primary care physician discussion of BRCA1/2 testing (adjusted odds ratio for African American vs white, 0.28; 95% confidence interval, 0.09-0.89). Conclusions Racial disparities in the use of BRCA1/2 counseling are large and do not appear to be explained by differences in risk factors for carrying a BRCA1/2 mutation, socioeconomic factors, risk perception, attitudes, or primary care physician recommendations. The benefit of predictive genetic testing will not be fully realized unless these disparities can be addressed. C1 Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Armstrong, K (reprint author), 1204 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM karmstro@mail.med.upenn.edu NR 42 TC 164 Z9 164 U1 4 U2 24 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 13 PY 2005 VL 293 IS 14 BP 1729 EP 1736 DI 10.1001/jama.293.14.1729 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 915JS UT WOS:000228301100026 PM 15827311 ER PT J AU Shlipak, MG Fried, LF Cushman, M Manolio, TA Peterson, D Stehman-Breen, C Bleyer, A Newman, A Siscovick, D Psaty, B AF Shlipak, MG Fried, LF Cushman, M Manolio, TA Peterson, D Stehman-Breen, C Bleyer, A Newman, A Siscovick, D Psaty, B TI Cardiovascular mortality risk in chronic kidney disease - Comparison of traditional and novel risk factors SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID CORONARY-HEART-DISEASE; ATHEROSCLEROSIS RISK; RENAL-INSUFFICIENCY; HEALTH; COMMUNITIES; EVENTS; ASSOCIATION; DYSFUNCTION; POPULATION; CREATININE AB Context Elderly persons with chronic kidney disease have substantial risk for cardiovascular mortality, but the relative importance of traditional and novel risk factors is unknown. Objective To compare traditional and novel risk factors as predictors of cardiovascular mortality. Design, Setting, and Patients A total of 5808 community-dwelling persons aged 65 years or older living in 4 communities in the United States participated in the Cardiovascular Health Study cohort. Participants were initially recruited from 1989 to June 1990; an additional 687 black participants were recruited in 1992-1993. The average length of follow-up in this longitudinal study was 8.6 years. Main Outcome Measures Cardiovascular mortality among those with and without chronic kidney disease. Chronic kidney disease was defined as an estimated glomerular filtration rate of less than 60 mL/min per 1.73 m(2). Results Among the participants, 1249 (22%) had chronic kidney disease at baseline. The cardiovascular mortality risk rate was 32 deaths/1000 person-years among those with chronic kidney disease vs 16/1000 person-years among those without it. In multivariate analyses, diabetes, systolic hypertension, smoking, low physical activity, nonuse of alcohol, and left ventricular hypertrophy were predictors of cardiovascular mortality in persons with chronic kidney disease (all P values <.05). Among the novel risk factors, only log C-reactive protein (P=.05) and log interleukin 6 (P<.001) were associated with the outcome as linear predictors. Traditional risk factors were associated with the largest absolute increases in risks for cardiovascular deaths among persons with chronic kidney disease: for left ventricular hypertrophy, there were 25 deaths per 1000 person-years; current smoking, 20 per 1000 person-years; physical inactivity, 15 per 1000 person-years; systolic hypertension, 14 per 1000 person-years; diabetes, 14 per 1000 person-years; and nonuse of alcohol, 11 per 1000 person-years vs 5 deaths per 1000 person-years for those with increased C-reactive protein and 5 per 1000 person-years for those with increased interleukin 6 levels. A receiver operating characteristic analysis found that traditional risk factors had an area under the curve of 0.73 (95% confidence interval, 0.70-0.77) among those with chronic kidney disease. Adding novel risk factors only increased the area under the curve to 0.74 (95% confidence interval, 0.71-0.78; P for difference =. 15). Conclusions Traditional cardiovascular risk factors had larger associations with cardiovascular mortality than novel risk factors in elderly persons with chronic kidney disease. Future research should investigate whether aggressive lifestyle intervention in patients with chronic kidney disease can reduce their substantial cardiovascular risk. C1 Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. Univ Vermont, Coll Med, Dept Med, Colchester, VT USA. Univ Vermont, Coll Med, Dept Pathol, Colchester, VT USA. Univ Vermont, Coll Med, Dept Biochem, Colchester, VT USA. NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA. Collaborat Hlth Studies Coordinating Ctr, Seattle, WA USA. Amgen Inc, Thousand Oaks, CA 91320 USA. Wake Forest Univ, Bowman Gray Sch Med, Nephrol Sect, Winston Salem, NC USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. Univ Pittsburgh, Div Geriatr Med, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. Univ Washington, Dept Med, Seattle, WA USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Shlipak, MG (reprint author), Vet Affairs Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM shlip@itsa.ucsf.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU NHLBI NIH HHS [N01-HC-85080, N01 HC-15103, N01-HC-35129, N01-HC-85079, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, R01 HL073208-01] NR 29 TC 358 Z9 377 U1 1 U2 13 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 13 PY 2005 VL 293 IS 14 BP 1737 EP 1745 DI 10.1001/jama.293.14.1737 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 915JS UT WOS:000228301100027 PM 15827312 ER PT J AU Hall, DA Leehey, MA Filley, CM Steinbart, E Montine, T Schellenberg, GD Bosque, P Nixon, R Bird, T AF Hall, DA Leehey, MA Filley, CM Steinbart, E Montine, T Schellenberg, GD Bosque, P Nixon, R Bird, T TI PRNP H187R mutation associated with neuropsychiatric disorders in childhood and dementia SO NEUROLOGY LA English DT Article ID PRION PROTEIN GENE; ENCEPHALOPATHY; FEATURES AB Described is a large family with an autosomal dominant dementia associated with an H187R mutation in the prion protein gene (PRNP). Clinical features include neuropsychiatric disturbances in childhood and adolescence, dementia in young adulthood with frontotemporal manifestations, and long disease duration. Neuropathology revealed atrophy and mild gliosis, whereas prion protein analysis revealed an abnormal conformer with unusual sensitivity to protease digestion. Mutations in PRNP may cause neuropsychiatric disorders that predate dementia by many years. C1 Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Dept Neurol, Denver, CO USA. Denver Hlth Med Ctr, Dept Med, Denver, CO USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Pathol, Seattle, WA 98195 USA. Geriatr Res Educ & Clin Ctr, Seattle, WA USA. Vet Affairs Med Ctr, Seattle, WA 98108 USA. Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. RP Hall, DA (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, 4200 E 9th Ave, Denver, CO 80262 USA. EM deborah.hall@uchsc.edu FU NIA NIH HHS [AG05136] NR 8 TC 14 Z9 14 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR 12 PY 2005 VL 64 IS 7 BP 1304 EP 1306 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA 915BO UT WOS:000228272800048 PM 15824374 ER PT J AU Pannu, R Singh, AK Singh, I AF Pannu, R Singh, AK Singh, I TI A novel role of lactosylceramide in the regulation of tumor necrosis factor alpha-mediated proliferation of rat primary astrocytes - Implications for astrogliosis following neurotrauma SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID SPINAL-CORD-INJURY; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; LIPID RAFTS; REACTIVE ASTROCYTES; ERK/MAP KINASE; MESSENGER-RNA; CELL-LINE; TNF-ALPHA; EXPRESSION AB The present study describes the role of glycosphingolipids in neuroinflammatory disease and investigates tumor necrosis factor alpha (TNF alpha)-induced astrogliosis following spinal cord injury. Astrogliosis is the hallmark of neuroinflammation and is characterized by proliferation of astrocytes and increased glial fibrillary acidic protein (GFAP) gene expression. In primary astrocytes, TNF alpha stimulation increased the intracellular levels of lactosylceramide (LacCer) and induced GFAP expression and astrocyte proliferation. D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol.HCl (PDMP), a glucosylceramide synthase and LacCer synthase (GalT-2) inhibitor, inhibited astrocyte proliferation and GFAP expression, which were reversed by exogenous supplementation of LacCer but not by other glycosphingolipids. TNF alpha caused a rapid increase in the activity of GalT-2 and synthesis of LacCer. Silencing of GalT-2 gene using antisense oligonucleotides also attenuated the proliferation of astrocytes and GFAP expression. The PDMP and antisense-mediated inhibition of proliferation and GFAP expression was well correlated with decreased Ras/ERK1/2 pathway activation. Furthermore, TNF alpha-mediated astrocyte proliferation and GFAP expression was also inhibited by LY294002, a phosphatidylinositol 3-kinase inhibitor, which was reversed by exogenous LacCer. LY294002 also inhibited TNF alpha-induced GalT-2 activation and LacCer synthesis, suggesting a phosphatidylinositol 3-kinase-mediated regulation of GalT-2. In vivo, PDMP treatment attenuated chronic ERK1/2 activation and spinal cord injury (SCI)-induced astrocyte proliferation with improved functional recovery post-SCI. Therefore, the in vivo studies support the conclusions drawn from cell culture studies and provide evidence for the role of LacCer in TNF alpha-induced astrogliosis in a rat model of SCI. To our knowledge, this is the first report demonstrating the role of LacCer in the regulation of TNF alpha-induced proliferation and reactivity of primary astrocytes. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Dept Pediat, Charleston, SC USA. Ralph H Johnson Vet Affairs Med Ctr, Dept Pathol, Charleston, SC USA. RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 316 Clin Sci Bldg,96 Jonathan Lucas St, Charleston, SC 29425 USA. EM singhi@musc.edu FU NINDS NIH HHS [NS-34741, NS-40144, NS-37766, NS-22576] NR 50 TC 28 Z9 28 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 8 PY 2005 VL 280 IS 14 BP 13742 EP 13751 DI 10.1074/jbc.M411959200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 912QW UT WOS:000228095500070 PM 15668227 ER PT J AU Leeper, NJ Wener, LS Dhaliwal, G Saint, S Wachter, RM AF Leeper, NJ Wener, LS Dhaliwal, G Saint, S Wachter, RM TI One surprise after another SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID MYOCARDITIS C1 Univ Calif San Francisco, Dept Med, Sch Med, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. Ann Arbor Vet Affairs Med Ctr, Ann Arbor Vet Affairs Hlth Serv Res & Dev Ctr Exc, Ann Arbor, MI USA. Ann Arbor Vet Affairs Med Ctr, Patient Safety Enhancement Program, Ann Arbor, MI USA. Univ Michigan Hlth Syst, Ann Arbor, MI USA. Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. RP Wachter, RM (reprint author), Univ Calif San Francisco, Dept Med, Sch Med, Box 0120,Room M-994, San Francisco, CA 94143 USA. EM bobw@medicine.ucsf.edu FU AHRQ HHS [P20-HS11540] NR 8 TC 2 Z9 2 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 7 PY 2005 VL 352 IS 14 BP 1474 EP 1479 DI 10.1056/NEJMcps040755 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 913IP UT WOS:000228145200012 PM 15814884 ER PT J AU Wright, JT Dunn, JK Cutler, JA Davis, BR Cushman, WC Ford, CE Haywood, LJ Leenen, FHH Margolis, KL Papademetriou, V Probstfield, JL Whelton, PK Habib, GB AF Wright, JT Dunn, JK Cutler, JA Davis, BR Cushman, WC Ford, CE Haywood, LJ Leenen, FHH Margolis, KL Papademetriou, V Probstfield, JL Whelton, PK Habib, GB CA ALLHAT Collaborative Res Grp TI Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID LIPID-LOWERING TREATMENT; HEART-ATTACK TRIAL; CONVERTING-ENZYME-INHIBITOR; CALCIUM-CHANNEL BLOCKER; HIGH BLOOD-PRESSURE; ISOLATED SYSTOLIC HYPERTENSION; LEFT-VENTRICULAR DYSFUNCTION; MAJOR CARDIOVASCULAR EVENTS; JOINT NATIONAL COMMITTEE; RANDOMIZED-TRIAL AB Context Few cardiovascular outcome data are available for blacks with hypertension treated with angiotensin-converting enzyme (ACE) inhibitors or calcium channel blockers (CCBs). Objective To determine whether an ACE inhibitor or CCB is superior to a thiazide-type diuretic in reducing cardiovascular disease (CVD) incidence in racial subgroups. Design, Setting, and Participants Prespecified subgroup analysis of ALLHAT, a randomized, double-blind, active-controlled, clinical outcome trial conducted between February 1994 and March 2002 in 33 357 hypertensive US and Canadian patients aged 55 years or older (35% black) with at least 1 other cardiovascular risk factor. Interventions Anti hypertensive regimens initiated with a CCB (amlodipine) or an ACE inhibitor (lisinopril) vs a thiazide-type diuretic (chlorthalidone). Other medications were added to achieve goal blood pressures (BPs) less than 140/90 mm Hg. Main Outcome Measures The primary outcome was combined fatal coronary heart disease (CHD) or nonfatal myocardial infarction (MI), analyzed by intention-to-treat. Secondary outcomes included all-cause mortality, stroke, combined CVD (CND death, nonfatal MI, stroke, angina, coronary revascularization, heart failure [HF], or peripheral vascular disease), and end-stage renal disease. Results No significant difference was found between treatment groups for the primary CHD outcome in either racial subgroup. For amlodipine vs chlorthalidone only, HF was the only prespecified clinical outcome that differed significantly (overall: relative risk [RR], 1.37; 95% confidence interval [Cl], 1.24-1.51; blacks: RR, 1.46; 95% CI, 1.24-1.73; nonblacks: RR, 1.32; 95% CI, 1.17-1.49; P<.001 for each comparison) with no difference in treatment effects by race (P=.38 for interaction). For lisinopril vs chlorthalidone, results differed by race for systolic BP (greater decrease in blacks with chlorthalidone), stroke, and combined CVD outcomes (P<.001, P=.01, and P=.04, respectively, for interactions). In blacks and nonblacks, respectively, the RRs for stroke were 1.40 (95% CI, 1.17-1.68) and 1.00 (95% CI, 0.85-1.17) and for combined CVD were 1.19 (95% CI, 1.09-1.30) and 1.06(95% CI, 1.00-1.13). For HF, the RRs were 1.30 (95% CI, 1.10-1.54) and 1.13 (95% CI, 1.00-1.28), with no significant interaction by race. Time-dependent BP adjustment did not significantly alter differences in outcome for lisinopril vs chlorthalidone in blacks. Conclusions In blacks and nonblack subgroups, rates were not lower in the amlodipine or lisinopril groups than in the chlorthalidone group for either the primary CHD or any other prespecified clinical outcome, and diuretic-based treatment resulted in the lowest risk of heart failure. While the improved outcomes with chlorthalidone were more pronounced for some outcomes in blacks than in nonblacks, thiazide-type diuretics remain the drugs of choice for initial therapy of hypertension in both black and nonblack hypertensive patients. C1 Case Western Reserve Univ, Gen Clin Res Ctr, Cleveland, OH 44106 USA. Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Houston, TX USA. NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA. Memphis Vet Affairs Med Ctr, Memphis, TN USA. Univ So Calif, Los Angeles Cty Med Ctr, Los Angeles, CA 90033 USA. Univ Ottawa, Inst Heart, Ottawa, ON, Canada. Berman Ctr Outcomes & Clin Res, Minneapolis, MN USA. Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. Vet Affairs Med Ctr, Washington, DC 20422 USA. Univ Washington, Seattle, WA 98195 USA. Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA. Houston Vet Affairs Med Ctr, Houston, TX USA. RP Wright, JT (reprint author), Case Western Reserve Univ, Gen Clin Res Ctr, 11000 Euclid Ave,Bowell Bldg,5th Floor, Cleveland, OH 44106 USA. EM jackson.wright@case.edu OI Papademetriou, Vasilios/0000-0002-2882-2757 FU NHLBI NIH HHS [N01-HC-35130] NR 52 TC 191 Z9 198 U1 0 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD APR 6 PY 2005 VL 293 IS 13 BP 1595 EP 1607 DI 10.1001/jama.293.13.1595 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 913EV UT WOS:000228135300022 PM 15811979 ER PT J AU Sarnak, MJ Katz, R Stehman-Breen, CO Fried, LF Jenny, NS Psaty, BM Newman, AB Siscovick, D Shlipak, MG AF Sarnak, MJ Katz, R Stehman-Breen, CO Fried, LF Jenny, NS Psaty, BM Newman, AB Siscovick, D Shlipak, MG CA Cardio Hlth Study TI Cystatin C concentration as a risk factor for heart failure in older adults SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID GLOMERULAR-FILTRATION-RATE; EARLY RENAL IMPAIRMENT; MYOCARDIAL-INFARCTION; CARDIOVASCULAR OUTCOMES; SERUM CREATININE; ELDERLY PATIENTS; BLOOD-PRESSURE; INSUFFICIENCY; MARKER; DYSFUNCTION AB Background: Previous studies that evaluated the association of kidney function with incident heart failure may be limited by the insensitivity of serum creatinine concentration for detecting abnormal kidney function. Objective: To compare serum concentrations of cystatin C (a novel marker of kidney function) and creatinine as predictors of incident heart failure. Design: Observational study based on measurement of serum cystatin C from frozen sera obtained at the 1992-1993 visit of the Cardiovascular Health Study. Follow-up occurred every 6 months. Setting: Adults 65 years of age or older from 4 communities in the United States. Participants: 4384 persons without previous heart failure who had measurements of serum cystatin C and serum creatinine. Measurements: incident heart failure. Results: The mean ( +/- SD) serum concentrations of cystatin C and creatinine were 82 +/- 25 nmol/L (1.10 +/- 0.33 mg/L) and 89 +/- 34 mu mol/L (1.01 +/- 0.39 mg/dL, respectively. During a median follow-up of 8.3 years (maximum, 9.1 years), 763 (17%) participants developed heart failure. After adjustment for demographic factors, traditional and novel cardiovascular risk factors, cardiovascular disease status, and medication use, sequential quintiles of cystatin C concentration were associated with a stepwise increased risk for heart failure in Cox proportional hazards models (hazard ratios, 1.0 [reference], 1.30 [95% Cl, 0.96 to 1.75], 1.44 [CI, 1.07 to 1.94], 1.58 [CI, 1.18 to 2.12], and 2.16 [CI, 1.61 to 2.91]). In contrast, quintiles of serum creatinine concentration were not associated with risk for heart failure in adjusted analysis (hazard ratios, 1.0 [reference], 0.77 [Cl, 0.59 to 1.01), 0.85 [CI, 0.64 to 1.131, 0.97 [Cl, 0.72 to 1.29], and 1.14 [CI, 0.87 to 1.491). Limitations: The mechanism by which cystatin C concentration predicts risk for heart failure remains unclear. Conclusions: The cystatin C concentration is an independent risk factor for heart failure in older adults and appears to provide a better measure of risk assessment than the serum creatinine concentration. C1 Tufts New England Med Ctr, Boston, MA USA. Collaborat Hlth Studies Coordinating Ctr, Seattle, WA USA. Univ Washington, Seattle, WA 98195 USA. Amgen Inc, Thousand Oaks, CA 91320 USA. Vet Affairs Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. Univ Vermont, Burlington, VT USA. RP Shlipak, MG (reprint author), Vet Affairs Med Ctr 111A1, 4150 Clement St, San Francisco, CA 94121 USA. EM shlip@itsa.ucsf.edu RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 FU NHLBI NIH HHS [N01 HC-15103, N01-HC-85079, N01-HC-85080, N01-HC-35129, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, R01 HL073208-01]; NIDDK NIH HHS [K23 DK67303] NR 40 TC 198 Z9 215 U1 1 U2 6 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 5 PY 2005 VL 142 IS 7 BP 497 EP 505 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 913QL UT WOS:000228167800003 PM 15809461 ER PT J AU Li, ZP Maglione, M Tu, WL Mojica, W Arterburn, D Shugarman, LR Hilton, L Suttorp, M Solomon, V Shekelle, PG Morton, SC AF Li, ZP Maglione, M Tu, WL Mojica, W Arterburn, D Shugarman, LR Hilton, L Suttorp, M Solomon, V Shekelle, PG Morton, SC TI Meta-analysis: Pharmacologic treatment of obesity SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; TYPE-2 DIABETIC-PATIENTS; LONG-TERM MAINTENANCE; WEIGHT-LOSS; DOUBLE-BLIND; BODY-WEIGHT; CLINICAL-TRIALS; US ADULTS AB Background: in response to the increase in obesity, pharmacologic treatments for weight loss have become more numerous and more commonly used. Purpose: To assess the efficacy and safety of weight loss medications approved by the U.S. Food and Drug Administration and other medications that have been used for weight loss. Data Sources: Electronic databases, experts in the field, and unpublished information. Study Selection: Up-to-date meta-analyses of sibutramine, phentermine, and diethylpropion were identified. The authors assessed in detail 50 studies of orlistat, 13 studies of fluoxetine, 5 studies of bupropion, 9 studies of topiramate, and 1 study each of sertraline and zonisamide. Meta-analysis was performed for all medications except sertraline, zonisamide, and fluoxetine, which are summarized narratively. Data Extraction: The authors abstracted information about study design, intervention, co-interventions, population, outcomes, and methodologic quality, as well as weight loss and adverse events from controlled trials of medication. Data Synthesis: All pooled weight loss values are reported relative to placebo. A meta-analysis of sibutramine reported a mean difference in weight loss of 4.45 kg (95% Cl, 3.62 to 5.29 kg) at 12 months. In the meta-analysis of orlistat, the estimate of the mean weight loss for orlistat-treated patients was 2.89 kg (Cl, 2.27 to 3.51 kg) at 12 months. A recent meta-analysis of phentermine and diethylpropion reported pooled mean differences in weight loss at 6 months of 3.6 kg (Cl, 0.6 to 6.0 kg) for phentermine-treated patients and 3.0 kg (Cl, -1.6 to 11.5 kg) for diethyl propion -treated patients. Weight loss in fluoxetine studies ranged from 14.5 kg of weight lost to 0.4 kg of weight gained at 12 or more months. For bupropion, 2.77 kg (Cl, 1.1 to 4.5 kg) of weight was lost at 6 to 12 months. Weight loss due to topiramate at 6 months was 6.5% (Cl, 4.8% to 8.3%) of pretreatment weight. With one exception, long-term studies of health outcomes were lacking. Significant side effects that varied by drug were reported. Limitations: Publication bias may exist despite a comprehensive search and despite the lack of statistical evidence for the existence of bias. Evidence of heterogeneity was observed for all metaanalyses. Conclusions: Sibutramine, orlistat, phentermine, probably diethylpropion, bupropion, probably fluoxetine, and topiramate promote modest weight loss when given along with recommendations for diet. Sibutramine and orlistat are the 2 most-studied drugs. C1 So Calif Evidence Based Practice Ctr, RAND Hlth Div, Santa Monica, CA USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. Dept Vet Affairs, Cincinnati, OH USA. RP Li, ZP (reprint author), LA Vet Affairs Med Ctr, W111A,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. NR 96 TC 390 Z9 403 U1 2 U2 41 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 5 PY 2005 VL 142 IS 7 BP 532 EP 546 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA 913QL UT WOS:000228167800007 PM 15809465 ER PT J AU Maggard, MA Shugarman, LR Suttorp, M Maglione, M Sugarman, HJ Livingston, EH Nguyen, NT Li, ZP Mojica, WA Hilton, L Rhodes, S Morton, SC Shekelle, PG AF Maggard, MA Shugarman, LR Suttorp, M Maglione, M Sugarman, HJ Livingston, EH Nguyen, NT Li, ZP Mojica, WA Hilton, L Rhodes, S Morton, SC Shekelle, PG TI Meta-analysis: Surgical treatment of obesity SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID VERTICAL BANDED GASTROPLASTY; QUALITY-OF-LIFE; ROUX-EN-Y; GASTRIC BYPASS-SURGERY; INDUCED WEIGHT-LOSS; MORBID-OBESITY; BARIATRIC SURGERY; LONG-TERM; RANDOMIZED-TRIAL; SUBJECTS SOS AB Background: controversy exists regarding the effectiveness of surgery for weight loss and the resulting improvement in healthrelated outcomes. Purpose: To perform a meta-analysis of effectiveness and adverse events associated with surgical treatment of obesity. Data Sources: MEDLINE, EMBASE, Cochrane Controlled Trials Register, and systematic reviews. Study Selection: Randomized, controlled trials; observational studies; and case series reporting on surgical treatment of obesity. Data Extraction: Information about study design, procedure, population, comorbid conditions, and adverse events. Data Synthesis: The authors assessed 147 studies. Of these, 89 contributed to the weight loss analysis, 134 contributed to the mortality analysis, and 128 contributed to the complications analysis. The authors identified 1 large, matched cohort analysis that reported greater weight loss with surgery than with medical treatment in individuals with an average body mass index (BMI) of 40 kg/m(2) or greater. Surgery resulted in a weight loss of 20 to 30 kg, which was maintained for up to 10 years and was accompanied by improvements in some comorbid conditions. For BMIs of 35 to 39 kg/m(2), data from case series strongly support superiority of surgery but cannot be considered conclusive. Gastric bypass procedures result in more weight loss than gastroplasty. Bariatric procedures in current use (gastric bypass, laparoscopic adjustable gastric band, vertical banded gastroplasty, and biliopancreatic diversion and switch) have been performed with an overall mortality rate of less than 1%. Adverse events occur in about 20% of cases. A laparoscopic approach results in fewer wound complications than an open approach. Limitations: only a few controlled trials were available for analysis. Heterogeneity was seen among studies, and publication bias is possible. Conclusions: Surgery is more effective than nonsurgical treatment for weight loss and control of some comorbid conditions in patients with a BMI of 40 kg/m(2) or greater. More data are needed to determine the efficacy of surgery relative to nonsurgical therapy for less severely obese people. Procedures differ in efficacy and incidence of complications. C1 Univ Calif Los Angeles, Med Ctr, Dept Surg, Los Angeles, CA 90095 USA. So Calif Evidence Based Practice Ctr, RAND Hlth Div, Santa Monica, CA USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RP Maggard, MA (reprint author), Univ Calif Los Angeles, Med Ctr, Dept Surg, CHS Room 72-215,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM mmaggard@mednet.ucla.edu NR 94 TC 791 Z9 811 U1 5 U2 53 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 5 PY 2005 VL 142 IS 7 BP 547 EP 559 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 913QL UT WOS:000228167800008 PM 15809466 ER PT J AU Mann, DL AF Mann, DL TI Clinical evaluation of the CorCap Cardiac Support Device in patients with dilated cardiomyopathy SO CIRCULATION LA English DT Meeting Abstract CT 77th Scientific Meeting of the American-Heart-Association CY NOV 07-10, 2004 CL New Orleans, LA SP Amer Heart Assoc C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD APR 5 PY 2005 VL 111 IS 13 BP 1725 EP 1725 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 913CZ UT WOS:000228129900051 ER PT J AU Tsuang, D Simpson, KL Li, G Barnhart, RL Edland, SD Bowen, J McCormick, W Teri, L Nochlin, D Larson, EB Thompson, ML Leverenz, JB AF Tsuang, D Simpson, KL Li, G Barnhart, RL Edland, SD Bowen, J McCormick, W Teri, L Nochlin, D Larson, EB Thompson, ML Leverenz, JB TI Evaluation of selection bias in an incident-based dementia autopsy case series SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE Alzheimer disease; selection bias; autopsy; dementia ID ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; LEWY BODIES; PREVALENCE; FREQUENCY; DIAGNOSIS; JAPANESE; SAMPLE AB Neuropathological (np) relative frequency estimates of dementia may be biased if the autopsied subjects are not representative of all dementia subjects within a target population. We identified characteristics that differed between autopsied and nonautopsied subjects from an incident-based dementia case series and compared autopsy-based estimates of the relative frequency of np diagnoses before and after adjusting for potential selection bias. Clinically demented subjects who were autopsied (n = 206), had died but were not autopsied (n = 271), were still alive (n = 71), or had dropped out of the study (n = 82) were included. Compared with non-autopsied subjects, autopsied subjects were more likely to be Caucasian, educated beyond high school, and married. They also tended to have a lower baseline Mini-Mental State Examination score and were more likely to have a clinical diagnosis of Alzheimer disease (AD) than non-autopsied subjects. Neuropathological AD with Lewy bodies (LB) had the largest crude relative frequency estimate at 38% of the autopsy sample, followed by 25% for AD with vascular lesions, 13% for pure AD, 13% for LB (with or without vascular lesions), and 8% for pure vascular pathologies. Adjustment for potential sources of selection bias had little effect on relative frequency estimates, suggesting that np diagnoses in the autopsied subjects provide reasonable dementia relative frequency estimates among all clinically demented cases in this series. C1 Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. Univ Washington, Dept Environm Hlth, Seattle, WA 98195 USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Mayo Clin & Mayo Fdn, Div Clin Epidemiol, Rochester, MN 55905 USA. Univ Washington, Dept Internal Med, Seattle, WA 98195 USA. Univ Washington, Sch Nursing, Seattle, WA 98195 USA. Univ Washington, Dept Pathol, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Parkinsons Dis Res Educ & Clin Ctr, Seattle, WA USA. RP Tsuang, D (reprint author), VAPSHCS, 1660 S Columbian Way, Seattle, WA 98108 USA. EM dwt1@u.washington.edu RI Tsuang, Debby/L-7234-2016 OI Tsuang, Debby/0000-0002-4716-1894 FU NIA NIH HHS [AG05136, AG06781, P50 AG005136, U01 AG006781]; NINDS NIH HHS [R01 NS048595, R01 NS48595] NR 19 TC 20 Z9 20 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD APR-JUN PY 2005 VL 19 IS 2 BP 67 EP 73 DI 10.1097/01.wad.0000165507.67993.47 PG 7 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 939FM UT WOS:000230057800003 PM 15942323 ER PT J AU Dulai, GS Shekelle, PG Jensen, DM Spiegel, BMR Chen, J Oh, D Kahn, KL AF Dulai, GS Shekelle, PG Jensen, DM Spiegel, BMR Chen, J Oh, D Kahn, KL TI Dysplasia and risk of further neoplastic progression in a regional veterans administration Barrett's cohort SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID COLUMNAR-LINED ESOPHAGUS; LOW-GRADE DYSPLASIA; FLOW-CYTOMETRY; CANCER-RISK; ENDOSCOPIC SURVEILLANCE; OBSERVER VARIATION; ADENOCARCINOMA; DIAGNOSIS; PREDICTORS; REPRODUCIBILITY AB OBJECTIVES: No published data are available on the risk of further neoplastic progression in Barrett's patients stratified by baseline dysplasia status. Our aims were to estimate and compare the risk of progression to high-grade dysplasia or cancer in groups of Barrett's patients stratified by baseline dysplasia status. METHODS: Consecutive Barrett's cases from 1988-2002 were identified via pathology databases in a regional VA health-care system and medical record data were abstracted. The risk of progression to high-grade dysplasia or cancer was measured and compared in cases with versus without low-grade dysplasia within 1 yr of index endoscopy using survival analysis. RESULTS: A total of 575 Barrett's cases had 2,775 patient-years of follow-up. There were 13 incident cases of high-grade dysplasia and two of cancer. The crude rate of high-grade dysplasia or cancer was 1 of 78 patient-years for those with baseline dysplasia versus 1 of 278 patient-years for those without (p = 0.001). One case of high-grade dysplasia in each group underwent successful therapy. One incident cancer case underwent successful resection and the other was unresectable. Two cases with high-grade dysplasia later developed cancer, one died postoperatively, the other was unresectable. When these two cases were included (total of four cancers), the crude rate of cancer was 1 of 274 patient-years for those with baseline dysplasia versus 1 of 1,114 patient-years for those without. CONCLUSIONS: In a large cohort study of Barrett's, incident malignancy was uncommon. The rate of progression to high-grade dysplasia or cancer was significantly higher in those with baseline low-grade dysplasia. These data may warrant reevaluation of current Barrett's surveillance strategies. C1 Univ Calif Los Angeles, Greater Los Angeles Vet Adm Healthcare Syst, Sch Med,Dept Med, Div Gastroenterol,Div Gen Internal Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, UCLA Ctr Study Digest Healthcare Qual & Outcomes, Dept Med,Div Digest Dis, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA. RAND Corp, Hlth, Santa Monica, CA USA. RP Dulai, GS (reprint author), Greater Los Angeles Vet Adm Healthcare Syst, Ctr Study Digest Healthcare Qual & Outcomes, Bldg 115,Room 215C,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NCRR NIH HHS [K23 RR 1618801]; NIDDK NIH HHS [K24 DK 02650] NR 50 TC 67 Z9 68 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD APR PY 2005 VL 100 IS 4 BP 775 EP 783 DI 10.1111/j.1572-0241.2005.41300.x PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 907LU UT WOS:000227720400009 PM 15784018 ER PT J AU Tillisch, K Labus, JS Naliboff, BD Bolus, R Shetzline, M Mayer, EA Chang, L AF Tillisch, K Labus, JS Naliboff, BD Bolus, R Shetzline, M Mayer, EA Chang, L TI Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID DIARRHEA-PREDOMINANT; SYMPTOMS; CONSTIPATION; SUBGROUPS; COMMUNITY; RESPONSES; PATTERNS; SAMPLES; IMPACT; WOMEN AB Background: Due to a wide range of symptom patterns, patients with irritable bowel syndrome (IBS) are often subgrouped by bowel habit. However, the IBS subgroup with alternating bowel habits (IBS-A) has been poorly characterized. Objectives: (I) To determine a set of bowel habit symptom criteria, which most specifically identifies IBS patients with an alternating bowel habit, (II) to describe IBS-A bowel symptom patterns, and (III) to compare clinical characteristics among IBS-A, constipation-predominant (IBS-C), and diarrhea-predominant IBS (IBS-D). Methods: One thousand one hundred and two Rome I positive IBS patients were analyzed. Three sets of potential criteria for IBS-A were developed and compared by multirater Kappa test. Gastrointestinal, psychological, extraintestinal symptoms, and health-related quality of life were compared in IBS-A, IBS-C, and IBS-D using 2 test and analysis of variance (ANOVA). Results: Stool consistency was determined to be the most specific criteria for alternating bowel habits. IBS-A patients reported rapid fluctuations in bowel habits with short symptom flares and remissions. There was a greater prevalence of psychological and extraintestinal symptoms in the IBS-A subgroup compared to IBS-C and IBS-D. No differences were seen between bowel habit subtypes in health-related quality of life. Conclusions: IBS-A patients have rapidly fluctuating symptoms and increased psychological comorbidity, which should be taken into account for clinical practice and clinical trials. C1 Univ Calif Los Angeles, CNS WH Ctr Neurovisceral Sci & Womens Hlth, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, CNS WH Ctr Neurovisceral Sci & Womens Hlth, Dept Physiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, CNS WH Ctr Neurovisceral Sci & Womens Hlth, Dept Psychiat & Behav Sci, Los Angeles, CA 90073 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Nova Pharmaceut Corp, E Hanover, NJ USA. RP Tillisch, K (reprint author), Univ Calif Los Angeles, CNS WH Ctr Neurovisceral Sci & Womens Hlth, Dept Med, CURE Bldg 115,Room 223,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NIDDK NIH HHS [P50 DK64539] NR 29 TC 74 Z9 78 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD APR PY 2005 VL 100 IS 4 BP 896 EP 904 DI 10.1111/j.1572-0241.2005.41211.x PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 907LU UT WOS:000227720400029 PM 15784038 ER PT J AU Seliger, SL Sampson, J Kestenbaum, B Young, B Rudser, K Andress, DL Sherrard, DJ AF Seliger, SL Sampson, J Kestenbaum, B Young, B Rudser, K Andress, DL Sherrard, DJ TI Anemia and adverse outcomes in veterans with chronic kidney disease (CKD) SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT Spring Clinical Meeting of the National-Kidney-Foundation CY MAY 04-08, 2005 CL Washington, DC SP Natl Kindney Fdn C1 Univ Washington, Div Nephrol, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. VA Puget Sound Healthcare Syst, Div Nephrol, Seattle, WA USA. VA Puget Sound Healthcare Syst, Div Gen Internal Med, Seattle, WA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2005 VL 45 IS 4 MA 120 BP A46 EP A46 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 920VJ UT WOS:000228718000151 ER PT J AU Jackson, GL Yano, EM Edelman, D Krein, SL Ibrahim, MA Carey, TS Lee, SYD Hartmann, KE Dudley, TK Weinberger, M AF Jackson, GL Yano, EM Edelman, D Krein, SL Ibrahim, MA Carey, TS Lee, SYD Hartmann, KE Dudley, TK Weinberger, M TI Veterans affairs primary care organizational characteristics associated with better diabetes control SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Review ID QUALITY-OF-CARE; BLOOD-GLUCOSE CONTROL; CHRONIC ILLNESS CARE; HEALTH-CARE; GLYCEMIC CONTROL; UNITED-STATES; PUBLIC-HEALTH; ADMINISTRATIVE DATA; MULTILEVEL MODELS; MEDICAL-RECORDS AB Objective: To examine organizational features of Veterans Affairs (VA) primary care programs hypothesized to be associated with better diabetes control, as indicated by hemoglobin A(1c) (HbA(1c)) levels. Study Design: Cross-sectional cohort. Methods: We established a cohort of 224 221 diabetic patients using the VA Diabetes Registry and Dataset and VA corporate databases. The 1999 VHA (Veterans Health Administration) Survey of Primary Care Practices results were combined with individual patient data. A 2-level hierarchical model was used to determine the relationship between organizational characteristics and HbA(1c) levels in 177 clinics with 82 428 cohort members. Results: The following attributes were associated with lower (better) HbA(1c) and were statistically significant at P < .05: greater authority to establish or implement clinical policies (lower by 0.21%), greater staffing authority (0.28%), computerized diabetes reminders (0.17%), notifying all patients of their assigned provider (0.21%), hiring needed new staff during fiscal year 1999 (0.18%), having nurses that report only to the program (0.16%), and being a large academic practice (0.27%). Associated with higher (worse) HbA(1c) were programs reporting that patients almost always see their assigned provider (greater by 0.18%), having a quality improvement program involving all nurses without all physicians (0.38%), having general internal medicine physicians report only to the program (0.20%), and being located at an acute care hospital (0.20%). Conclusion: Programs that are associated with better diabetes control simultaneously have teams that actively involve physicians in quality improvement, use electronic health information systems, have authority to respond to staffing and programmatic issues, and engage patients in care. C1 Durham Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence Hlth Serv Res, HSR&D Serv 152, Durham, NC 27705 USA. Duke Univ, Div Gen Internal Med, Durham, NC USA. Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA. Univ N Carolina, Div Gen Med & Clin Epidemiol, Chapel Hill, NC USA. Univ N Carolina, Dept Hlth Policy & Adm, Chapel Hill, NC USA. Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC USA. Vet Affairs Greater Los Angeles Healthcare Syst, Hlth Serv Res & Dev Ctr Excellence Study Healthca, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA USA. Ann Arbor Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence Pratice Manage, Ann Arbor, MI USA. Univ Michigan, Div Gen Med, Ann Arbor, MI 48109 USA. Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA. RP Jackson, GL (reprint author), Durham Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Excellence Hlth Serv Res, HSR&D Serv 152, 508 Fulton St, Durham, NC 27705 USA. EM georg_jackson@alumni.unc.edu RI Krein, Sarah/E-2742-2014 OI Krein, Sarah/0000-0003-2111-8131 FU AHRQ HHS [2T32HS000079-06] NR 89 TC 29 Z9 29 U1 0 U2 5 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD APR PY 2005 VL 11 IS 4 BP 225 EP 237 PG 13 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 913YH UT WOS:000228191000004 PM 15839183 ER PT J AU Aujesky, D Auble, TE Yealy, DM Stone, RA Obrosky, DS Meehan, TP Graff, LG Fine, JM Fine, MJ AF Aujesky, D Auble, TE Yealy, DM Stone, RA Obrosky, DS Meehan, TP Graff, LG Fine, JM Fine, MJ TI Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE clinical prediction rule; community-acquired pneumonia ID MANAGEMENT; SEVERITY; ADULTS; GUIDELINES; TRIAL; ETIOLOGY; INTERVENTION; UPDATE; INDEX AB PURPOSE: We assessed the performance of 3 validated prognostic rules in predicting 30-day mortality in community-acquired pneumonia: the 20 variable Pneumonia Severity Index and the easier to calculate CURB (confusion, urea nitrogen, respiratory rate, blood pressure) and CURB-65 severity scores. SUBJECTS AND METHODS: We prospectively followed 3181 patients with community-acquired pneumonia from 32 hospital emergency departments (January-December 2001) and assessed mortality 30 days after initial presentation. Patients were stratified into Pneumonia Severity Index risk classes (I-V) and CURB (0-4) and CURB-65 (0-5) risk strata. We compared the discriminatory power (area under the receiver operating characteristic curve) of these rules to predict mortality and their accuracy based on sensitivity, specificity, predictive values, and likelihood ratios RESULTS: The Pneumonia Severity Index (risk classes I-III) classified a greater proportion of patients as low risk (68% [2152/3181]) than either a CURB score < 1 (51% [1635/3181]) or a CURB-65 score < 2 (61% [1952/3181]). Low-risk patients identified based on the Pneumonia Severity Index had a slightly lower mortality (1.4% [31/2152]) than patients classified as low-risk based on the CURB (1.7% [28/1635]) or the CURB-65 (1.7% [33/1952]). The area under the receiver operating characteristic curve was higher for the Pneumonia Severity Index (0.81) than for either the CURB (0.73) or CURB-65 (0.76) scores (P < 0.001, for each pairwise comparison). At comparable cut-points, the Pneumonia Severity Index had a higher sensitivity and a somewhat higher negative predictive value for mortality than either CURB score. CONCLUSIONS: The more complex Pneumonia Severity Index has a higher disciminatory power for short-term mortality, defines a greater proportion of patients at low risk, and is slightly more accurate in identifying patients at low risk than either CURB score. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Pittsburgh, Grad Sch Publ Hlth, Div Gen Internal Med, Dept Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Emergency Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15260 USA. Yale Univ, Sch Med, New Haven, CT 06520 USA. Univ Connecticut, Sch Med, Dept Traumatol & Emergency Med, Storrs, CT 06269 USA. RP Aujesky, D (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Bldg 28 Suite 1A129,Univ Dr C, Pittsburgh, PA 15240 USA. EM aujesky@swissonline.ch FU AHRQ HHS [R01 HS 10049-03] NR 28 TC 160 Z9 164 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD APR PY 2005 VL 118 IS 4 BP 384 EP 392 DI 10.1016/j.amjmed.2005.01.006 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 915CM UT WOS:000228275200010 PM 15808136 ER PT J AU McCarley, PB Salai, PB AF McCarley, PB Salai, PB TI Cardiovascular disease in chronic kidney disease - Recognizing and reducing the risk of a common CKD comorbidity. SO AMERICAN JOURNAL OF NURSING LA English DT Article ID CHRONIC RENAL-DISEASE; AMERICAN-HEART-ASSOCIATION; HEALTH-CARE PROFESSIONALS; HIGH BLOOD-PRESSURE; MYOCARDIAL-INFARCTION; DYSFUNCTION; PREVENTION; FAILURE; REDUCTION; STATEMENT C1 Diablo Nephrol Med Grp, Walnut Creek, CA 94598 USA. Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP McCarley, PB (reprint author), Diablo Nephrol Med Grp, 112 La Casa Via,Suite 210, Walnut Creek, CA 94598 USA. EM bargo1@pacbell.net; triumphantrn@aol.com NR 56 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-936X J9 AM J NURS JI Am. J. Nurs. PD APR PY 2005 VL 105 IS 4 BP 40 EP 52 PG 13 WC Nursing SC Nursing GA 912MP UT WOS:000228083200027 PM 15791076 ER PT J AU Baker, FC Shah, S Stewart, D Angara, C Gong, H Szymusiak, R Opp, MR McGinty, D AF Baker, FC Shah, S Stewart, D Angara, C Gong, H Szymusiak, R Opp, MR McGinty, D TI Interleukin 1 beta enhances non-rapid eye movement sleep and increases c-Fos protein expression in the median preoptic nucleus of the hypothalamus SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE cytokines; preoptic area; rapid eye movement sleep ID WAKING DISCHARGE PATTERNS; IN-VITRO; BRAIN TEMPERATURE; RAT-BRAIN; NEURONS; AREA; ACTIVATION; DEPRIVATION; INVOLVEMENT; INJECTION AB Interleukin 1 beta (IL-1) is a key mediator of the acute phase response in an infected host and acts centrally to coordinate responses to an immune challenge, such as fever and increased non-rapid eye movement (NREM) sleep. The preoptic area (POA) is a primary sleep regulatory center in the brain: the ventrolateral POA (VLPO) and median preoptic nucleus (MnPN) each contain high numbers of c-Fos protein immunoreactive (IR) neurons after sleep but not after waking. We hypothesized that IL-1 mediates increased NREM sleep through activation of these sleep-active sites. Rats injected intracerebroventricularly with IL-1 (10 ng) at dark onset spent significantly more time in NREM sleep 4-5 h after injection. This increase in NREM sleep was associated with increased numbers of Fos-IR neurons in the MnPN, but not in the VLPO. Fos IR in the rostral MnPN was significantly increased 2 h post IL-1 injection, although the percentage of NREM sleep in the preceding 2 h was the same as controls. Fos IR was also increased in the extended VLPO 2 h postinjection. Finally, Fos IR in the MnPN did not differ significantly between IL-1 and vehicle-treated rats that had been sleep deprived for 2 h postinjection, but it was increased in VLPO core. Taken together, these results suggest that Fos IR in the MnPN after IL-1 is not independent of behavioral state and may require some threshold amount of sleep for its expression. Our results support a hypothesis that IL-1 enhances NREM sleep, in part, through activation of neurons in the MnPN of the hypothalamus. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv 151A3, North Hills, CA 91343 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. Univ Witwatersrand, Sch Physiol, Brain Funct Res Unit, Johannesburg, South Africa. Univ Michigan, Sch Med, Dept Anesthesiol, Ann Arbor, MI USA. RP McGinty, D (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91343 USA. EM dmcginty@ucla.edu FU NIMH NIH HHS [MH-47480, MH-66323] NR 46 TC 32 Z9 37 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD APR PY 2005 VL 288 IS 4 BP R998 EP R1005 DI 10.1152/ajpregu.00615.2004 PG 8 WC Physiology SC Physiology GA 908YV UT WOS:000227827000028 PM 15604300 ER PT J AU Johnson, FK Johnson, RA Peyton, KJ Durante, W AF Johnson, FK Johnson, RA Peyton, KJ Durante, W TI Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE salt-sensitive hypertension; vascular tone; arterioles ID OXIDE SYNTHASE ACTIVITY; HEME OXYGENASE INHIBITOR; VASCULAR SMOOTH-MUSCLE; NITRIC-OXIDE; L-ARGININE; SENSITIVE HYPERTENSION; CORPUS CAVERNOSUM; CELLS; EXPRESSION; DYSFUNCTION AB Vascular tissues express arginase that metabolizes L-arginine to L-ornithine and urea and thus reduces substrate availability for nitric oxide formation. Dahl salt-sensitive (Dahl-S) rats with salt-induced hypertension show endothelial dysfunction, including decreased vascular nitric oxide formation. This study tests the hypothesis that increased vascular arginase activity contributes to endothelial dysfunction in hypertensive Dahl-S rats. Male Dahl-S rats (5-6 wk) were placed on high (8%) or low (0.3%) NaCl diets for 4 wk. With respect to the low-salt group, mean arterial blood pressure was increased in the high-salt animals. Immunohistochemical stainings for arginase I and II were enhanced in arterioles isolated from high-salt Dahl-S rats. Experiments used isolated Krebs buffer-superfused first-order gracilis muscle arterioles with constant pressure (80 mmHg) and no luminal flow or constant midpoint but altered endpoint pressures to establish graded levels of luminal flow (0-50 mu l/min). In high-salt arterioles, responses to an endothelium-dependent vasodilator acetylcholine (1 nmol/l to 3 mu mol/l) and flow-induced dilation were decreased. Acute in vitro treatment with an inhibitor of arginase, 100 mu mol/l (S)-(2-boronoethyl)-L-cystine, or the nitric oxide precursor, 1 mmol/l L-arginine, similarly enhanced acetylcholine and flow-induced maximal dilations and abolished the differences between high- and low-salt arterioles. These data show that arteriolar arginase expression is increased and that endothelium-dependent vasodilation is decreased in high-salt Dahl-S rats. Acute pretreatment with an arginase inhibitor or with L-arginine restores endothelium-dependent vasodilation and abolishes the differences between high- and low-salt groups. These results suggest that enhanced vascular arginase activity contributes to endothelial dysfunction in Dahl-S rats with salt-induced hypertension and identifies arginase as a potential therapeutic target to prevent endothelial dysfunction. C1 Houston Vet Adm Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Tulane Univ, Hlth Sci Ctr, Dept Physiol, New Orleans, LA 70118 USA. Tulane Univ, Hlth Sci Ctr, Tulane Hypertens & Renal Ctr Excellence, New Orleans, LA 70118 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Durante, W (reprint author), Houston Vet Adm Med Ctr, 2002 Holcombe Blvd,Bldg 109,Rm 130, Houston, TX 77030 USA. EM wdurante@bcm.tmc.edu FU NCRR NIH HHS [P20 RR-017659]; NHLBI NIH HHS [R01 HL-59976, R01 HL-64577, R01 HL-76187] NR 34 TC 78 Z9 83 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD APR PY 2005 VL 288 IS 4 BP R1057 EP R1062 DI 10.1152/ajpregu.00758.2004 PG 6 WC Physiology SC Physiology GA 908YV UT WOS:000227827000035 PM 15591155 ER PT J AU Xu, HS Tian, W Lindsley, JN Oyama, TT Capasso, JM Rivard, CJ Cohen, HT Bagnasco, SM Anderson, S Cohen, DM AF Xu, HS Tian, W Lindsley, JN Oyama, TT Capasso, JM Rivard, CJ Cohen, HT Bagnasco, SM Anderson, S Cohen, DM TI EphA2: expression in the renal medulla and regulation by hypertonicity and urea stress in vitro and in vivo SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE osmotic; cell volume regulation; receptor tyrosine kinase; signal transduction; rat; kidney ID EPIDERMAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; CELLS REQUIRES TRANSACTIVATION; NA-K-ATPASE; EPITHELIAL-CELLS; GENE-TRANSCRIPTION; ENDOTHELIAL-CELLS; SIGNAL TRANSDUCER; DEPENDENT PATHWAY; ACTIVATION AB EphA2, a member of the large family of Eph receptor tyrosine kinases, is highly expressed in epithelial tissue and has been implicated in cell-cell and cell-matrix interactions, as well as cell growth and survival. Expression of EphA2 mRNA and protein was markedly upregulated by both hypertonic stress and by elevated urea concentrations in cells derived from the murine inner medullary collecting duct. This upregulation likely required transactivation of the epidermal growth factor (EGF) receptor tyrosine kinase and metalloproteinase-dependent ectodomain cleavage of an EGF receptor ligand, based on pharmacological inhibitor studies. A human EphA2 promoter fragment spanning nucleotides -4030 to +21 relative to the putative EphA2 transcriptional start site was responsive to tonicity but insensitive to urea. A promoter fragment spanning -1890 to +128 recapitulated both tonicity- and urea-dependent upregulation of expression, consistent with transcriptional activation. Neither the bona fide p53 response element at approximately -1.5 kb nor a pair of putative TonE elements at approximately -3 kb conferred the tonicity responsiveness. EphA2 mRNA and protein were expressed at low levels in rat renal cortex but at high levels in the collecting ducts of the renal medulla and papilla. Water deprivation in rats increased EphA2 expression in renal papilla, whereas dietary supplementation with 20% urea increased EphA2 expression in outer medulla. These data indicate that transcription and expression of the EphA2 receptor tyrosine kinase are regulated by tonicity and urea in vitro and suggest that this phenomenon is also operative in vivo. Renal medullary EphA2 expression may represent an adaptive response to medullary hypertonicity or urea exposure. C1 Oregon Hlth Sci Univ, Div Nephrol & Hypertens, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. Boston Univ, Sch Med, Dept Med, Nephrol Sect, Boston, MA 02215 USA. Boston Med Ctr, Boston, MA USA. Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Dept Renal Dis & Hypertens, Denver, CO 80202 USA. RP Cohen, DM (reprint author), Oregon Hlth Sci Univ, Div Nephrol & Hypertens, Mailcode PP262,3314 SW,US Vet Hosp Rd, Portland, OR 97201 USA. EM cohend@ohsu.edu FU NCI NIH HHS [R01 CA079830]; NIA NIH HHS [AG-14699]; NIDDK NIH HHS [R01 DK067569, DK-52494] NR 57 TC 14 Z9 15 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD APR PY 2005 VL 288 IS 4 BP F855 EP F866 DI 10.1152/alprenal.00347.2004 PG 12 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 904JY UT WOS:000227495000031 PM 15561974 ER PT J AU Allison, JJ Kiefe, CI Wall, T Casebeer, L Ray, MN Spettell, CM Hook, EW Oh, MK Person, SD Weissman, NW AF Allison, JJ Kiefe, CI Wall, T Casebeer, L Ray, MN Spettell, CM Hook, EW Oh, MK Person, SD Weissman, NW TI Multicomponent Internet continuing medical education to promote chlamydia screening SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID PELVIC-INFLAMMATORY-DISEASE; DNA AMPLIFICATION ASSAYS; COST-EFFECTIVENESS; PAP-SMEAR; TRACHOMATIS; INFECTIONS; CARE; WOMEN; PERFORMANCE; PREVALENCE AB Background: Low Chlamydia trachomatis screening rates create an opportunity to test innovative continuing medical education (CME) programs. Few studies of Internet-based physician learning have been evaluated with objective data on practice patterns. Design: This randomized controlled trial tested a multicomponent Internet CME (mCME) intervention for increasing chlamydia screening of at-risk women aged 16 to 26 years. Setting: Eligible physician offices had >= 20 patients at risk for chlamydia as defined by the Health Plan Employer Data and Information Set (HEDIS), had at least one primary care physician (internal medicine, family medicine/general practice, pediatrics) with Internet access, and participated in the study managed care organization. The 191 randomized primary care offices represented 20 states. Intervention: The intervention, available from February to December 2001, consisted of four case-based learning modules, was tailored in real time to each physician based on theory of behavior change, and included office-level feedback of chlamydia screening rates. Main outcome measures: HEDIS chlamydia screening rates for the pre-intervention (2000) and post-intervention (2002) periods. Results: Pre-intervention screening rates for the intervention and comparison offices were 18.9% and 16.2% (p =0.135). Post-intervention screening rates for the intervention and comparison offices were 15.5% and 12.4%, respectively (p =0.044, adjusting for baseline performance). Conclusions: The substantial decline in chlamydia screening rates observed in the comparison offices was significantly attenuated for the intervention offices. The mCME favorably influenced chlamydia screening by primary care physicians. (Am J Prev Med 2005;28 (3):285-290) (c) 2005 American Journal of Preventive Medicine. C1 Univ Alabama, Div Gen Internal Med, Birmingham, AL 35294 USA. Univ Alabama, Div Prevent Med, Birmingham, AL 35294 USA. Univ Alabama, Ctr Outcomes & Effectivness Res & Educ, Birmingham, AL 35294 USA. Univ Alabama, Dept Hlth Serv Adm, Birmingham, AL 35294 USA. Univ Alabama, Div Continuing Med Educ, Birmingham, AL 35294 USA. Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA. Univ Alabama, Div Infect Dis, Birmingham, AL 35294 USA. Aetna Integrated Informat Inc, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Allison, JJ (reprint author), Univ Alabama, Div Gen Internal Med, 720 Fac Off Tower,1530 3rd Ave S, Birmingham, AL 35294 USA. EM jallison@uab.edu OI Allison, Jeroan/0000-0003-4472-2112 FU AHRQ HHS [HS 11124] NR 46 TC 42 Z9 42 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD APR PY 2005 VL 28 IS 3 BP 285 EP 290 DI 10.1016/j.amepre.2004.12.013 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 908MA UT WOS:000227789900007 PM 15766617 ER PT J AU Alexopoulos, GS Katz, IR Bruce, ML Heo, M Ten Have, T Raue, P Bogner, HR Schulberg, HC Mulsant, BH Reynolds, CF AF Alexopoulos, GS Katz, IR Bruce, ML Heo, M Ten Have, T Raue, P Bogner, HR Schulberg, HC Mulsant, BH Reynolds, CF CA PROSPECT Grp TI Remission in depressed geriatric primary care patients: A report from the PROSPECT study SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; SUICIDAL IDEATION; COLLABORATIVE CARE; MAJOR DEPRESSION; OLDER-ADULTS; MANAGEMENT; SYMPTOMS; HOPELESSNESS; SCALE; SETTINGS AB Objective: This study compared time to first remission for elderly depressed patients in primary care for practices that implemented a care management model versus those providing usual care. In addition, it sought to identify risk factors for nonremission that could guide treatment planning and referral to care managers or specialists. Method: Prevention of Suicide in Primary Care Elderly: Collaborative Trial ( PROSPECT) data were analyzed. Participants were older patients (>= 60 years) selected following screening of 9,072 randomly identified primary care patients. The present analysis examined patients with major depression and a 24-item Hamilton Depression Rating Scale score of 18 or greater who were followed for at least 4 months ( N = 215). Primary care practices were randomly assigned to offer the PROSPECT intervention or usual care. The intervention consisted of services of trained care managers, who offered algorithm-based recommendations to physicians and helped patients with treatment adherence over 18 months. Results: First remission occurred earlier and was more common among patients receiving the intervention than among those receiving usual care. For all patients, limitations in physical and emotional functions predicted poor remission rate. Patients experiencing hopelessness were more likely to achieve remission if treated in intervention practices. Similarly, the intervention was more effective in patients with low baseline anxiety. Conclusions: Longitudinal assessment of depression, hopelessness, anxiety, and physical and emotional functional limitations in depressed older primary care patients is critical. Patients with prominent symptoms or impairment in these areas may be candidates for care management or mental health care, since they are at risk for remaining depressed and disabled. C1 Cornell Univ, Weill Med Coll, Dept Psychiat, New York, NY USA. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Univ Penn, Dept Med, Philadelphia, PA 19104 USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. VA Pittsburgh Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. RP Alexopoulos, GS (reprint author), Cornell Med Ctr, Westchester Div, 21 Bloomingdale Rd, White Plains, NY 10605 USA. EM gsalexop@med.cornell.edu FU NIMH NIH HHS [R01 MH-59366, P30 MH-066270, P30 MH-52247, P30 MH-68638, P30 MH052247, P30 MH052247-10, P30 MH066270, P30 MH066270-01, P30 MH068638, P30 MH068638-01, R01 MH-059380, R01 MH-59318, R01 MH059366, R01 MH059366-02, R01 MH059380, R01 MH059380-02, R037 MH-51842, R37 MH051842, R37 MH051842-06] NR 40 TC 99 Z9 100 U1 3 U2 8 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD APR PY 2005 VL 162 IS 4 BP 718 EP 724 DI 10.1176/appi.ajp.162.4.718 PG 7 WC Psychiatry SC Psychiatry GA 911XR UT WOS:000228040600014 PM 15800144 ER PT J AU Bradley, TD Miller, YE Martinez, FJ Angus, DC MacNee, W Abraham, E AF Bradley, TD Miller, YE Martinez, FJ Angus, DC MacNee, W Abraham, E TI Interstitial lung disease, lung cancer, lung transplantation, pulmonary vascular disorders, and sleep-disordered breathing in AJRCCM in 2004 SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review ID POSITIVE AIRWAY PRESSURE; BRONCHIOLITIS OBLITERANS SYNDROME; ARTERIAL-HYPERTENSION; ENDOTHELIAL FUNCTION; NATRIURETIC PEPTIDE; APNEA SYNDROME; RISK-FACTORS; SARCOIDOSIS; FIBROSIS; RATS C1 Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Dept Med & Pulm Sci,Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Dept Crit Care Med, Denver, CO 80262 USA. Univ Toronto, Toronto Gen Hosp, Hlth Network, Toronto, ON M5G 1L7, Canada. Univ Michigan, Div Pulm & Crit Care Med, Hlth Syst, Ann Arbor, MI 48109 USA. Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA. Univ Edinburgh, MRC, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland. RP Abraham, E (reprint author), Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Dept Med & Pulm Sci,Div Pulm Sci & Crit Care Med, 4200 E 9th Ave,Box C272,Room 5503, Denver, CO 80262 USA. EM edward.abraham@uchsc.edu RI Angus, Derek/E-9671-2012 NR 70 TC 0 Z9 0 U1 0 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD APR 1 PY 2005 VL 171 IS 7 BP 675 EP 685 DI 10.1164/rccm.2412008 PG 11 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 912BV UT WOS:000228053000004 PM 15790865 ER PT J AU Rafi, A Crawford, W Klaustermeyer, W AF Rafi, A Crawford, W Klaustermeyer, W TI Declining cell-mediated immunity and increased chronic disease burden SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Article ID ILLNESS RATING-SCALE; DELAYED CUTANEOUS HYPERSENSITIVITY; NURSING-HOME; ADULTS; AGE; POPULATION; SYSTEM; IGE; ANTIGENS; ASTHMA AB Background: The effects of chronic disease have been proposed as an explanation for conflicting results in studies of age effects on cell-mediated immunity. Objective: To examine the hypothesis that declining cell-mediated immunity is more closely linked to chronic disease burden than to chronological age. Methods: Fifty-eight elderly individuals were tested for delayed-type hypersensitivity (DTH) responses to Candida and tetanus antigens. Disease burden was quantified using the Cumulative Illness Rating Scale (CIRS). Higher CIRS scores reflect,greater disease burden. Mean DTH response by age group (< 71, 71-78, and > 78 years) was compared with mean DTH response by CIRS score (< 11, 11-15, > 15). Total serum IgE levels were measured and similarly stratified by age and CIRS score. Results: Mean Candida DTH responsiveness declined progressively with increasing disease burden (increasing CIRS score). Mean DTH responses were 7.78, 3.05, and 0.0 mm for CIRS scores less than 11, 11 to 15, and greater than 15, respectively. Candida DTH responses showed no progressive decline with advancing age. Mean DTH responses were 4.7, 3.5, and 5.0 rum in participants younger than 71, 7 1 to 78, and older than 78 years, respectively. Total serum IgE levels increased with advancing age. Mean total IgE levels were 182, 249, and 342 IU/mL in participants younger than 71, 71 to 78, and older than 78 years, respectively. No correlation was observed between mean total I-E levels and CIRS scores. Conclusions: An inverse relationship between Candida DTH response and CIRS score suggests that increased chronic disease burden is associated with diminished cell-mediated immune response. Advancing age did not predict a diminished DTH response in our patients. No relationship was observed between chronic disease burden and total serum IgE level. C1 Univ Calif Los Angeles, Div Allergy & Immunol, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Rafi, A (reprint author), Univ Calif Los Angeles, Div Allergy & Immunol, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM asifrafi1@yahoo.com NR 33 TC 4 Z9 4 U1 0 U2 1 PU AMER COLL ALLERGY ASTHMA IMMUNOLOGY PI ARLINGTON HTS PA 85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA SN 1081-1206 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD APR PY 2005 VL 94 IS 4 BP 445 EP 450 PG 6 WC Allergy; Immunology SC Allergy; Immunology GA 918WM UT WOS:000228578300005 PM 15875525 ER PT J AU Czaja, C Crossette, L Metlay, JP AF Czaja, C Crossette, L Metlay, JP TI Accuracy of adult reported pneumococcal vaccination status of children SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE sensitivity and specificity; pneumococcal vaccines; interviews ID CONJUGATE VACCINE; MOTHERS REPORTS; INFECTIONS; COVERAGE; RECORDS; RECALL; CARDS AB PURPOSE: A pneumococcal conjugate vaccine was licensed in 2000 for use in children. To evaluate the accuracy of an adult's recall of children's vaccination status with the pneumococcal vaccine, the authors conducted a cross-sectional survey of adults in Philadelphia County from January to December 2003. METHODS: Subjects were identified by random digit dialing and interviewed regarding the age and vaccination status of all children 6 years old or younger with whom they had significant contact. The gold standard for determining the accuracy of vaccine status reports was the Kids Immunization Database/ Tracking System (KIDS) at the City of Philadelphia Department of Public Health. RESULTS: One hundred twenty-two interviews were completed with vaccination data collected on 185 children. One hundred sixty-six children (90%) were matched with records in the KIDS registry. The sensitivity and specificity of adult reported child vaccine status were 0.65 (95% CI, 0.55, 0.74) and 0.47 (95% CI, 0.34, 0.61), respectively. Agreement between adult report and the KIDS registry was 59%. Significant variation in agreement was not found to be related to demographic characteristics of the adult subjects. CONCLUSION: Adult report of the pneumococcal vaccination status of children was found to be relatively inaccurate and did not vary by known demographic characteristics. (c) 2004 Elsevier Inc. All rights reserved. C1 Univ Penn, Dept Med, Philadelphia, PA 19104 USA. Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. RP Metlay, JP (reprint author), 712 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM jmetlay@cceb.med.upenn.edu FU NIAID NIH HHS [AI46645-01] NR 16 TC 17 Z9 17 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD APR PY 2005 VL 15 IS 4 BP 253 EP 256 DI 10.1016/j.annepidem.2004.07.091 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 914RZ UT WOS:000228246600002 PM 15780771 ER PT J AU Ho, PM Masoudi, FA Spertus, JA Peterson, PN Shroyer, AL McCarthy, M Grover, FL Hammermeister, KE Rumsfeld, JS AF Ho, PM Masoudi, FA Spertus, JA Peterson, PN Shroyer, AL McCarthy, M Grover, FL Hammermeister, KE Rumsfeld, JS TI Depression predicts mortality following cardiac valve surgery SO ANNALS OF THORACIC SURGERY LA English DT Article ID ARTERY-BYPASS-SURGERY; MENTAL-HEALTH; MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; HEART-FAILURE; GRAFT-SURGERY; PRIMARY-CARE; RISK; OUTCOMES; DISEASE AB Background. Depression is associated with mortality in several cardiovascular populations, but has not been evaluated in patients undergoing cardiac valve surgery. Because identifying nonsurgical mediators of survival is important for accurate risk adjustment and the development of interventions to improve outcomes of care, we evaluated the hypothesis that depression predicts mortality following cardiac valve surgery. Methods. This prospective cohort study enrolled 648 patients undergoing valve surgery at 14 Veteran Administration hospitals. A preoperative mental health inventory (MHI) depression screen was performed in all patients and patients were classified as depressed or not depressed using the standard MHI cutoff score of less than or equal to 52. Multivariable logistic regression was used to evaluate the association between depression and 6-month all-cause mortality, adjusting for other clinical risk variables. Results. Overall, 29.2% (189/648) of the patients were depressed at baseline. Depressed patients were younger, more frequently had New York Heart Association class III/IV symptoms, and more likely required emergent surgery, preoperative intravenous nitroglycerin, or intraaortic balloon pump. Unadjusted 6-month mortality was 13.2% for depressed patients compared with 7.6% for nondepressed patients (p = 0.03). In multivariable analyses, depression remained significantly associated with mortality (odds ratio 1.90; 95% confidence interval 1.07 to 3.40, P = 0.03). These findings were consistent across subgroups of patients undergoing aortic valve replacement, mitral valve replacement and valve replacement without coronary artery bypass graft. Conclusions. Preoperative depression is an independent risk factor for mortality following cardiac valve surgery. Depression screening should be incorporated into preoperative risk stratification, and future studies are warranted to determine if preoperative or postoperative interventions to treat depression can improve outcomes. (c) 2005 by The Society of Thoracic Surgeons. C1 Denver VA Med Ctr, Denver, CO USA. Univ Colorado, Ctr Hlth Sci, Dept Med, Colorado Hlth Outcomes Program, Denver, CO 80202 USA. Univ Colorado, Ctr Hlth Sci, Dept Surg, Colorado Hlth Outcomes Program, Denver, CO 80202 USA. Denver Hlth Med Ctr, Denver, CO USA. Mid Amer Heart Inst, Kansas City, MO USA. Univ Missouri, Kansas City, MO 64110 USA. Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. RP Ho, PM (reprint author), Cardiol 111B,1055 Clermont St, Denver, CO 80220 USA. EM michael.ho@uchsc.edu RI Shroyer, Annie Laurie/B-8836-2016 OI Shroyer, Annie Laurie/0000-0001-6461-0623 FU NHLBI NIH HHS [F32 HL69596]; NIA NIH HHS [K08-AG01011] NR 30 TC 33 Z9 34 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD APR PY 2005 VL 79 IS 4 BP 1255 EP 1259 DI 10.1016/j.arthoracsur.2004.09.047 PG 5 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 912PH UT WOS:000228091100026 PM 15797059 ER PT J AU Carmosino, MJ Brousseau, KM Arciniegas, DB Corboy, JR AF Carmosino, MJ Brousseau, KM Arciniegas, DB Corboy, JR TI Initial evaluations for multiple sclerosis in a university multiple sclerosis center - Outcomes and role of magnetic resonance imaging in referral SO ARCHIVES OF NEUROLOGY LA English DT Article ID TECHNOLOGY-ASSESSMENT SUBCOMMITTEE; ACADEMY-OF-NEUROLOGY; DIAGNOSTIC-CRITERIA; MRI; MS; CONVERSION; MISDIAGNOSIS; THERAPEUTICS; GUIDELINES; DISABILITY AB Objective: To evaluate diagnostic outcomes, especially as they relate to reason for referral, of patients referred to a university-based multiple sclerosis (MS) center for possible MS. Methods: Retrospective medical record review of all new patient visits to University of Colorado Multiple Sclerosis Center, Denver, from January 1, 2001, to June 30, 2003. Results: Of 281 patients referred to evaluate the possibility of MS, after initial review 33% were diagnosed with MS or possible MS by the McDonald criteria. The rest had other neurological conditions (31.5%), probable psychiatric diagnoses (22.5%), or no clear diagnosis was made (12.5%). Of patients with typical, possible, or atypical demyelinating syndromes, 71%, 27%, and 0%, respectively (P < .001), had MS or possible MS. Of the 63% of patients referred on the basis of clinical symptoms and signs, 46% were diagnosed with MS or possible MS vs 11% of patients referred primarily on the basis of abnormal brain magnetic resonance imaging (MRI) results (P < .001). Of patients referred because of abnormal MRI results who did not have MS or possible MS, 70% had a clear alternative etiology for the abnormal MRI results, including migraine, age older than 50 years, other neurological disease, or hypertension. Conclusions: A significant percentage of patients referred to a university-based MS center have little or no likelihood of having MS, and many have undiagnosed, untreated psychiatric illness or common conditions with abnormal brain MRI results. With respect to the diagnosis of MS, greater training of primary care professionals, neurologists, and radiologists is necessary. C1 Univ Colorado, Sch Med, Multiple Sclerosis Ctr, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Corboy, JR (reprint author), Univ Colorado, Sch Med, Multiple Sclerosis Ctr, 4200 E 9th Ave,B 183, Denver, CO 80262 USA. EM john.corboy@uchsc.edu RI Arciniegas, David/A-3792-2009 NR 21 TC 34 Z9 36 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD APR PY 2005 VL 62 IS 4 BP 585 EP 590 DI 10.1001/archneur.62.4.585 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 914KZ UT WOS:000228227800009 PM 15824257 ER PT J AU Denslow, S Lomarev, M George, MS Bohning, DE AF Denslow, S Lomarev, M George, MS Bohning, DE TI Cortical and subcortical brain effects of transcranial magnetic stimulation (TMS)-induced movement: An interleaved TMS/functional magnetic resonance imaging study SO BIOLOGICAL PSYCHIATRY LA English DT Article DE BOLD; fMRI; motor cortex; motor circuits; transcranial magnetic stimulation ID PRIMARY MOTOR CORTEX; CEREBRAL-BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; FUNCTIONAL MRI; SENSORIMOTOR CORTEX; BASAL GANGLIA; FMRI SIGNAL; BOLD-FMRI; ACTIVATION; TMS AB Background: To date, interleaved transcranial magnetic stimulation and functional magnetic resonance imaging (TMS/fMRI) studies of motor activation have not recorded whole brain patterns. We hypothesized that TMS would activate known motor circuitry with some additional regions plus some areas dropping out. Methods: We used interleaved TMS/fMRI (11 subjects, three scans each) to elucidate whole brain activation patterns from 1-Hz TMS over left primary motor cortex. Results: Both TMS (110016 motor threshold) and volitional movement of the same muscles excited by TMS caused blood oxygen level-dependent (BOLD) patterns encompassing known motor circuitry. Additional activation was observed bilaterally in superior temporal auditory areas. Decreases in BOLD signal with unexpected posttask "rebounds" were observed for both tasks in the right motor area, right superior parietal lobe, and in occipital regions. Paired t test of parametric contrast maps failed to detect significant effects. Differences were detectable, however, in primary data time-intensity profiles differences between TMS- and volition-induced of diferrence. Conclusions: Using this interleaved TMS/fMRI technique, TMS over primary motor cortex produces a whole brain pattern of BOLD activation similar to known motor circuitry, without detectable differences from mimicked volitional movement. Some differences may exist between time courses of BOLD intensity during TMS circuit activation and volitional circuit activation. C1 Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA. Med Univ S Carolina, Ctr Adv Imaging Res, Charleston, SC 29425 USA. Med Univ S Carolina, Brain Stimulat Labs, Charleston, SC 29425 USA. Ralph H Johnson Vet Hosp, Charleston, SC USA. NINDS, Bethesda, MD 20892 USA. Inst Human Brain, St Petersburg, Russia. RP Denslow, S (reprint author), Med Univ S Carolina, Dept Radiol, 171 Ashley Ave, Charleston, SC 29425 USA. EM denslows@musc.edu FU NCRR NIH HHS [R01 RR14080-02] NR 45 TC 45 Z9 45 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2005 VL 57 IS 7 BP 752 EP 760 DI 10.1016/j.biopsych.2004.12.017 PG 9 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 913BK UT WOS:000228125000009 PM 15820232 ER PT J AU Zhou, XH AF Zhou, XH TI Nonparametric confidence intervals for the one- and two-sample problems SO BIOSTATISTICS LA English DT Article DE BCa; bootstrap; confidence interval; cost data; edgeworth expansion; positive skewness ID SKEWED DISTRIBUTIONS AB Confidence intervals for the mean of one sample and the difference in means of two independent samples based on the ordinary-t statistic suffer deficiencies when samples come from skewed families. In this article we evaluate several existing techniques and propose new methods to improve coverage accuracy. The methods examined include the ordinary-t, the bootstrap-t, the biased-corrected acceleration and three new intervals based on transformation of the t-statistic. Our study shows that our new transformation intervals and the bootstrap-t intervals give best coverage accuracy for a variety of skewed distributions, and that our new transformation intervals have shorter interval lengths. C1 Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98101 USA. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, Box 357232, Seattle, WA 98195 USA. EM azhou@u.washington.edu FU AHRQ HHS [R01 HS 013105] NR 13 TC 26 Z9 26 U1 1 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1465-4644 J9 BIOSTATISTICS JI Biostatistics PD APR PY 2005 VL 6 IS 2 BP 187 EP 200 DI 10.1093/biostatistics/kxi002 PG 14 WC Mathematical & Computational Biology; Statistics & Probability SC Mathematical & Computational Biology; Mathematics GA 917AM UT WOS:000228428200002 PM 15772099 ER PT J AU Song, X Zhou, XH AF Song, X Zhou, XH TI A marginal model approach for analysis of multi-reader multi-test receiver operating characteristic (ROC) data SO BIOSTATISTICS LA English DT Article DE ANOVA; AUC; GEE; marginal model; ROC sparse correlation ID OF-VARIANCE MODELS AB The receiver operating characteristic curve is a popular tool to characterize the capabilities of diagnostic tests with continuous or ordinal responses. One common design for assessing the accuracy of diagnostic tests involves multiple readers and multiple tests, in which all readers read all test results from the same patients. This design is most commonly used in a radiology setting, where the results of diagnostic tests depend on a radiologist's subjective interpretation. The most widely used approach for analyzing data from such a study is the Dorfman-Berbaum-Metz (DBM) method (Dorfman et al., 1992) which utilizes a standard analysis of variance (ANOVA) model for the jackknife pseudovalues of the area under the ROC curves (AUCs). Although the DBM method has performed well in published simulation studies, there is no clear theoretical basis for this approach. In this paper, focusing on continuous outcomes, we investigate its theoretical basis. Our result indicates that the DBM method does not satisfy the regular assumptions for standard ANOVA models, and thus might lead to erroneous inference. We then propose a marginal model approach based on the AUCs which can adjust for covariates as well. Consistent and asymptotically normal estimators are derived for regression coefficients. We compare our approach with the DBM method via simulation and by an application to data from a breast cancer study. The simulation results show that both our method and the DBM method perform well when the accuracy of tests under the study is the same and that our method outperforms the DBM method for inference on individual AUCs when the accuracy of tests is not the same. The marginal model approach can be easily extended to ordinal outcomes. C1 Univ Washington, Dept Biostat, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA 98018 USA. RP Song, X (reprint author), Univ Washington, Dept Biostat, Box 357232,1705 NE Pacific St, Seattle, WA 98195 USA. EM xsong@stat.ncsu.edu; azhou@u.washington.edu FU AHRQ HHS [R01 HS 013105-01]; NIAID NIH HHS [U01 AI 46702] NR 12 TC 14 Z9 15 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1465-4644 J9 BIOSTATISTICS JI Biostatistics PD APR PY 2005 VL 6 IS 2 BP 303 EP 312 DI 10.1093/biostatistics/kxi011 PG 10 WC Mathematical & Computational Biology; Statistics & Probability SC Mathematical & Computational Biology; Mathematics GA 917AM UT WOS:000228428200011 PM 15772108 ER PT J AU Sanches, M Roberts, RL Sassi, RB Axelson, D Nicoletti, M Brambilla, P Hatch, JP Keshavan, MS Ryan, ND Birmaher, B Soares, JC AF Sanches, M Roberts, RL Sassi, RB Axelson, D Nicoletti, M Brambilla, P Hatch, JP Keshavan, MS Ryan, ND Birmaher, B Soares, JC TI Developmental abnormalities in striatum in young bipolar patients: a preliminary study SO BIPOLAR DISORDERS LA English DT Article DE affective disorders; basal ganglia; magnetic resonance imaging; mood disorders; neuroimaging; pediatric ID BASAL GANGLIA VOLUMES; MOOD DISORDERS; CAUDATE NUCLEI; WHITE-MATTER; IN-VIVO; SCHIZOPHRENIA; NEUROPSYCHIATRY; 1ST-EPISODE; DEPRESSION; CHILDREN AB Objectives: Anatomical abnormalities in the basal ganglia of adult mood disorder patients have been reported. To investigate whether these abnormalities are present early in illness course, we compared the volume of striatal structures in young bipolar patients and healthy controls. Methods: Brain magnetic resonance images of 15 children and adolescents who met DSM-IV criteria for bipolar disorders and 21 healthy controls were obtained. Measurements were performed manually, by trained evaluators, who were blind to subjects' diagnosis. The volumes of caudate and putamen were compared in patients and controls. Results: The volumes of striatal structures were not significantly different in patients and controls (ANCOVA, p > 0.05). However, we found a significant inverse relationship between age and the volumes of left caudate (r = -0.72, p < 0.01), right caudate (r = -0.66, p = 0.02) and left putamen (r = -0.71, p = 0.01) in bipolar patients, not present in healthy controls. Conclusions: Abnormalities in striatal development may be involved in the pathophysiology of bipolar disorder. C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Univ Fed Sao Paulo, Dept Psychiat, Sao Paulo, Brazil. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Dept Psychiat, Pittsburgh, PA USA. Univ Udine, Dept Pathol & Expt & Clin Med, Sect Psychiat, I-33100 Udine, Italy. Univ Texas, Hlth Sci Ctr, Dept Radiol, San Antonio, TX 78284 USA. RP Soares, JC (reprint author), Univ Texas, Hlth Sci Ctr, Dept Psychiat, Div Mood & Anxiety Disorders, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM soares@uthscsa.edu RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 FU NIMH NIH HHS [MH 30915, MH 55123, MH 01736] NR 29 TC 38 Z9 38 U1 0 U2 1 PU BLACKWELL MUNKSGAARD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD APR PY 2005 VL 7 IS 2 BP 153 EP 158 DI 10.1111/j.1399-5618.2004.00178.x PG 6 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 905SG UT WOS:000227589400007 PM 15762856 ER PT J AU Walters, DK Stoffregen, EP Heinrich, MC Deininger, MW Druker, BJ AF Walters, DK Stoffregen, EP Heinrich, MC Deininger, MW Druker, BJ TI RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518 SO BLOOD LA English DT Article ID ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; ACUTE MYELOGENOUS LEUKEMIA; TYROSINE KINASE; RISK GROUP; MUTATIONS; MALIGNANCIES; ACTIVATION; INTERFERENCE; INHIBITION AB FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that is constitutively activated in approximately 30% of acute myelogenous leukemia (AML) patients and appears to confer an adverse prognosis. Thus, development of inhibitors and/or antibodies that specifically target FLT3 has been of substantial interest. In this regard, phase 1 and 2 trials involving FLT3 inhibitors have recently reported FLT3 inhibition and leukemic blast reduction in some patients. Despite this, issues such as specificity and resistance need to be addressed. Consequently, the development of alternative approaches for targeting FLT3 would be of great consequence. In the present report, we demonstrate that FLT3 siRNA effectively down-regulates FLT3 expression in Ba/F3 cells transfected with FLT3 containing an activating internal tandem duplication (ITD) in the juxtamembrane domain and FLT3-ITD-positive Molm-14 human leukemia cells. Treatment with the FLT3 siRNA results in growth inhibition and apoptosis of these cells. Furthermore, siRNA-induced down-regulation of FLT3 increased the sensitivity of both cell lines to treatment with the FLT3 inhibitor MLN518. This illustrates the potential benefit of combined therapeutic approaches. C1 Oregon Hlth & Sci Univ, Inst Canc, Howard Hughes Med Inst, Dept Hematol & Oncol, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR USA. RP Walters, DK (reprint author), Oregon Hlth & Sci Univ, Inst Canc, Howard Hughes Med Inst, Dept Hematol & Oncol, 3181 Sam Jackson Pk Rd, Portland, OR 97239 USA. EM waltersd@ohsu.edu NR 23 TC 31 Z9 33 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD APR 1 PY 2005 VL 105 IS 7 BP 2952 EP 2954 DI 10.1182/blood-2004-07-2758 PG 3 WC Hematology SC Hematology GA 911YM UT WOS:000228042900055 PM 15585651 ER PT J AU Beresford, TP Arciniegas, D Clapp, L Martin, B Alfers, J AF Beresford, TP Arciniegas, D Clapp, L Martin, B Alfers, J TI Reduction of affective lability and alcohol use following traumatic brain injury: A clinical pilot study of anti-convulsant medications SO BRAIN INJURY LA English DT Article ID RELAPSE PREVENTION; AFFECTIVE-DISORDER; GABA(A) RECEPTOR; AXIS-I; CARBAMAZEPINE; ASSOCIATION; DIVALPROEX; VALPROATE; RELEASE; GENE AB Objective: A large and under-recognized sub-set of patients suffer both traumatic brain injury (TBI) and alcohol dependence (ADep). This group appears to use alcohol to self-treat affective and anxiety lability following TBI, resulting in new ADep or worsened prior ADep. This study hypothesized that treatment of such patients with mood-stabilizing medications would relieve post-TBI emotional dysregulation and facilitate reduction in alcohol use. Design: This study reported retrospective medical record data from outpatients in the Substance Abuse Treatment Programme who were treated for labile mood. Medications followed clinical indication and were given in non-blind fashion. Method: Subjects included 18 patients who (1) complained of debilitating affective lability following TBI, ( 2) described drinking alcohol to ease lability symptoms, (3) met DSM-IV criteria for current ADep and (4) were treated with a mood stabilizing medication. Results: During 6 weeks of treatment, 16 (89%) achieved abstinence from alcohol. All but two (14/16 or 88%) also showed improvement in their affective and anxiety symptoms. Conclusions: These preliminary data are limited by the retrospective collection, clinical impression and non-blinded trial. Nonetheless, the results suggest further investigation of anti-convulsants as potentially useful agents in co-morbid emotional lability and ADep following TBI. C1 Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA. Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA. Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Aurora, CO USA. RP Beresford, TP (reprint author), Denver Vet Affairs Med Ctr, 151,1055 Clermont St, Denver, CO 80220 USA. EM thomas.beresford@uchsc.edu RI Arciniegas, David/A-3792-2009 FU NIAAA NIH HHS [AA12095] NR 21 TC 9 Z9 9 U1 1 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 J9 BRAIN INJURY JI Brain Inj. PD APR PY 2005 VL 19 IS 4 BP 309 EP 313 DI 10.1080/02699050410001720121 PG 5 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 917MN UT WOS:000228466400007 PM 15832875 ER PT J AU Marciniak, RA Cavazos, D Montellano, R Chen, QJ Guarente, L Johnson, FB AF Marciniak, RA Cavazos, D Montellano, R Chen, QJ Guarente, L Johnson, FB TI A novel telomere structure in a human alternative lengthening of telomeres cell line SO CANCER RESEARCH LA English DT Article ID IMMORTALIZED HUMAN-CELLS; WERNER-SYNDROME; DNA HELICASE; RECOMBINATION; MAINTENANCE; ABSENCE; CANCER; CHROMOSOMES; FIBROBLASTS; EXONUCLEASE AB Cancer cells require mechanisms to maintain telomeres. Most use telomerase, but 5% to 20% of tumors use alternative lengthening of telomeres (ALT), a telomerase-independent mechanism that seems to depend on recombination. ALT is characterized by amplification of telomere TTAGGG repeats to lengths beyond 50 kb, by elevated rates of telomere recombination, and by nuclear structures called ALT-associated promyelocytic leukemia bodies. In Saccharomyces cerevisiae, survivors of telomerase inactivation also use recombination to maintain telomeres. There are two types of survivors, which differ in telomere structure. The first possesses telomere repeats and the V subtelomeric element amplified together as a tandem array at chromosome termini (type 1), and the other possesses amplification of telomeric repeats alone (type 11), similar to previously described human ALT cells. Here, we describe the first human ALT cell line having "tandem array" telomeres with a structure similar to that of type I yeast survivors. The chromosome termini consist of a repeat unit containing similar to 2.5 kb of SV40 DNA and a variable amount of TTAGGG sequence repeated in tandem an average of 10 to 20 times. Similar to previously described ALT cells, they show evidence of telomere recombination, but unlike standard ALT cells, they lack ALT-associated promyelocytic leukemia bodies and their telomeres are transcribed. These findings have implications for the pathogenesis and diagnosis of cancer. C1 Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Change Labs 405A, Philadelphia, PA 19104 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. MIT, Dept Biol, Cambridge, MA 02139 USA. RP Johnson, FB (reprint author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Change Labs 405A, 422 Curie Blvd, Philadelphia, PA 19104 USA. EM marciniak@uthsesa.edu; johnsonb@mail.med.upenn.edu FU NIA NIH HHS [K08AG000775] NR 41 TC 47 Z9 52 U1 0 U2 1 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD APR 1 PY 2005 VL 65 IS 7 BP 2730 EP 2737 DI 10.1158/0008-5472.CAN-04-2888 PG 8 WC Oncology SC Oncology GA 911AB UT WOS:000227972300034 PM 15805272 ER PT J AU Venkatasubbarao, K Choudary, A Freeman, JW AF Venkatasubbarao, K Choudary, A Freeman, JW TI Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3((Tyr705)) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases SO CANCER RESEARCH LA English DT Article ID GROWTH-FACTOR-BETA; STAT3 ACTIVATION; SERINE PHOSPHORYLATION; FARNESYLTRANSFERASE INHIBITORS; TRANSCRIPTIONAL ACTIVATION; TYROSINE PHOSPHORYLATION; ERK PHOSPHORYLATION; MOLECULAR TARGETS; SUPPRESSES GROWTH; INDUCED APOPTOSIS AB In this study, we report that R115777, a nonpeptidomimetic farnesyl transferase inhibitor, suppresses the growth of human pancreatic adenocarcinoma cell lines and that this growth inhibition is associated with modulation in the phosphorylation levels of signal transducers and activators of transcription 3 (STAT3) and extracellular signal-regulated kinases (ERK). Treatment of cells with R115777 inhibited the tyrosine phosphorylation of STAT3((Tyr705)), while increasing the serine phosphorylation of STAT3((Ser727)). We found the differential phosphorylation of STAT3 was due to an increased and prolonged activation of ERKs. The biological significance of ERK-mediated inhibition of STAT3 (Tyr705) phosphorylation was further assessed by treating the cells with an inhibitor (PD98059) of mitogen-activated protein kinase kinase (MEK) or by transfecting the cells with a vector that expresses constitutively active MEK-1. Expression of constitutively active MEK-1 caused an increase of ERK activity and inhibited STAT3((Tyr705)) phosphorylation. Conversely, inhibition of ERK activity by PD98059 reversed the R115777-induced inhibition of STAT3((Tyr705)) phosphorylation. R115777 also caused the inhibition of the binding of STAT3 to its consensus binding element. An increase in the activation of ERKs either by overexpressing MEK-1 or treatment of cells with R115777 caused an up-regulation in the levels of a cyclin-dependent kinase (cdk) inhibitor, p21(cip1/waf1). These observations suggest that R115777-induced growth inhibition is partly due to the prolonged activation of ERKs that mediates an inhibition of STAT3((Tyr705)) phosphorylation and an increase in the levels of p21(cip1/waf1) in human pancreatic adenocarcinoma cell lines. C1 Univ Texas, Ctr Hlth, Dept Med, Div Med Oncol, San Antonio, TX 78229 USA. Audie L Murphy Mem Vet Adm Med Ctr, Res & Dev, San Antonio, TX USA. Univ Texas, Ctr Hlth, Dept Cell & Struct Biol, San Antonio, TX 78229 USA. RP Freeman, JW (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM freemanjw@uthscsa.edu NR 73 TC 34 Z9 34 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD APR 1 PY 2005 VL 65 IS 7 BP 2861 EP 2871 DI 10.1158/0008-5472.CAN-04-2396 PG 11 WC Oncology SC Oncology GA 911AB UT WOS:000227972300050 PM 15805288 ER PT J AU Palevsky, PM AF Palevsky, PM TI Renal replacement therapy I: Indications and timing SO CRITICAL CARE CLINICS LA English DT Article ID CONTINUOUS VENOVENOUS HEMOFILTRATION; PROPHYLACTIC DIALYSIS; SODIUM-BICARBONATE; RANDOMIZED-TRIAL; LACTIC-ACIDOSIS; FAILURE; MORTALITY; HEMODIALYSIS; MULTICENTER; EXPERIENCE AB The indications for initiation of renal replacement therapy in acute renal failure are controversial. Although volume overload, metabolic acidosis, hyperkalemia and other electrolyte disturbances, and overt uremic manifestations are commonly accepted indications for renal replacement therapy, specific criteria for initiation of therapy based on these conditions are highly subjective. Progressive azotemia in the absence of overt uremia is another common indication for renal replacement therapy although there is no consensus on the degree of azotemia that warrants initiation of therapy. The clinical data regarding timing and initiation of renal support in patients who have acute renal failure are reviewed. Definitive resolution of the appropriate indications and timing for initiation of renal replacement therapy in acute renal failure requires prospective evaluation in a randomized clinical trial. C1 Univ Dr Div, VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. RP Palevsky, PM (reprint author), Univ Dr Div, VA Pittsburgh Healthcare Syst, Renal Sect, Room 7E123, Pittsburgh, PA 15240 USA. EM palevsky@pitt.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 34 TC 20 Z9 23 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0749-0704 J9 CRIT CARE CLIN JI Crit. Care Clin. PD APR PY 2005 VL 21 IS 2 BP 347 EP + DI 10.1016/j.ccc.2004.12.002 PG 11 WC Critical Care Medicine SC General & Internal Medicine GA 915FE UT WOS:000228282600013 PM 15781167 ER PT J AU Tong, J Fujimoto, WY Kahn, SE Weigle, DS McNeely, MJ Leonetti, DL Shofer, JB Boyko, EJ AF Tong, J Fujimoto, WY Kahn, SE Weigle, DS McNeely, MJ Leonetti, DL Shofer, JB Boyko, EJ TI Insulin, C-peptide, and leptin concentrations predict increased visceral adiposity at 5-and 10-year follow-ups in nondiabetic Japanese Americans SO DIABETES LA English DT Article ID BODY-FAT DISTRIBUTION; DEPENDENT DIABETES-MELLITUS; IMPAIRED GLUCOSE-TOLERANCE; HIGH FASTING INSULIN; WEIGHT-GAIN; PLASMA LEPTIN; ABDOMINAL FAT; COMPUTED-TOMOGRAPHY; TISSUE DISTRIBUTION; GENE-EXPRESSION AB We prospectively examined the relationship between leptin and markers of insulin resistance and secretion and future visceral adipose tissue accumulation. In this study, 518 nondiabetic Japanese-American men and women underwent the following measurements at baseline and at 5- and 10-year follow-ups: plasma glucose and insulin measured after an overnight fast and during a 75-g oral glucose tolerance test, insulin secretion ratio (ISR) [(30-min insulin - fasting insulin)/30-min glucose], fasting C-peptide levels, plasma leptin (baseline only), and fat areas (intra-abdominal and subcutaneous) measured by computed tomography. Predictors of future intra-abdominal fat (IAF) were determined using multiple linear regression. Fasting insulin and C-peptide levels at baseline were significantly associated with IAF area at 5 years (coefficient = 0.041, P = 0.001 and coefficient = 1.283, P < 0.001, respectively) and 10 years (coefficient = 0.031, P = 0.020 and coefficient = 0.221, P = 0.035, respectively). ISR was not significantly associated with IAF at 5 or 10 years. Leptin level at baseline was positively associated with IAF at 5 years (coefficient = 0.055, P = 0.002) and 10 years (coefficient = 0.059, P = 0.003). In conclusion, higher levels of fasting insulin, C-peptide, and circulating leptin level predicted visceral fat accumulation independent from subcutaneous fat accumulation in nondiabetic Japanese-American men and women in both short-term (5 years) and long-term (10 years) followup. C1 VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. Univ Washington, Harborview Med Ctr, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Res & Dev Serv, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. RP Tong, J (reprint author), VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, S-151,1660 S Columbian Way, Seattle, WA 98108 USA. EM tongj@u.washington.edu OI Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X FU NIDDK NIH HHS [DK-02860, DK-55460] NR 53 TC 24 Z9 24 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD APR PY 2005 VL 54 IS 4 BP 985 EP 990 DI 10.2337/diabetes.54.4.985 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 912QM UT WOS:000228094300009 PM 15793236 ER PT J AU Bryer-Ash, M Garber, AJ AF Bryer-Ash, M Garber, AJ TI Point: Inpatient glucose management - The emperor finally has clothes SO DIABETES CARE LA English DT Editorial Material ID CRITICALLY-ILL PATIENTS; INTENSIVE INSULIN THERAPY; II DIABETES-MELLITUS; MYOCARDIAL-INFARCTION; HYPERGLYCEMIA; MORTALITY; INFUSION; ARTERY; RISK C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Gonda Diabet Ctr, Los Angeles, CA 90095 USA. W Los Angeles Vet Adm Med Ctr, Endocrinol Sect, Los Angeles, CA USA. Baylor Coll Med, Div Endocrinol, Houston, TX 77030 USA. RP Bryer-Ash, M (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, Gonda Diabet Ctr, 900 Veteran Ave,Suite 24-130, Los Angeles, CA 90095 USA. EM mbryerash@mednet.ucla.edu NR 25 TC 5 Z9 6 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD APR PY 2005 VL 28 IS 4 BP 973 EP 975 DI 10.2337/diacare.28.4.973 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 001PE UT WOS:000234548000039 PM 15793209 ER PT J AU Kudolo, GB Delaney, D Blodgett, J AF Kudolo, GB Delaney, D Blodgett, J TI Short-term oral ingestion of Ginkgo biloba extract (EGb 761) reduces malondialdehyde levels in washed platelets of type 2 diabetic subjects SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE Ginkgo biloba; EGb 761; type 2 diabetes; platelets; malondialdehyde ID HEALTHY MALE-VOLUNTEERS; BETA-CELL FUNCTION; INSULIN-RESISTANCE; DOUBLE-BLIND; MELLITUS; DISEASE; HYPERTENSION; INDIVIDUALS; ATHEROGENESIS; LIPOPROTEINS AB We have recently reported that ingestion of Ginkgo biloba extract (EGb 761) (a) significantly reduced collagen-induced platelet aggregation and thromboxane B-2 (TXB2) production in both non-diabetic individuals as well as those with type 2 diabetes mellitus (T2DM), (b) significantly reduced platelet malondialdehyde (MDA), an index of lipid peroxidation, in nondiabetic subjects. In the present study we report that ingestion of EGb 761 (120 mg daily for 3 months), significantly decreased platelet MDA-thiobarbituric acid reacting substances (TBARS) (41 +/- 9 pmol/ 10(7) platelets versus 30 +/- 11 Pruol/10(7) platelets) (p < 0.005) in T2DM subjects with normal cholestertol levels (total cholesterol, 164 +/- 22 mg/dl; age, 54 +/- 9 years; BMI, 35.0 +/- 28.8 kg/m(2), n = 12). In T2DM subjects with high cholesterol (total cholesterol, 218 +/- 15 mg/dl; age, 52 +/- 5 years; BMI, 36.2 +/- 6.6 kg/m(2), n = 7), EGb 761 ingestion reduced the platelet TBARS from 29 +/- 9 to 22 +/- 9 pmol/10(7) platelets (p < 0.04). Because ingestion of EGb 761 did not alter platelet counts it is concluded that EGb 761, probably due to the flavonoid fraction, reduced the TBARS by inhibiting cyclooxygenase (COX)-1-mediated arachidonic acid oxygenation or by reducing the arachidonic acid pool. This is likely to lead to a reduction of platelet hyperactivity, a significant contributor to the development of cardiovascular disease in T2DM patients. Because of other reported beneficial properties of EGb 761, such as stimulation of pancreatic beta-cell function in T2DM subjects with pancreatic exhaustion, it appears that T2DM subjects might benefit from ingesting EGb 761 as a dietary supplement. (c) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Univ Texas, HSC, Dept Clin Lab Sci, San Antonio, TX 78229 USA. Audie L Murphy Vet Affairs Hosp, San Antonio, TX 78284 USA. RP Kudolo, GB (reprint author), Univ Texas, HSC, Dept Clin Lab Sci, MSC 6246,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kudolo@uthscsa.edu FU NCCIH NIH HHS [R01-AT-00832]; NCRR NIH HHS [M01-RR-01346] NR 49 TC 17 Z9 20 U1 0 U2 3 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD APR PY 2005 VL 68 IS 1 BP 29 EP 38 DI 10.1016/j.diabres.2004.08.007 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 920EF UT WOS:000228671500004 PM 15811563 ER PT J AU Ishizuka, S Kurihara, N Reddy, SV Cornish, J Cundy, T Roodman, GD AF Ishizuka, S Kurihara, N Reddy, SV Cornish, J Cundy, T Roodman, GD TI (23S)-25-dehydro-1 alpha-hydroxyvitamin D-3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease SO ENDOCRINOLOGY LA English DT Article; Proceedings Paper CT 12th Workshop on Vitamin D CY 2003 CL Masstricht, NETHERLANDS ID 1-ALPHA,25-DIHYDROXYVITAMIN D-3-26,23-LACTONE ANALOGS; 1,25-DIHYDROXYVITAMIN D-3; VIRUS; CELLS; PRECURSORS; DIFFERENTIATION AB Osteoclast ( OCL) precursors from patients with Paget's disease ( PD) and normal OCL precursors transduced with the measles virus nucleocapsid protein gene ( MVNP) are hyperresponsive to 1 alpha, 25- dihydroxyvitamin D-3 [ 1 alpha, 25-( OH) D-2(3)] and can form OCLs at physiologic concentrations of 1 alpha, 25( OH) D-2(3). This hyperresponsivity to 1 alpha, 25-( OH)(2)D-3 is due to increased expression of TATA box- associated factor II- 17, a potential coactivator of the vitamin D receptor. Hyperresponsivity to 1 alpha, 25-( OH)(2)D-3 may permit OCL formation in PD patients with low levels of 1 alpha, 25-( OH)(2)D-3 and play a role in the pathogenesis of PD. Therefore, we tested the effects of a vitamin D antagonist, ( 23S)- 25- dehydro- 1 alpha- hydroxyvitamin D-3- 26,23- lactone ( TEI- 9647), to determine its potential to inhibit the enhanced OCL formation and bone resorption seen in patients with PD. TEI- 9647, by itself, was not a vitamin D receptor agonist and did not induce OCL formation in vitro, even at 10(-6) M. However, it dose- dependently ( 10(-10) M to 10(-6) M) inhibited osteoclast formation induced by concentrations of 1 alpha, 25-( OH)(2)D-3 ( 41 pg/ ml, 10(-10) M) detected in PD patients by bone marrow cells of patients with PD and MVNP- transduced colony- forming unit- granulocyte macrophage ( CFU- GM) cells, which form pagetic- like OCL. Moreover, bone resorption by OCLs derived from MVNP- transduced CFU- GM treated with 10(-9) M 1 alpha,25-( OH)(2)D-3 was dose- dependently inhibited by TEI- 9647 ( 10(-9) M to 10(-6) M). Furthermore, 10(-7) M TEI- 9647 by itself did not cause 1 alpha, 25-( OH)(2)D-3- dependent gene expression but almost completely suppressed expression of the TATA box- associated factor II- 17 and 25- hydroxyvitamin D-3- 24-hydroxylase genes induced by 1 alpha, 25-(OH)(2)D-3 treatment of MVNP- transduced CFU- GM cells. These results demonstrate that TEI- 9647 can suppress the excessive bone resorption and OCL formation seen in marrow cultures from patients with PD. C1 Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. Teijin Inst Biomed Res, Tokyo 1918512, Japan. Univ Pittsburgh, Div Hematol Oncol, Pittsburgh, PA 15261 USA. Univ Auckland, Dept Med, Auckland 92019, New Zealand. RP Roodman, GD (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Univ Dr, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu NR 19 TC 28 Z9 30 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD APR PY 2005 VL 146 IS 4 BP 2023 EP 2030 DI 10.1210/en.2004-1140 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 906TW UT WOS:000227667400044 PM 15618361 ER PT J AU Richardson-Burns, SM Tyler, KL AF Richardson-Burns, SM Tyler, KL TI Minocycline delays disease onset and mortality in reovirus encephalitis SO EXPERIMENTAL NEUROLOGY LA English DT Article DE apoptosis; central nervous system; microglia; neurons; mouse ID CENTRAL-NERVOUS-SYSTEM; HUNTINGTONS-DISEASE; MOUSE MODEL; TETRACYCLINE DERIVATIVES; MICROGLIAL ACTIVATION; PARKINSONS-DISEASE; LATERAL-SCLEROSIS; CYTOCHROME-C; NITRIC-OXIDE; CELL-DEATH AB Minocycline is neuroprotective in many experimental models of neurodegenerative diseases and central nervous system (CNS) injury but has not previously been tested in a model of viral encephalitis. Experimental infection of neonatal mice with neurotropic reoviruses is a classic model for studying the pathogenesis of viral encephalitis. Intracerebral inoculation of serotype 3 reovirus strain Dearing (T3D) in neonatal mice results in lethal encephalitis caused by neuronal apoptosis throughout the CNS. Minocycline significantly delayed death in mice to 11.6 +/- 0.9 days post-infection vs. 8.6 +/- 0.7 days post-infection in controls (P < 0.01). Virus-induced CNS injury, apoptosis, viral titer and antigen expression were significantly decreased in the brains of minocycline-treated mice on 6 and 8 days post-infection compared to controls. Virus-induced injury and viral titer in minocycline-treated infected mice at 11 days post-infection were similar to those seen in untreated T3D-infected mice at 8 days post-infection. Little microglial or astrocytic invasion of brain regions with viral injury was found at any time-point in untreated or minocycline-treated mice, suggesting that in this model system the neuroprotective effect exerted by minocycline is more likely due to its anti-apoptotic properties rather than its capacity to inhibit microglial activation and limit gliosis. These findings, similar to those reported for neurodegenerative diseases, indicate that minocycline does not prevent development of fatal reovirus encephalitis but delays disease onset and progression, suggesting that minocycline treatment may provide a useful adjunctive therapy in viral CNS infections. (c) 2004 Elsevier Inc. All rights reserved. C1 Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Neurosci Program, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO 80220 USA. RP Tyler, KL (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, B-182,4200 E 9th Ave, Denver, CO 80262 USA. EM ken.tyler@uchsc.edu OI Tyler, Kenneth/0000-0003-3294-5888 FU NINDS NIH HHS [1R01NS050138, R01 NS050138, R01 NS050138-04, R01 NS051403-03] NR 38 TC 34 Z9 35 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD APR PY 2005 VL 192 IS 2 BP 331 EP 339 DI 10.1016/j.expneurol.2004.11.015 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 908ZH UT WOS:000227828200010 PM 15755550 ER PT J AU Book, SW Myrick, H AF Book, SW Myrick, H TI Novel anticonvulsants in the treatment of alcoholism SO EXPERT OPINION ON INVESTIGATIONAL DRUGS LA English DT Review DE alcohol dependence; alcoholism; alcohol withdrawal; anticonvulsants; carbamazepine; gabapentin; recurrence; topiramate; valproic acid; vigabatrin ID RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; WITHDRAWAL SYNDROME; DIVALPROEX SODIUM; ORAL TOPIRAMATE; CARBAMAZEPINE; GABAPENTIN; DEPENDENCE; PLACEBO; CLOMETHIAZOLE AB There have been many recent developments in the pharmacological management of alcohol withdrawal and alcohol dependence. Although previous treatments had included benzodiazepines as their mainstay, the use of these agents in the alcoholic population is problematic. Benzodiazepines are themselves addictive and they may increase the risk of alcohol relapse. Non-benzodiazepine anticonvulsants such as carbamazepine, valproic acid, gabapentin, vigabatrin and topiramate have been shown to be excellent treatments of both alcohol withdrawal and the prevention of alcohol relapse. Although none of these agents have yet been approved by the FDA, there is growing evidence in the literature to support their use. C1 Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston Alcohol Res Ctr, Charleston, SC 29425 USA. Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv Line, Charleston, SC 29401 USA. RP Book, SW (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston Alcohol Res Ctr, 67 President St, Charleston, SC 29425 USA. EM booksw@musc.edu FU NIAAA NIH HHS [2 P50 AA10761-03, K23 AA00314-01, K23 AA014430] NR 42 TC 43 Z9 45 U1 2 U2 7 PU ASHLEY PUBLICATIONS LTD PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1354-3784 J9 EXPERT OPIN INV DRUG JI Expert Opin. Investig. Drugs PD APR PY 2005 VL 14 IS 4 BP 371 EP 376 DI 10.1517/13543784.14.4.371 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 930JC UT WOS:000229410900002 PM 15882114 ER PT J AU Jutabha, R Jensen, DM Martin, P Savides, T Han, SH Gornbein, J AF Jutabha, R Jensen, DM Martin, P Savides, T Han, SH Gornbein, J TI Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices SO GASTROENTEROLOGY LA English DT Article ID CONTROLLED-TRIAL; PRIMARY PROPHYLAXIS; ENDOSCOPIC LIGATION; INJECTION SCLEROTHERAPY; ISOSORBIDE MONONITRATE; PORTAL-HYPERTENSION; CLINICAL-TRIAL; 1ST HEMORRHAGE; LIVER-DISEASE; CIRRHOSIS AB Background & Aims: Standard care for prevention of first esophageal variceal hemorrhage is beta-blockade, but this may be ineffective or unsafe. Our purpose was to compare endoscopic banding with propranolol for prevention of first variceal hemorrhage. Methods: In a multicenter, prospective trial, 62 patients with cirrhosis with high-risk esophageal varices were randomized to propranolol (titrated to reducing resting pulse by 25%) or banding (performed monthly until varices were eradicated) and were followed up on the same schedule for a mean duration of 15 months. The primary end point was treatment failure, defined as the development of endoscopically documented variceal hemorrhage or a severe medical complication requiring discontinuation of therapy. Direct costs were estimated from Medicare reimbursements and fixed or variable charges for services up to treatment failure. Results: Background variables of the treatment groups were similar. The trial was stopped early after an interim analysis showed that the failure rate of propranolol was significantly higher than that of banding (6/31 vs. 0/31; difference, 1.9.4%; P =.0098; 95% confidence interval for true difference, 6.4%-37.2%). Significantly more propranolol than banding patients had esophageal variceal hemorrhage (4/31 vs. 0/31; difference, 12.9%; P =.0443; 95% confidence interval for true difference, 0.8%-29%), and the cumulative mortality rate was significantly higher in the propranolol than in the banding group (4/31 vs. 0/31; difference, 12.9%; P =.0443; 95% confidence interval for true difference, 0.8%-29%). Direct costs of care were not significantly different. Conclusions: For patients with cirrhosis with high-risk esophageal varices and no history of variceal hemorrhage, propranolol-treated patients had significantly higher failure rates of failure, first esophageal varix hemorrhage, and cumulative mortality than banding patients. Direct costs of medical care were not significantly different. C1 Univ Calif Los Angeles, David Geffen Sch Med, Hlth Sci Ctr, Dept Med,Div Digest Dis, Los Angeles, CA USA. Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif San Diego, Med Ctr, Ctr Ulcer Res & Educ, Digest Dis Res Ctr, San Diego, CA 92103 USA. Univ Calif San Diego, Med Ctr, Cedars Sinai Med Ctr, San Diego, CA 92103 USA. Univ Calif Los Angeles, Sch Med, Dept Biomath, Los Angeles, CA 90024 USA. RP Jensen, DM (reprint author), W Los Angeles Vet Affairs Med Ctr, Digest Dis Res Ctr, CURE, Bldg 115,Room 318,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM djensen@mednet.ucia.edu FU NCRR NIH HHS [5 M01-RR008658-25]; NIDDK NIH HHS [IK24 DK 02650, DK 41301] NR 44 TC 75 Z9 81 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2005 VL 128 IS 4 BP 870 EP 881 DI 10.1053/j.gastro.2005.01.047 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 914SS UT WOS:000228248600013 PM 15825071 ER PT J AU Morgan, TR Weiss, DG Nemchausky, B Schiff, ER Anand, B Simon, F Kidao, J Cecil, B Mendenhall, CL Nelson, D Lieber, C Pedrosa, M Jeffers, L Bloor, J Lumeng, L Marsano, L McClain, C Mishra, G Myers, B Leo, M Ponomarenko, Y Taylor, D Chedid, A French, S Kanel, G Murray, N Pinto, P Fong, TL Sather, MR AF Morgan, TR Weiss, DG Nemchausky, B Schiff, ER Anand, B Simon, F Kidao, J Cecil, B Mendenhall, CL Nelson, D Lieber, C Pedrosa, M Jeffers, L Bloor, J Lumeng, L Marsano, L McClain, C Mishra, G Myers, B Leo, M Ponomarenko, Y Taylor, D Chedid, A French, S Kanel, G Murray, N Pinto, P Fong, TL Sather, MR TI Colchicine treatment of alcoholic cirrhosis: A randomized, placebo-controlled clinical trial of patient survival SO GASTROENTEROLOGY LA English DT Article ID PRIMARY BILIARY-CIRRHOSIS; CHRONIC HEPATITIS; URSODEOXYCHOLIC ACID; LIVER-CIRRHOSIS; DOUBLE-BLIND; FIBROSIS; DAMAGE; REVERSIBILITY; PREVENTION; SECRETION AB Background & Aims: Colchicine improved survival and reversed cirrhosis in several small clinical trials. We compared the efficacy and safety of long-term colchicine, as compared with placebo, in patients with advanced alcoholic cirrhosis. Methods: Five hundred forty-nine patients with advanced (Pugh B or C) alcoholic cirrhosis were randomized to receive either colchicine 0.6 mg twice per day (n = 274) or placebo (n = 275). Treatment lasted from 2 to 6 years. The primary outcome was all-cause mortality. Secondary outcomes were liver-related morbidity and mortality. Liver biopsy was requested prior to entry and after 24 months of treatment. Results: Attendance at scheduled clinic visits and adherence with study medication were similar in colchicine and placebo groups. Alcohol intake was less than 1 drink per day in 69% of patients. In an intention-to-treat analysis, all-cause mortality was similar in colchicine (49%) and placebo (45%) patients (P =.371). Mortality attributed to liver disease was 32% in colchicine and 28% in placebo patients (P =.337). Fewer patients receiving colchicine developed hepatorenal syndrome. In 54 patients with repeat liver biopsies after 24 or more months of treatment, cirrhosis improved to septal fibrosis in 7 patients (3 colchicine, 4 placebo) and to portal fibrosis in I patient (colchicine). Conclusions: In patients with advanced alcoholic cirrhosis, colchicine does not reduce overall or liver-specific mortality. Liver histology improves to septal fibrosis in a minority of patients after 24 months of treatment, with similar rates of improvement in patients receiving placebo and colchicine. Colchicine is not recommended for patients with advanced alcoholic cirrhosis. C1 Vet Adm Med Ctr, VA Long Beach Healthcare Syst, Long Beach, CA 90822 USA. VA Med Ctr, Perry Point, MD USA. VA Med Ctr, Hines, IL USA. VA Med Ctr, Miami, FL USA. VA Med Ctr, Houston, TX USA. VA Med Ctr, Denver, CO USA. VA Med Ctr, Louisville, KY USA. VA Med Ctr, Cincinnati, OH USA. VA Med Ctr, Minneapolis, MN USA. VA Med Ctr, Bronx, NY USA. VA Med Ctr, Boston, MA USA. VA Med Ctr, Indianapolis, IN USA. VA Med Ctr, Lexington, KY USA. VA Med Ctr, Gainesville, FL USA. VA Med Ctr, N Chicago, IL USA. Harbor UCLA Med Ctr, Torrance, CA 90509 USA. Univ So Calif, Med Ctr, LAC, Los Angeles, CA USA. Baylor Hosp, Dallas, TX USA. VA Med Ctr, Albuquerque, NM USA. RP Morgan, TR (reprint author), Vet Adm Med Ctr, VA Long Beach Healthcare Syst, 5901 E 7th St, Long Beach, CA 90822 USA. EM timothy.morgan@med.va.gov NR 38 TC 34 Z9 35 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2005 VL 128 IS 4 BP 882 EP 890 DI 10.1053/j.gastro.2005.01.057 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 914SS UT WOS:000228248600014 PM 15825072 ER PT J AU Quiram, P Dumars, S Parwar, B Sarraf, D AF Quiram, P Dumars, S Parwar, B Sarraf, D TI Viagra-associated serous macular detachment SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY LA English DT Article ID SILDENAFIL CITRATE VIAGRA; UVEAL EFFUSION; CHORIORETINOPATHY; DEGENERATION; FEATURES; THERAPY; SERIES AB Purpose: To describe the OCT findings in two cases of idiopathic serous macular detachments associated with Sildenafil ( Viagra) use. Methods: Two patients were identified with idiopathic serous macular detachments associated with Viagra use. Each patient underwent rigorous historical questioning to rule out known causes of serous macular detachments and to determine contributing factors. A comprehensive ocular examination was performed including dilated biomicroscopic examination of the macula and indirect ophthalmoscopic evaluation of the retinal periphery. Additional evaluation included color fundus photography with FA and ICG, OCT analysis of the macula and B-scan ultrasonography. Systemic workup included MRI of the brain and orbits, CT of the brain, orbits, chest and abdomen, blood chemistries and electrophoresis, lumbar puncture with CSF analysis and chest radiographs. Results: Both patients demonstrated idiopathic serous macular detachment associated with peri-macular vitelliform deposits. Although notable peripapillary atrophy and RPE mottling were present, there was no evidence of heme, exudate, or fibrosis to suggest a CNVM. FA showed no focal areas of leakage. Early and late frames of the ICG demonstrated engorged choroidal vessels without frank leakage. Extensive medical evaluation failed to reveal a systemic etiology. OCT findings demonstrated large serous macular detachments that corresponded to the use or discontinuation of Viagra. Discontinuation of Viagra coincided with complete resolution of the serous macular detachment in one patient and improvement of the serous macular detachment in the other. When one patient resumed Viagra use, he experienced a recurrent serous macular detachment. Conclusions: We report the OCT findings of two cases of idiopathic serous macular detachment associated with use of the potent vasodilator Sildenafil ( Viagra). C1 Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA. Greater Los Angeles Vet Adm Healthcare Ctr, Los Angeles, CA USA. Charles Drew Univ Med, ML King Med Ctr, Los Angeles, CA USA. Kaiser Permanente Med Grp, Dept Ophthalmol, Woodland Hills, CA USA. Kaiser Permanente Med Grp, Dept Ophthalmol, Baldwin Pk, CA USA. RP Quiram, P (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM quiram@jsei.ucla.edu NR 37 TC 15 Z9 15 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0721-832X J9 GRAEF ARCH CLIN EXP JI Graefes Arch. Clin. Exp. Ophthalmol. PD APR PY 2005 VL 243 IS 4 BP 339 EP 344 DI 10.1007/s00417-004-1099-0 PG 6 WC Ophthalmology SC Ophthalmology GA 922RW UT WOS:000228856700010 PM 15756578 ER PT J AU Rivers, PA Dobalian, A Germinario, FA AF Rivers, PA Dobalian, A Germinario, FA TI A review and analysis of the clinical laboratory improvement amendment of 1988: Compliance plans and enforcement policy SO HEALTH CARE MANAGEMENT REVIEW LA English DT Review AB In 1988, Congress passed the Clinical Laboratory Improvement Amendment (CLIA), thereby extending coverage of the Clinical Laboratory Improvement Act of 1967 to include quality standards for all laboratory-based testing. The CLIA was enacted to ensure the accuracy, reliability, and timeliness of patient test results, regardless of the location where the tests were performed. This article assessed trends in the enforcement policy of the CLIA through an examination of the Laboratory Registry, an annual publication of those individuals or entities that have had sanctions imposed on them by the Centers for Medicare and Medicaid Services. We reviewed the CLIA, including its oversight, regulations that were promulgated based on it, and its enforcement procedures. We obtained the Laboratory Registries for 1993-2001. Sanctions were categorized into groups per the enforcement regulations (42 C.F.R . 493.2 2000). The data indicated an increasing use of more lenient sanctions from 1997 to 2001, and a gradual increase in fraudulent activity for that same period. One possible explanation for this finding is that implementation of compliance plans by participating clinical laboratories had a mitigating effect on enforcement policy. Compliance plan guidance from the OIG provides an opportunity for laboratory service providers to be proactive in their attempts to decrease errors, and thus improve accuracy and reliability by documenting laboratory policies, procedures, and objectives. C1 So Illinois Univ, Coll Appl Sci & Arts, Hlth Management Program, Carbondale, IL USA. VA Greater Los Angles Healthcare Syst, HSR&D Ctr Excellence Study Healthcare Provider Be, Sepulveda, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. Arizona State Univ, Coll Business, Sch Hlth Adm & Policy, Tempe, AZ 85287 USA. RP Rivers, PA (reprint author), So Illinois Univ, Coll Appl Sci & Arts, Hlth Management Program, Carbondale, IL USA. EM privers@siu.edu; adobalia@ucla.edu; franco.germinario@asu.edu NR 16 TC 14 Z9 14 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0361-6274 J9 HEALTH CARE MANAGE R JI Health Care Manage. Rev. PD APR-JUN PY 2005 VL 30 IS 2 BP 93 EP 102 PG 10 WC Health Policy & Services SC Health Care Sciences & Services GA 924NJ UT WOS:000228985200003 PM 15923911 ER PT J AU Nelson, KM Chapko, MK Reiber, G Boyko, EJ AF Nelson, KM Chapko, MK Reiber, G Boyko, EJ TI The association between health insurance coverage and diabetes care; Data from the 2000 Behavioral Risk Factor Surveillance System SO HEALTH SERVICES RESEARCH LA English DT Article; Proceedings Paper CT 62nd Annual Meeting of the American-Diabetes-Association CY JUN 14-18, 2002 CL SAN FRANCISCO, CA SP Amer Diabet Assoc DE quality of care; health insurance; diabetes ID UNITED-STATES; MEDICAL-CARE; ADULTS; RELIABILITY; MELLITUS; US AB To describe the association between type of health insurance coverage and the quality of care provided to individuals with diabetes in the United States. The 2000 Behavioral Risk Factor Surveillance System. Our study cohort included individuals who reported a diagnosis of diabetes (n=11,647). We performed bivariate and multivariate logistic regression analyses by age greater or less than 65 years to examine the association of health insurance coverage with diabetes-specific quality of care measures, controlling for the effects of race/ethnicity, annual income, gender, education, and insulin use. Most individuals with diabetes are covered by private insurance (39 percent) or Medicare (44 percent). Among persons under the age of 65 years, 11 percent were uninsured. The uninsured were more likely to be African American or Hispanic and report low incomes. The uninsured were less likely to report annual dilated eye exams, foot examinations, or hemoglobin A1c (HbA1c) tests and less likely to perform daily blood glucose monitoring than those with private health insurance. We found few differences in quality indicators between Medicare, Medicaid, or the Department of Veterans Affairs (VA) as compared with private insurance coverage. Persons who received care through the VA were more likely to report taking a diabetes education class and HbA1c testing than those covered by private insurance. Uninsured adults with diabetes are predominantly minority and low income and receive fewer preventive services than individuals with health insurance. Among the insured, different types of health insurance coverage appear to provide similar levels of care, except for higher rates of diabetes education and HbA1c testing at the VA. C1 Univ Washington, Dept Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98107 USA. RP Nelson, KM (reprint author), VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, 1660 S Columbian Way,S-111-GIMC, Seattle, WA 98107 USA. OI Boyko, Edward/0000-0002-3695-192X NR 21 TC 68 Z9 69 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD APR PY 2005 VL 40 IS 2 BP 361 EP 372 DI 10.1111/j.1475-6773.2005.0d362.x PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 015ZK UT WOS:000235590000005 PM 15762896 ER PT J AU Shahidzadeh, R Opekun, A Shiotani, A Graham, DY AF Shahidzadeh, R Opekun, A Shiotani, A Graham, DY TI Effect of the carbonic anhydrase inhibitor, acetazolamide, on Helicobacter pylori infection in vivo: A pilot study SO HELICOBACTER LA English DT Article DE Helicobacter pylori; treatment; acetazolamide; clinical trial; urea breath testing ID RESISTANCE; UREASE AB Background. Carbonic anhydrase inhibitors have been successfully used to treat peptic ulcers. Although carbonic anhydrase restriction does not inhibit Helicobacter pylori in vitro, recent studies suggest that carbonic anhydrase inhibition reduces the ability of H. pylori to survive in an acid environment as present in the stomach. Methods. In a pilot study, we examined the effect of acetazolamide 500 mg as twice a day for 4 days in volunteers with active H. pylori infection. Effectiveness was judged by changes in the results of the urea breath test. Results. Eight H. pylori infected volunteers completed the test. No urea breath test reverted to negative and there was a trend for the urea breath test value to increase [e.g. delta over baseline (DOB) mean +/- SE increased from 50.9 +/- 13 at baseline to 64.9 +/- 13 at day 5] during treatment with acetazolamide. Conclusion. The potential effect of carbonic anhydrase inhibitors on acid secretion may prevent effect on H. pylori in vivo and/or the sites of infection at the surface of the stomach may have a pH higher for any postulated acid-dependent effect to have an effect clinically. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP Graham, DY (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Rm 3 A-320 111D,2002 Holcombe Blvd, Houston, TX 77030 USA. EM dgraham@bcm.tmc.edu FU NIDDK NIH HHS [DK56338] NR 10 TC 10 Z9 10 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 1083-4389 J9 HELICOBACTER JI Helicobacter PD APR PY 2005 VL 10 IS 2 BP 136 EP 138 DI 10.1111/j.1523-5378.2005.00306.x PG 3 WC Gastroenterology & Hepatology; Microbiology SC Gastroenterology & Hepatology; Microbiology GA 905TN UT WOS:000227593200006 PM 15810944 ER PT J AU Spiegel, BMR Younossi, ZM Hays, RD Revicki, D Robbins, S Kanwal, F AF Spiegel, BMR Younossi, ZM Hays, RD Revicki, D Robbins, S Kanwal, F TI Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment SO HEPATOLOGY LA English DT Article ID CLINICALLY IMPORTANT DIFFERENCES; ANTIVIRAL THERAPY; VIRAL-HEPATITIS; VIRUS-INFECTION; LIVER-DISEASE; HCV-INFECTION; QUESTIONNAIRE; COMBINATION; DIFFERENCE; UTILITIES AB Hepatitis C virus (HCV) diminishes health related quality of life (HRQOL), and it is now common to measure HRQOL in clinical trials. We sought to summarize the HRQOL data in HCV, and to establish the minimally clinically important difference (MCID) in HRQOL scores in HCV. We performed a systematic review to identify relevant studies, and converted HRQOL data from each study into clinically interpretable statistics. An expert panel used a modified Delphi technique to estimate the MCID in HCV. We found that patients with HCV scored lower than controls across all scales of the SF-36. Patients achieving sustained virological response (SVR) scored higher across all scales versus patients without SVR, especially in the physical health domains. HRQOL differences did not correspond with differences in liver histology or ALT levels. Based upon the published data, the expert panel concluded that the SF-36 vitality scale was most relevant in patients with HCV, and generated a mean MCID of 4.2 points on this scale. In conclusion, patients with HCV have a clinically significant decrement in HRQOL versus controls, and physical HRQOL improves in patients achieving SVR but not in those without SVR. The data further suggest that traditional outcomes fail to capture the full spectrum of illness related to chronic HCV. A difference of 4.2 points on the SF-36 vitality scale can be used as an estimate of the MCID in HCV, and this value may be used as the basis for power calculations in clinical trials evaluating HRQOL. C1 Univ Calif Los Angeles, David Geffen Sch Med,Div Gastroenterol, VA Greater Los Angeles Healthcare Syst, Ctr Study Digest Healthcare Qual & Outcomes, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90073 USA. Inova Fairfax Hosp, Ctr Study Digest Healthcare Qual & Outcomes, Falls Church, VA USA. Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. RAND Corp, Santa Monica, CA USA. Amgen Inc, Global Hlth Econ, Thousand Oaks, CA USA. RP Kanwal, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med,Div Gastroenterol, VA Greater Los Angeles Healthcare Syst, Ctr Study Digest Healthcare Qual & Outcomes, 11301 Wilshire Blvd,Bldg 115 Room 215E, Los Angeles, CA 90073 USA. EM fkanwal@mednet.ucla.edu RI Hays, Ronald/D-5629-2013 FU NIA NIH HHS [AG-02-004]; NIMHD NIH HHS [P20-MD00148-01] NR 47 TC 200 Z9 209 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD APR PY 2005 VL 41 IS 4 BP 790 EP 800 DI 10.1002/hep.20659 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 911MD UT WOS:000228006000015 PM 15791608 ER PT J AU Ioannou, GN AF Ioannou, GN TI Percutaneous ablation for hepatocellular carcinoma SO HEPATOLOGY LA English DT Letter C1 Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Seattle, WA 98108 USA. Univ Washington, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Seattle, WA 98108 USA. RI Llovet, Josep M /D-4340-2014 OI Llovet, Josep M /0000-0003-0547-2667 NR 1 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD APR PY 2005 VL 41 IS 4 BP 942 EP 942 DI 10.1002/hep.206411 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 911MD UT WOS:000228006000036 PM 15791609 ER PT J AU Lee, YH Harley, JB Nath, SK AF Lee, YH Harley, JB Nath, SK TI CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis SO HUMAN GENETICS LA English DT Article ID SIGNIFICANT ASSOCIATION; SUSCEPTIBILITY GENE; T-CELLS; PROMOTER; EXON-1; POPULATION; JAPANESE; DISEASE; AUTOIMMUNITY; ACTIVATION AB Several reports demonstrate association between variants of the cytotoxic T lymphocyte antigen-4 (CTLA-4) and autoimmune diseases. CTLA-4 may generate autoimmunity by immune dysregulation, making CTLA-4 an attractive candidate gene for systemic lupus erythematosus (SLE) susceptibility. Previous CTLA-4 association studies with SLE, however, have produced inconsistent results. We have performed a meta-analysis to better assess the purported associations. A total of 14 independent studies (to July 2004) testing association between one or more CTLA-4 polymorphisms and SLE were used in this analysis. We have compared allele and genotype frequencies at four polymorphic sites found in exon-1 (at +49), the promoter region (at -318 and -1722), and the 3' untranslated region (3'UTR) (dinucleotide repeat). We have evaluated both fixed and random effect models, depending on the presence of between-study heterogeneity. The data demonstrate that the exon-1 +49 polymorphism is significantly associated with SLE susceptibility. The overall risk, measured by odds ratio (OR), for exon-1 +49 GG genotype is 1.287 [95% confidence interval (CI)=1.031-1.562, P=0.011]. Stratification by ethnicity indicates the exon-1 +49 GG genotype is associated with SLE, at least in Asians (OR=1.293, 95% CI=1.031-1.620, P=0.026). European-derived populations have an effect of similar magnitude (OR=1.268, 95% CI=0.860-1.870, P=0.230), though not significant. Similar trends are found in allele-specific risk estimates and disease association. The OR for the exon-1 +49 risk allele (G) in Asians is 1.246 (95% CI=1.057-1.469, P=0.009), while Europeans have no evidence of allelic association (OR=0.978, 95% CI=0.833-1.148, P=0.780). In conclusion, this meta-analysis supports the CTLA-4 exon-1 +49 (A/G) polymorphism influencing the risk for developing SLE, especially in Asians. C1 Oklahoma Med Res Fdn, Arthritis & Immunol Res Program, Oklahoma City, OK 73104 USA. Oklahoma Med Res Fdn, Genet Epidemiol Unit, Oklahoma City, OK 73104 USA. US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA. RP Nath, SK (reprint author), Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK 73190 USA. EM swapan-nath@omrf.ouhsc.edu FU NCRR NIH HHS [RR01577, RR020143, RR14467]; NIAID NIH HHS [AI053747, AI063622, AI24717]; NIAMS NIH HHS [AR048928, AR049084, AR12253, AR42460, AR48940]; NIDCR NIH HHS [DE15223] NR 37 TC 85 Z9 95 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0340-6717 J9 HUM GENET JI Hum. Genet. PD APR PY 2005 VL 116 IS 5 BP 361 EP 367 DI 10.1007/s00439-004-1244-1 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA 914LZ UT WOS:000228230500005 PM 15688186 ER PT J AU Loftis, JM Hauser, P AF Loftis, JM Hauser, P TI Comments on the paper 'The effect of a herbal medicine (Mao-to) for the prevention of interferon-induced psychiatric complications in chronic hepatitis C: A pilot study SO HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL LA English DT Letter ID ALPHA-INDUCED DEPRESSION; THERAPY; SYMPTOMS; DISORDER C1 Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97239 USA. NW Hepatitis C Resource Ctr, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. Portland VA Med Ctr, JENS Lab, Portland, OR USA. RP Loftis, JM (reprint author), Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. NR 15 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0885-6222 J9 HUM PSYCHOPHARM CLIN JI Hum. Psychopharmacol.-Clin. Exp. PD APR PY 2005 VL 20 IS 3 BP 211 EP 212 DI 10.1002/hup.680 PG 2 WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry; Psychology SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry; Psychology GA 918TW UT WOS:000228571500008 PM 15799008 ER PT J AU Ding, D Cooper, RA AF Ding, D Cooper, RA TI Electric-powered wheel chairs SO IEEE CONTROL SYSTEMS MAGAZINE LA English DT Review ID ASSISTED WHEELCHAIR; SEAT-BELT; DESIGN; SYSTEM; STABILITY; DISABILITIES; PERFORMANCE; CONTROLLER; SUSPENSION; VIBRATION C1 Univ Pittsburgh, Med Ctr, Vet Affairs Pittsburgh Hlth Care Syst, Human Engn Res Labs, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA 15260 USA. RP Univ Pittsburgh, Med Ctr, Vet Affairs Pittsburgh Hlth Care Syst, Human Engn Res Labs, 151-R1,7180 Highland Dr, Pittsburgh, PA 15260 USA. EM rcooper@pitt.edu NR 91 TC 92 Z9 93 U1 1 U2 7 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1066-033X EI 1941-000X J9 IEEE CONTR SYST MAG JI IEEE Control Syst. Mag. PD APR PY 2005 VL 25 IS 2 BP 22 EP 34 DI 10.1109/MCS.2005.1411382 PG 13 WC Automation & Control Systems SC Automation & Control Systems GA 907XY UT WOS:000227752800003 ER PT J AU Yamaoka, Y Yamauchi, K Ota, H Sugiyama, A Ishizone, S Graham, DY Maruta, F Murakami, M Katsuyama, T AF Yamaoka, Y Yamauchi, K Ota, H Sugiyama, A Ishizone, S Graham, DY Maruta, F Murakami, M Katsuyama, T TI Natural history of gastric mucosal cytokine expression in Helicobacter pylori gastritis in Mongolian gerbils SO INFECTION AND IMMUNITY LA English DT Article ID IMMUNE-RESPONSES; INTESTINAL METAPLASIA; GAMMA-INTERFERON; CELL RESPONSES; TH1 PHENOTYPE; PEPTIC-ULCER; CAGA GENE; INFECTION; CANCER; MICE AB Data regarding the chronological changes in gastric mucosal cytokines in the different phases of Helicobacter pylori infection are unavailable. We examined Mongolian gerbils for up to 52 weeks after H. pylori (ATCC 43504) inoculation. Levels of mRNAs of mucosal cytokines (interleukin-1 beta [IL-1 beta], gamma interferon [IFN-gamma], IL-4, IL-6, and IL-10) were assessed using real-time reverse transcription-PCR. Starting 26 weeks after H. pylori inoculation, two clinicohistologic patterns appeared: gastric ulcers in 32% and hyperplastic polyps in 68% of gerbils. High levels of mucosal IL-10 mRNA were observed early in the infection, reaching maximum at 4 weeks and then rapidly declining. Mucosal IFN-gamma mRNA also reached maximal levels at 4 weeks but remained high thereafter. Both IL-1 beta and IFN-gamma mRNA levels were consistently higher in the pyloric mucosa than in the fundic mucosa. In contrast, IL-4, IL-6, and IL-10 mRNA levels peaked at 8 to 26 weeks and levels were similar in the pyloric mucosa and the fundic mucosa. IFN-gamma mRNA levels were significantly higher in gerbils with ulcers than in those with hyperplastic polyps (median IFN-gamma/glyceraldehyde-3 -phosphate dehydrogenase ratio x 100,000 = 650 versus 338, respectively [antrum], and 172 versus 40, respectively [corpus]) (P < 0.05). We propose that the different outcomes (e.g., ulcers or hyperplastic polyps) might relate to imbalances among cytokines. C1 Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. Shinshu Univ Hosp, Matsumoto, Nagano, Japan. Shinshu Univ, Sch Med, Dept Biomed Lab Sci, Sch Hlth Sci, Matsumoto, Nagano, Japan. Shinshu Univ, Sch Med, Dept Surg, Matsumoto, Nagano, Japan. Shinshu Univ, Sch Med, Dept Lab Med, Matsumoto, Nagano 390, Japan. RP Yamaoka, Y (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Dept Med Gastroenterol, 111D,Rm 3A-320,2002 Holcombe Blvd, Houston, TX 77030 USA. EM yyamaoka@bcm.tmc.edu FU NIDDK NIH HHS [R01 DK062813, R01 DK062813-02, R01 DK62813] NR 32 TC 35 Z9 35 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD APR PY 2005 VL 73 IS 4 BP 2205 EP 2212 DI 10.1128/IAI.73.4.2205-2212.2005 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 911BB UT WOS:000227975000035 PM 15784564 ER PT J AU Stout, JE Sens, K Mietzner, S Obman, A Yu, VL AF Stout, JE Sens, K Mietzner, S Obman, A Yu, VL TI Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS LA English DT Article DE Legionella pneumophila; susceptibility; quinolones; ketolides; macrolides ID COMMUNITY-ACQUIRED PNEUMONIA; ANTIMICROBIAL AGENTS; GUINEA-PIGS; HL-60 CELLS; PNEUMOPHILA PNEUMONIA; CHLAMYDIA-PNEUMONIAE; HMR 3647; LEVOFLOXACIN; EFFICACY; ANTIBACTERIAL AB The comparative in vitro activity of quinolones (trovafloxacin, gemifloxacin, levofloxacin, ciprofloxacin, moxifloxacin and grepafloxacin), ketolides (ABT-773 and telithromycin) and macrolides (clarithromycin, azithromycin and erythromycin) were evaluated against Legionella pneumophila by broth dilution and an HL-60 intracellular model. The MIC90 of the quinolones, clarithromycin and ABT-773 were more than eight times lower than for erythromycin. Telithromycin, ABT-773 and azithromycin had significantly greater intracellular activity against L. pneumophila than erythromycin at 1 x MIC and 8 x MIC. The rank order of intracellular activity against L. pneumophila serogroup I was quinolones > ketolides > macrolides. Clinical trials to determine the clinical efficacy of ketolides for the treatment of Legionnaires' disease are warranted. Published by Elsevier B.V. on behalf of the International Society of Chemotherapy. C1 VA Pittsburgh Healthcare Syst, VA Med Ctr, Infect Dis Sect, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Pittsburgh, PA USA. RP Yu, VL (reprint author), VA Pittsburgh Healthcare Syst, VA Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM vly+@pitt.edu NR 27 TC 33 Z9 38 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-8579 J9 INT J ANTIMICROB AG JI Int. J. Antimicrob. Agents PD APR PY 2005 VL 25 IS 4 BP 302 EP 307 DI 10.1016/j.jantimicag.2004.08.019 PG 6 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 916SK UT WOS:000228406100005 PM 15784309 ER PT J AU Bauer, MS Altshuler, L Evans, DR Beresford, T Williford, WO Hauger, R AF Bauer, MS Altshuler, L Evans, DR Beresford, T Williford, WO Hauger, R CA VA Coopertive Study 430 Team TI Prevalence and distinct correlates of anxiety, substance, and combined comorbidity in a multi-site public sector sample with bipolar disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE bipolar disorder; substance use disorders; anxiety disorders; assessment; function; adherence; post-traumatic stress disorder; panic disorder; obsessive-compulsive disorder; alcohol; cocaine ID POSTTRAUMATIC-STRESS-DISORDER; OBSESSIVE-COMPULSIVE DISORDER; PANIC DISORDER; DRUG-ABUSE; I DISORDER; PSYCHIATRIC COMORBIDITY; UNIPOLAR DEPRESSION; GENERAL-POPULATION; ALCOHOL-ABUSE; PURE-MANIA AB Background: Recent data indicate high prevalence of both anxiety and substance comorbidity in bipolar disorder. However, few studies have utilized public sector samples, and only one has attempted to separate contributions of each type of comorbidity. Methods: 328 inpatient veterans with bipolar disorder across I I sites were assessed using selected Structured Clinical Interview for DSM-IV modules and self-reports. Results: Comorbidity was common (current: 57.3%; lifetime: 78.4%), with multiple current comorbidities in 29.8%. Substance comorbidity rate was comparable to rates typically reported in non-veteran inpatient samples (33.8% current, 72.3% lifetime). Selected anxiety comorbidity rates exceeded those in other inpatient samples and appeared more chronic than episodic/recurrent (38.3% current, 43.3% lifetime). 49% of PTSD was due to non-combat stressors. Major correlates of current substance comorbidity alone were younger age, worse marital status, and higher current employability. Correlates of current anxiety comorbidity alone were early age of onset, greater number of prior-year depressive episodes, higher rates of disability pension receipt, and lower self-reported mental and physical function. Combined comorbidity resembled anxiety comorbidity. Limitations: This is a cross-sectional analysis of acutely hospitalized veterans. Conclusions: Distinct patterns of substance and anxiety comorbidity are striking, and may be subserved by distinct neurobiologic mechanisms. The prevalence, chronicity and functional impact of anxiety disorders indicate the need for improved recognition and treatment of this other dual diagnosis group is warranted. Clinical and research interventions should recognize these divergent comorbidity patterns and provide individualized treatment built "from the patient out." (c) 2005 Elsevier B.V. All rights reserved. C1 VAMC, Providence, RI 02908 USA. Brown Univ, Providence, RI 02908 USA. W LA VAMC, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Augusta VAMC, Augusta, GA USA. Med Coll Georgia, Augusta, GA USA. Denver VAMC, Denver, CO USA. Univ Colorado, Denver, CO USA. Perry Point VAMC, Perry Point, MD USA. Univ Maryland, Perry Point, MD USA. San Diego VAMC, San Diego, CA USA. Univ Calif San Diego, San Diego, CA USA. RP Bauer, MS (reprint author), VAMC, 830 Chalkstone Ave,116R, Providence, RI 02908 USA. EM mark.bauer@med.va.gov NR 84 TC 104 Z9 104 U1 2 U2 16 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD APR PY 2005 VL 85 IS 3 BP 301 EP 315 DI 10.1016/j.jad.2004.11.009 PG 15 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 916WM UT WOS:000228417300007 PM 15780700 ER PT J AU Regenold, WT Hisley, KC Obuchowski, A Lefkowitz, DM Marano, C Hauser, P AF Regenold, WT Hisley, KC Obuchowski, A Lefkowitz, DM Marano, C Hauser, P TI Relationship of white matter hyperintensities to cerebrospinal fluid glucose polyol pathway metabolites - a pilot study in treatment-resistant affective disorder patients SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE white matter; affective; polyol; sorbitol; glucose ID BIPOLAR AFFECTIVE-DISORDER; SIGNAL HYPERINTENSITIES; MAJOR DEPRESSION; RISK-FACTORS; DIABETIC-NEUROPATHY; RATING-SCALE; LESIONS; PREVALENCE; MRI; ABNORMALITIES AB Background: Magnetic resonance imaging (MRI) white matter hyperintensities (WMHs) are found at higher rates in patients with affective disorders, particularly late-life or treatment-resistant disorders. Studies support a vascular pathogenesis for WMHs in late-life onset disorders; however, pathogenesis in typical early-life onset disorders is less clear. Based on associations between diabetes mellitus and both WMHs and affective disorders, this study investigated the relationship between WMHs and brain glucose metabolism by the polyol pathway-a pathway linked to nervous tissue disease in diabetes. Methods: Burdens of fluid-attenuated inversion recovery (FLAIR) WMHs were quantified and correlated with cerebrospinal fluid (CSF) concentrations of glucose metabolites in 10 nondiabetic inpatients with treatment-resistant bipolar, unipolar, and schizoaffective disorders and 10 nondiabetic control patients who had been investigated clinically for transient neurological symptoms. Results: Deep but not periventricular WMH burden correlated positively and significantly with elevated CSF concentrations of sorbitol, the specific polyol pathway metabolite of glucose (rho=0.86, p=0.002), in the affective disorders but not the control group. Limitations: This was a pilot study with a relatively small number of subjects; therefore, conclusions are tentative. Controls were not healthy subjects; they were patients with transient neurological symptoms. Conclusions: This is the first reported evidence of a relationship between WMHs and increased brain glucose metabolism by the polyol pathway in patients with affective disorders. More extensive studies are necessary to determine whether this preliminary finding represents a pathogenetic relationship. (c) 2004 Elsevier B.V. All rights reserved. C1 Univ Maryland, Sch Med, Dept Psychiat, Div Geriatr Psychiat, Baltimore, MD 21201 USA. Univ Maryland, Sch Med, Dept Diagnost Radiol, Baltimore, MD 21201 USA. Oregon Hlth Sci Univ, Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR 97207 USA. Oregon Hlth Sci Univ, NW Hepatitis C Resource Ctr, Portland, OR 97207 USA. RP Regenold, WT (reprint author), Univ Maryland, Sch Med, Dept Psychiat, Div Geriatr Psychiat, Baltimore, MD 21201 USA. EM wregenol@psych.umaryland.edu NR 53 TC 15 Z9 16 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD APR PY 2005 VL 85 IS 3 BP 341 EP 350 DI 10.1016/j.jad.2004.10.010 PG 10 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 916WM UT WOS:000228417300012 PM 15780705 ER PT J AU Zhang, J Goodlett, DR Quinn, JF Peskind, E Kaye, JA Zhou, Y Pan, C Yi, E Eng, J Wang, Q Aebersold, RH Montine, TJ AF Zhang, J Goodlett, DR Quinn, JF Peskind, E Kaye, JA Zhou, Y Pan, C Yi, E Eng, J Wang, Q Aebersold, RH Montine, TJ TI Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer disease; biomarkers; cerebrospinal fluid; proteomics ID MASS-SPECTROMETRY; DIAGNOSIS; MARKERS AB Biomarkers to assist in the diagnosis and medical management of Alzheimer disease (AD) are a pressing need. We have employed a proteomic approach, microcapillary liquid chromatography mass spectrometry of proteins labeled with isotope-coded affinity tags (ICAT), to quantify relative changes in the proteome of human cerebrospinal fluid (CSF) obtained from the lumbar cistern. Using CSF from well-characterized AD patients and age-matched controls at 2 different institutions, we quantified protein concentration ratios of 42% of the 390 CSF proteins that we have identified and found differences >= 20% in over half of them. We confirmed our findings by western blot and validated this approach by quantifying relative levels of amyloid precursor protein and cathepsin B in 17 AD patients and 16 control individuals. Quantitative proteomics of CSF from AD patients compared to age-matched controls, as well as from other neurodegenerative diseases, will allow us to generate a roster of proteins that may serve as specific biomarker panels for AD and other geriatric dementias. C1 Univ Washington, Harborview Med Ctr, Sch Med, Div Neuropathol,Dept Pathol, Seattle, WA 98104 USA. Univ Washington, Dept Med Chem, Sch Med, Seattle, WA 98104 USA. Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98104 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR USA. VA Puget Sound Hlth Care Syst, Mentall Illness Res Educ & Clin Ctr, Seattle, WA USA. Inst Syst Biol, Seattle, WA USA. RP Montine, TJ (reprint author), Univ Washington, Harborview Med Ctr, Sch Med, Div Neuropathol,Dept Pathol, Box 359791, Seattle, WA 98104 USA. EM tmontine@u.washington.edu RI Eng, Jimmy/I-4202-2012 OI Eng, Jimmy/0000-0001-6352-6737; Kaye, Jeffrey/0000-0002-9971-3478 FU NCRR NIH HHS [RR000334]; NIA NIH HHS [AG024011, AG05136, AG08017, AG16835] NR 14 TC 122 Z9 125 U1 0 U2 10 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PD APR PY 2005 VL 7 IS 2 BP 125 EP 133 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 942KN UT WOS:000230281400005 PM 15851850 ER PT J AU Echevarria, K Datta, P Cadena, J Lewis, JS AF Echevarria, K Datta, P Cadena, J Lewis, JS TI Severe myopathy and possible hepatotoxicity related to daptomycin SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Letter DE anti-infective agents; adverse reactions; lipopeptide antibiotics ID SAFETY C1 S Texas Vet Healthcare Syst, Serv Pharm, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Serv Pharm, Univ Hlth Syst, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Clin Pharm, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA. RP Echevarria, K (reprint author), S Texas Vet Healthcare Syst, Serv Pharm, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM kelly.echevarria@med.va.gov NR 5 TC 32 Z9 34 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD APR PY 2005 VL 55 IS 4 BP 599 EP 600 DI 10.1093/jac/dki058 PG 3 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 912KH UT WOS:000228076300040 PM 15743894 ER PT J AU Massie, BM AF Massie, BM TI Heart failure trials: Are they becoming impractical? SO JOURNAL OF CARDIAC FAILURE LA English DT Editorial Material C1 San Francisco VAMC, Cardiol Div 111C, San Francisco, CA 94121 USA. RP Massie, BM (reprint author), San Francisco VAMC, Cardiol Div 111C, 4150 Clement St, San Francisco, CA 94121 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD APR PY 2005 VL 11 IS 3 BP 161 EP 163 DI 10.1016/j.cardfail.2005.03.001 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 919NV UT WOS:000228625700001 PM 15812741 ER PT J AU Little, WC Zile, MR Kitzman, DW Hundley, WG O'Brien, TX Degroof, RC AF Little, WC Zile, MR Kitzman, DW Hundley, WG O'Brien, TX Degroof, RC TI The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE diastolic heart failure; diastolic function; left ventricular mass; glucose cross-link ID PULMONARY-EDEMA; DYSFUNCTION; EXERCISE; ARTERIAL AB Background: Despite its high prevalence, optimal therapy for diastolic heart failure (DHF) has not been determined. Alagebrium chloride (ALT-711) is a novel compound that breaks glucose crosslinks and may improve ventricular and arterial compliance. Methods and Results: A total of 23 patients, mean age 71 years, with stable DHF, ejection fraction (EF) > 50%, were enrolled in a 16-week, open-label trial of alagebrium 420 mg per day. Assessments included: peak exercise oxygen consumption, aortic distensibility, and left ventricular EF and mass by magnetic resonance imaging, Doppler diastolic filling, and quality of life by the Minnesota Living with Heart Failure questionnaire. One patient discontinued treatment because of a myocardial infarction after 12 days of treatment, and a second died suddenly after 10 weeks of treatment. Thus 2 1 patients completed the study. Left ventricular mass was 124 +/- 35 g at baseline and decreased to 119 +/- 34 g at follow up (P =.036). This was accompanied by a decrease in the ratio of Doppler early diastolic flow velocity to Doppler early diastolic mitral annulus velocity (E') from 10.6 +/- 2.7 to 9.4 +/- 1.9 (P =.076) and an increase in E' front 7.3 +/- 1.2 to 8.4 +/- 1.7 cm/s (P =.045). The Minnesota Living with Heart Failure total score improved from 41 +/- 21 to 32 +/- 21 (P =.01). There were no changes in EF (64 +/- 4% at baseline), blood pressure, peak exercise oxygen consumption, and aortic distensibility. Conclusion: Sixteen weeks of treatment with the glucose crosslink breaker, algebrium, resulted in a decrease in left ventricular mass and improvements in left ventricular diastolic filling and quality of life in patient with DHF. C1 Wake Forest Univ, Sch Med, Dept Internal Med, Cardiol Sect, Winston Salem, NC 27157 USA. Med Univ S Carolina, Gazes Cardiac Res Inst, Ralph H Johnson Dept Vet Affairs Med Ctr, Dept Med,Div Cardiol, Charleston, SC 29425 USA. Alteon Inc, Parsippany, NJ USA. RP Little, WC (reprint author), Wake Forest Univ, Sch Med, Dept Internal Med, Cardiol Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA. FU NCRR NIH HHS [M01 RR 07122]; NHLBI NIH HHS [P01 HL 48788]; NIA NIH HHS [AG 18915, P60 AG 10484] NR 15 TC 162 Z9 171 U1 2 U2 9 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD APR PY 2005 VL 11 IS 3 BP 191 EP 195 DI 10.1016/j.cardfail.2004.09.010 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 919NV UT WOS:000228625700006 PM 15812746 ER PT J AU Soltero, ER Petersen, NJ Earle, NR Glaeser, DH Urbauer, DL Deswal, A AF Soltero, ER Petersen, NJ Earle, NR Glaeser, DH Urbauer, DL Deswal, A TI Long-term results of coronary artery bypass grafting in patients with ischemic cardiomyopathy: The impact of renal insufficiency and noncardiac vascular disease SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE coronary artery bypass surgery; heart failure; ischemic heart disease; revascularization; renal insufficiency; comorbidities ID CHRONIC HEART-FAILURE; LEFT-VENTRICULAR DYSFUNCTION; SYSTOLIC DYSFUNCTION; EJECTION FRACTIONS; VETERANS-AFFAIRS; RANDOMIZED TRIAL; CARDIAC-SURGERY; REVASCULARIZATION; MORTALITY; SURVIVAL AB Background: We examined outcomes of patients with ischemic cardiomyopathy (ICMP), defined by left ventricular ejection fraction (LVEF) < 35%, compared with patients with better-preserved LVEF, undergoing coronary bypass graft surgery (CABG). In addition, we examined the relative impact of a reduced LVEF in comparison with other comorbidities on long-term mortality in these patients. Methods and Results: We evaluated 1381 patients (114 with ICMP, 1267 with better-preserved LVEF) who underwent isolated CABG at a tertiary Veterans Administration (VA) hospital between 1990 and 2000 using data from the VA Continuous Improvement in Cardiac Surgery Program and other VA databases. The 5-year survival was 74.0% in patients with ICMP and 84.4% in the group with better-preserved LVEF (p =.005). LVEF < 35% remained a significant predictor of long-term mortality in multivariable models (hazard ratio [HR] 1.55, 95% confidence interval [CI] 1.02-2.35). However, the presence of comorbidifies, especially renal insufficiency, peripheral vascular disease, and cerebrovascular disease, had a similar or greater impact on long-term mortality. Renal insufficiency (serum creatinine > 1.5 mg/dL) was associated with the highest risk of long-term mortality (HR 2.02, 95% CI 1.46-2.80). The use of a left internal thoracic artery graft reduced the risk of long-term mortality (HR 0.72, 95% Cl 0.54-0.98). Conclusion: Even though severely depressed LVEF is associated with an increased risk of long-term mortality, the presence of comorbid factors, especially renal dysfunction and noncardiac vascular disease, increase the risk of long-term mortality by a similar or even larger magnitude. These comorbid factors should be given important consideration when evaluating the risks and benefits of CABG. C1 Michael E DeBakey Vet Affairs Med Ctr, Sect Cardiothorac Surg, Operat Care Line, Houston, TX USA. Michael E DeBakey Vet Affairs Med Ctr, Dept Surg, Houston, TX USA. Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. Michael E DeBakey Vet Affairs Med Ctr, Winters Ctr Heart Failure Res, Houston, TX USA. RP Deswal, A (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Sect Cardiothorac Surg, Operat Care Line, Houston, TX USA. NR 29 TC 4 Z9 4 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD APR PY 2005 VL 11 IS 3 BP 206 EP 212 DI 10.1016/j.cardfail.2004.07.008 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 919NV UT WOS:000228625700009 PM 15812749 ER PT J AU Aujesky, D Stone, RA Obrosky, DS Yealy, DM Auble, TE Meehan, TP Graff, LG Fine, JM Fine, MJ AF Aujesky, D Stone, RA Obrosky, DS Yealy, DM Auble, TE Meehan, TP Graff, LG Fine, JM Fine, MJ TI Using randomized controlled trial data, the agreement between retrospectively and prospectively collected data comprising the pneumonia severity index was substantial SO JOURNAL OF CLINICAL EPIDEMIOLOGY LA English DT Article DE community-acquired pneumonia; risk stratification; Cohen's kappa ID COMMUNITY-ACQUIRED PNEUMONIA; MANAGEMENT; QUALITY; CARE; OUTCOMES; KAPPA AB Objective: To assess the agreement between prospectively and retrospectively determined variables comprising the Pneumonia Severity Index (PSI), assignment to PSI risk class, and designation as low risk, based on these two methods of data collection. Study Design and Setting: We analyzed data from a randomized trial of patients with community-acquired pneumonia managed in 32 hospital emergency departments (EDs). For all enrolled patients, the 20 PSI variables were collected prospectively by ED providers and retrospectively by medical record abstractors. We examined the agreement for each of the 20 PSI variables, assignment to the five PSI risk classes, and classification of patients as low (classes I-III) vs. high (classes IV and V) risk. Agreement was measured using total percent agreement and the K statistic. Results: Among the 3,220 enrolled patients, percent agreement was > 90% for 18 of the 20 variables comprising the PSI, with most unweighted kappa's being > 0.6. Agreement was substantial for assignment to PSI risk class (percent agreement: 92.7%; weighted kappa: 0.79) and for classification as low vs. high risk (percent agreement: 88.5%; unweighted kappa: 0.74). Conclusion: There was substantial agreement between retrospective and prospective assignment to PSI risk class, classification as low vs. high risk, and the-determination of most individual variables that constitute the PSI. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15261 USA. Qualidigm, Middletown, CT USA. Yale Univ, Sch Med, New Haven, CT USA. Univ Connecticut, Sch Med, Dept Emergency Med, Farmington, CT USA. New Britain Gen Hosp, Dept Emergency Med, New Britain, CT USA. Norwalk Hosp, Pulm & Crit Care Med Sect, Norwalk, CT 06856 USA. RP Aujesky, D (reprint author), Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. EM Aujesky@swissonline.ch FU AHRQ HHS [R01 HS10049-03] NR 19 TC 8 Z9 8 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0895-4356 J9 J CLIN EPIDEMIOL JI J. Clin. Epidemiol. PD APR PY 2005 VL 58 IS 4 BP 357 EP 363 DI 10.1016/j.jclinepi.2004.08.011 PG 7 WC Health Care Sciences & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 912CR UT WOS:000228055200004 PM 15862721 ER PT J AU Hussein, MR Haemel, AK Sudilovsky, O Wood, GS AF Hussein, MR Haemel, AK Sudilovsky, O Wood, GS TI Genomic instability in radial growth phase melanoma cell lines after ultraviolet irradiation SO JOURNAL OF CLINICAL PATHOLOGY LA English DT Article ID HUMAN EPIDERMAL LAYERS; INDUCED DNA-DAMAGE; MICROSATELLITE INSTABILITY; B IRRADIATION; HUMAN MELANOCYTES; MOUSE SKIN; UV-LIGHT; APOPTOSIS; CANCER; INDUCTION AB Background/Aims: Although ultraviolet (UV) irradiation, apoptosis, and genomic instability are all potentially involved in the pathogenesis of melanoma, in vitro studies investigating these changes in the radial growth phase of this neoplasm are still lacking; therefore, this study was designed to investigate these changes. Method: An in vitro system consisting of three radial growth phase Wistar melanoma cell lines (WM35, WM3211, and WM1650) was established. Cells were UV irradiated (10 mJ/cm(2) for UVB and 6 J/cm(2) for UVA), harvested after UV exposure, and evaluated for viability and apoptosis using Trypan blue and terminal deoxynucleotidyl transferase mediated dUTP digoxigenin nick end labelling assays, respectively. Polymerase chain reaction based microsatellite assays were used to examine the cell lines for the presence of microsatellite instability (MSI) using 21 markers at the 1p, 2p, 3p, 4q, 9p, and 17p regions. Results: Exposure to UV initiated progressive cell death associated with pronounced apoptosis, with UVA having a greater effect than UVB. MSI was found in UVB (WM35 and WM3211) and UVA (WM35) irradiated cell lines at 1p, 9p, and 17p, but not in non-irradiated cells. The prevalence of MSI was higher after UVB irradiation (14%) than UVA irradiation (4.7%), and was most frequently found at D1S233. Conclusions: The ability of erythemogenic UV irradiation to induce both apoptosis and MSI in radial growth phase melanoma cells is suggestive of its role in melanoma pathogenesis. This instability may reflect a hypermutability state, oxidative stress induced DNA damage, replication infidelity, or a combination of these factors. C1 Assiut Univ, Fac Med, Dept Pathol, Assiut, Egypt. Brown Univ, Sch Med, Providence, RI 02912 USA. Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA. Univ Hosp Cleveland, Cleveland, OH 44106 USA. Univ Wisconsin, Dept Dermatol, Madison, WI 53705 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Hussein, MR (reprint author), Assiut Univ Hosp, Dept Pathol, Assiut, Egypt. EM mrh17@swissinfo.org FU NIAMS NIH HHS [AR01326] NR 54 TC 10 Z9 10 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0021-9746 J9 J CLIN PATHOL JI J. Clin. Pathol. PD APR PY 2005 VL 58 IS 4 BP 389 EP 396 DI 10.1136/jcp.2004.021519 PG 8 WC Pathology SC Pathology GA 909PL UT WOS:000227872000011 PM 15790703 ER PT J AU Poon, IO Braun, U AF Poon, IO Braun, U TI High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans SO JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS LA English DT Article DE elderly; medication; orthostatic hypotension; prevalence ID BLOOD-PRESSURE; POSTURAL HYPOTENSION; ATHEROSCLEROSIS RISK; INSTITUTIONAL CARE; GENDER-DIFFERENCES; FOLLOW-UP; FALLS; HYPERTENSION; COMMUNITIES; MORTALITY AB Background: Orthostatic hypotension (OH) is defined as a reduction of systolic blood pressure of at least 20 mmHg, or diastolic blood pressure of at least 10 mmHg from a sitting to a standing position. It is a common physical finding among older adults and associated with significant morbidity and mortality. Use of medications that have the potential to induce OH, particularly concomitant use of several of such medications, is a major factor for the development of OH. Objectives: To describe the prevalence of symptomatic and asymptomatic OH in veterans aged 75 years and older attending a geriatric clinic, and to assess the association between OH and the number of potentially causative medications used. Methods: Charts of all patients who attended a VA geriatric clinic (Michael E. DeBakey VA Medical Center) during the period of 1 June 2002 to 1 June 2003 were reviewed retrospectively for (i) the use of potentially causative medications, i.e. medications that were reported to cause OH in at least 1% of the general population and that were available in the VA formulary, (ii) the presence or absence of OH, and (iii) the presence or absence of symptomatic OH. Patients with primary autonomic dysfunction, Parkinson's disease, and patients who were unable to stand, or who had no assessment for both sitting and standing blood pressure for other reasons were excluded. Results: A total of 505 individual patients attended the clinic during the study period, and 342 patients fit the inclusion criteria. About 189 of these patients (55%) had OH. Among patients with OH, 61 patients (33%) were symptomatic, including 52 patients who had falls. The prevalence of OH in patients receiving zero, one, two, and three or more potentially causative medications was 35, 58, 60 and 65% respectively. Receiving hydrochlorothiazide was associated with the highest prevalence of OH (65%), followed by receiving lisinopril (60%), trazodone (58%), furosemide (56%) and terazosin (54%). Conclusion: The prevalence of OH is very high in older veterans and significantly related to the number of concurrent causative medications used. Providers should be educated to reduce the amount of potentially causative medications in the elderly and better assess patients in which use of such medications is necessary to avoid symptomatic OH. C1 Texas So Univ, Coll Pharm & Hlth Sci, Dept Pharm Practice, Houston, TX 77004 USA. Baylor Coll Med, VA Med Ctr, Houston Ctr Qual Care & Utilizat Study, Sect Geriatr & Hlth Sci Res, Houston, TX 77030 USA. RP Poon, IO (reprint author), Texas So Univ, Coll Pharm & Hlth Sci, Dept Pharm Practice, 3100 Cleburne Ave, Houston, TX 77004 USA. EM chui_io@tsu.edu NR 27 TC 100 Z9 106 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0269-4727 J9 J CLIN PHARM THER JI J. Clin. Pharm. Ther. PD APR PY 2005 VL 30 IS 2 BP 173 EP 178 DI 10.1111/j.1365-2710.2005.00629.x PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 906NO UT WOS:000227649100012 PM 15811171 ER PT J AU Albers, LJ Ozdemir, V Marder, SR Raggi, MA Aravagiri, M Endrenyi, L Reist, C AF Albers, LJ Ozdemir, V Marder, SR Raggi, MA Aravagiri, M Endrenyi, L Reist, C TI Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements - A prospective dose-adjusted drug interaction strategy SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Article ID PERFORMANCE LIQUID-CHROMATOGRAPHY; IN-VITRO; ATYPICAL ANTIPSYCHOTICS; POTENT INHIBITOR; PLASMA; CAFFEINE; SCHIZOPHRENIA; DISPOSITION; METABOLISM; PAROXETINE AB Despite the advances in antipsychotic pharmacotherapy over the past decade, many atypical antipsychotic agents are not readily accessible by patients with major psychosis or in developing countries where the acquisition costs may be prohibitive. Olanzapine is an efficacious and widely prescribed atypical antipsychotic agent. In theory, olanzapine therapeutic dose requirement may be reduced during concurrent treatment with inhibitors of drug metabolism. In vitro studies suggest that smoking-inducible cytochrome P450 (CYP) 1A2 contributes to formation of the metabolite 4'-N-desmethylolanzapine. The present prospective study tested the hypothesis that olanzapine steady-state doses can be significantly decreased by coadministration of a low subclinical dose of fluvoxamine, a potent inhibitor of cytochrome P450 1A2. The study design followed a targeted "at-risk" population approach with a focus on smokers who were likely to exhibit increased cytochrome P450 1A2 expression. Patients with stable psychotic illness (N = 10 men, all smokers) and receiving chronic olanzapine treatment were evaluated for steady-state plasma concentrations of olanzapine and 4'-N-desmethylolanzapine. Subsequently, olanzapine dose was reduced from 17.5 +/- 4.2 mg/d (mean SD) to 13.0 +/- 3.3 mg/d, and a nontherapeutic dose of fluvoxamine (25 mg/d, PO) was added to regimen. Patients were reevaluated at 2, 4, and 6 weeks during olanzapine-fluvoxamine cotreatment. There was no significant change in olanzapine plasma concentration, antipsychotic response, or metabolic indices (eg, serum glucose and lipids) after dose reduction in the presence of fluvoxamine (P > 0.05). 4'-N-desmethylolanzapine/olanzapine metabolic ratio decreased from 0.45 +/- 0.20 at baseline to 0.25 +/- 0.11 at week 6, suggesting inhibition of the cytochrome P450 1A2-mediated olanzapine 4'-N-demethylation by fluvoxamine (P < 0.05). In conclusion, this prospective pilot study suggests that a 26% reduction in olanzapine therapeutic dose requirement may be achieved by coadministration of a nontherapeutic oral dose of fluvoxamine. C1 Univ Calif Irvine, Dept Psychiat & Human Behav, Coll Med, Long Beach, CA USA. So Calif Inst Res & Educ, Long Beach, CA USA. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Mental Illness Res, Ctr Clin, VISN 22, Los Angeles, CA USA. Univ Bologna, Dept Pharmaceut Sci, Fac Pharm, Alma Mater Studiorum, I-40126 Bologna, Italy. Univ Toronto, Dept Pharmacol, Fac Med, Toronto, ON, Canada. RP Albers, LJ (reprint author), Univ Calif Irvine, Mental Hlth Care Grp, VA Long Beach Heatlhcare Syst, 5901 E 7th St, Long Beach, CA 90822 USA. EM larry.albers@med.va.gov RI Raggi, Maria Augusta/A-4545-2011 NR 27 TC 19 Z9 20 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD APR PY 2005 VL 25 IS 2 BP 170 EP 174 DI 10.1097/01.jcp.0000155825.97703.01 PG 5 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 908TX UT WOS:000227814200010 PM 15738749 ER PT J AU Henderson, C Roux, AVD Jacobs, DR Kiefe, CI West, D Williams, DR AF Henderson, C Roux, AVD Jacobs, DR Kiefe, CI West, D Williams, DR TI Neighbourhood characteristics, individual level socioeconomic factors, and depressive symptoms in young adults: the CARDIA study SO JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH LA English DT Article ID DISEASE RISK-FACTORS; MENTAL-HEALTH; ETHNIC DENSITY; ATHEROSCLEROSIS RISK; AREA CHARACTERISTICS; MULTILEVEL ANALYSIS; INCOME INEQUALITY; DISORDERS; CONTEXT; LONDON AB Study objective: To investigate the relation between neighbourhood socioeconomic and ethnic characteristics with depressive symptoms in a population based sample. Design: Cross sectional data from the CARDIA study, including the Center for Epidemiological Studies depression scale score (CES-D). Neighbourhoods were 1990 US census blocks of 1000 people; six census variables reflecting wealth/income, education, and occupation investigated separately and as a summary score; neighbourhood racial composition (percentage white and black) and individual level income and education were also examined. Setting: Participants recruited in 1985/86 from community lists in Birmingham, AL; Chicago, IL; Minneapolis MN; from a health plan in Oakland, CA. Participants: 3437 adults aged 28 - 40 years in 1995/96: 24% white men, 27% white women, 20% black men, 29% black women. Main results: For each race-sex group, CES-D was inversely related to neighbourhood score and individual income and education. Associations of neighbourhood score with CES-D became weak and inconsistent after adjusting for individual level factors; personal income remained strongly and inversely associated with CES-D. Age adjusted mean differences (standard errors) in CES-D between the lowest and highest income categories were 3.41 (0.62) for white men, 4.57 (0.64) for white women, 5.80 (0.87) for black men, and 5.74 (0.83) for black women. For both black and white participants, CES-D was associated negatively with percentage of white people and positively with percentage of black people in their census block, before, but not after, adjustment for individual and neighbourhood socioeconomic variables. Conclusions: Neither neighbourhood socioeconomic characteristics nor ethnic density were consistently related to depressive symptoms once individual socioeconomic characteristics were taken into account. C1 Inst Psychiat, Hlth Serv Res Dept, London, England. Univ Michigan, Ctr Social Epidemiol & Populat Hlth, Ann Arbor, MI 48109 USA. Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA. Univ Oslo, Dept Nutr, Oslo, Norway. Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Univ Arkansas Med Sci, Little Rock, AR 72205 USA. Univ Michigan, Inst Social Res, Ann Arbor, MI 48109 USA. RP Henderson, C (reprint author), Publ Psychiat Fellowship, Room 317,722 W 168th St, New York, NY 10032 USA. EM hendersc@nypdrat.cpmc.columbia.edu RI Henderson, Claire/E-4664-2010 OI Henderson, Claire/0000-0002-6998-5659 FU NHLBI NIH HHS [N01-HC-48050, N01-HC-48048, N01-HC-95095, N01-HC-48047, N01-HC-48049]; NIMHD NIH HHS [MD00206 P60] NR 46 TC 70 Z9 70 U1 0 U2 13 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0143-005X J9 J EPIDEMIOL COMMUN H JI J. Epidemiol. Community Health PD APR PY 2005 VL 59 IS 4 BP 322 EP 328 DI 10.1136/jech.2003.018846 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 911NL UT WOS:000228010300016 PM 15767387 ER PT J AU Eckstrom, E Bowen, JL Tanner, C Ririe, M Joseph, C Desai, S AF Eckstrom, E Bowen, JL Tanner, C Ririe, M Joseph, C Desai, S TI Improving care for geriatric patients: Meeting the challenge. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Legacy Emanuel Hosp, Portland, OR USA. Good Samaritan Hosp, Portland, OR 97210 USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 33 EP 33 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000029 ER PT J AU Collard, CL Bryant, BL Hanesworth, E Wolinsky, A Rehman, SU AF Collard, CL Bryant, BL Hanesworth, E Wolinsky, A Rehman, SU TI Multidisciplinary primary care morning report. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Ralph H Johnson VAMC, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 35 EP 35 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000036 ER PT J AU Lindner, SA Davoren, JB Vollmer, A Landefeld, C AF Lindner, SA Davoren, JB Vollmer, A Landefeld, C TI Electronic medical record intervention increased nursing home advance directive orders and documentation SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 53 EP 53 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000099 ER PT J AU Lawrence, V Cornell, J Hazuda, HP AF Lawrence, V Cornell, J Hazuda, HP TI Improving eleders' recovery after major abdominal surgery SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 56 EP 56 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000112 ER PT J AU Bair, MJ Richardson, KM Dobscha, SK Yi, EJ Gerrity, MS Kroenke, K AF Bair, MJ Richardson, KM Dobscha, SK Yi, EJ Gerrity, MS Kroenke, K TI Chronic pain management guidelines: A systematic review of content and strength of evidence SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Indiana Univ, Sch Med, Indianapolis, IN USA. Richard L Roudebush VA Med Ctr, Indianapolis, IN USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland VA Med Ctr, Portland, OR USA. Indiana Univ, Sch Med, Indianapolis, IN USA. Regenstrief Inst Hlth Care, Indianapolis, IN USA. NR 0 TC 5 Z9 5 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 62 EP 62 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000134 ER PT J AU Rose, SA Kertesz, SG Safford, MM Palonen, KP Halanych, JH Kiefe, CI AF Rose, SA Kertesz, SG Safford, MM Palonen, KP Halanych, JH Kiefe, CI TI Diabetes diagnostic codes associated with primary care visits: Interpret with caution. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Birmingham VA Med Ctr, Birmingham, AL USA. Univ Alabama, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 63 EP 63 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000138 ER PT J AU Yano, E Chaney, EF Simon, B Bonner, L Lanto, AB Campbell, D Rubenstein, LV AF Yano, E Chaney, EF Simon, B Bonner, L Lanto, AB Campbell, D Rubenstein, LV TI Health and health care needs of depressed patients detected in primary care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA. Univ Washington, Seattle, WA 98195 USA. VA Greater Los Angeles, Los Angeles, CA USA. VA Puget Sound Healthcare Syst, Seattle, WA USA. Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 68 EP 68 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000151 ER PT J AU Safford, MM Kirk, K Kiefe, C AF Safford, MM Kirk, K Kiefe, C TI Reducing cardiovascular risk in diabetes: Room for improved intensity of hypertension medication management. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 71 EP 72 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000163 ER PT J AU Shrank, WH Hoang, T Ettner, S Glassman, PA Nair, K London, R Delapp, D Dirstine, J Avorn, J Asch, SM AF Shrank, WH Hoang, T Ettner, S Glassman, PA Nair, K London, R Delapp, D Dirstine, J Avorn, J Asch, SM TI The implications of choice: Does prescribing generic or preferred pharmaceuticals improve medication adherence for chronic conditions?. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. W Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. Anthem Blue Cross Blue Shield, Denver, CO USA. Brigham & Womens Hosp, Boston, MA 02115 USA. RAND, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 73 EP 73 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000168 ER PT J AU Shrank, WH Asch, SM Ettner, S Kirk, A Glassman, PA Fox, SA AF Shrank, WH Asch, SM Ettner, S Kirk, A Glassman, PA Fox, SA TI Putting their mouth where their money is: Are patients enrolled in incentive-based pharmacy plans more likely to talk to their physicians about out-of-pocket costs? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RAND, Los Angeles, CA USA. VA W LA, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 80 EP 80 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000191 ER PT J AU Kelly, PA Haidet, PM DeBakey, ME AF Kelly, PA Haidet, PM DeBakey, ME TI Health literacy: Patients' performance and physicians' perceptions SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Baylor Coll Med, VA Med Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 99 EP 99 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000254 ER PT J AU Mohanty, SA Alegria, M Lau, AS Asch, S AF Mohanty, SA Alegria, M Lau, AS Asch, S TI Are Latinos and Asian Americans/Pacific islanders using fewer mental health care services? Findings from the California Health interview SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ So Calif, Los Angeles, CA USA. Cambridge Hlth Alliance, Cambridge, MA USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RAND Corp, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 108 EP 108 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000286 ER PT J AU Volpp, K Stone, RA Jha, A Lave, JR Pauly, MV Klusaritz, H Chen, H Polsky, D AF Volpp, K Stone, RA Jha, A Lave, JR Pauly, MV Klusaritz, H Chen, H Polsky, D TI Are reverse disparities limited to age-defined subgroups of the VA patient population? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Philadelphia VA Med Ctr, CHERP, Philadelphia, PA USA. Pittsburgh VA Med Ctr, CHERP, Pittsburgh, PA USA. Boston VA Med Ctr, Boston, MA USA. Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 109 EP 109 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000289 ER PT J AU Saha, S Morse, E Jimison, J AF Saha, S Morse, E Jimison, J TI Cultural competence among health professionals: A taxonomy SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 111 EP 111 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000298 ER PT J AU Fultz, SI Goulet, J Weissman, S Rimland, D Leaf, D Gibert, CL Rodriguez-Barradas, M Justice, AC AF Fultz, SI Goulet, J Weissman, S Rimland, D Leaf, D Gibert, CL Rodriguez-Barradas, M Justice, AC TI Differences between infectious disease and general medical providers in comfort with providing primary care. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Yale Univ, Sch Med, West Haven, CT 06516 USA. Hosp St Raphael, New Haven, CT USA. Emory Univ, Decatur, GA 30322 USA. Univ Calif Los Angeles, Los Angeles, CA USA. George Washington Univ, Med Ctr, Vet Affairs Med Ctr, Washington, DC 20052 USA. Baylor Coll Med, Houston, TX 77030 USA. VA Med Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 113 EP 113 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000302 ER PT J AU Levine, DA Kiefe, CI Houston, T Allison, JJ Mccarthy, EP Ayanian, JZ AF Levine, DA Kiefe, CI Houston, T Allison, JJ Mccarthy, EP Ayanian, JZ TI Do younger US stroke survivors have reduced access to care and medications?. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ Alabama, Birmingham, AL USA. Birmingham VA Med Ctr, Birmingham, AL USA. Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA. RI Houston, Thomas/F-2469-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 113 EP 114 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000305 ER PT J AU Borrero, S Kwoh, K Sartorius, J Ibrahim, SA AF Borrero, S Kwoh, K Sartorius, J Ibrahim, SA TI Gender and total knee/hip arthroplasty utilization rate in the VA system. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. NR 0 TC 0 Z9 1 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 115 EP 115 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000312 ER PT J AU Kertesz, SG Safford, MM Rose, S Palonen, KP Gordan, AJ Halanych, JH Kirk, K Kiefe, CI AF Kertesz, SG Safford, MM Rose, S Palonen, KP Gordan, AJ Halanych, JH Kirk, K Kiefe, CI TI Outpatient diabetes care for homeless and housed veterans: More equal than not?. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ Alabama, Birmingham, AL USA. Birmingham VA Med Ctr, Birmingham, AL USA. Univ Pittsburgh, Pittsburgh, PA USA. Pittsburgh VAMC, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 121 EP 122 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000334 ER PT J AU Gordan, HS Street, RL Kelly, PA Sharf, B Soucheck, J AF Gordan, HS Street, RL Kelly, PA Sharf, B Soucheck, J TI Perceptions of physician-patient communication explain racial differences in trust. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 VA Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Texas A&M Univ, College Stn, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 122 EP 123 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000338 ER PT J AU Mohanty, SA Washington, D Lambe, S Asch, S AF Mohanty, SA Washington, D Lambe, S Asch, S TI Predictors of on-call specialist response times in california emergency departments. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ So Calif, Los Angeles, CA 90089 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RAND Corp, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 123 EP 123 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000340 ER PT J AU Gordon, HS Street, RL Sharf, B Souchek, J Kelly, PA AF Gordon, HS Street, RL Sharf, B Souchek, J Kelly, PA TI Racial differences in doctors' information-giving and patients' participation. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Baylor Coll Med, Houston, TX 77030 USA. VA Med Ctr, Houston, TX 77030 USA. Texas A&M Univ, College Stn, TX 77843 USA. RI Gordon, Howard/E-4420-2010 OI Gordon, Howard/0000-0002-6712-5954 NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 125 EP 126 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000348 ER PT J AU Mcginnis, KA Skanderson, M Conigliaro, J Gibert, CL Gandhi, NR Backus, LI Justice, AC AF Mcginnis, KA Skanderson, M Conigliaro, J Gibert, CL Gandhi, NR Backus, LI Justice, AC TI Race/ethnic disparities in health and utilization among human immunodeficiency virus (HIV) positive veterans. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ Pittsburgh, Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA 15260 USA. George Washington Univ, Med Ctr, Vet Affairs Med Ctr, Washington, DC 20052 USA. Ctr Qual Management Publ Hlth Palo Alto, Palo Alto, CA USA. Yale Univ, Vet Aging Cohort Study, VA Connecticut Healthcare Syst, New Haven, CT 06520 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 125 EP 125 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000347 ER PT J AU Long, JA Metlay, JP AF Long, JA Metlay, JP TI Racial disparities in health care goals for diabetic veterans. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Philadelphia VA CHERP, Philadelphia, PA USA. Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 126 EP 126 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000350 ER PT J AU Saha, S Shipman, S AF Saha, S Shipman, S TI The evidence base for diversity in the health professions. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 128 EP 129 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000361 ER PT J AU Saha, S Morse, E Gipson, T Loudd, R O'Brien, C AF Saha, S Morse, E Gipson, T Loudd, R O'Brien, C TI What is "cultural competence?"- African Americans' perspectives on patient-physician interactions. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Portland VA Med Ctr, Portland, OR USA. Oregon Hlth & Sci Univ, Portland, OR USA. Univ Rochester, Rochester, NY USA. Portland State Univ, Portland, OR USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 131 EP 131 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000369 ER PT J AU Hayes, J Walczak, H Prochazka, AV AF Hayes, J Walczak, H Prochazka, AV TI Comparison of Medicare prescription benefit costs with a discount internet pharmacy: What's a patient's best deal? SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 134 EP 135 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000382 ER PT J AU Volpp, K Konetzka, T Sochalski, J Zhu, J AF Volpp, K Konetzka, T Sochalski, J Zhu, J TI Effects of financial stress from price competition on hospital quality of care. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 CHERP Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Chicago, Chicago, IL USA. Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 135 EP 135 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831000383 ER PT J AU Solotaroff, R Carlson, M Wright, B Devoe, JE Smith, J Boone, J Edlund, Y AF Solotaroff, R Carlson, M Wright, B Devoe, JE Smith, J Boone, J Edlund, Y TI The impact of Medicaid program changes on a chronically ill, low income population. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Portland VA Med Ctr, Portland, OR USA. Portland State Univ, Portland, OR 97207 USA. Providence Hlth Syst, Portland, OR USA. Oregon Hlth Sci Univ, Portland, OR 97201 USA. Oregon Hlth Policy & Res, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 140 EP 140 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001004 ER PT J AU Mortensen, E Restrepo, M Anzueto, A Pugh, J AF Mortensen, E Restrepo, M Anzueto, A Pugh, J TI An assessment of empiric antimicrobial therapy with a beta-lactam and fluoroquinolone on mortality for patients hospitalized with community-acquired pneumonia. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 141 EP 141 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001008 ER PT J AU Mohanty, SA Diamant, AL Lagomasino, I Asch, S AF Mohanty, SA Diamant, AL Lagomasino, I Asch, S TI Are public/private partnerships delivering better public mental health services for the safety net population?. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ So Calif, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RAND Corp, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 171 EP 172 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001118 ER PT J AU Seal, KH Kral, AH Lorvick, J Gee, L Tsui, JI Edlin, BR AF Seal, KH Kral, AH Lorvick, J Gee, L Tsui, JI Edlin, BR TI Among injection drug users, interest is high, but access low to HCV antiviral therapy. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 7 Z9 7 U1 0 U2 1 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 171 EP 171 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001116 ER PT J AU Hepner, KA Rubenstein, LV Rowe, M Rost, KM Sherbourne, CD Ford, DE AF Hepner, KA Rubenstein, LV Rowe, M Rost, KM Sherbourne, CD Ford, DE CA RAND Corporation TI Does adherence to depression guidelines in primary care improve outcomes?. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 RAND Corp, Santa Monica, CA USA. VA Greater Los Angeles, Los Angeles, CA USA. Univ Colorado, Denver, CO 80202 USA. Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 175 EP 176 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001130 ER PT J AU Hepner, KA Rubenstein, LV Rowe, M Rost, KM Sherbourne, CD Ford, DE AF Hepner, KA Rubenstein, LV Rowe, M Rost, KM Sherbourne, CD Ford, DE TI The importance of primary care practitioners in depression quality of care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 RAND Corp, Santa Monica, CA USA. VA Greater Los Angeles, Los Angeles, CA USA. Univ Colorado, Denver, CO 80202 USA. Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 181 EP 181 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001149 ER PT J AU Yang, E Soban, L Etzioni, D Parkerton, P AF Yang, E Soban, L Etzioni, D Parkerton, P TI Practice organization determinants of colorectal cancer screening rates SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 187 EP 188 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001172 ER PT J AU Walter, LC Lindquist, K O'Hare, A Johansen, KL AF Walter, LC Lindquist, K O'Hare, A Johansen, KL TI Use of screening mammography among women on dialysis SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 San Francisco VA Med Ctr, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 191 EP 191 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001185 ER PT J AU Aujesky, D Obrosky, DS Stone, RA Auble, TE Fine, MJ AF Aujesky, D Obrosky, DS Stone, RA Auble, TE Fine, MJ TI A prediction rule to identify low-risk patients with pulmonary embolism SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ Pittsburgh, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 195 EP 195 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001198 ER PT J AU Bean-Mayberry, B Yano, E Judith, N Bayliss, N Weisman, C Scholle, S AF Bean-Mayberry, B Yano, E Judith, N Bayliss, N Weisman, C Scholle, S TI Contrasting the program characteristics at federally supported comprehensive women's health centers. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ Pittsburgh, Pittsburgh, PA USA. VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Penn State Univ, Hershey, PA 17033 USA. NCQA, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 198 EP 198 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001209 ER PT J AU Kerr, EA Hofer, TP Hayward, RA Hogan, MM Adams, JL Asch, S AF Kerr, EA Hofer, TP Hayward, RA Hogan, MM Adams, JL Asch, S TI How should we monitor the quality of care?: A comparison of three methods to assess quality differences across sites of care. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ Michigan, Ann Arbor, MI 48109 USA. VA Ann Arbor Healthcare Syst, Ann Arbor, MI USA. RAND Corp, Santa Monica, CA USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RAND Corp, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 202 EP 203 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001224 ER PT J AU Steinman, M Kaboli, P Landefeld, C Rosenthal, GE AF Steinman, M Kaboli, P Landefeld, C Rosenthal, GE TI Measures of drug prescribing quality frequently disagree. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 San Francisco VA Med Ctr, San Francisco, CA USA. Iowa City VA Med Ctr, Iowa City, IA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 203 EP 204 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001228 ER PT J AU Steinman, M Covinsky, K AF Steinman, M Covinsky, K TI National patterns of COX-2 inhibitor use SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 204 EP 204 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001229 ER PT J AU Shrank, WH Asch, SM Adams, J Setodji, C Kerr, EA Keesey, J Malik, S Mcglynn, E AF Shrank, WH Asch, SM Adams, J Setodji, C Kerr, EA Keesey, J Malik, S Mcglynn, E TI The quality of pharmacologic care for adults in the United States. SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RAND Corp, Los Angeles, CA USA. RAND Corp, Santa Monica, CA USA. Univ Michigan, Ann Arbor, MI 48109 USA. Univ Calif Irvine, Irvine, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 207 EP 207 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001242 ER PT J AU Washington, D Simon, B Sun, S Yano, E AF Washington, D Simon, B Sun, S Yano, E TI Rape and assault of women in the US military - Prevalence, treatment, and health consequences SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 214 EP 215 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001268 ER PT J AU Palonen, KP Kertesz, SG Safford, MM Rose, SA Kirk, K Halanych, JH Kiefe, CI AF Palonen, KP Kertesz, SG Safford, MM Rose, SA Kirk, K Halanych, JH Kiefe, CI TI Utilization of Veteran's Health Administration services among women veterans with diabetes SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Univ Alabama, Birmingham, AL USA. Birmingham VA Natl Qual Scholars, Birmingham, AL USA. Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 216 EP 216 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001273 ER PT J AU Firooz, N Vazirani, S AF Firooz, N Vazirani, S TI Numerous complications of MRSA endocarditis in a single patient SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Meeting Abstract CT 28th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 11-14, 2005 CL New Orleans, LA SP Soc General Internal Med C1 Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2005 VL 20 SU 1 BP 254 EP 254 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 922IQ UT WOS:000228831001420 ER PT J AU Musher, DM Ceasar, H Kojic, EM Musher, BL Gathe, JC Romero-Steiner, S White, AC AF Musher, DM Ceasar, H Kojic, EM Musher, BL Gathe, JC Romero-Steiner, S White, AC TI Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID POSTSPLENECTOMY INFECTION; CAPSULAR POLYSACCHARIDES; STREPTOCOCCUS-PNEUMONIAE; RISK; INDIVIDUALS; PENICILLIN; ASPLENIA; CHILDREN; FAILURE; DEATH AB Patients who undergo splenectomy are at greatly increased risk for overwhelming pneumococcal bacteremia and death. Twenty-three-valent pneumococcal polysaccharide vaccine ( PPV- 23), which contains capsular polysaccharides (PSs) from 23 common serotypes of Streptococcus pneumoniae, is strongly recommended for such patients. The capacity to respond to PPV- 23 by producing immunoglobulin (Ig) G is genetically regulated. Some proportion of adults do not respond and, despite postsplenectomy administration of PPV- 23, may remain susceptible to recurrent pneumococcal sepsis. Here, we describe 2 patients who had recurring pneumococcal bacteremia after undergoing splenectomy despite having received numerous doses of PPV- 23. Heptavalent protein-conjugate pneumococcal vaccine (PCPV-7) was then administered, and it induced high levels of IgG to all 7 PSs; in one of the patients, functional activity against 5 of the 7 PSs was demonstrable, both in vitro and in vivo. Recurrent pneumococcal bacteremia in patients who have undergone splenectomy may indicate a genetically regulated failure to respond to PPV- 23; PCPV-7 may stimulate production of IgG to PSs in such patients. C1 Michael E DeBakey Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX USA. Ben Taub Gen Hosp, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. Ctr Dis Control & Prevent, Atlanta, GA USA. RP Musher, DM (reprint author), Vet Affairs Med Ctr, Infect Dis Sect, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM daniel.musher@med.va.gov OI White, A Clinton/0000-0002-9668-4632; Romero-Steiner, Sandra/0000-0003-4128-7768 NR 22 TC 26 Z9 28 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD APR 1 PY 2005 VL 191 IS 7 BP 1063 EP 1067 DI 10.1086/428135 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 903IB UT WOS:000227418200007 PM 15747240 ER PT J AU Chen, T Bertenthal, D Sen, S Sahay, A Chren, M AF Chen, T Bertenthal, D Sen, S Sahay, A Chren, M TI Predictors of skin-related quality of life after treatment of nonmelanoma skill cancer SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2005 CL St Louis, MO SP Soc Investigat Dermatol C1 San Francisco VAMC, San Francisco, CA USA. Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2005 VL 124 IS 4 SU S MA 329 BP A55 EP A55 PG 1 WC Dermatology SC Dermatology GA 913UT UT WOS:000228179900329 ER PT J AU Kwon, E Bashir, MM Zhang, W Lin, JH Werth, VP AF Kwon, E Bashir, MM Zhang, W Lin, JH Werth, VP TI Chloroquine does not affect keratinocyte tumor necrosis factor-a gene expression or secretion induced by ultraviolet-B irradiation and interleukin-1 beta SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2005 CL St Louis, MO SP Soc Investigat Dermatol C1 Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2005 VL 124 IS 4 SU S MA 080 BP A14 EP A14 PG 1 WC Dermatology SC Dermatology GA 913UT UT WOS:000228179900081 ER PT J AU Li, W Li, Y Fan, JH Chen, M Woodley, DT AF Li, W Li, Y Fan, JH Chen, M Woodley, DT TI Hypoxia enhances collagen-initiated human dermal fibroblast migration via HIF - induction of a pro-motility autocrine SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2005 CL St Louis, MO SP Soc Investigat Dermatol C1 Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. Univ So Calif, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2005 VL 124 IS 4 SU S MA 198 BP A33 EP A33 PG 1 WC Dermatology SC Dermatology GA 913UT UT WOS:000228179900198 ER PT J AU Li, Y Fan, JH Chen, M Li, W Woodley, DT AF Li, Y Fan, JH Chen, M Li, W Woodley, DT TI Transforming growth factor alpha and insulin are the two main factors in human serum that promote human keratinocyte migration SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2005 CL St Louis, MO SP Soc Investigat Dermatol C1 Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA USA. Univ So Calif, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2005 VL 124 IS 4 SU S MA 573 BP A96 EP A96 PG 1 WC Dermatology SC Dermatology GA 913UT UT WOS:000228179901116 ER PT J AU Binesh, N Huda, A Bugbee, M Gupta, R Rasgon, N Kumar, A Green, M Han, S Thomas, MA AF Binesh, N Huda, A Bugbee, M Gupta, R Rasgon, N Kumar, A Green, M Han, S Thomas, MA TI Adding another spectral dimension to H-1 magnetic resonance spectroscopy of hepatic encephalopathy SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE hepatic encephalopathy; MR spectroscopy; COSY; cerebral metabolites; neuropsychology ID CORRELATED MR SPECTROSCOPY; NEUROPSYCHOLOGICAL CHARACTERIZATION; CIRRHOTIC-PATIENTS; BRAIN; PROTON; DEFECTS; TAURINE AB Purpose: To evaluate a localized two-dimensional correlated magnetic resonance spectroscopic (L-COSY) technique in patients with hepatic encephalopathy (HE) and healthy subjects, and to correlate the cerebral metabolite changes with neuropsychological (NP) test scores. Materials and Methods: Eighteen minimal hepatic-encephalopathy (MHE) patients and 21 healthy controls have been investigated. A GE 1.5-T magnetic resonance (MR) scanner was used in combination with a body MR coil for transmission and a 3-inch surface coil for reception. A 27-mL voxel was localized by three slice-selective radio frequency (RF) pulses (90 degrees-180 degrees-90 degrees) in the anterior cingulate region. The total duration of each two-dimensional L-COSY spectrum was approximately 25 minutes. The NP battery included a total of 15 tests, which were grouped into six domains. Results: MR spectroscopic results showed a statistically significant decrease in myo-mositol (mI) and choline (Ch) and an increase in glutamate/glutamine (Glx) in patients when compared to healthy controls. There was also an increase in taurine (Tau) in patients. The NP results indicated a significant correlation between motor function assessed by NP tests and mI ratios recorded using two-dimensional L-COSY. Conclusion: The study demonstrated the feasibility of evaluating the two-dimensional L-COSY sequence in a clinical environment. The results showed additional cerebral metabolites that can be measured with the technique in comparison to one-dimensional study. (c) 2005 Wiley-Liss, Inc. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, Los Angeles, CA 90024 USA. Calif State Univ Fresno, Dept Phys, Fresno, CA 93740 USA. Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiol, Lucknow, Uttar Pradesh, India. Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Hepatol, Los Angeles, CA USA. RP Binesh, N (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol Sci, CHS BL 428,10833 Le Conte Ave, Los Angeles, CA 90024 USA. EM nbinesh@mednet.ucla.edu RI Huda, Amir/I-5987-2015; Thomas, m. albert/A-6176-2012 OI Huda, Amir/0000-0002-0171-3796; FU NIMH NIH HHS [MH06595, MH58284] NR 33 TC 20 Z9 26 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1053-1807 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD APR PY 2005 VL 21 IS 4 BP 398 EP 405 DI 10.1002/jmri.20291 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 911UD UT WOS:000228029900012 PM 15779041 ER PT J AU Haddy, C Strack, S Choca, JP AF Haddy, C Strack, S Choca, JP TI Linking personality disorders and clinical syndromes on the MCMI-III SO JOURNAL OF PERSONALITY ASSESSMENT LA English DT Article ID COMMON MENTAL-DISORDERS; AXIS-II; MULTIAXIAL INVENTORY; PARALLEL ANALYSIS; SELF-REPORT; DSM-III; NUMBER; DEPRESSION; DIAGNOSIS; PSYCHOPATHOLOGY AB We examined the relationship between personality disorders (PDs) and clinical syndromes (CSs) as measured by the Millon Clinical Multiaxial Inventory-III (MCMI-III; Millon, 1997) in a large, heterogeneous sample of psychiatric patients N = 2,366) who completed the instrument as part of routine assessment following presentation for treatment. Using separate sets of base rate (BR) and nonoverlapping scale scores, we factor analyzed the PD and CS scales together and then separately. We correlated results from the latter analyses to determine how trait dimensions were associated with syndrome dimensions. We also studied co-occurrence at the scale level by examining CS score profiles of patients who were grouped according to their highest PD scale elevation >= BR75. Results for the two score sets were very similar and were consistent with previous research on the MCMI-III and its predecessors that identified 3 underlying dimensions loading both PD and CS scales. Three fourths (76.2%) of the sample had a highest PD scale >= BR75, and among these, 90% had at least 1 CS scale >= BR75, whereas 62.4% had 3 or more CS scales above this elevation. Findings underscore the substantial overlap between PDs and CSs along 3 dimensions that resemble Homey's (1945) tripartite interpersonal distinction of moving toward, away, and against, as well as Eysenck's (1994) higher order factors of neuroticism, extraversion, and psychoticism. C1 Univ So Calif, Dept Counseling Psychol, Los Angeles, CA 90089 USA. US Dept Vet Affairs, Ctr Ambulatory Care, Los Angeles, CA USA. RP Strack, S (reprint author), VA Ambulatory Care Ctr, Psychol Serv 116B, 351 E Temple St, Los Angeles, CA 90012 USA. EM snstrack@aol.com NR 47 TC 9 Z9 11 U1 1 U2 6 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA SN 0022-3891 J9 J PERS ASSESS JI J. Pers. Assess. PD APR PY 2005 VL 84 IS 2 BP 193 EP 204 DI 10.1207/s15327752jpa8402_09 PG 12 WC Psychology, Clinical; Psychology, Social SC Psychology GA 912KT UT WOS:000228077600009 PM 15799894 ER PT J AU Montoya, ID Schroeder, JR Preston, KL Covi, L Umbricht, A Contoreggi, C Fudala, PJ Johnson, RE Gorelick, DA AF Montoya, ID Schroeder, JR Preston, KL Covi, L Umbricht, A Contoreggi, C Fudala, PJ Johnson, RE Gorelick, DA TI Influence of psychotherapy attendance on buprenorphine treatment outcome SO JOURNAL OF SUBSTANCE ABUSE TREATMENT LA English DT Article; Proceedings Paper CT 65th Annual Meeting of the College-on-Problems-of-Drug-Dependence CY JUN 14-19, 2003 CL Bal Harbor, FL SP Coll Problems Drug Dependence DE buprenorphine; cocaine; heroin; dual dependence; psychotherapy ID METHADONE-MAINTENANCE TREATMENT; COLLABORATIVE COCAINE TREATMENT; COGNITIVE-BEHAVIORAL THERAPY; VOUCHER-BASED REINFORCEMENT; SUBSTANCE-ABUSE TREATMENT; CONTINGENCY MANAGEMENT; RANDOMIZED-TRIAL; FOLLOW-UP; DEPENDENCE; HEROIN AB We evaluated the influence of psychotherapy attendance on treatment outcome in 90 dually (cocaine and heroin) dependent outpatients who completed 70 days of a controlled clinical trial of sublingual buprenorphine (16 mg, 8 mg, or 2 mg daily, or 16 mg every other day) plus weekly individual standardized interpersonal cognitive psychotherapy. Treatment outcome was evaluated by quantitative urine benzoylecgonine (BZE) and morphine levels (log-transformed), performed three times per week. Repeated-measures linear regression was used to assess the effects of psychotherapy attendance (percent of visits kept), medication group, and study week on urine drug metabolite levels. Mean psychotherapy attendance was 71% of scheduled visits. Higher psychotherapy attendance was associated with lower urine BZE levels, and this association grew more pronounced as the study progressed (p = 0.04). The inverse relationship between psychotherapy attendance and urine morphine levels varied by medication group, being most pronounced for subjects receiving 16 mg every other day (p = 0.02). These results suggest that psychotherapy can improve the outcome of buprenorphine maintenance treatment for patients with dual (cocaine and opioid) dependence. Published by Elsevier Inc. C1 NIDA, Div Pharmacotherapie & Med Consequences Drug Abus, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. NIDA, Clin Pharmacol & Therapeut Res Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. NIDA, Brain Imaging Branch, Intramural Res Program, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA. Univ Penn, Sch Med, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21224 USA. Reckitt Benckiser Pharmaceut Inc, Baltimore, MD 21224 USA. RP Montoya, ID (reprint author), NIDA, Div Pharmacotherapie & Med Consequences Drug Abus, NIH, Dept Hlth & Human Serv, 6001 Execut Blvd, Bethesda, MD 20892 USA. EM imontoya@mail.nih.gov RI Preston, Kenzie/J-5830-2013 OI Preston, Kenzie/0000-0003-0603-2479 FU Intramural NIH HHS [Z99 DA999999] NR 49 TC 20 Z9 21 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0740-5472 J9 J SUBST ABUSE TREAT JI J. Subst. Abus. Treat. PD APR PY 2005 VL 28 IS 3 BP 247 EP 254 DI 10.1016/j.jsat.2005.01.004 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 925ZT UT WOS:000229093100005 PM 15857725 ER PT J AU Barzilai, DA Freiman, A Dellavalle, RP Weinstock, MA Mostow, EN AF Barzilai, DA Freiman, A Dellavalle, RP Weinstock, MA Mostow, EN TI Dermatoepidemiology SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Review ID RANDOMIZED CONTROLLED-TRIALS; EVIDENCE-BASED MEDICINE; EVIDENCE-BASED DERMATOLOGY; DISSEMINATING SYSTEMATIC REVIEWS; CUTANEOUS MALIGNANT-MELANOMA; CLINICAL-TRIALS; SKIN-CANCER; HEALTH-CARE; INTERNAL MALIGNANCY; CONSORT STATEMENT C1 Case Western Reserve Univ, Sch Med, Cleveland, OH USA. McGill Univ, Ctr Hlth, Div Dermatol, Montreal, PQ, Canada. Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Dept Dermatol, Denver, CO USA. NE Ohio Univ, Coll Med, Dept Med, Div Dermatol, Akron, OH USA. Dept Vet Affairs Med Ctr, Dermatoepidemiol Unit, Providence, RI USA. RP Barzilai, DA (reprint author), 2185 Cornell Rd, Cleveland, OH 44106 USA. EM david.barzilai@case.edu RI Dellavalle, Robert/L-2020-2013 OI Dellavalle, Robert/0000-0001-8132-088X NR 121 TC 15 Z9 15 U1 1 U2 3 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD APR PY 2005 VL 52 IS 4 BP 559 EP 573 DI 10.1016/j.jaad.2004.09.019 PG 15 WC Dermatology SC Dermatology GA 912WN UT WOS:000228110700001 PM 15793504 ER PT J AU Boockvar, KS Gruber-Baldini, AL Burton, L Zimmerman, S May, C Magaziner, J AF Boockvar, KS Gruber-Baldini, AL Burton, L Zimmerman, S May, C Magaziner, J TI Outcomes of infection in nursing home residents with and without early hospital transfer SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Geriatrics-Society CY MAY 14-18, 2003 CL BALTIMORE, MD SP Amer Geriatr Soc DE infection; nursing homes; treatment outcome ID RESPIRATORY-TRACT INFECTION; TERM-CARE FACILITIES; ADVERSE EVENTS; PROPENSITY SCORES; ELDERLY-PATIENTS; RISK-FACTORS; DEMENTIA; SURVEILLANCE; DELIRIUM; ILLNESS AB OBJECTIVES: To compare outcomes of infection in nursing home residents with and without early hospital transfer. DESIGN: Observational cohort study. SETTING: Fifty-nine nursing homes in Maryland. PARTICIPANTS: Two thousand one hundred fifty-three individuals admitted to nursing homes between 1992 and 1995. MEASUREMENTS: Incident infection was recorded when a new infectious diagnosis was documented in the medical record or nonprophylactic antibiotic therapy was prescribed. Early hospital transfer was defined as transfer to the emergency department or admission to the hospital within 3 days of infection onset. Infection, resident, and facility characteristics were entered into a multivariate model to create a propensity score for early hospital transfer. Association between early hospital transfer and outcomes of infection, namely pressure ulcers and death between Days 4 and 34 after infection onset, were examined, controlling for propensity score. RESULTS: Four thousand nine hundred ninety infections occurred in 1,301 residents. Genitourinary (28%), skin (19%), upper respiratory (13%), and lower respiratory (12%) were the most common types. Three hundred seventy-five episodes in which residents survived 3 days (7.6%) resulted in early hospital transfer. In multivariate regression, individuals with early hospital transfer had higher mortality (odds ratio (OR) 1.44, 95% confidence interval (CI)=1.04-1.99) and, in 1-month survivors, a greater occurrence of pressure ulcers (OR 1.61, 95% CI=1.17-2.20) than those without, after adjusting for propensity score. CONCLUSION: Using observational data and propensity score methods, outcomes were worse in nursing home residents transferred to the hospital within 3 days of infection onset than in those who remained in the nursing home. C1 Bronx Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY 10468 USA. Mt Sinai Sch Med, Brookdale Dept Geriatr & Adult Dev, New York, NY USA. Univ Maryland, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA. Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21218 USA. Univ N Carolina, Cecil G sheps Ctr Hlth Serv Res, Chapel Hill, NC USA. RP Boockvar, KS (reprint author), Bronx Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, 130 W Kingsbridge Rd,Suite 4 A-17, Bronx, NY 10468 USA. EM kenneth.boockvar@mssm.edu OI Boockvar, Kenneth/0000-0003-1165-5558 FU NIA NIH HHS [R01 AG 08211, R29 AG 11407] NR 43 TC 56 Z9 58 U1 2 U2 2 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2005 VL 53 IS 4 BP 590 EP 596 DI 10.1111/j.1532-5415.2005.53205.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 909ZM UT WOS:000227899200005 PM 15817003 ER PT J AU Abdel-Karim, I Sammel, RB Prange, MA AF Abdel-Karim, I Sammel, RB Prange, MA TI Autopsy findings among patients in an inpatient hospice program. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 11-15, 2005 CL Orlando, FL SP Amer Geriatr Soc C1 Univ Texas, Dept Med, Div Geriatr, San Antonio, TX 78285 USA. Audie L Murphy Mem Vet Adm Med Ctr, S Texas Vet Affairs Hlth Care Syst, Educ & Clin Ctr, San Antonio, TX 78284 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2005 VL 53 IS 4 SU S BP S152 EP S152 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 917HE UT WOS:000228450900439 ER PT J AU Alam, T Martin, JL Harker, JO Josephson, KR Alessi, CA AF Alam, T Martin, JL Harker, JO Josephson, KR Alessi, CA TI A pilot study of sleep-wake patterns in assisted living facilities. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 11-15, 2005 CL Orlando, FL SP Amer Geriatr Soc C1 GRECC, VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2005 VL 53 IS 4 SU S BP S210 EP S211 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 917HE UT WOS:000228450900606 ER PT J AU Boockvar, KS Mordiglia, T Fridman, B Fried, T AF Boockvar, KS Mordiglia, T Fridman, B Fried, T TI IPFS versus APACHE for predicting hospital outcomes of disabled older adults. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 11-15, 2005 CL Orlando, FL SP Amer Geriatr Soc C1 Mt Sinai Sch Med, New York, NY USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. Yale Univ, New Haven, CT USA. Jewish Home & Hosp, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2005 VL 53 IS 4 SU S BP S201 EP S201 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 917HE UT WOS:000228450900579 ER PT J AU Chi, R Neuzil, KM Reiber, GE AF Chi, R Neuzil, KM Reiber, GE TI Influenza and pneumococcal vaccine coverage among older veterans: Results from the behavioral risk factor surveillance system. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 11-15, 2005 CL Orlando, FL SP Amer Geriatr Soc C1 Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2005 VL 53 IS 4 SU S BP S83 EP S84 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 917HE UT WOS:000228450900237 ER PT J AU Chun, A Granieri, E Fernandez, H AF Chun, A Granieri, E Fernandez, H TI Evaluating fellows as teachers. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 11-15, 2005 CL Orlando, FL SP Amer Geriatr Soc C1 Mt Sinai Sch Med, New York, NY USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2005 VL 53 IS 4 SU S BP S37 EP S38 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 917HE UT WOS:000228450900104 ER PT J AU DeCherrie, L Penrod, J Ornstein, K Hochman, T Boal, J AF DeCherrie, L Penrod, J Ornstein, K Hochman, T Boal, J TI Predictors of death among a homebound admission cohort of a home-based primary care program. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 11-15, 2005 CL Orlando, FL SP Amer Geriatr Soc C1 Mt Sinai Sch Med, New York, NY USA. Bronx Vet Adm Med Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2005 VL 53 IS 4 SU S BP S201 EP S202 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 917HE UT WOS:000228450900580 ER PT J AU Fox, AR Conn, V Guthrie, M AF Fox, AR Conn, V Guthrie, M TI Concealed weapons : firearm access among homebound veterans with depression and dementia. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 11-15, 2005 CL Orlando, FL SP Amer Geriatr Soc C1 VA Pittsburgh Healthcare Syst, GRECC, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2005 VL 53 IS 4 SU S BP S214 EP S214 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 917HE UT WOS:000228450900615 ER PT J AU Hajjar, ER Hanlon, JT Sloane, RJ Lindblad, CI Pieper, CF Ruby, CM Branch, LC Schmader, KE AF Hajjar, ER Hanlon, JT Sloane, RJ Lindblad, CI Pieper, CF Ruby, CM Branch, LC Schmader, KE TI Unnecessary drug use in frail elderly at hospital discharge. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 11-15, 2005 CL Orlando, FL SP Amer Geriatr Soc C1 Univ Sci Philadelphia, Philadelphia Coll Pharm, Philadelphia, PA USA. Univ Pittsburgh, Dept Geriatr Med, Pittsburgh, PA USA. Ctr Hlth Equit Res & Promot, Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC USA. Univ Minnesota, Inst Study Geriatr Pharmacotherapy, Minneapolis, MN USA. Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Minneapolis, MN USA. Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA. Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. Univ N Carolina, Sch Pharm, Chapel Hill, NC USA. Univ S Florida, Coll Publ Hlth, Tampa, FL USA. FU NIA NIH HHS [R01-AG-14158]; NIAID NIH HHS [K24-AI-51324-01] NR 0 TC 81 Z9 82 U1 2 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2005 VL 53 IS 4 SU S BP S178 EP S178 DI 10.1111/j.1532-5415.2005.53523.x PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 917HE UT WOS:000228450900515 PM 16137281 ER PT J AU Martin, JL Webber, AP Alam, T Harker, JO Josephson, KR Alessi, CA AF Martin, JL Webber, AP Alam, T Harker, JO Josephson, KR Alessi, CA TI Prevalence and correlates of daytime sleepiness in nursing home residents. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 11-15, 2005 CL Orlando, FL SP Amer Geriatr Soc C1 Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. VA Greater Los Angeles, GRECC, Sepulveda, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2005 VL 53 IS 4 SU S BP S178 EP S179 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 917HE UT WOS:000228450900517 ER PT J AU Ray, LM Fang, MA Hahn, TJ AF Ray, LM Fang, MA Hahn, TJ TI The role of abnormal DXA results in the evaluation and treatment of low bone density in older male veterans SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 11-15, 2005 CL Orlando, FL SP Amer Geriatr Soc C1 Albert Einstein Coll Med, Bronx, NY 10467 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2005 VL 53 IS 4 SU S BP S111 EP S111 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 917HE UT WOS:000228450900317 ER PT J AU Rodriguez, KL Young, AJ AF Rodriguez, KL Young, AJ TI Patient and healthcare provider understanding of life-sustaining treatment. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 11-15, 2005 CL Orlando, FL SP Amer Geriatr Soc C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. Univ Memphis, Dept Commun, Memphis, TN 38152 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2005 VL 53 IS 4 SU S BP S96 EP S96 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 917HE UT WOS:000228450900275 ER PT J AU Sims, RV Ahmed, A Baker, PS Allman, RM AF Sims, RV Ahmed, A Baker, PS Allman, RM TI Self-reported health predicts driving cessation among community-dwelling older adults. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 11-15, 2005 CL Orlando, FL SP Amer Geriatr Soc C1 Birmingham VAMC, Birmingham, AL USA. Univ Alabama Birmingham, Ctr Aging, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2005 VL 53 IS 4 SU S BP S195 EP S195 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 917HE UT WOS:000228450900563 ER PT J AU Walston, J Festa, F Ho, L Morrison, S Pasinetti, GM AF Walston, J Festa, F Ho, L Morrison, S Pasinetti, GM TI From biomarker discovery to clinical diagnostic in age-related frailty SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 11-15, 2005 CL Orlando, FL SP Amer Geriatr Soc C1 Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA. Bronx Vet Adm Med Ctr, GRECC Program, Bronx, NY USA. Johns Hopkins Med Inst, Baltimore, MD 21205 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2005 VL 53 IS 4 SU S BP S120 EP S120 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 917HE UT WOS:000228450900344 ER PT J AU Wu, P Lorenz, KA Rubenstein, LZ Chodosh, J AF Wu, P Lorenz, KA Rubenstein, LZ Chodosh, J TI Advance planning in the last year of life: How are we doing? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Meeting of the American-Geriatrics-Society CY MAY 11-15, 2005 CL Orlando, FL SP Amer Geriatr Soc C1 UMDNJ SOM, Stratford, NJ USA. VA Greater Los Angeles Healthcare Syst, HSR&D, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2005 VL 53 IS 4 SU S BP S202 EP S202 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 917HE UT WOS:000228450900582 ER PT J AU Poon, B Safrit, JT McClure, H Kitchen, C Hsu, JF Gudeman, V Petropoulos, C Wrin, T Chen, ISY Grovit-Ferbas, K AF Poon, B Safrit, JT McClure, H Kitchen, C Hsu, JF Gudeman, V Petropoulos, C Wrin, T Chen, ISY Grovit-Ferbas, K TI Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1 SO JOURNAL OF VIROLOGY LA English DT Article ID NEUTRALIZING ANTIBODIES; SOLUBLE CD4; HIV TYPE-1; CHEMICAL INACTIVATION; GP120 GLYCOPROTEIN; SIV VACCINE; IN-VITRO; INFECTIVITY; PROTEINS; MACAQUES AB The lack of success of subunit human immunodeficiency virus type 1 (HIV-1) vaccines to date suggests that multiple components or a complex virion structure may be required. We previously demonstrated retention of the major conformational epitopes of HIV-1 envelope following thermal treatment of virions. Moreover, antibody binding to some of these epitopes was significantly enhanced following thermal treatment. These included the neutralizing epitopes identified by monoclonal antibodies 1b12, 2G12, and 17b, some of which have been postulated to be partially occluded or cryptic in native virions. Based upon this finding, we hypothesized that a killed HIV vaccine could be derived to elicit protective humoral immune responses. Shedding of HIV-1 envelope has been described for some strains of HIV-1 and has been cited as one of the major impediments to developing an inactivated HIV-1 vaccine. In the present study, we demonstrate that treatment of virions with low-dose formaldehyde prior to thermal inactivation retains the association of viral envelope with virions. Moreover, mice and nonhuman primates vaccinated with formaldehyde-treated, thermally inactivated virions produce antibodies capable of neutralizing heterologous strains of HIV in peripheral blood mononuclear cell-, MAGI cell-, and U87-based infectivity assays. These data indicate that it is possible to create an immunogen by using formaldehyde-treated, thermally inactivated HIV-1 virions to induce neutralizing antibodies. These findings have broad implications for vaccine development. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, AIDS Inst, Los Angeles, CA USA. Elizabeth Glaser Pediat AIDS Fdn, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Biostat, Ctr Hlth Sci, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA. ViroLog Inc, San Francisco, CA USA. Emory Univ, Yerkes Reg Primate Res Ctr, Atlanta, GA 30322 USA. Emory Univ, Sch Med, Atlanta, GA 30322 USA. RP Grovit-Ferbas, K (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, 11-934 Factor Bldg, Los Angeles, CA 90095 USA. EM kferbas@ucla.edu FU NCI NIH HHS [CA016042, P30 CA016042]; NCRR NIH HHS [P51 RR000165, RR-00165]; NIAID NIH HHS [R21AI42687, AI028697, P30 AI028697, 1R01AI052012, R01 AI052012] NR 46 TC 28 Z9 30 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD APR PY 2005 VL 79 IS 8 BP 4927 EP 4935 DI 10.1128/JVI.79.8.4927-4935.2005 PG 9 WC Virology SC Virology GA 912JJ UT WOS:000228073700037 PM 15795278 ER PT J AU Beeri, MS Silverman, JM Davis, KL Marin, D Grossman, HZ Schmeidler, J Purohit, DP Perl, DP Davidson, M Mohs, RC Haroutunian, V AF Beeri, MS Silverman, JM Davis, KL Marin, D Grossman, HZ Schmeidler, J Purohit, DP Perl, DP Davidson, M Mohs, RC Haroutunian, V TI Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article ID BLOOD-BRAIN-BARRIER; RISK-FACTORS; COGNITIVE DECLINE; DEMENTIA; MELLITUS; POPULATION; EPSILON-4; GLUCOSE; MEMORY; HYPERINSULINEMIA AB Background. In cross-sectional and longitudinal studies, type 2 diabetes has been positively associated with the risk of Alzheimer's disease (AD). The present descriptive study compared diabetic and nondiabetic Subjects on the severity of neuritic plaques and neurofibrillary tangles (NFTs) in the cerebral cortex and in the hippocampus. Methods. The study included specimens from 385 consecutive autopsies of residents of a nursing home (15.8% diabetics). Mean age at death = 84 years [standard deviation (SD) = 10], 66% were female, Clinical Dementia Rating mean = 3.0 (SD = 1.6), and 32.5% had an APOE4 allele. Additional analyses limited the sample to 268 subjects (14.1% diabetics) without neuropathology other than AD. Results. Analyses of covariance controlling for age at death, dementia severity (Clinical Dementia Rating score), and APOE4 allele indicated that diabetics had significantly fewer neuritic plaques (p = .008) and NFTs (p = .047) in the cerebral cortex than did nondiabetics. In the hippocampus, diabetics had significantly lower plaque ratings than did nondiabetics (p = .019), but the lower ratings of NFTs did not achieve statistical significance (p = .082). In the entire sample, diabetics had significantly less AD-associated neuropathology in all four analyses. Conclusions. These results raise the possibility that the varied associations observed between diabetes and AD may be specific to as yet ill-defined subgroups of dementia and diabetic patients or may be more characteristic Of Younger patients than of those who survive to a mean age of 84 years. Future studies are encouraged to examine a variety of other characteristics such as age that may interact with diabetes affecting the incidence of AD. C1 Bronx Vet Adm Med Ctr, Psychiat Serv, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. Mt Sinai Sch Med, Dept Biomath Sci, New York, NY USA. Mt Sinai Sch Med, Dept Pathol, New York, NY USA. Chaim Sheba Med Ctr, Dept Psychiat, IL-52621 Tel Hashomer, Israel. Lilly Res Labs, Indianapolis, IN USA. RP Haroutunian, V (reprint author), Bronx Vet Adm Med Ctr, Psychiat Serv, Psychiat Res 4F-33B,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM Vahram.Haroutunian@mssm.edu FU NIA NIH HHS [K01 AG023515-05, K01 AG023515, P01 AG002219, P01-AG02219] NR 41 TC 89 Z9 92 U1 3 U2 9 PU GERONTOLOGICAL SOCIETY AMER PI WASHINGTON PA 1275 K STREET NW SUITE 350, WASHINGTON, DC 20005-4006 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD APR PY 2005 VL 60 IS 4 BP 471 EP 475 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 928VX UT WOS:000229300900011 PM 15933386 ER PT J AU Sohn, M Tan, Y Klein, RL Jaffa, AA AF Sohn, M Tan, Y Klein, RL Jaffa, AA TI Evidence for low-density lipoprotein-induced expression of connective tissue growth factor in mesangial cells SO KIDNEY INTERNATIONAL LA English DT Article DE MAPK; TGF-beta; collagen I; JNK ID DEPENDENT DIABETIC-PATIENTS; EARLY NATURAL-HISTORY; FACTOR-BETA; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; RENAL FIBROSIS; HIGH GLUCOSE; KINASE; NEPHROPATHY; DISEASE AB Background. Although hyperlipidemia is a risk factor for the progression of renal damage, the relationship between increased plasma lipoproteins and glomerular injury is poorly defined. Connective tissue growth factor (CTGF) is emerging as a key determinant of progressive fibrotic diseases and its expression is up-regulated by diabetes. To define the mechanisms through which low-density lipoproteins (LDLs) promote glomerular injury, we evaluated whether LDL can modulate the expression of CTGF and collagen I. Methods. The effects of LDL on CTGF and collagen I expression were carried out in rat mesangial cells. Results. Treatment of mesangial cells with LDL for 24 hours produced a significant increase in the protein levels of CTGF and collagen I compared to unstimulated controls. To explore if CTGF and collagen I are downstream targets for regulation by transforming growth factor-beta (TGF-beta), mesangial cells were treated with various concentration of TGF-beta for 24 hours. TGF-beta produced a concentration-dependent increase in the protein levels of CTGF and collagen I. The increase in CTGF and collagen I induced by LDL was significantly inhibited by neutralizing anti-TGF-beta antibodies. Inhibition of p38(mapk) or p42/44(mapk) activities did not affect LDL-induced TGF-beta 1, CTGF, and collagen I expression, whereas inhibition of c-Jun NH2-terminal kinase (JNK) suppressed LDL-induced TGF-beta, CTGF, and collagen I expression. Conclusion. These findings implicate JNK pathway and TGF-beta 1 as key players in LDL signaling leading to CTGF and collagen I expression in mesangial cells. The data also point to a potential mechanistic pathway through which lipoproteins may promote glomerular injury. C1 Med Univ S Carolina, Dept Med Endocrinol Diabet Med Genet, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Jaffa, AA (reprint author), Med Univ S Carolina, Dept Med Endocrinol Diabet Med Genet, 114 Doughty St,POB 250776, Charleston, SC 29425 USA. EM jaffaa@musc.edu FU NHLBI NIH HHS [HL-55782]; NIDDK NIH HHS [DK-46543] NR 47 TC 11 Z9 15 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD APR PY 2005 VL 67 IS 4 BP 1286 EP 1296 DI 10.1111/j.1523-1755.2005.00206.x PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 905UR UT WOS:000227596500008 PM 15780081 ER PT J AU Merrick, DT Haney, J Petrunich, S Sugita, M Miller, YE Keith, RL Kennedy, TC Franklin, WA AF Merrick, DT Haney, J Petrunich, S Sugita, M Miller, YE Keith, RL Kennedy, TC Franklin, WA TI Overexpression of vascular endothelial growth factor and its receptors in bronchial dypslasia demonstrated by quantitative RT-PCR analysis SO LUNG CANCER LA English DT Article DE angiogenesis; precancerous conditions; early detection; tumor progression; chemoprevention; RT-PCR (reverse transcription polymerase chain reaction) ID CELL LUNG CARCINOMAS; EXON 7-ENCODED DOMAIN; FACTOR MESSENGER-RNA; MICROVESSEL DENSITY; TUMOR-CELLS; PRENEOPLASTIC LESIONS; EXPRESSION PATTERN; POSSIBLE RELEVANCE; VEGF EXPRESSION; ORAL-TISSUES AB Neoangiogenesis is required for the growth of invasive lung carcinoma, however, the role of angiogenesis in the progression of premalignant changes to carcinoma of the lung is less clear. We have evaluated vascular endothelial growth factor (VEGF) expression and microvessel densities (MVDs) in 62 bronchoscopic biopsies from normal, reactive (basal cell hyperplasia (BCH)) and dysplastic bronchial epithelium and in tissue from twenty-seven invasive Lung carcinomas in an effort to demonstrate angiogenic activity in these preneoptastic lesions and determine whether it is associated with increased bronchial epithelial VEGF expression. MVDs and VEGF RNA expression measured by quantitative RT-PCR were found to be elevated in comparison to normal bronchial tissue in bronchial dysplasias and invasive lung carcinomas but not in basal cell hyperplasias. Immunohistochemical (IHC) analyses revealed that expression of VEGF arose predominantly from bronchial epithelium. ELISA analysis of lung tumor tissue showed that elevated VEGF protein expression correlated with VEGF RNA levels (r=0.59, p=0.004). Increased expression of VEGF RNA was also found in histologically normal bronchial mucosa from patients with either dysplasia at other sites or a history of heavy tobacco use suggesting a possible field effect in regard to the elaboration of VEGF. Furthermore, analysis of VEGF isoforms and VEGF receptors by semi-quantitative RT-PCR in dysplastic and invasive lesions revealed characteristic altered patterns of expression in dysplasia and early cancer as compared to normal tissue. These results indicate that angiogenesis develops early in lung carcinogenesis and is associated with overexpression of VEGF. (c) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Denver Vet Affairs Med Ctr, Dept Pathol, Denver, CO 80220 USA. Denver Vet Affairs Med Ctr, Dept Pulm Med, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80260 USA. RP Merrick, DT (reprint author), Denver Vet Affairs Med Ctr, Dept Pathol, 1055 Clermont St, Denver, CO 80220 USA. EM Daniel.Merrick@med.va.gov FU NCI NIH HHS [CA 58187] NR 53 TC 30 Z9 32 U1 0 U2 1 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0169-5002 J9 LUNG CANCER-J IASLC JI Lung Cancer PD APR PY 2005 VL 48 IS 1 BP 31 EP 45 DI 10.1016/j.lungcan.2004.07.049 PG 15 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 916WZ UT WOS:000228418600004 PM 15777969 ER PT J AU Groeneveld, PW Laufer, SB Garber, AM AF Groeneveld, PW Laufer, SB Garber, AM TI Technology diffusion, hospital variation, and racial disparities among elderly Medicare beneficiaries 1989-2000 SO MEDICAL CARE LA English DT Article DE race and ethnicity; disparities; variation; hospital; diffusion of innovation ID ACUTE MYOCARDIAL-INFARCTION; VENA-CAVAL FILTERS; UNITED-STATES; REVASCULARIZATION PROCEDURES; CORONARY-REVASCULARIZATION; SOCIOECONOMIC-STATUS; GEOGRAPHIC-VARIATION; VETERANS-AFFAIRS; CLINICAL-TRIAL; HEALTH-CARE AB Background: Low rates of technology utilization in hospitals with high proportions of black inpatients may be a remediable cause of healthcare disparities. Objectives: Our objective was to determine how differences in technology utilization among hospitals contributed to racial disparity and if temporal reduction in hospital procedure rate variation resulted in decreased racial disparity for these technologies. Methods: We identified 2,348,952 elderly Medicare beneficiaries potentially eligible for 1 of 5 emerging medical technologies from 1989-2000 and determined if these patients had received the indicated procedure within 90 days of their qualifying hospital admission. Initial multivariate regression models adjusted for age, race, sex, admission year, clinical comorbidity, community levels of education and income, and academic/urban hospital admission. The inpatient racial composition of each patient's admitting hospital and time-race interactions were added as covariates to subsequent models. Results: Blacks had significantly lower adjusted rates (P < 0.001) compared with whites for tissue replacement of the aortic valve, internal mammary artery coronary bypass grafting, dual-chambered pacemaker implantation, and lumbar spinal fusion. Hospitals with > 20% black inpatients were less likely to perform these procedures on both white and black patients than hospitals with < 9% black inpatients, and racial disparity was greater in hospitals with larger black populations. There were no temporal reductions in racial disparities. Conclusions: Blacks may be disadvantaged in access to new procedures by receiving care at hospitals that have both lower procedure rates and greater racial disparity. Policies designed to ameliorate racial disparities in health care must address hospital variation in the provision of care. C1 Vet Affairs Med Ctr, Philadelphia, PA USA. Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. Univ Penn, Sch Med, Div Gen Internal Med, Philadelphia, PA USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA USA. Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA USA. Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. Natl Bur Econ Res, Stanford, CA USA. RP Groeneveld, PW (reprint author), 1122 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM peter.groeneveld@med.va.gov RI Garber, Alan/F-1476-2010 FU AHRQ HHS [T32-HS000028]; NIA NIH HHS [P01-AG005842, P30-AG017253] NR 44 TC 89 Z9 89 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD APR PY 2005 VL 43 IS 4 BP 320 EP 329 DI 10.1097/01.mlr.0000156849.15166.ec PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 910EU UT WOS:000227914000003 PM 15778635 ER PT J AU Ashton, CM Pietz, K AF Ashton, CM Pietz, K TI Response to an editorial in the January 2005 issue of Medical Care - Response SO MEDICAL CARE LA English DT Letter ID PREVENTABLE HOSPITALIZATIONS; ACCESS C1 Baylor Coll Med, VA Med Ctr, Dept Med, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. RP Ashton, CM (reprint author), Baylor Coll Med, VA Med Ctr, Dept Med, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD APR PY 2005 VL 43 IS 4 BP 421 EP 422 DI 10.1097/01.mlr.0000158784.73460.91 PG 2 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 910EU UT WOS:000227914000015 ER PT J AU Kraml, PJ Klein, RL Huang, Y Nareika, A Lopes-Virella, MF AF Kraml, PJ Klein, RL Huang, Y Nareika, A Lopes-Virella, MF TI Iron loading increases cholesterol accumulation and macrophage scavenger receptor I expression in THP-1 mononuclear phagocytes SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article ID LOW-DENSITY-LIPOPROTEIN; ISCHEMIC-HEART-DISEASE; ATHEROSCLEROSIS; OXIDATION; STORES; RISK; CELL; LDL; TRANSCRIPTION; METABOLISM AB Epidemiological studies have established that a high level of iron body stores is associated with increased risk of acute coronary heart disease. To explain this association, it has been proposed that iron catalyzes the production of highly reactive forms of free oxygen species, and thus, promotes low-density lipoprotein (LDL) oxidation, a lipoprotein that plays a critical role in atherogenesis. However, few studies have provided evidence to support this hypothesis. In the present study, we determined the effect of iron loading of THP-1 mononuclear phagocytes on LDL metabolism. We demonstrated that iron loading of THP-1 cells stimulated conjugated diene formation in LDL in the culture medium. In addition, iron loading of THP-1 cells significantly increased cholesteryl ester accumulation in cells exposed to native LDL, suggesting that during the incubation of the cells with native LDL, the LDL became oxidized and was taken up by the cells. We further demonstrated that the degradation of I-125-oxidized LDL was significantly increased in iron-loaded THP-1 cells. Lastly, we demonstrated that iron loading of THP-1 cells stimulated scavenger receptor expression in these cells. In conclusion, this study demonstrates that loading of mononuclear phagocytes with iron leads to oxidization of LDL, increased cellular cholesterol accumulation and scavenger receptor expression, and supports the hypothesis that increased macrophage iron levels promote atherogenesis. (c) 2005 Elsevier Inc. All rights reserved. C1 Med Univ S Carolina, Dept Med, Div Endocrinol Metab & Med Genet, Charleston, SC 29425 USA. Charles Univ Prague, Fac Med 3, Div Metab Diabet & Endocrinol, Dept Med 2, Prague 10034, Czech Republic. Med Univ S Carolina, Div Endocrinol Metab & Med Genet, Dept Med, Charleston, SC 29425 USA. Ralph H Johnson Dept, Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA. RP Lopes-Virella, MF (reprint author), Med Univ S Carolina, Dept Med, Div Endocrinol Metab & Med Genet, POB 250770, Charleston, SC 29425 USA. EM virellam@musc.edu FU NHLBI NIH HHS [HL55782] NR 27 TC 31 Z9 32 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0026-0495 J9 METABOLISM JI Metab.-Clin. Exp. PD APR PY 2005 VL 54 IS 4 BP 453 EP 459 DI 10.1016/j.metabol.2004.10.012 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 916AE UT WOS:000228352600005 PM 15798950 ER PT J AU Grotzke, JE Lewinsohn, DM AF Grotzke, JE Lewinsohn, DM TI Role of CD8(+) T lymphocytes in control of Mycobacterium tuberculosis infection SO MICROBES AND INFECTION LA English DT Review DE tuberculosis; CD8-positive T-lymphocytes; antigen presentation; immunologic surveillance ID BACILLUS-CALMETTE-GUERIN; NITRIC-OXIDE SYNTHASE; CLASS-I PRESENTATION; CELL-DEFICIENT MICE; INTERFERON-GAMMA; DENDRITIC CELLS; PULMONARY TUBERCULOSIS; EXOGENOUS ANTIGENS; CROSS-PRESENTATION; PROCESSING PATHWAY AB Tuberculosis remains a global health concern. Control of infection is dependent on cell-mediated immune responses, with CD4(+) T lymphocytes playing a central role. In this article, data supporting the importance of CD8(+) T lymphocytes is reviewed, with an emphasis on the unique functional roles that this lymphocyte subset may play. (c) 2005 Elsevier SAS. All rights reserved. C1 Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Div Pulm & Crit Care Med, Portland VA Med Ctr, Portland, OR 97239 USA. RP Lewinsohn, DM (reprint author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM lewinsod@OHSU.edu RI Lewinsohn, David/I-4936-2013 OI Lewinsohn, David/0000-0001-9906-9494 NR 114 TC 64 Z9 74 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1286-4579 J9 MICROBES INFECT JI Microbes Infect. PD APR PY 2005 VL 7 IS 4 BP 776 EP 788 DI 10.1016/j.micinf.2005.03.001 PG 13 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 932DO UT WOS:000229534600025 PM 15823514 ER PT J AU Newhall, KJ Cummings, DE Nolan, MA McKnight, GS AF Newhall, KJ Cummings, DE Nolan, MA McKnight, GS TI Deletion of the RII beta-subunit of protein kinase A decreases body weight and increases energy expenditure in the obese, leptin-deficient ob/ob mouse SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID BROWN ADIPOSE-TISSUE; MELANIN-CONCENTRATING HORMONE; UNCOUPLING PROTEIN; MESSENGER-RNA; ADAPTIVE THERMOGENESIS; TARGETED DISRUPTION; GENE-EXPRESSION; MUTANT MICE; FOOD-INTAKE; OB PROTEIN AB Disruption of the RII beta regulatory subunit of protein kinase A (PKA) results in mice with a lean phenotype, nocturnal hyperactivity, and increased resting metabolic rate. In this report, we have examined whether deletion of RII beta would lead to increased metabolism and rescue the obese phenotype of the leptin-deficient ob/ob (ob) mouse. Body weight gain and food consumption were decreased, whereas basal oxygen consumption and nocturnal locomotor activity were increased in the double mutant animals compared with ob mice. The ob mice are unable to maintain body temperature when placed in a cold environment due to a loss of brown adipose tissue activation, and this cold sensitivity was partially rescued by concomitant disruption of RII beta. These findings indicate that PKA modifies the phenotype of the leptin-deficient mouse, leading to increases in both thermogenesis and energy expenditure. C1 Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Div Metab, Seattle, WA 98195 USA. Wyeth Res, Collegeville, PA 19426 USA. RP McKnight, GS (reprint author), Univ Washington, Dept Pharmacol, Box 357750, Seattle, WA 98195 USA. EM mcknight@u.washington.edu OI Nolan, Michael/0000-0002-2581-0814 FU NIGMS NIH HHS [T32 GM07270, GM32875] NR 41 TC 20 Z9 21 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD APR PY 2005 VL 19 IS 4 BP 982 EP 991 DI 10.1210/me.2004-0343 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 908YN UT WOS:000227826200014 PM 15618289 ER PT J AU Anselmi, L Cervio, E Guerrini, S Vicini, R Agazzi, A Dellabianca, A Reeve, JRJ Tonini, M Sternini, C AF Anselmi, L Cervio, E Guerrini, S Vicini, R Agazzi, A Dellabianca, A Reeve, JRJ Tonini, M Sternini, C TI Identification of galanin receptor 1 on excitatory motor neurons in the guinea pig ileum SO NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Article DE enteric neurons; ascending and descending pathways; interneurons; intrinsic primary afferent neurons ID SMALL-INTESTINE; SYNAPTIC-TRANSMISSION; MYENTERIC NEURONS; MOTILITY REFLEXES; ENTERIC NEURONS; CL-SECRETION; SUBTYPES; EXPRESSION; IMMUNOREACTIVITY; ACETYLCHOLINE AB Exogenously administered galanin inhibits cholinergic transmission to the longitudinal muscle and reduces peristaltic efficiency in the guinea pig ileum with a mechanism partially mediated by galanin receptor 1 (GAL-R1). We investigated the effect of exogenous galanin 1-16, which has high affinity for GAL-R1, on the ascending excitatory reflex of the circular muscle elicited by radial distension in isolated segments of guinea pig ileum. We used a three-compartment bath that allows dissecting the ascending pathway into the oral (site of excitatory motor neurons), intermediate (site of ascending interneurons) and caudal compartment (site of intrinsic primary afferent neurons). Galanin 1-16 (0.3-3 mu mol L-1) applied to the oral compartment inhibited in a concentration-dependent manner the ascending excitatory reflex elicited by the wall distension in the caudal compartment. This effect was antagonized by the GAL-R1 antagonist, RWJ-57408 (1 and 10 mu mol L-1). By contrast, galanin 1-16 was ineffective when added to the intermediate or caudal compartment up to 3 mu mol L-1. GAL-R1 immunoreactive neurons did not contain neuron-specific nuclear protein, a marker for intrinsic primary afferent neurons. These findings indicate that GAL-R1s are present on motor neurons responsible for the ascending excitatory reflex, but not on ascending interneurons and intrinsic primary afferent neurons. C1 Vet Adm Greater Los Angeles Healthcare Syst, Digest Dis Res Ctr, Div Digest Dis, CURE, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA USA. Univ Pavia, Dept Pharmacol & Physiol Sci, I-27100 Pavia, Italy. Univ Bologna, Dept Internal Med, Bologna, Italy. S Maugeri Fdn, Pavia, Italy. RP Anselmi, L (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Digest Dis Res Ctr, Div Digest Dis, CURE, Bldg 115,Room 224,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM lanselmi@mednet.ucla.edu OI Cervio, Elisabetta/0000-0002-9922-077X FU NIDDK NIH HHS [DK41301, DK57037] NR 36 TC 6 Z9 6 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 1350-1925 J9 NEUROGASTROENT MOTIL JI Neurogastroenterol. Motil. PD APR PY 2005 VL 17 IS 2 BP 273 EP 280 DI 10.1111/j.1365-2982.2004.00590.x PG 8 WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences SC Gastroenterology & Hepatology; Neurosciences & Neurology GA 912TU UT WOS:000228103600015 PM 15787947 ER PT J AU Habecker, BA Gritman, KR Willison, BD Van Winkle, DM AF Habecker, BA Gritman, KR Willison, BD Van Winkle, DM TI Myocardial infarction stimulates galanin expression in cardiac sympathetic neurons SO NEUROPEPTIDES LA English DT Article DE vasoactive intestinal peptide; substance P; neuropeptide Y; galanin; axotomy ID VASOACTIVE-INTESTINAL-PEPTIDE; SUPERIOR CERVICAL-GANGLION; NERVE GROWTH-FACTOR; SUBSTANCE-P; NEUROPEPTIDE EXPRESSION; SENSORY NEURONS; ANESTHETIZED CATS; MESSENGER-RNAS; CANINE HEART; RAT-HEART AB Cardiac ischemia-reperfusion alters sympathetic neurotransmission in the heart, but little is known about its effect on neuropeptide expression in sympathetic neurons. Ischemia followed by reperfusion induces the production of inflammatory cytokines in the heart, including interleukin-6 and cardiotrophin-1. These cytokines and related molecules inhibit the expression of neuropeptide Y (NPY), and stimulate the expression of vasoactive intestinal peptide (VIP), substance P (SubP), and galanin (GAL) in cultured sympathetic neurons. Therefore, we quantified NPY, VIP, SubP, and GAL mRNA in neurons of the stellate ganglia I week after ischemia-reperfusion to determine if neuropeptide expression was altered in cardiac sympathetic neurons. NPY, VIP, and SubP mRNAs were unchanged compared to unoperated control animals, but GAL mRNA was increased significantly. The increased GAL mRNA was not accompanied by elevated GAL peptide content in the stellate ganglia. Galanin content was increased significantly in the heart, however, indicating that elevated GAL mRNA led to increased peptide production. GAL content was increased in the left ventricle below the coronary artery ligation, but was not increased significantly in the atria or the base of the heart above the ligation. The buildup of GAL specifically in the damaged left ventricle is consistent with previous reports that GAL is transported to regenerating nerve endings after axon damage. (c) 2004 Elsevier Ltd. All rights reserved. C1 Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Anesthesiol, Portland, OR 97239 USA. Portland VA Med Ctr, Anesthesiol Serv, Portland, OR 97239 USA. RP Habecker, BA (reprint author), Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM habecker@ohsu.edu OI Habecker, Beth/0000-0002-4658-8730 FU NHLBI NIH HHS [HL68231, R01 HL068231] NR 53 TC 19 Z9 20 U1 0 U2 1 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0143-4179 J9 NEUROPEPTIDES JI Neuropeptides PD APR PY 2005 VL 39 IS 2 BP 89 EP 95 DI 10.1016/j.npep.2004.11.003 PG 7 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 909MC UT WOS:000227863000004 PM 15752542 ER PT J AU Binder, DK Rau, GM Starr, PA AF Binder, DK Rau, GM Starr, PA TI Risk factors for hemorrhage during microelectrode-guided deep brain stimulator implantation for movement disorders SO NEUROSURGERY LA English DT Article DE deep brain stimulation; globus pallidus; hemorrhage; microelectrode recording; subthalamic nucleus; thalamus ID ADVANCED PARKINSONS-DISEASE; CHRONIC ELECTRICAL-STIMULATION; VENTRALIS INTERMEDIUS NUCLEUS; SUBTHALAMIC NUCLEUS; TECHNICAL APPROACH; ESSENTIAL TREMOR; GLOBUS-PALLIDUS; POSTEROVENTRAL PALLIDOTOMY; THALAMIC-STIMULATION; FOLLOW-UP AB OBJECTIVE: Although hemorrhage is a well-known complication of microelectrodeguided deep brain stimulation (DBS) surgery, risk factors for the development of hemorrhage have not been well defined. We analyzed the risk factors for symptomatic and asymptornatic hemorrhage in a large series of DBS implantations into the subthalamic nucleus, ventrolateral thalamus, and internal globus pallidus. METHODS: All DBS procedures performed by a single surgeon at our institution between June 1998 and May 2004 were included in this study. All patients had postoperative imaging (magnetic resonance imaging or computed tomography) 4 to 24 hours after surgery. Hematomas were noted and scored as symptomatic or asymptomatic. Statistical correlation of factors affecting risk of hematoma formation was performed by use of logistic regression analysis. RESULTS: The total number of lead implantations was 481. There were 6 symptomatic hematomas and 10 asymptornatic hematomas. Three of the symptomatic hematomas resulted in permanent new neurological deficit. The risk of hematorna (of any type) per lead implantation was 3.3%, whereas the risk of permanent deficit from hematoma was 0.6%. Patients who developed hematomas had a slightly greater number of microelectrode recording penetrations than patients who did not have hematomas, but this difference did not reach statistical significance. There was not a statistically significant relationship between risk of hematoma and patient age or diagnosis. There was a significant effect of brain target (P = 0.001), with only I hemorrhage detected after thalamic DBS. CONCLUSION: DBS is generally safe, with only 0.6% of implantations associated with permanent neurological deficit. The incremental risk of successive serial microelectrode penetrations is small. C1 Univ Calif San Francisco, Moffitt Hosp, Dept Neurol Surg, San Francisco, CA 94143 USA. San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Care Ctr, San Francisco, CA USA. RP Binder, DK (reprint author), Univ Calif San Francisco, Moffitt Hosp, Dept Neurol Surg, M779,Box 0112, San Francisco, CA 94143 USA. EM dbinder@itsa.ucsf.edu NR 38 TC 129 Z9 137 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-396X EI 1524-4040 J9 NEUROSURGERY JI Neurosurgery PD APR PY 2005 VL 56 IS 4 BP 722 EP 728 DI 10.1227/01.NEU.0000156473.57196.7E PG 7 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 915EH UT WOS:000228280200019 PM 15792511 ER PT J AU Kassan, H Cohavy, O Rosenbaum, JT Braun, J Gordon, LK AF Kassan, H Cohavy, O Rosenbaum, JT Braun, J Gordon, LK TI Uveitis seroreactivity to candidate pANCA antigens: Mycobacterial HupB and histone H1(69-171) SO OCULAR IMMUNOLOGY AND INFLAMMATION LA English DT Article DE uveitis; inflammation; pANCA; HupB; histone H1(69-171) ID ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; INFLAMMATORY-BOWEL-DISEASE; CHROMOSOMAL-PROTEINS HMG1; ULCERATIVE-COLITIS; CROHNS-DISEASE; AUTOIMMUNE HEPATITIS; TARGET ANTIGENS; ANCA; AUTOANTIBODIES; IDENTIFICATION AB Purpose: Certain uveitis patients express the disease-marker antibody pANCA. Histone H1 ( H1) and mycobacterial HupB ( HupB) are recently identified candidate pANCA antigens. This study addresses the hypothesis that H1 and HupB are targets of disease-associated seroreactivity in pANCA+ uveitis. Methods: Sera from 293 uveitis patients were categorized for pANCA activity. H1(69-171) and HupB recombinant proteins were used as antigenic targets in ELISA studies. Selected sera were analyzed for reactivity by Western blot. Results: Seroreactivities to ANCA, H1(69-171), and HupB were frequently detected in uveitis patients. No significant relationship existed between the level of ANCA antibody and reactivity to either recombinant antigen. There was, however, a significant, positive correlation between H1(69-171) and HupB seroreactivities. Conclusions: Correlation between H1(69-171) and HupB reactivities suggests the presence of a shared dominant epitope, which is recognized by antibodies in a substantial number of uveitis patients. Seroreactivities to ANCA and HupB/H1 are independent immunologic markers that may identify biologically distinctive subsets of uveitis. C1 Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA. Greater Los Angeles VA Healthcare Syst, Ophthalmol Sect, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Pathol & Lab Med, David Geffen Sch Med, Los Angeles, CA 90095 USA. Oregon Hlth Sci Univ, Casey Eye Inst, Portland, OR 97201 USA. RP Gordon, LK (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM lgordon@ucla.edu OI Braun, Jonathan/0000-0003-1646-2974 FU NEI NIH HHS [EY13708, EY00360] NR 33 TC 4 Z9 4 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0927-3948 J9 OCUL IMMUNOL INFLAMM JI Ocul. Immunol. Inflamm. PD APR-JUN PY 2005 VL 13 IS 2-3 BP 191 EP 198 DI 10.1080/09273940490912452 PG 8 WC Ophthalmology SC Ophthalmology GA 935DM UT WOS:000229759700009 PM 16019678 ER PT J AU Friedlander, A AF Friedlander, A TI Carotid artery atheromatosis after radiation therapy for head and neck tumors. Diagnosis, clinical implications and preventive measures SO ORAL ONCOLOGY LA English DT Meeting Abstract CT 10th International Congress on Oral Cancer CY APR 19-24, 2005 CL Crete, GREECE C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1368-8375 J9 ORAL ONCOL JI Oral Oncol. PD APR PY 2005 VL 1 IS 1 SU S BP 35 EP 35 DI 10.1016/S1744-7895(05)80029-X PG 1 WC Oncology; Dentistry, Oral Surgery & Medicine SC Oncology; Dentistry, Oral Surgery & Medicine GA 000XE UT WOS:000234494900028 ER PT J AU Yuan, PQ Kimura, H Million, M Bellier, JP Wang, LX Ohning, GV Tache, Y AF Yuan, PQ Kimura, H Million, M Bellier, JP Wang, LX Ohning, GV Tache, Y TI Central vagal stimulation activates enteric cholinergic neurons in the stomach and VIP neurons in the duodenum in conscious rats SO PEPTIDES LA English DT Article DE peripheral choline acetyltransferase; vagus; enteric nervous system; cold; duodenum; vasoactive intestinal peptide ID THYROTROPIN-RELEASING-HORMONE; GENE-RELATED PEPTIDE; GASTRIC MYENTERIC NEURONS; NERVOUS-SYSTEM ACTION; DORSAL MOTOR NUCLEUS; TRH ANALOG; INTRACISTERNAL TRH; COLD-RESTRAINT; FOS EXPRESSION; GUINEA-PIG AB The influence of central vagal stimulation induced by 2 h cold exposure or intracisternal injection of thyrotropin-releasing hormone (TRH) analog, RX-77368, on gastro-duodenal enteric cholinergic neuronal activity was assessed in conscious rats with Fos and peripheral choline acetyltransferase (pChAT) immunoreactivity (IR). pChAT-IR was detected in 68%, 70% and 73% of corpus, antrum and duodenum submucosal neurons, respectively, and in 65% of gastric and 46% of duodenal myenteric neurons. Cold and RX-77368 induced Fos-IR in over 90% of gastric submucosal and myenteric neurons, while in duodenum only 25-27% of submucosal and 50-51% myenteric duodenal neurons were Fos positive. In the stomach, cold induced Fos-IR in 93% of submucosal and 97% of myenteric pChAT IR neurons, while in the duodenum only 7% submucosal and 5% myenteric pChAT IR neurons were Fos positive. In the duodenum, cold induced Fos in 91% of submucosal and 99% of myenteric VIP-IR neurons. RX-77368 induces similar percentages of Fos/pChAT-IR and Fos/VIP-IR neurons. These results indicate that increased central vagal outflow activates cholinergic neurons in the stomach while in the duodenum, VIP neurons are preferentially stimulated. (c) 2004 Elsevier Inc. All rights reserved. C1 Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, VA Greater Los Angeles Healthcare Syst, Digest Dis Div,Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90073 USA. Shiga Univ Med Sci, Mol Neurosci Res Ctr, Otsu, Shiga 5202192, Japan. RP Yuan, PQ (reprint author), Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Bldg 115,Room 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM pqyuan@ucla.edu OI Bellier, Jean-Pierre/0000-0002-8758-8075 FU NIDDK NIH HHS [DK 41301, R01 DK-33061] NR 51 TC 15 Z9 16 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD APR PY 2005 VL 26 IS 4 BP 653 EP 664 DI 10.1016/j.peptides.2004.11.015 PG 12 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 909WD UT WOS:000227890500016 PM 15752581 ER PT J AU Netscher, DT AF Netscher, DT TI Repair of fingertip amputations with local digital flaps and perionychial composite grafrs from the amputated part SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Letter ID RECONSTRUCTION C1 Baylor Coll Med, Dept Vet Affairs Med Ctr, Div Plast Surg, Plast Surg Serv, Houston, TX USA. RP Netscher, DT (reprint author), 6624 Fannin,Suite 2730, Houston, TX 77030 USA. EM netscher@bcn.tmc.edu NR 4 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD APR 1 PY 2005 VL 115 IS 4 BP 1217 EP 1218 DI 10.1097/01.PRS.0000157514.76438.F5 PG 2 WC Surgery SC Surgery GA 912LN UT WOS:000228079800047 PM 15793479 ER PT J AU Flick, KC Orendurff, MS Berge, JS Segal, AD Klute, GK AF Flick, KC Orendurff, MS Berge, JS Segal, AD Klute, GK TI Comparison of human turning gait with the mechanical performance of lower limb prosthetic transverse rotation adapters SO PROSTHETICS AND ORTHOTICS INTERNATIONAL LA English DT Article ID AMPUTATION; PAIN AB Given the importance of minimizing transverse plane shear stress on soft tissue, several transverse rotational adapters (TRAs) are available for incorporation in lower limb prostheses. This study compares kinetic and kinematic data from human subjects during straight and turning gaits to the mechanical performance of several TRAs. Physiological data were collected from three individuals walking straight and turning at self-selected speeds around a 1m radius circle. The average peak torques and range of motion for normal subjects while turning were 8.2 Nm and 26 degrees (outside leg), 11.8Nm and 20 degrees (inside leg), and 11.4Nm and 20 degrees (right leg) during straight gait. Each TRA was mechanically tested without axial loading in a servo-hydraulic material testing system (MTS) over its rotational range at 0.5 degrees/s and 60 degrees/s. The TRAs with axial compression were also tested at 0.5 degrees/s under a 736N (75kg mass) axial load. Applying these torques to the different TRAs yielded 3 to 35 degrees rotation, depending on the elastomer installed. Some TRAs had nearly constant stiffness, while others stiffened with rotation. The TRAs also varied in their average maximum stiffness from 0.4Nm/degrees to 2.7Nm/degrees. Normal subjects exhibit interior vs. exterior asymmetrical torques and displacements; however, only one of the TRAs is designed to allow asymmetrical stiffness, and none have asymmetric ranges. Prosthetists and physicians can use these data to better interpret amputees' qualitative remarks and to prescribe the correct TRA and/or elastomer. This information also forms a basis for further design and development of novel torque absorbing prosthetic adapters. C1 Vet Adm Rehabil Res & Dev Ctr Excellence Limb Los, Seattle, WA USA. Univ Washington, Dept Biol, Seattle, WA 98195 USA. RP Flick, KC (reprint author), VA Puget Sound, 1660 S Columbian Way,MS 151, Seattle, WA 98108 USA. EM kflick@u.washington.edu NR 10 TC 14 Z9 14 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0309-3646 J9 PROSTHET ORTHOT INT JI Prosthet. Orthot. Int. PD APR PY 2005 VL 29 IS 1 BP 73 EP 81 DI 10.1080/03093640500088120 PG 9 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA 944WG UT WOS:000230461000008 PM 16180379 ER PT J AU Caroff, SN Stinnett, JL AF Caroff, SN Stinnett, JL TI Medically unexplained symptoms SO PSYCHIATRIC ANNALS LA English DT Editorial Material C1 Univ Penn, Philadelphia, PA 19104 USA. Dept Vet Affairs Med Ctr, Inpatient Psychiat Serv, Philadelphia, PA 19104 USA. Hosp Univ Penn, Psychiat Consultat Serv, Philadelphia, PA 19104 USA. RP Caroff, SN (reprint author), Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0048-5713 J9 PSYCHIAT ANN JI Psychiatr. Ann. PD APR PY 2005 VL 35 IS 4 BP 281 EP 282 PG 2 WC Psychiatry SC Psychiatry GA 948MP UT WOS:000230720300002 ER PT J AU Verduin, ML Carter, RE Brady, KT Myrick, H Timmerman, MA AF Verduin, ML Carter, RE Brady, KT Myrick, H Timmerman, MA TI Health service use among persons with comorbid bipolar and substance use disorders SO PSYCHIATRIC SERVICES LA English DT Article; Proceedings Paper CT 157th Annual Meeting of the American-Psychiatric-Association CY MAY 01-06, 2004 CL New York, NY SP Amer Psychiat Assoc ID ABUSE DISORDERS; ILLNESS; CARE; COSTS AB Objective: This study tested the hypothesis that patients with comorbid bipolar and substance use disorders use health services to a greater extent than patients with either bipolar or substance use disorder alone. Methods: A retrospective chart review was conducted among patients who used health services at the Ralph H. Johnson Department of Veterans Affairs medical center in Charleston, South Carolina, and had bipolar disorder alone, substance use disorder alone, and comorbid bipolar and substance use disorders. Patients with a psychiatric admission between 1999 and 2003 were included in the study. Information was collected on the use of health services one year before and including the index admission. Results: The records of 106 eligible patients were examined for this study: 18 had bipolar disorder alone, 39 had substance use disorder alone, and 49 had both bipolar and substance use disorders. Compared with the other two groups, the group with comorbid bipolar and substance use disorders was significantly more likely to be suicidal. Compared with the group with bipolar disorder alone, the group with comorbid disorders had significantly fewer outpatient psychiatric visits and tended to have shorter psychiatric hospitalizations. Among patients with an alcohol use disorder, those who also had bipolar disorder were significantly less likely than those with an alcohol use disorder alone to have had an alcohol-related seizure. Patients with comorbid bipolar and substance use disorders were significantly less likely than those with substance use disorder alone to be referred for intensive substance abuse treatment, even though both groups were equally likely to enter and complete treatment when they were referred. Conclusions: Despite significant functional impairment among patients with comorbid bipolar and substance use disorders, they had significantly fewer psychiatric outpatient visits than those with bipolar disorder alone and were referred for intensive substance abuse treatment significantly less often than those with substance use disorder alone. C1 Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. Ralph H Johnson Vet Adm Med Ctr, Dept Psychiat, Charleston, SC USA. RP Verduin, ML (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,POB 250861, Charleston, SC 29425 USA. EM verduim@musc.edu NR 17 TC 16 Z9 16 U1 4 U2 5 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2005 VL 56 IS 4 BP 475 EP 480 DI 10.1176/appi.ps.56.4.475 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 913KP UT WOS:000228150800018 PM 15812100 ER PT J AU Hart, S Fonareva, I Merluzzi, N Mohr, DC AF Hart, S Fonareva, I Merluzzi, N Mohr, DC TI Treatment for depression and its relationship to improvement in quality of life and psychological well-being in multiple sclerosis patients SO QUALITY OF LIFE RESEARCH LA English DT Article DE depression; multiple sclerosis; quality of life ID MAJOR DEPRESSION; DISABILITY; SYMPTOMS; FATIGUE; DISEASE; PEOPLE; IMPACT; PSYCHOTHERAPY; DISTRESS; OUTCOMES AB Depression, a common problem in multiple sclerosis (MS), is generally associated with poorer quality of life (QOL). However, it is unclear whether treating depression also extends to better perceived QOL. Understanding QOL in MS has been limited by narrow definitions and exclusive focus on symptomology, with little emphasis on positive aspects of QOL. This study examined the impact of treating depression on QOL in 60 patients with a relapsing form of MS and moderate to severe depression, who were randomly assigned to one of three validated 16-week treatments for depression: individual cognitive-behavioral therapy, group psychotherapy, or sertraline. QOL was measured by the MSQOL-54, a version of the SF-36 adapted for MS, and Ryff's scales of psychological well-being, which measure positive attitudes and functioning. Depression and QOL were measured at baseline and immediately following treatment completion. Controlling for baseline neurological impairment and baseline QOL scores, regression analyses showed treating depression was significantly associated with improvements in the MSQOL-54 scales (R(2)s = 0.19-0.55, p < 0.001) and in four of the six scales of psychological well-being: environmental mastery (R-2 = 0.13, p < 0.001), positive relations (R-2 = 0.08, p < 0.001), purpose in life (R-2 = 0.16, p < 0.001), and self-acceptance (R-2 = 0.26, p < 0.001). Findings suggest treating depression influences both the negative and positive aspects of QOL and underscore the importance of examining QOL with two complementary approaches. C1 Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Hart, S (reprint author), Univ Calif San Francisco, San Francisco VA Med Ctr, 4150 Clement St 116-A, San Francisco, CA 94121 USA. EM slhart@itsa.ucsf.edu RI Hart, Stacey/E-4819-2011 FU NIMH NIH HHS [R01 MH-59708, R01 MH059708, R01 MH059708-06] NR 51 TC 51 Z9 53 U1 3 U2 14 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 J9 QUAL LIFE RES JI Qual. Life Res. PD APR PY 2005 VL 14 IS 3 BP 695 EP 703 DI 10.1007/s11136-004-1364-z PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 942VJ UT WOS:000230310700011 PM 16022063 ER PT J AU Waldo, MC Woodward, LA Cawthra, EM Adler, LE AF Waldo, MC Woodward, LA Cawthra, EM Adler, LE TI The virtual water maze, P50 sensory gating, and cognitive functioning SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 20th International Congress on Schizophernia Research CY APR 02-06, 2005 CL Savannah, GA C1 Denver VAMC, VISN 19, MIRECC, Denver, CO USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD APR PY 2005 VL 31 IS 2 BP 346 EP 346 PG 1 WC Psychiatry SC Psychiatry GA 914PY UT WOS:000228241201115 ER PT J AU Steinhauer, SR Condray, R Siegle, GJ Gurklis, JA AF Steinhauer, SR Condray, R Siegle, GJ Gurklis, JA TI Cognitive inhibition of the pupillary light reaction in schizophrenia and alcoholism: Physiological evidence for effortful processing SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 20th International Congress on Schizophernia Research CY APR 02-06, 2005 CL Savannah, GA C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD APR PY 2005 VL 31 IS 2 BP 378 EP 378 PG 1 WC Psychiatry SC Psychiatry GA 914PY UT WOS:000228241201211 ER PT J AU Tapp, A Wood, AE Kilzieh, N Kennedy, A AF Tapp, A Wood, AE Kilzieh, N Kennedy, A TI Double-blind comparison of quetiapine and haloperidol on cognitive functioning in patients with schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 20th International Congress on Schizophernia Research CY APR 02-06, 2005 CL Savannah, GA C1 VA Puget Sound Hlth Care Syst, Tacoma, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD APR PY 2005 VL 31 IS 2 BP 379 EP 379 PG 1 WC Psychiatry SC Psychiatry GA 914PY UT WOS:000228241201214 ER PT J AU Nagamoto, HT Adler, LE Kisley, MA Hea, RA Cawthra, E Griffith, JM McRae, KA Freedman, R AF Nagamoto, HT Adler, LE Kisley, MA Hea, RA Cawthra, E Griffith, JM McRae, KA Freedman, R TI P50 gating in schizophrenia at 500 and 100 MSEC intervals in typical antipsychotics versus clozapine SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 20th International Congress on Schizophernia Research CY APR 02-06, 2005 CL Savannah, GA ID AUDITORY P50 C1 Denver VA Med Ctr, MHS, Denver, CO USA. Denver VA Med Ctr, VISN 19 MIRECC, Denver, CO USA. NR 2 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD APR PY 2005 VL 31 IS 2 BP 460 EP 460 PG 1 WC Psychiatry SC Psychiatry GA 914PY UT WOS:000228241202046 ER PT J AU Yao, JK Magan, S Gurklis, J Sonel, A Reddy, R AF Yao, JK Magan, S Gurklis, J Sonel, A Reddy, R TI Effect of omega-3 fatty acid on clinically-stable schizophrenic patients with a high risk for coronary artery disease SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 20th International Congress on Schizophernia Research CY APR 02-06, 2005 CL Savannah, GA C1 VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD APR PY 2005 VL 31 IS 2 BP 507 EP 507 PG 1 WC Psychiatry SC Psychiatry GA 914PY UT WOS:000228241202183 ER PT J AU Gaither, ML Nazzaro, D Huegel, S Jacoby, A Haas, G AF Gaither, ML Nazzaro, D Huegel, S Jacoby, A Haas, G TI Cognitive-behavioral treatment applications in individuals with chronic schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 20th International Congress on Schizophernia Research CY APR 02-06, 2005 CL Savannah, GA C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD APR PY 2005 VL 31 IS 2 BP 524 EP 525 PG 2 WC Psychiatry SC Psychiatry GA 914PY UT WOS:000228241202230 ER PT J AU Wood, AE Tapp, A Kennedy, A Kilzieh, N AF Wood, AE Tapp, A Kennedy, A Kilzieh, N TI Use of the independent living scales to measure community functioning in patients with schizophrenia SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 20th International Congress on Schizophernia Research CY APR 02-06, 2005 CL Savannah, GA C1 VA Puget Sound Healthcare Syst, Tacoma, WA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD APR PY 2005 VL 31 IS 2 BP 535 EP 536 PG 2 WC Psychiatry SC Psychiatry GA 914PY UT WOS:000228241202263 ER PT J AU Black, JE Hirshkowitz, M AF Black, JE Hirshkowitz, M TI Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome SO SLEEP LA English DT Article DE modafinil; obstructive sleep apnea/hypopnea syndrome; sleepiness; wakefulness ID APNEA-HYPOPNEA SYNDROME; QUALITY-OF-LIFE; DAYTIME SLEEPINESS; BLOOD-PRESSURE; APNOEA/HYPOPNOEA SYNDROME; RANDOMIZED-TRIAL; ADJUNCT THERAPY; PARALLEL TRIAL; CPAP THERAPY; ASSOCIATION AB Objectives: Nasal continuous positive airway pressure (nCPAP) usually reduces sleepiness in patients with obstructive sleep apnea/hypopnea syndrome. However, even with regular use of nCPAP, some patients experience residual excessive sleepiness. We evaluated the efficacy and safety of the wake-promoting agent modafinil for treating residual excessive sleepiness in nCPAP-treated patients. Design: 12-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled trial. Patients: Patients aged 18 to 70 years diagnosed with obstructive sleep apnea/hypopnea syndrome and having residual excessive sleepiness during nCPAP therapy were eligible. Interventions: Once-daily modafinil, 200 mg or 400 mg, or placebo. Measurements and Results: Assessments included the Maintenance of Wakefulness Test, Epworth Sleepiness Scale, Clinical Global Impression of Change, and Functional Outcomes of Sleep Questionnaire. Both doses of modafinil significantly improved mean (SD) sleep latency on the Maintenance of Wakefulness Test at weeks 4, 8, and 12 compared with placebo (week 12: modafinil 400 mg, 15.0 [5.3] minutes; 200 mg, 14.8 [5.3] minutes; placebo, 12.6 [5.8] minutes; P < .0001). The Epworth Sleepiness Scale score decreased more in patients taking modafinil compared with those in the placebo group (week 12: modafinil 400 mg, -4.5 [4.3]; 200 mg, -4.5 [4.7]; placebo, -1.8 [3.5]; P < .0001). At week 12, overall clinical condition improved for 61% and 68% of patients treated with modafinil 200 mg and 400 mg, respectively, versus 37% of placebo-treated patients (P < .001). Modafinil was generally well tolerated and did not adversely affect nighttime sleep or nCPAP use. Conclusions: These results confirm previous shorter-term controlled trials, indicating modafinil is a useful adjunct therapy for improving wakefulness in patients with residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome who were treated with nCPAP. C1 Stanford Univ, Stanford Sleep Disorder Clin, Stanford, CA 94305 USA. VA Med Ctr, Sleep Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Black, JE (reprint author), Stanford Univ, Stanford Sleep Disorder Clin, 401 Quarry Rd,Suite 3301, Stanford, CA 94305 USA. EM jedblack@stanford.edu NR 44 TC 70 Z9 73 U1 0 U2 0 PU AMER ACADEMY SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CENTER STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD APR 1 PY 2005 VL 28 IS 4 BP 464 EP 471 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 913ER UT WOS:000228134900012 PM 16171291 ER PT J AU Kushida, CA Littner, MR Morgenthaler, T Alessi, CA Bailey, D Coleman, J Friedman, L Hirshkowitz, M Kapen, S Kramer, M Lee-Chiong, T Loube, DL Owens, J Pancer, JP Wise, M AF Kushida, CA Littner, MR Morgenthaler, T Alessi, CA Bailey, D Coleman, J Friedman, L Hirshkowitz, M Kapen, S Kramer, M Lee-Chiong, T Loube, DL Owens, J Pancer, JP Wise, M TI Practice parameters for the indications for polysomnography and related procedures: An update for 2005 SO SLEEP LA English DT Review DE practice parameters; practice guidelines; standards of practice; polysomnography; sleep related breathing disorders; sleep disorders; narcolepsy; parasomnias; restless legs syndrome; periodic limb movement sleep disorder; insomnia; circadian rhythm sleep disorders ID OBSTRUCTIVE SLEEP-APNEA; POSITIVE AIRWAY PRESSURE; AMYOTROPHIC-LATERAL-SCLEROSIS; CONGESTIVE-HEART-FAILURE; CHEYNE-STOKES RESPIRATION; RESTLESS LEGS SYNDROME; NOCTURNAL NASAL VENTILATION; PULMONARY-DISEASE PATIENTS; BRAIN-COMPUTER INTERFACE; HYPOPNEA SYNDROME AB These practice parameters are an update of the previously-published recommendations regarding the indications for polysomnography and related procedures in the diagnosis of sleep disorders. Diagnostic categories include the following: sleep related breathing disorders, other respiratory disorders, narcolepsy, parasomnias, sleep related seizure disorders, restless legs syndrome, periodic limb movement sleep disorder, depression with insomnia, and circadian rhythm sleep disorders. Polysomnography is routinely indicated for the diagnosis of sleep related breathing disorders; for continuous positive airway pressure (CPAP) titration in patients with sleep related breathing disorders; for the assessment of treatment results in some cases; with a multiple sleep latency test in the evaluation of suspected narcolepsy; in evaluating sleep related behaviors that are violent or otherwise potentially injurious to the patient or others; and in certain atypical or unusual parasomnias. Polysomnography may be indicated in patients with neuromuscular disorders and sleep related symptoms; to assist in the diagnosis of paroxysmal arousals or other sleep disruptions thought to be seizure related; in a presumed parasomnia or sleep related seizure disorder that does not respond to conventional therapy; or when there is a strong clinical suspicion of periodic limb movement sleep disorder. Polysomnography is not routinely indicated to diagnose chronic lung disease; in cases of typical, uncomplicated, and noninjurious parasomnias when the diagnosis is clearly delineated; for patients with seizures who have no specific complaints consistent with a sleep disorder; to diagnose or treat restless legs syndrome; for the diagnosis of circadian rhythm sleep disorders; or to establish a diagnosis of depression. C1 Stanford Univ, Ctr Excellence Sleep Disorders, Stanford, CA 94305 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Sepulveda, CA USA. Mayo Clin, Mayo Sleep Disorders Ctr, Rochester, MN USA. Univ Calif Los Angeles, Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Greenwood Dent Assoc, Englewood, CO USA. Middle Tennessee ENT, Murfreesboro, TN USA. Stanford Univ, Sch Med, Stanford, CA 94305 USA. Baylor Coll Med, Houston, TX 77030 USA. VA Med Ctr, Houston, TX 77030 USA. VA Med Ctr, Detroit, MI USA. Wayne State Univ, Detroit, MI USA. Maimonides Hosp, Dept Psychiat, Brooklyn, NY 11219 USA. NYU, Sch Med, New York, NY USA. Natl Jewish Med & Res Ctr, Sleep Clin, Denver, CO USA. Swedish Med Ctr, Sleep Med Inst, Seattle, WA USA. Brown Univ, Rhode Isl Hosp, Dept Pediat, Providence, RI 02903 USA. Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. RP Stanford Univ, Ctr Excellence Sleep Disorders, Stanford, CA 94305 USA. OI Morgenthaler, Timothy/0000-0002-2614-3793 NR 150 TC 592 Z9 631 U1 4 U2 32 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD APR 1 PY 2005 VL 28 IS 4 BP 499 EP 521 PG 23 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 913ER UT WOS:000228134900015 PM 16171294 ER PT J AU Wagner, M Garzotto, M Lemmon, D Eilers, KM Beer, TM AF Wagner, M Garzotto, M Lemmon, D Eilers, KM Beer, TM TI Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer SO UROLOGY LA English DT Article ID ANTIANDROGEN WITHDRAWAL; MEGESTROL-ACETATE; FLUTAMIDE; DISCONTINUATION; NILUTAMIDE; EXPRESSION; RECEPTORS; CASODEX; CELLS AB A 66-year-old man with androgen-independent prostate cancer was treated with abarelix, a gonadotropin-releasing hormone antagonist, for 20 weeks in an experimental protocol. He did not respond to therapy, but his serum prostate-specific antigen level dropped from 15.8 ng/mL to a confirmed 0.8 ng/mL after abarelix was stopped. His prostate-specific antigen level did not return to greater than 15.8 ng/mL for 14 months. This is the first report of a withdrawal response after therapy with a gonadotropin-releasing hormone antagonist, a new class of agents for prostate cancer. Additional observations are needed to determine whether this is an isolated case or a harbinger of a more common phenomenon. (c) 2005 Elsevier Inc. C1 Oregon Hlth Sci Univ, Dept Med, Div Urol, Portland, OR USA. Oregon Hlth Sci Univ, Div Hematol, Portland, OR USA. Oregon Hlth Sci Univ, Div Med Oncol, Portland, OR USA. Portland Vet Affairs Med Ctr, Div Urol, Portland, OR USA. RP Beer, TM (reprint author), Oregon Hlth Sci Univ, Dept Med, Div Urol, Mail Code CR145,3181 SW Sam Jackson Pk Rd, Portland, OR USA. EM beert@ohsu.edu NR 16 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD APR PY 2005 VL 65 IS 4 BP E37 EP E39 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 918OQ UT WOS:000228557900047 ER PT J AU Pearlman, RA Starks, H Cain, KC Cole, WG AF Pearlman, RA Starks, H Cain, KC Cole, WG TI Improvements in advance care planning in the veterans affairs system - Results of a multifaceted intervention SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID LIFE-SUSTAINING TREATMENT; RANDOMIZED CONTROLLED TRIAL; FAMILY DECISION-MAKING; HOSPITALIZED-PATIENTS; PATIENT PREFERENCES; HEALTH-CARE; DIRECTIVES; END; COMPLETION; PHYSICIANS AB Background: Advance care planning (ACP) aims to 0 Guide health care in the event of decisional incapacity. Interventions to promote ACP have had limited effectiveness. We conducted an educational and motivational intervention in Department of Veterans Affairs outpatient clinics to increase ACP use and proxy and health care provider understanding of patients' preferences and values. Methods: We recruited 23 providers and up to 14 of each of their patients; the patients were randomized to the control or intervention group. Eligibility criteria included a preexisting relationship with the provider, age 55 years or older, chronic health condition(s), and no recorded advance directive. The intervention group (n = 119) received an ACP workbook, motivational counseling by social workers, and cues to providers to discuss ACP. The control group (n = 129) received an advance directive booklet. Results: The intervention patients reported more ACP discussions with their providers (64% vs 38%; P <.001). Living wills were filed in the medical record twice as often in the intervention group (48% vs 23%; P <.001). Provider-patient dyads in the intervention group had higher agreement scores than the control group for treatment preferences, values, and personal beliefs (58% vs 48%, 57% vs 46%, and 61% vs 47%, respectively; P <.01. for all comparisons). The agreement scores for the proxy-patient dyads did not differ between groups for treatment preferences and values, but were higher in the intervention than the control group for personal beliefs (67% vs 56%). Conclusion: This intervention demonstrates mixed results and highlights the ongoing challenges of helping health care providers and potential proxy decision makers represent patient preferences and values. C1 Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Med Hist & Eth, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Lewis & Clark Coll, Dept Psychol, Portland, OR 97219 USA. RP Pearlman, RA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, S-182-IGP,1660 S Columbian Way, Seattle, WA 98108 USA. EM robert.pearlman@med.va.gov NR 38 TC 55 Z9 56 U1 2 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAR 28 PY 2005 VL 165 IS 6 BP 667 EP 674 DI 10.1001/archinte.165.6.667 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 909WW UT WOS:000227892400011 PM 15795344 ER PT J AU Hagopian, K Ramsey, JJ Weindruch, R AF Hagopian, K Ramsey, JJ Weindruch, R TI Serine utilization in mouse liver: Influence of caloric restriction and aging SO FEBS LETTERS LA English DT Article DE caloric restriction; serine dehydratase; serine : pyruvate transaminase; glycerate dehydrogenase; glycerate kinase ID AMINO-ACID METABOLISM; RAT-LIVER; PYRUVATE AMINOTRANSFERASE; ENZYME-ACTIVITIES; GLYCERATE KINASE; NEONATAL RAT; GLUCONEOGENESIS; DIETARY; MITOCHONDRIAL; DEHYDRATASE AB The influence of caloric restriction (CR) on the activities of hepatic serine metabolizing enzymes in young (3 months) and old (30 months) mice was studied. Serine dehydratase (SDH) activity increased markedly with age in both diet groups and in old mice was higher in the CR group. No effects of CR were observed in the young. Serine:pyruvate transaminase (SPT) and glycerate kinase activities were unaffected by age and diet. However, glycerate dehydrogenase activity was decreased in old CR mice but not in young CR. The results of this study show that long-term CR influenced serine utilization only in the pathway catalyzed by SDH. This suggests that in mouse liver this pathway is critical for serine utilization in gluconeogenesis, while the SPT pathway plays a minor role. The increase in SDH activity with long-term CR is consistent with sustained increase in gluconeogenesis. (c) 2005 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. C1 Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA. Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53706 USA. William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. RP Hagopian, K (reprint author), Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, 1 Shields Ave, Davis, CA 95616 USA. EM khagopian@ucdavis.edu FU NIA NIH HHS [P01 AG11915, R01 AG17902] NR 36 TC 10 Z9 10 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-5793 J9 FEBS LETT JI FEBS Lett. PD MAR 28 PY 2005 VL 579 IS 9 BP 2009 EP 2013 DI 10.1016/j.febslet.2005.02.062 PG 5 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 913LJ UT WOS:000228152800021 PM 15792811 ER PT J AU Shi, YJ Sharma, A Wu, H Lichtenstein, A Gera, J AF Shi, YJ Sharma, A Wu, H Lichtenstein, A Gera, J TI Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID RIBONUCLEOPROTEIN-K PROTEIN; 5' UNTRANSLATED REGION; MESSENGER-RNA; MAMMALIAN TARGET; GENE-EXPRESSION; KINASE-B; IN-VITRO; SEGMENT; INITIATION; BINDING AB The macrolide antibiotic rapamycin inhibits the mammalian target of rapamycin protein (mTOR) kinase resulting in the global inhibition of cap-dependent protein synthesis, a blockade in ribosome component biosynthesis, and G(1) cell cycle arrest. G1 arrest may occur by inhibiting the protein synthesis of critical factors required for cell cycle progression. Hypersensitivity to mTOR inhibitors has been demonstrated in cells having elevated levels of AKT kinase activity, whereas cells containing quiescent AKT activity are relatively resistant. Our previous data suggest that low AKT activity induces resistance by allowing continued cap-independent protein synthesis of cyclin D1 and c-Myc proteins. In support of this notion, the current study demonstrates that the human cyclin D1 mRNA 5 similar to untranslated region contains an internal ribosome entry site (IRES) and that both this IRES and the c-myc IRES are negatively regulated by AKT activity. Furthermore, we show that cyclin D1 and c-myc IRES function is enhanced following exposure to rapamycin and requires both p38 MAPK and RAF/MEK/ERK signaling, as specific inhibitors of these pathways reduce IRES-mediated translation and protein levels under conditions of quiescent AKT activity. Thus, continued IRES-mediated translation initiation may permit cell cycle progression upon mTOR inactivation in cells in which AKT kinase activity is relatively low. C1 Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Res & Dev, Los Angeles, CA 91343 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 91343 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 91343 USA. Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 91343 USA. Univ Calif Los Angeles, David Geffen Sch Med, Howard Hughes Med Inst, Los Angeles, CA 91343 USA. RP Gera, J (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Res & Dev, Los Angeles, CA 91343 USA. EM gera@ucla.edu FU NCI NIH HHS [CA096920] NR 53 TC 98 Z9 102 U1 1 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 25 PY 2005 VL 280 IS 12 BP 10964 EP 10973 DI 10.1074/jbc.M407874200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 908BI UT WOS:000227761800012 PM 15634685 ER PT J AU Lim, GP Calon, F Morihara, T Yang, FS Teter, B Ubeda, O Salem, N Frautschy, SA Cole, GM AF Lim, GP Calon, F Morihara, T Yang, FS Teter, B Ubeda, O Salem, N Frautschy, SA Cole, GM TI A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model SO JOURNAL OF NEUROSCIENCE LA English DT Article DE DHA; polyunsaturated fatty acid; A beta; APP; secretase; Alzheimer ID N-3 FATTY-ACIDS; ALPHA-SECRETASE CLEAVAGE; RETINOID-X-RECEPTOR; PRECURSOR PROTEIN; TRANSGENIC MICE; OXIDATIVE STRESS; PLAQUE-FORMATION; DISINTEGRIN METALLOPROTEASE; DOCOSAPENTAENOIC ACID; LIPID-PEROXIDATION AB Epidemiological studies suggest that increased intake of the omega-3 ( n-3) polyunsaturated fatty acid (PUFA) docosahexaenoic acid (DHA) is associated with reduced risk of Alzheimer's disease (AD). DHA levels are lower in serum and brains of AD patients, which could result from low dietary intake and/or PUFA oxidation. Because effects of DHA on Alzheimer pathogenesis, particularly on amyloidosis, are unknown, we used the APPsw (Tg2576) transgenic mouse model to evaluate the impact of dietary DHA on amyloid precursor protein (APP) processing and amyloid burden. Aged animals (17-19 months old) were placed in one of three groups until 22.5 months of age: control (0.09% DHA), low-DHA (0%), or high-DHA (0.6%) chow. beta-Amyloid (A beta) ELISA of the detergent-insoluble extract of cortical homogenates showed that DHA-enriched diets significantly reduced total A beta by > 70% when compared with low-DHA or control chow diets. Dietary DHA also decreased A beta 42 levels below those seen with control chow. Image analysis of brain sections with an antibody against A beta (amino acids 1-13) revealed that overall plaque burden was significantly reduced by 40.3%, with the largest reductions (40-50%) in the hippocampus and parietal cortex. DHA modulated APP processing by decreasing both alpha- and beta-APP C-terminal fragment products and full-length APP. BACE1 (beta-secretase activity of the beta-site APP-cleaving enzyme), ApoE (apolipoprotein E), and transthyretin gene expression were unchanged with the high-DHA diet. Together, these results suggest that dietary DHA could be protective against beta-amyloid production, accumulation, and potential downstream toxicity. C1 Vet Affairs Healthcare Syst, North Hills, CA 91343 USA. Geriatr Res Educ Clin Ctr, North Hills, CA 91343 USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. NIAAA, Sect Nutrit Neurosci, Lab Membrane Biochem & Biophys, Div Intramural Clin & Biol Res,NIH, Rockville, MD 20852 USA. RP Cole, GM (reprint author), Greater Los Angeles Vet Affairs Healthcare Syst, Geriatr Res Educ & Clin Ctr, 11E,16111 Plummer St, Sepulveda, CA 91343 USA. EM gmcole@ucla.edu FU NCCIH NIH HHS [R01 AT003008]; NIA NIH HHS [AG13471, AG16793, P50 AG016570] NR 68 TC 377 Z9 396 U1 3 U2 70 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD MAR 23 PY 2005 VL 25 IS 12 BP 3032 EP 3040 DI 10.1523/JNEUROSCI.4225-04.2005 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 909JP UT WOS:000227856500004 PM 15788759 ER PT J AU Lambrecht, NWG Yakubov, I Scott, D Sachs, G AF Lambrecht, NWG Yakubov, I Scott, D Sachs, G TI Identification of the K efflux channel coupled to the gastric H-K-ATPase during acid secretion SO PHYSIOLOGICAL GENOMICS LA English DT Article DE parietal cell; oligonucleotide expression microarray; potassium channel; KCNQ1; KCNE2 ID CARDIAC POTASSIUM CHANNELS; I-KS; PARIETAL-CELLS; APICAL MEMBRANE; OXYNTIC CELLS; PUMP; INHIBITION; SUBUNITS; BLOCKER; BINDING AB Genomic microarray analysis of genes specifically expressed in a pure cell isolate from a heterocellular organ identified the likely K efflux channel associated with the gastric H-K-ATPase. The function of this channel is to supply K to the luminal surface of the pump to allow H for K exchange. KCNQ1-KCNE2 was the most highly expressed and significantly enriched member of the large variety of K channels expressed in the gastric epithelium. The function of this K channel in acid secretion was then shown by inhibition of secretion in isolated gastric glands with specific KCNQ inhibitors and by colocalization of the channel with the H-K-ATPase in the secretory canaliculus of the parietal cell. KCNQ1-KCNE2 appears to be the K efflux channel that is essential for gastric acid secretion. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Lab Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, Membrane Biol Lab, Los Angeles, CA 90073 USA. RP Lambrecht, NWG (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. EM nilslam@ucla.edu OI Lambrecht, Nils/0000-0002-1275-1384 FU NIDDK NIH HHS [DK-41301, DK-53462, DK-46917] NR 34 TC 51 Z9 53 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1094-8341 J9 PHYSIOL GENOMICS JI Physiol. Genomics PD MAR 21 PY 2005 VL 21 IS 1 BP 81 EP 91 DI 10.1152/physiolgenomics.00212.2004 PG 11 WC Cell Biology; Genetics & Heredity; Physiology SC Cell Biology; Genetics & Heredity; Physiology GA 916LW UT WOS:000228387500007 PM 15613615 ER PT J AU Baron, F Maris, MB Sandmaier, BM Storer, BE Sorror, M Diaconescu, R Woolfrey, AE Chauncey, TR Flowers, MED Mielcarck, M Maloney, DG Storb, R AF Baron, F Maris, MB Sandmaier, BM Storer, BE Sorror, M Diaconescu, R Woolfrey, AE Chauncey, TR Flowers, MED Mielcarck, M Maloney, DG Storb, R TI Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID BONE-MARROW-TRANSPLANTATION; HLA-IDENTICAL SIBLINGS; BLOOD STEM-CELL; DONOR LYMPHOCYTE INFUSIONS; HOST-DISEASE; HEMATOLOGIC MALIGNANCIES; APLASTIC-ANEMIA; AUTOLOGOUS TRANSPLANTATION; COMPARING METHOTREXATE; ENGRAFTMENT KINETICS AB Purpose We have used a nonmyelorablative conditioning regimen consisting of total-body irradiation (2 Gy) with or without fludarabine (30 mg/m(2)/d for 3 days) for related and unrelated hematopoietic cell transplantation (HCT) in patients with hematologic malignancies who were not candidates for conventional HCT because of age, medical comorbidities, or preceding high-dose HCT. This approach relied on graft-versus-tumor (GVT) effects for control of malignancy. Patients and Methods We analyzed GVT effects in 322 patients given grafts from HILA-matched related (n = 192) or unrelated donors (n = 130). Results Of the 221 patients with measurable disease at HCT, 126 (57%) achieved complete (n = 98) or partial (n = 28) remissions. In multivariate analysis, there was a higher probability trend of achieving complete remissions in patients with chronic extensive graft-versus-host disease (GVHD, P = .07). One hundred eight patients (34%) relapsed or progressed. In multivariate analysis, achievement of full donor chimerism was associated with a decreased risk of relapse or progression (P = .002). Grade 2 to 4 acute GVHD had no significant impact on the risk of relapse or progression but was associated with increased risk of nonrelapse mortality and decreased probability of progression-free survival (PFS). Conversely, extensive chronic GVHD was associated with decreased risk of relapse or progression (P = .006) and increased probability of PFS (P = .003). Conclusion New approaches aimed at reducing the incidence of grade 2 to 4 acute GVHD might improve survival after allogeneic HCT after nonmyeloablative conditioning. (c) 2005 by American Society of Clinical Oncology. C1 Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. Univ Washington, Sch Med, Seattle, WA 98195 USA. Childrens Hosp & Reg Med Ctr, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Liege, Dept Hematol, Liege, Belgium. RP Storb, R (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D1-100,POB 19024, Seattle, WA 98109 USA. EM rstorb@fhcrc.org FU NCI NIH HHS [CA15704, CA18029, CA78902, CA92058, P01 CA078902]; NHLBI NIH HHS [HL36444]; NIDDK NIH HHS [DK064715] NR 56 TC 214 Z9 219 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 330 JOHN CARLYLE ST, STE 300, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAR 20 PY 2005 VL 23 IS 9 BP 1993 EP 2003 DI 10.1200/JCO.2005.08.0136 PG 11 WC Oncology SC Oncology GA 911SK UT WOS:000228024800027 PM 15774790 ER PT J AU Huang, WQ Zhao, SJ Ammanamanchi, S Brattain, M Venkatasubbarao, K Freeman, JW AF Huang, WQ Zhao, SJ Ammanamanchi, S Brattain, M Venkatasubbarao, K Freeman, JW TI Trichostatin a induces transforming growth factor ss type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1 center dot NF-Y complex SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID BREAST-CANCER CELLS; HISTONE DEACETYLASE INHIBITOR; TRANSCRIPTION FACTOR; PANCREATIC-CANCER; NF-Y; BETA RECEPTOR; FUNCTIONAL INTERACTION; GENETIC ALTERATIONS; ACTIVATION; EXPRESSION AB Transforming growth factor beta type II receptor (T beta RII) is a tumor suppressor gene that can be transcriptionally silenced by histone deacetylases (HDACs) in cancer cells. In this report, we demonstrated the mechanism by which trichostatin A (TSA), an inhibitor of HDAC, induces the expression of T beta RII in human pancreatic cancer cell lines by modulating the transcriptional components that bind a specific DNA region of the T beta RII promoter. This region of the T beta RII promoter possesses Sp1 and NF-Y binding sites in close proximity ( located at -102 and -83, respectively). Treatment of cells with TSA activates the T beta RII promoter in a time-dependent manner through the recruitment of p300 and PCAF into a Sp1(.)NF-Y(.)HDAC complex that binds this DNA element. The recruitment of p300 and PCAF into the complex is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. Transient overexpression of p300 or PCAF potentiated TSA-induced T beta RII promoter activity. The effect of PCAF was dependent on its histone acetyltransferase activity, whereas that of p300 was independent. Stable transfection of PCAF caused an increase in T beta RII mRNA expression, the association of PCAF with T beta RII promoter, and the acetylation of Sp1. Taken together, these results showed that TSA treatment of pancreatic cancer cells leads to transcriptional activation of the T beta RII promoter through modulation of the components of a Sp1(.)NF-Y(.)p300(.)PCAF(.)HDAC-1 multiprotein complex. Moreover, the interaction of NF-Y with the Sp1-associated complex may further explain why this specific Sp1 site mediates transcriptional responsiveness to TSA. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA. Audie L Murphy Mem Vet Adm Med Ctr, Res & Dev, San Antonio, TX 78229 USA. RP Freeman, JW (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM freemanjw@uthscsa.edu RI Huang, Weiqi/E-4341-2010 FU NCI NIH HHS [CA96122] NR 41 TC 91 Z9 96 U1 0 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 18 PY 2005 VL 280 IS 11 BP 10047 EP 10054 DI 10.1074/jbc.M408680200 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 905HQ UT WOS:000227559600039 PM 15647279 ER PT J AU Ioannou, GN Weiss, NS Kearney, DJ AF Ioannou, GN Weiss, NS Kearney, DJ TI Is Helicobacter pylori seropositivity related to body mass index in the United States? SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID PEPTIC-ULCER DISEASE; INFECTION; ERADICATION; OBESITY; LEPTIN; ADULTS; PREVALENCE; GHRELIN; STRAINS; PLASMA AB Background: Helicobacter pylori infection may decrease serum ghrelin and increase gastric leptin levels, which may, in turn, decrease body mass index. Aim: To determine whether H. pylori seropositivity is associated with body mass index. Methods: Serum H. pylori and cytotoxin-associated gene product A (CagA) antibody levels were measured on 6724 adult participants of the third National Health and Nutrition Examination Survey (1988-91). We evaluated the association between H. pylori/CagA antibody status [both negative (-/-), H. pylori-positive/CagA-negative (+/-), or both positive (+/+)] and body mass index, adjusting for sociodemographic factors. We also investigated whether H. pylori/cytotoxin-associated gene product A antibody status was associated with fasting serum leptin levels. Results: H. pylori/CagA antibody status was not associated with obesity (body mass index >= 30 kg/m(2)) [adjusted odds ratio (OR) 1.2, 95% CI: 0.9-1.6 comparing (+/+) to (-/-) and adjusted OR 1.1, 95% CI: 0.8-1.5 comparing (+/-) to (-/-)], overweight (body mass index 25 to < 30 kg/m(2)) [adjusted OR 1.0, 95% CI: 0.7-1.2 comparing (+/+) to (-/-) and adjusted OR 1.0, 95% CI: 0.8-1.3 comparing (+/-) to (-/-)], or fasting serum leptin level in the USA population. Conclusions: H. pylori seropositivity and CagA antibody status are not associated with body mass index or fasting serum leptin level. C1 VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA USA. Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Seattle VA Med Ctr, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu NR 36 TC 31 Z9 31 U1 0 U2 2 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD MAR 15 PY 2005 VL 21 IS 6 BP 765 EP 772 DI 10.1111/j.1365-2036.2005.02369.x PG 8 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 907LX UT WOS:000227720700015 PM 15771763 ER PT J AU Boyko, EJ Fihn, SD Scholes, D Abraham, L Monsey, B AF Boyko, EJ Fihn, SD Scholes, D Abraham, L Monsey, B TI Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE diabetes mellitus; postmenopause; prospective studies; risk factors; urinary tract infection; women ID MELLITUS; PREVALENCE; DIAGNOSIS; NIDDM AB No prospective data exist on the risk of microbiologically confirmed urinary tract infection (UTI) and asymptomatic bacteriuria (AB) in relation to diabetes mellitus and its characteristics. The authors prospectively (1998-2002) followed 218 diabetic and 799 nondiabetic Washington State women aged 55-75 years for UTI and AB. The baseline examination and two annual follow-up examinations included urine culture, measurement of hemoglobin A1c and postvoid residual bladder volume, and a survey of diabetes and other characteristics. Surveillance for UTI included self-reports confirmed by microbiologic culture and medical record review. UTI incidence per 100 person-years was 12.2 for diabetic women and 6.7 for nondiabetic women (relative risk (RR) = 1.8, 95% confidence interval (CI): 1.2, 2.7). AB incidence per 100 person-years was 6.7 for diabetic women and 3.0 for nondiabetic women (RR = 2.3, 95% CI: 1.3, 3.9). In Cox models adjusted for multiple covariates, the increased UTI risk occurred mainly in women taking insulin (RR = 3.7, 95% CI: 1.8, 7.3) and women with a longer diabetes duration (greater than or equal to10 years; RR = 2.6, 95% CI: 1.3, 5.1) compared with nondiabetic women. No clear linear trend between hemoglobin A1c and UTI or AB risk was seen. Postmenopausal women with diabetes have higher risks of UTI and AB in relation to diabetes duration and severity but not to recent glucose control. C1 VA Peget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Program, Seattle, WA USA. Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA. Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA. RP Boyko, EJ (reprint author), VA Peget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, S-152E,1660 S Columbian Way, Seattle, WA 98108 USA. EM eboyko@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X FU NIDDK NIH HHS [R01 DK 43134] NR 38 TC 69 Z9 82 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD MAR 15 PY 2005 VL 161 IS 6 BP 557 EP 564 DI 10.1093/aje/kwi078 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 903DQ UT WOS:000227406100007 PM 15746472 ER PT J AU Tseng, CL Brimacombe, M Xie, M Rajan, M Wang, HW Kolassa, J Crystal, S Chen, TC Pogach, L Safford, M AF Tseng, CL Brimacombe, M Xie, M Rajan, M Wang, HW Kolassa, J Crystal, S Chen, TC Pogach, L Safford, M TI Seasonal patterns in monthly hemoglobin A(1c) values SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE diabetes mellitus; hemoglobin A; glycosylated; seasons; veterans ID TIME PHYSICAL-ACTIVITY; ACUTE MYOCARDIAL-INFARCTION; CORONARY HEART-DISEASE; QUALITY-OF-CARE; BLOOD-PRESSURE; DIETARY-INTAKE; INSULIN SENSITIVITY; AMBIENT-TEMPERATURE; VETERANS-AFFAIRS; RISK-FACTORS AB The purpose of this study was to investigate seasonal variations in population monthly hemoglobin A(1c) (A1c) values over 2 years (from October 1998 to September 2000) among US diabetic veterans. The study cohort included 285,705 veterans with 856,181 A1c tests. The authors calculated the monthly average A1c values for the overall population and for subpopulations defined by age, sex, race, insulin use, and climate regions. A1c values were higher in winter and lower in summer with a difference of 0.22. The proportion of A1c values greater than 9.0% followed a similar seasonal pattern that varied from 17.3% to 25.3%. Seasonal autoregressive models including trigonometric function terms were fit to the monthly average A1c values. There were significant seasonal effects; the seasonal variation was consistent across different subpopulations. Regions with colder winter temperatures had larger winter-summer contrasts than did those with warmer winter temperatures. The seasonal patterns followed trends similar to those of many physiologic markers, cardiovascular and other diabetes outcomes, and mortality. These findings have implications for health-care service research in quality-of-care assessment, epidemiologic studies investigating population trends and risk factors, and clinical trials or program evaluations of treatments or interventions. C1 Ctr Hlth Care Knowledge Management, Dept Vet Affairs New Jersey Hlth Care Syst, E Orange, NJ USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Prevent Med & Community Hlth, Newark, NJ 07103 USA. Rutgers State Univ, Dept Stat, New Brunswick, NJ 08903 USA. CTC Technol Inc, Short Hills, NJ USA. Rutgers State Univ, Hlth Serv Res Inst Hlth Hlth Care Policy & Aging, New Brunswick, NJ USA. Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA. Birmingham VA Med Ctr, Birmingham, AL USA. RP Tseng, CL (reprint author), E Orange VA Med Ctr, Dept Vet Affairs New Jersey Hlth Care Syst, 385 Tremont Ave,129, E Orange, NJ 07018 USA. EM Tseng@njneuromed.org OI Brimacombe, Michael/0000-0002-3276-9071 NR 73 TC 62 Z9 69 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD MAR 15 PY 2005 VL 161 IS 6 BP 565 EP 574 DI 10.1093/aje/kwi083 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 903DQ UT WOS:000227406100008 PM 15746473 ER PT J AU Birbes, H Luberto, C Hsu, YT Bawab, SEL Hannun, YA Obeid, LM AF Birbes, H Luberto, C Hsu, YT Bawab, SEL Hannun, YA Obeid, LM TI A mitochondrial pool of sphingomyelin is involved in TNF alpha-induced Bax translocation to mitochondria SO BIOCHEMICAL JOURNAL LA English DT Article DE apoptosis; Bax translocation; ceramide; mitochondrion; sphingomyelinase; tumour necrosis factor alpha (TNF alpha) ID CERAMIDE-INDUCED APOPTOSIS; CELL-PERMEABLE CERAMIDE; CYTOCHROME-C; NEUTRAL SPHINGOMYELINASE; FAMILY PROTEINS; ACTIVATION; INHIBITION; PATHWAY; STRESS; DEATH AB We recently showed that targeting bSMase (bacterial sphingomyelinase) specifically to mitochondria caused accumulation of ceramide in mitochondria, and induced cytochrome c release and cell death [Birbes, El Bawab, Hannun and Obeid (2001) FASEB J., 15, 2669-2679]. In the present study, we investigated the role of this mitochondrial pool of ceramide in response to a receptor-mediated event, namely TNF alpha (tumour necrosis factor alpha), and the involvement of this mitochondrial pool of ceramide in Bax translocation to mitochondria, an event that precedes cytochrome c release. Treatment of MCF7 cells with TNF alpha caused an increase in ceramide levels in the mitochondrial fraction which accompanied Bax translocation to mitochondria. Targeting bSMase to mitochondria specifically resulted in Bax translocation to mitochondria, suggesting that the mitochondrial ceramide pool is involved in Bax translocation. Moreover, in a reconstituted cell-free system, treatment of isolated mitochondria with bSMase enhanced Bax association with mitochondrial membranes. Collectively, these results suggest that the generation of ceramide in mitochondria in response to TNF alpha is sufficient to induce Bax translocation to mitochondria and subsequent cytochrome c release and cell death. C1 Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Ralph H Johnson Vet Adm, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. RP Obeid, LM (reprint author), Inst Natl Sci Appl, INSERM, U585, F-69621 Villeurbanne, France. EM obeidl@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NIA NIH HHS [R01 AG016583, AG16583]; NIDDK NIH HHS [DK59340, P01 DK059340]; NINDS NIH HHS [R01 NS040932] NR 38 TC 92 Z9 95 U1 0 U2 1 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0264-6021 J9 BIOCHEM J JI Biochem. J. PD MAR 15 PY 2005 VL 386 BP 445 EP 451 DI 10.1042/BJ20041627 PN 3 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 912SJ UT WOS:000228099500005 PM 15516208 ER PT J AU Sonel, AF Good, CB Mulgund, J Roe, MT Gibler, WB Smith, SC Cohen, MG Pollack, CV Ohman, EM Peterson, ED AF Sonel, AF Good, CB Mulgund, J Roe, MT Gibler, WB Smith, SC Cohen, MG Pollack, CV Ohman, EM Peterson, ED CA CRUSADE Invest TI Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes - Insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA guidelines?) SO CIRCULATION LA English DT Article DE ethnic groups; coronary disease; therapy; myocardial infarction ID ACUTE MYOCARDIAL-INFARCTION; COOPERATIVE CARDIOVASCULAR PROJECT; PLATELET GLYCOPROTEIN IIB/IIIA; OF-VETERANS-AFFAIRS; MEDICARE PATIENTS; ELDERLY-PATIENTS; REVASCULARIZATION PROCEDURES; CARDIAC-CATHETERIZATION; SOCIOECONOMIC-STATUS; NATIONAL REGISTRY AB Background - Black patients with acute myocardial infarction are less likely than whites to receive coronary interventions. It is unknown whether racial disparities exist for other treatments for non-ST-segment elevation acute coronary syndromes (NSTE ACS) and how different treatments affect outcomes. Methods and Results - Using data from 400 US hospitals participating in the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines?) National Quality Improvement Initiative, we identified black and white patients with high-risk NSTE ACS (positive cardiac markers and/or ischemic ST-segment changes). After adjustment for demographics and medical comorbidity, we compared the use of therapies recommended by the American College of Cardiology/American Heart Association guidelines for NSTE ACS and outcomes by race. Our study included 37 813 (87.3%) white and 5504 (12.7%) black patients. Black patients were younger; were more likely to have hypertension, diabetes, heart failure, and renal insufficiency; and were less likely to have insurance coverage or primary cardiology care. Black patients had a similar or higher likelihood than whites of receiving older ACS treatments such as aspirin, beta-blockers, or ACE inhibitors but were significantly less likely to receive newer ACS therapies, including acute glycoprotein IIb/IIIa inhibitors, acute and discharge clopidogrel, and statin therapy at discharge. Blacks were also less likely to receive cardiac catheterization, revascularization procedures, or smoking cessation counseling. Acute risk-adjusted outcomes were similar between black and white patients. Conclusions - Black patients with NSTE ACS were less likely than whites to receive many evidence-based treatments, particularly those that are costly or newer. Longitudinal studies are needed to assess the long-term impact of these treatment disparities on clinical outcomes. C1 Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. Duke Clin Res Inst, Div Cardiol, Durham, NC USA. Univ Cincinnati, Sch Med, Cincinnati, OH USA. Univ N Carolina, Sch Med, Chapel Hill, NC USA. Wayne State Univ, Sch Med, Detroit, MI USA. Penn Hosp, Dept Emergency Med, Philadelphia, PA 19107 USA. RP Sonel, AF (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr Div, 111C-U, Pittsburgh, PA 15240 USA. EM ali.sonel@med.va.gov NR 54 TC 125 Z9 125 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 15 PY 2005 VL 111 IS 10 BP 1225 EP 1232 DI 10.1161/01.CIR.0000157732.03358.64 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 906CB UT WOS:000227617000006 PM 15769762 ER PT J AU Werner, RM Asch, DA Polsky, D AF Werner, RM Asch, DA Polsky, D TI Racial profiling - The unintended consequences of coronary artery bypass graft report cards SO CIRCULATION LA English DT Article DE ethnic groups; revascularization; myocardial infarction ID NEW-YORK-STATE; COMORBIDITY MEASURES; PERFORMANCE REPORTS; HEALTH-CARE; SURGERY; QUALITY; RACE; REVASCULARIZATION; DISPARITIES; INFORMATION AB Background - Although public release of quality information through report cards is intended to improve health care, there may be unintended consequences of report cards, such as physicians avoiding high-risk patients to improve their ratings. If physicians believe that racial and ethnic minorities are at higher risk for poor outcomes, report cards could worsen existing racial and ethnic disparities in health care. Methods and Results - To investigate the impact of New York's CABG report card on racial and ethnic disparities in cardiac care, we estimated differences in the use of CABG, PTCA, and cardiac catheterization between white versus black and Hispanic patients hospitalized for acute myocardial infarction in New York before and after New York's first CABG report card was released, adjusting for patient and hospital characteristics and national changes in racial and ethnic disparities in cardiac care. The racial and ethnic disparity in CABG use significantly increased in New York immediately after New York's CABG report card was released, whereas disparities did not change significantly in the comparison states. There was no differential change in racial and ethnic disparities between New York and the comparison states in the use of cardiac catheterization or PTCA after the CABG report card was released. Over time, this increase in racial and ethnic disparities decreased to levels similar to those before the release of report cards. Conclusions - The release of CABG report cards in New York was associated with a widening of the disparity in CABG use between white versus black and Hispanic patients. C1 Univ Penn, Div Gen Internal Med, Sch Med, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Dept Hlth Care Syst, Wharton Sch, Philadelphia, PA 19104 USA. RP Werner, RM (reprint author), Univ Penn, Div Gen Internal Med, Sch Med, 1208 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rwerner@wharton.upenn.edu FU AHRQ HHS [1-F32-HS-14644-01, 2-T32-HS-00009] NR 32 TC 138 Z9 139 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 15 PY 2005 VL 111 IS 10 BP 1257 EP 1263 DI 10.1116/01.CIR.000157729.59754.09 PG 7 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 906CB UT WOS:000227617000010 PM 15769766 ER PT J AU Smith, GL Shlipak, MG Havranek, EP Masoudi, FA McClellan, WM Foody, JM Rathore, SS Krumholz, HM AF Smith, GL Shlipak, MG Havranek, EP Masoudi, FA McClellan, WM Foody, JM Rathore, SS Krumholz, HM TI Race and renal impairment in heart failure - Mortality in blacks versus whites SO CIRCULATION LA English DT Article DE ethnic groups; kidney; heart failure; mortality ID LEFT-VENTRICULAR DYSFUNCTION; CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; RENIN-ANGIOTENSIN SYSTEM; RACIAL-DIFFERENCES; AFRICAN-AMERICANS; UNITED-STATES; RISK-FACTOR; CARDIOVASCULAR-DISEASE; CONTEMPORARY TREATMENT AB Background - Renal impairment is an emerging prognostic indicator in heart failure (HF) patients. Despite known racial differences in the progression of both HF and renal disease, it is unclear whether the prognosis for renal impairment in HF patients differs by race. We sought to determine in HF patients the 1-year mortality risks associated with elevated creatinine and impaired estimated glomerular filtration rate (eGFR) and to quantify racial differences in mortality. Methods and Results - We retrospectively evaluated the National Heart Care Project nationally representative cohort of 53 640 Medicare patients hospitalized with HF. Among 5669 black patients, mean creatinine was 1.6 +/- 0.9 mg/dL, and 54% had an eGFR <= 60, compared with creatinine 1.5 +/- 0.7 mg/dL and 68% eGFR <= 60 in 47 971 white patients. Higher creatinine predicted increased mortality risk, although the magnitude of risk differed by race (interaction P = 0.0001). Every increase in creatinine of 0.5 mg/dL was associated with a > 10% increased risk in adjusted mortality for blacks, compared with > 15% increased risk in whites (interaction P = 0.0001), with the most striking racial disparities at the highest levels of renal impairment. Depressed eGFR showed similar racial differences (interaction P = 0.0001). Conclusions - Impaired renal function predicts increased mortality in elderly HF patients, although risks are more pronounced in whites. Distinct morbidity and mortality burdens in black versus white patients underscore the importance of improving patient risk-stratification, defining optimal therapies, and exploring physiological underpinnings of racial differences. C1 Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, Sect Cardiovasc Med,Dept Int Med, New Haven, CT 06520 USA. San Francisco VA Med Ctr, Gen Internal Med Sect, Med Serv, San Francisco, CA USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Denver Hlth Med Ctr, Div Cardiol, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Div Geriatr Med, Denver, CO 80262 USA. Colorado Fdn Med Care, Aurora, CO USA. Emory Univ, Sch Med, Div Renal, Dept Med, Atlanta, GA USA. Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA. RP Krumholz, HM (reprint author), Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, Sect Cardiovasc Med,Dept Int Med, Sterling Hall Med,I Wing,Suite 456,333 Cedar St, New Haven, CT 06520 USA. EM harlan.krumholz@yale.edu FU NIA NIH HHS [K08-AG01011, K08-AG20623-01]; NIGMS NIH HHS [GM-07205] NR 50 TC 50 Z9 53 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 15 PY 2005 VL 111 IS 10 BP 1270 EP 1277 DI 10.1161/01.CIR.0000158131.7881.D5 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 906CB UT WOS:000227617000012 PM 15769768 ER PT J AU Thompson, CR Iyer, SS Melrose, N VanOosten, R Johnson, K Pitson, SM Obeid, LM Kusner, DJ AF Thompson, CR Iyer, SS Melrose, N VanOosten, R Johnson, K Pitson, SM Obeid, LM Kusner, DJ TI Sphingosine kinase 1 (SK1) is recruited to nascent phagosomes in human macrophages: Inhibition of SK1 translocation by Mycobacterium tuberculosis SO JOURNAL OF IMMUNOLOGY LA English DT Article ID DEPENDENT SIGNAL-TRANSDUCTION; INTRACELLULAR CA2+ STORES; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; J774 MACROPHAGES; LYSOSOME FUSION; SPHINGOSINE-1-PHOSPHATE RECEPTORS; MATURATION ARREST; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE AB Mycobacterium tuberculosis (M.tb) is a leading cause of global infectious mortality. The pathogenesis of tuberculosis involves inhibition of phagosome maturation, leading to survival of M.tb within human macrophages. A key determinant is M.tb-induced inhibition of macrophage sphingosine kinase (SK) activity, which normally induces Ca2+ signaling and phagosome maturation. Our objective was to determine the spatial localization of SK during phagocytosis and its inhibition by M.tb. Stimulation of SK activity by killed M.tb, live Staphylococcus aureus, or latex beads was associated with translocation of cytosolic SKI to the phagosome membrane. In contrast, SK1 did not associate with phagosomes containing live M.tb. To characterize the mechanism of phagosomal translocation, live cell confocal microscopy was used to compare the localization of wild-type SKI, catalytically inactive SK1(G82D), and a phosphorylation-defective mutant that does not undergo plasma membrane translocation (SK1(S225A)). The magnitude and kinetics of translocation of SK1(G82D) and SK1(S225A) to latex bead phagosomes were indistinguishable from those of wild-type SKI, indicating that novel determinants regulate the association of SKI with nascent phagosomes. These data are consistent with a model in which M.tb inhibits both the activation and phagosomal translocation of SK1 to block the localized Ca2+ transients required for phagosome maturation. The Journal of Immunology, 2005, 174: 3551-3561. C1 Univ Iowa, Carver Coll Med, Dept Internal Med, Inflammat Program,Div Infect Dis, Coralville, IA 52241 USA. Univ Iowa, Carver Coll Med, Dept Physiol & Biophys, Coralville, IA 52241 USA. Univ Iowa, Carver Coll Med, Grad Program Immunol, Coralville, IA 52241 USA. Univ Iowa, Carver Coll Med, Grad Program Mol Biol, Coralville, IA 52241 USA. Vet Affairs Med Ctr, Iowa City, IA 52242 USA. Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Mol Biol, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. Inst Med & Vet Sci, Div Human Immunol, Hanson Inst, Adelaide, SA 5000, Australia. RP Kusner, DJ (reprint author), Univ Iowa, Carver Coll Med, Dept Internal Med, Inflammat Program,Div Infect Dis, 2501 Crosspk Rd,D156-MTF, Coralville, IA 52241 USA. EM david-kusner@uiowa.edu OI obeid, lina/0000-0002-0734-0847 FU NIAID NIH HHS [R01 AI055916]; NIGMS NIH HHS [R01 GM062887, R01 GM62302] NR 54 TC 60 Z9 67 U1 0 U2 5 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD MAR 15 PY 2005 VL 174 IS 6 BP 3551 EP 3561 PG 11 WC Immunology SC Immunology GA 904PT UT WOS:000227510900054 PM 15749892 ER PT J AU Dracheva, S McGurk, SR Haroutunian, V AF Dracheva, S McGurk, SR Haroutunian, V TI MRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE AMPA receptors; AMPA receptor binding proteins; mRNA expression; real-time PCR; schizophrenia; dorsolateral prefrontal cortex; occipital cortex ID IONOTROPIC GLUTAMATE RECEPTORS; SYNAPSE-ASSOCIATED PROTEIN-97; DORSOLATERAL PREFRONTAL CORTEX; DOMAIN-CONTAINING PROTEIN; SUBUNIT EXPRESSION; MOLECULAR BEACONS; IMMUNOCYTOCHEMICAL LOCALIZATION; DIFFERENTIAL PALMITOYLATION; NEUROPSYCHIATRIC DISORDERS; INTERACTING PROTEIN AB L-alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors (AMPARs) mediate the majority of the fast excitatory transmission in the CNS. To determine whether gene expression of AMPARs and/or AMPAR binding proteins, which control response/sensitivity of AMPAR-bearing neurons to glutamate, are altered in schizophrenia, mRNA expression and abundance of AMPAR subunits (GluR1-4) and several AMPAR binding proteins (SAP97, PICK1, GRIP, ABP) were measured in the dorsolateral prefrontal cortex (DLPFC) and the occipital cortex of elderly schizophrenia patients (n = 36) and matched normal controls (n - 26) by quantitative real-time PCR. The mRNA expression of GluR1, GluR4, and GRIP in the DLPFC and expression of the GluR4, GRIP, and ABP in the occipital cortex were significantly elevated in schizophrenics. GluR1 and ABP mRNA expression in the occipital cortex and GluR2, GluR3, SAP97, and PICK1 expression in either cortical area were not significantly altered. The data also demonstrated significant differences in the abundances of mRNAs encoding GluR1-4 subunits (GluR2 > GluR3 > GluR1 > GluR4) and of AMPAR binding proteins (SAP97 > PICK1 > GRIP > ABP) in both diagnostic groups. GluR2 (58-64%) and GluR3 (24-29%) were the major components of the AMPAR mRNA in both cortical areas, implying that the major AMPAR complexes in the human cortex are probably those containing GluR2 and GluR3 subunits. Small but significant differences in the amounts of GluR2, GluR3, and GRIP mRNAs were detected between the two cortical areas: more GluR3 and GRIP but less GluR2 were detected in the DLPFC than in the occipital cortex. (C) 2005 Wiley-Liss, Inc. C1 Bronx Vet Adm Med Ctr, Bronx, NY 10468 USA. Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. RP Haroutunian, V (reprint author), Bronx Vet Adm Med Ctr, 3F-02,1300 W Kingsbridge Rd, Bronx, NY 10468 USA. EM vahram.haroutunian@mssm.edu FU NIMH NIH HHS [MH45212, R01-MH064673] NR 85 TC 59 Z9 61 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0360-4012 J9 J NEUROSCI RES JI J. Neurosci. Res. PD MAR 15 PY 2005 VL 79 IS 6 BP 868 EP 878 DI 10.1002/jnr.20423 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 902NV UT WOS:000227364700015 PM 15696539 ER PT J AU Crowley-Matoka, M Switzer, G AF Crowley-Matoka, M Switzer, G TI Nondirected living donation: A survey of current trends and practices SO TRANSPLANTATION LA English DT Article DE organ procurement; preservation; donation; organ banking; procurement ID ALTRUISTIC STRANGERS; TRANSPLANT CENTERS; KIDNEY DONATION; DONORS; ATTITUDES; FRIENDS AB The use of living donors in general is increasing, and there is evidence of increasing willingness among transplant centers to consider nondirected living donation (NDLD) as well. Yet few systematic data are available on the number of centers performing NDLD and the degree to which current policies and practices reflect existing guideline recommendations. We conducted a telephone survey of the 25 highest volume transplant centers and 25 highest volume organ procurement organizations (OPOs) to describe their NDLD-related policies and experiences. Survey responses revealed that inquiries about NDLD from interested potential donors are common, likely to increase, and generally not formally monitored. More than half of transplant centers surveyed currently perform or are willing to perform NDLD (14/25), and although only three OPOs currently facilitate NDLD, the majority of the remaining organizations reported that an NDLD policy was in development. Among those organizations that did facilitate NDLD, the majority applied current living-donor guidelines and practices to NDLDs. Most transplant centers performing NDLD distributed these donations to patients from their own waiting list by using United Network for Organ Sharing criteria. This preliminary description of current NDLD experiences suggests that although NDLD is growing, the policies and practices governing it are being developed on an ad hoc basis at the level of individual organizations. Additional research is needed to characterize the full range of NDLD activity at both higher and lower volume organizations, and to explore a broader range of questions about current NDLD policy and practice in the United States. C1 Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Dept Anthropol, Pittsburgh, PA USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. Vet Affairs Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Crowley-Matoka, M (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr C,151-C, Pittsburgh, PA 15240 USA. EM mcm29@pitt.edu NR 17 TC 14 Z9 14 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD MAR 15 PY 2005 VL 79 IS 5 BP 515 EP 519 DI 10.1097/01.TP.000015501.39936.50 PG 5 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA 905OZ UT WOS:000227580000002 PM 15753839 ER PT J AU Quinn, J Kulhanek, D Nowlin, J Jones, R Pratico, D Rokach, J Stackman, R AF Quinn, J Kulhanek, D Nowlin, J Jones, R Pratico, D Rokach, J Stackman, R TI Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: Implications for clinical trials SO BRAIN RESEARCH LA English DT Article DE Alzheimer's disease; beta amyloid; melatonin ID ALZHEIMERS-DISEASE; NEUROBLASTOMA-CELLS; ANIMAL-MODEL; ANTIOXIDANT; STRESS; INFLAMMATION; PATHOLOGY; PROTECTS; CORTEX; ACID AB Melatonin has been proposed as a treatment for Alzheimer's disease based on the demonstration of antioxidant and "anti-amyloid' effects in vitro and in vivo. Chronic melatonin therapy in old, amyloid plaque-bearing transgenic mice was studied. Tg2576 mice started melatonin treatment at 14 months of age. After 4 months of treatment, there were no differences between untreated and melatonin-treated mice in cortical levels of soluble, formic acid extracted, or histologically detectable beta amyloid (A), nor in brain levels of lipid peroxidation product (total 8,12-isoprostane F-2 alpha-VI), despite marked elevations in plasma melatonin. We conclude that melatonin fails to produce antiamyloid or antioxidant effects when initiated after the age of amyloid plaque deposition. These findings diminish the possibility that melatonin will be useful for the treatment of established Alzheimer's disease. (c) 2005 Elsevier B.V. All rights reserved. C1 Portland Vet Affairs Med Ctr, Dept Neurol, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. Univ Penn, Ctr Expt Therapeut, Dept Pharmacol, Philadelphia, PA 19104 USA. Florida Inst Technol, Melbourne, FL 32901 USA. Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. RP Quinn, J (reprint author), Portland Vet Affairs Med Ctr, Dept Neurol, P3 R&D,US Vet Hosp Rd, Portland, OR 97239 USA. EM quinnj@ohsu.edu OI Stackman Jr, Robert/0000-0002-5950-046X; Rokach, Joshu/0000-0003-1814-7505 FU NCCIH NIH HHS [AT00066] NR 17 TC 49 Z9 50 U1 2 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 J9 BRAIN RES JI Brain Res. PD MAR 10 PY 2005 VL 1037 IS 1-2 BP 209 EP 213 DI 10.1016/j.brainres.2005.01.023 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 914TT UT WOS:000228251400027 PM 15777772 ER PT J AU Werner, RM Asch, DA AF Werner, RM Asch, DA TI The unintended consequences of publicly reporting quality information SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID NEW-YORK-STATE; BYPASS GRAFT-SURGERY; CARDIAC-SURGERY; OF-CARE; MEDICARE BENEFICIARIES; IMPROVEMENT EFFORTS; PERFORMANCE REPORTS; HEALTH-CARE; HOSPITAL PERFORMANCE; MORTALITY HOSPITALS AB Health care report cards publicly report information about physician, hospital, and health plan quality in an attempt to improve that quality. Reporting quality information publicly is presumed to motivate quality improvement through 2 main mechanisms. First, public quality information allows patients, referring physicians, and health care purchasers to preferentially select high-quality physicians. Second, public report cards may motivate physicians to compete on quality and, by providing feedback and by identifying areas for quality improvement initiatives, help physicians to do so. Despite these plausible mechanisms of quality improvement, the value of publicly reporting quality information is largely undemonstrated and public reporting may have unintended and negative consequences on health care. These unintended consequences include causing physicians to avoid sick patients in an attempt to improve their quality ranking, encouraging physicians to achieve "target rates" for health care interventions even when it may be inappropriate among some patients, and discounting patient preferences and clinical judgment. Public reporting of quality information promotes a spirit of openness that may be valuable for enhancing trust of the health professions, but its ability to improve health remains undemonstrated, and public reporting may inadvertently reduce, rather than improve, quality. Given these limitations, it may be necessary to reassess the role of public quality reporting in quality improvement. C1 Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equit Res & Promot, Philadelphia, PA 19104 USA. RP Werner, RM (reprint author), Univ Penn, Div Gen Internal Med, 1208 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rwerner@wharton.upenn.edu FU AHRQ HHS [2-T32-HS-00009, F32-HS-14644-01] NR 61 TC 322 Z9 326 U1 1 U2 14 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 9 PY 2005 VL 293 IS 10 BP 1239 EP 1244 DI 10.1001/jama.293.10.1239 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 904LB UT WOS:000227498400024 PM 15755946 ER PT J AU Deschamps, AM Yarbrough, WM Squires, CE Allen, RA McClister, DM Dowdy, KB McLean, JE Mingoia, JT Sample, JA Mukherjee, R Spinale, FG AF Deschamps, AM Yarbrough, WM Squires, CE Allen, RA McClister, DM Dowdy, KB McLean, JE Mingoia, JT Sample, JA Mukherjee, R Spinale, FG TI Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion - Relation to interstitial membrane type-1 matrix metalloproteinase activity SO CIRCULATION LA English DT Article DE ischemia; metalloproteinases; myocytes; remodeling; reperfusion ID ACUTE MYOCARDIAL-INFARCTION; TISSUE INHIBITOR; CELL-SURFACE; GELATINASE-A; ACTIVATION; MT1-MMP; EXPRESSION; COLLAGENASE; ENDOCYTOSIS; MECHANISMS AB Background - The matrix metalloproteinases ( MMPs) contribute to regional remodeling after prolonged periods of ischemia and reperfusion (I/ R), but specific MMP types activated during this process remain poorly understood. A novel class, the membrane-type MMPs (MT- MMPs), has been identified in the myocardium, but activity of these MMP types has not been assessed in vivo, particularly during I/R. Methods and Results - Pigs ( 30 kg, n = 8) were instrumented with microdialysis catheters to measure MT1-MMP activity in both ischemic and nonischemic (remote) myocardium. A validated MT1-MMP fluorogenic substrate was infused through the microdialysis system, and changes in fluorescence were reflective of MT1-MMP activity at steady state, during ischemia (90 minutes), and during reperfusion (120 minutes). At peak ischemia, MT1-MMP activity was increased by > 40 % in the ischemic region, with no change in the remote region, which persisted with reperfusion (P < 0.05). After I/R, MT1-MMP abundance was increased by > 50 % (P < 0.05). Differential centrifugation revealed that the endosomal fraction (which contains subcellular organelles) within the ischemic myocardium was associated with a > 135 % increase in MT1-MMP (P < 0.05). Furthermore, in an isolated left ventricular myocyte model of I/ R, hypoxia ( simulated ischemia) induced a > 70 % increase in MT1-MMP abundance in myocytes, and confocal microscopy revealed MT1-MMP internalization during this time period and reemergence to the membrane with reperfusion. Conclusions - These unique results demonstrate that a specific MMP type, MT1-MMP, is increased in abundance and activity with I/R and is likely attributed, at least in part, to changes in intracellular trafficking. C1 Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29403 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Spinale, FG (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Room 625,Strom Thurmond Res Bldg,114 Doughty St, Charleston, SC 29403 USA. EM wilburnm@musc.edi OI Deschamps, Anne/0000-0001-7415-1408 FU NHLBI NIH HHS [HL-97012, HL-07260, HL59165, P01-HL-48788, HL-45024] NR 45 TC 48 Z9 50 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD MAR 8 PY 2005 VL 111 IS 9 BP 1166 EP 1174 DI 10.1161/01.CIR.0000157149.71297.3A PG 9 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 904BH UT WOS:000227469600013 PM 15723986 ER PT J AU Birdsall, HH Porter, WJ Trial, JA Rossen, RD AF Birdsall, HH Porter, WJ Trial, JA Rossen, RD TI Generation of regulatory cells by 110 kD fibronectin fragment SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2005 Meeting/35th International Congress of Physiological Sciences CY MAR 31-APR 06, 2005 CL San Diego, CA SP Amer Assoc Anatomists, Amer Assoc Immunologists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Invest Pathol, Amer Soc Nutr Sci, Amer Soc Pharmacol & Exptl Therapeut, Int Union Physiol Sci C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 7 PY 2005 VL 19 IS 5 SU S BP A1414 EP A1414 PN 2 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 905ZS UT WOS:000227610903061 ER PT J AU Jones, RE Moes, N Zwickey, H Bourdette, D Cunningham, C Oken, B AF Jones, RE Moes, N Zwickey, H Bourdette, D Cunningham, C Oken, B TI Conditioned therapeutic response in EAE SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2005 Meeting/35th International Congress of Physiological Sciences CY MAR 31-APR 06, 2005 CL San Diego, CA SP Amer Assoc Anatomists, Amer Assoc Immunologists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Invest Pathol, Amer Soc Nutr Sci, Amer Soc Pharmacol & Exptl Therapeut, Int Union Physiol Sci C1 Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Portland, OR 97239 USA. Natl Coll Naturopath Med, Portland, OR 97201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 7 PY 2005 VL 19 IS 5 SU S BP A1441 EP A1442 PN 2 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 905ZS UT WOS:000227610903192 ER PT J AU Link, JM Rich, C Vandenbark, AA AF Link, JM Rich, C Vandenbark, AA TI RTL effects on myelin specific T cells in vivo: relationship between myelin-specific T cells in peripheral blood and EAE SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2005 Meeting/35th International Congress of Physiological Sciences CY MAR 31-APR 06, 2005 CL San Diego, CA SP Amer Assoc Anatomists, Amer Assoc Immunologists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Invest Pathol, Amer Soc Nutr Sci, Amer Soc Pharmacol & Exptl Therapeut, Int Union Physiol Sci C1 Portland Vet Affairs Med Ctr, R&D 31, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 7 PY 2005 VL 19 IS 5 SU S BP A1442 EP A1443 PN 2 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 905ZS UT WOS:000227610903197 ER PT J AU Rossen, RD Trial, JA Rubio, JA Siwak, EB Hamill, RI Rodriguez-Barradas, MC Breaux, K Birdsall, HH DeBakey, ME AF Rossen, RD Trial, JA Rubio, JA Siwak, EB Hamill, RI Rodriguez-Barradas, MC Breaux, K Birdsall, HH DeBakey, ME TI Predicting susceptibility to secondary infection in HIV-1 infected people SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2005 Meeting/35th International Congress of Physiological Sciences CY MAR 31-APR 06, 2005 CL San Diego, CA SP Amer Assoc Anatomists, Amer Assoc Immunologists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Invest Pathol, Amer Soc Nutr Sci, Amer Soc Pharmacol & Exptl Therapeut, Int Union Physiol Sci C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 7 PY 2005 VL 19 IS 5 SU S BP A1436 EP A1436 PN 2 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 905ZS UT WOS:000227610903166 ER PT J AU Schutzer, WE Reed, JF Mader, SL AF Schutzer, WE Reed, JF Mader, SL TI Decline in caveolin-1 expression and scaffolding of G protein receptor kinase-2 with age in Fischer 344 aortic vascular smooth muscle SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2005 Meeting/35th International Congress of Physiological Sciences CY MAR 31-APR 06, 2005 CL San Diego, CA SP Amer Assoc Anatomists, Amer Assoc Immunologists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Invest Pathol, Amer Soc Nutr Sci, Amer Soc Pharmacol & Exptl Therapeut, Int Union Physiol Sci C1 Portland VA Med Ctr, Res Serv, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 7 PY 2005 VL 19 IS 5 SU S BP A1301 EP A1301 PN 2 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 905ZS UT WOS:000227610902198 ER PT J AU Shelburne, SA Visnegarwala, F Darcourt, J Graviss, EA Giordano, TP White, AC Hamill, RJ AF Shelburne, SA Visnegarwala, F Darcourt, J Graviss, EA Giordano, TP White, AC Hamill, RJ TI Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy SO AIDS LA English DT Article DE HIV; opportunistic infections; HAART; immune reconstitution inflammatory syndrome; incidence; risk factors ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HIV-INFECTED PATIENTS; RESTORATION DISEASE; CRYPTOCOCCUS-NEOFORMANS; PROTEASE-INHIBITOR; UNITED-STATES; TUBERCULOSIS; PATIENT; AIDS; INITIATION AB Background: There is little systematic information regarding the immune reconstitution inflammatory syndrome (IRIS). Objective: To determine the incidence, risk factors, and long-term outcome of IRIS in HIV-infected patients receiving highly active antiretroviral therapy (HAART) who were coinfected with one of three common opportunistic pathogens. Design: A retrospective cohort identified through a city-wide prospective surveillance program. Methods: A retrospective chart review was performed for 180 HIV-infected patients who received HAART and were coinfected with Mycobacterium tuberculosis, Mycobacterium avium complex, or Cryptococcus neoformans between 1997 and 2000. Medical records were reviewed for baseline demographics, receipt and type of HAART, response to antiretroviral therapy, development of IRIS, and long-term outcome. Results: In this cohort, 31.7% of patients who received HAART developed IRIS. Patients with IRIS were more likely to have initiated HAART nearer to the time of diagnosis of their opportunistic infection (P < 0.001), to have been antiretroviral naive at time of diagnosis of their opportunistic infection (P < 0.001), and to have a more rapid initial fall in HIV-1 RNA level in response to HAART (P < 0.001). Conclusions: IRIS is common among HIV-infected persons coinfected with M. tuberculosis, M. avium complex, or C. neoformans. Antiretroviral drug-naive patients who start HAART in close proximity to the diagnosis of an opportunistic infection and have a rapid decline in HIV-1 RNA level should be monitored for development of this disorder. (c) 2005 Lippincott Williams & Wilkins. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Infect Dis Sect, Houston, TX USA. Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. Michael E De Bakey VA Med Ctr, Houston, TX USA. RP Hamill, RJ (reprint author), Vet Affairs Med Ctr, Sect Infect Dis 111G, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM richard.hamill@med.va.gov OI White, A Clinton/0000-0002-9668-4632 FU NIAID NIH HHS [T32-AI055413]; NIMH NIH HHS [K23-MH067505] NR 35 TC 354 Z9 370 U1 0 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD MAR 4 PY 2005 VL 19 IS 4 BP 399 EP 406 DI 10.1097/01.aids.0000161769.06158.8a PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 912XO UT WOS:000228113400005 PM 15750393 ER PT J AU Gray, M Zhou, HZ Swanson, R Simonis, U Ma, XK Cecchini, G AF Gray, M Zhou, HZ Swanson, R Simonis, U Ma, XK Cecchini, G TI Mitochondrial respiratory complex I function contributes to cardioprotection caused by inhibition or disruption of PARP-1 SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2005 Meeting/35th International Congress of Physiological Sciences CY MAR 31-APR 06, 2005 CL San Diego, CA SP Amer Assoc Anatomists, Amer Assoc Immunol, Amer Phtsiol Soc & Int Union Physiol Sci, Amer Soc Biochem & Mole Biol, Amer Soc Investigat Pathol, Amer Soc Nutr Sci, Amer Soc Pharmacol & Exptl Therapeut C1 Univ Calif San Francisco, Div Cardiol, San Francisco Gen Hosp, San Francisco, CA 94110 USA. Univ Calif San Francisco, San Francisco VA Med Ctr, Neurol Serv, San Francisco, CA 94121 USA. San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA 94132 USA. Univ Calif San Francisco, Div Mol Biol, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 4 PY 2005 VL 19 IS 4 SU S BP A259 EP A260 PN 1 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 905ZQ UT WOS:000227610701569 ER PT J AU Hsu, HC Yang, PA Wu, Q Zhou, JL Wu, YL Freeman, BA Mountz, JD AF Hsu, HC Yang, PA Wu, Q Zhou, JL Wu, YL Freeman, BA Mountz, JD TI Nitrotyrosine-modified proteins as target autoantigens for lupus nephritis in BXD2 mice SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2005 Meeting/35th International Congress of Physiological Sciences CY MAR 31-APR 06, 2005 CL San Diego, CA SP Amer Assoc Anatomists, Amer Assoc Immunol, Amer Phtsiol Soc & Int Union Physiol Sci, Amer Soc Biochem & Mole Biol, Amer Soc Investigat Pathol, Amer Soc Nutr Sci, Amer Soc Pharmacol & Exptl Therapeut C1 Univ Alabama, Ctr Free Rad Biol, Birmingham, AL 35294 USA. Birmingham VAMC, Birmingham, AL 35233 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 4 PY 2005 VL 19 IS 4 SU S BP A884 EP A884 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 905ZQ UT WOS:000227610706257 ER PT J AU Jones, RE Kitzerow, N Moes, N Estrada, M Bourdette, D Whitham, R Vandenbark, A Offner, H AF Jones, RE Kitzerow, N Moes, N Estrada, M Bourdette, D Whitham, R Vandenbark, A Offner, H TI Bone marrow-derived CNS APC and EAE susceptibility influenced by gender SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2005 Meeting/35th International Congress of Physiological Sciences CY MAR 31-APR 06, 2005 CL San Diego, CA SP Amer Assoc Anatomists, Amer Assoc Immunol, Amer Phtsiol Soc & Int Union Physiol Sci, Amer Soc Biochem & Mole Biol, Amer Soc Investigat Pathol, Amer Soc Nutr Sci, Amer Soc Pharmacol & Exptl Therapeut C1 Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 4 PY 2005 VL 19 IS 4 SU S BP A349 EP A349 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 905ZQ UT WOS:000227610702331 ER PT J AU Lathers, DMR Cigal, ML Sutton, KK Young, MR AF Lathers, DMR Cigal, ML Sutton, KK Young, MR TI Squamous cell carcinoma-derived factors selectively recruit T-cell subpopulations SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2005 Meeting/35th International Congress of Physiological Sciences CY MAR 31-APR 06, 2005 CL San Diego, CA SP Amer Assoc Anatomists, Amer Assoc Immunol, Amer Phtsiol Soc & Int Union Physiol Sci, Amer Soc Biochem & Mole Biol, Amer Soc Investigat Pathol, Amer Soc Nutr Sci, Amer Soc Pharmacol & Exptl Therapeut C1 Med Univ S Carolina, Ralph H Johnson VAMC, Charleston, SC 29401 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 4 PY 2005 VL 19 IS 4 SU S BP A39 EP A39 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 905ZQ UT WOS:000227610700184 ER PT J AU Montfort, MJ Bouwer, HGA Wagner, CR Hinrichs, DJ AF Montfort, MJ Bouwer, HGA Wagner, CR Hinrichs, DJ TI CD4+ CD25+ regulatory T cells control the upper limit of peptide-specific CD8+ T-cell expansion following secondary L-monocytogenes infection SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2005 Meeting/35th International Congress of Physiological Sciences CY MAR 31-APR 06, 2005 CL San Diego, CA SP Amer Assoc Anatomists, Amer Assoc Immunol, Amer Phtsiol Soc & Int Union Physiol Sci, Amer Soc Biochem & Mole Biol, Amer Soc Investigat Pathol, Amer Soc Nutr Sci, Amer Soc Pharmacol & Exptl Therapeut C1 Oregon Hlth Sci Univ, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. Earle A Chiles Res Inst, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 4 PY 2005 VL 19 IS 4 SU S BP A395 EP A396 PN 1 PG 2 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 905ZQ UT WOS:000227610702547 ER PT J AU Nelson, AG Million, M Chaudhuri, G Tache, Y AF Nelson, AG Million, M Chaudhuri, G Tache, Y TI Effects of estrogen on stress related alterations in colonic motor function in rats SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2005 Meeting/35th International Congress of Physiological Sciences CY MAR 31-APR 06, 2005 CL San Diego, CA SP Amer Assoc Anatomists, Amer Assoc Immunol, Amer Phtsiol Soc & Int Union Physiol Sci, Amer Soc Biochem & Mole Biol, Amer Soc Investigat Pathol, Amer Soc Nutr Sci, Amer Soc Pharmacol & Exptl Therapeut C1 Univ Calif Los Angeles, Los Angeles, CA 90095 USA. VA Greater LA Healthcare, Ctr Neurovisceral Sci & Womens Hlth, CURE, Digest Dis Res Ctr, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 4 PY 2005 VL 19 IS 4 SU S BP A98 EP A98 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 905ZQ UT WOS:000227610700450 ER PT J AU Orson, FM Kinsey, BM Densmore, CL Mbawuike, IN Wyde, PR AF Orson, FM Kinsey, BM Densmore, CL Mbawuike, IN Wyde, PR TI Protection against fatal influenza infection by aerosol genetic immunization in mice SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2005 Meeting/35th International Congress of Physiological Sciences CY MAR 31-APR 06, 2005 CL San Diego, CA SP Amer Assoc Anatomists, Amer Assoc Immunologists, Amer Physiol Soc, Amer Soc Biochem & Mol Biol, Amer Soc Investigat Pathol, Amer Soc Nutr Sci, Amer Soc Pharmacol & Expt Therapeut, Int Union Physiol Sci C1 Baylor Coll Med, VA Med Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 4 PY 2005 VL 19 IS 4 SU S BP A896 EP A896 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 905ZQ UT WOS:000227610706310 ER PT J AU Wilhelm, CJ Johnson, RA Eshleman, AJ Janowsky, A AF Wilhelm, CJ Johnson, RA Eshleman, AJ Janowsky, A TI Methamphetamine: one curious transporter substrate SO FASEB JOURNAL LA English DT Meeting Abstract CT Experimental Biology 2005 Meeting/35th International Congress of Physiological Sciences CY MAR 31-APR 06, 2005 CL San Diego, CA SP Amer Assoc Anatomists, Amer Assoc Immunol, Amer Phtsiol Soc & Int Union Physiol Sci, Amer Soc Biochem & Mole Biol, Amer Soc Investigat Pathol, Amer Soc Nutr Sci, Amer Soc Pharmacol & Exptl Therapeut C1 Oregon Hlth Sci Univ, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD MAR 4 PY 2005 VL 19 IS 4 SU S BP A513 EP A513 PN 1 PG 1 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 905ZQ UT WOS:000227610703448 ER PT J AU Nagy, AK Kane, DJ Tran, CM Farley, RA Faller, LD AF Nagy, AK Kane, DJ Tran, CM Farley, RA Faller, LD TI Evidence calcium pump binds magnesium before inorganic phosphate SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID SARCOPLASMIC-RETICULUM ATPASE; ADENOSINE-TRIPHOSPHATASE; O-18 EXCHANGE; INDEPENDENT PHOSPHORYLATION; CONFORMATIONAL CHANGE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; MECHANISM; ENZYME; ION AB Calcium pump-catalyzed O-18 exchange between inorganic phosphate and water was studied to test the hypothesis that all P-type pumps bind Mg2+ before P-i and validate utilization of the rate equation for ordered binding to interpret differences between site-directed mutants and wild-type enzyme. The results were remarkably similar to those obtained earlier with sodium pump ( Kasho, V. N., Stengelin, M., Smirnova, I. N., and Faller, L. D. ( 1997) Biochemistry 36, 8045 - 8052). The equation for ordered binding of Mg2+ before P-i fit the data best with only a slight chance ( 0.6%) of P-i binding to apoenzyme. Therefore, P-i is the substrate, and Mg2+ is an obligatory cofactor. The intrinsic Mg2+ dissociation constant from metalloenzyme ( K-M = 3.5 +/- 0.3 mM) was experimentally indistinguishable from the sodium pump value. However, the half-maximal concentration for P-i binding to metalloenzyme ( K'(P) = 6.3 +/- 0.6 mM) was significantly higher ( similar to 6-fold), and the probability of calcium pump forming phosphoenzyme from bound P-i ( P-c = 0.04 +/- 0.03) was significantly lower ( similar to 6-fold) than for the sodium pump. From estimates of the rate constants for phosphorylation and dephosphorylation, the calcium pump appears to catalyze phosphoryl group transfer less efficiently than the sodium pump. Ordered binding of Mg2+ before P-i implies that both calcium pump and sodium pump form a ternary enzyme(.)metal(.)phosphate complex, consistent with molecular structures of other haloacid dehalogenase superfamily members that were crystallized with Mg2+ and phosphate, or a phosphate analogue, bound. C1 Vet Adm Greater Los Angeles Healthcare Syst, CURE, Los Angeles, CA 90073 USA. Univ So Calif, Sch Med, Dept Physiol & Biochem, Los Angeles, CA 90033 USA. Univ So Calif, Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA. Univ Calif Los Angeles, Sch Med, CURE, Digest Dis Res Ctr,Dept Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA. RP Vet Adm Greater Los Angeles Healthcare Syst, CURE, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM lfaller@ucla.edu FU NIDDK NIH HHS [DK52802] NR 44 TC 3 Z9 3 U1 0 U2 1 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 4 PY 2005 VL 280 IS 9 BP 7435 EP 7443 DI 10.1074/jbc.M412319200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 902ZR UT WOS:000227395700004 PM 15591322 ER PT J AU Gonzalez, E Kulkarni, H Bolivar, H Mangano, A Sanchez, R Catano, G Nibbs, RJ Freedman, BI Quinones, MP Bamshad, MJ Murthy, KK Rovin, BH Bradley, W Clark, RA Anderson, SA O'Connell, RJ Agan, BK Ahuja, SS Bologna, R Sen, L Dolan, MJ Ahuja, SK AF Gonzalez, E Kulkarni, H Bolivar, H Mangano, A Sanchez, R Catano, G Nibbs, RJ Freedman, BI Quinones, MP Bamshad, MJ Murthy, KK Rovin, BH Bradley, W Clark, RA Anderson, SA O'Connell, RJ Agan, BK Ahuja, SS Bologna, R Sen, L Dolan, MJ Ahuja, SK TI The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility SO SCIENCE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; DISEASE PROGRESSION; BETA-CHEMOKINES; IN-VITRO; MACROPHAGE; INFECTION; CCR5; LYMPHOCYTES; PROTECTION; EVOLUTION AB Segmental duplications in the human genome are selectively enriched for genes involved in immunity, although the phenotypic consequences for host defense are unknown. We show that there are significant interindividual and interpopulation differences in the copy number of a segmental duplication encompassing the gene encoding CCL3L1 (MIP-1alphaP), a potent human immunodeficiency virus-1 (HIV-1)-suppressive chemokine and ligand for the HIV coreceptor CCR5. Possession of a CCL3L1 copy number lower than the population average is associated with markedly enhanced HIV/acquired immunodeficiency syndrome (AIDS) susceptibility. This susceptibility is even greater in individuals who also possess disease-accelerating CCR5 genotypes. This relationship between CCL3L1 dose and altered HIV/AIDS susceptibility points to a central role for CCL3L1 in HIV/AIDS pathogenesis and indicates that differences in the dose of immune response genes may constitute a genetic basis for variable responses to infectious diseases. C1 Univ Texas, Hlth Sci Ctr, Vet Adm Res Ctr AIDS & HIV1 Infect, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA. Consejo Nacl Invest Cient & Tecn, Lab Biol Celular & Retrovirus, RA-1245 Buenos Aires, DF, Argentina. Hosp Pediat JP Garrahan, Serv Infectol, RA-1245 Buenos Aires, DF, Argentina. Cancer Res UK Beatson Labs, Glasgow G61 1BD, Lanark, Scotland. Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA. Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA. Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA. SW Fdn Biomed Res, San Antonio, TX 78227 USA. Ohio State Univ, Div Nephrol, Columbus, OH 43210 USA. Wilford Hall USAF Med Ctr, Infect Dis Serv, Lackland AFB, TX 78236 USA. Wilford Hall USAF Med Ctr, Tri Serv AIDS Clin Consortium, Lackland AFB, TX 78236 USA. Wilford Hall USAF Med Ctr, Henry M Jackson Fdn, Lackland AFB, TX 78236 USA. Def Inst Med Operat, Brooks AFB, TX 78235 USA. RP Ahuja, SK (reprint author), Univ Texas, Hlth Sci Ctr, Vet Adm Res Ctr AIDS & HIV1 Infect, S Texas Vet Hlth Care Syst, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM matthew.dolan@brooks.af.mil; ahujas@uthscsa.edu OI Agan, Brian/0000-0002-5114-1669; Nibbs, Robert/0000-0002-8150-0044 FU NIAID NIH HHS [AI043279, AI046326]; NIMH NIH HHS [MH069270] NR 21 TC 782 Z9 831 U1 5 U2 42 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD MAR 4 PY 2005 VL 307 IS 5714 BP 1434 EP 1440 DI 10.1126/science.1101160 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 904MT UT WOS:000227503100037 PM 15637236 ER PT J AU Cully, JA Molinari, VA Snow, AL Burruss, J Kotrla, KJ Kunik, ME AF Cully, JA Molinari, VA Snow, AL Burruss, J Kotrla, KJ Kunik, ME TI Utilization of emergency center services by older adults with a psychiatric diagnosis SO AGING & MENTAL HEALTH LA English DT Article ID CONSULTATIONS AB Information regarding older adult emergency center (EC) patient characteristics remains limited, despite its increasing importance in health care delivery systems. This retrospective study encompasses all EC visits over an eight-year period (n = 825,682) to a large urban county hospital. Only participants with a primary psychiatric diagnosis were examined, and included a total of 53,894 adults, 18-64 years old and 1,478 adults, >= 65 years old. Despite an increasing aging population, EC visits for older adults with psychiatric disorders did not increase over time. Within the older adult sample, cognitive, psychotic, and bipolar disorders were associated with higher rates of admission to the hospital, while substance use, depressive, and anxiety disorders were associated with lower numbers of inpatient admissions. African-Americans were overrepresented in the EC and admitted to the hospital at higher rates, compared to other ethnic groups. Caucasian patients were the group most frequently diagnosed with a substance use disorder. In conclusion, differences in race, and diagnosis support the idea that such variables directly relate to utilization rates, presentation, and disposition within the EC. C1 Michael E DeBakey Vet Affairs Med Ctr, Vet Affairs HSR&D Ctr Excellence, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. Univ S Florida, Louis de la Parte Florida Mental Hlth Inst, Dept Aging & Mental Hlth, Tampa, FL 33620 USA. Texas A&M Coll Med, Dept Psychiat & Behav Sci, Temple, TX USA. Cent Texas Vet Hlth Care Syst, Temple, TX USA. RP Cully, JA (reprint author), 2002 Holcombe 152, Houston, TX 77030 USA. EM jcully@bcm.tmc.edu NR 13 TC 6 Z9 6 U1 0 U2 2 PU ROUTLEDGE TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1360-7863 J9 AGING MENT HEALTH JI Aging Ment. Health PD MAR PY 2005 VL 9 IS 2 BP 172 EP 176 DI 10.1080/13607860412331336779 PG 5 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 915AB UT WOS:000228268900012 PM 15804636 ER PT J AU Behler, C Shade, S Gregory, K Abrams, D Volberding, P AF Behler, C Shade, S Gregory, K Abrams, D Volberding, P TI Anemia and HIV in the antiretroviral era: Potential significance of testosterone SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; QUALITY-OF-LIFE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; HUMAN-BONE MARROW; INFECTED PATIENTS; TREATMENT OPTIONS; CHRONIC DISEASE; AIDS PATIENTS; THERAPY; MEN AB Anemia, the most common hematological disorder in human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), is associated with decreased quality of life and survival. Hypogonadism is prevalent in advanced HIV disease, however, low testosterone levels have not been customarily implicated in HIV-associated anemia. This study was undertaken to determine whether there is a relationship between testosterone levels and androgen use with anemia in HIV, and to characterize other clinical correlates of HIV-associated anemia. This was a cross-sectional, observational study of 200 HIV-positive patients at a public hospital HIV clinic from July 2000 to August 2001. A written questionnaire detailed previous and current medication use, opportunistic infections, and malignancies. Hematological and virological parameters, testosterone, and erythropoietin levels were measured; CD4(+) T lymphocyte count and viral load nadir and peak levels were obtained from the computerized medical record. Anemia was defined as hemoglobin <13.5 g/dl in men and <11.6 g/dl in women. Twenty-four percent of women and 28% of men were anemic. Anemia was associated with lymphopenia (adjusted OR 4.0, 95% CI 1.36-11.80), high erythropoietin levels (adjusted OR 7.73, 95% CI 2.92-20.48), and low testosterone levels (adjusted OR 3.27, 95% CI 1.01-10.60). Anemia was negatively associated with female sex (adjusted OR 0.30, 95% CI 0.11-0.85), current antiretroviral therapy (adjusted OR 0.43, 95% CI 0.20-0.95), current androgen use (adjusted OR 0.20, 95% CI 0.05-0.84), and macrocytosis (adjusted OR 0.23, 95% CI 0.09-0.61). Low testosterone levels may have a positive association and supplemental androgens a negative association with anemia in HIV disease. C1 Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. Univ Calif San Francisco, San Francisco Gen Hosp, Posit Hlth Program, San Francisco, CA 94143 USA. RP Behler, C (reprint author), Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, Box 0654, San Francisco, CA 94143 USA. EM behlerc@itsa.ucsf.edu FU NIAID NIH HHS [P30 AI 27763-11] NR 35 TC 4 Z9 5 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD MAR PY 2005 VL 21 IS 3 BP 200 EP 206 DI 10.1089/aid.2005.21.200 PG 7 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 913WT UT WOS:000228187000002 PM 15795525 ER PT J AU Schwartz, GG AF Schwartz, GG TI Statins in acute coronary syndromes: The sooner, the better? SO AMERICAN HEART JOURNAL LA English DT Editorial Material ID C-REACTIVE PROTEIN; AVERAGE CHOLESTEROL LEVELS; MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; CONTROLLED TRIAL; HEART-DISEASE; SIMVASTATIN; PRAVASTATIN; EVENTS; INFLAMMATION C1 VA Med Ctr, Cardiol Sect, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. RP Schwartz, GG (reprint author), Denver VA Med Ctr, Cardiol Sect 111B, 1055 Clermont St, Denver, CO 80220 USA. EM gregory.schwartz@med.va.gov NR 26 TC 0 Z9 0 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0002-8703 J9 AM HEART J JI Am. Heart J. PD MAR PY 2005 VL 149 IS 3 BP 377 EP 380 DI 10.1016/j.ahj.2004.09.043 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 917RV UT WOS:000228487800001 PM 15864223 ER PT J AU Kilbourne, AM Reynolds, CF Good, CB Sereika, SM Justice, AC Fine, MJ AF Kilbourne, AM Reynolds, CF Good, CB Sereika, SM Justice, AC Fine, MJ TI How does depression influence diabetes medication adherence in older patients? SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article; Proceedings Paper CT 16th Annual Meeting of the American-Association-for-Geriatric-Psychiatry CY MAR 01-04, 2003 CL HONOLULU, HI SP Amer Assoc Geriatr Psychiat ID ANTIHYPERTENSIVE MEDICATIONS; PHARMACY RECORDS; ALCOHOL-CONSUMPTION; REPORTED ADHERENCE; THERAPY; NONCOMPLIANCE; VALIDATION; IMPACT; CARE; PREVALENCE AB Objective: Using various measures (electronic monitoring, patient/provider report, pharmacy data), the authors assessed the association between depression and diabetes medication adherence among older patients with Type 2 diabetes. Methods: Patients completed a baseline survey on depression ( Patient Health Questionnaire) and were given electronic monitoring caps (EMCs) to use with their oral hypoglycemic medication. At the time of the patient baseline survey, providers completed a survey on their patients' overall medication adherence. Upon returning the caps after 30 days, patients completed a survey on their overall medication adherence. EMC adherence was defined as percent of days out of 30 with correct number of doses. Using pharmacy refill data from the patient baseline through 1 year later, they defined adherence as the percentage of days with adequate medication, based on days' supply across refill periods. Results: Of 203 patients ( mean age: 67 years), 10% ( N = 19) were depressed. Depressed patients were less likely to self-report good adherence and had a lower median percentage of days with adequate medication coverage ( on the basis of pharmacy refill data). After adjustment for alcohol use, cognitive impairment, age, and other medication use, depression was still negatively associated with adequate adherence, according to patient report and pharmacy data. Depression showed no associated with adherence on the basis of provider or EMC data. Conclusions: Depression was independently associated with inadequate medication adherence on the basis of patient self-report and pharmacy data. C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Sch Med, Dept Neurosci, Pittsburgh, PA USA. Intervent Res Ctr Study Late Life Mood Disorders, Pittsburgh, PA USA. Univ Pittsburgh, Sch Nursing, Ctr Res Chron Disorders, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. W Haven VA Med Ctr, West Haven, CT USA. RP Kilbourne, AM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr C, Pittsburgh, PA 15240 USA. EM Amy.Kilbourne@med.va.gov NR 42 TC 26 Z9 26 U1 0 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2005 VL 13 IS 3 BP 202 EP 210 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 900JH UT WOS:000227210700005 PM 15728751 ER PT J AU Kilbourne, AM Cornelius, JR Han, XY Haas, GL Salloum, I Conigliaro, J Pincus, HA AF Kilbourne, AM Cornelius, JR Han, XY Haas, GL Salloum, I Conigliaro, J Pincus, HA TI General-medical conditions in older patients with serious mental illness SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article ID BIPOLAR DISORDER; SCHIZOPHRENIA; COMORBIDITY; COSTS AB Objective: The burden of medical comorbidities was compared between older (greater than or equal to 60 years) and younger patients with serious mental illness. Methods: Patients (N = 8,083) diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder in 2001 were identified from VA facilities in the mid-Atlantic region. Medical comorbidities were identified by an ICD-9 based clinical classification algorithm. Results: Older, versus younger, patients were more likely to be diagnosed with cardiovascular or pulmonary conditions, and less likely to be diagnosed with substance-use disorders or hepatic conditions. Conclusions: More aggressive detection and management of general-medical comorbidities in older patients with serious mental illness is paramount. C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot 151C, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. RAND Corp, Pittsburgh, PA USA. Univ Pittsburgh, Hlth Inst, Pittsburgh, PA USA. RP Kilbourne, AM (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot 151C, Univ Dr C, Pittsburgh, PA 15240 USA. EM Amy.Kilbourne@med.va.gov NR 10 TC 55 Z9 55 U1 1 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1064-7481 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2005 VL 13 IS 3 BP 250 EP 254 DI 10.1176/appi.ajgp.13.3.250 PG 5 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 900JH UT WOS:000227210700011 PM 15728757 ER PT J AU Dave, S Honney, S Raymond, J Flume, PA AF Dave, S Honney, S Raymond, J Flume, PA TI An unusual presentation of cystic fibrosis in an adult SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE cystic fibrosis (CF); adult; metabolic alkalosis; diagnosis; hypokalemia ID METABOLIC ALKALOSIS; CHLORIDE DEFICIENCY; DIAGNOSIS; COMPLICATION; MUTATIONS; DISEASE AB The diagnosis of cystic fibrosis (CF) generally is made within the first few years of life, although some cases will not be diagnosed until adulthood. For most patients the diagnosis is suggested by typical CF-related symptoms such as chronic respiratory infection or maldigestion. The authors describe an adult patient with newly diagnosed CF whose presenting abnormalities consisted of hypokalemia and metabolic alkalosis. These are known complications of CF but are not common presenting features that lead to the diagnosis of CF. The authors discuss their patient's presentation and review his metabolic manifestations of CF. C1 Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Dept Pediat, Charleston, SC 29425 USA. RP Dave, S (reprint author), Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Dept Med, 96 Jonathan Lucas St,812-CSB, Charleston, SC 29425 USA. EM dave@musc.edu NR 21 TC 9 Z9 10 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAR PY 2005 VL 45 IS 3 BP E41 EP E44 DI 10.1053/j.ajkd2004.11.009 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 909PT UT WOS:000227873000023 PM 15754262 ER PT J AU Linder, JA Huang, ES Steinman, MA Gonzales, R Stafford, RS AF Linder, JA Huang, ES Steinman, MA Gonzales, R Stafford, RS TI Fluoroquinolone prescribing in the United States: 1995 to 2002 SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE fluoroquinolones; antibiotics; physicians' practice patterns ID COMMUNITY-ACQUIRED PNEUMONIA; UNCOMPLICATED ACUTE BRONCHITIS; GROUP-A STREPTOCOCCI; ACUTE OTITIS-MEDIA; ANTIBIOTIC USE; ERYTHROMYCIN RESISTANCE; ANTIMICROBIAL THERAPY; ESCHERICHIA-COLI; ADULTS; GUIDELINES AB PURPOSE: To measure changes in the rate and type of fluoroquinolones prescribed in the United States from 1995 to 2002. METHODS: We performed a longitudinal analysis of the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey of adult visits to physicians in ambulatory clinics and emergency departments throughout the United States from 1995 to 2002. The main outcomes were fluoroquinolone prescribing rates and prescribing in accordance with Food and Drug Administration approval as of December 2002. RESULTS: Between 1995 and 2002, fluoroquinolones became the most commonly prescribed class of antibiotics to adults in the United States. Fluoroquinolone prescribing rose threefold, from 7 million visits in 1995 to 22 million visits in 2002 (P < 0.0001). Fluoroquinolone prescribing increased as a proportion of overall antibiotic prescribing (from 10% to 24%; P < 0.0001) and as a proportion of the U.S. population (from 39 to 106 prescriptions per 1000 adults; P < 0.001). These increases were due to the use of newer fluoroquinolones with activity against Streptococcus pneumoniae. Forty-two percent of fluoroquinolone prescriptions were for nonapproved diagnoses. Among patients receiving antibiotics, nonapproved fluoroquinolone prescribing increased over time (odds ratio = 1.18 per year; 95% confidence interval: 1.13 to 1.24). CONCLUSION: Fluoroquinolone prescribing increased threefold in outpatient clinics and emergency departments in the United States from 1995 to 2002. Fluoroquinolones became the most commonly prescribed class of antibiotics to adults in 2002. Nonapproved fluoroquinolone prescribing was common and increased over time. Such prescribing patterns are likely to be followed by an increasing prevalence of fluoroquinolone-resistant bacteria. (c) 2005 Elsevier Inc. All rights reserved. C1 Brigham & Womens Hosp, Div Gen Med, Boston, MA USA. Harvard Univ, Sch Med, Boston, MA USA. Univ Chicago, Gen Internal Med Sect, Chicago, IL 60637 USA. San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. Stanford Prevent Res Ctr, Program Prevent Outcomes & Practices, Stanford, CA USA. RP Linder, JA (reprint author), Brigham & Womens Hosp, Div Gen Med, 1620 Tremont St,BC-3-2X, Boston, MA USA. FU AHRQ HHS [K08 HS014563, R01 HS11313]; BHP HRSA HHS [5T32PE11001-12]; NIA NIH HHS [K23 AG021963] NR 51 TC 155 Z9 158 U1 1 U2 4 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD MAR PY 2005 VL 118 IS 3 BP 259 EP 268 DI 10.1016/j.amjmed.2004.09.015 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 906PJ UT WOS:000227653900012 PM 15745724 ER PT J AU Houston, TK Allison, JJ Person, S Kovac, S Williams, OD Kiefe, CI AF Houston, TK Allison, JJ Person, S Kovac, S Williams, OD Kiefe, CI TI Post-myocardial infarction smoking cessation counseling: Associations with immediate and late mortality in older Medicare patients SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE myocardial infarctions; tobacco cessation; directive counseling; inpatients; mortality ID ACUTE MYOCARDIAL-INFARCTION; COOPERATIVE CARDIOVASCULAR PROJECT; CORONARY-ARTERY DISEASE; HEART-DISEASE; HOSPITALIZED-PATIENTS; QUALITY IMPROVEMENT; RANDOMIZED TRIAL; SUDDEN-DEATH; APACHE-II; CARE UNIT AB PURPOSE: To assess the difference in immediate (30 and 60 days after admission) and late (2-year) mortality between those who received inpatient post-myocardial infarction smoking cessation counseling and those who did not receive counseling METHODS: We conducted an observational study of a national random sample of inpatients front 2971 U.S. acute care hospitals participating in the Cooperative Cardiovascular Project in 1994-95. Medicare beneficiaries who were Current smokers over age 65, admitted with a documented acute myocardial infarction, and who were discharged to home were included (n = 16 743). Our main outcome measures were early (30-, 60-day) and late (1-, 2-year) mortality. RESULTS: Smoking cessation counseling was documented during their index hospitalization for 41 % of patients. Compared with those not counseled, those who received inpatient counseling had lower 30-day (2.0% vs. 3.0%), 60-day (3.7% vs. 5.6%), and 2-year mortality (25.0% vs. 30%) (logrank P < 0.0001). After adjustment for demographic characteristics, comorbid conditions, APACHE score, and receipt of treatments including aspirin, reperfusion, beta-blockers, and angiotensin-converting enzyme inhibitors, those receiving counseling were less likely to die within I year, but the effect was lost between I and 2 years [hazard ratio (HR) = 0.99 (0.91- 1.10)]. The greatest reduction in relative hazard (19%) was seen within 30 days [HR = 0.81 (95% confidence interval 0.65-0.99)]. CONCLUSION: Immediate and long-term mortality rates were lower among those receiving inpatient smoking cessation Counseling. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Alabama, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Deep S Ctr Effectiveness, Birmingham, AL USA. Univ Alabama, Div Gen Internal Med, Birmingham, AL 35294 USA. Univ Alabama, Ctr Outcomes & Effectiveness Res & Educ, Birmingham, AL 35294 USA. RP Houston, TK (reprint author), Univ Alabama, Dept Med, Div Prevent Med, 1530 3rd Ave S,FOT 720B, Birmingham, AL 35294 USA. EM tkhouston@uabmc.edu RI Houston, Thomas/F-2469-2013 OI Allison, Jeroan/0000-0003-4472-2112 NR 44 TC 37 Z9 37 U1 1 U2 3 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD MAR PY 2005 VL 118 IS 3 BP 269 EP 275 DI 10.1016/j.amjmed.2004.12.007 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 906PJ UT WOS:000227653900013 PM 15745725 ER PT J AU Gallagher, RM AF Gallagher, RM TI Rational integration of pharmacologic behavioral and rehabilitation strategies in the treatment of chronic pain SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Review DE biopsychosocial; chronicity; chronic pain; pain conditions; pain management; pain medicine; persistent pain; rational polypharmacy; treatment planning ID LOW-BACK-PAIN; FUNCTIONAL RESTORATION; FOLLOW-UP; COGNITIVE INTERVENTION; PSYCHOLOGICAL-FACTORS; WORKERS COMPENSATION; OPIOID THERAPY; LUMBAR FUSION; PRIMARY-CARE; MANAGEMENT AB Historically, the concept of a mind-body duality in medicine, which supports a biomedical approach to pain management, has impeded the development of adequate treatments for persistent pain conditions and diseases. Although usually there is an initiating pathophysiologic nociceptive cause of pain, over time, the conditioning of neurophysiologic and affective systems by environmental and internal events can promote chronicity and frustrate the efforts of physicians to attenuate nociceptive processes. A full elucidation of the environmental and psychological factors contributing to pain and suffering may prove difficult using a traditional biomedical approach. Prevention of chronicity, by early identification and treatment of pain generators and the pain response to tissue injury and by recognition of those general factors that contribute to risk for chronicity (e.g., depressive illness, poor pain control), is crucial for any healthcare system that wishes to reduce the morbidity and costs of persistent pain. Goal-directed, outcomes-focused biopsychosocial treatment plans that efficiently integrate physical, behavioral, and medical approaches more frequently achieve better pain control and improved function. The following article presents a general overview of evidence for effectiveness of these approaches and some central principles of integrated treatment planning. C1 Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia Vet Affairs Off,Pain Management Serv, Philadelphia, PA 19104 USA. RP Gallagher, RM (reprint author), Univ Penn, Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia Vet Affairs Off,Pain Management Serv, Univ & Woodland Ave, Philadelphia, PA 19104 USA. NR 84 TC 10 Z9 10 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD MAR PY 2005 VL 84 IS 3 SU S BP S64 EP S76 DI 10.1097/01.PHM.0000154910.01200.0B PG 13 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 900KQ UT WOS:000227214200007 PM 15722785 ER PT J AU Gallagher, RM AF Gallagher, RM TI Pain science and rational polypharmacy - An historical perspective SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Editorial Material DE chronic pain; pharmacology; history C1 Univ Penn, Sch Med, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. RP Gallagher, RM (reprint author), Univ Penn, Sch Med, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 0 TC 8 Z9 8 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD MAR PY 2005 VL 84 IS 3 SU S BP S1 EP S3 DI 10.1097/01.PHM.0000154909.96213.60 PG 3 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 900KQ UT WOS:000227214200001 PM 15722779 ER PT J AU Cohen, DM AF Cohen, DM TI SRC family kinases in cell volume regulation SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Review DE hypotonicity; transient receptor potential; hypertonicity; ion transport; tyrosine kinase ID EPIDERMAL-GROWTH-FACTOR; K-CL COTRANSPORTER; ACTIVATED PROTEIN-KINASE; OSMOTIC RESPONSE ELEMENT; RECEPTOR TYROSINE KINASES; GATED POTASSIUM CHANNEL; COLLECTING DUCT CELLS; MICE LACKING TRPV4; FACTOR HB-EGF; SIGNAL-TRANSDUCTION AB SRC family kinases are a group of nine cytoplasmic protein tyrosine kinases essential for many cell functions. Some appear to be ubiquitously expressed, whereas others are highly tissue specific. The ability of members of the SRC family to influence ion transport has been recognized for several years. Mounting evidence suggests a broad role for SRC family kinases in the cell response to both hypertonic and hypotonic stress, and in the ensuing regulatory volume increase or decrease. In addition, members of this tyrosine kinase family participate in the mechanotransduction that accompanies cell membrane deformation. Finally, at least one SRC family member operates in concert with the p38 MAPK to regulate tonicity-dependent gene transcription. C1 Oregon Hlth & Sci Univ, Dept Med, Div Nephrol & Hypertens, Portland, OR 97239 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Cohen, DM (reprint author), Oregon Hlth & Sci Univ, Div Nephrol, Mailcode PP262,3314 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM cohend@ohsu.edu NR 159 TC 54 Z9 57 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD MAR PY 2005 VL 288 IS 3 BP C483 EP C493 DI 10.1152/ajpcell.00452.2004 PG 11 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 894ME UT WOS:000226795100001 PM 15692147 ER PT J AU Furukawa, O Hirokawa, M Zhang, LN Takeuchi, T Bi, LC Guth, PH Engel, E Akiba, Y Kaunitz, JD AF Furukawa, O Hirokawa, M Zhang, LN Takeuchi, T Bi, LC Guth, PH Engel, E Akiba, Y Kaunitz, JD TI Mechanism of augmented duodenal HCO3- secretion after elevation of luminal CO2 SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE bicarbonate; duodenum; carbon dioxide; carbonic anhydrase; cyclooxygenase; epithelial cells; sodium hydrogen exchanger 1; sodium hydrogen exchanger 3; sodium bicarbonate cotransporter 1 ID MUCOSAL ALKALINE SECRETION; APICAL CL-/HCO3-EXCHANGER; BICARBONATE SECRETION; CARBONIC-ANHYDRASE; CYSTIC-FIBROSIS; GASTROINTESTINAL-TRACT; RAT; ACID; CFTR; TRANSPORT AB The proximal duodenum is exposed to extreme elevations of PCO2 because of the continuous mixture of secreted HCO3- with gastric acid. These elevations (up to 80 kPa) are likely to place the mucosal cells under severe acid stress. Furthermore, we hypothesized that, unlike most other cells, the principal source of CO2 for duodenal epithelial cells is from the lumen. We hence examined the effect of elevated luminal PCO2 on duodenal HCO3- secretion (DBS) in the rat. DBS was measured by the pH-stat method. For CO2 challenge, the duodenum was superfused with a high PCO2 solution. Intracellular pH (pH(i)) of duodenal epithelial cells was measured by ratio microfluorometry. CO2 challenge, but not isohydric solutions, strongly increased DBS to approximately two times basal for up to 1 h. Preperfusion of the membrane-permeant carbonic anhydrase inhibitor methazolamide, or continuous exposure with indomethacin, fully inhibited CO2-augmented DBS. Dimethyl amiloride (0.1 mM), an inhibitor of the basolateral sodium-hydrogen exchanger 1, also inhibited CO2-augumented DBS, although S-3226, a specific inhibitor of apical sodium-hydrogen exchanger 3, did not. DIDS, an inhibitor of basolateral sodium-HCO3- cotransporter, also inhibited CO2-augemented DBS, as did the anion channel inhibitor 5-nitro-2-(3-phenylpropylamino) benzoic acid. CO2 decreased epithelial cell pHi, followed by an overshoot after removal of the CO2 solution. We conclude that luminal CO2 diffused in the duodenal epithelial cells and was converted to H+ and HCO3- by carbonic anhydrase. H+ initially exited the cell, followed by secretion of HCO3-. Secretion was dependent on a functioning basolateral sodium/proton exchanger, a functioning basolateral HCO3- uptake mechanism, and submucosal prostaglandin generation and facilitated hydration of CO2 into HCO3- and H+. C1 Digest Dis Res Ctr, Ctr Ulcer Res & Educ, Los Angeles, CA USA. Univ Calif Irvine, Dept Med, Div Gastroenterol, Irvine, CA 92717 USA. Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. RP Kaunitz, JD (reprint author), W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd,Rm 217,Bldg 114, Los Angeles, CA 90073 USA. EM jake@ucla.edu NR 46 TC 23 Z9 25 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD MAR PY 2005 VL 288 IS 3 BP G557 EP G563 DI 10.1152/ajpgi.00344.2004 PG 7 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 895AM UT WOS:000226833100020 PM 15499081 ER PT J AU Xu, Y Gen, M Lu, L Fox, J Weiss, SO Brown, RD Perlov, D Ahmad, H Zhu, PL Greyson, C Long, CS Schwartz, GG AF Xu, Y Gen, M Lu, L Fox, J Weiss, SO Brown, RD Perlov, D Ahmad, H Zhu, PL Greyson, C Long, CS Schwartz, GG TI PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE nuclear receptor; thiazolidinedione; energy metabolism; cytokine; ventricular function ID NECROSIS-FACTOR-ALPHA; RECEPTOR-GAMMA; ISCHEMIA/REPERFUSION INJURY; PEROXISOME PROLIFERATION; MITOCHONDRIAL-FUNCTION; ANTIDIABETIC AGENT; SKELETAL-MUSCLE; GENE-EXPRESSION; INFARCT SIZE; YOUNG-PIGS AB PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol 288: H1314-H1323, 2005. First published November 4, 2004; doi:10.1152/ajpheart. 00618.2004.-Peroxisome proliferator-activated receptor (PPAR)-gamma modulates substrate metabolism and inflammatory responses. In experimental rats subjected to myocardial ischemia-reperfusion (I/R), thiazolidinedione PPAR-gamma activators reduce infarct size and preserve left ventricular function. Troglitazone is the only PPAR-gamma activator that has been shown to be protective in I/R in large animals. However, because troglitazone contains both alpha-tocopherol and thiazolidinedione moieties, whether PPAR-gamma activation per se is protective in myocardial I/R in large animals remains uncertain. To address this question, 56 pigs were treated orally for 8 wk with troglitazone ( 75 mg(.)kg(-1) (.) day(-1)), rosiglitazone (3 mg (.) kg(-1 .) day(-1)), or alpha-tocopherol (73 mg (.) kg(-1) (.) day(-1), equimolar to troglitazone dose) or received no treatment. Pigs were then anesthetized and subjected to 90 min of low-flow regional myocardial ischemia and 90 min of reperfusion. Myocardial expression of PPAR-gamma, determined by ribonuclease protection assay, increased with troglitazone and rosiglitazone compared with no treatment. Rosiglitazone had no significant effect on myocardial contractile function (Frank-Starling relations), substrate uptake, or expression of proinflammatory cytokines during I/R compared with untreated pigs. In contrast, preservation of myocardial contractile function and lactate uptake were greater and cytokine expression was attenuated in pigs treated with troglitazone or alpha-tocopherol compared with untreated pigs. Multivariate analysis indicated that presence of an alpha-tocopherol, but not a thiazolidinedione, moiety in the test compound was significantly related to greater contractile function and lactate uptake and lower cytokine expression during I/R. We conclude that PPAR-gamma activation is not protective in a porcine model of myocardial I/R. Protective effects of troglitazone are attributable to its alpha-tocopherol moiety. These findings, in conjunction with prior rat studies, suggest interspecies differences in the response to PPAR-gamma activation in the heart. C1 Denver VA Med Ctr, Cardiol Sect, Denver, CO 80220 USA. Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA. RP Schwartz, GG (reprint author), Denver VA Med Ctr, Cardiol Sect, 111B,1055 Clermont St, Denver, CO 80220 USA. EM Gregory.Schwartz@med.va.gov FU NHLBI NIH HHS [R56 HL049944, R01 HL049944-09, HL-68606, HL-49944, R01 HL049944, R01 HL068606] NR 60 TC 32 Z9 34 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD MAR PY 2005 VL 288 IS 3 BP H1314 EP H1323 DI 10.1152/ajpheart.00618.2004 PG 10 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 896CB UT WOS:000226911100044 PM 15528232 ER PT J AU Teran, FJ Johnson, RA Stevenson, BK Peyton, KJ Jackson, KE Appleton, SD Durante, W Johnson, FK AF Teran, FJ Johnson, RA Stevenson, BK Peyton, KJ Jackson, KE Appleton, SD Durante, W Johnson, FK TI Heme oxygenase-derived carbon monoxide promotes arteriolar endothelial dysfunction and contributes to salt-induced hypertension in Dahl salt-sensitive rats SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE salt-sensitive hypertension; vascular tone; arterioles; blood pressure ID NITRIC-OXIDE SYNTHASE; GRACILIS MUSCLE ARTERIOLES; ANGIOTENSIN-II; VENTRICULAR HYPERTROPHY; GUANYLYL CYCLASE; L-ARGININE; VASODILATION; INHIBITION; EXPRESSION; VASOCONSTRICTION AB Vascular tissues express heme oxygenase (HO), which metabolizes heme to form carbon monoxide (CO). Heme-derived CO inhibits nitric oxide synthase and promotes endothelium-dependent vasoconstriction. After 4 wk of high-salt diet, Dahl salt-sensitive (Dahl-S) rats display hypertension, increased vascular HO-1 expression, and attenuated vasodilator responses to ACh that can be completely restored by acute treatment with an inhibitor of HO. In this study, we examined the temporal development of HO-mediated endothelial dysfunction in isolated pressurized first-order gracilis muscle arterioles, identified the HO product responsible, and studied the blood pressure effects of HO inhibition in Dahl-S rats on a high-salt diet. Male Dahl-S rats (5-6 wk) were placed on high-salt (8% NaCl) or low-salt (0.3% NaCl) diets for 0-4 wk. Blood pressure increased gradually, and responses to an endothelium-dependent vasodilator, ACh, decreased gradually with the length of high-salt diet. Flow-induced dilation was abolished in hypertensive Dahl-S rats. Acute in vitro pretreatment with an inhibitor of HO, chromium mesoporphyrin (CrMP), restored endothelium-dependent vasodilation and abolished the differences between groups. The HO product CO prevented the restoration of endothelium-dependent dilation by CrMP. Furthermore, administration of an HO inhibitor lowered blood pressure in Dahl-S rats with salt-induced hypertension but did not do so in low-salt control rats. These results suggest that hypertension and HO-mediated endothelial dysfunction develop gradually and simultaneously in Dahl-S rats on high-salt diets. They also suggest that HO-derived CO underlies the impaired endothelial dysfunction and contributes to hypertension in Dahl-S rats on high-salt diets. C1 Tulane Univ, Hlth Sci Ctr, Dept Physiol, New Orleans, LA 70112 USA. Tulane Univ, Hlth Sci Ctr, Tulane Hyperten & Renal Ctr Excellence, New Orleans, LA 70112 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA. Dept Vet Affairs Med Ctr, Houston, TX USA. RP Johnson, FK (reprint author), Tulane Univ, Hlth Sci Ctr, Dept Physiol, 1430 Tulane Ave,SL39, New Orleans, LA 70112 USA. EM Fruzsi123@aol.com FU NCRR NIH HHS [P20 RR 017659]; NHLBI NIH HHS [R01 HL 64577, R01 HL 76187, R01 HL 59976] NR 46 TC 34 Z9 36 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD MAR PY 2005 VL 288 IS 3 BP R615 EP R622 DI 10.1152/ajpregu.00123.2004 PG 8 WC Physiology SC Physiology GA 895AJ UT WOS:000226832800010 PM 15528397 ER PT J AU Feliers, D Duraisamy, S Barnes, JL Ghosh-Choudhury, G Kasinath, BS AF Feliers, D Duraisamy, S Barnes, JL Ghosh-Choudhury, G Kasinath, BS TI Translational regulation of vascular endothelial growth factor expression in renal epithelial cells by angiotensin II SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE protein expression; polysomes; nephropathy ID MESSENGER-RNA; PROTEIN-SYNTHESIS; DIABETIC-NEPHROPATHY; SIGNALING PATHWAY; FACTOR-BETA; RETINAL NEOVASCULARIZATION; VEGF EXPRESSION; INITIATION; PHOSPHORYLATION; RECEPTOR AB Translational regulation of vascular endothelial growth factor expression in renal epithelial cells by angiotensin II. Am J Physiol Renal Physiol 288: F521-F529, 2005. First published November 30, 2004; doi:10.1152/ ajprenal.00271.2004.-ANG II regulates growth factor expression in the kidney. We investigated whether ANG II regulated vascular endothelial growth factor (VEGF) synthesis in proximal tubular epithelial (MCT) cells. ANG II (1 nM) increased VEGF protein expression within 5 min, the effect lasting for 30 min. There was no change in VEGF mRNA levels or mRNA stability, and transcription inhibitors did not affect ANG II-induced VEGF expression. Regulation of VEGF translation was investigated. Polyribosomal analysis revealed selective enrichment of heavy ribosomes (polysomes) with VEGF mRNA transcripts compared with light ribosomes in ANG II-treated cells, although distribution of GAPDH was unaltered. In vitro translation of total RNA from polysomal fractions showed selective increase in VEGF protein synthesis in ANG II-treated cells. Preincubation with LY-294002, a PI 3-kinase inhibitor, or expression of dominant-negative Akt prevented ANG II-stimulated increase in VEGF translation. ANG 11 increased phosphorylation of eukaryouic initiation factor 4E and its binding protein 4E-BP1, critical events that regulate the initiation phase of protein translation. ANG 11 failed to increase VEGF mRNA translation in cells stably expressing the phosphorylation mutant of 4E-BP1. Our data illustrate that a rapid increase in VEGF protein expression by ANG 11 is regulated at the initiation phase of translation of VEGF mRNA in renal epithelial cells. Regulation of VEGF translation by ANG 11 represents a novel pathway of renal response to injury. C1 Univ Texas, Hlth Sci Ctr, Dept Med Nephrol, S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Kasinath, BS (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Mail Code 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kasinath@uthscsa.edu FU NIDDK NIH HHS [R01-DK-55815, R01-DK-50190] NR 52 TC 34 Z9 35 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD MAR PY 2005 VL 288 IS 3 BP F521 EP F529 DI 10.1152/ajprenal.00271.2004 PG 9 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 898IK UT WOS:000227070300012 PM 15572520 ER PT J AU Kern, RS Green, MF Mitchell, S Kopelowicz, A Mintz, J Liberman, RP AF Kern, RS Green, MF Mitchell, S Kopelowicz, A Mintz, J Liberman, RP TI Extensions of errorless learning for social problem-solving deficits in schizophrenia SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article; Proceedings Paper CT 42nd Meeting of the American-College-of-Neuropsychopharmacology CY DEC 07-11, 2003 CL San Juan, PR SP Amer Coll Neuropsychopharmacol ID MEMORY; PERFORMANCE; REHABILITATION; INDIVIDUALS; IMPAIRMENT; DEMENTIA; SKILLS; TRIAL AB Objective: There is a clear need to develop psychosocial rehabilitation methods that compensate for neurocognitive deficits common to persons with severe and persistent mental illness. Errorless learning, a compensatory training intervention, has been successful in teaching entry-level job tasks. However, errorless learning's applicability to broader, more complex functions is unknown. The present study tested the extension of errorless learning for deficits in social problem-solving skills in patients with schizophrenia. Method: Sixty clinically stable outpatients with schizophrenia or schizoaffective disorder were stratified by gender and level of memory impairment before being randomly assigned to one of two training programs: errorless learning or symptom management. Groups were matched for training time, format and structure of training, and types of teaching aids used. Social problem-solving ability, measured by the Assessment of Interpersonal Problem-Solving Skills, was assessed at baseline, within 2 days of training completion, and after 3 months. Dependent measures were the scores for the receiving, processing, and sending skills areas from the Assessment of Interpersonal Problem-Solving Skills. Results: A repeated-measures analysis of covariance was conducted for each dependent measure with baseline Assessment of Interpersonal Problem-Solving Skills score entered as a covariate. For all three skills, there was a significant training group effect favoring errorless learning. Durability of errorless learning training effects extended to the 3-month follow-up assessment for processing and sending skills but not receiving skills. Conclusions: Results support the extension of errorless learning to complex functions such as social problem-solving skills in the rehabilitation of persons with schizophrenia. C1 Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. San Fernando Mental Hlth Ctr, Mission Hills, CA USA. Dept Vet Affairs VISN 22 Mental Illness Res Educ, Mission Hills, CA USA. RP Kern, RS (reprint author), VA Greater Los Angeles Healthcare Syst MIRECC 210, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM rkern@ucla.edu OI kopelowicz, alex/0000-0002-1728-4105 NR 37 TC 50 Z9 54 U1 1 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD MAR PY 2005 VL 162 IS 3 BP 513 EP 519 DI 10.1176/appi.ajp.162.3.513 PG 7 WC Psychiatry SC Psychiatry GA 904UP UT WOS:000227523500014 PM 15741468 ER PT J AU Qin, M Escuadro, B Sharma, S Batra, RK AF Qin, M Escuadro, B Sharma, S Batra, RK TI Gene transfer mediated by native versus fibroblast growth factor-retargeted adenoviral vectors into lung cancer cells SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY LA English DT Article DE CAR; FGF2; gene therapy; lungcancer; molecular conjugates ID FACTOR RECEPTORS; REDUCED TOXICITY; FGF RECEPTORS; DELIVERY; EXPRESSION; TROPISM; CARCINOMAS; EFFICIENCY; PATHWAYS; ANTIBODY AB We compared native Adenoviral (Ad) vectors to a basic Fibroblast Growth Factor-retargeted Adenovirus (FGF2-Ad) for gene delivery into a diverse panel of lung cancer cells in vitro and xenografts in vivo. Cells were first evaluated for vector-specific receptor expression. Marked variations of surface coxsackie-adenovirus receptor (CAR), but relatively similar levels of a v integrin and FGF receptor expression were evident. Transduction efficiency by Ad directly correlated (R = 0.77, 95% CI 0.28-0.94, P = 0.0085) with CAR, but not with a v integrin expression. Transduction efficiency by FGF2-Ad did not correlate with the measured FGF receptor expression. Blocking studies indicated that gene transfer by FGF2-Ad occurred by a CAR-independent pathway, and could be inhibited by free FGF in a dose-dependent manner. Ad-antiserum inhibited FGF2-Ad gene transfer, suggesting that the Ad-component was needed for post-entry DNA-delivery. Soluble heparin sulfate proteoglycans (HSPG) or a v integrin blockers marginally decreased FGF2-Ad transduction. Both Ad and FGF2-Ad equally transduced CAR-positive non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells. By contrast, FGF2-Ad had a distinct transduction advantage in CAR-deficient NSCLC cells. This improvement in transduction of CAR-deficient cells by FGF2-Ad persisted in vivo. These data justify the need for an improved FGF2-Ad vector for clinical use in CAR-deficient lung cancer. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. Vet Adm Greater Los Angeles Hlth Care Syst, Div Pulm & Crit Care Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Lung Canc Res Program, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90073 USA. RP Batra, RK (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, 111Q,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM rbatra@ucla.edu OI Batra, Raj K./0000-0002-1126-543X FU NCI NIH HHS [R01 CA078654-03, R01 CA 78654]; PHS HHS [1P50 90388] NR 36 TC 7 Z9 7 U1 0 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1044-1549 J9 AM J RESP CELL MOL JI Am. J. Respir. Cell Mol. Biol. PD MAR PY 2005 VL 32 IS 3 BP 211 EP 217 DI 10.1165/rcmb.2004-0226OC PG 7 WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System GA 900DS UT WOS:000227196200006 PM 15626775 ER PT J AU Hathout, GM Bhidayasiri, R AF Hathout, GM Bhidayasiri, R TI Midbrain ataxia: An introduction to the mesencephalic locornotor region and the pedunculopontine nucleus SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article ID PARKINSONS-DISEASE; LOCOMOTOR REGION; DECEREBRATE CAT; PROJECTIONS; STIMULATION; FAILURE; NEURONS; MONKEY; LEVEL AB OBJECTIVE. Although gait ataxia is usually associated with cerebellar lesions, we review a less familiar cause. We present three patients with dorsal midbrain lesions and correlate these presentations with recent findings in the functional anatomy of the midbrain. CONCLUSION. We suggest that these lesions involve a well-studied but generally unfamiliar area of the dorsal midbrain known as the mesencephalic locomotor region. More specifically, we hypothesize that involvement of the pedunculopontine nucleus, a major component of the mesencephalic locomotor region, may be at least partially responsible for producing midbrain ataxia. C1 W Los Angeles Vet Affairs Med Ctr, Dept Radiol, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Med Ctr, Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Med Ctr, Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. W Los Angeles Vet Affairs Med Ctr, PADRECC, Los Angeles, CA 90073 USA. RP Hathout, GM (reprint author), W Los Angeles Vet Affairs Med Ctr, Dept Radiol, 11301 Wilshire Blvd,Bldg 500, Los Angeles, CA 90073 USA. EM ghathout@ucla.edu OI Bhidayasiri, Roongroj/0000-0002-6901-2064 NR 20 TC 30 Z9 32 U1 0 U2 3 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD MAR PY 2005 VL 184 IS 3 BP 953 EP 956 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 901MH UT WOS:000227286100037 PM 15728623 ER PT J AU Streblow, DN Kreklywich, CN Smith, P Soule, JL Meyer, C Yin, M Beisser, P Vink, C Nelson, JA Orloff, SL AF Streblow, DN Kreklywich, CN Smith, P Soule, JL Meyer, C Yin, M Beisser, P Vink, C Nelson, JA Orloff, SL TI Rat cytomegalovirus-accelerated transplant vascular sclerosis is reduced with mutation of the chemokine-receptor R33 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article DE chemokine receptor; cytomegalovirus; transplant vascular sclerosis (TVS); transplant vasculopathy ID PROTEIN-COUPLED RECEPTOR; CHRONIC REJECTION; MURINE CYTOMEGALOVIRUS; ALLOGRAFT ARTERIOSCLEROSIS; HERPESVIRUS SAIMIRI; CELL-PROLIFERATION; CARDIAC ALLOGRAFTS; AORTIC ALLOGRAFTS; HEART-TRANSPLANTS; VIRAL-INFECTION AB Cytomegalovirus (CMV) infection accelerates transplant vascular sclerosis (TVS) and chronic rejection (CR) in both human and animal solid organ transplantation models. The host/viral mechanisms involved in this process are unclear. We examine the role of the rat CMV (RCMV)-encoded chemokine-receptor R33 in the development of TVS using a rat heart transplantation/CR model. F344 heart grafts were transplanted heterotopically into Lewis recipients. The ability of RCMV lacking the R33 gene (RCMV-Deltar33) to accelerate CR/TVS (neointimal index, NI) was compared to wild-type (WT) RCMV. Allograft recipients were infected with 1 x 10(5) pfu RCMV or RCMV-Deltar33 on postoperative day (POD) 1. Grafts from RCMV-Deltar33-infected recipients demonstrated an accelerated time to allograft CR compared to grafts from uninfected recipients (POD = 56 vs. 90), this was slower than that seen in grafts from WT-RCMV-infected recipients (POD = 45). Similarly, the degree of graft TVS formation at terminal rejection in RMCV-Deltar33 infected recipients was more severe than uninfected recipients (NI = 63 vs. 45), yet not as severe as in WT-RCMV infected recipients (NI = 83). In parallel, RCMV-Deltar33 failed to induce vascular smooth muscle cell (SMC) migration in vitro, whereas WT-RCMV induced substantial migration. The RCMV-encoded chemokine-receptor r33 is critical for RCMV-accelerated TVS/CR and vascular SMC migration. C1 Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97239 USA. Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97239 USA. Univ Maastricht, Dept Med Microbiol, Maastricht, Netherlands. RP Streblow, DN (reprint author), Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. EM streblow@ohsu.edu FU NHLBI NIH HHS [HL71695, HL65754, HL 66238-01] NR 46 TC 44 Z9 46 U1 0 U2 0 PU BLACKWELL MUNKSGAARD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAR PY 2005 VL 5 IS 3 BP 436 EP 442 DI 10.1111/j.1600-6143.2004.00711.x PG 7 WC Surgery; Transplantation SC Surgery; Transplantation GA 896UB UT WOS:000226958200006 PM 15707397 ER PT J AU Crawford, SA Fiebelkorn, KR Patterson, JE Jorgensen, JH AF Crawford, SA Fiebelkorn, KR Patterson, JE Jorgensen, JH TI International clone of Neisseria meningitidis serogroup A with tetracycline resistance due to tet(B) SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID PENICILLIN; DISEASE; SUSCEPTIBILITY; GENES; SPAIN AB Thirteen Neisseria meningitidis clinical isolates from Africa, Asia, and the United States for which the tetracycline MICs were elevated (greater than or equal to8 mug/ml) were examined for 14 recognized resistance genes. Only the drug efflux mechanism encoded by tet(B) was detected. All isolates were in serogroup A, belonged to complex ST-5, and were closely related by pulsed-field gel electrophoresis analysis. C1 Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Med Serv, San Antonio, TX USA. RP Jorgensen, JH (reprint author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM Jorgensen@uthscsa.edu NR 20 TC 9 Z9 10 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAR PY 2005 VL 49 IS 3 BP 1198 EP 1200 DI 10.1128/AAC.49.3.1198-1200.2005 PG 3 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 902FJ UT WOS:000227339500049 PM 15728926 ER PT J AU McNeill, MR Matthews, CT Hula, WD Doyle, PJ Rubinsky, HJ Fossett, TRD AF McNeill, MR Matthews, CT Hula, WD Doyle, PJ Rubinsky, HJ Fossett, TRD TI A dual-task tool for quantifying normal comprehension of aphasic connected speech production: A constructive replication SO APHASIOLOGY LA English DT Article; Proceedings Paper CT 34th Annual Clinical Aphasiology Conference CY 2004 CL Park City, TX ID DIVIDED-ATTENTION; RESOURCE-ALLOCATION; MULTIPLE RESOURCES; MANUAL TRACKING; PERFORMANCE; INDIVIDUALS; SENSITIVITY; DIFFICULTY; LANGUAGE; STIMULI AB Background: Deficits of attention or its control secondary to brain damage have been proposed as all or part of the underlying mechanisms for the linguistic impairments that characterise aphasia (Clark & Robin, 1995; Granier, Robin, Shapiro, Peach, & Zimba, 2000; McNeil, 1982, 1988; McNeil, Odell, & Tseng, 1991; Murray, Holland, & Beeson, 1997a; Tseng, McNeil, & Milenkovic, 1993). McNeil, Doyle, Hula, Rubinsky, Fossett, and Matthews (2004) developed a set of tasks to quantify the difficulty that normal listeners have in understanding the language production of persons with varying amounts of aphasia. In their dual-task study, a significant decrement was found in the visual-manual tracking accuracy of normal older individuals while concurrently listening to the connected language of a person with moderate, as compared to mild, aphasia. No performance costs were observed on the listening tasks across three tracking difficulty levels. Possible reasons for the unidirectional performance cost were speculated and the present study was designed to investigate one of them. Aims: Using the same story comprehension task used in the previous study and the same visual-manual tracking task, but increased in difficulty, this study sought to investigate whether the increased demands of the tracking task were sufficient to elicit a concurrent cost on story comprehension performance. Methods & Procedures: A total of 24 normal participants performed the tracking and story comprehension tasks concurrently and in isolation. Story retell performance was evaluated within subjects across two tracking difficulty levels (easy and hard) and tracking performance was evaluated between subjects across three story difficulty levels (no story, mild difficulty, and moderate difficulty). Outcomes & Results: Tracking performance varied significantly across story task difficulty in the easy tracking condition, with participants demonstrating better tracking performance in the mild story condition than in either the moderate story or no story conditions. None of the comparisons made with the harder tracking condition reached significance. There was no effect of tracking difficulty on story comprehension as measured by subsequent story retell performance. Conclusions: The findings from this study replicate the findings from the McNeil et al. (2004) study that these dual-tasks show a reliable cost of story difficulty on concurrent tracking performance. Contrary to predictions, no effect of tracking difficulty on story retell performance was found, despite the increased tracking difficulty used compared to the previous study. While this finding does diminish the probability that insufficient tracking task difficulty was the source of the unidirectional costs in the previous study, it leaves a number of alternative explanations for the findings viable and unaddressed. C1 Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA. VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP McNeill, MR (reprint author), Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Commun Sci & Disorders, 4033 Forbes Tower, Pittsburgh, PA 15260 USA. EM meneil+@pitt.edu NR 42 TC 3 Z9 3 U1 0 U2 0 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0268-7038 J9 APHASIOLOGY JI Aphasiology PD MAR-MAY PY 2005 VL 19 IS 3-5 BP 473 EP 484 DI 10.1080/02687030444000895 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA 931IL UT WOS:000229478900022 ER PT J AU Reger, MA Martin, DJ Cole, SL Strauss, G AF Reger, MA Martin, DJ Cole, SL Strauss, G TI The relationship between plasma viral load and neuropsychological functioning in HIV-1 infection SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE HIV; viral load; HIV RNA; cognition; neuropsychological functioning ID IMMUNODEFICIENCY-VIRUS INFECTION; CEREBROSPINAL-FLUID; RNA LEVELS; TYPE-1 RNA; DEMENTIA; ENCEPHALITIS; PATHOGENESIS; IMPAIRMENT; AIDS AB Plasma viral load is helpful in monitoring systemic HIV infection but the relationship between plasma viral load and CNS functioning remains unclear. Equivocal results have been reported on the relationship between plasma viral load and cognitive functioning. The present study tested cognitive functions with a standardized neuropsychological battery consisting of 28 test scores. Participants (N = 140) were grouped into undetectable (<400 copies), low (401-10,000 copies), or moderate (10,001-100,000 copies) viral load groups. Statistical analyses (MANOVA and MANCOVA) revealed no differences in neuropsychological test performance between the viral load groups. Fairly healthy patients with moderate plasma viral loads do not appear to show increased neuropsychological dysfunction. CSF viral load may be more helpful in evaluating cognitive correlates of HIV encephalitis. (C) 2004 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved. C1 Univ Washington, Sch Med, Dept Psychiat & Behav Sci, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Sch Med, Res & Educ Inst,Dept Psychiat & Biobehav Sci, Torrance, CA 90509 USA. RP Martin, DJ (reprint author), Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Sch Med, Res & Educ Inst,Dept Psychiat & Biobehav Sci, 1000 W Carson St,Box 488, Torrance, CA 90509 USA. EM djmartin@ucla.edu FU NIMH NIH HHS [1 R01 MH62966-01A1]; PHS HHS [5 H97 HA00054] NR 17 TC 12 Z9 12 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD MAR PY 2005 VL 20 IS 2 BP 137 EP 143 DI 10.1016/j.acn.2004.03.009 PG 7 WC Psychology, Clinical; Psychology SC Psychology GA 903AU UT WOS:000227398600001 PM 15708723 ER PT J AU Goldstein, G Shemansky, WJ Allen, DN AF Goldstein, G Shemansky, WJ Allen, DN TI Cognitive function in schizoaffective disorder and clinical subtypes of schizophrenia SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE schizophrenia; mood disorder; cognitive heterogeneity ID HETEROGENEITY AB Cognitive studies of patients with Schizoaffective Disorder typically indicate that the cognitive function of these patients resembles that of patients with Schizophrenic Disorder more than it does patients with nonpsychotic Mood Disorder. In this study patients with Schizoaffective Disorder were compared with patients with Paranoid, Undifferentiated and Residual clinical subtypes on a number of measures of cognitive function. Multivariate analyses of variance indicated that the cognitive function of Schizoaffective and Paranoid patients had more intact cognitive function that did Undifferentiated and Residual patients. Application of cluster analysis indicated that there were relative high percentages of Schizoaffective and Paranoid patients in a "Neuropsychologically Normal" cluster. It was concluded that Schizoaffective Disorder as well as other clinical subtypes of schizophrenia are cognitively heterogeneous, and it was suggested that a subgroup of patients with Schizoaffective Disorder may not differ in cognitive ability from patients with nonpsychotic Mood Disorder. (C) 2004 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved. C1 VA Pittsburgh Healthcare Syst, Res 151R, Pittsburgh, PA 15206 USA. Univ Nevada, Las Vegas, NV 89154 USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, Res 151R, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM ggold@nb.net NR 10 TC 37 Z9 38 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6177 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD MAR PY 2005 VL 20 IS 2 BP 153 EP 159 DI 10.1016/j.acn.2004.03.008 PG 7 WC Psychology, Clinical; Psychology SC Psychology GA 903AU UT WOS:000227398600003 PM 15708725 ER PT J AU Algood, SD Cooper, RA Fitzgerald, SG Cooper, R Boninger, ML AF Algood, SD Cooper, RA Fitzgerald, SG Cooper, R Boninger, ML TI Effect of a pushrim-activated power-assist wheelchair on the functional capabilities of persons with tetraplegia SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article; Proceedings Paper CT 27th International Conference of the RESNA CY JUN 18-24, 2004 CL Orlando, FL SP RESNA DE activities of daily living; rehabilitation; tetraplegia; wheelchairs ID MANUAL WHEELCHAIR; PHYSICAL STRAIN; UPPER EXTREMITY; PROPULSION; PERFORMANCE; PARAPLEGIA; PHYSIOLOGY; EFFICIENCY; USERS; PAIN AB Objectives: To test the differences between a pushrim-activated power-assisted wheelchair (PAPAW) and a traditional manual wheelchair while performing common driving activities and to assess their relative merits for people with tetraplegia. Design: Repeated measures. Setting: An activities of daily living (ADL) laboratory within a rehabilitation research center. Participants: Fifteen full-time manual wheelchair users with tetraplegia due to a spinal cord injury. Interventions: Participants propelled both their own manual wheelchairs and a PAPAW 3 times over an ADL course. The order in which the 2 different wheelchairs were presented to the participants was randomized. Main Outcome Measures: Each participant's heart rate was monitored throughout testing by a digital, wireless heart-rate monitor. Time to complete the course was recorded, and participants were surveyed with a visual analog scale after the first, third, fourth, and sixth trials to determine the ease of completing each obstacle and their ergonomic preferences between the 2 wheelchairs. Participants also were observed throughout the trials to determine how much assistance they needed to complete each obstacle course. Results: After using a Bonferroni adjustment, 4 obstacles (carpet, dimple strips, up a ramp, up a curb cut) were rated as being significantly easier (P < .001) to complete when using the PAPAW. Participants also showed a significant decrease in mean heart rate throughout all 3 trials (P = .015, P = .001, P = .003, respectively) when using a PAPAW. The amount of assistance needed by participants, the responses to ergonomic questions, and the overall time to complete the ADL course did not differ significantly between the 2 wheelchairs. Conclusions: For subjects with tetraplegia, PAPAWs have the potential to improve functional capabilities during certain ADLs, especially when propelling up ramps, over uneven surfaces, and over thick carpet. (C) 2005 by American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation. C1 VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151 R1, VA Rehabil Res & Dev Ctr, Pittsburgh, PA 15206 USA. Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs 151 R1, VA Rehabil Res & Dev Ctr, 7180 Highland Dr, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu OI Boninger, Michael/0000-0001-6966-919X NR 22 TC 27 Z9 30 U1 1 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2005 VL 86 IS 3 BP 380 EP 386 DI 10.1016/j.apmr.2004.05.017 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 904DB UT WOS:000227475200003 PM 15759215 ER PT J AU Hughes, RB Robinson-Whelan, S Taylor, HB Petersen, NJ Nosek, MA AF Hughes, RB Robinson-Whelan, S Taylor, HB Petersen, NJ Nosek, MA TI Characteristics of depressed and nondepressed women with physical disabilities SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE depression; disabled persons; rehabilitation; women's health ID SECONDARY CONDITIONS; INVENTORY-II; SYMPTOMS; GENDER; CARE; DISPARITIES; POPULATION; PREVALENCE; RACE; PAIN AB Objectives: To describe the characteristics of depressed versus nondepressed women with disabilities. Design: Survey. Setting: Women were recruited through private and public health clinics and various community organizations. Participants: A sample of 443 predominantly ethnic-minority women, ages 18 to 83 years, with physical disabilities. Interventions: Not applicable. Main Outcome Measure: Beck Depression Inventory-II (BDI-II). Results: Approximately half (51%) of the sample had scores in the mildly depressed range or higher on the BDI-II. Women classified as depressed were more likely to have multiple sclerosis, to be younger, or to have a shorter duration of disability. Only 44% of the women with scores exceeding the BDI-II cutoff for significant depressive symptomatology had received recent treatment for depression, with Hispanic women being the least likely to report receiving treatment. Depressed women reported significantly more health conditions, reflecting common symptoms of depression, conditions linked with depression in the general population, conditions known to be secondary to the primary condition, and conditions known to be common side effects of medications. Depression was not related to functional limitations. Conclusions: Depression is a serious mental health problem facing many women with physical disabilities that does not appear to be adequately addressed by health care professionals. (C) 2005 by American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation. C1 Baylor Coll Med, Ctr Res Women Disabil, Dept Phys Med & Rehabil, Houston, TX 77030 USA. Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA. Dept Vet Affairs Med Ctr, Rehabil Res & Dev Serv, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res& Dev Serv, Houston, TX USA. RP Hughes, RB (reprint author), Baylor Coll Med, Ctr Res Women Disabil, Dept Phys Med & Rehabil, 6550 Fannin,Ste 1421, Houston, TX 77030 USA. EM rhughes@bcm.tmc.edu FU ODCDC CDC HHS [R04/CCR618805] NR 33 TC 15 Z9 16 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2005 VL 86 IS 3 BP 473 EP 479 DI 10.1016/j.apmr.2004.06.068 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 904DB UT WOS:000227475200019 PM 15759231 ER PT J AU Saam, T Cai, JM Cai, YQ An, NY Kampschulte, A Xu, D Kerwin, WS Takaya, N Polissar, NL Hatsukami, TS Yuan, C AF Saam, T Cai, JM Cai, YQ An, NY Kampschulte, A Xu, D Kerwin, WS Takaya, N Polissar, NL Hatsukami, TS Yuan, C TI Carotid plaque composition differs between ethno-racial groups - An MRI pilot study comparing mainland Chinese and American Caucasian patients SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY LA English DT Article DE atherosclerosis; carotid arteries; epidemiology; MRI ID CORONARY-ARTERY CALCIFICATION; HIGH-RESOLUTION MRI; IN-VIVO ACCURACY; RISK-FACTORS; ATHEROSCLEROTIC LESIONS; WHITE SUBJECTS; CLASSIFICATION; HYPERTENSION; PREVALENCE; HEMORRHAGE AB Objective - Ethnicity-based research may identify new clues to the pathogenesis of atherosclerotic disease. Therefore, we sought to determine whether carotid lesions differ between 20 Chinese and 20 Caucasian Americans by MRI. Methods and Results - Inclusion criteria were > 50% stenosis as measured by duplex ultrasound and recent symptoms attributed to carotid artery disease. The patients were imaged in 2 centers ( Beijing, China and Seattle, Wash) using a standardized protocol. Both carotid arteries were reviewed quantitatively ( lumen, wall, outer wall, tissue components) and morphologically ( lesion types, fibrous cap status). Significant differences between the Chinese and Americans were found for the mean size of the lipid/necrotic core (13.6 versus 7.8 mm(2); P = 0.002), percentage of slices with calcified type VII lesions (1.6 versus 12.4%; P = 0.03), and percentage of slices with early type III lesions (19.3 versus 9.3%; P = 0.02). Furthermore, the mean outer wall area in the common carotid artery was larger in the Chinese population ( P = 0.007). Conclusions - This pilot study suggests that composition and morphology of atherosclerotic lesions in symptomatic carotid disease differ between ethno-racial groups. Quantitative MRI-based review of carotid atherosclerosis comparing plaque morphology and composition between ethno-racial groups is feasible, and future MRI studies may improve our understanding of the pathophysiology of this disease. C1 Univ Washington, Dept Radiol, Seattle, WA 98195 USA. Peoples Liberat Army Gen Hosp, Dept Radiol, Beijing, Peoples R China. Mt Whisper Light Stat Consulting, Seattle, WA USA. Univ Washington, Dept Surg, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Yuan, C (reprint author), Univ Washington, Dept Radiol, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA. EM cyuan@u.washington.edu FU NHLBI NIH HHS [R01HL56874, R01HL61851] NR 24 TC 25 Z9 26 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1079-5642 J9 ARTERIOSCL THROM VAS JI Arterioscler. Thromb. Vasc. Biol. PD MAR PY 2005 VL 25 IS 3 BP 611 EP 616 DI 10.1161/01.ATV.0000155965.54679.79 PG 6 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 900NL UT WOS:000227221500025 PM 15653565 ER PT J AU Becker, MA Schumacher, HR Wortmann, RL MacDonald, PA Palo, WA Eustace, D Vernillet, L Joseph-Ridge, N AF Becker, Michael A. Schumacher, H. Ralph, Jr. Wortmann, Robert L. MacDonald, Patricia A. Palo, William A. Eustace, Denise Vernillet, Laurent Joseph-Ridge, Nancy TI Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase SO ARTHRITIS AND RHEUMATISM LA English DT Article ID ALLOPURINOL HYPERSENSITIVITY SYNDROME; CHRONIC GOUT; HYPERURICEMIA; TEI-6720; THERAPY; ATTACKS; METABOLISM; MANAGEMENT; REDUCTION; MECHANISM AB Objective. Gout affects similar to 1-2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in establishing normal serum urate (sUA) concentrations in gout patients with hyperuricemia (>= 8.0 mg/dl). Methods. We conducted a phase 11, randomized, double-blind, placebo-controlled trial in 153 patients (ages 23-80 years). Subjects received febuxostat (40 mg, 80 mg, 120 mg) or placebo once daily for 28 days and colchicine prophylaxis for 14 days prior to and 14 days after randomization. The primary end point was the proportion of subjects with sUA levels <6.0 mg/dl on day 28. Results. Greater proportions of febuxostat-treated patients than placebo-treated patients achieved an sUA level < 6.0 mg/dl at each visit (P < 0.001 for each comparison). The targeted sUA level was attained on day 28 in 0% of those taking placebo and in 56% of those taking 40 mg, 76% taking 80 mg, and 94% taking 120 mg of febuxostat. The mean sUA reduction from baseline to day 28 was 2% in the placebo group and 37% in the 40-mg, 44% in the 80-mg, and 59% in the 120-mg febuxostat groups. Gout flares occurred with similar frequency in the placebo (37%) and 40-mg febuxostat (35%) groups and with increased frequency in the higher dosage febuxostat groups (43% taking 80 mg; 55% taking 120 mg). During colchicine prophylaxis, gout flares occurred less frequently (8-13%). Incidences of treatment-related adverse events were similar in the febuxostat and placebo groups. Conclusion. Treatment with febuxostat resulted in a significant reduction of sUA levels at all dosages. Febuxostat therapy was safe and well tolerated. C1 [Becker, Michael A.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA. [Schumacher, H. Ralph, Jr.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Schumacher, H. Ralph, Jr.] Vet Affairs Med Ctr, Philadelphia, PA USA. [Wortmann, Robert L.] Univ Oklahoma, Tulsa, OK USA. [MacDonald, Patricia A.; Palo, William A.; Eustace, Denise; Vernillet, Laurent; Joseph-Ridge, Nancy] TAP Pharmaceut Prod Inc, Lake Forest, IL USA. RP Becker, MA (reprint author), 5841 S Maryland Ave,MC0930, Chicago, IL 60637 USA. EM mbecker@medicine.bsd.uchicago.edu NR 42 TC 130 Z9 143 U1 3 U2 15 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0004-3591 J9 ARTHRITIS RHEUM JI Arthritis Rheum. PD MAR PY 2005 VL 52 IS 3 BP 916 EP 923 DI 10.1002/art.20935 PG 8 WC Rheumatology SC Rheumatology GA 905LU UT WOS:000227570600031 PM 15751090 ER PT J AU Salinsky, MC Storzbach, D AF Salinsky, MC Storzbach, D TI The Portland neurotoxicity scale - Validation of a brief self-report measure of antiepileptic-drug-related neurotoxicity SO ASSESSMENT LA English DT Article DE antiepileptic drugs; cognition; neurotoxicity; self-reporting ID ASSESSMENT SCHEDULE ABNAS; TONIC-CLONIC SEIZURES; PATIENT-BASED SCALE; QUALITY-OF-LIFE; NEUROPSYCHOLOGICAL ASSESSMENT; DOUBLE-BLIND; COGNITIVE PERFORMANCE; HEALTHY-VOLUNTEERS; EPILEPSY; CARBAMAZEPINE AB The Portland Neurotoxicity Scale (PNS) is a brief patient-based survey of neurotoxicity complaints commonly encountered with the use of antiepileptic drugs (AEDs). The authors present data on the validity of this scale, particularly when used in longitudinal studies. Participants included 55 healthy controls, 23 epilepsy patient controls, and 86 healthy volunteers who took various AEDs or placebos for 12 weeks as part of randomized, double-blind studies of AED effects on cognitive abilities. Test-retest reliability in the control groups averaged .80 (total score). Test-retest changes in the PNS were sensitive to AED usage in general (p < .001) and to each of the five AEDs tested but not to placebo. Test-retest changes in the PNS were strongly correlated with several scales of the Profile of Mood States but only weakly correlated with objective cognitive test measures. The PNS has satisfactory psychometric properties and is sensitive to AED usage in test-retest studies. C1 Oregon Hlth Sci Univ, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Salinsky, MC (reprint author), Oregon Hlth Sci Univ, Portland, OR 97201 USA. NR 35 TC 10 Z9 10 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1073-1911 J9 ASSESSMENT JI Assessment PD MAR PY 2005 VL 12 IS 1 BP 107 EP 117 DI 10.1177/1073191104272857 PG 11 WC Psychology, Clinical SC Psychology GA 901MM UT WOS:000227286600011 PM 15695749 ER PT J AU Oshima, M Ohtani, M Deitiker, PR Smith, RG Mosier, DR Atassi, MZ AF Oshima, M Ohtani, M Deitiker, PR Smith, RG Mosier, DR Atassi, MZ TI Suppression by mAbs against DQB1 peptides of in vitro proliferation of AChR-specific T cells from myasthenia gravis patients SO AUTOIMMUNITY LA English DT Article DE acetylcholine receptor; antigen-presenting region; MHC; monoclonal antibodies; myasthenia gravis ID HUMAN ACETYLCHOLINE-RECEPTOR; PERIPHERAL-BLOOD LYMPHOCYTES; MHC CLASS-II; ALPHA-SUBUNIT; BETA-CHAIN; EXTRACELLULAR PART; HLA-DR; ANTIBODY; REGION; BINDING AB It has been indicated that multiple genes, including HLA genes, are collectively involved in the susceptibility to myasthenia gravis (MG). DQB1 alleles represent one of those associated with MG. We have prepared B-cell hybridomas that produce mAbs against peptides corresponding to the tip of the MHC antigen-binding cavity (region 70-90) of alleles DQB1*02, *03, *05 and *06. The mAbs bound to DQ molecules isolated from cells. In the assays using peripheral blood lymphocytes (PBL) from patients with MG, the mAbs against peptides of the correlate HLA DQ sequences inhibited the in vitro proliferation of acetylcholine receptor (AChR)-specific T cells. The results indicate that the function of disease-related MHC alleles may be blocked by directly and selectively targeting the antigen-presenting region on these MHC molecules. The results also suggest that DQ molecules are one of those involved in the restriction of autoimmune anti-AChR responses in MG. The strategy could provide an effective means for immunointervention in MG. It may also potentially be adapted for down-regulation of undesirable immune responses such as in other autoimmune diseases, allergic reactions, or clinical conditions where immune responses to a therapeutic protein develop. C1 Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA. Univ Texas, Med Branch, Dept Neurol, Galveston, TX 77555 USA. Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. ME DeBakey VA Med Ctr, Neurol Serv, Houston, TX 77030 USA. ME DeBakey VA Med Ctr, Med Res Serv, Houston, TX 77030 USA. Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA. RP Oshima, M (reprint author), Baylor Coll Med, Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA. EM moshima@bcm.tmc.edu NR 45 TC 6 Z9 6 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0891-6934 J9 AUTOIMMUNITY JI Autoimmunity PD MAR PY 2005 VL 38 IS 2 BP 161 EP 169 DI 10.1080/08916930500050491 PG 9 WC Immunology SC Immunology GA 939YO UT WOS:000230109000008 PM 16040337 ER PT J AU Yamashita, Y Chiba, Y Xia, C Hirayoshi, K Satoh, M Saitoh, Y Shimada, A Nakamura, E Hosokawa, M AF Yamashita, Y Chiba, Y Xia, C Hirayoshi, K Satoh, M Saitoh, Y Shimada, A Nakamura, E Hosokawa, M TI Different adaptive traits to cold exposure in young senescence-accelerated mice SO BIOGERONTOLOGY LA English DT Article DE body temperature; cold exposure; senescence-accelerated mouse (SAM); spontaneous motor activity (SMA); uncoupling protein 1 (UCP1) ID BROWN ADIPOSE-TISSUE; UNCOUPLING PROTEIN; NONSHIVERING THERMOGENESIS; THERMOREGULATION; MODEL; RATS AB A reduced adaptation to cold is a prominent feature in aged mammals, including humans. The accelerated senescence-prone strain of mice (SAMP) has been studied as an animal model for several age-associated disorders and in the acceleration of senescence. Recent studies revealed that SAMP strains have dysfunctional hyperactive mitochondria and are under a higher oxidative stress status from a young age. To investigate whether young SAMP mice show impaired cold adaptation abilities, we performed cold-exposure experiments. There were no strain differences in baseline body temperature and lowest reached temperature during cold exposure. SAMP1 mice took longer times to reach their lowest temperature in comparison to SAMR1 mice. SAMR1 mice showed an elevation in temperature following cold exposure, whereas SAMP1 mice did not. Behavioral observations demonstrated that SAMP1 mice moved more actively than SAMR1 during cold exposure. However, mRNA levels of uncoupling protein 1 (UCP1), a heat generating protein, as well as plasma norepinephrine levels, were higher in SAMP1 than in SAMR1 mice. This newly found physiological phenotype in SAMP1 mice provides us with a tool to clarify the genetic mechanism which accelerates the senescence process and helps us develop medical means which will bring mankind to a healthy old age. C1 Aichi Human Serv Ctr, Inst Dev Res, Dept Pathol, Aichi 4800392, Japan. Kyoto Univ, Grad Sch Human & Environm Studies, Lab Aging Study, Sakyo Ku, Kyoto 6068507, Japan. Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. Houston Dept Vet Affairs Med Ctr, Houston, TX 77030 USA. Kyoto Univ, Inst Frontier Med Sci, Dept Ultrastruct Res, Sakyo Ku, Kyoto 6068507, Japan. RP Chiba, Y (reprint author), Aichi Human Serv Ctr, Inst Dev Res, Dept Pathol, Aichi 4800392, Japan. EM ychiba@inst-hsc.jp NR 17 TC 1 Z9 1 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 1389-5729 J9 BIOGERONTOLOGY JI Biogerontology PD MAR PY 2005 VL 6 IS 2 BP 133 EP 139 DI 10.1007/s10522-005-3499-x PG 7 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 948GX UT WOS:000230705200005 PM 16034680 ER PT J AU Bartzokis, G Lu, PH Turner, J Mintz, J Saunders, CS AF Bartzokis, G Lu, PH Turner, J Mintz, J Saunders, CS TI Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder SO BIOLOGICAL PSYCHIATRY LA English DT Article; Proceedings Paper CT 58th Annual Convention of the Society-of-Biological-Psychiatry CY MAY 15-17, 2003 CL SAN FRANCISCO, CA SP Soc Biol Psychiat DE PTSD; posttraumatic stress disorder; risperidone; antipsychotic; atypical; combat; chronic ID DOUBLE-BLIND; RATING-SCALE; PLACEBO; SCHIZOPHRENIA; OLANZAPINE; DEPRESSION; SERTRALINE; CLOZAPINE; SYMPTOMS; CHILDREN AB Background: The efficacy and safety of risperidone was evaluated in veteran patients with chronic combat-related postraumatic stress disorder (PTSD) who were referred to a residential treatment program. Methods. Seventy-three subjects volunteered to participate in this double-blind. placebo-controlled study, which comprised of a 5 week residential program followed by a 3-month outpatient follow-up. Risperidone was added to a stable psychotropic medication regimen in 92% of subjects. Primary outcome measures were the Clinician-Administered PTSD scale (CAPS-total) and its three subscales; B (Re-experiencing), C(Avoidance) and D (Arousal). Secondary outcome measures were the Hamilton Anxiety (HAM-A) and Depression (HAM-D) scales, and the Positive and Negative Syndrome Scale, Positive Subscale (PANSS-P). Results: Sixty-five subjects were randomized and 48 completed the 4-month study. Significantly greater improvement in symptoms was observed in subjects receiving risperidone compared to placebo on the CAPS-total and CAPS-D subscale scores and also on HAM-A and PANSS-P. Numerically greater improvements in all the remaining measures were noted with risperidone, but the differences did not reach statistical significance. Risperidone was well tolerated. Conclusions. These results suggest that adjunctive risperidone improved a broad range of pychiatric symptoms in patients with chronic combat-related PTSD. The data support the concept that a typical antipsychotic medications may have a wider therapeutic spectrum that goes beyond the treatment of psychosis. C1 Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA. RP Bartzokis, G (reprint author), Reed Neurol Res Ctr, 710 Westwood Pl,Room 2-238, Los Angeles, CA 90095 USA. EM gbar@ucla.edu RI Bartzokis, George/K-2409-2013 NR 31 TC 108 Z9 111 U1 1 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 1 PY 2005 VL 57 IS 5 BP 474 EP 479 DI 10.1016/j.biopsych.2004.11.039 PG 6 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 903HB UT WOS:000227415400005 PM 15737661 ER PT J AU Shaughnessy, PJ Bachier, C Grimley, M Freytes, CO Callander, NS Essell, YH Flomenberg, N Selby, G Lemaistre, CE AF Shaughnessy, PJ Bachier, C Grimley, M Freytes, CO Callander, NS Essell, YH Flomenberg, N Selby, G Lemaistre, CE TI Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE denileukin diftitox; steroid resistance; graft-versus-host disease ID BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; INTERLEUKIN-2 RECEPTOR; RETROSPECTIVE ANALYSIS; PHASE-II; T-CELLS; ANTIBODY; THERAPY; TRIAL; DAB(389)IL-2 AB Acute graft-versus-host disease (aGVHD) is partly mediated through activated T cells, and these cells are known to express the high-affinity receptor for interleukin 2 (IL-2R). Denileukin diftitox is composed of human IL-2 and diphtheria toxin that is cytotoxic to activated lymphocytes expressing the high-affinity IL-2R. We describe the results of a phase H study of denileukin diftitox in 22 patients with steroid-resistant aGVHD. Twenty patients were treated at dose level 1 (4.5 mu g/kg daily on days 1-5 and then weekly on study days 8, 15, 22, and 29), and 2 patients were treated at dose level 2 (9.0 mu g/kg delivered on the same schedule). Dose level 2 was associated with grade 3/4 renal and hepatic toxicity and vascular leak syndrome, and no further patients were treated at this level. Dose level I was generally well tolerated. The response of aGVHD was assessed at study days 36 and 100. Nine patients (41%) responded, all with a complete response at study day 36, and 6 patients (27%) responded at study day 100 (4 complete responses and 2 partial responses). Denileukin diftitox has promising activity in steroid-resistant aGVHD, and further study is warranted. (c) 2005 American Society for Blood and Marrow Transplantation. C1 Texas Transplant Inst, San Antonio, TX 78229 USA. Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Jewish Hosp, Cincinnati, OH USA. Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. Univ Oklahoma, Oklahoma City, OK USA. RP Shaughnessy, PJ (reprint author), Texas Transplant Inst, 8201 Ewing Halsell,Ste 280, San Antonio, TX 78229 USA. EM Paul.Shaughnessy@MHShealth.com NR 31 TC 43 Z9 48 U1 0 U2 1 PU CARDEN JENNINGS PUBL CO LTD PI CHARLOTTESVILLE PA BLAKE CTR, STE 200, 1224 W MAIN ST, CHARLOTTESVILLE, VA 22903 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD MAR PY 2005 VL 11 IS 3 BP 188 EP 193 DI 10.1016/j.bbmt.2004.11.022 PG 6 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 910US UT WOS:000227958300004 PM 15744237 ER PT J AU Mielcarek, M Gooley, T Martin, P Chauncey, TR Young, BA Storb, R Torok-Storb, B AF Mielcarek, M Gooley, T Martin, P Chauncey, TR Young, BA Storb, R Torok-Storb, B TI Effects of race on survival after stem cell transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE hematopoietic stem cell transplantation; race; mortality; graft-versus-host disease; relapse; socioeconomic factors ID VERSUS-HOST-DISEASE; ALLOGENEIC MARROW TRANSPLANTATION; CHRONIC MYELOID-LEUKEMIA; ACUTE GRAFT; SOCIOECONOMIC-STATUS; ETHNIC-DIFFERENCES; AFRICAN-AMERICANS; DONOR PROGRAM; PROPHYLAXIS; GENE AB Effects of race or ethnicity on survival after high-dose chemoradiation followed by stem cell transplantation (SCT) have not been thoroughly evaluated. We analyzed survival according to racial/ethnic categories for 3587 consecutive patients who had SCT at a single US institution between July 1992 and December 2000. Among 1366 patients who received autologous SCT, race or ethnicity was not significantly associated with survival. In contrast, among 2221 patients who received allogeneic SCT from IIIA-matched unrelated or sibling donors, blacks had a significantly greater mortality than whites (unadjusted hazard ratio, 1.65; 95% confidence interval, 1.21-2.25). Mortality among other racial or ethnic groups was not significantly different from that among whites. The greater mortality hazard among blacks persisted after controlling for donor type, pretransplantation risk category, patient age, donor/patient sex, and cytomegalovirus exposure (hazard ratio, 1.71; 95% confidence interval, 1.25-2.34). SCT from both HLA-matched unrelated and IRA-identical sibling donors was associated with more severe acute graft-versus-host disease and higher nonrelapse mortality among blacks compared with whites. Furthermore, blacks who received SCT for chronic myeloid leukemia had longer diagnosis-to-transplantation intervals than whites. A matched-cohort analysis showed that the higher mortality among blacks could not be explained by obvious socioeconomic differences. The higher incidence of severe graft-versus-host disease among blacks compared with whites, both with PILA-identical sibling donors, might be related to yet-unidentified "immune-enhancing" genetic polymorphisms. We cannot exclude the possibility that the increased mortality risk among blacks after discharge from the transplant center might in part be related to unidentified sociocultural differences that influence medical care. 2005 American Society for Blood and Marrow Transplantation. C1 Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Mielcarek, M (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D1-100, Seattle, WA 98109 USA. EM mmielcar@fhcrc.org NR 38 TC 23 Z9 23 U1 0 U2 0 PU CARDEN JENNINGS PUBL CO LTD PI CHARLOTTESVILLE PA BLAKE CTR, STE 200, 1224 W MAIN ST, CHARLOTTESVILLE, VA 22903 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD MAR PY 2005 VL 11 IS 3 BP 231 EP 239 DI 10.1016/j.bbmt.2004.12.327 PG 9 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 910US UT WOS:000227958300009 PM 15744242 ER PT J AU Panse, JP Heimfeld, S Guthrie, KA Maris, MB Maloney, DG Baril, BB Little, MT Chauncey, TR Storer, BE Storb, R Sandmaier, BM AF Panse, JP Heimfeld, S Guthrie, KA Maris, MB Maloney, DG Baril, BB Little, MT Chauncey, TR Storer, BE Storb, R Sandmaier, BM TI Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE graft composition; non-myeloablative transplantation; chimaerism ID COLONY-STIMULATING FACTOR; BONE-MARROW TRANSPLANTATION; VERSUS-HOST-DISEASE; HEMATOPOIETIC PROGENITOR CELLS; UNRELATED DONORS; HEMATOLOGICAL MALIGNANCIES; IMMUNE RECONSTITUTION; ENGRAFTMENT KINETICS; LEUKEMIA; DEPLETION AB We have studied the influence of cell subsets [CD34, CD3, CD4, CD8, CD14, CD20, natural killer (NK; CD3(-)/CD56(+)), NKT (CD3(+)/CD56(+)), DC1, and DC2 cells] of granulocyte colony-stimulating factor mobilized peripheral blood stem cells (PBSC) on early T-cell chimaerism and later clinical outcomes in 125 patients with haematological malignancies who received human leucocyte antigen (HLA)-matched related grafts after non-myeloablative conditioning. Conditioning consisted of 2 Gy total body irradiation (TBI) alone (n = 28), or 2 Gy TBI preceded by either 90 mg/m(2) fludarabine (n = 62) or planned autologous haematopoietic cell transplantation (HCT) (n = 35). Post-transplant immunosuppression included mycophenolate mofetil and ciclosporin. Multivariate analysis showed that higher numbers of grafted NK cells predicted higher early T-cell chimaerism (P = 0.03), while higher numbers of B cells were associated with better clinical outcomes and a higher risk for chronic graft-versus-host disease (P = 0.05). Higher numbers of CD14(+) cells were associated with worse overall survival (P = 0.03), while higher numbers of CD34(+) cells showed better survival (P = 0.03). The addition of fludarabine or autologous HCT predicted higher early T-cell chimaerism (P = 0.001), while advanced donor age predicted lower chimaerism (P less than or equal to 0.02). Patients with aggressive diseases were at higher risk for relapse/disease progression, and shorter progression-free and overall survival (P < 0.01). These results suggest that the dosing of certain cellular subsets of PBSC products can influence important outcomes post-HCT after non-myeloablative conditioning. C1 Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. Univ Washington, Dept Biostat, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA. Univ Washington, Dept Med, Sch Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Sandmaier, BM (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D1-100,POB 19024, Seattle, WA 98109 USA. EM bsandmai@fhcrc.org FU NCI NIH HHS [CA 15704, CA 18029, CA 78902, P01 CA078902]; NHLBI NIH HHS [HL36444]; NIDDK NIH HHS [DK56465] NR 50 TC 47 Z9 48 U1 2 U2 4 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0007-1048 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD MAR PY 2005 VL 128 IS 5 BP 659 EP 667 DI 10.1111/j.1365-2141.2005.05363.x PG 9 WC Hematology SC Hematology GA 899XE UT WOS:000227178300011 PM 15725088 ER PT J AU Rudolph, RE Dominitz, JA Lampe, JW Levy, L Qu, PP Li, SYS Lampe, PD Bronner, MP Potter, JD AF Rudolph, RE Dominitz, JA Lampe, JW Levy, L Qu, PP Li, SYS Lampe, PD Bronner, MP Potter, JD TI Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID HUMAN COLON; QUANTIFICATION; INSTABILITY; CARCINOGENESIS; IDENTIFICATION; PROGRESSION; DYSPLASIA; DISEASE; RATS AB Several characteristics of aberrant crypt foci (ACF) suggest that they are precursors of colorectal cancer, but the factors that promote or inhibit their growth are largely unknown. We conducted a pilot study to explore whether factors associated with risk of colorectal cancer are also associated with number or size of rectal ACF. Thirty-two U.S. veterans, ages 50 to 80 years, were recruited to undergo magnifying chromoendoscopy for imaging of rectal ACF and colonoscopy for identification of polyps or cancer. Participants completed a questionnaire on cigarette smoking, use of nonsteroidal anti-inflammatory drugs (NSAIDs), and family history of colorectal cancer. Fisher's exact test was used to assess the statistical significance of associations between colorectal cancer risk factors and characteristics of ACF. Cochran-Mantel-Haenszel statistics and polytomous regression were used to test the significance of associations adjusted for age. Participants with a history of adenoma had more ACF than those without (age-adjusted P = 0.02), but the numbers in the two groups overlapped markedly. Older participants had more (P = 0.06) and larger (P = 0.009) ACF than younger participants. No associations were identified between either ACF number or size and cigarette smoking, use of NSAIDs, or family history of colorectal cancer. These findings suggest that persons with adenomas have somewhat more rectal ACF than persons without, and that older age is a risk factor for ACF growth. Future research should be directed toward developing techniques to identify ACF that are likely to progress to cancer and the modifiable factors that promote or inhibit such progression. C1 Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98109 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Dept Med, Seattle, WA USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA. Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA. RP Rudolph, RE (reprint author), Fred Hutchinson Canc Res Ctr, Canc Prevent Program, POB 19024,M3-B232, Seattle, WA 98109 USA. EM rrudolph@fhcrc.org OI Potter, John/0000-0001-5439-1500; Dominitz, Jason/0000-0002-8070-7086 FU NCI NIH HHS [P01 CA074184] NR 24 TC 47 Z9 51 U1 0 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD MAR PY 2005 VL 14 IS 3 BP 605 EP 608 DI 10.1158/1055-9965.EPI-04-0058 PG 4 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 905CS UT WOS:000227545900012 PM 15767337 ER PT J AU Peters, N Armstrong, K AF Peters, N Armstrong, K TI Racial differences in prostate cancer treatment outcomes - A systematic review SO CANCER NURSING LA English DT Article DE African Americans; blacks; prostate cancer; prostate neoplasm; treatment outcome ID AFRICAN-AMERICAN MEN; DISEASE-FREE SURVIVAL; ACCESS MEDICAL-CENTER; RADICAL PROSTATECTOMY; WHITE MEN; RADIATION-THERAPY; INDEPENDENT PREDICTOR; HEALTH-CARE; PROGNOSTIC-SIGNIFICANCE; BIOCHEMICAL RECURRENCE AB Although differences in prostate cancer incidence and mortality between black and white men are widely accepted, the existence of racial differences in treatment outcomes remains controversial. We conducted a systematic review of racial differences in prostate cancer treatment outcomes. Systematic review of literature from 1992-2002 was conducted. Database searches were performed using the terms: "prostate cancer" (keyword) or "prostate neoplasm" (subject heading) + "blacks" (subject heading) or "blacks" (keyword) + "African-Americans" (subject heading) or "African-Americans" (keyword). Two hundred fifty-eight relevant articles were identified; 29 fit the inclusion criteria. All but 3 were retrospective. Seven (24%) studies were conducted at Veterans Affairs medical centers. Treatment included radical prostatectomy (15 studies), hormonal therapy (5 studies), and radiotherapy (12 studies). Three studies included more than 1 treatment. Twenty-three (79%) studies, observed no significant difference in treatment outcomes between races. The remainder found worse outcomes among black men, including worse 5-year survival (HR range, 2.35-96.74) and higher rates of PSA failure (OR range, 1.15-1.69). Most studies Investigating racial differences in prostate cancer treatment outcomes over the past 10 years found no difference between races after controlling for tumor and patient characteristics. Efforts to narrow the gap between black and white prostate cancer mortality should focus on ensuring that all patients receive optimal treatment and that all patients become informed about the use of screening for early cancer detection. Research should focus on interventions to reduce advanced presentation of the disease and disease-related mortality among black men. C1 Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. Univ Penn, Dept Med, Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Abramson Canc Ctr, Sch Med, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Peters, N (reprint author), 1101 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM npeters@nursing.upenn.edu NR 51 TC 41 Z9 41 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0162-220X J9 CANCER NURS JI Cancer Nurs. PD MAR-APR PY 2005 VL 28 IS 2 BP 108 EP 118 PG 11 WC Oncology; Nursing SC Oncology; Nursing GA 916UE UT WOS:000228410900004 PM 15815180 ER PT J AU Precht, TA Phelps, RA Linseman, DA Butts, BD Le, SS Laessig, TA Bouchard, RJ Heidenreich, KA AF Precht, TA Phelps, RA Linseman, DA Butts, BD Le, SS Laessig, TA Bouchard, RJ Heidenreich, KA TI The permeability transition pore triggers Bax translocation to mitochondria during neuronal apoptosis SO CELL DEATH AND DIFFERENTIATION LA English DT Article DE cerebellar granule neurons; cytochrome c; cyclosporin A; Bcl-2 family ID CYTOCHROME-C RELEASE; CEREBELLAR GRANULE NEURONS; BCL-2 FAMILY PROTEINS; GROWTH-FACTOR-I; CELL-DEATH; CASPASE ACTIVATION; BIM; POTASSIUM; CHANNEL; COMPLEX AB Cerebellar granule neurons (CGNs) require depolarization for their survival in culture. When deprived of this stimulus, CGNs die via an intrinsic apoptotic cascade involving Bim induction, Bax translocation, cytochrome c release, and caspase-9 and -3 activation. Opening of the mitochondrial permeability transition pore (mPTP) is an early event during intrinsic apoptosis; however, the precise role of mPTP opening in neuronal apoptosis is presently unclear. Here, we show that mPTP opening acts as an initiating event to stimulate Bax translocation to mitochondria. A C-terminal (alpha9 helix) GFP-Bax point mutant (T182A) that constitutively localizes to mitochondria circumvents the requirement for mPTP opening and is entirely sufficient to induce CGN apoptosis. Collectively, these data indicate that the major role of mPTP opening in CGN apoptosis is to trigger Bax translocation to mitochondria, ultimately leading to cytochrome c release and caspase activation. C1 Univ Colorado, Hlth Sci Ctr Fitzsimons, Dept Pharmacol, Aurora, CO 80045 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Heidenreich, KA (reprint author), Univ Colorado, Hlth Sci Ctr Fitzsimons, Dept Pharmacol, POB 6511,Mail Stop 8303, Aurora, CO 80045 USA. EM Kim.Heidenreich@UCHSC.edu NR 42 TC 58 Z9 61 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1350-9047 J9 CELL DEATH DIFFER JI Cell Death Differ. PD MAR PY 2005 VL 12 IS 3 BP 255 EP 265 DI 10.1038/sj.cdd.4401552 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 897ME UT WOS:000227007500006 PM 15637643 ER PT J AU Restrepo, MI Anzueto, A AF Restrepo, MI Anzueto, A TI Antimicrobial treatment of community-acquired pneumonia SO CLINICS IN CHEST MEDICINE LA English DT Article ID BACTEREMIC PNEUMOCOCCAL PNEUMONIA; RESISTANT STREPTOCOCCUS-PNEUMONIAE; INITIAL EMPIRIC THERAPY; HOSPITALIZED-PATIENTS; PROGNOSTIC-FACTORS; ELDERLY-PATIENTS; MEDICAL OUTCOMES; PSEUDOMONAS-AERUGINOSA; BACTERIAL PNEUMONIA; SEVERITY CRITERIA AB Community-acquired pneumonia (CAP) is a clinical diagnosis that has a significant impact on health care management around the world. Early clinical suspicion and prompt empiric antimicrobial therapies are mandatory in patients with CAP. This article provides a review of recent studies and guidelines addressing antimicrobial therapy for hospitalized patients with CAP. C1 Univ Texas, Hlth Sci Ctr, Div Pulm & Crit Care Med, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Anzueto, A (reprint author), Univ Texas, Hlth Sci Ctr, Div Pulm & Crit Care Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM anzueto@uthscsa.edu NR 75 TC 7 Z9 7 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0272-5231 J9 CLIN CHEST MED JI Clin. Chest Med. PD MAR PY 2005 VL 26 IS 1 BP 65 EP + DI 10.1016/j.ccm.2004.10.006 PG 11 WC Respiratory System SC Respiratory System GA 913RD UT WOS:000228169800009 PM 15802167 ER PT J AU Khalid, A Finkelstein, S McGrath, K AF Khalid, A Finkelstein, S McGrath, K TI Molecular diagnosis of solid and cystic lesions of the pancreas SO CLINICS IN LABORATORY MEDICINE LA English DT Reprint ID K-RAS MUTATIONS; DETECTING TELOMERASE ACTIVITY; POLYMERASE-CHAIN-REACTION; INTRAEPITHELIAL NEOPLASIA; DUCTAL ADENOCARCINOMA; GENE-MUTATIONS; PREOPERATIVE DIAGNOSIS; BRUSH CYTOLOGY; IMMUNOHISTOCHEMICAL EVALUATION; HER-2/NEU EXPRESSION AB Pancreatic cancer is associated with a poor prognosis, and long-term survival has not changed significantly over the last several decades. Significant efforts are focused on improved diagnosis and earlier detection of pancreatic cancer through identification of specific biomarkers. This article reviews clinical applications of molecular diagnosis of solid and cystic pancreatic neoplasia. C1 Univ Pittsburgh, Med Ctr, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA. RP McGrath, K (reprint author), Univ Pittsburgh, Med Ctr, Div Gastroenterol Hepatol & Nutr, M2,C Wing,A6163,200 Lothrop St, Pittsburgh, PA 15213 USA. EM mcgrathkm@upmc.edu NR 86 TC 10 Z9 11 U1 0 U2 3 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0272-2712 J9 CLIN LAB MED JI Clin. Lab. Med. PD MAR PY 2005 VL 25 IS 1 BP 101 EP + DI 10.1016/j.cll.2004.12.009 PG 17 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 911LP UT WOS:000228004300007 PM 15749234 ER PT J AU Pekow, C AF Pekow, C TI Defining, measuring, and interpreting stress in laboratory animals SO CONTEMPORARY TOPICS IN LABORATORY ANIMAL SCIENCE LA English DT Article ID SPRAGUE-DAWLEY RATS; COMMON PROCEDURES; BEHAVIORAL-RESPONSES; PARAMETERS; MICE AB One basis of scientific research with animal subjects is consistency of subject physiology, physical parameters, and behavior. Ideally, selected experimental variables account for primary differences measured between test and control groups. One intangible variable to control is stress experienced by the animals. In common parlance, the word stress is often used to indicate a negative experience. However, stress is not inherently bad, and a stress response should not be assumed to indicate an experience of distress or pain. This paper examines ways in which research animal stress may be defined, measured, and interpreted. C1 Vet Affairs Puget Sound Hlth Care Syst, Vet Med Unit, Seattle, WA 98108 USA. RP Pekow, C (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Vet Med Unit, Res 151-L,1660 S Columbian Way, Seattle, WA 98108 USA. NR 43 TC 11 Z9 11 U1 1 U2 6 PU AMER ASSOC LABORATORY ANIMAL SCIENCE PI MEMPHIS PA 9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA SN 1060-0558 J9 CONTEMP TOP LAB ANIM JI Contemp. Top. Lab. Anim. Sci. PD MAR PY 2005 VL 44 IS 2 BP 41 EP 45 PG 5 WC Veterinary Sciences; Zoology SC Veterinary Sciences; Zoology GA 947GG UT WOS:000230630800007 PM 15773775 ER PT J AU Cummings, DE Foster-Schubert, KE Overduin, J AF Cummings, DE Foster-Schubert, KE Overduin, J TI Ghrelin and energy balance: Focus on current controversies SO CURRENT DRUG TARGETS LA English DT Review DE Ghrelin; obesity; body-weight regulation; energy homeostasis; weight loss; cachexia; gastric motility; insulin secretion; meals ID GROWTH-HORMONE SECRETAGOGUE; PRADER-WILLI-SYNDROME; INSULIN-INDUCED HYPOGLYCEMIA; AGOUTI-RELATED PROTEIN; RAT ARCUATE NUCLEUS; DES-ACYL GHRELIN; GASTRIC-ACID-SECRETION; BODY-MASS INDEX; CEREBROSPINAL-FLUID GHRELIN; GLUCAGON-LIKE PEPTIDE-1 AB Ghrelin is an enteric peptide that is the only known circulating appetite stimulant. This feature of the hormone has garnered widespread attention, as reflected by more than 1000 scientific papers featuring ghrelin that have been published since the first reports of its orexigenic actions, approximately four years ago. In this review, we discuss data that support roles for ghrelin in the short-term regulation of pre-meal hunger and meal initiation, functioning as a unique orexigenic counterpart to short-acting gastrointestinal satiation factors, such as cholecystokinin (CCK). We also highlight evidence indicating that ghrelin satisfies recognized criteria to be viewed as a participant in long-term body-weight regulation - a potential anabolic counterpart to the traditional adiposity hormones, leptin and insulin. We then discuss the following controversial questions in ghrelin research and offer our opinions regarding these debates. (1) Is ghrelin synthesized within the brain? (2) How does ghrelin increase food intake? (3) Does des-acyl ghrelin have a physiologic function? (4) Are there receptors for ghrelin other than GHS-R1a? (5) Does ghrelin regulate insulin secretion? (6) Does ghrelin regulate gastrointestinal motility? (7) Can ghrelin or ghrelin-receptor agonists be used to treat wasting conditions? Finally, we offer a speculative model of ghrelin as a thrifty gene product that evolved to help animals consume and store fat well, thereby increasing their chances of survival during times of famine. We suggest that ghrelin is a "saginary" hormone, from the Latin, saginare, which means, "to fatten". C1 Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. RP Cummings, DE (reprint author), Univ Washington, VA Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 1660 S Columbian Way,S-111-Endo, Seattle, WA 98108 USA. EM davidec@u.washington.edu FU NIDDK NIH HHS [R01 DK 61516, P01 DK 68384, U01 DK 66568] NR 270 TC 127 Z9 133 U1 2 U2 17 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1389-4501 J9 CURR DRUG TARGETS JI Curr. Drug Targets PD MAR PY 2005 VL 6 IS 2 BP 153 EP 169 PG 17 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 903JR UT WOS:000227422600003 PM 15777186 ER PT J AU Krishnan, LL Suarez-Almazor, ME AF Krishnan, LL Suarez-Almazor, ME TI Evidence-based rheumatology practice SO CURRENT OPINION IN RHEUMATOLOGY LA English DT Review DE evidence based medicine; professional practice; rheumatic diseases; rheumatology ID RANDOMIZED CONTROLLED-TRIALS; QUALITY INDICATOR SET; OF-THE-LITERATURE; ARTHRITIS CARE; KNEE OSTEOARTHRITIS; HYALURONIC-ACID; METAANALYSIS; METHOTREXATE; INJECTIONS; EFFICACY AB Purpose of review This review is intended to update readers on recent developments in the evidence-based practice of rheumatology. Recent findings Several new or updated evidence-based practice guidelines have recently emerged. In addition, a large body of evidence upon which to base practice has been addressed in the many systematic reviews and meta-analyses that have been newly published, including nine new or updated Cochrane reviews. Several studies have also investigated adherence to practice guidelines, interventions to improve clinical practice, and quality of care in the field of rheumatology in the past year. Summary Evidence-based rheumatology is an ongoing effort, with continuing revision and update of recommendations. It may currently be used to address a wide variety of clinical questions. The initiatives on practice based research to establish quality indicators and identify areas where rheumatology practice can be enhanced are a welcome addition to health services research in this field. C1 Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. RP Suarez-Almazor, ME (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM mes@bcm.tmc.edu NR 59 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8711 J9 CURR OPIN RHEUMATOL JI CURR. OPIN. RHEUMATOL. PD MAR PY 2005 VL 17 IS 2 BP 117 EP 123 PG 7 WC Rheumatology SC Rheumatology GA 912LH UT WOS:000228079200001 PM 15711221 ER PT J AU Oba, Y Lee, JW Ehrlich, LA Chung, HY Jelinek, DF Callander, NS Horuk, R Choi, SJ Roodman, GD AF Oba, Y Lee, JW Ehrlich, LA Chung, HY Jelinek, DF Callander, NS Horuk, R Choi, SJ Roodman, GD TI MIP-1 alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells SO EXPERIMENTAL HEMATOLOGY LA English DT Article ID MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; HUMAN MULTIPLE-MYELOMA; CHEMOKINE RECEPTOR; BONE-DISEASE; PROTEIN 1-ALPHA; NONPEPTIDE CCR1; EXPRESSION; ALPHA; ANTAGONIST; MODULATION AB Objectives. Macrophage inflammatory protein-let (MIP-1 alpha), an osteoclast (OCL) stimulatory factor produced by primary multiple myeloma (MM) cells, increases bone destruction and tumor burden in murine models of MM. Several chemokine receptors (CCR1, CCR5, and CCR9) mediate the effects of MIP-1 alpha. In this study, we determined which of these mediates the effects of MIP-1 alpha on human OCL formation and myeloma cells. Methods. We employed RT-PCR analysis, neutralizing antibodies to CCR1 and CCR5 as well as a CCR1-specific antagonist and OCL formation assays to identify the MIP-1 alpha receptors involved in MIP-1 alpha's effects on myeloma cells and OCL formation. Results. RT-PCR analysis demonstrated that both CCR1 and CCR5 were expressed by highly purified human OCL precursors, myeloma cell lines, and purified marrow plasma cells from MM patients. Neutralizing antibodies to CCR1 or CCR5 inhibited MIP-1 alpha-induced OCL formation. Furthermore, monocyte chemotactic protein-3 (MCP-3), which binds CCR1 but not CCR5 and the CCR1-specific antagonist, BX471, markedly inhibited OCL formation stimulated with MIP-1 alpha. Anti-CCR1, anti-CCR5, or BX471 also inhibited the upregulation of 01 integrin mRNA in myeloma cells induced by MIP-1 alpha, as well as the adherence of myeloma cells to stromal cells and IL-6 production by stromal cells in response to myeloma cells. Conclusion. These data demonstrate that MIP-1 alpha utilizes either CCR1 or CCR5 for its effects on OCL formation and myeloma cells, and that blocking either CCR1 or CCR5 inhibits OCL formation and myeloma cell adhesion to stromal cells. (c) 2005 International Society for Experimental Hematology. Published by Elsevier Inc. C1 Univ Pittsburgh, Inst Canc, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA. Dept Vet Affairs, Ctr Med, Pittsburgh, PA USA. Mayo Clin, Dept Immunol, Rochester, MN USA. Univ Texas, Ctr Hlth Sci, Dept Med Hematol, San Antonio, TX 78285 USA. Berlex Biosci, Richmond, CA USA. RP Roodman, GD (reprint author), VA Pittsburgh Healthcare Syst, Res & Dev, 151-U,Univ Dr, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu NR 26 TC 98 Z9 105 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0301-472X J9 EXP HEMATOL JI Exp. Hematol. PD MAR PY 2005 VL 33 IS 3 BP 272 EP 278 DI 10.1016/j.exphem.2004.11.015 PG 7 WC Hematology; Medicine, Research & Experimental SC Hematology; Research & Experimental Medicine GA 908ZS UT WOS:000227829300002 PM 15730850 ER PT J AU Kim, A Murphy, MP Oberley, TD AF Kim, A Murphy, MP Oberley, TD TI Mitochondrial redox state regulates transcription of the nuclear-encoded mitochondrial protein manganese superoxide dismutase: a proposed adaptive response to mitochondrial redox imbalance SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE MnSOD; thioredoxin 2; transcription; mRNA; mitochondrial redox; H2O2; mitochondrial antioxidant; MitoQ; free radicals ID PROSTATE CARCINOMA-CELLS; CYSTEINE SULFINIC ACID; REACTIVE OXYGEN; NIH/3T3 FIBROBLASTS; OXIDATIVE STRESS; OVEREXPRESSION; INHIBITION; PEROXIREDOXINS; ANTIOXIDANT; MODULATION AB Overexpression of human manganese superoxide dismutase (MnSOD) in mouse NIH/3T3 cells using an inducible retroviral system led to alterations in the mitochondrial redox state since levels of reactive oxygen species rapidly increased after induction of human MnSOD (Antioxid. Redox Signal. 6:489-500; 2004). Alterations in exogenous human MnSOD led to large increases in levels of endogenous mouse MnSOD (sod2) and thioredoxin 2 (txn2) mRNAs, but smaller increases in MnSOD and thioredoxin 2 protein expression. Tight regulation of mitochondrial protein levels seems to be necessary for optimal cellular function, since mitochondrial antioxidant protein levels did not increase to the same extent as antioxidant protein mRNA levels. We hypothesize that these changes in antioxidant proteins are adaptations to the altered mitochondrial redox state elicited by MnSOD overexpression. The mitochondrial-specific antioxidant MitoQ reversed cell growth inhibition, and greatly decreased levels of endogenous sod2 and txn2 transcripts following induction of exogenous MnSOD. Elevated levels of mouse sod2 transcripts resulted from transcriptional activation of the endogenous sod2 gene since actinomycin D prevented transcription of this gene. Therefore, the mitochondrial redox state appears to modulate a nuclear-driven biochemical event, i.e., transcriptional activation of a nuclear gene encoding a protein targeted to mitochondria. (C) 2004 Elsevier Inc. All rights reserved. C1 William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Madison, WI 53705 USA. Univ Wisconsin, Sch Med, Dept Pathol & Lab Med, Madison, WI USA. MRC, Dunn Human Nutr Unit, Cambridge, England. Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI USA. RP Oberley, TD (reprint author), William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Room A35,2500 Overlook Terrace, Madison, WI 53705 USA. EM toberley@wisc.edu RI Murphy, Michael/C-2120-2009 OI Murphy, Michael/0000-0003-1115-9618 NR 31 TC 31 Z9 31 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD MAR 1 PY 2005 VL 38 IS 5 BP 644 EP 654 DI 10.1016/j.freeradbiomed.2004.10.030 PG 11 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 898CY UT WOS:000227054900011 PM 15683720 ER PT J AU Shaib, YH El-Serag, HB Davila, JA Morgan, R McGlynn, KA AF Shaib, YH El-Serag, HB Davila, JA Morgan, R McGlynn, KA TI Risk factors of intrahepatic cholangiocarcinoma in the United States: A case-control study SO GASTROENTEROLOGY LA English DT Article ID HEPATITIS-C VIRUS; PRIMARY SCLEROSING CHOLANGITIS; DIABETES-MELLITUS; LIVER-CANCER; POPULATION; INFECTION; CARCINOMA; CIRRHOSIS; DENMARK; COHORT AB Background & Aims: The incidence of intrahepatic cholangiocarcinoma has been recently increasing in the United States. In this case-control study, we used the Surveillance, Epidemiology, and End Results-Medicare database to evaluate the prevalence of known risk factors for intrahepatic cholangiocarcinoma and explore other potential risk factors. Methods: We identified all patients with intrahepatic cholangiocarcinoma aged 65 years and older diagnosed between 1993 and 1999 in the population-based Surveillance, Epidemiology, and End Results registries (14% of the US population). Controls were randomly chosen from individuals without any cancer diagnosis in the underlying population of the Surveillance, Epidemiology, and End Results regions. We obtained information on risk factors from Medicare claims (parts A and 13) for all cases and controls with at least 2 years of continuous Medicare enrollment. Unadjusted and adjusted odds ratios were calculated in logistic regression analysis. Results: A total of 625 cases and 90,834 controls satisfied the inclusion and exclusion criteria. Cases were older than controls (78.7 vs. 76.5 years; P = .02) and were more likely to be male (48.3% vs. 36.8%; P < .0001). The racial composition was similar between cases and controls. Several risk factors were significantly more prevalent among cases. These included nonspecific cirrhosis (adjusted odds ratio, 27.2; P < .0001), alcoholic liver disease (adjusted odds ratio, 7.4; P < .0001), hepatitis C virus infection (adjusted odds ratio, 6.1; P < .0001), human immunodeficiency virus infection (adjusted odds ratio, 5.9; P = .003), diabetes (adjusted odds ratio, 2.0; P < .0001), and inflammatory bowel diseases (adjusted odds ratio, 2.3; P = .002). Conclusions: This population-based study shows that in addition to previously well described risk factors, several others could be associated with intrahepatic cholangiocarcinoma. These include hepatitis C virus, human immunodeficiency virus, liver cirrhosis, and diabetes. C1 Baylor Coll Med, Michael E Debakey Vet Affairs Med Ctr, Sect Hlth Serv Res, Houston, TX 77030 USA. Baylor Coll Med, Michael E Debakey Vet Affairs Med Ctr, Dept Gastroenterol, Houston, TX 77030 USA. NCI, NIH, Dept Human & Hlth Serv, Bethesda, MD 20892 USA. RP Shaib, YH (reprint author), Houston Vet Affairs Med Ctr, 2002 Holcombe Blvd,152, Houston, TX 77030 USA. EM yshalb@bcm.tmc.edu NR 18 TC 253 Z9 267 U1 1 U2 13 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD MAR PY 2005 VL 128 IS 3 BP 620 EP 626 DI 10.1053/j.gastro.2004.12.048 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 903SO UT WOS:000227446100015 PM 15765398 ER PT J AU Ioannou, GN Weiss, NS Boyko, EJ Kahn, SE Lee, SP AF Ioannou, GN Weiss, NS Boyko, EJ Kahn, SE Lee, SP TI Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease SO GASTROENTEROLOGY LA English DT Article ID NONALCOHOLIC FATTY LIVER; CHRONIC HEPATITIS-C; INSULIN-RESISTANCE; UNITED-STATES; NATURAL-HISTORY; VIRUS-INFECTION; US ADULTS; STEATOHEPATITIS; OBESITY; ASSOCIATION AB Background & Aims: Nonalcoholic fatty liver disease has been defined by the presence of hepatic steatosis in the absence of other chronic liver diseases. We sought to determine whether obesity, insulin resistance, and the metabolic syndrome, which are the main risk factors for nonalcoholic fatty liver disease, are associated with similar elevations in serum alanine aminotransferase activity in persons with and those without other causes of chronic liver disease. Methods: Adult participants of the third National Health and Nutrition Examination Survey were divided into those with causes of chronic liver disease (n = .1037), defined as viral hepatitis, excessive alcohol consumption, or increased transferrin-iron saturation, and those without (n = 8004). Result : Among persons with other causes of chronic liver disease, obesity (adjusted odds ratio, 4.9; 95% confidence interval, 2.5-9.4), insulin resistance (adjusted odds ratio, 6.8; 95% confidence interval, 3.0-15.5, comparing the highest and the lowest quartile), and the metabolic syndrome (adjusted odds ratio, 3.3; 95% confidence interval, 1.4-8.0) were all strongly associated with increased alanine aminotransferase activity (> 43 IU/L). Among persons without other causes of chronic liver disease, statistically similar associations were identified. Conclusions: Obesity, insulin resistance, and the metabolic syndrome are strong predictors of increased alanine aminotransferase activity in the US population, both in persons with and in persons without other causes of chronic liver disease. We hypothesize that metabolic fatty liver disease related to these conditions is the cause of the increased alanine aminotransferase activity and may be under-recognized in persons with other causes of chronic liver disease. C1 Vet Affairs Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Gastroenterol, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Endocrinol, Seattle, WA USA. Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Nutr, Seattle, WA USA. Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Seattle Vet Affairs Med Ctr, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu RI Lee, Sum Ping/C-4333-2009 OI Kahn, Steven/0000-0001-7307-9002; Boyko, Edward/0000-0002-3695-192X NR 52 TC 49 Z9 50 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD MAR PY 2005 VL 128 IS 3 BP 627 EP 635 DI 10.1043/j.gastro.2004.12.004 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 903SO UT WOS:000227446100016 PM 15810122 ER PT J AU El-Serag, HB AF El-Serag, HB TI Obesity and disease of the esophagus and colon SO GASTROENTEROLOGY CLINICS OF NORTH AMERICA LA English DT Article ID BODY-MASS INDEX; GASTROESOPHAGEAL-REFLUX DISEASE; Y GASTRIC BYPASS; RISK-FACTORS; ADENOMATOUS POLYPS; SPHINCTER PRESSURE; COLORECTAL-CANCER; HIATAL-HERNIA; UNITED-STATES; FAT INTAKE AB This article discusses the evidence linking obesity to the different manifestations of gastroesophageal reflux disease and colorectal cancer. C1 Baylor Coll Med, Gastroenterol Sect, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Sect Hlth Serv Res, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Baylor Coll Med, Gastroenterol Sect, Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu NR 62 TC 21 Z9 22 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0889-8553 J9 GASTROENTEROL CLIN N JI Gastroenterol. Clin. North Am. PD MAR PY 2005 VL 34 IS 1 BP 63 EP + DI 10.1016/j.gtc.2004.12.006 PG 21 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 921KA UT WOS:000228761900007 PM 15823439 ER PT J AU Lieberman, D AF Lieberman, D TI Quality and colonoscopy: a new imperative SO GASTROINTESTINAL ENDOSCOPY LA English DT Editorial Material ID PREVENT COLORECTAL ADENOMAS; CLINICAL IMPORTANCE; RANDOMIZED-TRIAL; FLAT ADENOMAS; CANCER; RECURRENCE; SIGMOIDOSCOPY; TUMORIGENESIS; ASPIRIN; CALCIUM C1 Oregon Hlth Sci Univ, Div Gastroenterol, Portland VA Med Ctr, Portland, OR 97201 USA. RP Lieberman, D (reprint author), Oregon Hlth Sci Univ, Div Gastroenterol, Portland VA Med Ctr, Portland, OR 97201 USA. NR 28 TC 24 Z9 24 U1 0 U2 1 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD MAR PY 2005 VL 61 IS 3 BP 392 EP 394 DI 10.1016/S0016-5107(05)00133-1 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 909LL UT WOS:000227861300007 PM 15758909 ER PT J AU Fremont, AM Bierman, A Wickstrom, SL Bird, CE Shah, M Escarce, JJ Horstman, T Rector, T AF Fremont, AM Bierman, A Wickstrom, SL Bird, CE Shah, M Escarce, JJ Horstman, T Rector, T TI Use of geocoding in managed care settings to identify quality disparities - How indirect measures of race/ethnicity and socioeconomic status can be used by the nation's health plans to demonstrate disparities SO HEALTH AFFAIRS LA English DT Article; Proceedings Paper CT AcadrmyHealth Annual Meeting 2002 CY JUN, 2002 CL Washington, DC ID RACIAL VARIATION; ENROLLEES AB Tracking quality-of-care measures is essential for improving care, particularly for vulnerable populations. Although managed care plans routinely track quality measures, few examine whether their performance differs by enrollee race/ethnicity or socioeconomic status (SES), in part because plans do not collect that information. We show that plans can begin examining and targeting potential disparities using indirect measures of enrollee race/ethnicity and SES based on geocoding. Using such measures, we demonstrate disparities within both Medicare+Choice and commercial plans on Health Plan Employer Data and Information Set (HEDIS) measures of diabetes and cardiovascular care, including instances in which race/ethnicity and SES have distinct effects. C1 RAND Hlth, Santa Monica, CA USA. Univ Toronto, Toronto, ON, Canada. W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Div Gen Internal Med, Westwood, CA USA. RP Fremont, AM (reprint author), RAND Hlth, Santa Monica, CA USA. EM fremont@rand.org RI Bird, Chloe/C-7107-2008 NR 12 TC 35 Z9 35 U1 1 U2 3 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD MAR-APR PY 2005 VL 24 IS 2 BP 516 EP 526 DI 10.1377/hlthaff.24.2.516 PG 11 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 909CE UT WOS:000227835700031 PM 15757939 ER PT J AU Noel, P Frueh, BC Larme, AC Pugh, JA AF Noel, P Frueh, BC Larme, AC Pugh, JA TI Cottaborative care needs and preferences of primary care patients with muttimorbidity SO HEALTH EXPECTATIONS LA English DT Article DE chronic illness; collaborative care; multimorbidity; primary care; qualitative methods ID GENERAL-PRACTICE; DEPRESSIVE-DISORDERS; CHRONIC DISEASES; CHRONIC ILLNESS; MANAGEMENT; COMORBIDITY; MORBIDITY; QUALITY AB Objective To explore the collaborative care needs and preferences in primary care patients with multiple chronic illnesses. Design Focus groups utilizing a series of open-ended questions elicited self-identified problems, experiences in communicating with self-management needs, and preferences for monitoring providers, and follow-up. Responses were organized and interpreted in light of the essential elements of collaborative care for chronic illness. Setting and Participants Sixty patients having two or more chronic illnesses at eight geographically dispersed primary care clinics within the Veterans Health Administration in the United States. Results Identified problems included poor functioning, negative psychological reactions, negative effects on relationships and interference with work or leisure. Polypharmacy was a major concern. Problematic interactions with providers and the health care system were also mentioned, often in relation to specialty care and included incidents in which providers had ignored concerns or provided conflicting advice. Most participants, however, expressed overall satisfaction with their care and appreciation of their primary care physicians. Knowledge and skills deficits interfered with self-management. Participants were willing to use technology for monitoring or educational purposes if it did not preclude human contact, and were receptive to non-physician providers as long as they were used to augment, not eliminate, a physician's care. Conclusions Findings are consistent with the basic tenets of patient-centred, collaborative care, and suggested that health care can be organized and delivered to meet the complex needs of patients with multimorbidity. C1 Hlth Serv Res Ctr Excellence, VERDICT, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78285 USA. Vet Affairs Med Ctr, Charleston, SC 29403 USA. Med Univ S Carolina, Charleston, SC 29425 USA. Univ Texas, Hlth Sci Ctr, Dept Family & Community Med, San Antonio, TX 78285 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Noel, P (reprint author), Hlth Serv Res Ctr Excellence, VERDICT, S Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd,11C6, San Antonio, TX 78229 USA. EM pollyh@verdict.uthscsa.edu OI Pugh, Jacqueline/0000-0003-4933-141X NR 27 TC 59 Z9 59 U1 0 U2 7 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 1369-6513 J9 HEALTH EXPECT JI Health Expect. PD MAR PY 2005 VL 8 IS 1 BP 54 EP 63 DI 10.1111/j.1369-7625.2004.00312.x PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 905VV UT WOS:000227599800007 PM 15713171 ER PT J AU Lim, HJ Gordon, NH Justice, AC AF Lim, HJ Gordon, NH Justice, AC TI Evaluation of multiple failure time analyses of observational data in patients treated for HIV SO HIV CLINICAL TRIALS LA English DT Article DE HIV/AIDS; multiple failures; observational data; treatment sequences ID ZIDOVUDINE COMBINATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; REGRESSION-ANALYSIS; PLUS LAMIVUDINE; STAVUDINE; DIDANOSINE; MONOTHERAPY; INFECTION; EFFICACY; SAFETY AB The development of protease inhibitors and nonnucleoside reverse transcriptase inhibitors has substantially increased the number of combinations available for multi-drug therapies in human immunodeficiency virus (HIV) infection. Unfortunately, all antiretroviral therapies lose efficacy over time or induce side effects, thus making secondary and tertiary alternatives necessary. With the multiplicity of multi-drug combination therapies, the challenge is to determine which multi-drug combination to use as initial therapy and which to use as subsequent therapy to maximize survival. No standard methodologic approach has been developed to answer this question within the context of observational clinical HIV data. We demonstrate the use of semi-parametric models employing repeated, multiple failure time analysis to compare the relative efficacy of treatments containing zidovudine, stavudine, or other multi-drug combinations for patients in the CHORUS (Collaborations in HIV Outcomes Research - US) database. C1 Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA. Case Western Reserve Univ, Sch Med, Dept Bioeth, Cleveland, OH 44106 USA. VA Pittsburgh Healthcare Syst, Ctr Hlth Serv Res, Pittsburgh, PA USA. RP Lim, HJ (reprint author), Med Coll Wisconsin, Div Biostat, 8701 Water Plank, Milwaukee, WI 53226 USA. EM hyun@mcw.edu NR 19 TC 2 Z9 2 U1 0 U2 0 PU THOMAS LAND PUBLISHERS, INC PI ST LOUIS PA 255 JEFFERSON RD, ST LOUIS, MO 63119 USA SN 1528-4336 J9 HIV CLIN TRIALS JI HIV Clin. Trials PD MAR-APR PY 2005 VL 6 IS 2 BP 81 EP 91 PG 11 WC Infectious Diseases; Pharmacology & Pharmacy SC Infectious Diseases; Pharmacology & Pharmacy GA 943CU UT WOS:000230330500003 PM 15983892 ER PT J AU Rollins, KE Kleinschmidt-DeMasters, BK Corboy, JR Damek, DM Filley, CM AF Rollins, KE Kleinschmidt-DeMasters, BK Corboy, JR Damek, DM Filley, CM TI Lymphomatosis cerebri as a cause of white matter dementia SO HUMAN PATHOLOGY LA English DT Article DE primary central nervous system lymphoma; white matter; dementia; immunocompetent; magnetic resonance imaging ID CENTRAL-NERVOUS-SYSTEM; RAPIDLY PROGRESSIVE DEMENTIA; PRIMARY MALIGNANT-LYMPHOMA; CNS LYMPHOMA; BRAIN; FEATURES; CT; AIDS AB Primary central nervous system lymphoma most often presents as a solitary, isolated lesion in immunocompetent patients. Rarely, the disease presents as a diffuse, infiltrating condition without formation of a cohesive mass, a pattern called lymphomatosis cerebri. We present 3 immunocompetent individuals who developed rapidly progressive dementia. Magnetic resonance imaging features mimicked other disorders of white matter and prompted preoperative diagnoses of Binswanger's disease (subcortical ischemic vascular dementia), unknown leukoencephalopathy, viral infection, or infiltrating glioma. Neuropathologic examination at biopsy (Poon T, Matoso I, Tchertkoff V, Weitzner I Jr, Gade M. CT features of primary cerebral lymphoma in AIDS and non-AIDS patients. J Comput Assist Tomogr. 1989;13:6-9) and autopsy (Schwaighofer BW, Hesselink JR, Press GA, Wolf RL, Healy ME, Berthoty DP. Primary intracranial CNS lymphoma: MR manifestations. Am J Neuroradiol. 1993;10:725-9) demonstrated nonnecrotic, diffusely infiltrating, large-cell B-cell lymphoma of white matter, with relative sparing of gray matter, and without significant leptomeningeal involvement or bulky periventricular disease at autopsy. Microglial and astrocytic reactions, but only subtle myelin pallor, were evident as individual tumor cells permeated the entire brain and spinal cord, albeit with considerable variation in cell density. Individual tumor cells Could be identified from the optic nerve to spinal cord, documenting the "whole-brain" nature of the disease. CD20 immunostaining was necessary to fully appreciate the extent of individual lymphoma cell percolation through the white matter. The neurobehavioral deficits manifested by these patients demonstrate that lymphomatosis cerebri is an additional neoplastic cause of white matter dementia and can be added to the growing list of disorders responsible for this syndrome. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Colorado, Hlth Sci Ctr, Dept Pathol, Sch Med, Denver, CO 80262 USA. Univ Colorado, Sch Med, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Sch Med, Dept Neurosurg, Denver, CO 80262 USA. Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Neurol Serv, Denver, CO 80220 USA. RP Kleinschmidt-DeMasters, BK (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Pathol, Sch Med, Box B-216, Denver, CO 80262 USA. EM bk.demasters@uchsc.edu NR 39 TC 42 Z9 43 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0046-8177 J9 HUM PATHOL JI Hum. Pathol. PD MAR PY 2005 VL 36 IS 3 BP 282 EP 290 DI 10.1016/j.humpath.2005.01.014 PG 9 WC Pathology SC Pathology GA 915DR UT WOS:000228278400009 PM 15791573 ER PT J AU Haake, DA Matsunaga, J AF Haake, DA Matsunaga, J TI Leptospiral membrane proteins - variations on a theme? Commentary SO INDIAN JOURNAL OF MEDICAL RESEARCH LA English DT Editorial Material ID OUTER-MEMBRANE; INTERROGANS; SURFACE C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Haake, DA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. EM dhaake@ucla.edu FU NIAID NIH HHS [R01 AI034431, R01 AI034431-08] NR 16 TC 4 Z9 6 U1 0 U2 0 PU INDIAN COUNCIL MEDICAL RES PI NEW DELHI PA PO BOX 4911 ANSARI NAGAR, NEW DELHI 110029, INDIA SN 0971-5916 J9 INDIAN J MED RES JI Indian J. Med. Res. PD MAR PY 2005 VL 121 IS 3 BP 143 EP 145 PG 3 WC Immunology; Medicine, General & Internal; Medicine, Research & Experimental SC Immunology; General & Internal Medicine; Research & Experimental Medicine GA 915UV UT WOS:000228337700003 PM 15802754 ER PT J AU Suswam, EA Nabors, LB Huang, YY Yang, XH King, PH AF Suswam, EA Nabors, LB Huang, YY Yang, XH King, PH TI IL-1 beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3 ' untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE posttranscriptional gene regulation; AU-rich element; HuR; KH-type splicing regulatory protein; T-cell inhibitor of apoptosis-related protein; breast cancer ID ACTIVATED PROTEIN-KINASE; AU-RICH ELEMENTS; INTERLEUKIN-8 GENE-EXPRESSION; MAMMALIAN STRESS GRANULES; TUMOR-NECROSIS-FACTOR; IN-VIVO; POSTTRANSCRIPTIONAL REGULATION; 3'-UNTRANSLATED REGION; STABILITY FACTOR; TNF-ALPHA AB IL-8 plays an integral role in promoting the malignant phenotype in breast cancer, and its production is directly influenced by inflammatory cytokines in the tumor microenvironment. Here, we show that activation of IL-1beta receptors on malignant HS578t and MDA-MB-231 breast cancer cells strongly induces IL-8 expression and that RNA stabilization is persistently activated at least 12-24 hr after stimulation. SB 203580 and rapamycin reversed the RNA stabilization effect of IL-1beta in a dose-dependent manner, suggesting involvement of the p38/MAP kinase and mTOR pathways. A luciferase reporter assay indicated that the stabilization effect was dependent on cis elements in the 3'-untranslated region (UTR) of the IL-8 transcript. By UV cross-linking, we identified multiple cellular factors that interact with the IL-8 3'UTR, ranging 34-76 kDa. Immunoprecipitation analysis indicated that HuR, KSRP and TIAR bound to one or more loci in the 3'UTR. While the cross-linking patterns were similar, quantitative immunoprecipitation of native IL-8 RNA from IL-1beta-stimulated cytoplasmic extract revealed a 20-fold greater association of transcript with the stabilizing factor HuR vs. the destabilizing factor KSRP. In conclusion, IL-1beta is a potent cytokine stimulus for IL-8 RNA stabilization in breast cancer cells, possibly by enhanced binding of cytoplasmic HuR to the 3'UTR. Published 2004 Wiley-Liss, Inc(dagger). C1 Birmingham Veterans Affairs Med Ctr, Birmingham, AL USA. Univ Alabama, Dept Neurol, Birmingham, AL USA. Univ Alabama, Dept Physiol & Biophys, Birmingham, AL USA. RP King, PH (reprint author), 1235 Jefferson Tower,625 S 19th St, Birmingham, AL 35294 USA. EM pking@uab.edu NR 58 TC 62 Z9 64 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD MAR 1 PY 2005 VL 113 IS 6 BP 911 EP 919 DI 10.1002/ijc.20675 PG 9 WC Oncology SC Oncology GA 888BD UT WOS:000226348300007 PM 15514971 ER PT J AU Arterburn, DE Maciejewski, ML Tsevat, J AF Arterburn, DE Maciejewski, ML Tsevat, J TI Impact of morbid obesity on medical expenditures in adults SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article DE health services; economic; cost; overweight ID COST-EFFECTIVENESS; GASTRIC BYPASS; UNITED-STATES; BODY-WEIGHT; US ADULTS; SURGERY; OVERWEIGHT; BURDEN; TRENDS; RISK AB CONTEXT: Morbid obesity (body mass index (BMI) greater than or equal to40 kg/m(2)) is associated with substantially increased morbidity and mortality from chronic health conditions and with poorer health-related quality of life; however, less is known about the impact of morbid obesity on healthcare expenditures. OBJECTIVE: To examine the impact of morbid obesity on healthcare expenditures using a nationally representative sample of US adults. DESIGN, SETTING, AND PARTICIPANTS: We performed a cross-sectional analysis of 16 262 adults from the 2000 Medical Expenditure Panel Survey, a nationally representative survey of the noninstitutionalized civilian population of the United States. Per capita healthcare expenditures were calculated for National Institutes of Health BMI categories, based on self-reported height and weight, using a two-part, multivariable model adjusted for age, gender, race, income, education level, type of health insurance, marital status, and smoking status. MAIN OUTCOME MEASURES: Odds of incurring any healthcare expenditure and per capita healthcare expenditures associated with morbid obesity in 2000. RESULTS: When compared with normal-weight adults, the odds of incurring any healthcare expenditure in 2000 were two-fold greater among adults with morbid obesity. Per capita healthcare expenditures for morbidly obese adults were 81% (95% confidence interval (CI): 48-121%) greater than normal-weight adults, 65% (95% CI: 37-110%) greater than overweight adults, and 47% (95% CI: 11-96%) greater than adults with class I obesity. Excess costs among morbidly obese adults resulted from greater expenditures for office-based visits, outpatient hospital care, in-patient care, and prescription drugs. Aggregate US healthcare expenditures associated with excess body weight among morbidly obese US adults exceeded $11 billion in 2000. CONCLUSIONS: The economic burden of morbid obesity among US adults is substantial. Further research is needed to identify interventions to reduce the incidence and prevalence of morbid obesity and improve the health and economic outcomes of morbidly obese adults. C1 Univ Cincinnati, Med Ctr, Dept Internal Med, Div Gen Internal Med,Sect Outcomes Res, Cincinnati, OH 45267 USA. Cincinnati Vet Affairs Med Ctr, Hlth Serv Res & Dev, Cincinnati, OH USA. Univ Cincinnati, Inst Hlth Policy & Hlth Serv Res, Cincinnati, OH 45267 USA. Vet Affairs Puget Sound Hlth Care Syst, NW Hlth Serv Res & Dev Ctr, Seattle, WA USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Arterburn, DE (reprint author), Univ Cincinnati, Med Ctr, Dept Internal Med, Div Gen Internal Med,Sect Outcomes Res, POB 670840, Cincinnati, OH 45267 USA. EM david.arterburn@uc.edu NR 28 TC 118 Z9 118 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 J9 INT J OBESITY JI Int. J. Obes. PD MAR PY 2005 VL 29 IS 3 BP 334 EP 339 DI 10.1038/sj.ijo.0802896 PG 6 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 897CK UT WOS:000226981400012 PM 15685247 ER PT J AU Bartsch, P Mairbaurl, H Maggiorini, M Swenson, ER AF Bartsch, P Mairbaurl, H Maggiorini, M Swenson, ER TI Physiological aspects of high-altitude pulmonary edema SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Review DE pulmonary artery pressure; hypoxic pulmonary vasoconstriction; nitric oxide; inflammation; alveolar fluid clearance; pathophysiology; review ID ACUTE MOUNTAIN-SICKNESS; ISOLATED RAT LUNGS; TRANSEPITHELIAL SODIUM-TRANSPORT; INDUCED PERMEABILITY INCREASES; ALVEOLAR EPITHELIAL-CELLS; I/D GENE POLYMORPHISM; NITRIC-OXIDE SYNTHASE; BRONCHOALVEOLAR LAVAGE; VASCULAR-RESISTANCE; DIFFUSING-CAPACITY AB High-altitude pulmonary edema ( HAPE) develops in rapidly ascending nonacclimatized healthy individuals at altitudes above 3,000 m. An excessive rise in pulmonary artery pressure ( PAP) preceding edema formation is the crucial pathophysiological factor because drugs that lower PAP prevent HAPE. Measurements of nitric oxide ( NO) in exhaled air, of nitrites and nitrates in bronchoalveolar lavage (BAL) fluid, and forearm NO-dependent endothelial function all point to a reduced NO availability in hypoxia as a major cause of the excessive hypoxic PAP rise in HAPE-susceptible individuals. Studies using right heart catheterization or BAL in incipient HAPE have demonstrated that edema is caused by an increased microvascular hydrostatic pressure in the presence of normal left atrial pressure, resulting in leakage of large-molecular-weight proteins and erythrocytes across the alveolarcapillary barrier in the absence of any evidence of inflammation. These studies confirm in humans that high capillary pressure induces a high-permeability-type lung edema in the absence of inflammation, a concept first introduced under the term "stress failure." Recent studies using microspheres in swine and magnetic resonance imaging in humans strongly support the concept and primacy of nonuniform hypoxic arteriolar vasoconstriction to explain how hypoxic pulmonary vasoconstriction occurring predominantly at the arteriolar level can cause leakage. This compelling but as yet unproven mechanism predicts that edema occurs in areas of high blood flow due to lesser vasoconstriction. The combination of high flow at higher pressure results in pressures, which exceed the structural and dynamic capacity of the alveolar capillary barrier to maintain normal alveolar fluid balance. C1 Med Univ Hosp Heidelberg, Div Sports Med, Dept Internal Med, D-69120 Heidelberg, Germany. Med Clin, Dept Cardiol, Zurich, Switzerland. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Bartsch, P (reprint author), Med Univ Hosp Heidelberg, Div Sports Med, Dept Internal Med 6, Neuenheimer Feld 410, D-69120 Heidelberg, Germany. EM peter_bartsch@med.uni-heidelberg.de NR 123 TC 154 Z9 162 U1 3 U2 23 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD MAR PY 2005 VL 98 IS 3 BP 1101 EP 1110 DI 10.1152/japplphysiol.01167.2004 PG 10 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 895LG UT WOS:000226863100045 PM 15703168 ER PT J AU Zhang, XK Watson, DK AF Zhang, XK Watson, DK TI The FLI-1 transcription factor is a short-lived phosphoprotein in T cells SO JOURNAL OF BIOCHEMISTRY LA English DT Article DE FLI-1-1 transcription factor; phosphatase 2A; phosphoprotein; protein kinase; T cell activation ID DNA-BINDING; ETS FAMILY; PROTEIN-KINASE; RENAL-DISEASE; PHOSPHORYLATION; GENE; ACTIVATION; EXPRESSION; MEMBER; GENERATION AB The FLI-1 transcription factor is a member of the ETS gene family, most closely related to ERG. In this study, the FLI-1 protein products were characterized using a specific monoclonal antibody previously developed against bacterially expressed protein. In the human T-cell line Jurkat, both isoforms of FLI-1, p51 and p48, are phosphorylated, primarily on serine residues. FLI-1 phosphorylation is increased by a Ca2+-mediated process, and inhibitor studies indicate that protein phosphatase 2A, at least in part, controls FLI-1 phosphorylation level. FLI-1 phosphorylation is not stimulated by phorbal 12-myristate 13-acetate (PMA), a protein kinase C activator, and in this it differs from ERG protein phosphorylation. The p51 isoform has a half-life of 105 min, and p48 has a half-life of 80 min; in contrast, the ERG protein is much more stable with a half-life of 21 h. Newly synthesized FLI-1 protein decreased during human T cell activation. Our data suggest that although the FLI-1 and ERG genes are highly homologous, their distinct properties may contribute to their different roles in gene regulation. C1 Ralph H Johnson VAMC, Med Res Serv, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA. Dept Pathol & Lab Med, Charleston, SC 29425 USA. Hollings Canc Ctr, Charleston, SC 29425 USA. RP Zhang, XK (reprint author), Ralph H Johnson VAMC, Med Res Serv, Dept Med, Div Rheumatol & Immunol, 96 Jonathan Lucas St,POB 250623, Charleston, SC 29425 USA. EM zhangjo@musc.edu FU NCI NIH HHS [P01 CA78582] NR 41 TC 13 Z9 13 U1 0 U2 1 PU JAPANESE BIOCHEMICAL SOC PI TOKYO PA ISHIKAWA BLDG-3F, 25-16 HONGO-5-CHOME, BUNKYO-KU, TOKYO, 113, JAPAN SN 0021-924X J9 J BIOCHEM JI J. Biochem. PD MAR PY 2005 VL 137 IS 3 BP 297 EP 302 DI 10.1093/jb/mvi032 PG 6 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 922KI UT WOS:000228836400007 PM 15809330 ER PT J AU Hansen, KE Binkley, N Christian, R Vallarta-Ast, N Krueger, D Drezner, MK Blank, RD AF Hansen, KE Binkley, N Christian, R Vallarta-Ast, N Krueger, D Drezner, MK Blank, RD TI Interobserver reproducibility of criteria for vertebral body exclusion SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article DE aging; epidemiology; evidence/guidelines; osteoporosis; quantitation; bone densitometry ID BONE-MINERAL DENSITY; QUANTITATIVE COMPUTED-TOMOGRAPHY; PREDICT HIP FRACTURE; X-RAY ABSORPTIOMETRY; ELDERLY-WOMEN; POPULATION; ULTRASOUND; RISK; OSTEOPOROSIS; OSTEOPENIA AB We studied reproducibility of the ISCD vertebral exclusion criteria among four interpreters. Surprisingly, agreement among interpreters was only moderate, because of differences in threshold for diagnosing focal structural defects and choice of which vertebra among a pair discordant for T-score, area, or BMC to exclude. Our results suggest that reproducibility may be improved by specifically addressing the sources of interobserver disagreement. Introduction: Although DXA is widely used to measure vertebral BNID, its interpretation is subject to multiple confounders including osteoarthritis, aortic calcification, and scoliosis. In an attempt to standardize interpretation and minimize the impact of artifacts, the International Society for Clinical Densitometry (ISCD) established criteria for vertebral exclusion, including the presence of a focal structural defect (FSD), discrepancy of >1 SD in T-score between adjacent vertebrae, and a lack of increase in BMC or area from L, to L, Whereas the efforts of the ISCD represent an important advance in BMD interpretation, the interobserver reproducibility with application of these criteria is unknown. We hypothesized that there would be substantial agreement among four interpreters regarding application of the exclusion criteria and the final lumbar spine T-score. Materials and Methods: Each interpreter read a set of 200 lumbar DXA scans obtained on male veterans, applying the ISCD vertebral body exclusion criteria. Results: Surprisingly, agreement among interpreters was only moderate. Differences in interpretation resulted from differing thresholds for recognition of FSD and the choice of excluding the upper or lower vertebral body for the criteria requiring comparison between adjacent vertebrae. Conclusions: Despite their apparent simplicity, the ISCD vertebral exclusion criteria are difficult to apply consistently. In principle, appropriate refinement of the exclusion criteria may significantly improve interobserver agreement. C1 Univ Wisconsin, Hosp & Clin, William S Middleton Mem Vet Hosp, Dept Med,Rheumatol Sect, Madison, WI 53792 USA. Univ Wisconsin, Osteoporosis Clin Ctr, Madison, WI 53792 USA. Univ Wisconsin, Res Program, Madison, WI 53792 USA. Univ Wisconsin, Dept Med, Endocrinol Diabet & Metab Sect, Madison, WI 53792 USA. Univ Wisconsin, Dept Med, Geriatr Sect, Madison, WI 53792 USA. Univ Wisconsin, Dept Radiol, William S Middleton Mem Vet Hosp, Madison, WI 53792 USA. Univ Wisconsin, Geriatr Res Educ & Clin Ctr, William S Middleton Mem Vet Hosp, Madison, WI 53792 USA. RP Hansen, KE (reprint author), Univ Wisconsin, Hosp & Clin, William S Middleton Mem Vet Hosp, Dept Med,Rheumatol Sect, Mailbox 3244,600 Highland Ave, Madison, WI 53792 USA. EM keh@medicine.wisc.edu OI Blank, Robert Daniel/0000-0003-2950-1944 FU NCRR NIH HHS [1K12RR017614-01, 1K12RR017614-1]; NIAMS NIH HHS [R01 AR27032-33]; NIDDK NIH HHS [R01 DK58363-01]; PHS HHS [R01 SK 65830-1] NR 19 TC 34 Z9 34 U1 0 U2 0 PU AMER SOC BONE & MINERAL RES PI WASHINGTON PA 2025 M ST, N W, STE 800, WASHINGTON, DC 20036-3309 USA SN 0884-0431 J9 J BONE MINER RES JI J. Bone Miner. Res. PD MAR PY 2005 VL 20 IS 3 BP 501 EP 508 DI 10.1359/JBMR.041134 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 898TB UT WOS:000227098000016 PM 15746996 ER PT J AU Stroud, RE Deschamps, AM Lowry, AS Hardin, AE Mukherjee, R Lindsey, ML Ramamoorthy, S Zile, MR Spencer, WH Spinale, FG AF Stroud, RE Deschamps, AM Lowry, AS Hardin, AE Mukherjee, R Lindsey, ML Ramamoorthy, S Zile, MR Spencer, WH Spinale, FG TI Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE hypertrophy; TIMP-4; HOCM; alcohol-induced myocardial infarction ID FAILING HUMAN HEART; MATRIX-METALLOPROTEINASES; REDUCTION THERAPY; EXPRESSION; FAILURE; GLYCOSYLATION; INFARCTION; SUPPORT; SYSTEM; TIMP-4 AB Background: The overall goal of this study was to develop an assay procedure for measuring the relative abundance of tissue inhibitor of metalloproteinase (TIMP)-4 in plasma, and then use this approach to determine dynamic changes of TIMP-4 levels in hypertrophic obstructive carchomyopathic (HOCM) patients after an acute myocardial infarction (MI). Matrix metalloproteinases (MMPs) contribute to tissue remodeling and are regulated by the endogenous TIMPs. TIMP-4 is observed to be expressed in higher abundance in the myocardium when compared with other types of tissues. Recent clinical studies have measured changes in TIMP-4 levels; however, these studies have been limited to measuring this protein from myocardial tissue samples. To date, no studies have monitored TIMP-4 levels in plasma samples. Methods and Results: Plasma TIMP-4 levels were examined (by semiquantitative immunoblotting) in normal (n = 18) and HOCM (n = 16) patients after alcohol-induced MI. Serial measurements of plasma TIMP-4 levels were examined up to 60 hours after alcohol-induced MI in patients with HOCM. Unglycosylated plasma TIMP-4 levels increased 250% in the HOCM patients when compared with normal controls. Total plasma TIMP-4 levels decreased by 20% at 30 hours after alcohol-induced MI. Conclusions: The unique results demonstrated that an induction of a controlled MI, specifically through alcohol ablation, caused a reduction in plasma TIMP-4 levels in HOCM patients after alcohol-induced MI that would facilitate myocardial remodeling in the early post-MI setting. C1 Med Univ S Carolina, Div Cardiothorac Surg, Charleston, SC 29403 USA. Ralph H Johnson Vet Assoc Med Ctr, Charleston, SC USA. RP Spinale, FG (reprint author), Med Univ S Carolina, Div Cardiothorac Surg, Strom Thurmond Res Bldg,114 Doughty St,Room 625, Charleston, SC 29403 USA. RI Lindsey, Merry/B-2650-2012 OI Deschamps, Anne/0000-0001-7415-1408 FU NCRR NIH HHS [M01-RR01070]; NHLBI NIH HHS [HL-97012, HL-45024, R01 HL075360] NR 32 TC 14 Z9 14 U1 0 U2 2 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD MAR PY 2005 VL 11 IS 2 BP 124 EP 130 DI 10.1016/j.cardfail.2004.05.002 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 907AW UT WOS:000227688100008 PM 15732032 ER PT J AU Page, ST Amory, JK Bowman, FD Anawalt, BD Matsumoto, AM Bremner, WJ Tenover, JL AF Page, ST Amory, JK Bowman, FD Anawalt, BD Matsumoto, AM Bremner, WJ Tenover, JL TI Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID BONE-MINERAL DENSITY; RANDOMIZED CONTROLLED-TRIAL; HEALTHY-YOUNG MEN; MIDDLE-AGED MEN; MUSCLE STRENGTH; ADIPONECTIN LEVELS; HYPOGONADAL MEN; TRANSDERMAL TESTOSTERONE; INSULIN SENSITIVITY; REPLACEMENT THERAPY AB Testosterone ( T) therapy in older men with low serum T levels increases lean body mass and decreases fat mass. These changes might improve physical performance and strength; however, it has not been established whether T therapy improves functional outcome in older men. Moreover, concerns exist about the impact of T therapy on the prostate in older men. The administration of finasteride ( F), which partially blocks the conversion of T to the more potent androgen, dihydrotestosterone, attenuates the impact of T replacement on prostate size and prostate-specific antigen. We hypothesized that T replacement in older, hypogonadal men would improve physical function and that the addition of F to this regimen would continue to provide the T-induced improvements in physical performance, strength, and body composition. Seventy men with low serum T (< 350 ng/dl), age 65 yr and older, were randomly assigned to receive one of three regimens for 36 months: 1) T enanthate, 200 mg im every 2 wk, with placebo pills daily (T-only); 2) T enanthate, 200 mg every 2 wk, with 5 mg F daily ( T + F); or 3) placebo injections and pills ( placebo). We obtained serial measurements of timed physical performance, grip strength, lower extremity strength, body composition ( by dual-energy x-ray absorptiometry), fasting cholesterol profiles, and hormones. Fifty men completed the 36-month protocol. After 36 months, T therapy significantly improved performance in a timed functional test when compared with baseline and placebo [ 4.3 +/- 1.6% ( mean +/- SEM, T-only) and 3.8 +/- 1.0% ( T + F) vs. - 5.6 +/- 1.9% for placebo ( P < 0.002 for both T and T +F vs. placebo)] and increased handgrip strength compared with baseline and placebo ( P < 0.05). T therapy increased lean body mass [ 3.77 +/- 0.55 kg ( T-only) and 3.64 +/- 0.56 kg ( T + F) vs. - 0.21 +/- 0.55 kg for placebo ( P < 0.0001)], decreased fat mass, and significantly decreased total cholesterol, low-density lipoprotein, and leptin, without affecting high-density lipoprotein, adiponectin, or fasting insulin levels. These results demonstrate that T therapy in older men with low serum T improves physical performance and strength over 36 months, when administered alone or when combined with F, and suggest that high serum levels of dihydrotestosterone are not essential for these beneficial effects of T in men. C1 Emory Univ, Sch Med, Dept Med, Atlanta, GA 30329 USA. Rollins Sch Publ Hlth, Dept Biostat, Atlanta, GA 30322 USA. Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Sch Med, Ctr Geriatr Res Educ & Clin, Seattle, WA 98195 USA. RP Tenover, JL (reprint author), Wesley Woods Hlth Ctr, 1841 Clifton Rd NE, Atlanta, GA 30329 USA. EM page@u.washington.edu FU NHLBI NIH HHS [HL007028]; NIA NIH HHS [AG10975, K23 AG027238, K23 AG027238-01A1] NR 47 TC 291 Z9 304 U1 4 U2 16 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD MAR PY 2005 VL 90 IS 3 BP 1502 EP 1510 DI 10.1210/jc.2004-1933 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 904UQ UT WOS:000227523600036 PM 15572415 ER PT J AU Morton, GJ Blevins, JE Williams, DL Niswender, KD Gelling, RW Rhodes, CJ Baskin, DG Schwartz, MW AF Morton, GJ Blevins, JE Williams, DL Niswender, KD Gelling, RW Rhodes, CJ Baskin, DG Schwartz, MW TI Leptin action in the forebrain regulates the hindbrain response to satiety signals SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID PROOPIOMELANOCORTIN MESSENGER-RNA; DECREASES FOOD-INTAKE; CAUDAL BRAIN-STEM; MELANOCYTE-STIMULATING HORMONE; LATERAL HYPOTHALAMIC AREA; CENTRAL-NERVOUS-SYSTEM; REDUCING MEAL SIZE; NEUROPEPTIDE-Y; FEEDING-BEHAVIOR; ARCUATE NUCLEUS AB The capacity to adjust energy intake in response to changing energy requirements is a defining feature of energy homeostasis. Despite the identification of leptin as a key mediator of this process, the mechanism whereby changes of body adiposity are coupled to adaptive, short-term adjustments of energy intake remains poorly understood. To investigate the physiological role of leptin in the control of meal size and the response to satiety signals, and to identify brain areas mediating this effect, we studied Koletsky (fa(k)/fa(k)) rats, which develop severe obesity due to the genetic absence of leptin receptors. Our finding of markedly increased meal size and reduced satiety in response to the gut peptide cholecystokinin (CCK) in these leptin receptor-deficient animals suggests a critical role for leptin signaling in the response to endogenous signals that promote meal termination. To determine if the hypothalamic arcuate nucleus (ARC) (a key forebrain site of leptin action) mediates this leptin effect, we used adenoviral gene therapy to express either functional leptin receptors or a reporter gene in the area of the ARC of fa(k)/fa(k) rats. Restoration of leptin signaling to this brain area normalized the effect of CCK on the activation of neurons in the nucleus of the solitary tract and area postrema, key hindbrain areas for processing satiety-related inputs. This intervention also reduced meal size and enhanced CCK-induced satiety in fa(k)/fa(k) rats. These findings demonstrate that forebrain signaling by leptin, a long-term regulator of body adiposity, limits food intake on a meal-to-meal basis by regulating the hindbrain response to short-acting satiety signals. C1 Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Washington, Pacific NW Res Inst, Seattle, WA 98195 USA. Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. Univ Washington, Dept Biol Struct, Seattle, WA 98104 USA. RP Schwartz, MW (reprint author), Univ Washington, Harborview Med Ctr, Dept Med, 325 9Th Ave,Box 359675, Seattle, WA 98104 USA. EM mschwart@u.washington.edu RI Schwartz, Michael/H-9950-2012; Williams, Diana/C-1699-2014 OI Williams, Diana/0000-0002-3548-7440 FU NIDDK NIH HHS [DK12829, DK52989, DK68340, R01 DK052989]; NINDS NIH HHS [R01 NS032273, NS32273] NR 61 TC 147 Z9 152 U1 0 U2 3 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD MAR PY 2005 VL 115 IS 3 BP 703 EP 710 DI 10.1172/JCI200522081 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 902YN UT WOS:000227392700034 PM 15711637 ER PT J AU Aora, S Xu, C Teng, A Peterson, J Yeh, LT Gish, R Lou, D Rossi, S Lin, C AF Aora, S Xu, C Teng, A Peterson, J Yeh, LT Gish, R Lou, D Rossi, S Lin, C TI Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection SO JOURNAL OF CLINICAL PHARMACOLOGY LA English DT Article DE viramidine; ribavirin; hepatitis C; pharmacokinetics ID INTERFERON-ALPHA-2B PLUS RIBAVIRIN; HUMAN-IMMUNODEFICIENCY-VIRUS; INITIAL TREATMENT; RANDOMIZED-TRIAL; TOLERANCE AB The current study was carried out to evaluate pharmacokinetic profiles of viramidine and ribavirin in patients (n = 8 per dose group) with compensated hepatitis C infection following oral dosing of viramidine (400,600, or 800 mg bid for 4 weeks). Pharmacokinetic parameters were determined on days 1 and 29 based on plasma, red blood cell, and urine concentrations of viramidine and ribavirin. The results indicate rapid absorption and conversion of viramidine to ribavirin after oral administration of viramidine, Viramidine and ribavirin exposure in plasma and RBCs generally increased from the 400- to 600-mg dose level of viramidine. However, no further increase in exposure was noted at the 800-mg dose. Long half-lives for viramidine (66-76 hours in plasma and 200-420 hours in red blood cells) and ribavirin (340-410 hours in plasma and 360-430 hours in red blood cells) were noted, A negligible amount of viramidine (1%-4% of dose) and a small amount of ribavirin (9%-14% of dose) were excreted in the urine. The renal clearance was low for both viramidine (5-8L/h) and ribavirin (4-7L/h). Significant accumulation of viramidine was noted in red blood cells (accumulation factor [R] = 5-8) but not in plasma (B = 2). Extensive accumulation of ribavirin was noted in both plasma (R = 917) and red blood cells (R = 77-129). Steady-state levels of ribavirin and viramidine in plasma and red blood cells were achieved by day 22. At steady state, there was extensive conversion of viramidine to ribavirin in both plasma and red blood cells. Both viramidine and ribavirin were preferentially distributed into red blood cells than plasma. C1 Valeant Pharmaceut Int, Res & Dev, Costa Mesa, CA 92626 USA. Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM USA. Calif Pacific Med Ctr, San Francisco, CA USA. Univ Texas, Med Branch, Galveston, TX 77555 USA. San Francisco Vet Adm Med Ctr, San Francisco, CA USA. RP Lin, C (reprint author), Valeant Pharmaceut Int, Res & Dev, 3300 Hyland Ave, Costa Mesa, CA 92626 USA. NR 19 TC 14 Z9 15 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0091-2700 J9 J CLIN PHARMACOL JI J. Clin. Pharmacol. PD MAR PY 2005 VL 45 IS 3 BP 275 EP 285 DI 10.1177/0031270004270152 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 896WK UT WOS:000226964700004 PM 15703363 ER PT J AU Dodds, MWJ Johnson, DA Yeh, CK AF Dodds, MWJ Johnson, DA Yeh, CK TI Health benefits of saliva: a review SO JOURNAL OF DENTISTRY LA English DT Article; Proceedings Paper CT Symposium in Honour of the Work of Professor WM Edgor CY OCT 07, 2001 CL Cumbria, ENGLAND DE saliva; aging; diabetes; hypertension ID PROLINE-RICH PROTEINS; HUMAN-PAROTID SALIVA; DEPENDENT DIABETES-MELLITUS; CARIES-FREE INDIVIDUALS; ORAL SUGAR CLEARANCE; HUMAN WHOLE SALIVA; FLOW-RATES; DENTAL-CARIES; APATITIC SURFACES; PH CHANGES AB Objective. The aim is to present a review of the literature on human saliva composition, flow rates and some of the health benefits of saliva, with emphasis on studies from our laboratory that have looked at effects of age and age-related diseases on saliva output and composition. Data. Saliva influences oral health both through its non-specific physico-chemical properties, as well as through more specific effects. The proline-rich proteins, statherin and the histatins are salivary proteins that influence calcium phosphate chemistry, initial plaque formation and candida infection. Increases or decreases in mastication may affect saliva output. Our cross-sectional studies of saliva in a large population-based study cohort (N=1130) indicate that there is an age-related decline in saliva output for unstimulated whole, stimulated parotid, unstimulated submandibular/sublingual and stimulated submandibular/sublingual saliva, as well as some compositional alterations in anti-microbial and other proteins. Some of these alterations also appear to be specific for certain age-related medical conditions, such as diabetes mellitus. Conclusions. These studies and data presented confirm the importance of saliva in maintaining a healthy oral environment; the practitioner is encouraged to consider saliva output and medical conditions that may compromise it as part of routine dental treatment planning. (c) 2004 Elsevier Ltd. All rights reserved. C1 Wm Wrigley Jr Co, Chicago, IL 60609 USA. Univ Texas, Hlth Sci Ctr San Antonio, Dept Community Dent, San Antonio, TX 78285 USA. Univ Texas, Hlth Sci Ctr San Antonio, Dept Dent Diagnost Sci, San Antonio, TX 78284 USA. Univ Texas, Hlth Sci Ctr San Antonio, Dept Community Dent, San Antonio, TX 78284 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78284 USA. RP Dodds, MWJ (reprint author), Wm Wrigley Jr Co, 3535 S Ashland Ave, Chicago, IL 60609 USA. EM mdodds@wrigley.com FU NIDCR NIH HHS [DE 10756] NR 92 TC 217 Z9 240 U1 7 U2 62 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0300-5712 J9 J DENT JI J. Dent. PD MAR PY 2005 VL 33 IS 3 BP 223 EP 233 DI 10.1016/j.jdent.2004.10.009 PG 11 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 905RN UT WOS:000227587400007 PM 15725522 ER PT J AU McNeely, MJ Boyko, EJ AF McNeely, MJ Boyko, EJ TI Diabetes-related comorbidities in Asian Americans - Results of a National Health Survey SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE diabetes in minorities; National Health Surveys; complications; hypertension; hypercholesterolemia ID LOWER-EXTREMITY AMPUTATION; BLOOD-GLUCOSE; POPULATION; DISEASE; RISK; NEPHROPATHY; PREVALENCE; NEUROPATHY; VETERANS; HEIGHT AB Objective: The aim of this study was to compare the prevalence of diabetes-related comorbidities in Asian Americans to the prevalence in other racial and ethnic groups in the United States using data from the 2001 Behavioral Risk Factor Surveillance System (BRFSS). Methods: The BRFSS is a population-based telephone survey of the health status and health behaviors of 212,510 Americans aged 18 years in all 50 states, Guam, Puerto Rico, and the U.S. Virgin Islands. In 2001, participants included 196 Asian Americans, 1138 African Americans, 1276 Hispanics, 294 Native Americans, 71 Pacific Islanders, and 7799 non-Hispanic Whites with a self-reported physician diagnosis of diabetes. Comorbidity was determined by self-report. Odds ratios (OR) were adjusted for age, sex, body mass index (BMI) or height and weight, duration of diabetes, smoking, and health-insurance status. Results: The adjusted prevalences of hypercholesterolemia and retinopathy were similar across groups. Relative to Asian Americans, only African Americans were more likely to report hypertension [adjusted OR = 2.1, 95% confidence interval (CI) = 1.0-4.2, P < .05]. Higher odds of current or past foot ulceration was observed for Hispanics (adjusted OR = 2.8, 95% CI = 1.2-6.9), Native Americans (adjusted OR = 4.2, 95% CI = 1.4-12.8), and Pacific Islanders (adjusted OR = 7.4, 95% CI = 1.3-41.2) compared with Asian Americans. Conclusions: Among Americans with diabetes, Asian Americans have a prevalence of hypertension, hypercholesterolemia, retinopathy, and foot ulceration that is similar to that in Whites. Asian Americans had a significantly lower prevalence of hypertension than African Americans did and a lower prevalence of foot ulceration than Hispanics, Native Americans, and Pacific Islanders did. (c) 2005 Elsevier Inc. All rights reserved. C1 Univ Washington, Div Gen Internal Med, Dept Med, Seattle, WA 98105 USA. Vet Affairs Epidemiol Res & Informat Ctr, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP McNeely, MJ (reprint author), Univ Washington, Div Gen Internal Med, Dept Med, Campus Box 354981,Suite 230,4311 11th Ave NE, Seattle, WA 98105 USA. EM mcneely@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X NR 17 TC 16 Z9 17 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD MAR-APR PY 2005 VL 19 IS 2 BP 101 EP 106 DI 10.1016/j.jdiacomp.2004.08.003 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 908NZ UT WOS:000227795000007 PM 15745840 ER PT J AU Fan, VS Burman, M McDonell, MB Fihn, SD AF Fan, VS Burman, M McDonell, MB Fihn, SD TI Continuity of care and other determinants of patient satisfaction with primary care SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE patient satisfaction; health services research; quality of care; questionnaire design; linear models ID QUALITY-OF-LIFE; MEDICAL-CARE; GENERAL-PRACTICE; HEALTH-STATUS; OLDER PATIENTS; META-ANALYSIS; PHYSICIANS; SERVICES; OUTCOMES; HOSPITALIZATION AB OBJECTIVE: The patient-clinician relationship is a central feature of primary care, and recent developments in the delivery of health care have tended to limit continuity of care. The objective of this study was to evaluate the extent to which continuity of care and other factors are related to patient satisfaction. DESIGN: Cross-sectional, mailed questionnaire study. SETTING: Primary care clinics at 7 Veterans Affairs medical centers. PATIENTS/PARTICIPANTS: Patients (N=21,689) participating in the Ambulatory Care Quality Improvement Project who returned the baseline Seattle Outpatient Satisfaction Questionnaire (SOSQ). MEASUREMENTS AND MAIN RESULTS: We evaluated the association between self-reported continuity and satisfaction, after adjusting for characteristics of patients, clinics, and providers. The humanistic scale of the SOSQ measures patient satisfaction with communication skills and humanistic qualities of providers, whereas the organizational scale measures satisfaction with delivery of health care services. The mean adjusted humanistic score for patients who reported always seeing the same provider was 17.3 (95% confidence interval [CI], 15.5 to 19.1) points higher than for those who rarely saw the same provider. Similarly, the mean adjusted organizational score was 16.3 (95% CI, 14.5 to 18.1) points higher for patients who always saw the same provider compared to rarely. Demographic factors, socioeconomic status, health status, clinic site, and patient utilization of services were all associated with both the adjusted humanistic and organizational scores of the SOSQ. CONCLUSIONS: Self-reported continuity of care is strongly associated with higher patient satisfaction. This suggests that improving continuity of care may improve patient satisfaction with providers as well as with their health care organization. C1 VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. Univ Washington, Dept Med, Seattle, WA USA. RP Fan, VS (reprint author), 1660 S Columbian Way, Seattle, WA 98108 USA. EM vfan@u.washington.edu NR 56 TC 104 Z9 105 U1 2 U2 17 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2005 VL 20 IS 3 BP 226 EP 233 DI 10.1111/j.1525-1497.2005.40135.x PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 915UB UT WOS:000228335700003 PM 15836525 ER PT J AU Pearlman, RA Hsu, C Starks, H Back, AL Gordon, JR Bharucha, AJ Koenig, BA Battin, MP AF Pearlman, RA Hsu, C Starks, H Back, AL Gordon, JR Bharucha, AJ Koenig, BA Battin, MP TI Motivations for physician-assisted suicide - Patient and family voices SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article; Proceedings Paper CT 24th Annual Meeting of the Society-of-General-Internal-Medicine CY MAY 02-05, 2001 CL SAN DIEGO, CA SP Soc Gen Internal Med DE physician-assisted suicide; euthanasia; decision making; end-of-life issues; qualitative research ID TERMINALLY-ILL PATIENTS; EUTHANASIA; ATTITUDES; REQUESTS; OREGON; DEATH; HOPELESSNESS; ONCOLOGISTS; EXPERIENCES; CARE AB OBJECTIVE: To obtain detailed narrative accounts of patients' motivations for pursuing physician-assisted suicide (PAS). DESIGN: Longitudinal case studies. PARTICIPANTS: Sixty individuals discussed 35 cases. Participants were recruited through advocacy organizations that counsel individuals interested in PAS, as well as hospices and grief counselors. SETTING: Participants' homes. MEASUREMENTS AND RESULTS: We conducted a content analysis of 159 semistructured interviews with patients and their family members, and family members of deceased patients, to characterize the issues associated with pursuit of PAS. Most patients deliberated about PAS over considerable lengths of time with repeated assessments of the benefits and burdens of their current experience. Most patients were motivated to engage in PAS due to illness-related experiences (e.g., fatigue, functional losses), a loss of their sense of self, and fears about the future. None of the patients were acutely depressed when planning PAS. CONCLUSIONS: Patients in this study engaged in PAS after a deliberative and thoughtful process. These motivating issues point to the importance of a broad approach in responding to a patient's request for PAS. The factors that motivate PAS can serve as an outline of issues to explore with patients about the far-reaching effects of illness, including the quality of the dying experience. The factors also identify challenges for quality palliative care: assessing patients holistically, conducting repeated assessments of patients' concerns over time, and tailoring care accordingly. C1 VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98108 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Natl Ctr Eth Hlth Care VHA, Washington, DC USA. Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. Univ Washington, Dept Psychol, Seattle, WA 98195 USA. Univ Washington, Dept Med Hist, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. Stanford Univ, Ctr Biomed Eth, Stanford, CA 94305 USA. Univ Utah, Dept Philosophy, Salt Lake City, UT USA. RP Pearlman, RA (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div, 1660 S Columbian Way S-182-GRECC, Seattle, WA 98108 USA. EM Robert.Pearlman@med.va.gov NR 34 TC 32 Z9 32 U1 5 U2 18 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2005 VL 20 IS 3 BP 234 EP 239 DI 10.1111/j.1525-1497.2005.40225.x PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 915UB UT WOS:000228335700004 PM 15836526 ER PT J AU Beach, MC Saha, S AF Beach, MC Saha, S TI Free to be you and me? Balancing professionalism, culture, and self-expression SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID ATTITUDES; APPEARANCE; PHYSICIANS C1 Johns Hopkins Univ, Baltimore, MD 21218 USA. Portland VA Med Ctr, Portland, OR USA. RP Beach, MC (reprint author), Johns Hopkins Univ, Baltimore, MD 21218 USA. NR 8 TC 3 Z9 3 U1 0 U2 2 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2005 VL 20 IS 3 BP 312 EP 313 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 915UB UT WOS:000228335700016 PM 15836538 ER PT J AU Kramer, JR Giordano, TP Souchek, J El-Serag, HB AF Kramer, JR Giordano, TP Souchek, J El-Serag, HB TI Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era SO JOURNAL OF HEPATOLOGY LA English DT Article DE hepatitis C virus; HIV coinfection; fulminant hepatic failure; Veterans Affairs Medical Center; retrospective cohort study; highly active antiretroviral therapy ID HUMAN-IMMUNODEFICIENCY-VIRUS; CONTAINING ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; PROTEASE INHIBITORS; LIVER-FAILURE; HEPATOTOXICITY; NEVIRAPINE; MORTALITY; DISEASE; IMPACT AB Background/Aims: It is uncertain if patients coinfected with hepatitis C and HIV are more likely to suffer fulminant hepatic failure (FHF) when compared to patients with HIV-only. Methods: We conducted a retrospective cohort study using national administrative databases from the Department of Veterans Affairs in patients hospitalized for the first time with HIV and/or hepatitis C between 10/1991 and 9/2000. Fulminant hepatic failure was defined as occurring after the index hospitalization through 9/2001 in the absence of preexisting liver disease. We calculated incidence rates, Kaplan Meier cumulative incidence curves, and Cox proportional hazards ratios while adjusting for demographics and other potential confounders. Results: We identified 11,678 patients with HIV-only and 4761 patients with coinfection. There were 92 cases of fulminant hepatic failure yielding an incidence rate of 1.1/1000 person-years and 2.5/1000 person-years in the HIV-only and coinfected groups. The cumulative incidence of fulminant hepatic failure in the coinfected group was higher than in the HIV-only group (P < 0.0001). The risk of fulminant hepatic failure in patients with coinfection compared to HIV-only during the HAART era was several folds higher than that during the pre-HAART era. Conclusions: HAART and hepatitis C coinfection appeared to act synergistically in HIV-infected patients to increase the risk of fulminant hepatic failure, a rare but often fatal disease. (c) 2004 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX 77030 USA. Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. Baylor Coll Med, Infect Dis Sect, Houston, TX 77030 USA. Baylor Coll Med, Gastroenterol Sect, Dept Med, Houston, TX 77030 USA. RP Kramer, JR (reprint author), Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res & Dev Serv, Houston, TX 77030 USA. EM jkramer@bcm.tmc.edu FU NIMH NIH HHS [K23MH67505] NR 23 TC 51 Z9 57 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PD MAR PY 2005 VL 42 IS 3 BP 309 EP 314 DI 10.1016/j.jhep.2004.11.017 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 905BP UT WOS:000227542900006 PM 15710213 ER PT J AU Bohnen, NI Kaufer, DI Hendrickson, R Ivanco, LS Lopresti, BJ Koeppe, RA Meltzer, CC Constantine, G Davis, JG Mathis, CA DeKosky, ST Moore, RY AF Bohnen, NI Kaufer, DI Hendrickson, R Ivanco, LS Lopresti, BJ Koeppe, RA Meltzer, CC Constantine, G Davis, JG Mathis, CA DeKosky, ST Moore, RY TI Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; PARKINSONS-DISEASE; IN-VIVO; CHOLINESTERASE-INHIBITORS; CHOLINERGIC SYSTEM; HUMAN BRAIN; PET; PROPIONATE; THERAPY; MEMORY AB Objectives: To determine in vivo cortical acetylcholinesterase (AChE) activity and cognitive effects in subjects with mild Alzheimer's disease (AD, n = 14) prior to and after 12 weeks of donepezil therapy. Methods: Cognitive and N-[C-11]methyl-piperidin-4-yl propionate ([C-11]PMP) AChE positron emission tomography (PET) assessments before and after donepezil therapy. Results: Analysis of the PET data revealed mean (temporal, parietal, and frontal) cortical donepezil induced AChE inhibition of 19.1% (SD 9.4%) (t= -7.9; p<0.0001). Enzyme inhibition was most robust in the anterior cingulate cortex (24.2% (6.9%), t= -14.1; p<0.0001). Donepezil induced cortical inhibition of AChE activity correlated with changes in the Stroop Color Word interference scores (R-2 = 0.59, p<0.01), but not with primary memory test scores. Analysis of the Stroop test data indicated that subjects with AChe inhibition greater than the median value (<22.2%) had improved scores on the Stroop Color Word Test compared with subjects with less inhibition who had stable to worsening scores (t= -2.7; p<0.05). Conclusions: Donepezil induced inhibition of cortical AChE enzyme activity is modest in patients with mild AD. The degree of cortical enzyme inhibition correlates with changes in executive and attentional functions. C1 Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA. Univ Pittsburgh, Dept Math & Stat, Pittsburgh, PA 15260 USA. RP Bohnen, NI (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Liliane S Kaufmann Bldg,Suite 811,3471 5th Ave, Pittsburgh, PA 15213 USA. EM nbohnen@pitt.edu RI Mathis, Chester/A-8607-2009 FU NIA NIH HHS [AG05133] NR 35 TC 87 Z9 88 U1 0 U2 3 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-3050 J9 J NEUROL NEUROSUR PS JI J. Neurol. Neurosurg. Psychiatry PD MAR PY 2005 VL 76 IS 3 BP 315 EP 319 DI 10.1136/jnnp.2004.038729 PG 5 WC Clinical Neurology; Psychiatry; Surgery SC Neurosciences & Neurology; Psychiatry; Surgery GA 901TM UT WOS:000227304800005 PM 15716518 ER PT J AU Paul, RH Brickman, AM Navia, B Hinkin, C Malloy, PF Jefferson, AL Cohen, RA Tate, DF Flanigan, TP AF Paul, RH Brickman, AM Navia, B Hinkin, C Malloy, PF Jefferson, AL Cohen, RA Tate, DF Flanigan, TP TI Apathy is associated with volume of the nucleus accumbens in patients infected with HIV SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID FRONTAL-SUBCORTICAL CIRCUITS; BASAL GANGLIA; HUMAN BRAIN; DEMENTIA; PROTEINS; ADULTS; AIDS AB Apathy refers to a reduction in self-initiated behavior, and it is commonly reported by patients infected with human immunodeficiency virus (HIV). It remains unclear whether apathy among HIV patients reflects a direct effect of the virus on subcortical brain circuits or a secondary neuropsychiatric symptom. In the present study we examined the relationship between ratings of apathy and quantitative analysis of the nucleus accumbens (NA), a subcortical brain structure that regulates initiation of behavioral activation. Twelve HIV-positive individuals without dementia were administered the Marin Apathy Scale and underwent neuroimaging. Voxel-based quantification of the nucleus accumbens was completed using a segmentation protocol. Results of our study revealed that increased ratings of apathy were significantly correlated with lower volume of the nucleus accumbens. By contrast, ratings of depression were unrelated to either apathy or nucleus accumbens volume. These findings provide preliminary evidence that apathy reflects direct involvement of the central nervous system in patients with HIV. C1 Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI USA. Tufts Univ, Dept Psychiat & Neurol, Boston, MA 02111 USA. Brown Med Sch, Dept Med, Providence, RI USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. VA Greater Los Angeles Hlth Care Systemepartment, Los Angeles, CA USA. RP Paul, RH (reprint author), Brown Med Sch, Ctr AIDS Res, Ctr Behav & Prevent Med, 1 Hoppin St, Providence, RI 02903 USA. EM RPaul@Lifespan.org RI Tate, David/G-5166-2011; Tate, David/I-3963-2013 OI Tate, David/0000-0003-0213-1920; FU NIA NIH HHS [P30 AG013846-05, F32 AG022773, F32 AG022773-01, F32 AG022773-02, P30 AG013846, R01 AG017975]; NIDA NIH HHS [R03DA15045-01, T32 DA013911, T32DA13911]; NIMH NIH HHS [K23 MH065857, K23MH65857, K23MH65857-01]; NINDS NIH HHS [NS36524, R01 NS036524] NR 27 TC 51 Z9 55 U1 0 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD SPR PY 2005 VL 17 IS 2 BP 167 EP 171 DI 10.1176/appi.neuropsych.17.2.167 PG 5 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 932GA UT WOS:000229541000005 PM 15939969 ER PT J AU Studer, RK Chu, CR AF Studer, RK Chu, CR TI p38 MAPK and COX2 inhibition modulate human chondrocyte response to TGF-beta SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE p38 MAPK; COX2; TGF-beta; arthritic human chondrocytes ID ACTIVATED PROTEIN-KINASE; HUMAN ARTICULAR CHONDROCYTES; NITRIC-OXIDE; TISSUE INHIBITOR; MATRIX METALLOPROTEINASE-3; CULTURED CHONDROCYTES; SELECTIVE INHIBITOR; CELL-PROLIFERATION; PROSTAGLANDIN E-2; GENE-EXPRESSION AB These studies compare actions of p38 MAPK inhibition and COX2 inhibition to modulate human arthritic chondrocyte responses to TGF-beta and FCS under basal and IL-1 activated conditions. Chondrocytes isolated from arthritic human femoral condyle cartilage obtained at total knee replacement were grown to 80% confluence. Proteoglycan synthesis and proliferation were measured with and without IL-1 activation in the presence and absence of growth factors and with and without inhibition of p38 MAPK or COX2 activity. Experiments to evaluate TIMP-1 production under these conditions were done using cartilage organ cultures. Neither p38 MAPK inhibitors nor COX2 inhibition affected basal proliferation. However both inhibitors enhanced the proliferative response to TGF-beta and FCS in IL-1 activated chondrocytes. TGF-beta stimulated proteoglycan synthesis was decreased by p38 MAPK inhibition, however COX2 inhibition restored the response to TGF-beta in IL-1 activated cells. In contrast, COX2 inhibition did not modulate TIMP-1 production while p38 MAPK inhibitors potentiated TGF-beta stimulated production of TIMP-1 in IL-1 activated cartilage. p38 MAPK inhibition and COX2 inhibition have unique and similar abilities to counteract some of the effects of IL-1 on human chondrocyte/cartilage metabolism. Both will partially restore the proliferative response to growth factors. p38 MAPK inhibition blunts TGF-beta stimulation of proteoglycan synthesis, but increases TIMP-1 synthesis. COX2 inhibition can restore the proteoglycan synthetic response to TGF-beta, but has no effect on cartilage TIMP-1 production. Use of these inhibitors to minimize cartilage damage in arthritic and mechanically stressed joints should reflect these characteristics. Published by Elsevier Ltd. on behalf of Orthopaedic Research Society. C1 Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Med Ctr, Pittsburgh, PA USA. Dept Orthopaed Surg, Ferguson Lab, Pittsburgh, PA USA. RP Studer, RK (reprint author), Vet Adm Med Ctr, Univ Dr C, Pittsburgh, PA 15240 USA. EM rstuder@pitt.edu NR 33 TC 18 Z9 18 U1 2 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0736-0266 J9 J ORTHOP RES JI J. Orthop. Res. PD MAR PY 2005 VL 23 IS 2 BP 454 EP 461 DI 10.1016/j.orthres.2004.08.012 PG 8 WC Orthopedics SC Orthopedics GA 905KN UT WOS:000227567100032 PM 15734262 ER PT J AU Peery, JT Ledoux, WR Klute, GK AF Peery, JT Ledoux, WR Klute, GK TI Residual-limb skin temperature in transtibial sockets SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE amputation; artificial limbs; biomechanics; heat transfer; prosthetics; rehabilitation; residual limb; skin temperature; transtibial sockets; veterans ID FRICTION AB The insulated environment of the lower-limb prosthesis can result in elevated residual-limb skin temperatures that may contribute to skin initation, blistering, and a reduced quality of life. The design and materials of the prosthetic socket, suspension system, and liner can potentially alleviate these conditions, but the thermal load may vary with activity and location within the socket. To characterize the thermal environment at the skin-prosthesis interface, we made temperature measurements on five transtibial amputees at 14 locations on the residual limbs. After the participants donned their prosthesis and rested in the seated position for 15 min, the mean skin temperatures of their residual limbs increased by 0.8 degrees Celcius. Subsequent walking for 10 min resulted in a 1.7 degrees Celsius total increase in mean skin temperature. Thermal contour maps revealed the skin was coolest at the interior proximal location and warmest across the posterior section, con-elating with areas of low and high perfusion. From the results, we determined that residual-limb skin temperature depends on activity and locality. This information may aid in understanding where and why skin problems develop on lower-limb residual limbs and may provide design requirements for new prosthetic socket systems intended to alleviate temperature-related discomfort. C1 VA Puget Sound, Dept Vet Affairs VA, Rehabil Res & Dev Ctr Excellence Limb Loss Preven, Seattle, WA 98108 USA. Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. RP Klute, GK (reprint author), VA Puget Sound, Dept Vet Affairs VA, Rehabil Res & Dev Ctr Excellence Limb Loss Preven, 1660 S Columbian Way,MS-151, Seattle, WA 98108 USA. EM gklute@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 NR 9 TC 23 Z9 23 U1 0 U2 13 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD MAR-APR PY 2005 VL 42 IS 2 BP 147 EP 154 DI 10.1682/JRRD.2004.01.0013 PG 8 WC Rehabilitation SC Rehabilitation GA 935TT UT WOS:000229807000004 PM 15944879 ER PT J AU Goldstein, G Haas, GL Shemansky, WJ Barnett, B Salmon-Cox, S AF Goldstein, G Haas, GL Shemansky, WJ Barnett, B Salmon-Cox, S TI Rehabilitation during alcohol detoxication in comorbid neuropsychiatric patients SO JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT LA English DT Article DE attention control condition; cognitive rehabilitation; comorbid alcohol abuse; detoxication; dual diagnosis; intervention; memory; neuropsychology; rehabilitation; veteran ID RECOVERY AB For this study, we evaluated the effectiveness of a cognitive training program in improving cognitive function in patients with alcoholism comorbid with another neuropsychiatric disorder and going through the subacute phase of detoxication. We employed a randomized clinical trial design in which 20 subjects were assigned to a five-session cognitive rehabilitation program and 20 subjects were assigned to an attention placebo control condition. All subjects received a battery of cognitive tests for reasoning, attention, and visual-spatial abilities. These tests were repeated at the completion of the study. The training consisted of a number of component tasks designed to improve attention, speed of information processing, perceptual analysis, and visual-spatial cognition. We plotted performance on training results across sessions to detect evidence of learning effects. Comparisons of the cognitive tests revealed greater improvement in the training as compared to the attention placebo group on measures of attention and conceptual flexibility. We concluded that the training produced significant improvement over and above natural recovery during detoxication. C1 Pittsburgh Healthcare Syst, Vet Integrated Serv Network Mental Illness Res Ed, Pittsburgh, PA USA. VA Pittsburgh Healthcare Syst, Ctr Clin, Dept Vet Affairs, Pittsburgh, PA 15206 USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, Ctr Clin, Dept Vet Affairs, 7180 Highland Dr 151 R, Pittsburgh, PA 15206 USA. EM ggold@nb.net NR 17 TC 10 Z9 10 U1 0 U2 0 PU JOURNAL REHAB RES & DEV PI BALTIMORE PA DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA SN 0748-7711 J9 J REHABIL RES DEV JI J. Rehabil. Res. Dev. PD MAR-APR PY 2005 VL 42 IS 2 BP 225 EP 234 DI 10.1682/JRRD.2004.03.0040 PG 10 WC Rehabilitation SC Rehabilitation GA 935TT UT WOS:000229807000012 PM 15944887 ER PT J AU Gardella, C Johnson, KM Dobie, DJ Bradley, KA AF Gardella, C Johnson, KM Dobie, DJ Bradley, KA TI Prevalence of hysterectomy and associated factors in women veterans affairs patients SO JOURNAL OF REPRODUCTIVE MEDICINE LA English DT Article DE hysterectomy; veterans hospitals; veterans ID FEMALE VETERANS; SEXUAL ASSAULT; UNITED-STATES; PRIMARY-CARE; HEALTH-CARE; OUTPATIENTS; MILITARY; ABUSE AB OBJECTIVE: To estimate the prevalence of hysterectomy and associated factors in women veterans who access care at a Veterans Affairs medical center. STUDY DESIGN: A survey that included questions regarding hysterectomy status, demographics, medical history and validated mental health measures was mailed to 1,935 women who received care at the VA Puget Sound Health Care System between October 1996 and January 1998. RESULTS: The overall prevalence of hysterectomy was 32%, with 12% of 18-39-year-olds, 35% of 40-49-year-olds, and 57% of women 50 years old or older reporting having had a hysterectomy. In multivariable analyses, older age (OR 1.1, 95% CI 1.07-1.09), multiparity (OR 1.6, 1.14-2.2), self-reported polycystic ovary syndrome (OR 3.3, 1.81-5.9), chronic pelvic pain (OR 3.2, 2.1-4.9), irritabie bowel syndrome (OR 1.8,1.3-3.1) and premenstrual syndrome (OR 1.6, 1.1-2.3) were associated with prior hysterectomy. When factors associated with posttraumatic stress disorder in this population were omitted from the model, age (OR 1.07, 1.05-1.08), multiparity (OR 1.4, 1.0-1.9), a family history of ovarian cancer (OR 1.8, 1.2-2.8) and posttraumatic stress disorder (OR 1.4, 1.02-1.87) were associated with prior hysterectomy. CONCLUSION: The prevalence of hysterectomy may be higher among women veterans as compared with published rates for the general population and may be related to chronic pain syndromes and/or posttraumatic stress disorder. C1 Univ Washington, Med Ctr, Dept Obstet & Gynecol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Vet Hlth Adm, Dept Vet Affairs, Hlth Serv Res & Dev, Seattle, WA USA. RP Gardella, C (reprint author), Univ Washington, Med Ctr, Dept Obstet & Gynecol, Box 356460, Seattle, WA 98195 USA. EM cgardel@u.washington.edu FU NIAAA NIH HHS [K23 AA00313] NR 25 TC 9 Z9 9 U1 0 U2 0 PU SCI PRINTERS & PUBL INC PI ST LOUIS PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA SN 0024-7758 J9 J REPROD MED JI J. Reprod. Med. PD MAR PY 2005 VL 50 IS 3 BP 166 EP 172 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 908ND UT WOS:000227792800003 PM 15841928 ER PT J AU Shannon, SE Schumacher, HR Self, S Brown, AN AF Shannon, Sean E. Schumacher, H. Ralph Self, Sally Brown, Alan N. TI Multicentric Reticulohistiocytosis Responding to Tumor Necrosis Factor-alpha Inhibition in a Renal Transplant Patient SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE HISTIOCYTOSIS; NON-LANGERHANS CELL; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANT; RECEPTORS; TUMOR NECROSIS FACTOR AB Multicentric reticulohistiocytosis (MRH) is a rare systemic disease that characteristically produces severe erosive arthritis of the distal and proximal interphalangeal joints along with cutaneous nodules over the upper extremities and face, but it can be found in other organs. There is no known etiology, and it often remits spontaneously within 5-10 years, but can result in severe disfigurement. The diagnosis is made when histologic analysis of involved synovium or cutaneous nodules reveals characteristic histopathology. We describe a case of MRH manifesting as erosive arthritis that developed despite immunosuppressive therapy. Based on studies reporting tumor necrosis factor-alpha (TNF-alpha) positive cells within MRH lesions, we began treatment with TNF-alpha inhibition. Within 2 months the patient showed dramatic clinical and serologic improvement that was maintained until she stopped treatment secondary to an upper respiratory tract infection. Once treatment was restarted, the symptoms again improved. C1 Med Univ S Carolina, Dept Rheumatol Immunol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA. Univ Penn, Vet Affairs Med Ctr, Div Rheumatol, Philadelphia, PA 19104 USA. RP Shannon, SE (reprint author), Med Univ S Carolina, Div Rheumatol & Immunol, 96 Jonathan Lucas St,Suite 912,CSB,POB 250637, Charleston, SC 29425 USA. NR 13 TC 24 Z9 25 U1 0 U2 0 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD MAR PY 2005 VL 32 IS 3 BP 565 EP 567 PG 3 WC Rheumatology SC Rheumatology GA V40ON UT WOS:000209488000031 PM 15742455 ER PT J AU Gonzalez, J Williams, JW Noel, PH Lee, S AF Gonzalez, J Williams, JW Noel, PH Lee, S TI Adherence to mental health treatment in a primary care clinic SO JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE LA English DT Article ID MAJOR DEPRESSIVE DISORDER; ANTIDEPRESSANT TREATMENT; TREATMENT GUIDELINES; COMMUNITY PRACTICE; NON-ATTENDANCE; PHYSICIAN; PHARMACOTHERAPY; PATIENT; COMMUNICATION; APPOINTMENTS AB Background: Patient nonadherence is common for the standard mental health treatments in primary care: antidepressants and referrals to specialty mental health treatment. This is one of few studies to prospectively identify predictors of nonadherence. Methods: We observed 95 veterans attending an internal medicine clinic prescribed antidepressant medication or referred to mental health treatment. We collected information on sociodemographic factors, health beliefs, preferences about treatment, past experiences, and treatment knowledge. Results: At 1 month, medication adherence was greater when patients experienced previous pharmacy trouble and traveled for less than 30 minutes to reach the clinic. Appointment attendance improved when patients were ready for treatment, perceived benefits, and saw their physician as collaborative. At 6 months, medication adherence was greater when patients reported a preference for medicine treatment, traveled for less than 30 minutes, and perceived greater benefits. Fewer negative effects from previous mental health treatment improved adherence to appointments. In multivariate analyses examining adherence to all treatments, greater readiness for treatment predicted 1-month adherence, whereas being unmarried and seeing the physician as more collaborative improved 6-month adherence. Conclusions: Adherence to antidepressant medications and to mental health referrals should be examined separately. A brief initial assessment for nonadherence risk factors may identify persons for targeted adherence promoting interventions. C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, VERDICT Ctr Excellence, San Antonio, TX 78229 USA. Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA. Duke Univ, Sch Med, Durham, NC USA. RP Gonzalez, J (reprint author), Univ Texas, Hlth Sci Ctr, Dept Psychiat, S Texas Vet Hlth Care Syst, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM gonzalezjm1@uthscsa.edu RI Williams, Jr., John/A-3696-2008 OI Williams, Jr., John/0000-0002-5267-5558 NR 41 TC 34 Z9 40 U1 0 U2 6 PU AMER BOARD FAMILY PRACTICE PI LEXINGTON PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA SN 0893-8652 J9 J AM BOARD FAM PRACT JI J. Am. Board Fam. Pract. PD MAR-APR PY 2005 VL 18 IS 2 BP 87 EP 96 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 911MT UT WOS:000228007900002 PM 15798137 ER PT J AU Shlipak, MG Katz, R Fried, LF Jenny, NS Stehman-Breen, CO Newman, AB Siscovick, D Psaty, BM Sarnak, MJ AF Shlipak, MG Katz, R Fried, LF Jenny, NS Stehman-Breen, CO Newman, AB Siscovick, D Psaty, BM Sarnak, MJ TI Cystatin-C and mortality in elderly persons with heart failure. (vol 45, pg 268, 2004) SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Correction C1 Univ Calif San Francisco, Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Collaborat Hlth Studies Coordinating Ctr, Seattle, WA USA. Vet Affairs Pittsburgh Healthcare Syst, Renal Sect, Med Serv, Pittsburgh, PA USA. Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA. Amgen Inc, Thousand Oaks, CA 91320 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Tufts Univ, New England Med Ctr, Dept Med, Div Nephrol, Boston, MA 02111 USA. RP Shlipak, MG (reprint author), Univ Calif San Francisco, Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94143 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 1 PY 2005 VL 45 IS 5 BP 811 EP 811 DI 10.1016/j.acc.2005.01.007 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 901FP UT WOS:000227268700035 ER PT J AU Callahan, CM Kroenke, K Counsell, SR Hendrie, HC Perkins, AJ Katon, W Noel, PH Harpole, L Hunkeler, EM Unutzer, J AF Callahan, CM Kroenke, K Counsell, SR Hendrie, HC Perkins, AJ Katon, W Noel, PH Harpole, L Hunkeler, EM Unutzer, J CA IMPACT Investigators TI Treatment of depression improves physical functioning in older adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE depression; physical function; physical disability; collaborative care management ID LATE-LIFE DEPRESSION; RANDOMIZED CONTROLLED-TRIAL; CHRONIC DISEASE SCORE; PRIMARY-CARE PATIENTS; FUTURE-RESEARCH; ELDERLY-PEOPLE; HEALTH SURVEY; DISABILITY; MANAGEMENT; SYMPTOMS AB OBJECTIVES: To determine the effect of collaborative care management for depression on physical functioning in older adults. DESIGN: Multisite randomized clinical trial. SETTING: Eighteen primary care clinics from eight healthcare organizations. PARTICIPANTS: One thousand eight hundred one patients aged 60 and older with major depressive disorder. INTERVENTION: Patients were randomized to the Improving Mood: Promoting Access to Collaborative Treatment (IMPACT) intervention (n=906) or to a control group receiving usual care (n=895). Control patients had access to all health services available as part of usual care. Intervention patients had access for 12 months to a depression clinical specialist who coordinated depression care with their primary care physician. MEASUREMENTS: The 12-item short form Physical Component Summary (PCS) score (range 0-100) and instrumental activities of daily living (IADLs) (range 0-7). RESULTS: The mean patient age was 71.2, 65% were women, and 77% were white. At baseline, the mean PCS was 40.2, and the mean number of IADL dependencies was 0.7; 45% of participants rated their health as fair or poor. Intervention patients experienced significantly better physical functioning at 1 year than usual-care patients as measured using between-group differences on the PCS of 1.71 (95% confidence interval (CI)=0.96-2.46) and IADLs of -0.15 (95% CI=-0.29 to -0.01). Intervention patients were also less likely to rate their health as fair or poor (37.3% vs 52.4%, P<.001). Combining both study groups, patients whose depression improved were more likely to experience improvement in physical functioning. CONCLUSION: The IMPACT collaborative care model for late-life depression improves physical function more than usual care. C1 Indiana Univ, Ctr Aging Res, Regenstrief Inst Inc, Indianapolis, IN 46202 USA. Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA. Univ Washington, Sch Med, Seattle, WA USA. Grp Hlth Cooperat Puget Sound, Seattle, WA 98121 USA. S Texas Vet Hlth Care Syst, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, San Antonio, TX USA. Duke Univ, Sch Med, Durham, NC USA. Kaiser Permanente, Div Res, Oakland, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. RP Callahan, CM (reprint author), Indiana Univ, Ctr Aging Res, Regenstrief Inst Inc, 1050 Wishard Blvd,RG6, Indianapolis, IN 46202 USA. EM ccallaha@iupui.edu NR 37 TC 105 Z9 107 U1 6 U2 10 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2005 VL 53 IS 3 BP 367 EP 373 DI 10.1111/j.1532-5415.2005.53151.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 900BG UT WOS:000227189800001 PM 15743276 ER PT J AU Hamel, MB Henderson, WG Khuri, SF Daley, J AF Hamel, MB Henderson, WG Khuri, SF Daley, J TI Surgical outcomes for patients aged 80 and older: Morbidity and mortality from major noncardiac surgery SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE elderly; surgery; outcomes; morbidity; mortality ID CARDIAC OPERATIONS; RISK ADJUSTMENT; CARE; QUALITY; LENGTH; STAY; OCTOGENARIANS; COMPLICATIONS; PROGRAM C1 Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA. Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Colorado Hlth Outcomes Program, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. Boston Vet Affairs Healthcare Syst, W Roxbury, MA USA. Tenet Hlth Syst, Dallas, TX USA. RP Hamel, MB (reprint author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA. EM mhamel@bidmc.harvard.edu NR 22 TC 197 Z9 203 U1 0 U2 5 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2005 VL 53 IS 3 BP 424 EP 429 DI 10.1111/j.1532-5415.2005.53159.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 900BG UT WOS:000227189800009 PM 15743284 ER PT J AU Lindberg, JS Culleton, B Wong, G Borah, MF Clark, RV Shapiro, WB Roger, SD Husserl, FE Klassen, PS Guo, MD Albizem, MB Coburn, JW AF Lindberg, JS Culleton, B Wong, G Borah, MF Clark, RV Shapiro, WB Roger, SD Husserl, FE Klassen, PS Guo, MD Albizem, MB Coburn, JW TI Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in Hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID STAGE RENAL-DISEASE; PARATHYROID-HORMONE; PHOSPHATE-METABOLISM; MORTALITY RISK; BONE-DISEASE; CALCIUM; CALCIFICATION; RECEPTOR; AMG-073; ASSOCIATION AB Management of secondary hyperparathyroidism is challenging with traditional therapy. The calcimimetic cinacalcet HCI acts on the calcium-sensing receptor to increase its sensitivity to calcium, thereby reducing parathyroid hormone (PTH) secretion. This phase 3, multicenter, randomized, placebo-controlled, double-blind study evaluated the efficacy and safety of cinacalcet in hemodialysis (HD) and peritoneal dialysis (PD) patients with PTH greater than or equal to 300 pg/ml despite traditional therapy. A total of 395 patients received once-daily oral cinacalcet (260 HD, 34 PD) or placebo (89 HD, 12 PD) titrated from 30 to 180 mg to achieve a target intact PTH (iPTH) level of less than or equal to 250 pg/ml. During a 10-wk efficacy assessment phase, cinacalcet was more effective than control for PTH reduction outcomes, including proportion of patients with mean iPTH levels less than or equal to 300 pg/ml (46 versus 9%), proportion of patients with greater than or equal to 30% reduction in iPTH from baseline (65 versus 13%), and proportion of patients with greater than or equal to 20, greater than or equal to 40, or greater than or equal to 50% reduction from baseline. Cinacalcet had comparable efficacy in HD and PD patients; 50% of PD patients achieved a mean iPTH less than or equal to 300 pg/ml. Cinacalcet also significantly reduced serum calcium, phosphorus, and Ca x P levels compared with control treatment. The most common side effects, nausea and vomiting, were usually mild to moderate in severity and transient. Once-daily oral cinacalcet was effective in rapidly and safely reducing PTH, Ca x P, calcium, and phosphorus levels in patients who received HD or PD. Cinacalcet offers a new therapeutic option for controlling secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. C1 New Orleans Nephrol Associates, New Orleans, LA USA. Alton Ochsner Med Fdn & Ochsner Clin, New Orleans, LA 70121 USA. Foothills Prov Gen Hosp, Calgary, AB T2N 2T9, Canada. Credit Valley Hosp, Mississauga, ON, Canada. Calif Pacific Med Ctr, San Francisco, CA 94115 USA. Our Lady Lourdes RMC, Lafayette, LA USA. Brookdale Plaza Nephrol Associates, Brooklyn, NY USA. Gosford Hosp, Gosford, NSW, Australia. Amgen Inc, Thousand Oaks, CA 91320 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. RP Lindberg, JS (reprint author), New Orleans Nephrol Associates, 4228 Houma Blvd, Metairie, LA 70006 USA. EM jlindberg@bellsouth.net NR 28 TC 236 Z9 249 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD MAR PY 2005 VL 16 IS 3 BP 800 EP 807 DI 10.1681/ASN.2004060512 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 902QQ UT WOS:000227372000029 PM 15689407 ER PT J AU Holmes, WC Foa, EB Sammel, MD AF Holmes, WC Foa, EB Sammel, MD TI Men's pathways to risky sexual behavior: Role of co-occurring childhood sexual abuse, posttraumatic stress disorder, and depression histories SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article; Proceedings Paper CT Workshop on New Dynamics of HIV Risk Among Drug-Using Men Who Have Sex With Men CY MAR 01-02, 2004 CL Bethesda, MD SP NIDA DE depression; men; posttraumatic stress disorder; sexual abuse; sexual behavior ID YOUNG-ADULTS; HIV-RISK; PREVALENCE; CHILDREN; HEALTH; ASSOCIATION; COMORBIDITY; WOMEN; TRANSMISSION; ADOLESCENTS AB Recent reports of sexually transmitted infection-rate increases among men indicate the need for renewed study of male sexual risk behavior to aid development of updated and novel risk reduction interventions. Men who have childhood sexual abuse (CSA) histories consistently report frequent sexual risk behavior. The objective of this sturdy is to explore whether posttraumatic stress disorder (PTSD) and depression are moderators and/or mediators of the association between CSA and sexual risk in adult men. A cross-sectional survey study employing random digit dial recruitment was administered to men aged 18-49 years from Philadelphia County. Two hundred ninety eight men were recruited and screened for CSA history, administered items from the Posttraumatic Stress Diagnostic Scale (PDS) and Center for Epidemiologic Studies-Depression (CES-D), and asked to estimate their number of lifetime sexual partners (LSPs). Effects of sociodemograpbic characteristics, CSA, PTSD, and depression on the number of LSPs were modeled using Poisson regression. Results show that 197 (66%) men participated; 43 (22%) had CSA histories. CSA was significantly associated with PTSD/depression (P = .03). Four sociodemographic variables (age, race, sexual identity, and education), CSA (incidence rate ratio, IRR = 1.47, P <.001), PTSD (IRR = 1.19, P = .04), depression (IRR = 1.2 9, P = .001), all 2-way interactions, and the 3-way CSA/PTSD/depression interaction (IRR = 11.00, P < .001) were associated with the number of LSPs (R-2 = 0.27). In conclusion, sexual partnership patterns unique to men with CSA histories and comorbid PTSD/depression appear to lead to substantially higher numbers of LSPs. Estimates of this relationship may have been biased toward the null by underreporting that can occur with phone surveys. Cross-sectional studies do not support causal inferences; however, the identification of a moderating and mediating influence of PTSD/depression on the relationship between CSA and sexual risk behavior is important and suggests the need for future studies with larger samples that examine trajectories for CSA, psychiatric illness, and sexual partnerships. C1 Univ Penn, Sch Med, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Ctr Treatment & Study Anxiety, Philadelphia, PA USA. RP Holmes, WC (reprint author), Univ Penn, Sch Med, MSCE, 733 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM holmeswc@mail.med.upenn.edu FU NIAAA NIH HHS [AA012428]; NIDA NIH HHS [DA015635]; NIMH NIH HHS [MH62003] NR 46 TC 21 Z9 21 U1 4 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 J9 J URBAN HEALTH JI J. Urban Health PD MAR PY 2005 VL 82 IS 1 SU 1 BP I89 EP I99 DI 10.1093/jurban/jti028 PG 11 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 911OM UT WOS:000228013900011 PM 15738316 ER PT J AU Litwin, MS Saigal, CS Yano, EM Avila, C Geschwind, SA Hanley, JM Joyce, GF Madison, R Pace, J Polich, SM Wang, MM AF Litwin, MS Saigal, CS Yano, EM Avila, C Geschwind, SA Hanley, JM Joyce, GF Madison, R Pace, J Polich, SM Wang, MM CA Urologic diseases in America TI Urologic Diseases in America project: Analytical methods and principal findings SO JOURNAL OF UROLOGY LA English DT Article DE urologic diseases; healthcare common procedure system; diagnosis AB Purpose: The burden of urological diseases on the American public is immense in human and financial terms but it has been under studied. We undertook a project, Urologic Diseases in America, to quantify the burden of urological diseases on the American public. Materials and Methods: We identified public and private data sources that contain population based data on resource utilization by patients with benign and malignant urological conditions. Sources included the Centers for Medicare and Medicaid Services, National Center for Health Statistics, Medical Expenditure Panel Survey, National Health and Nutrition Examination Survey, Department of Veterans Affairs, National Association of Children's Hospitals and Related Institutions, and private data sets maintained by MarketScan Health and Productivity Management (MarketScan, Chichester, United Kingdom), Ingenix (Ingenix, Salt Lake City, Utah) and Center for Health Care Policy and Evaluation. Using diagnosis and procedure codes we described trends in the utilization of urological services. Results: In 2000 urinary tract infections accounted for more than 6.8 million office visits and 1.3 million emergency room visits, and 245,000 hospitalizations in women with an annual cost of more than $2.4 billion. Urinary tract infections accounted for more than 1.4 million office visits, 424,000 emergency room visits and 121,000 hospitalizations in men with an annual cost of more than $1 billion. Benign prostatic hyperplasia was the primary diagnosis in more than 4.4 million office visits, 117,000 emergency room visits and 105,000 hospitalizations, accounting for $1.1 billion in expenditures that year. Urolithiasis was the primary diagnosis for almost 2 million office visits, more than 600,000 emergency room visits, and more than 177,000 hospitalizations, totaling more than $2 billion in annual expenditures. Urinary incontinence in women was the primary cause for more than 1.1 million office visits in 2000 and $452 million in aggregate primary cause for more than 1.1 million office visits in 2000 and $452 million in aggregate annual expenditures. Other manuscripts in this series present further detail for specific urologic conditions. Conclusions: Recent trends in epidemiology, practice patterns, resource utilization and costs for urological diseases have broad implications for quality of health care, access to care and the equitable allocation of scarce resources for clinical care and research. C1 Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med & Sch, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Hlth Serv, Sch Publ Hlth, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. Vet Affairs Hlth Serv Res & Dev Ctr Excellence, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RAND HLTH, Santa Monica, CA USA. RP Litwin, MS (reprint author), Univ Calif Los Angeles, Dept Urol, David Geffen Sch Med & Sch, Box 951738, Los Angeles, CA 90095 USA. EM mlitwin@mednet.ucla.edu NR 7 TC 120 Z9 121 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD MAR PY 2005 VL 173 IS 3 BP 933 EP 937 DI 10.1097/01.ju.0000152365.43125.3b PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 898KK UT WOS:000227075500057 PM 15711342 ER PT J AU Hoyt, CC Richardson-Burns, SM Goody, RJ Robinson, BA DeBiasi, RL Tyler, KL AF Hoyt, CC Richardson-Burns, SM Goody, RJ Robinson, BA DeBiasi, RL Tyler, KL TI Nonstructural protein sigma 1s is a determinant of reovirus virulence and influences the kinetics and severity of apoptosis induction in the heart and central nervous system SO JOURNAL OF VIROLOGY LA English DT Article ID CELL-CYCLE REGULATION; SIALIC-ACID; TRANSLATION PRODUCTS; NEURONAL APOPTOSIS; MOLECULAR-BASIS; S1 GENES; INHIBITION; PROTEIN; INJURY; IDENTIFICATION AB The mechanisms by which viruses kill susceptible cells in target organs and ultimately produce disease in the infected host remain poorly understood. Dependent upon the site of inoculation and strain of virus, experimental infection of neonatal mice with reoviruses can induce fatal encephalitis or myocarditis. Reovirus-induced apoptosis is a major mechanism of tissue injury, leading to disease development in both the brain and heart. In cultured cells, differences in the capacity of reovirus strains to induce apoptosis are determined by the S1 gene segment, which also plays a major role as a determinant of viral pathogenesis in both the heart and the central nervous system (CNS) in vivo. The S1 gene is bicistronic, encoding both the viral attachment protein sigma-1 and the nonstructural protein sigma-1-small (sigma1s). Although sigma1s is dispensable for viral replication in vitro, we wished to investigate the expression of sigma1s in the infected heart and brain and its potential role in reovirus pathogenesis in vivo. Two-day-old mice were inoculated intramuscularly or intracerebrally with either sigma1s(-) or sigma1s(+) reovirus strains. While viral replication in target organs did not differ between sigma1s(-) and sigma1s(+) viral strains, virus-induced caspase-3 activation and resultant histological tissue injury in both the heart and brain were significantly reduced in sigma1s(-) reovirus-infected animals. These results demonstrate that sigma1s is a determinant of the magnitude and extent of reovirus-induced apoptosis in both the heart and CNS and thereby contributes to reovirus pathogenesis and virulence. C1 Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Program Neurosci, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Tyler, KL (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, B-182,4200 E 9th Ave, Denver, CO 80262 USA. EM Ken.Tyler@uchsc.edu OI Tyler, Kenneth/0000-0003-3294-5888 FU NINDS NIH HHS [R01 NS050138-04, R01 NS051403-03, 1R01NS50138, R01 NS051403, R01 NS050138] NR 38 TC 22 Z9 24 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAR PY 2005 VL 79 IS 5 BP 2743 EP 2753 DI 10.1128/JVI.79.5.2743-2753.2005 PG 11 WC Virology SC Virology GA 898TF UT WOS:000227098400010 PM 15708993 ER PT J AU Ahmad, S Vlachaki, MT Teslow, TN Amosson, CM McGary, J Teh, BS Woo, SY Butler, EB Grant, WH AF Ahmad, S Vlachaki, MT Teslow, TN Amosson, CM McGary, J Teh, BS Woo, SY Butler, EB Grant, WH TI Impact of setup uncertainty in the dosimetry of prostate and surrounding tissues in prostate cancer patients treated with Peacock/IMRT SO MEDICAL DOSIMETRY LA English DT Article DE prostate cancer; IMRT; setup error ID MODULATED RADIATION-THERAPY; CONFORMAL RADIOTHERAPY; ACUTE TOXICITY; BOOST THERAPY; CARCINOMA; BLADDER; RECTUM; MOVEMENT; DELIVERY; ISSUES AB The purpose of this paper was to assess the effect of setup uncertainty on dosimetry of prostate, seminal vesicles, bladder, rectum, and colon in prostate cancer patients treated with Peacock intensity-modulated radiation therapy (IMRT). Ten patients underwent computed tomography (CT) scans using the "prostate box" for external, and an "endorectal balloon" for target immobilization devices, and treatment plans were generated (T1). A maximum of +/- 5-mm setup error was chosen to model dosimetric effects. Isodose lines from the T1 treatment plan were then superimposed on each patient's CT anatomy shifted by 5 mm toward the cephalad and caudal direction, generating 2 more dosimetric plans (H1 and H2, respectively). Average mean doses ranged from 74.5 to 74.92 Gy for prostate and 73.65 to 74.94 Gy for seminal vesicles. Average percent target volume below 70 Gy increased significantly for seminal vesicles, from 0.53% to 6.26%, but minimally for prostate, from 2.08% to 4.4%. Dose statistics adhered to prescription limits for normal tissues. Setup uncertainty had minimum impact on target dose escalation and normal tissue dosing. The impact of target dose inhomogeneity is currently evaluated in clinical studies. (C) 2005 American Association of Medical Dosimetrists. C1 Dept Vet Affairs Med Ctr, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. RP Ahmad, S (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Radiat Oncol, Everett Tower,1200 N Everett Dr,Room B603, Oklahoma City, OK 73104 USA. NR 39 TC 6 Z9 8 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0958-3947 J9 MED DOSIM JI Med. Dosim. PD SPR PY 2005 VL 30 IS 1 BP 1 EP 7 DI 10.1016/j.meddos.2004.10.001 PG 7 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 018XK UT WOS:000235797900001 PM 15749004 ER PT J AU Sillanpaa, J Chang, J Mageras, G Riem, H Ford, E Todor, D Ling, CC Amols, H AF Sillanpaa, J Chang, J Mageras, G Riem, H Ford, E Todor, D Ling, CC Amols, H TI Developments in megavoltage cone beam CT with an amorphous silicon EPID: Reduction of exposure and synchronization with respiratory gating SO MEDICAL PHYSICS LA English DT Article DE electronic portal imaging device; cone beam CT; setup verfication ID FLAT-PANEL IMAGER; PORTAL IMAGING DEVICE; COMPUTED-TOMOGRAPHY; CONFORMAL RADIOTHERAPY; TREATMENT VERIFICATION; RADIATION-THERAPY; LUNG-CANCER; RECONSTRUCTION; SCANNER; FEASIBILITY AB We have studied the feasibility of a low-dose megavoltage cone beam computed tomography (MV CBCT) system for visualizing the gross tumor volume in respiratory gated radiation treatments of nonsmall-cell lung cancer. The system consists of a commercially available linear accelerator (LINAC), an amorphous silicon electronic portal imaging device, and a respiratory gating system. The gantry movement and beam delivery are controlled using dynamic beam delivery toolbox, a commercial software package for executing scripts to control the LINAC. A specially designed interface box synchronizes the LINAC, image acquisition electronics, and the respiratory gating system. Images are preprocessed to remove artifacts due to detector sag and LINAC output fluctuations. We report on the output, flatness, and symmetry of the images acquired using different imaging parameters. We also examine the quality of three-dimensional (3D) tomographic reconstruction with projection images of anthropomorphic thorax, contrast detail, and motion phantoms. The results show that, with the proper choice of imaging parameters, the flatness and symmetry are reasonably good with as low as three beam pulses per projection image. Resolution of 5% electron density differences is possible in a contrast detail phantom using 100 projections and 30 MU. Synchronization of image acquisition with simulated respiration also eliminated motion artifacts in a moving phantom, demonstrating the system's capability for imaging patients undergoing gated radiation therapy. The acquisition time is limited by the patient's respiration (only one image per breathing cycle) and is under 10 min for a scan of 100 projections. In conclusion, we have developed a MV CBCT system using commercially available components to produce 3D reconstructions, with sufficient contrast resolution for localizing a simulated lung tumor, using a dose comparable to portal imaging. (c) 2005 American Association of Physicists in Medicine. C1 Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA. Varian Med Syst, Baden, Switzerland. VA Puget Sound, Seattle, WA 98108 USA. Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA. RP Sillanpaa, J (reprint author), Mem Sloan Kettering Canc Ctr, Dept Med Phys, 1275 York Ave, New York, NY 10021 USA. EM changj@mskcc.org RI Grams, Michael/G-5197-2011 OI Mageras, Gikas/0000-0001-9851-4306 FU NCI NIH HHS [P01-CA59017] NR 34 TC 45 Z9 46 U1 0 U2 2 PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0094-2405 J9 MED PHYS JI Med. Phys. PD MAR PY 2005 VL 32 IS 3 BP 819 EP 829 DI 10.1118/1.1861522 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 910DN UT WOS:000227910600020 PM 15839355 ER PT J AU Hu, W Xu, RJ Zhang, GF Jin, JF Szulc, ZM Bielawski, J Hannun, YA Obeid, LM Mao, CG AF Hu, W Xu, RJ Zhang, GF Jin, JF Szulc, ZM Bielawski, J Hannun, YA Obeid, LM Mao, CG TI Golgi fragmentation is associated with ceramide-induced cellular effects SO MOLECULAR BIOLOGY OF THE CELL LA English DT Article ID ACTIN CYTOSKELETON; INDUCED APOPTOSIS; FOCAL ADHESION; CELLS; GLYCOSYLATION; FIBRONECTIN; METABOLISM; RECEPTOR; BETA-1-INTEGRINS; ORGANIZATION AB Ceramide has been shown to cause anoikis, a subtype of apoptosis due to inadequate cell adhesion. However, the underlying mechanism is unclear. Herein, we report that D-e-C-6-ceramide (D-e-Cer), via generating sphingosine, disrupts the Golgi complex (GC), which is associated with various cellular effects, including anoikis. Treatment of HeLa cells with D-e-Cer caused cell elongation, spreading inhibition, rounding, and detachment before apoptosis (anoikis). In D-e-Cer-treated cells, glycosylation of beta1 integrin in the GC was inhibited, thus its associated integrin receptors failed to translocate to the cell surface. Ceramide treatment also inhibited the reorganization of both microtubule and F-actin cytoskeletons, focal adhesions, and filopodia. These cellular effects were preceded by fragmentation of the Golgi complex. In contrast, L-e-C-6-ceramide (L-e-Cer), the enantiomer of D-e-Cer, failed to induce these cellular effects. Mass spectrometric analysis revealed that treatment HeLa cells with D-e-Cer but not L-e-Cer caused a >50-fold increase in the levels of sphingosine, a product of hydrolysis of ceramide. Treatment with D-e-sphingosine and its enantionter, L-e-sphingosine, caused massive perinuclear vacuolization, Golgi fragmentation, and cell rounding. Together, these results suggest that sphingosine generated from hydrolysis of ceramide causes the GC disruption, leading to various cellular effects. C1 Med Univ S Carolina, Dept Med & Biochem, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Mol Biol, Charleston, SC 29425 USA. NIH, Div Bioengn & Phys Sci, Bethesda, MD 20892 USA. Ralph H Johnson Vet Adm Hosp, Charleston, SC 29401 USA. RP Mao, CG (reprint author), Med Univ S Carolina, Dept Med & Biochem, Charleston, SC 29425 USA. EM maoc@musc.edu OI obeid, lina/0000-0002-0734-0847 FU NCI NIH HHS [P01 CA097132, R01 CA104834]; NCRR NIH HHS [P20 RR017677, P20RR017677] NR 45 TC 53 Z9 56 U1 0 U2 0 PU AMER SOC CELL BIOLOGY PI BETHESDA PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA SN 1059-1524 J9 MOL BIOL CELL JI Mol. Biol. Cell PD MAR PY 2005 VL 16 IS 3 BP 1555 EP 1567 DI 10.1091/mbc.E04-07-0594 PG 13 WC Cell Biology SC Cell Biology GA 902SZ UT WOS:000227378100046 PM 15647381 ER PT J AU Martin, FC Le, AT Handforth, A AF Martin, FC Le, AT Handforth, A TI Harmaline-induced tremor as a potential preclinical screening method for essential tremor medications SO MOVEMENT DISORDERS LA English DT Article DE essential tremor; harmaline propranolol; ethanol; octanol ID ANIMAL-MODELS; ETHANOL; ALCOHOL; PROPRANOLOL; TRIAL AB No preclinical method to evaluate potential new medications for essential tremor (ET) is available currently. Although harmaline tremor is a well known animal model of ET, it has not found utility as a preclinical drug screen and has not been validated with anti-ET medications. We measured harmaline tremor in rats (10 mg/kg s.c.) and mice (20 mg/kg s.c.) with a load sensor under the cage floor and performed spectral analysis on 20-minute epochs. The motion power over the tremor frequency bandwidth (8-12 Hz in rats 10-16 Hz in mice) was divided by the motion power over the full motion frequency range (0-15 Hz in rats; 0-34 Hz in mice). The use of these measures greatly reduced data variability, permitting experiments with small sample sizes. Three drugs that suppress ET (propranolol, ethanol, and octanol) all significantly suppressed harmaline-induced tremor. We propose that, with this methodology, harmaline-induced tremor may be useful as a preclinical method to identify potential medications for ET. (c) 2004 Movement Disorder Society. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA 90073 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Neurol Serv, Los Angeles, CA 90073 USA. RP Martin, FC (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, 11301 Wilshire Blvd,Bldg 114,Room 226, Los Angeles, CA 90073 USA. EM fredricka.martin@med.va.gov NR 29 TC 48 Z9 48 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD MAR PY 2005 VL 20 IS 3 BP 298 EP 305 DI 10.1002/mds.20331 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 910EC UT WOS:000227912100004 PM 15580562 ER PT J AU de Vasconcelos, AP Bouilleret, V Riban, V Wasterlain, C Nehlig, A AF de Vasconcelos, AP Bouilleret, V Riban, V Wasterlain, C Nehlig, A TI Role of nitric oxide in cerebral blood flow changes during kainate seizures in mice: genetic and pharmacological approaches SO NEUROBIOLOGY OF DISEASE LA English DT Article DE neuronal nitric oxide synthase; knockout mice; 7-nitroindazole; kainate seizures; intrahippocampal injection; cerebral blood flow ID TEMPORAL-LOBE EPILEPSY; KAINIC ACID; HIPPOCAMPAL SCLEROSIS; SYNTHASE GENE; ELECTRICAL-STIMULATION; STATUS EPILEPTICUS; 7-NITRO INDAZOLE; LIMBIC SEIZURES; RAT-BRAIN; INHIBITION AB The role of neuronal nitric oxide (NO) in the cerebrovascular response to partial seizures induced by intrahippocampal injection of kainate (KA) was investigated in mice deleted for the neuronal NO synthase gene (nNOS-/-) and in wild-type controls (WT). A second group of WT mice received the nNOS inhibitor, 7-nitroindazole (WT-7NI). Local cerebral blood flow (LCBF) was measured using the quantitative C-14-iodoantipyrine method. Within the epileptic focus, all three groups of seizing mice (WT, WT-7NI, and nNOS-/-) showed significant 26-88% LCBF increases in ipsilateral hippocampus, compared to saline-injected mice. Contralaterally to the epileptic focus, KA seizures induced a 21-47% LCBF decreases in hippocampus and limbic cortex of WT mice and in most contralateral brain structures of nNOS-/- mice, while WT-7NI mice showed no contralateral CBF change. Neuronal NO appears to be not involved in the cerebrovascular response within the epileptic focus, but may rather have a role in the maintenance of distant LCBF regulation during seizures. (C) 2004 Elsevier Inc. All rights reserved. C1 Fac Med Strasbourg, INSERM U398, F-67085 Strasbourg, France. Univ Calif Los Angeles, Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Inst Brain Res, Los Angeles, CA USA. RP de Vasconcelos, AP (reprint author), ULP, CNRS, UMR 7521, LN2C, 12 Rue Goethe, F-67000 Strasbourg, France. EM Pereira@neurochem.u-strasbg.fr NR 70 TC 16 Z9 16 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 J9 NEUROBIOL DIS JI Neurobiol. Dis. PD MAR PY 2005 VL 18 IS 2 BP 270 EP 281 DI 10.1016/j.nbd.2004.09.014 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 896RC UT WOS:000226950200003 PM 15686955 ER PT J AU Szlyk, JP Seiple, W Stelmack, J McMahon, T AF Szlyk, JP Seiple, W Stelmack, J McMahon, T TI Use of prisms for navigation and driving in hemianopic patients SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS LA English DT Article DE devices; driving; follow-up; hemianopsia; low vision; prisms ID VISUAL-FIELD LOSS; HOMONYMOUS HEMIANOPIA; CONTRAST SENSITIVITY; RETINITIS-PIGMENTOSA; PERFORMANCE; VISION; AGE AB Purpose: (1) To compare the outcomes of orientation and mobility and driving training with Fresnel prisms and the Gottlieb Visual Field Awareness System for patients with homonymous hemianopsia, and (2) To determine whether the patients continue to use the optical enhancement devices at a 2-year follow-up point. Methods: Patients with homonymous hemianopsia were provided with a rehabilitation program where they were fitted with prism lenses and trained to use them for navigation and driving. Telephone interviews were used to obtain information about device usage 2 years following the completion of the training program. Results: Patients' performance was compared with a test-retest criterion in the visual skills areas of recognition, mobility, peripheral detection, scanning, tracking, and visual memory. Patients with hemianopic loss showed improvements in all of the visual skills categories, ranging from the highest improvements of 26% of tasks improved in the mobility category to 13% in the recognition category. The majority of the hemianopic patients reported using the devices at the 2-year follow-up interview. Conclusions: The patients with homonymous hemianopsia showed improvements in visual functioning using prism lenses, although these improvements were smaller than those found in previous studies with central or bilateral peripheral vision loss groups who were trained to use other optical enhancement devices for navigation and driving using a similar curriculum. However, given the evidence of increased risk of accidents for patients with peripheral vision loss, the safety of peripheral enhancement devices for driving must be thoroughly evaluated before their impact on public safety is known. C1 VA Chicago Hlth Care Syst, W Side Div, Res & Dev Serv, Chicago, IL 60612 USA. Univ Illinois, Coll Med, Dept Ophthalmol & Visual Sci, Chicago, IL USA. NYU, Sch Med, Dept Ophthalmol, New York, NY USA. Illinois Coll Optometry, Chicago, IL USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Blind Rehabil Ctr, Hines, IL 60141 USA. RP Szlyk, JP (reprint author), VA Chicago Hlth Care Syst, W Side Div, Res & Dev Serv, M-C 151,820 S Damen Ave, Chicago, IL 60612 USA. EM janeszly@uic.edu OI Seiple, William/0000-0002-5750-650X FU NEI NIH HHS [EY1792] NR 24 TC 24 Z9 25 U1 0 U2 8 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0275-5408 J9 OPHTHAL PHYSL OPT JI Ophthalmic Physiol. Opt. PD MAR PY 2005 VL 25 IS 2 BP 128 EP 135 DI 10.1111/j.1475-1313.2004.00265.x PG 8 WC Ophthalmology SC Ophthalmology GA 901YP UT WOS:000227318500006 PM 15713204 ER PT J AU Shifrin, AL Chirmule, N Gao, GP Wilson, JM Raper, SE AF Shifrin, AL Chirmule, N Gao, GP Wilson, JM Raper, SE TI Innate immune responses to adenoviral vector-mediated acute pancreatitis SO PANCREAS LA English DT Article DE rodent; adenoviral vector; macrophages; natural killer cells; natural killer T lymphocytes; interleukin-6; interleukin-10; interleukin-12 ID GENE-TRANSFER; RECOMBINANT ADENOVIRUS; MOUSE-LIVER; EXPRESSION; CELLS; INFECTION; MACROPHAGES; IMMUNODEFICIENCY; STRATEGIES; CYTOLYSIS AB Objectives: The role of innate immunity in the development of acute viral pancreatitis is not well understood. The aim of the study was to characterize the role of the innate immune system, especially macrophages, natural killer (NK), and NK T (NKT) cells, in the generation of immune responses to intrapancreatic delivery of recombinant adenoviral vector. Methods: Adenoviral vectors expressing beta-galactosidase or green fluorescent protein genes with viral capsid conjugated covalently with carbocyanine dye were directly injected into the pancreas of C57Bl/6 mice. Results: Fluorescent microscopy of the pancreas showed that 30 minutes after vector administration, adenoviral particles localized to cell membranes, internalized, and localized to the nucleus by 4 hours, and transgene expression began at 24 hours. Immunohistochemical staining showed macrophages entering the pancreas shortly after vector administration, with maximal infiltration at day 4, and then disappearing as antigen-expressing cells were eliminated. Intrapancreatic macrophages appeared to deliver viral capsid proteins to the spleen. Flow cytometry showed that NK and NKT cells migrate to the pancreas and persist. Serum cytokines IL-6, IL-10, and IL-12 were all elevated. Conclusion: Macrophages and NK and NKT cells play a major role in the development of acute adenovirus-mediated pancreatitis. C1 Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA. Merck & Co Inc, Wayne, PA USA. Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. RP Raper, SE (reprint author), Univ Penn, Sch Med, Dept Surg, 4 Silverstein Pavil,3400 Spruce St, Philadelphia, PA 19104 USA. EM rapers@uphs.upenn.edu RI Wilson, James/F-9220-2011 OI Wilson, James/0000-0002-9630-3131 FU NIDDK NIH HHS [DK47787, DK54208] NR 42 TC 11 Z9 13 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 J9 PANCREAS JI Pancreas PD MAR PY 2005 VL 30 IS 2 BP 122 EP 129 DI 10.1097/01.mpa.0000151578.99413.88 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 903DH UT WOS:000227405200005 PM 15714134 ER PT J AU Thompson, AN Osgood, TS AF Thompson, AN Osgood, TS TI Doctor of pharmacy student impact on patient care in the critical care units. SO PHARMACOTHERAPY LA English DT Meeting Abstract CT Spring Practice and Research Forum of the American-College-of-Clinical-Pharmacy CY APR 10-13, 2005 CL Myrtle Beach, SC SP Amer Coll Clin Pharm C1 Med Univ S Carolina, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU PHARMACOTHERAPY PUBLICATIONS INC PI BOSTON PA NEW ENGLAND MEDICAL CENTER, 806, 750 WASHINGTON ST, BOSTON, MA 02111 USA SN 0277-0008 J9 PHARMACOTHERAPY JI Pharmacotherapy PD MAR PY 2005 VL 25 IS 3 MA 155 BP 477 EP 477 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 901NJ UT WOS:000227288900136 ER PT J AU Zile, MR Baicu, CF Bonnema, DD AF Zile, MR Baicu, CF Bonnema, DD TI Diastolic heart failure: Definitions and terminology SO PROGRESS IN CARDIOVASCULAR DISEASES LA English DT Review ID VENTRICULAR EJECTION FRACTION; SYSTOLIC DYSFUNCTION; THERAPEUTIC OPTIONS; PART II; ABNORMALITIES; MECHANISMS; MORTALITY; EXERCISE C1 Med Univ S Carolina, Div Cardiol, Dept Med, Charleston, SC 29425 USA. Med Univ S Carolina, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. RP Zile, MR (reprint author), Med Univ S Carolina, Div Cardiol, Dept Med, 135 Rutledge Ave,Suite 1201,POB 250592, Charleston, SC 29425 USA. EM zilem@musc.edu FU NHLBI NIH HHS [P01-HL-48788] NR 39 TC 29 Z9 33 U1 0 U2 2 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0033-0620 J9 PROG CARDIOVASC DIS JI Prog. Cardiovasc. Dis. PD MAR-APR PY 2005 VL 47 IS 5 BP 307 EP 313 DI 10.1016/j.pcad.2005.02.006 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 949IK UT WOS:000230778300001 PM 16003645 ER PT J AU Thoma, RJ Hanlon, FM Moses, SN Ricker, D Huang, MX Edgar, C Irwin, J Torres, F Weisend, MP Adler, LE Miller, GA Canive, JM AF Thoma, RJ Hanlon, FM Moses, SN Ricker, D Huang, MX Edgar, C Irwin, J Torres, F Weisend, MP Adler, LE Miller, GA Canive, JM TI M50 sensory gating predicts negative symptoms in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE schizophrenia; auditory sensory gating; magnetoencephalography; electroencephalography; MEG; EEG; negative symptoms ID CEREBRAL BLOOD-FLOW; P50 SUPPRESSION; PREPULSE INHIBITION; PREFRONTAL CORTEX; POSITIVE SYMPTOMS; COGNITIVE MODEL; RELIABILITY; DEFICITS; STARTLE; SCALE AB Impaired auditory sensory gating is considered characteristic of schizophrenia and a marker of the information processing deficit inherent to that disorder. Predominance of negative symptoms also reflects the degree of deficit in schizophrenia and is associated with poorer pre-morbid functioning, lower IQ, and poorer outcomes. However, a consistent relationship between auditory sensory gating and negative symptoms in schizophrenia has yet to be demonstrated. The absence of such a finding is surprising, since both impaired auditory gating and negative symptoms have been linked with impaired fronto-temporal cortical function. The present study measured auditory gating using the P50 event related potential (ERP) in a paired-click paradigm and capitalized on the relative localization advantage of magnetoencephalography (MEG) to assess auditory sensory gating in terms of the event related field (ERF) M50 source dipoles on bilateral superior temporal gyrus (STG). The primary hypothesis was that there would be a positive correlation between lateralized M50 auditory sensory gating measures and negative symptoms in patients with schizophrenia. A standard paired-click paradigm was used during simultaneous EEG and MEG data collection to determine S2/S1 sensory gating ratios in a group of 20 patients for both neuroimaging techniques. Participants were administered the Schedule for the Assessment of Negative Symptoms (SANS), the Positive and Negative Symptom Scale (PANSS), and the Calgary Depression Scale for Schizophrenia. Consistent with previous reports, there was no relationship between ERP P50 sensory gating and negative symptoms. However, right (not left) hemisphere ERF M50 sensory gating ratio was significantly and positively correlated with negative symptoms. This finding is compatible with information processing theories of negative symptoms and with more recent findings of fronto-temporal abnormality in patients with predominantly negative symptoms. (C) 2004 Elsevier B.V. All rights reserved. C1 Vet Adm Med Ctr, New Mexico VA Hlth Care Syst, Psychiat Serv, Albuquerque, NM 87108 USA. Univ New Mexico, Dept Psychol, Albuquerque, NM 87108 USA. Univ New Mexico, Dept Psychiat, Hlth Sci Ctr, Albuquerque, NM 87108 USA. New Mexico VA Hlth Care Syst, Dept Radiol, Albuquerque, NM 87108 USA. Univ Illinois, Dept Psychol, Urbana, IL 61801 USA. Univ Illinois, Beckman Inst, Biomed Imaging Ctr, Urbana, IL 61801 USA. Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. Univ Colorado, Psychiat Serv, Denver VAMC, Denver, CO 80202 USA. Univ Illinois, Dept Psychiat, Urbana, IL 61801 USA. Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA. RP Thoma, RJ (reprint author), Vet Adm Med Ctr, New Mexico VA Hlth Care Syst, Psychiat Serv, 116A,1501 San Pedro SE, Albuquerque, NM 87108 USA. EM robert.thoma@med.va.gov FU NIMH NIH HHS [1 R01 MH65304-01] NR 33 TC 52 Z9 57 U1 2 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD MAR 1 PY 2005 VL 73 IS 2-3 BP 311 EP 318 DI 10.1016/j.schres.2004.07.001 PG 8 WC Psychiatry SC Psychiatry GA 892OY UT WOS:000226661100021 PM 15653276 ER PT J AU Wynn, JK Sergi, MJ Dawson, ME Schell, AM Green, MF AF Wynn, JK Sergi, MJ Dawson, ME Schell, AM Green, MF TI Sensorimotor gating, orienting and social perception in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE prepulse inhibition; prepulse facilitation; social perception; schizophrenia; sensorimotor gating; social cognition ID PREPULSE INHIBITION; EMOTION RECOGNITION; STARTLE REFLEX; COGNITION; HABITUATION; DISORDER; CONTEXT; DEFICIT; MEMORY AB Basic neurocognition and social cognition appear to influence the social impairments of persons with schizophrenia. This study examined relationships between two very basic automatic processes (i.e., sensorimotor gating and orienting) and social perception in schizophrenic patients. Thirty outpatients with schizophrenia completed psychophysiological measures of sensorimotor gating (prepulse inhibition, PPI), orienting (prepulse facilitation, PPF), and social perception (the Half Profile of Nonverbal Sensitivity, Half PONS). A median split was used to divide patients into poor and good gaters and poor and good orienters. Analyses revealed that patients with good PPI scored significantly higher on the Half PONS than patients with poor PPI. PPI showed a significant correlation (r=-0.54) with Half PONS performance, indicating that schizophrenia patients who were better able to gate out competing stimuli (i.e., less startle) were also better at detecting relevant social cues. Orienting (PPF) and social perception were not related. This study is the first to our knowledge to demonstrate an association between sensorimotor gating and social perception. The findings are consistent with other studies that have demonstrated relationships between basic neurocognition and social cognition. By showing a link between sensorimotor gating and social perception, this study supports social cognition's potential role as a mediator of the relationship between neurocognition and social functioning in schizophrenia. (C) 2004 Elsevier B.V All rights reserved. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA. Calif State Univ Northridge, Dept Psychol, Northridge, CA 91330 USA. Univ So Calif, Dept Psychol, Los Angeles, CA 90089 USA. RP Wynn, JK (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,MIRECC 210A,Bldg 210, Los Angeles, CA 90073 USA. EM jkwynn@ucla.edu RI Wynn, Jonathan/H-3749-2014 OI Wynn, Jonathan/0000-0002-1763-8540 FU NIMH NIH HHS [MH-46433, MH14584, MH-43292] NR 39 TC 29 Z9 30 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD MAR 1 PY 2005 VL 73 IS 2-3 BP 319 EP 325 DI 10.1016/j.schres.2004.07.013 PG 7 WC Psychiatry SC Psychiatry GA 892OY UT WOS:000226661100022 PM 15653277 ER PT J AU Pierre, JM Wirshing, DA Wirshing, WC Rivard, JM Marks, R Mendenhall, J Sheppard, K Saunders, DG AF Pierre, JM Wirshing, DA Wirshing, WC Rivard, JM Marks, R Mendenhall, J Sheppard, K Saunders, DG TI High-dose quetiapine in treatment refractory schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Letter ID SCHIZOAFFECTIVE DISORDER; OLANZAPINE C1 VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90024 USA. Atascadero State Hosp, Atascadero, CA USA. RP Pierre, JM (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Psychiat, 11301 Wilshire Blvd,Bldg 210,Room 15, Los Angeles, CA 90073 USA. EM drjoe@ucla.edu NR 9 TC 28 Z9 29 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD MAR 1 PY 2005 VL 73 IS 2-3 BP 373 EP 375 DI 10.1016/j.schres.2004.07.014 PG 3 WC Psychiatry SC Psychiatry GA 892OY UT WOS:000226661100030 PM 15653285 ER PT J AU Unruh, ML Weisbord, SD Kimmel, PL AF Unruh, ML Weisbord, SD Kimmel, PL TI Health-related quality of life in nephrology research and clinical practice SO SEMINARS IN DIALYSIS LA English DT Article ID STAGE RENAL-DISEASE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; PERITONEAL-DIALYSIS PATIENTS; URBAN HEMODIALYSIS-PATIENTS; PSYCHOSOCIAL FACTORS; FUNCTIONAL HEALTH; PATIENT; TRANSPLANTATION; SYMPTOMS; DEPRESSION AB Physical, psychosocial, and lifestyle disturbances, along with physical and emotional symptoms, have been shown to impact the health-related quality of life (HRQOL) of those dependent on renal replacement therapy. The value of HRQOL measurement as a tool to improve clinical care has been recognized by patients, clinical investigators, and health care providers. The potential importance of HRQOL assessment lies in the additional information it provides and the impact it has on the clinical decision-making process between a patient and a physician. There remain a multitude of challenges facing renal providers who wish to incorporate HRQOL measurement to improve patient care. These challenges include the clinician's understanding of the conceptual model of HRQOL, the quality of the scientific process that contributed to the current literature on HRQOL, a willingness of the clinician to incorporate HRQOL information into clinical practice, and the logistic difficulties of collecting and applying HRQOL data in a busy practice setting. Arguably, optimizing HRQOL may be the most substantial impact the health care team will have on the person with kidney failure. In order to implement HRQOL assessment at the point of care, providers may consider using computer adaptive testing and scoring algorithms using item response theory, which will allow adequate reliability for interpretation of change among individuals. Moreover, the effective assessment and interpretation of HRQOL will be aided by continued publication of norms, outcomes of randomized controlled trials, and continued experience of investigators and clinicians. C1 Univ Pittsburgh, Med Ctr, Sch Med, Dept Med,Renal Electrolyte Div, Pittsburgh, PA 15261 USA. VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. George Washington Univ, Med Ctr, Dept Med, Div Renal Dis & Hypertens, Washington, DC 20037 USA. RP Unruh, ML (reprint author), Univ Pittsburgh, Med Ctr, Sch Med, Dept Med,Renal Electrolyte Div, 3550 Terrace St,A909 Scaife Hall, Pittsburgh, PA 15261 USA. EM unruh@pitt.edu FU NIDDK NIH HHS [K23 DK66006-01] NR 85 TC 67 Z9 69 U1 1 U2 5 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0894-0959 J9 SEMIN DIALYSIS JI Semin. Dial. PD MAR-APR PY 2005 VL 18 IS 2 BP 82 EP 90 DI 10.1111/j.1525-139X.2005.18206.x PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 904EF UT WOS:000227478200003 PM 15771650 ER PT J AU Venkataraman, R Palevsky, P Kellum, JA AF Venkataraman, R Palevsky, P Kellum, JA TI Adequacy of dialysis in acute renal failure SO SEMINARS IN NEPHROLOGY LA English DT Review ID CONTINUOUS VENOVENOUS HEMOFILTRATION; INTENSIVE-CARE UNIT; TOTAL-BODY WATER; REPLACEMENT THERAPY; MAINTENANCE HEMODIALYSIS; RANDOMIZED-TRIAL; CRITICALLY ILL; INTERMITTENT; SURVIVAL; METAANALYSIS C1 Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Dept Med, CRISMA Lab, Pittsburgh, PA 15261 USA. VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. RP Kellum, JA (reprint author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Scaife Hall,Room 608,3550 Terrace St, Pittsburgh, PA 15261 USA. EM kellumja@ccm.upmc.edu OI Palevsky, Paul/0000-0002-7334-5400 NR 51 TC 5 Z9 5 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0270-9295 J9 SEMIN NEPHROL JI Semin. Nephrol. PD MAR PY 2005 VL 25 IS 2 BP 120 EP 124 DI 10.1016/j.semnephrol.2004.09.019 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 918MF UT WOS:000228545200009 PM 15791564 ER PT J AU Karlamangla, AS Singer, BH Williams, DR Schwartz, JE Matthews, KA Kiefe, CI Seeman, TE AF Karlamangla, AS Singer, BH Williams, DR Schwartz, JE Matthews, KA Kiefe, CI Seeman, TE TI Impact of socioeconomic status on longitudinal accumulation of cardiovascular risk in young adults: the CARDIA Study (USA) SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE socioeconomic status; cardiovascular risk factors; longitudinal risk accumulation; growth trajectories; tracking; USA ID CORONARY HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; ANALYZING DEVELOPMENTAL TRAJECTORIES; BLOOD-PRESSURE; SOCIAL-CLASS; RACIAL-DIFFERENCES; HEALTH; MORTALITY; TRACKING; RACE AB Our objectives were to describe the trajectories of biological risk factors of cardiovascular disease in young adults, and to study the association of socioeconomic status (SES) with aggregate risk scores that summarize longitudinal risk accumulation from multiple risk factors. We used data from a prospective, bi-racial. cohort study of 18-30-year-old adults in the USA, initiated in 1985, with 10-year follow-up. SES was measured by parental education level. financial hardship during the study, and the participant's education level by the end of the study. We studied growth patterns of seven biological risk factors for cardiovascular disease using a semi-parametric, class-mixture model to identify clusters, of individuals with distinct growth trajectories. Risk scores that summarize risk from all seven risk factors were created to reflect risk at baseline, longitudinal risk change over 10 years. and total accumulated risk. Multivariable regression was used to study their associations with SES within each race/gender group. We found tracking of all seven risk factors: in each case, the cluster with the highest baseline value maintained its position as the highest-risk cluster over the next 10 years. After adjustment for age, lifestyle, and healthcare access. SES was associated inversely with baseline risk score in women (black and white), with risk change score in all four race/gender groups, and with accumulated risk score in women (black and white) and in white men. Our findings suggest that individuals with high overall cardiovascular risk in midlife can be identified by their relatively higher values of risk factors in younger ages and that socioeconomic differences in cardiovascular risk start accumulating early in life. (C) 2004 Elsevier Ltd. All rights reserved. C1 Univ Calif Los Angeles, Sch Med, Div Geriatr, Los Angeles, CA 90095 USA. Princeton Univ, Off Populat Res, Princeton, NJ 08544 USA. Univ Michigan, Inst Social Res, Ann Arbor, MI 48106 USA. SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Karlamangla, AS (reprint author), Univ Calif Los Angeles, Sch Med, Div Geriatr, 10945 Le Conte 2339, Los Angeles, CA 90095 USA. EM akarlamangla@mednet.ucla.edu FU NHLBI NIH HHS [N01-HC-48049, N01-HC-48047, N01-HC-48048, N01-HC-48050, N01-HC-95095]; NIA NIH HHS [1K12AG01004, AG-17056, AG-17265] NR 68 TC 58 Z9 59 U1 2 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD MAR PY 2005 VL 60 IS 5 BP 999 EP 1015 DI 10.1016/j.socscimed.2004.06.056 PG 17 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 889YB UT WOS:000226477700008 PM 15589670 ER PT J AU Kelly, PA Haidet, P Schneider, V Searle, N Seidel, CL Richards, BE AF Kelly, PA Haidet, P Schneider, V Searle, N Seidel, CL Richards, BE TI A comparison of in-class learner engagement across lecture, problem-based learning, and team learning using the STROBE classroom observation tool SO TEACHING AND LEARNING IN MEDICINE LA English DT Article AB Background: Having recently introduced team learning into the preclinical medical curriculum, evidence of the relative impact of this instructional method on in-class learner engagement was sought. Purpose: To compare patterns of engagement behaviors among learners in class sessions across 3 distinct instructional inethods: lecture, problem-based learning (PBL), and team learning. Methods: Trained observers used the STROBE classroom observation tool to measure learner engagement in 7 lecture, 4 PBL, and 3 team learning classrooms oiler a 12-month period. Proportions of different types of engagement behaviors were compared using chi-square. Results: In PBL and team learning, the amount of learner-to-learner engagement was similar and much greater than in lecture, where most engagement was of the learner-to-instructor and self-engagement types. Also, learner-to-instructor engagement appeared greater in team learning than in PBL. Conclusions: Observed engagement behaviors confirm the potential of team learning to foster engagement similar to PBL, but with greater faculty input. C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Houston, TX 77030 USA. RP Kelly, PA (reprint author), Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd,152, Houston, TX 77030 USA. EM pakelly@bcm.edu NR 18 TC 47 Z9 49 U1 1 U2 15 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA SN 1040-1334 J9 TEACH LEARN MED JI Teach. Learn. Med. PD SPR PY 2005 VL 17 IS 2 BP 112 EP 118 DI 10.1207/s15328015tlm1702_4 PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 915YH UT WOS:000228347100004 PM 15833720 ER PT J AU Aujesky, D Smith, KJ Cornuz, J Roberts, MS AF Aujesky, D Smith, KJ Cornuz, J Roberts, MS TI Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism SO THROMBOSIS AND HAEMOSTASIS LA English DT Article DE cost-effectiveness; treatment; cancer; venous thromboembolism ID DEEP-VEIN THROMBOSIS; LONG-TERM SURVIVAL; PULMONARY-EMBOLISM; BLEEDING COMPLICATIONS; THROMBOLYTIC THERAPY; UNITED-STATES; WARFARIN; PREVENTION; STROKE; MANAGEMENT AB Although extended secondary prophylaxis with low-molecular-weight heparin was recently shown to be more effective than warfarin for cancer-related venous thromboembolism, its cost-effectiveness compared to traditional prophylaxis with warfarin is uncertain. We built a decision analytic model to evaluate the clinical and economic outcomes of a 6-month course of low-molecular-weight heparin or warfarin therapy in 65-year-old patients with cancer-related venous thromboembolism. We used probability estimates and utilities reported in the literature and published cost data. Using a US societal perspective, we compared strategies based on quality-adjusted life-years (QALYs) and lifetime costs. The incremental cost-effectiveness ratio of low-molecular-weight heparin compared with warfarin was $149,865/QALY. Low-molecular-weight heparin yielded a quality-adjusted life expectancy of 1.097 QALYs at the cost of $15,329. Overall, 46% ($7108) of the total costs associated with low-molecular-weight heparin were attributable to pharmacy costs. Although the low-molecular-weigh heparin strategy achieved a higher incremental quality-adjusted life expectancy than the warfarin strategy (difference of 0.051 QALYs), this clinical benefit was offset by a substantial cost increment of $7,609. Cost-effectiveness results were sensitive to variation of the early mortality risks associated with low-molecular-weight heparin and warfarin and the pharmacy costs for low-molecular-weight heparin. Based on the best available evidence, secondary prophylaxis with low-molecular-weight heparin is more effective than warfarin for cancer-related venous thromboembolism. However, because of the substantial pharmacy costs of extended low-molecular-weight heparin prophylaxis in the US, this treatment is relatively expensive compared with warfarin. C1 Univ Pittsburgh, Div Gen Internal Med, Dept Med, Pittsburgh, PA USA. Univ Pittsburgh, Sect Decis Sci & Clin Syst Modeling, Dept Med, Pittsburgh, PA USA. Univ Lausanne, Dept Internal Med, Lausanne, Switzerland. Univ Lausanne, Univ Outpatient Clin, Lausanne, Switzerland. Univ Lausanne, Clin Epidemiol Ctr, Inst Social & Prevent Med, Lausanne, Switzerland. RP Aujesky, D (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Univ Dr C,Bldg 28,Suite 1A129, Pittsburgh, PA 15240 USA. EM aujesky@swissonline.ch NR 38 TC 12 Z9 14 U1 0 U2 0 PU SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN PI STUTTGART PA HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY SN 0340-6245 J9 THROMB HAEMOSTASIS JI Thromb. Haemost. PD MAR PY 2005 VL 93 IS 3 BP 592 EP 599 DI 10.1160/TH04-11-0767 PG 8 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 908RT UT WOS:000227808200031 PM 15735815 ER PT J AU Freedland, SJ Aronson, WJ AF Freedland, SJ Aronson, WJ TI Obesity and prostate cancer SO UROLOGY LA English DT Review ID GROWTH-FACTOR-I; BODY-MASS INDEX; IGF-BINDING PROTEIN-3; DIABETES-MELLITUS; RADICAL PROSTATECTOMY; NORWEGIAN MEN; UNITED-STATES; FOLLOW-UP; PATHOLOGICAL VARIABLES; PHYSICAL-ACTIVITY C1 Johns Hopkins Sch Med, Dept Urol, Brady Urol Inst, Baltimore, MD 21287 USA. Vet Adm Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA. RP Freedland, SJ (reprint author), Johns Hopkins Sch Med, Dept Urol, Brady Urol Inst, 600 N Wolfe St, Baltimore, MD 21287 USA. EM sfreedl1@jhmi.edu FU NCI NIH HHS [CA100938, P50 CA92131-01A1] NR 59 TC 29 Z9 29 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 J9 UROLOGY JI Urology PD MAR PY 2005 VL 65 IS 3 BP 433 EP 439 DI 10.1016/j.urology.2004.08.035 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 908PT UT WOS:000227800400004 PM 15780350 ER PT J AU Clarke, P DeBiasi, RL Goody, R Hoyt, CC Richardson-Burns, S Tyler, KL AF Clarke, P DeBiasi, RL Goody, R Hoyt, CC Richardson-Burns, S Tyler, KL TI Mechanisms of reovirus-induced cell death and tissue injury: Role of apoptosis and virus-induced perturbation of host-cell signaling and transcription factor activation SO VIRAL IMMUNOLOGY LA English DT Review ID NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; DOUBLE-STRANDED-RNA; ATTACHMENT PROTEIN SIGMA-1; CARDIAC MYOCYTE CULTURES; TOLL-LIKE RECEPTOR-3; GENE-EXPRESSION; SIALIC-ACID; INHIBITION PROTECTS; ANTIVIRAL ACTIVITY AB Reoviruses have provided insight into the roles played by specific viral genes and the proteins they encode in virus-induced cell death and tissue injury. Apoptosis is a major mechanism of cell death induced by reoviruses. Reovirus-induced apoptosis involves both death-receptor and mitochondrial cell death pathways. Reovirus infection is associated with selective activation of mitogen activated protein kinase (MAPK) cascades including JNK/SAPK. Infection also perturbs transcription factor signaling resulting in the activation of c-Jun and initial activation followed by strain-specific inhibition of NF-kappa B. Infection results in changes in the expression of genes encoding proteins involved in cell cycle regulation, apoptosis, and DNA damage and repair processes. Apoptosis is a major mechanism of reovirus-induced injury to key target organs including the CNS and heart. Inhibition of apoptosis through the use of caspase or calpain inhibitors, minocycline, or in caspase 3(-/-) mice all reduce virus-associated tissue injury and enhance survival of infected animals. Reoviruses induce apoptotic cell death (oncolysis) in a wide variety of cancer cells and tumors. The capacity of reoviruses to grow efficiently in transformed cells is enhanced by the presence of an activated Ras signaling pathway likely through mechanisms involving inhibition of antiviral PKR signaling and activation of Ras/RaIGEF/p38 pathways. The potential of reovirus-induced oncolysis in therapy of human cancers is currently being investigated in phase I/II clinical trials. C1 Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Program Neurosci, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Tyler, KL (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Neurol, 4200 E 9th Ave, Denver, CO 80262 USA. EM Ken.Tyler@uchsc.edu OI Tyler, Kenneth/0000-0003-3294-5888 FU NIAID NIH HHS [K08 AI052261, 5K08AI52261]; NINDS NIH HHS [R01 NS050138-04, R01 NS051403-03, R01 NS051403, R01 NS050138] NR 104 TC 27 Z9 29 U1 1 U2 6 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0882-8245 J9 VIRAL IMMUNOL JI Viral Immunol. PD SPR PY 2005 VL 18 IS 1 BP 89 EP 115 DI 10.1089/vim.2005.18.89 PG 27 WC Immunology; Virology SC Immunology; Virology GA 915EW UT WOS:000228281800009 PM 15802955 ER PT J AU Patten, LC Berger, DH AF Patten, LC Berger, DH TI Role of proteases in pancreatic carcinoma SO WORLD JOURNAL OF SURGERY LA English DT Article ID PLASMINOGEN-ACTIVATOR SYSTEM; MATRIX-METALLOPROTEINASE INHIBITORS; TIMP-2 MESSENGER-RNAS; NEUTROPHIL ELASTASE; TUMOR INVASION; CANCER CELLS; MATRILYSIN EXPRESSION; COLORECTAL NEOPLASIA; UROKINASE RECEPTOR; LIVER METASTASIS AB Proteases play an important role in cancer invasion and metastasis. In this review we specifically discuss the role of these proteases in pancreatic carcinoma. Serine proteases and matrix metalloproteinases are the focus of intense research, as they appear to be related to the process of tumor progression. We discuss the diagnostic and prognostic value of these two groups of proteases. Lastly, we report on the current and recent clinical trials focusing on inhibition of these proteases. C1 Baylor Coll Med, Michael E DeBakey, Dept Surg, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Operat Care Line, Houston, TX 77030 USA. RP Berger, DH (reprint author), Baylor Coll Med, Michael E DeBakey, Dept Surg, 6550 Fannin St, Houston, TX 77030 USA. EM dhb@bcm.tmc.edu NR 75 TC 10 Z9 10 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013 USA SN 0364-2313 J9 WORLD J SURG JI World J.Surg. PD MAR PY 2005 VL 29 IS 3 BP 258 EP 263 DI 10.1007/s00268-04-7816-3 PG 6 WC Surgery SC Surgery GA 910TO UT WOS:000227955300002 PM 15706437 ER PT J AU Musher, DM AF Musher, DM TI The usefulness of sputum gram stain and culture SO ARCHIVES OF INTERNAL MEDICINE LA English DT Letter ID COMMUNITY-ACQUIRED PNEUMONIA C1 Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Musher, DM (reprint author), Michael E DeBakey Vet Affairs Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM daniel.musher@med.va.gov NR 6 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD FEB 28 PY 2005 VL 165 IS 4 BP 470 EP 471 DI 10.1001/archinte.165.4.470-b PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 901EN UT WOS:000227265900019 PM 15738381 ER PT J AU Cardenas, VA Studholme, C Meyerhoff, DJ Song, EM Weiner, MW AF Cardenas, VA Studholme, C Meyerhoff, DJ Song, EM Weiner, MW TI Chronic active heavy drinking and family history of problem drinking modulate regional brain tissue volumes SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE alcoholism; magnetic resonance imaging; image processing; segmentation; deformation morphometry ID MAGNETIC-RESONANCE SPECTROSCOPY; WHITE-MATTER; CORPUS-CALLOSUM; ABSTINENT ALCOHOLICS; SEX-DIFFERENCES; GRAY-MATTER; HIGH-RISK; HIPPOCAMPAL VOLUME; MR-IMAGES; YOUNG MEN AB The goals of this study were to measure if chronic active heavy drinking is associated with brain volume loss in nontreatment seeking men and women, and to assess the effect of positive family history of problem drinking on brain structure in heavy drinkers. Automated image processing was used to analyze high-resolution T1-weighted magnetic resonance images from 49 active heavy drinkers and 49 age- and sex-matched light drinkers, yielding gray matter, white matter and cerebrospinal fluid (CSF) volumes within the frontal, temporal, parietal and occipital lobes. Regional brain volume measures were compared as a function of group, sex and their interaction. Within heavy drinkers, volumes were correlated with measures of alcohol consumption and compared as a function of family history of problem drinking. Deformation morphometry explored localized patterns of atrophy associated with heavy drinking or severity of drinking. We found significant gray matter volume losses, but no white matter losses, in active heavy drinkers compared with light drinkers. Women had greater gray matter and smaller white matter and CSF volumes as a percentage of intracranial vault than men. Within heavy drinkers, smaller gray matter volumes were associated with higher current levels of drinking and older age, while a positive family history of problem drinking was associated with smaller CSF volumes. Community-dwelling heavy drinkers who are not in alcoholism treatment have dose-related gray matter volume losses, and family history of problem drinking ameliorates some structural consequences of heavy drinking. (c) 2005 Elsevier Ireland Ltd. All rights reserved. C1 Univ Calif San Francisco, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Univ Calif San Francisco, 4150 Clement St, San Francisco, CA 94121 USA. EM valerie@itsa.ucsf.edu FU NIA NIH HHS [P01 AG019724-050002]; NIAAA NIH HHS [P01 AA11493, R01 AA10788]; NIMH NIH HHS [R01 MH065392, R01 MH65392] NR 74 TC 66 Z9 68 U1 2 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 EI 1872-7506 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD FEB 28 PY 2005 VL 138 IS 2 BP 115 EP 130 DI 10.1016/j.pscychresns.2005.01.002 PG 16 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 913GH UT WOS:000228139100003 PM 15766635 ER PT J AU Brambilla, P Stanley, JA Nicoletti, MA Sassi, RB Mallinger, AG Frank, E Kupfer, DJ Keshavan, MS Soares, JC AF Brambilla, P Stanley, JA Nicoletti, MA Sassi, RB Mallinger, AG Frank, E Kupfer, DJ Keshavan, MS Soares, JC TI H-1 Magnetic prefrontal resonance spectroscopy study of dorsolateral cortex in unipolar mood disorder patients SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE neuroimaging; affective disorder; mood disorder; NAA; in vivo proton MRS ID MAJOR DEPRESSIVE DISORDER; ANTERIOR CINGULATE CORTEX; CEREBRAL BLOOD-FLOW; N-ACETYL-ASPARTATE; NEUROPSYCHIATRIC DISORDERS; ELECTROCONVULSIVE-THERAPY; BASAL GANGLIA; BRAIN; SCHIZOPHRENIA; ACETYLASPARTATE AB Neuroimaging and postmortem studies have suggested the involvement of the dorsolateral prefrontal cortex (DLPFC) in the pathophysioloy of unipolar disorder. We examined with in vivo H-1 magnetic resonance spectroscopy (MRS) the levels of specific metabolites in the DLPFC of adult unipolar patients and the role of illness chronicity on DLPFC abnormalities. Nineteen unmedicated unipolar mood disorder patients and 19 age- and gender-matched healthy controls underwent a short echo-time H-1 MRS examination localized to an 8-cm(3) single voxel placed in the left DLPFC. There were no significant differences in metabolite levels, including N-acetylaspartate (NAA), phosphocreatine plus creatine (PCr+Cr) and choline-containing-compounds (GPC+PC), between the two groups. However, NAA/PCr+Cr ratios were significantly lower in the chronic than in the less chronically ill patients and healthy controls. The low levels of NAA/PCr+Cr ratios in the left DLPFC of unipolar patients who had been more chronically ill suggest a potential role for illness chronicity in neuronal abnormalities in the DLPFC in unipolar disorder. This could possibly be accounted for by neurodegenerative processes arising with the progression of the illness. Future H-1 MRS investigations should longitudinally examine the role of illness chronicity on DLPFC abnormalities and their relationship with the symptoms of unipolar disorder. (c) 2005 Elsevier Ireland Ltd. All rights reserved. C1 Univ Texas, Hlth Sci Ctr, Div Mood & Anxiety Disorders, Dept Psychiat, San Antonio, TX 78229 USA. Univ Udine, Sch Med, Sect Psychiat, Dept Pathol & Expt & Clin Med, I-33100 Udine, Italy. Univ Genoa, Adv Biotechnol Ctr, Genoa, Italy. Univ Pittsburgh, Sch Med, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA USA. Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA. Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. RP Soares, JC (reprint author), Univ Texas, Hlth Sci Ctr, Div Mood & Anxiety Disorders, Dept Psychiat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM soares@uthscsa.edu RI brambilla, paolo/B-4184-2010 OI brambilla, paolo/0000-0002-4021-8456 FU NIMH NIH HHS [MH 01736, MH 30915] NR 47 TC 24 Z9 24 U1 3 U2 9 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0925-4927 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD FEB 28 PY 2005 VL 138 IS 2 BP 131 EP 139 DI 10.1016/j.pscychresns.2004.12.001 PG 9 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 913GH UT WOS:000228139100004 PM 15766636 ER PT J AU Poorkaj, P Moses, L Montimurro, JS Nutt, JG Schellenberg, GD Payami, H AF Poorkaj, P Moses, L Montimurro, JS Nutt, JG Schellenberg, GD Payami, H TI parkin mutation dosage and the phenomenon of anticipation: a molecular genetic study of familial parkinsonism SO BMC NEUROLOGY LA English DT Article ID LEVODOPA-RESPONSIVE PARKINSONISM; RECESSIVE JUVENILE PARKINSONISM; SPINOCEREBELLAR ATAXIA TYPE-2; PSEUDO-DOMINANT INHERITANCE; AUTOSOMAL-DOMINANT; LEWY BODIES; DISEASE; ONSET AB Background: parkin mutations are a common cause of parkinsonism. Possessing two parkin mutations leads to early-onset parkinsonism, while having one mutation may predispose to late-onset disease. This dosage pattern suggests that some parkin families should exhibit intergenerational variation in age at onset resembling anticipation. A subset of familial PD exhibits anticipation, the cause of which is unknown. The aim of this study was to determine if anticipation was due to parkin mutation dosage. Methods: We studied 19 kindreds that had early-onset parkinsonism in the offspring generation, late-onset parkinsonism in the parent generation, and >= 20 years of anticipation. We also studied 28 early-onset parkinsonism cases without anticipation. Patients were diagnosed by neurologists at a movement disorder clinic. parkin analysis included sequencing and dosage analysis of all 12 exons. Results: Only one of 19 cases had compound parkin mutations, but contrary to our postulate, the affected relative with late-onset parkinsonism did not have a parkin mutation. In effect, none of the anticipation cases could be attributed to parkin. In contrast, 21% of early-onset parkinsonism patients without anticipation had parkin mutations. Conclusion: Anticipation is not linked to parkin, and may signify a distinct disease entity. C1 New York State Dept Hlth, Wadsworth Ctr, Genom Inst, Albany, NY USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR USA. Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ Clin Ctr, Seattle, WA USA. Univ Washington, Dept Neurol, Seattle, WA 98195 USA. Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. RP Payami, H (reprint author), New York State Dept Hlth, Wadsworth Ctr, Genom Inst, Albany, NY USA. EM pips@u.washington.edu; lmoses2@tulane.edu; jsm05@health.state.ny.us; nuttj@ohsu.edu; zachdad@u.washington.edu; hpayami@wadsworth.org FU NINDS NIH HHS [R01 NS36960, R01 NS036960] NR 21 TC 7 Z9 7 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND SN 1471-2377 J9 BMC NEUROL JI BMC Neurol. PD FEB 22 PY 2005 VL 5 AR 4 DI 10.1186/1471-2377-5-4 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA 024HR UT WOS:000236186600001 PM 15725358 ER PT J AU Yang, FS Lim, GP Begum, AN Ubeda, OJ Simmons, MR Ambegaokar, SS Chen, PP Kayed, R Glabe, CG Frautschy, SA Cole, GM AF Yang, FS Lim, GP Begum, AN Ubeda, OJ Simmons, MR Ambegaokar, SS Chen, PP Kayed, R Glabe, CG Frautschy, SA Cole, GM TI Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NF-KAPPA-B; ALZHEIMERS-DISEASE; CONGO RED; TRANSGENIC MICE; CHEMOPREVENTIVE AGENT; CLINICAL-TRIAL; CACHE COUNTY; MOUSE MODEL; PROTEIN AB Alzheimer's disease (AD) involves amyloid beta (Abeta) accumulation, oxidative damage, and inflammation, and risk is reduced with increased antioxidant and anti-inflammatory consumption. The phenolic yellow curry pigment curcumin has potent anti-inflammatory and antioxidant activities and can suppress oxidative damage, inflammation, cognitive deficits, and amyloid accumulation. Since the molecular structure of curcumin suggested potential Abeta binding, we investigated whether its efficacy in AD models could be explained by effects on Abeta aggregation. Under aggregating conditions in vitro, curcumin inhibited aggregation (IC50 = 0.8 muM) as well as disaggregated fibrillar Abeta40 (IC50 = 1 muM), indicating favorable stoichiometry for inhibition. Curcumin was a better Abeta40 aggregation inhibitor than ibuprofen and naproxen, and prevented Abeta42 oligomer formation and toxicity between 0.1 and 1.0 muM. Under EM, curcumin decreased dose dependently Abeta fibril formation beginning with 0.125 muM. The effects of curcumin did not depend on Abeta sequence but on fibril-related conformation. AD and Tg2576 mice brain sections incubated with curcumin revealed preferential labeling of amyloid plaques. In vivo studies showed that curcumin injected peripherally into aged Tg mice crossed the blood-brain barrier and bound plaques. When fed to aged Tg2576 mice with advanced amyloid accumulation, curcumin labeled plaques and reduced amyloid levels and plaque burden. Hence, curcumin directly binds small beta-amyloid species to block aggregation and fibril formation in vitro and in vivo. These data suggest that low dose curcumin effectively disaggregates Abeta as well as prevents fibril and oligomer formation, supporting the rationale for curcumin use in clinical trials preventing or treating AD. C1 Univ Calif Los Angeles, Dept Med, Greater Los Angeles VA Healthcare Syst CRECC11E, Sepulveda, CA 91343 USA. Greater Los Angeles Vet Affairs Healthcare Syst, Ctr Geriatr Res Educ & Clin, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA. RP Cole, GM (reprint author), Univ Calif Los Angeles, Dept Med, Greater Los Angeles VA Healthcare Syst CRECC11E, 16111 Plummer St, Sepulveda, CA 91343 USA. EM gmcole@ucla.edu FU NCCIH NIH HHS [R01 AT003008]; NIA NIH HHS [P50 AG016570, R01 AG010685, R01 AG013741]; NINDS NIH HHS [NS43946] NR 65 TC 1057 Z9 1111 U1 34 U2 240 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 18 PY 2005 VL 280 IS 7 BP 5892 EP 5901 DI 10.1074/jbc.M404751200 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 900LT UT WOS:000227217100094 PM 15590663 ER PT J AU Majahalme, SK Baruch, L Aknay, N Goedel-Meinen, L Hofman, M Hester, A Prescott, MF Feliciano, N AF Majahalme, SK Baruch, L Aknay, N Goedel-Meinen, L Hofman, M Hester, A Prescott, MF Feliciano, N CA Val-HeFT Study Investigators TI Comparison of treatment benefit and outcome in women versus men with chronic heart failure (from the Valsartan Heart Failure Trial) SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID ANGIOTENSIN-RECEPTOR BLOCKER; LEFT-VENTRICULAR HYPERTROPHY; VAL-HEFT; MORTALITY; SURVIVAL AB The comparison of treatment effect and co-morbidity between the genders in the Valsartan Heart Failure Trial showed equal benefit of treatment in men and women. Co-morbidities, such as diabetes and coronary artery disease, increased nonfatal cardiac morbidity more in women than in men. (C) 2005 by Excerpta Medica Inc. C1 Appleton Heart Inst, Appleton, WI 54911 USA. Tampere Univ, FIN-33101 Tampere, Finland. Bronx Vet Affairs Med Ctr, New York, NY USA. Novartis Pharmaceut Corp, E Hanover, NJ USA. Tech Univ Munich, Deutsch Herzzentrum, D-8000 Munich, Germany. RP Majahalme, SK (reprint author), Appleton Heart Inst, 1818 N Meade St, Appleton, WI 54911 USA. EM silja.majahalme@thedacare.org NR 14 TC 7 Z9 7 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0002-9149 J9 AM J CARDIOL JI Am. J. Cardiol. PD FEB 15 PY 2005 VL 95 IS 4 BP 529 EP 532 DI 10.1016/j.amjcard.2004.10.026 PG 4 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 897EB UT WOS:000226985700023 PM 15695147 ER PT J AU Bland, LB Garzotto, M DeLoughery, TG Ryan, CW Schuff, KG Wersinger, EM Lemmon, D Beer, TM AF Bland, LB Garzotto, M DeLoughery, TG Ryan, CW Schuff, KG Wersinger, EM Lemmon, D Beer, TM TI Phase II study of transdermal estradiol in androgen-independent prostate carcinoma SO CANCER LA English DT Article DE prostate carcinoma; estradiol; estrogen; hormonal therapy; transdermal ID HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; PARENTERAL ESTROGEN; VENOUS THROMBOEMBOLISM; ORAL-CONTRACEPTIVES; CLINICAL-TRIALS; PROTEIN-C; CANCER; DIETHYLSTILBESTROL; SERUM AB BACKGROUND. oral estrogen therapy has activity in patients with hormone-naive and androgen-independent prostate carcinoma (AIPC), but its utility is limited by the associated risk of thromboembolic toxicity. Parenteral administration may be safer as it avoids "first pass" liver exposure to estrogen. The authors tested the safety and efficacy of transdermal estradiol (TDE), as well as the effect of therapy oil hot flashes, sex hormones, the procoagulant cascade, and bone turnover in patients with AIPC. METHODS. Patients with prostate carcinoma progressing after primary hormonal therapy received TDE 0.6 mg per 24 hours (administered as six 0.1 mg per 24-hour patches replaced every 7 days). Serum prostate-specific antigen (PSA) and hormone levels, coagulation factors, markers of bone turnover, bone density measurements, and a hot flash diary were collected at regular intervals. RESULTS. Three of 24 patients (12.5%; 95% confidence interval [Cl], 0-26%) had a confirmed PSA reduction > 50%. The Kaplan-Meier estimate of median time to disease progression was 12 weeks (95% Cl, 4.6-19.4 weeks). Toxicity was modest and no thromboembolic complications occurred. The mean (+/-95% Cl) serum estradiol level increased from 17.2 pg.mL (range, 14.8-19.6 pg/mL) to 460.7 pg/mL (range, 334.6-586.7 pg/mL). The total testosterone level remained stable ill the anorchid range during treatment, but the free testosterone level decreased as a result of increased sex hormone binding globulin. No change in factor VIII activity, F 1.2, or resistance to activated protein C was observed, whereas a modest decrease in the protein S level was observed. CONCLUSIONS. in patients with APIC, TDE was well tolerated and produced a modest response rate, but was not associated with thromboembolic complications or clinically important changes in several coagulation factors. (C) 2005 American Cancer Society. C1 Oregon Hlth Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Med, Div Endocrinol & Metab, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Div Urol, Portland, OR 97201 USA. Portland Vet Affairs Med Ctr, Portland, OR USA. RP Beer, TM (reprint author), Oregon Hlth Sci Univ, Dept Med, Div Hematol & Med Oncol, Mail Code Cr-145,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM beert@ohsu.edu FU NCRR NIH HHS [5 M01 RR00334] NR 28 TC 32 Z9 33 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0008-543X J9 CANCER JI Cancer PD FEB 15 PY 2005 VL 103 IS 4 BP 717 EP 723 DI 10.1002/cncr.20857 PG 7 WC Oncology SC Oncology GA 894NF UT WOS:000226797900011 PM 15641029 ER PT J AU Spertus, JA Nerella, R Kettlekamp, R House, J Marso, S Borkon, AM Rumsfeld, JS AF Spertus, JA Nerella, R Kettlekamp, R House, J Marso, S Borkon, AM Rumsfeld, JS TI Risk of restenosis and health status outcomes for patients undergoing percutaneous coronary intervention versus coronary artery bypass graft surgery SO CIRCULATION LA English DT Article DE angioplasty; bypass; restenosis; quality of life ID QUALITY-OF-LIFE; PRACTICE GUIDELINES COMMITTEE; ASSOCIATION TASK-FORCE; ANGINA RITA TRIAL; ACC/AHA GUIDELINES; FUNCTIONAL STATUS; AMERICAN-COLLEGE; ELUTING STENT; ANGIOPLASTY; DISEASE AB Background - Previous comparisons of percutaneous coronary interventions (PCIs) and coronary artery bypass graft (CABG) surgery have demonstrated similar survival but have also generally found better health status outcomes ( symptoms, function, and quality of life) with CABG. The principal limitation of PCI has been the occurrence of restenosis. No previous studies comparing the health status outcomes of PCI and CABG have examined differences in these outcomes as a function of patients' preprocedural risk for restenosis. Methods and Results - We examined the health status outcomes, using the Seattle Angina Questionnaire (SAQ), among 1459 consecutive patients ( 1027 treated with PCI and 432, with CABG), stratified by their risk for restenosis. In multivariable- adjusted, linear regression analyses, no differences in 1-year angina or quality of life were observed among the 37.4% of patients at low risk for restenosis. However, among the 46.7% at intermediate risk for restenosis, 1-year health status scores were moderately better after CABG surgery compared with PCI ( difference in SAQ angina frequency scores favoring CABG = 6.1 +/- 1.7 points, P = 0.0003; difference in SAQ quality of life = 5.8 +/- 1.6 points, P = 0.0004). Even larger differences in 1-year outcomes favoring CABG surgery were observed in patients at high risk for restenosis ( SAQ angina frequency difference = 10.8 +/- 4.2, P = 0.01; SAQ quality of life difference = 10.8 +/- 3.9, P = 0.006). Conclusions - The relative health status benefits of CABG surgery compared with PCI increase as the risk of restenosis increases. Although selecting CABG or PCI is complex, preprocedural restenosis risk should be considered. It should also be tested as a means for considering drug-eluting as opposed to bare metal stents in PCI. C1 Univ Missouri, Kansas City, MO 64110 USA. St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA. Denver VA Med Ctr, Denver, CO USA. RP Spertus, JA (reprint author), Mid Amer Heart Inst, 4401 Wornall Rd, Kansas City, MO 64111 USA. EM spertusj@umkc.edu NR 29 TC 30 Z9 32 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD FEB 15 PY 2005 VL 111 IS 6 BP 768 EP 773 DI 10.1161/01.CIR.0000155242.70417.60 PG 6 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 897MH UT WOS:000227007800010 PM 15699258 ER PT J AU Matejuk, A Hopke, C Vandenbark, AA Hurn, PD Offner, H AF Matejuk, A Hopke, C Vandenbark, AA Hurn, PD Offner, H TI Middle-age male mice have increased severity of experimental autoimmune encephalomyelitis and are unresponsive to testosterone therapy SO JOURNAL OF IMMUNOLOGY LA English DT Article ID REGULATORY T-CELLS; MULTIPLE-SCLEROSIS PATIENTS; CD4(+)CD25(+) TREG CELLS; CENTRAL-NERVOUS-SYSTEM; ANDROGEN RECEPTOR; BIOAVAILABLE TESTOSTERONE; SUPPRESSIVE ACTIVITY; LUTEINIZING-HORMONE; CYTOKINE SECRETION; GENDER-DIFFERENCES AB Treatment with sex hormones is known to protect against experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. However, little is known about how age affects the course of EAE or response to hormone treatment. This study demonstrates striking differences between middle-age vs young C57BL/6 male mice in the clinical course of EAE and response to both testosterone (T4) and estrogen (E2) hormone therapy. Unlike young males that developed an acute phase of EAE followed by a partial remission, middle-age males suffered severe chronic and unremitting EAE that was likely influenced by alterations in the distribution and function of splenic immunocytes and a significant reduction in suppressive activity of CD4(+)CD25(+) regulatory T cells in the spleen and spinal cord. Middle-age males had reduced numbers of splenic CD4(+) T cells that were generally hypoproliferative, but enhanced numbers of splenic macrophages and MHC class II-expressing cells, and increased secretion of the proinflammatory factors IFN-gamma and MCP-1. Surprisingly, middle-age males were unresponsive to the EAE-protective effects of T4 and had only a transient benefit from E2 treatment; young males were almost completely protected by both hormone treatments. T4 treatment of young males inhibited proliferation of myelin oligodendrocyte glycoprotein 35-55-specific T cells and secretion of TNF-alpha and IFN-gamma. The effects of T4 in vivo and in vitro were reversed by the androgen receptor antagonist, flutamide, indicating that the regulatory effects of T4 were mediated through the androgen receptor. These data are the first to define age-dependent differences in EAE expression and response to hormone therapy. C1 Portland VA Med Ctr, Neuroimmunol Res R&D 31, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. Oregon Hlth Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA. Polish Acad Sci, L Hirszfeld Inst Immunol & Expt Therapy, Wroclaw, Poland. RP Offner, H (reprint author), Portland VA Med Ctr, Neuroimmunol Res R&D 31, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NIAID NIH HHS [AI42376]; NINDS NIH HHS [NS23444, NS23221] NR 64 TC 38 Z9 39 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD FEB 15 PY 2005 VL 174 IS 4 BP 2387 EP 2395 PG 9 WC Immunology SC Immunology GA 897EL UT WOS:000226986700074 PM 15699175 ER PT J AU Matute-Bello, G Liles, WC Frevert, CW Dhanireddy, S Ballman, K Wong, V Green, RR Song, HY Witcher, DR Jakubowski, JA Martin, TR AF Matute-Bello, G Liles, WC Frevert, CW Dhanireddy, S Ballman, K Wong, V Green, RR Song, HY Witcher, DR Jakubowski, JA Martin, TR TI Blockade of the Fas/FasL system improves pneumococcal clearance from the lungs without preventing dissemination of bacteria to the spleen SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article; Proceedings Paper CT 99th International Conference of the American-Thoracic-Society CY MAY 16-23, 2003 CL SEATTLE, WA SP Amer Thorac Soc ID RESPIRATORY-DISTRESS-SYNDROME; EPITHELIAL-CELL APOPTOSIS; NF-KAPPA-B; FAS LIGAND; PULMONARY-FIBROSIS; DECOY RECEPTOR; SOLUBLE FORM; IN-VIVO; ACTIVATION; SEPSIS AB Background. The Fas/FasL system is both proapoptotic and proinflammatory. FasL is inhibited by decoy receptor-3 (DcR3), a naturally occurring decoy receptor. We determined the effects of systemic blockade of the Fas/FasL system by a DcR3 analog (DcR3-a) in mice with pneumococcal pneumonia. Methods. Streptococcus pneumoniae (7.2 x 10(5) or 1.9 x 10(7) cfu/mL) was instilled intratracheally into untreated C57Bl/6 mice, C57Bl/6 mice treated with DcR3-a, or Fas-deficient lpr mice, and the mice were studied 48 h later. Results. After instillation of the lower bacterial dose, disruption of the Fas/FasL system by either DcR3-a or the lpr mutation resulted in improved clearance of bacteria in the lungs (mean +/- SE, and 4.6 +/- 2.1 x 10(6) and 3.5 +/- 1.6 x 10(6) cfu/lung, respectively, vs. 21.9 +/- 9.3 x 10(6) cfu/lung in untreated C57Bl/6 mice; P < .05) and decreased percentage of polymorphonuclear neutrophils in bronchoalveolar lavage fluid (mean &PLUSMN; SE, and 19.3% &PLUSMN; 9.5%, respectively, vs. in untreated C57Bl/ 6 mice;). These changes were associated 20.2% &PLUSMN; 7.8% 55.0% &PLUSMN; 12.2% P < .05 with decreased lung concentrations of the proinflammatory cytokines tumor necrosis factor-alpha and macrophage inflammatory protein-2 and with a decrease in apoptotic cells in the alveolar walls. Conclusion. Blockade of the Fas/FasL system by DcR3-alpha in the lungs improves clearance of bacteria in mice with pneumococcal pneumonia. C1 Univ Washington, Sch Med, Vet Affairs Puget Sound Hlth Care Syst, Med Res Serv, Seattle, WA USA. Univ Washington, Sch Med, Dept Med, Div Pulm & Crit Care Med, Seattle, WA USA. Univ Washington, Sch Med, Dept Med, Div Allergy & Infect Med, Seattle, WA USA. Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. RP Matute-Bello, G (reprint author), Seattle VA Med Ctr, 151L,1660 S Columbian Way, Seattle, WA 98108 USA. EM matuteb@u.washington.edu FU NHLBI NIH HHS [HL73996, HL65892, HL70840-01, HL62995] NR 37 TC 26 Z9 26 U1 1 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 15 PY 2005 VL 191 IS 4 BP 596 EP 606 DI 10.1086/427261 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 888ZM UT WOS:000226413100016 PM 15655784 ER PT J AU Zhou, XH Qin, GS AF Zhou, XH Qin, GS TI Improved confidence intervals for the sensitivity at a fixed level of specificity of a continuous-scale diagnostic test SO STATISTICS IN MEDICINE LA English DT Article DE binomial proportion; sensitivity; specificity; diagnostic accuracy; bootstrap method; confidence intervals AB For a continuous-scale diagnostic test, it is of interest to construct a confidence interval for the sensitivity of the diagnostic test at the cut-off that yields a predetermined level of its specificity (for example. 80, 90 or 95 per cent). In this paper we propose two new intervals for the sensitivity of a continuous-scale diagnostic test at a fixed level of specificity. We then conduct simulation studies to compare the relative performance of these two intervals with the best existing BCa bootstrap interval, proposed by Plan et al. Our simulation results show that the newly proposed intervals are better than the BCa bootstrap interval in terms of covet-age accuracy and interval length. Copyright (C) 2005 John Wiley Sons. Ltd. C1 Vet Affairs Puget Sound Hlth Care Syst, Biostat Unit, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA 98108 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Georgia State Univ, Dept Math & Stat, Atlanta, GA 30302 USA. RP Zhou, XH (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Biostat Unit, Hlth Serv Res & Dev Ctr Excellence, Bldg 1,Rm 424,1660 S Columbian Way, Seattle, WA 98108 USA. EM azhou@u.washington.edu NR 10 TC 24 Z9 24 U1 1 U2 5 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 0277-6715 J9 STAT MED JI Stat. Med. PD FEB 15 PY 2005 VL 24 IS 3 BP 465 EP 477 DI 10.1002/sim.1563 PG 13 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 892OE UT WOS:000226659100009 PM 15635678 ER PT J AU Lin, SH Faller, LD AF Lin, SH Faller, LD TI Ionic-strength dependence of the conformational change in the unphosphorylated sodium pump SO BIOCHEMISTRY LA English DT Article ID FLUORESCEIN 5'-ISOTHIOCYANATE MODIFICATION; NUCLEOTIDE-BINDING SITE; ADENOSINE-TRIPHOSPHATASE; ENERGY-TRANSFER; CALCIUM-PUMP; NA+,K+-ATPASE; NA,K-ATPASE; MECHANISM; POTASSIUM; ATPASE AB The conformational change in the unphosphorylated sodium pump was studied as a function of ionic strength to learn whether the rate of the reaction is affected. The results corroborate our proposal [Smirnova, I. N., Lin, S.-H., and Faller, L. D. (1995) Biochemistry 34, 8657-8667] that competitive binding of the transported ions to two (or more) equivalent sites regulates a concerted change in protein conformation. An approximately 10-fold increase in ionic strength decreased the intrinsic affinity of the Na+ conformation of the enzyme for both Na+ and K+ roughly 3-fold, decreased the rate of the change from Na+ to K+ conformation by more than half, and increased the rate of the reverse reaction by about an order of magnitude. The logarithm of the first-order rate constant for the change from Na+ to K+ conformation depended inversely upon the square root of the ionic strength with the extrapolated value at zero ionic strength expressed as a second-order rate constant (1.1 x 10(9) M-1 sec(-1)) approaching the limit for a diffusion-controlled reaction. The first-order rate constant for the change from K+ to Na+ conformation depended directly upon ionic strength and extrapolated to a zero-ionic-strength value (0.002 s(-1)) far below the diffusion limit. The results are compatible with shielding of oppositely charged domains that move through the solvent when the pump cycles between conformations. Electrostatic interactions between domains evidently contribute to the driving force for the change from Na+ to K+ conformation and to the stability of the K+ conformation. C1 Univ Calif Los Angeles, Sch Med, CURE, Digest Dis Res Ctr,Dept Med, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90073 USA. Vet Adm Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. RP Univ Calif Los Angeles, Sch Med, CURE, Digest Dis Res Ctr,Dept Med, Los Angeles, CA 90073 USA. EM lfaller@ucla.edu FU NIDDK NIH HHS [DK52802] NR 50 TC 3 Z9 3 U1 0 U2 1 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD FEB 8 PY 2005 VL 44 IS 5 BP 1482 EP 1494 DI 10.1021/bi040018c PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 894OR UT WOS:000226802000012 PM 15683233 ER PT J AU Smith, RJ Doyle, GA Han, AM Crowley, JJ Oslin, DW Patkar, AA Mannelli, P Demaria, PA O'Brien, CP Berrettini, WH AF Smith, RJ Doyle, GA Han, AM Crowley, JJ Oslin, DW Patkar, AA Mannelli, P Demaria, PA O'Brien, CP Berrettini, WH TI Novel exonic mu-opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE genetics; drug addiction; susceptibility ID SAMPLE-SIZE REQUIREMENTS; LINKAGE DISEQUILIBRIUM; SUBSTANCE DEPENDENCE; FUNCTIONAL POLYMORPHISM; COMPLEX DISEASE; ALCOHOL; ADDICTION; ABUSE; CONVERSION; VARIANTS AB The mu-opioid receptor (MOR) mediates reward and dependence associated with opioids and other commonly abused substances. Variability in the MOR gene, OPRM1, may influence risk for opioid dependence. In this study, associations between two single nucleotide polymorphismg (SNPs), dbSNP rs540825 and dbSNP rs562859, and opioid dependence were investigated. The two SNPs are located in the protein coding region of the novel exon X of an alternative splice variant of OPRM1, and can be detected using polymerase chain reaction-restriction fragment length polymorphism. (PCR-RFLP) methods. Genotyping at the two SNPs was performed for 170 severe opioid dependent individuals and 128 carefully screened controls. Although no differences were found between cases and controls, there were significant prevalence differences between African-American (AA) subjects and European-American (EA) subjects for SNP 540825 allele and genotype frequencies. The 540825 and 562859 polymorphisms were found to be in complete linkage disequilibrium (LD) for both ethnic groups, and LD existed between the 562859 SNP and the A-1320G SNP in the promoter region of OPRM1 in AAs, based on genotyping data previously carried out on the same subjects. LD between these two markers, separated by 55 kb, links the entire distance studied in this project. The results indicate that polymorphisms in the novel splice variant are not associated with opioid dependence, but are in LD with other polymorphisms in OPRM1. (C) 2005 Wiley-Liss, Inc. C1 Univ Penn, Ctr Neurobiol & Behav, Philadelphia, PA 19104 USA. Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA. Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. Vet Affairs Med Ctr, Philadelphia, PA USA. Jefferson Med Coll, Dept Psychiat & Human Behav, Philadelphia, PA USA. Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA. RP Smith, RJ (reprint author), Univ Penn, Sch Med, Dept Neurosci, 415 Curie Blvd,Room 111, Philadelphia, PA 19104 USA. EM rjsmith@mail.med.upenn.edu FU NIDA NIH HHS [DA015504, DA001586, DA00340, DA11835, DA14008, P60DA005186]; NIGMS NIH HHS [T32-GM007517] NR 32 TC 12 Z9 13 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4841 J9 AM J MED GENET B JI Am. J. Med. Genet. B PD FEB 5 PY 2005 VL 133B IS 1 BP 105 EP 109 DI 10.1002/ajmg.b.30105 PG 5 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA 891ZN UT WOS:000226619600021 PM 15558714 ER PT J AU Lipschutz, JH Li, SX Arisco, A Balkovetz, DF AF Lipschutz, JH Li, SX Arisco, A Balkovetz, DF TI Extracellular signal-regulated kinases 1/2 control claudin-2 expression in Madin-Darby canine kidney strain I and II cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID GROWTH-FACTOR; EPITHELIAL-CELLS; MDCK CELLS; SELECTIVE CHANNELS; CONTACT INHIBITION; TIGHT JUNCTIONS; MOUSE NEPHRON; BARRIER; ACTIVATION; RESISTANCE AB The tight junction of the epithelial cell determines the characteristics of paracellular permeability across epithelium. Recent work points toward the claudin family of tight junction proteins as leading candidates for the molecular components that regulate paracellular permeability properties in epithelial tissues. Madin-Darby canine kidney (MDCK) strain I and II cells are models for the study of tight junctions and based on transepithelial electrical resistance (TER) contain "tight" and "leaky" tight junctions, respectively. Overexpression studies suggest that tight junction leakiness in these two strains of MDCK cells is conferred by expression of the tight junction protein claudin-2. Extracellular signal-regulated kinase (ERK) 1/2 activation by hepatocyte growth factor treatment of MDCK strain II cells inhibited claudin-2 expression and transiently increased TER. This process was blocked by the ERK 1/2 inhibitor U0126. Transfection of constitutively active mitogen-activated protein kinase/extracellular signal-regulated kinase kinase into MDCK strain II cells also inhibited claudin-2 expression and increased TER. MDCK strain I cells have higher levels of active ERK 1/2 than do MDCK strain II cells. U0126 treatment of MDCK strain I cells decreased active ERK 1/2 levels, induced expression of claudin-2 protein, and decreased TER by similar to20-fold. U0126 treatment also induced claudin-2 expression and decreased TER in a high resistance mouse cortical collecting duct cell line (94D). These data show for the first time that the ERK 1/2 signaling pathway negatively controls claudin-2 expression in mammalian renal epithelial cells and provide evidence for regulation of tight junction paracellular transport by alterations in claudin composition within tight junction complexes. C1 Univ Alabama, Dept Med, Birmingham, AL 35294 USA. Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA. Vet Adm Med Ctr, Birmingham, AL 35294 USA. Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. Univ Penn, Mol Biol Grad Grp, Philadelphia, PA 19104 USA. Univ Penn, Dept Med & Cell, Philadelphia, PA 19104 USA. Univ Alabama, Dept Surg, Birmingham, AL 35294 USA. RP Balkovetz, DF (reprint author), Univ Alabama, Dept Med, LHRB 642,1530 3rd Ave S, Birmingham, AL 35294 USA. EM balkovet@uab.edu NR 34 TC 88 Z9 90 U1 0 U2 3 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD FEB 4 PY 2005 VL 280 IS 5 BP 3780 EP 3788 DI 10.1074/jbc.M408122200 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 897DJ UT WOS:000226983900079 PM 15569684 ER PT J AU Allen, E Zerzan, J Choo, C Shenson, D Saha, S AF Allen, E Zerzan, J Choo, C Shenson, D Saha, S TI Teaching systems-based practice to residents by using independent study projects SO ACADEMIC MEDICINE LA English DT Article ID MANAGED CARE; CURRICULUM; MEDICINE AB The changing health care marketplace requires new graduates to be familiar with complex health systems. Since 1999 the Oregon Health & Science University internal medicine residency program has offered a seminar-based health systems curriculum, but residents lacked an opportunity to actively apply learned concepts. To achieve this goal, the authors developed a second curricular component, the Health Systems Independent Study Project (HSISP). The HSISP is a self-directed assessment of a health care system or delivery issue residents complete in their third year. The curriculum was implemented in 2001 with goals of gaining a focused understanding of a health systems concept and building related skills. Residents present their study projects to all curriculum participants. Topics addressed so far include adherence to coronary artery disease guidelines in a defined population, screening strategies for lung cancer, resident burnout, and many others. Residents have found that these projects enhance their systems knowledge, help them link systems-based-practice concepts to clinical practice, and foster opportunities for networking and early career development. C1 Portland VA Med Ctr, Gen Internal Med Sect, Portland, OR 97207 USA. Oregon Hlth Sci Univ, Dept Internal Med, Portland, OR 97201 USA. NW Permanente, Profess Corp, Dept Internal Med, Hlth Syst Curriculum, Portland, OR USA. Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA. Oregon Hlth Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. RP Allen, E (reprint author), Portland VA Med Ctr, Gen Internal Med Sect, P3 Med,POB 1034, Portland, OR 97207 USA. EM allenel@ohsu.edu NR 11 TC 22 Z9 22 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD FEB PY 2005 VL 80 IS 2 BP 125 EP 128 DI 10.1097/00001888-200502000-00003 PG 4 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 894FA UT WOS:000226774800003 PM 15671314 ER PT J AU Epler, AJ Kivlahan, DR Bush, KR Dobie, DJ Bradley, KA AF Epler, AJ Kivlahan, DR Bush, KR Dobie, DJ Bradley, KA TI A brief readiness to change drinking algorithm: Concurrent validity in female VA primary care patients SO ADDICTIVE BEHAVIORS LA English DT Article DE alcoholism; alcohol abuse; behavior change; motivation; primary health care; military veterans ID CHANGE QUESTIONNAIRE; ALCOHOL AB Brief primary care interventions for alcohol use should be tailored to patients' readiness to change; however, validated measures of readiness to change are too lengthy to be practical in most primary care settings. We compared a readiness to change drinking algorithm (RTC Algorithm) based on three standardized questions to a validated 12-item readiness to change questionnaire (Rollnick RTCQ) in 85 hazardous drinking female Veterans Affairs (VA) patients. Results from comparisons of mean Rollnick RTCQ scale scores across RTC Algorithm categories suggest good concurrent validity. Regular assessment using the RTC Algorithm questions may help primary care providers tailor alcohol-related discussions with hazardous drinking patients. (C) 2004 Elsevier Ltd. All rights reserved. C1 Univ Missouri, Dept Psychol Sci, Columbia, MO 65211 USA. VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA. Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Primary & Specialty Med Care Serv, Seattle, WA USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. RP Epler, AJ (reprint author), Univ Missouri, Dept Psychol Sci, Psychol Bldg,Room 105,200 S 7th St, Columbia, MO 65211 USA. EM aje4x9@mizzou.edu FU NIAAA NIH HHS [K23 AA00313, T32 AA013526, T32 AA13526-01] NR 10 TC 11 Z9 11 U1 0 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 J9 ADDICT BEHAV JI Addict. Behav. PD FEB PY 2005 VL 30 IS 2 BP 389 EP 395 DI 10.1016/j.addbeh.2004.05.015 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 887QX UT WOS:000226321700020 PM 15621412 ER PT J AU Farrar, C Houser, CR Clarke, S AF Farrar, C Houser, CR Clarke, S TI Activation of the PI3K/Akt signal transduction pathway and increased levels of insulin receptor in protein repair-deficient mice SO AGING CELL LA English DT Article DE Akt; enlarged brain; IGF-I receptor; insulin receptor; isoaspartate; PCMT1 ID CENTRAL-NERVOUS-SYSTEM; FACTOR-I RECEPTOR; O-METHYLTRANSFERASE; TUMOR-SUPPRESSOR; TRANSGENIC MICE; KINASE-B; IGF-I; ISOASPARTYL PEPTIDES; ASPARTYL RESIDUES; DAMAGED PROTEINS AB Protein L-isoaspartate (D-aspartate) O-methyltransferase is an enzyme that catalyses the repair of isoaspartyl damage in proteins. Mice lacking this enzyme (Pcmt1-/- mice) have a progressive increase in brain size compared with wild-type mice (Pcmt1+/+ mice), a phenotype that can be associated with alterations in the PI3K/Akt signal transduction pathway. Here we show that components of this pathway, including Akt, GSK3beta and PDK-1, are more highly phosphorylated in the brains of Pcmt1-/- mice, particularly in cells of the hippocampus, in comparison with Pcmt1+/+ mice. Examination of upstream elements of this pathway in the hippocampus revealed that Pcmt1-/- mice have increased activation of insulin-like growth factor-I (IGF-I) receptor and/or insulin receptor. Western blot analysis revealed an approximate 200% increase in insulin receptor protein levels and an approximate 50% increase in IGF-I receptor protein levels in the hippocampus of Pcmt1-/- mice. Higher levels of the insulin receptor protein were also found in other regions of the adult brain and in whole tissue extracts of brain, liver, heart and testes of both juvenile and adult Pcmt1-/- mice. There were no significant differences in plasma insulin levels for adult Pcmt1-/- mice during glucose tolerance tests. However, they did show higher peak levels of blood glucose, suggesting a mild impairment in glucose tolerance. We propose that Pcmt1-/- mice have altered regulation of the insulin pathway, possibly as a compensatory response to altered glucose uptake or metabolism or as an adaptive response to a general accumulation of isoaspartyl protein damage in the brain and other tissues. C1 Dept Chem & Biochem, Los Angeles, CA 90095 USA. Inst Mol Biol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst W Los Ange, Res Serv, Los Angeles, CA 90073 USA. RP Clarke, S (reprint author), Dept Chem & Biochem, 637 Paul D Boyer Hall,611 Charles E Young Dr E, Los Angeles, CA 90095 USA. EM clarke@mbi.ucla.edu FU BLRD VA [I01 BX000404]; NIA NIH HHS [AG18000]; NIGMS NIH HHS [GM26020]; NINDS NIH HHS [NS046524] NR 61 TC 26 Z9 27 U1 0 U2 0 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 1474-9718 J9 AGING CELL JI Aging Cell PD FEB PY 2005 VL 4 IS 1 BP 1 EP 12 DI 10.1111/j.1474-9728.2004.00136.x PG 12 WC Cell Biology; Geriatrics & Gerontology SC Cell Biology; Geriatrics & Gerontology GA 891LA UT WOS:000226581300001 PM 15659208 ER PT J AU Tavakoli-Tabasi, S Rowan, P Abdul-Latif, M Kunik, ME El-Serag, HB AF Tavakoli-Tabasi, S Rowan, P Abdul-Latif, M Kunik, ME El-Serag, HB TI Utility of a depression score to predict candidacy for hepatitis C virus therapy in veterans: a prospective longitudinal study SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID QUALITY-OF-LIFE; UNITED-STATES; PSYCHIATRIC-DISORDERS; ZUNG; SCALE; INFECTION; VALIDITY; HEALTH; BECK AB Background: The frequency and determinants of receipt of antiviral therapy once a diagnosis of a mood disorder is established in hepatitis C virus (HCV)-infected patients remains unknown. Aim: To examine the incidence and determinants of receiving antiviral therapy in HCV-infected veterans with abnormal scores of Zung Self-Rating Depression Scale (SDS). Methods: We systematically evaluated the presence of psychiatric disorders among HCV-infected patients with initial referral between September 2000 and May 2002. We reviewed medical records, obtained history, and administered Zung SDS to evaluate for depressive symptoms. Patients with psychiatric disorders were referred for psychiatric evaluation. The primary outcome was the receipt of antiviral therapy during and after the initial evaluation up to December 1, 2003. The association between SDS scores and receipt of antiviral therapy was examined in a multivariate Cox proportional hazards regression. Results: A total of 424 patients completed a Zung SDS. The scores were normal in only 43% of all patients, and were impaired mildly in 25%, moderately in 23%, and severely in 9%. Zung SDS scores were significantly higher in patients who served during the Vietnam War era, participated in combat, or had lower albumin levels. At the end of the first visit, 180 (42%) had psychiatric disorders. An abnormal Zung score (>55) was the only reason for referral to psychiatry in 83 of 180 patients; and in those 78 (94%) a formal psychiatric evaluation confirmed depressive disorder. Psychiatric disorders were the sole contraindication to therapy in 145 (34%) patients in whom eligibility for antiviral therapy was achieved in 42 (29%) during a mean follow-up duration of 27 months. Conclusions: Approximately one-quarter of patients with psychiatric disorders may become eligible for antiviral therapy following subsequent management of these disorders. The Zung self-screening test is an easy, valid method for detecting mood disorders in HCV-infected veterans. C1 Baylor Coll Med, Houston Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Dept Med, Houston, TX 77030 USA. Baylor Coll Med, Vet Affairs S Cent Mental Illness Res Educ & Clin, Houston Ctr Qual Care & Utilizat Studies, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. Univ St Thomas, Houston, TX 77006 USA. RP El-Serag, HB (reprint author), Baylor Coll Med, Houston Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Dept Med, 152,2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu NR 27 TC 11 Z9 11 U1 0 U2 1 PU BLACKWELL PUBLISHING LTD PI OXFORD PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND SN 0269-2813 J9 ALIMENT PHARM THERAP JI Aliment. Pharmacol. Ther. PD FEB 1 PY 2005 VL 21 IS 3 BP 235 EP 242 DI 10.1111/j.1365-2036.2005.02299.x PG 8 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 894MK UT WOS:000226795700004 PM 15691297 ER PT J AU Johansen, KL Chertow, GM AF Johansen, KL Chertow, GM TI Body mass index and survival in incident dialysis patients: the answer depends on the question - Reply SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Letter C1 Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Johansen, KL (reprint author), Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM johanse@itsa.ucsf.edu NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD FEB PY 2005 VL 81 IS 2 BP 536 EP 536 PG 1 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 896OJ UT WOS:000226943100031 ER PT J AU DuBois, S Kearney, DJ AF DuBois, S Kearney, DJ TI Iron-deficiency anemia and Helicobaeter pylori infection: A review of the evidence SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Review ID GASTRIC-ACID-SECRETION; JUICE ASCORBIC-ACID; SIDEROPENIC REFRACTORY-ANEMIA; ALASKA NATIVE POPULATION; SERUM FERRITIN; BINDING PROTEIN; HIGH PREVALENCE; CHILDREN; ERADICATION; ABSORPTION C1 Univ Washington, Sch Med, Div Gastroenterol, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Sch Med, Div Gastroenterol, Dept Med, Seattle, WA 98108 USA. RP Kearney, DJ (reprint author), Univ Washington, Sch Med, Div Gastroenterol, VA Puget Sound Hlth Care Syst, 1660 S Columbia Way, Seattle, WA 98108 USA. NR 61 TC 104 Z9 107 U1 0 U2 1 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-9270 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD FEB PY 2005 VL 100 IS 2 BP 453 EP 459 DI 10.1111/j.1572-0241.2005.30252.x PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 893NK UT WOS:000226726300030 PM 15667507 ER PT J AU Jonk, YC Sherman, SE Fu, SS Hamlett-Berry, KW Geraci, MC Joseph, AM AF Jonk, YC Sherman, SE Fu, SS Hamlett-Berry, KW Geraci, MC Joseph, AM TI National trends in the provision of smoking cessation aids within the veterans health administration SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID COST-EFFECTIVENESS; UNITED-STATES; CONTROLLED-TRIAL; CARE CHARGES; TOBACCO USE; VA; INSURANCE; SERVICES; RECOMMENDATIONS; POPULATION AB Objectives: To evaluate the effectiveness of the Veterans Health Administration (VHA) in providing treatment for tobacco dependence, accomplished by estimating national trends in the number and percent of smokers receiving smoking cessation aids (SCAB) within the VHA, trends in SCA utilization and expenditures, and the impact of lifting restrictions on patient access to SCAs. Study Design and Methods: All patients receiving an outpatient SCA prescription were identified within the Veterans Affairs (VA) Pharmacy Benefits Management database over a 4-year period-October 1, 1998 (n = 61 968) to September 30, 2002 (n = 76 641). Smoking prevalence was based on data from the VA's 1999 Large Health Survey of Enrollees. A subsample of sites was classified as having restricted access to SCAB if patients were required to attend smoking cessation classes. Changes in annual SCA utilization rates and expenditures by SCA type and restriction status were measured to assess changes in treatment of tobacco dependence. Results: Approximately 7% of smokers received SCA prescriptions, and SCAB accounted for less than 1% of the VHA's annual outpatient pharmacy budget in any given year. Following downward trends in the cost of 30-day SCA prescriptions, annual SCA expenditures per patient decreased over time. Expenditures were lower for restricted than unrestricted sites. More than two thirds of smokers who were prescribed medications received the nicotine patch, a quarter received bupropion sustained-release, and fewer than 10% received nicotine gum. Conclusions: Measures of SCA utilization and cost are low, stable, and less than the recommended rates in national smoking cessation guidelines, suggesting that this population of smokers is undertreated. Removing SCA restrictions is not prohibitively expensive and improves access to cost-effective care. C1 Minneapolis VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55417 USA. Univ Minnesota, Sch Publ Hlth, Div Hlth Serv Res & Policy, Minneapolis, MN USA. Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. VA Greater Los Angles Healthcare Syst, VA Ctr Study Healthcare Provider Behav, Los Angeles, CA USA. Dept Vet Affairs, Vet Hlth Adm, Pharm Benefits Management Strateg Healthcare Grp, Washington, DC USA. Publ Hlth Strateg Healthcare Grp, Publ Hlth Natl Prevent Program, Washington, DC USA. RP Jonk, YC (reprint author), Minneapolis VA Med Ctr, Ctr Chron Dis Outcomes Res, 1 Vet Dr 1110, Minneapolis, MN 55417 USA. EM yjonk@umn.edu NR 48 TC 24 Z9 24 U1 2 U2 6 PU AMER MED PUBLISHING, M W C COMPANY PI JAMESBURG PA 241 FORSGATE DR, STE 102, JAMESBURG, NJ 08831 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD FEB PY 2005 VL 11 IS 2 BP 77 EP 85 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 894XY UT WOS:000226826100002 PM 15726855 ER PT J AU Sales, MM Cunningham, FE Glassman, PA Valentino, MA Good, CB AF Sales, MM Cunningham, FE Glassman, PA Valentino, MA Good, CB TI Pharmacy benefits management in the veterans health administration: 1995 to 2003 SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID TORSADE-DE-POINTES; PHARMACOKINETIC INTERACTIONS; SCHIZOAFFECTIVE DISORDER; REDUCTASE INHIBITORS; DRUG-INTERACTIONS; QTC INTERVAL; SCHIZOPHRENIA; ZIPRASIDONE; RHABDOMYOLYSIS; THERAPY AB The Department of Veterans Affairs (VA) Pharmacy Benefits Management Strategic Healthcare Group (VA PBM) oversees the formulary for the entire VA system, which serves more than 4 million veterans and provides more than 108 million prescriptions per year. Since its establishment in 1995, the VA PBM has managed pharmaceuticals and pharmaceutical-related policies, including drug safety and efficacy evaluations, pharmacologic management algorithms, and criteria for drug use. These evidence-based practices promote, optimize, and assist VA providers with the safe and appropriate use of pharmaceuticals while allowing for formulary decisions that can result in substantial cost savings. The VA PBM also has utilized various contracting techniques to standardize generic agents as well as specific drugs and drug classes (eg, antihistamines, angiotensin-converting enzyme inhibitors, alpha-blockers, and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors [statins]). These methods have enabled the VA to save approximately $1.5 billion since 1996 even as drug expenditures continued to rise from roughly $1 billion in fiscal year (FY) 1996 to more than $3 billion in FY 2003. Furthermore, the VA PBM has established an outcomes research section to undertake quality-improvement and safety initiatives that ultimately monitor and determine the clinical impact of formulary decisions on the VA system nationwide. The experiences of this pharmacy benefits program, including clinical and, contracting processes/procedures and their impact on the VA healthcare system, are described. C1 Dept Vet Affairs, Pharm Benefits Management Strateg Healthcare Grp, Hines, IL 60141 USA. Univ Illinois, Dept Pharm Practice, Chicago, IL USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA. VA Greater Los Angles W LA, Los Angeles, CA USA. VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. Univ Pittsburgh, Dept Pharm, Pittsburgh, PA USA. Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. RP Sales, MM (reprint author), Dept Vet Affairs, Pharm Benefits Management Strateg Healthcare Grp, PSM SHG 119D,1st Ave,1 Blk N Cermak Rd,Bldg 37, Hines, IL 60141 USA. EM marie.sales@med.va.gov NR 49 TC 40 Z9 40 U1 0 U2 2 PU AMER MED PUBLISHING, M W C COMPANY PI JAMESBURG PA 241 FORSGATE DR, STE 102, JAMESBURG, NJ 08831 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD FEB PY 2005 VL 11 IS 2 BP 104 EP 112 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 894XY UT WOS:000226826100005 PM 15726858 ER PT J AU Lovelock, JD Baker, AH Gao, F Dong, JF Bergeron, AL McPheat, W Sivasubramanian, N Mann, DL AF Lovelock, JD Baker, AH Gao, F Dong, JF Bergeron, AL McPheat, W Sivasubramanian, N Mann, DL TI Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE matrix metalloproteinase; proliferation; apoptosis; phenotypic differentiation ID FAILING HUMAN HEART; GROWTH-FACTOR-BETA; RECOMBINANT ADENOVIRUSES; MOLECULAR-CLONING; DEATH DOMAIN; EXPRESSION; CELLS; RAT; MYOFIBROBLASTS; APOPTOSIS AB The balance between matrix metalloproteinases ( MMPs) and their natural inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), plays a critical role in cardiac remodeling. Although a number of studies have characterized the pathophysiological role of MMPs in the heart, very little is known with respect to the role of TIMPs in the heart. To delineate the role of TIMPs in the heart we examined the effects of adenovirus-mediated overexpression of TIMP-1, - 2, - 3, and - 4 in cardiac fibroblasts. Infection of cardiac fibroblasts with adenoviral constructs containing human recombinant TIMP (AdTIMP-1, - 2, - 3, and - 4) provoked a significant ( P < 0.0001) 1.3-fold in increase in bromodeoxyuridine ( BrdU) incorporation. Similarly, treatment of cardiac fibroblasts with AdTIMP-1-, - 2-, - 3-, and - 4-conditioned medium led to a 1.2-fold increase in BrdU incorporation ( P < 0.0001) that was abolished by pretreatment with anti-TIMP-1, - 2, - 3, and - 4 antibodies. The effects of TIMPs were not mimicked by treating the cells with RS-130830, a broad-based MMP inhibitor, suggesting that the effects of TIMPs were independent of their ability to inhibit MMPs. Infection with AdTIMP- 1, - 2, - 3, and - 4 led to a significant increase in alpha-smooth muscle actin staining, consistent with TIMP-induced phenotypic differentiation into myofibroblasts. Finally, infection with AdTIMP- 2 resulted in a significant increase in collagen synthesis, whereas infection with AdTIMP- 3 resulted in a significant increase in fibroblast apoptosis. TIMPs exert overlapping as well as diverse effects on isolated cardiac fibroblasts. The observation that TIMPs stimulate fibroblast proliferation as well as phenotypic differentiation into myofibroblasts suggests that TIMPs may play an important role in tissue repair in the heart that extends beyond their traditional role as MMP inhibitors. C1 Michael E DeBakey Dept Vet Affairs Med Ctr, Winters Ctr Heart Failure Res, Houston, TX 77030 USA. Baylor Coll Med, Thrombosis Sect, Houston, TX 77030 USA. Methodist Hosp, Houston, TX 77030 USA. Univ Glasgow, Div Cardiovasc & Med Sci, Glasgow, Lanark, Scotland. AstraZeneca Pharmaceut, AstraZeneca R&D Molndal, Dept Mol Pharmacol, Gothenburg, Sweden. RP Mann, DL (reprint author), Michael E DeBakey Dept Vet Affairs Med Ctr, Winters Ctr Heart Failure Res, MS 524,6565 Fannin, Houston, TX 77030 USA. EM dmann@bcm.tmc.edu OI Mann, Douglas /0000-0002-2516-0145 FU NHLBI NIH HHS [R01 HL-61543-01, HL-42250-10/10, P50-HL-06H, R01-HL-58081-01] NR 39 TC 77 Z9 80 U1 0 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD FEB PY 2005 VL 288 IS 2 BP H461 EP H468 DI 10.1152/ajpheart.00402.2004 PG 8 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 888FE UT WOS:000226358800002 PM 15650153 ER PT J AU Adler, LE Cawthra, EM Donovan, KA Harris, JG Nagamoto, HT Olincy, A Waldo, MC AF Adler, LE Cawthra, EM Donovan, KA Harris, JG Nagamoto, HT Olincy, A Waldo, MC TI Improved P50 auditory gating with ondansetron in medicated schizophrenia patients SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID NEUROPHYSIOLOGICAL EVIDENCE; PHYSIOLOGY; DEFECT AB Objective: Most schizophrenia patients have a deficit in auditory sensory gating, which appears to be mediated by the alpha-7 nicotinic receptor, that is not improved with conventional antipsychotic treatment. This study examined the effects of ondansetron, a highly selective 5-HT3 antagonist, on the P50 auditory evoked potential. Method: Eight medicated outpatients with schizophrenia were given either ondansetron ( 16 mg) or placebo in a double-blind, placebo-controlled design. Evoked potentials were recorded at baseline and 1 hour, 2 hours, and 3 hours after receipt of drug. Results: There was a highly significant improvement in P50 gating after ondansetron treatment. The maximal treatment difference was at 2 hours posttreatment ( ondansetron: mean= 41.4%, SD= 39.7%; placebo: mean= 80.2%, SD= 21.3%). Conclusions: Ondansetron significantly enhanced P50 auditory gating in schizophrenia patients treated with typical antipsychotics. C1 Denver VA Med Ctr, Mental Hlth Serv, Denver, CO 80220 USA. VA Rocky Mt Network VISN 19, Mental Illness Res Educ & Clin Ctr, Glendale, CO USA. Univ Colorado, Hlth Sci Ctr, Denver, CO USA. RP Adler, LE (reprint author), Denver VA Med Ctr, Mental Hlth Serv, 1055 Clermont St, Denver, CO 80220 USA. EM Lawrence.Adler@med.va.gov FU NIMH NIH HHS [2K02 MH-01121, 5R01 MH-50787] NR 11 TC 54 Z9 60 U1 0 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD FEB PY 2005 VL 162 IS 2 BP 386 EP U5 DI 10.1176/appi.ajp.162.2.386 PG 3 WC Psychiatry SC Psychiatry GA 900JI UT WOS:000227210800028 PM 15677607 ER PT J AU Tregellas, JR Tanabe, JL Martin, LF Freedman, R AF Tregellas, JR Tanabe, JL Martin, LF Freedman, R TI fMRI of response to nicotine during a smooth pursuit eye movement task in schizophrenia SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID CIGARETTE-SMOKING; CINGULATE CORTEX; POSTMORTEM BRAIN; TRACKING; ACTIVATION; RECEPTORS AB Objective: Nicotine temporarily normalizes smooth pursuit eye movement deficits in schizophrenia. This study used functional magnetic resonance imaging ( fMRI) to examine changes in brain hemodynamic response associated with nicotine administration during a smooth pursuit eye movement task in subjects with schizophrenia. Method: Nine subjects with schizophrenia performed the eye movement task while undergoing fMRI. Subjects then were given nicotine or placebo and repeated the task while being scanned. Subjects repeated the procedure the following week, receiving the counterbalanced condition. Results: Compared with placebo, nicotine was associated with greater activity in the anterior and posterior cingulate gyri, precuneus, and area MT/MST and less activity in the hippocampus and parietal eye fields. Conclusions: Changes in area MT/MST and the cingulate gyrus are consistent with an improvement in perception and attention to moving stimuli. The most important observed difference between nicotine and placebo - less activation of the hippocampus after nicotine than after placebo administration - is consistent with nicotinic receptor mediation of inhibitory neuronal dysfunction in schizophrenia. C1 Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA. Univ Colorado, Hlth Sci Ctr, Dept Radiol, Denver, CO 80262 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. RP Tregellas, JR (reprint author), Univ Colorado, Hlth Sci Ctr, Dept Psychiat, C268071,4200 E 9th Ave, Denver, CO 80262 USA. EM Jason.Tregellas@UCHSC.edu RI Tregellas, Jason/J-3637-2015 FU NIMH NIH HHS [MH-66533-01, MH-38321] NR 24 TC 36 Z9 39 U1 1 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X J9 AM J PSYCHIAT JI Am. J. Psychiat. PD FEB PY 2005 VL 162 IS 2 BP 391 EP 393 DI 10.1176/appi.ajp.162.2.391 PG 3 WC Psychiatry SC Psychiatry GA 900JI UT WOS:000227210800030 PM 15677609 ER PT J AU Ko, CY Escarce, JJ Baker, L Sharp, J Guarino, C AF Ko, CY Escarce, JJ Baker, L Sharp, J Guarino, C TI Predictors of surgery resident satisfaction with teaching by attendings - A national survey SO ANNALS OF SURGERY LA English DT Article ID GENERAL-SURGERY; WORKING HOURS; IMPACT; CARE; LIMITATIONS; EXPERIENCE; SKILLS; STATE AB Objective: To identify factors that predict fourth- and fifth-year surgical resident satisfaction of attending teaching quality. Summary Background Data: With the training of surgical residents undergoing major changes, a key issue facing surgical educators is whether high-quality surgeons can still be produced. Innovative techniques (eg, computer simulation surgery) are being developed to substitute partially for conventional teaching methods. However, an aspect of training a that cannot be so easily replaced is the faculty-resident interaction. This study investigates resident perceptions of attending teaching quality and the factors associated with this faculty-resident interaction to identify predictors of resident educational satisfaction. Methods: A national survey of clinical fourth- and fifth-year surgery residents in 125 academically affiliated general surgery training programs was performed. The survey contained 67 questions and addressed demographics, hospital, and service characteristics, as well as surgery, education, and clinical care-related factors. Univariate analyses were performed to describe the characteristics of the sample; multivariate analyses were performed to evaluate the factors associated with resident educational satisfaction. Results: The response rate was 61.5% (n = 756). Average age was 32 years; most were male (79%), white (72%), and married (69%); 42% had children. Ninety-five percent of respondents graduated from U.S. medical schools, and the average debt was $80,307. Of 20 potentially mutable factors, 6 variables had positive associations with resident education satisfaction and 7 had negative associations. Positive factors included the resident being the operating surgeon in major surgeries, substantial citing of evidence-based literature by the attending, attending physicians giving spontaneous or unplanned presentations, increasing the continuity of care, clinical teaching aimed at the chief resident level. and having clinical decisions made together by both the attending and resident. There were 7 negative factors such as overly supervising in surgery, being interrupted so much that teaching was ineffective. and attending physicians being rushed and/or eager to finish rounds. Conclusion: This study identifies several factors that were, associated with resident educational satisfaction. It offers the perspective of the learners (ie. residents) and. importantly. highlights mutable factors that surgery faculty (and departments)may consider changing to improve surgery resident education and satisfaction. Improving such satisfaction may help to produce a better product. C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. RAND Corp, Santa Monica, CA USA. W Los Angeles VA Hosp, Los Angeles, CA USA. Stanford Univ, Dept Hlth Policy & Res, Palo Alto, CA 94304 USA. RP Ko, CY (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 LeConte Ave,72-215 CHS, Los Angeles, CA 90095 USA. EM cko@mednet.ucla.edu OI Baker, Laurence/0000-0001-5032-794X NR 23 TC 36 Z9 37 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD FEB PY 2005 VL 241 IS 2 BP 373 EP 380 DI 10.1097/01.sla.0000150257.04889.70 PG 8 WC Surgery SC Surgery GA 891FR UT WOS:000226567200025 PM 15650650 ER PT J AU Mikuls, TR Farrar, JT Bilker, WB Fernandes, S Schumacher, HR Saag, KG AF Mikuls, TR Farrar, JT Bilker, WB Fernandes, S Schumacher, HR Saag, KG TI Gout epidemiology: results from the UK general practice research database, 1990-1999 SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID URIC-ACID; FOLLOW-UP; HEART-DISEASE; RISK-FACTORS; NEPHROLITHIASIS; MEN; ASSOCIATION; PREVALENCE; MORTALITY; HEALTH AB Objective: To examine the epidemiology of gout and gout treatment in the United Kingdom using a large national practice based population. Methods: Data from the UK General Practice Research Database from 1990 to 1999 were examined. Physician diagnoses and drug codes were used, and trends in gout incidence and treatment examined. Additionally, disease prevalence for the year 1999 was assessed. To examine the association of gout with comorbid disease, the prevalence of select health conditions and drug use was compared with the corresponding prevalences seen in osteoarthritis, adjusting for both age and sex. Results: From 1 January 1990 to 31 December 1999 overall gout incidence remained relatively stable, ranging from a low of 11.9 cases (95% confidence interval (CI) 11.5 to 12.3) in 1991 to a high of 18.0 cases (95% CI 17.6 to 18.4) per 10 000 patient-years in 1994. Gout prevalence in 1999 was 1.4% with rates approaching 7% in men over the age of 65. Drugs used for the treatment of gout remained constant in prevalent cases with the exception of a significant decline in non-steroidal anti-inflammatory drug use over the 10 year follow up. Compared with patients with osteoarthritis, patients with gout were significantly more likely to have cardiovascular disease, hypertension, diabetes, and chronic renal failure, and were more likely to have used diuretics or ciclosporin, or both. Conclusion: Although gout is common in the UK, particularly among older men, the incidence of the disease seems to have remained stable during the 1990s. C1 Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA. Univ Nebraska, Med Ctr, Dept Med, Omaha, NE 68105 USA. Omaha VA Med Ctr, Omaha, NE USA. Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Univ Penn, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. Univ Alabama, Ctr Educ & Res Therapeut Musculoskeletal Disorder, Birmingham, AL 35294 USA. RP Saag, KG (reprint author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, 510 20th St S,FOT 8th Floor, Birmingham, AL 35294 USA. EM ksaag@uab.edu RI Farrar, John/A-1037-2007; Research Datalink, Clinical Practice/H-2477-2013; CPRD, CPRD/B-9594-2017 OI Farrar, John/0000-0001-8656-5157; NR 30 TC 230 Z9 251 U1 1 U2 14 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD FEB PY 2005 VL 64 IS 2 BP 267 EP 272 DI 10.1136/ard.2004.024091 PG 6 WC Rheumatology SC Rheumatology GA 887CE UT WOS:000226279200021 PM 15647434 ER PT J AU Zandi, PP Sparks, DL Khachaturian, AS Tschanz, J Norton, M Steinberg, M Welsh-Bohmer, KA Breitner, JCS AF Zandi, PP Sparks, DL Khachaturian, AS Tschanz, J Norton, M Steinberg, M Welsh-Bohmer, KA Breitner, JCS CA Cache County Study Investigators TI Do statins reduce risk of incident dementia and Alzheimer disease? The cache county study SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article ID OLDER WOMEN; APOLIPOPROTEIN-E; CONTROLLED TRIAL; CHOLESTEROL; PREVALENCE; AD; STROKE; INDIVIDUALS; SIMVASTATIN; RELIABILITY AB Background: Prior reports suggest reduced occurrence of dementia and Alzheimer disease (AD) in statin users, but, to our knowledge, no prospective studies relate statin use and dementia incidence. Objective: To examine the association of statin use with both prevalence and incidence of dementia and AD. Design: Cross-sectional studies of prevalence and incidence and a prospective study of incidence of dementia and AD among 5092 elderly residents (aged 65 years or older) of a single county. Participants were assessed at home in 1995-1997 and again in 1998-2000. A detailed visual inventory of medicines, including statins and other lipid-lowering agents, was collected at both assessments. Main Outcome Measures: Diagnosis of dementia and of AD. Results: From 4895 participants with data sufficient to determine cognitive status, we identified 355 cases of prevalent dementia (200 with AD) at initial assessment. Statin use was inversely associated with prevalence of dementia (adjusted odds ratio. 0.44; 95% confidence interval, 0.17-0.94). Three years later, we identified 185 cases of incident dementia (104 with AD) among 3308 survivors at risk. Statin use at baseline did not predict incidence of dementia or AD (adjusted hazard ratio for dementia, 1.19; 95% confidence interval, 0.53-2-34; adjusted hazard ratio for AD, 1.19; 95% confidence interval, 0.35-2.96), nor did Stalin use at follow-up (adjusted odds ratio for dementia, 1.04; 95% confidence interval, 0.56-1.81; adjusted odds ratio for AD. 0.85: 95% confidence interval, 0.32-1.88). Conclusions: Although statin use might be less frequent in those with prevalent dementia, we found no association between statin use and subsequent onset of dementia or AD. Further research is warranted before costly dementia prevention trials with statins are undertaken. C1 VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA 98108 USA. RP Breitner, JCS (reprint author), VA Puget Sound Hlth Care Syst, GRECC, S-182,1660 S Columbian Way, Seattle, WA 98108 USA. EM jcsb@u.washington.edu RI Tschanz, JoAnn/E-5986-2010; Norton, Maria/E-6994-2013 FU NIA NIH HHS [R01-AG-11380] NR 45 TC 206 Z9 219 U1 2 U2 12 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD FEB PY 2005 VL 62 IS 2 BP 217 EP 224 DI 10.1001/archpsyc.62.2.217 PG 8 WC Psychiatry SC Psychiatry GA 893TN UT WOS:000226742300013 PM 15699299 ER PT J AU Dettmers, C Teske, U Hamzei, F Uswatte, G Taub, E Weiller, C AF Dettmers, C Teske, U Hamzei, F Uswatte, G Taub, E Weiller, C TI Distributed form of constraint-induced movement therapy improves functional outcome and quality of life after stroke SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article; Proceedings Paper CT 3rd World Congress of Neurological Rehabilitation CY APR 02-06, 2002 CL VENICE, ITALY DE evaluation studies; physical therapy techniques; recovery of function; rehabilitation; stroke; treatment effectiveness ID PHYSICAL REHABILITATION; CHRONIC HEMIPARESIS; UPPER EXTREMITY; LEARNED NONUSE; FORCED USE; RELIABILITY; RECOVERY; VERSION AB Objective: To evaluate the effectiveness of a distributed version of constraint-induced movement therapy (CIMT). Design: Within-subjects control intervention study. Setting: Outpatient rehabilitation center. Participants: Eleven persons with chronic stroke. All had active extension of at least 20degrees at the wrist and at least 10degrees for each finger of the more-affected hand. Interventions: Intensive motor training of the more-affected arm for 3 hours a day for 20 days; restraint of the other arm for 9.3 hours daily to limit its use. This intervention provides the same amount of training as provided in the conventional CIMT therapy protocol (60h) but distributes training time over twice the number of days. Main Outcome Measures: Real-world (Motor Activity Lou) and laboratory motor activity (Wolf Motor Function Test, Frenchay Arm Test, Nine Hole Peg Test), strength (grip force) and spasticity (Ashworth Scale), and quality of life (QOL; Stroke Impact Scale) were assessed. Results: Participants showed significant improvements in more-affected arm real-world motor activity, laboratory motor activity, strength and spasticity, as well as in some aspects of QOL, up to 6 months after treatment (P.05). Conclusions: Distributed CIMT is a promising intervention for improving motor function and QOL in patients with chronic stroke. C1 Reha Zentrum Berliner Tor, Neurol Therapiecent, D-20535 Hamburg, Germany. Neurol Univ Klin Hamburg Eppendorf, Hamburg, Germany. Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Dettmers, C (reprint author), Reha Zentrum Berliner Tor, Neurol Therapiecent, Jungestr 10, D-20535 Hamburg, Germany. EM c.dettmers@berliner-tor.de RI Uswatte, Gitendra/C-4913-2009 NR 39 TC 85 Z9 97 U1 1 U2 11 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD FEB PY 2005 VL 86 IS 2 BP 204 EP 209 DI 10.1016/j.apmr.2004.05.007 PG 6 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 894UY UT WOS:000226818300004 PM 15706544 ER PT J AU Chang, HT Evans, CT Weaver, FM Burns, SP Parada, JP AF Chang, HT Evans, CT Weaver, FM Burns, SP Parada, JP TI Etiology and outcomes of veterans with spinal cord injury and disorders hospitalized with community-acquired pneumonia SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Academy-of-Physical-Medicine-and-Rehabilitation CY OCT 10, 2003 CL Chicago, IL SP Amer Acad Phys Med & Rehabilitat DE community-acquired infections; disease management; pneumonia; rehabilitation; spinal cord injuries ID UNITED-STATES; MANAGEMENT; GUIDELINES; MORTALITY; SEVERITY; THERAPY; LENGTH; ADULTS; DEATH; STAY AB Objective: To determine whether documentation of a causative organism for community-acquired pneumonia (CAP) is associated with outcomes, including mortality and length of stay (LOS), in hospitalized veterans with spinal cord injuries and disorders (SCI&D). Design: Retrospective cohort study. Setting: Patients with SCI&D admitted with CAP to any Veterans Affairs medical center between September 1998 and October 2000. Participants: Hospital administrative data on 260 patients with SCI&D and a CAP diagnosis. Interventions: Not applicable. Main Outcomes Measures: All-cause, 30-day mortality and hospital LOS. Results: An organism was documented by International Classification of Diseases, 9th Revision, discharge codes in 24% of cases. Streptococcus pneumoniae and Pseudomonas aeruginosa accounted for 32% and 21%, respectively, of the identified bacterial pathogens. The overall mortality rate was 8.5%. No significant association was found between etiologic diagnosis of CAP and 30-day mortality. Lower mortality was associated with treatment at a designated SCI center (relative risk=.35; confidence interval, .12-.99). Pathogen-based CAP diagnosis was significantly associated with longer LOS (adjusted r(2)=.023, P=.024). Conclusions: There was no association between etiologic diagnosis of CAP and 30-day mortality among people with SCI&D. Documentation of CAP etiology was associated with the variance in LOS. Pneumococcal vaccination and antibiotic therapy with antipseudomonal activity may be particularly prudent in these patients given the high frequency of these pathogens among SCI&D patients with CAP. C1 Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA. Vet Affairs Edward Hines Jr Hosp, Dept Vet Affairs, Midwest Ctr Hlth Serv & Policy Res, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL USA. Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Chicago, IL USA. Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Spinal Cord Injury Serv, Seattle, WA USA. Loyola Univ, Dept Med, Div Infect Dis, Maywood, IL USA. RP Weaver, FM (reprint author), Edward Hines Jr Vet Adm Hosp, Dept Vet Affairs, Midwest Ctr Hlth Serv & Policy Res, 5th & Roosevelt Rd,POB 5000 151H, Hines, IL 60141 USA. EM frances.weaver@med.va.gov NR 33 TC 5 Z9 5 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD FEB PY 2005 VL 86 IS 2 BP 262 EP 267 DI 10.1016/j.apmr.2004.02.024 PG 6 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 894UY UT WOS:000226818300012 PM 15706552 ER PT J AU Game, BA Maldonado, A He, L Huang, Y AF Game, BA Maldonado, A He, L Huang, Y TI Pioglitazone inhibits MMP-1 expression in vascular smooth muscle cells through a mitogen-activated protein kinase-independent mechanism SO ATHEROSCLEROSIS LA English DT Article; Proceedings Paper CT 63rd Annual Meeting of the American-Diabetes-Association CY JUN 13-17, 2003 CL NEW ORLEANS, LA SP Amer Diabet Assoc DE matrix metalloproteinase; atherosclerosis; peroxisome proliferator-activated receptor; signal transcluction ID OXIDIZED LDL; GENE-EXPRESSION; MATRIX METALLOPROTEINASES; ENDOTHELIAL-CELLS; PPAR-GAMMA; TISSUE INHIBITORS; IMMUNE-COMPLEXES; IN-VITRO; MIGRATION; GROWTH AB Antidiabetic drug thiazoliclinedione (TZD) also has anti-atherogenic effects. Among these effects, inhibition of smooth muscle cell (SMC) migration is considered to be essential. However, the mechanism whereby TZD inhibits SMC migration is not well understood. Since it is known that matrix metalloproteinases (MMPs) play a permissive role for SMC migration, we determined if TZD inhibits the upregulation of MMP-1 expression in SMCs by oxidized LDL (oxLDL), a potent stimulator for atherogenesis. Results showed that oxLDL markedly stimulated MNIP-1 secretion, mRNA expression, and MMP-1 promoter activity, but pioglitazone significantly inhibited the oxLDL-upregulated MMP-1 expression. In an attempt to explore the signaling mechanism by which pioglitazone inhibits the oxLDL-upregulated MMP-1 expression, we found that extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK) pathways were required for the oxLDL-stimulated MMP-1 expression, but pioglitazone failed to antagonize the activation of ERK and JNK by oxLDL. Finally, our AP-1 activity assay showed that pioglitazone inhibited oxLDL-stimulated c-Junactivity. Taken together, the present study indicates that pioglitazone inhibits oxLDL-stimulated MMP-1 expression in VSMCs by inhibiting c-Jun transcriptional activity through a mitogen-activated protein kinase (MAPK)-independent mechanism. (C) 2004 Elsevier Ireland Ltd. All rights reserved. C1 Med Univ S Carolina, Div Endocrinol Diabet & Med Genet, Dept Med, Charleston, SC 29403 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. RP Huang, Y (reprint author), Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, 114 Doughty St,Room 531, Charleston, SC 29403 USA. EM huangyan@musc.edu NR 31 TC 13 Z9 14 U1 0 U2 1 PU ELSEVIER SCI IRELAND LTD PI CLARE PA CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND SN 0021-9150 J9 ATHEROSCLEROSIS JI Atherosclerosis PD FEB PY 2005 VL 178 IS 2 BP 249 EP 256 DI 10.1016/j.atherosclerosis.2004.09.012 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 900FM UT WOS:000227200800004 PM 15694931 ER PT J AU Siegel, JM AF Siegel, JM TI The incredible, shrinking sleep-learning connection SO BEHAVIORAL AND BRAIN SCIENCES LA English DT Editorial Material ID EYE-MOVEMENT SLEEP; REM-SLEEP; MEMORY CONSOLIDATION; DECLARATIVE MEMORY; HIPPOCAMPUS AB Initial claims that REM sleep is important in the consolidation of all memories have been revised and reduced to the claim that sleep has a role only in the consolidation of procedural learning. Now, Walker hypothesizes that sleep has no role in the "stabilization phase of consolidation" but only in the "enhanced learning" phase of procedural learning. Evidence for this vague, truncated hypothesis remains as inconsistent as that for prior claims. C1 VA Greater Los Angeles Hlth Syst, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, North Hills, CA 91343 USA. RP Siegel, JM (reprint author), VA Greater Los Angeles Hlth Syst, Sepulveda, CA 91343 USA. EM JSiegel@ucla.edu NR 16 TC 3 Z9 3 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA SN 0140-525X J9 BEHAV BRAIN SCI JI Behav. Brain Sci. PD FEB PY 2005 VL 28 IS 1 BP 82 EP + PG 10 WC Psychology, Biological; Behavioral Sciences; Neurosciences SC Psychology; Behavioral Sciences; Neurosciences & Neurology GA 937RV UT WOS:000229944100047 ER PT J AU Szymusiak, R AF Szymusiak, R TI The challenge of identifying cellular mechanisms of memory formation during sleep SO BEHAVIORAL AND BRAIN SCIENCES LA English DT Editorial Material AB Cellular mechanisms hypothesized to underlie sleep-dependent memory consolidation are expressed throughout the brain during sleep. Use of sleep deprivation to evaluate the functional importance of these mechanisms is confounded by degradation in waking performance resulting from impaired vigilance. There is a need for methods that will permit disruption of specific mechanisms during sleep only in the neuronal circuits most critically involved in learning. This should be accomplished without global sleep disruption and with preservation of the restorative aspects of sleep. C1 VA Greater Los Angeles Healthcare Syst, Res Serv 151A3, North Hills, CA 91343 USA. RP Szymusiak, R (reprint author), VA Greater Los Angeles Healthcare Syst, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91343 USA. EM rszym@ucla.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA SN 0140-525X J9 BEHAV BRAIN SCI JI Behav. Brain Sci. PD FEB PY 2005 VL 28 IS 1 BP 84 EP 85 PG 2 WC Psychology, Biological; Behavioral Sciences; Neurosciences SC Psychology; Behavioral Sciences; Neurosciences & Neurology GA 937RV UT WOS:000229944100049 ER PT J AU Pawlyk, AC Jha, SK Brennan, FX Morrison, AR Ross, RJ AF Pawlyk, AC Jha, SK Brennan, FX Morrison, AR Ross, RJ TI A rodent model of sleep disturbances in posttraumatic stress disorder: The role of context after fear conditioning SO BIOLOGICAL PSYCHIATRY LA English DT Article DE fear; fear conditioning; PTSD; anxiety; sleep; REMS ID EYE-MOVEMENT SLEEP; COMBAT-RELATED PTSD; REM-SLEEP; IMMOBILIZATION STRESS; ANXIETY DISORDERS; RAT; MICE; DEPRIVATION; PATTERN; INTENSITY AB Background: A prominent sleep disturbance, likely including a disruption of rapid eye movement sleep (REMS) continuity, characterizes posttraumatic stress disorder (PTSD). We set out to develop a fear conditioning paradigm in rats that displays alterations in sleep architecture analogous to those in PTSD. Methods: Baseline polysomnographic recordings of rats were performed in a neutral context to which the rats bad been habituated ,for several days. Rats were then shock- or mock-trained in a distinctly different context, and their sleep was studied the following day in that context. A separate group of rats was shock-trained and studied in the neutral context on the following 2 days. Results: Rats that slept in the neutral context exhibited a REMS-selective increase in sleep 24 hours after training and increases in REMS and non-REMS 48 hours after training. In contrast, rats that slept in the presence of situational reminders of the training context exhibited a REMS-selective decrease in sleep 24 hours later. Animals that were mock-trained showed no changes in sleep. Conclusions: Shock training induced days-long changes in sleep architecture that were disrupted when the animal was exposed to situational reminders of the training context. C1 Philadelphia VA Med Ctr, Behav Hlth Serv, Med Res Serv, Philadelphia, PA 19104 USA. Univ Penn, Sch Vet Med, Lab Study Brain Sleep, Dept Biol Anim, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Sleep & Resp Neurobiol, Philadelphia, PA USA. Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. RP Ross, RJ (reprint author), Philadelphia VA Med Ctr, Behav Hlth Serv, Med Res Serv, Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM ross_r@mail.trc.upenn.edu OI Jha, Sushil/0000-0001-8638-898X FU NHLBI NIH HHS [HL7953]; NIMH NIH HHS [MH42903] NR 41 TC 57 Z9 58 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD FEB 1 PY 2005 VL 57 IS 3 BP 268 EP 277 DI 10.1016/j.biopsych.2004.11.008 PG 10 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 895TL UT WOS:000226886400009 PM 15691528 ER PT J AU Kilbourne, AM Bauer, MS Pincus, H Williford, WO Kirk, GF Beresford, T AF Kilbourne, AM Bauer, MS Pincus, H Williford, WO Kirk, GF Beresford, T CA VA Cooperative Study 430 Team TI Clinical, psychosocial, and treatment differences in minority patients with bipolar disorder SO BIPOLAR DISORDERS LA English DT Article; Proceedings Paper CT 5th International Conference on Bipolar Disorder CY JUN, 2003 CL Pittsburgh, PA DE bipolar disorder; health services accessibility; minority groups; substance use disorders ID SUBSTANCE-ABUSE; PSYCHIATRIC-DISORDERS; RACIAL-DIFFERENCES; UNITED-STATES; DIAGNOSIS; PREVALENCE; VETERANS; BLACK; RACE; CARE AB Objectives: The clinical profile of minorities with bipolar disorder has been largely unexplored. We compared the clinical (e.g. psychiatric and substance use comorbidity), psychosocial, and treatment characteristics between white and minority patients with bipolar disorder (minorities were defined as black or other minority, which included Hispanic, Asian-American, or Native-Americans). Methods: We collected demographic, diagnosis, and treatment information using the Structured Clinical Interview for DSM-IV (SCID) from 330 inpatients with a current major affective episode across 11 Veterans Affairs (VA) Medical Centers enrolled in the VA Cooperative Study (Reducing the Efficacy-Effectiveness Gap in Bipolar Disorder). Results: Twenty-four percent (n = 80) were minority; 9% (n = 30) were women, 4% (n = 20) were greater than or equal to65 years old; and the majority (87%, n = 286) had bipolar type I. Minorities compared with whites were no more likely to have a current episode of psychosis (30% versus 37%, respectively; p = 0.28). However, minorities were more likely than whites to have a cocaine use disorder (adjusted odd's ratio, OR = 2.2; 95% CI: 1.4-3.5; p < 0.01) or current alcohol abuse disorder (adjusted OR = 1.8; 95% CI: 1.1-3.9;p < 0.05). Further breakdown by race/ethnicity revealed that cocaine use disorder was most prevalent among blacks (n = 14, 29%), compared with all other minorities (n = 2, 6%) or whites (n = 10, 4%; p < 0.001). Other minorities compared with blacks or whites were more likely involuntarily committed during some part of their index hospitalization (adjusted OR = 2.47; 95% CI: 1.1-5.7; p = 0.04). Conclusions: Minorities with bipolar disorder may be a more vulnerable population because of higher rates of substance use disorder and higher rates of involuntary psychiatric commitment. Moreover, the specific profile of vulnerability may differ across minority groups. C1 Univ Pittsburgh, Sch Med, Dept Med,VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Sch Med, Dept Psychiat,VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15240 USA. VA Providence Med Ctr, Providence, RI USA. Brown Univ, Providence, RI 02912 USA. RAND Corp, Pittsburgh, PA USA. Univ Maryland, Sch Med, VA Cooperat Studies Program, Perry Point, MD USA. VA Colorado Healthcare Syst, Denver, CO USA. Univ Colorado, Denver, CO 80202 USA. RP Kilbourne, AM (reprint author), Univ Pittsburgh, Sch Med, Dept Med,VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr C, Pittsburgh, PA 15240 USA. EM amy.kilbourne@med.va.gov FU NIMH NIH HHS [MH30915] NR 43 TC 17 Z9 17 U1 1 U2 4 PU BLACKWELL MUNKSGAARD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 1398-5647 J9 BIPOLAR DISORD JI Bipolar Disord. PD FEB PY 2005 VL 7 IS 1 BP 89 EP 97 DI 10.1111/j.1399-5618.2004.00161.x PG 9 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 887VZ UT WOS:000226334900011 PM 15654937 ER PT J AU Mims, MP Guan, YL Pospisilova, D Priwitzerova, M Indrak, K Ponka, P Divoky, V Prchal, JT AF Mims, MP Guan, YL Pospisilova, D Priwitzerova, M Indrak, K Ponka, P Divoky, V Prchal, JT TI Identification of a human mutation of DMT1 in a patient with microcytic anemia and iron overload SO BLOOD LA English DT Article ID TRANSPORTER; NRAMP2; CELLS; EXPRESSION; MEMBRANE; ERYTHROPOIETIN; LOCALIZATION; DEFICIENCY; ISOFORMS; MICE AB Divalent metal transporter 1 (DMT1) is a transmembrane protein crucial for duodenal iron absorption and erythroid iron transport. DMT1 function has been elucidated largely in studies of the mk mouse and the Belgrade rat, which have an identical single nucleotide mutation of this gene that affects protein processing, stability, and function. These animals exhibit hypochromic microcytic anemia due to impaired intestinal iron absorption, and defective iron utilization in red cell precursors. We report here the first human mutation of DMT1 identified in a female with severe hypochromic microcytic anemia and iron overload. This homozygous mutation in the ultimate nucleoticle of exon 12 codes for a conservative E399D amino acid substitution; however, its predominant effect is preferential skipping of exon 12 during processing of pre-messenger RNA (mRNA). The lack of full-length mRNA would predict deficient iron absorption in the intestine and deficient iron utilization in erythroid precursors; however, unlike the animal models of DMT1 mutation, the patient is iron overloaded. This does not appear to be due to up-regulation of total DMT1 mRNA. DMT1 protein is easily detectable by immunoblotting in the patient's duodenum, but it is unclear whether the protein is properly processed or targeted. (C) 2005 by The American Society of Hematology. C1 Baylor Coll Med, Div Hematol Oncol, Houston, TX 77030 USA. Houston VA Med Ctr, Houston, TX USA. Palacky Univ, Fac Med, Dept Pediat, CR-77147 Olomouc, Czech Republic. Palacky Univ, Fac Med, Dept Biol, CR-77147 Olomouc, Czech Republic. Palacky Univ, Fac Med, Dept Hematooncol, CR-77147 Olomouc, Czech Republic. McGill Univ, Montreal, PQ, Canada. RP Prchal, JT (reprint author), Baylor Coll Med, Div Hematol Oncol, Houston, TX 77030 USA. EM jprchal@bcm.tmc.edu RI Ponka, Prem/A-4123-2011 FU NHLBI NIH HHS [R01HL50077-11]; NIDDK NIH HHS [T32 DK60445] NR 21 TC 115 Z9 120 U1 0 U2 8 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD FEB 1 PY 2005 VL 105 IS 3 BP 1337 EP 1342 DI 10.1182/blood-2004-07-2966 PG 6 WC Hematology SC Hematology GA 891QX UT WOS:000226596700067 PM 15459009 ER PT J AU Cooper, RM Pacey, JA Bishop, MJ McCluskey, SA AF Cooper, RM Pacey, JA Bishop, MJ McCluskey, SA TI Early clinical experience with a new videolaryngoscope (GlideScope (R)) in 728 patients SO CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE LA English DT Article ID DIFFICULT TRACHEAL INTUBATION; BULLARD LARYNGOSCOPE; AIRWAY; MANAGEMENT; ANESTHESIOLOGISTS AB Purpose: To evaluate a new videolaryngoscope and assess its ability to provide laryngeal exposure and facilitate intubation. Methods: Five centres, involving 133 operators and a total of 728 consecutive patients, participated in the evaluation of a new videolaryngoscope [GlideScope((R)) (GS)]. Many operators had limited or no previous GS experience. We collected information about patient demographics and airway characteristics, Cormack-Lehane (C/L) views and the ease of intubation using the GS. Failure was defined as abandonment of the technique. Results: Data from six patients were incomplete and were excluded. Excellent (C/L 1) or good (C/L 2) laryngeal exposure was obtained in 92% and 7% of patients respectively. In all 133 patients in whom both GS and direct laryngoscopy (DL) were performed, GS resulted in a comparable or superior view. Among the 35 patients with C/L grade 3 or 4 views by DL, the view improved to a C/L 1 view in 24 and a C/L 2 view in three patients. Intubation with the GS was successful in 96.3% of patients. The majority of the failures occurred despite a good or excellent glottic view. Conclusions: GS laryngoscopy consistently yielded a comparable or superior glottic view compared with DL despite the limited or lack of prior experience with the device. Successful intubation was generally achieved even when DL was predicted to be moderately or considerably difficult. GS was abandoned in 3.7% of patients. This may reflect the lack of a formal protocol defining failure, limited prior experience or difficulty manipulating the endotracheal tube while viewing a monitor. C1 Toronto Gen Hosp, Dept Anesthesia, Toronto, ON M5G 2C4, Canada. Univ Toronto, Toronto, ON, Canada. Univ British Columbia, Fac Med, Saturn Biomed Syst, Vancouver, BC V5Z 1M9, Canada. Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Cooper, RM (reprint author), Toronto Gen Hosp, Dept Anesthesia & Pain Management, 200 Elizabeth St,3 EN-421, Toronto, ON M5G 2C4, Canada. EM richard.cooper@uhn.on.ca NR 23 TC 289 Z9 321 U1 2 U2 10 PU CANADIAN ANESTHESIOLOGISTS SOC PI TORONTO PA 1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA SN 0832-610X J9 CAN J ANAESTH JI Can. J. Anaesth.-J. Can. Anesth. PD FEB PY 2005 VL 52 IS 2 BP 191 EP 198 PG 8 WC Anesthesiology SC Anesthesiology GA 902JP UT WOS:000227351400015 PM 15684262 ER PT J AU Dowling, M Voong, KR Kim, M Keutmann, MK Harris, E Kao, GD AF Dowling, M Voong, KR Kim, M Keutmann, MK Harris, E Kao, GD TI Mitotic spindle checkpoint inactivation by trichostatin A defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents SO CANCER BIOLOGY & THERAPY LA English DT Article DE spindle-checkpoint; paclitaxel; microtubule disruption; trichostatin A; TSA; cell cycle ID HISTONE DEACETYLASE INHIBITORS; TUMOR-CELLS; HELA-CELLS; AURORA-B; KINETOCHORE LOCALIZATION; CHROMOSOME SEGREGATION; DEPSIPEPTIDE FR901228; H3 PHOSPHORYLATION; GENE-EXPRESSION; CENP-E AB Microtubule-disrupting agents such as the taxanes comprise some of the most clinically useful chemotherapeutic agents and invoke the spindle checkpoint in proliferating cells. A robust spindle checkpoint in turn may forestall mitotic catastrophe, potentially providing a mechanism that permits cancer cells to survive transient exposure to these drugs. Previous reports on G(2)-M cell cycle progression by histone deacetylase inhibitors suggested a potential role in modulating the therapeutic efficacy of microtubule-disrupting agents. As both classes of agents are generally administered in clinical trials as pulse treatments, we investigated in human cancer cells the effects of brief treatments with the histone deacetylase inhibitor trichostatin A (TSA) alone or with nocodazole or paclitaxel (Taxol) on cell cycle progression and the spindle checkpoint. Treatment of synchronized cells with 200 ng/ml of TSA alone for eight hours to completely block class I and II HDACs did not interfere with progression into mitosis with chromosomal condensation as confirmed by MPM-2 expression. TSA treatment at this concentration surprisingly did not interfere with formation of the mitotic spindle or centrosomal separation, but instead led to missegregation of chromosomes, suggesting effects on the spindle checkpoint. Consistent with this hypothesis, TSA abrogated the phosphorylation and kinetochore localization of the mitotic checkpoint protein BubR1 and the phosphorylation of histone H3 after paclitaxel and nocodazole treatment. These effects in turn led to rapid cell death and considerably reduced clonogenic survival. These results together suggest that by inactivating the spindle checkpoint, TSA can potentiate the lethal effects of microtubule-disrupting drugs, a strategy that might be usefully exploited for optimizing anticancer therapy. C1 Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Dept Radiat Oncol, Philadelphia, PA USA. RP Kao, GD (reprint author), Univ Penn, Sch Med, Dept Radiat Oncol, John Morgan 180 H, Philadelphia, PA 19104 USA. EM Kao@xrt.upenn.edu OI Harris, Eleanor/0000-0002-7529-7473 FU NCI NIH HHS [CA107956-01] NR 56 TC 49 Z9 54 U1 0 U2 2 PU LANDES BIOSCIENCE PI GEORGETOWN PA 810 SOUTH CHURCH STREET, GEORGETOWN, TX 78626 USA SN 1538-4047 J9 CANCER BIOL THER JI Cancer Biol. Ther. PD FEB PY 2005 VL 4 IS 2 BP 197 EP 206 PG 10 WC Oncology SC Oncology GA 957GX UT WOS:000231359400011 PM 15753652 ER PT J AU Hussein, MR AF Hussein, MR TI Alterations of p53 and Bcl-2 protein expression in the laryngeal intraepithelial neoplasia SO CANCER BIOLOGY & THERAPY LA English DT Article DE p53; Bcl-2; vocal cords ID SQUAMOUS-CELL CARCINOMA; RADIAL GROWTH-PHASE; PROGNOSTIC-SIGNIFICANCE; HUMAN-PAPILLOMAVIRUS; OVER-EXPRESSION; LESIONS; MICROSATELLITE; INSTABILITY; APOPTOSIS; MUTATION AB Background. The squamous cell carcinoma of the larynx (SCC) is a common head and neck malignancy. I hypothesize that the development of laryngeal intraepithelial neoplasia (LIN) involves alterations of tumor suppressor genes (p53) and protooncogenes (Bcl-2). Methods. To test this hypothesis, 40 vocal cord biopsy specimens were examined for p53 and Bcl-2 protein expression using immunoperoxidose staining methods and mouse monoclonal antibodies. Results. The lesions appeared as localized, flat or papillary areas with white (leukoplakic) red (erythroplakic), or gray appearance. Histologically, the lesions entailed variable associations of mild (LIN 1), moderate (LIN 11), sever dysplasia (LIN III or in situ carcinoma) and superficially invasive SCC. As compared to the normal mucosa, the average weighted immunoreactivity scores for p53 and Bcl-2 proteins showed significant upregulation with the transitions from LIN I to LIN 11 to LIN III to superficially invasive SCC, respectively (0.0 +/- 0.0, 0.0 +/- 0.0, 1.8 +/- 0.8, 2.3 +/- 0.8, 5.8 +/- 3.2, p = 0.00 for p53) and (4.4 +/- 0.4, 4.0 +/- 0.8, 6.0 +/- 2.0, 9.6 +/- 1.6 and 10.7 +/- 1.3, p = 0.00 for Bcl-2). There were insignificant positive correlation between p53 and both Bcl-2 (r = +0.8, p > 0.13) protein expression. Conclusions. Alterations of the p53 and 1362 proteins occur during the development of SCC. C1 Univ Wisconsin, Sch Med, Madison, WI 53705 USA. William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Hussein, MR (reprint author), Assiut Univ, Fac Med, Dept Pathol, Assiut, Egypt. EM mrh17@swissinfo.org NR 21 TC 11 Z9 13 U1 1 U2 1 PU LANDES BIOSCIENCE PI GEORGETOWN PA 810 SOUTH CHURCH STREET, GEORGETOWN, TX 78626 USA SN 1538-4047 J9 CANCER BIOL THER JI Cancer Biol. Ther. PD FEB PY 2005 VL 4 IS 2 BP 213 EP 217 PG 5 WC Oncology SC Oncology GA 957GX UT WOS:000231359400013 PM 15684608 ER PT J AU Gleason, CE Cholerton, B Carlsson, CM Johnson, SC Asthana, S AF Gleason, CE Cholerton, B Carlsson, CM Johnson, SC Asthana, S TI Neuroprotective effects of female sex steroids in humans: current controversies and future directions SO CELLULAR AND MOLECULAR LIFE SCIENCES LA English DT Review DE estrogen; estrogen replacement therapy; hormone replacement therapy; cognition; Alzheimers disease; postmenopausal cognition; Womens Health Initiative; prempro and premarin ID HORMONE-REPLACEMENT THERAPY; RANDOMIZED CONTROLLED-TRIAL; ESTROGEN-RECEPTOR-ALPHA; HEALTHY POSTMENOPAUSAL WOMEN; SURGICALLY MENOPAUSAL WOMEN; LONG-TERM POTENTIATION; CEREBRAL-BLOOD-FLOW; CARDIOVASCULAR RISK-FACTORS; CONJUGATED EQUINE ESTROGEN; PLASMA HOMOCYSTEINE LEVELS AB Recent findings from the Women's Health Initiative (WHI) have raised considerable concern over prolonged use of opposed and unopposed oral conjugated equine estrogen (CEE), given the increased risk of serious adverse effects, including stroke and venous thromboembolic complications. Furthermore, results from the WHI Memory Study (WHIMS) indicated that over 5 years of therapy with Prempro impaired performance on global cognitive tests and nearly doubled the risk of dementia. These surprising findings were contradictory to cumulative evidence from basic science, epidemiological and some intervention studies suggesting hormone therapy was cardioprotective and could potentially reduce the risk of dementia. This review paper focuses on the neurobiology of estrogen, summarizing the clinical evidence for neuroprotective and cognition-enhancing efficacy of estrogen. Further, the paper briefly discusses variables that may account for the unexpected findings of WHIMS, and offers suggestions for future research. C1 William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. RP Asthana, S (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,GRECC 11G, Madison, WI 53705 USA. EM ceg@medicine.wisc.edu FU NIA NIH HHS [AG 17196] NR 208 TC 33 Z9 33 U1 3 U2 6 PU SPRINGER BASEL AG PI BASEL PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND SN 1420-682X EI 1420-9071 J9 CELL MOL LIFE SCI JI Cell. Mol. Life Sci. PD FEB PY 2005 VL 62 IS 3 BP 299 EP 312 DI 10.1007/s00018-004-4385-z PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 899MW UT WOS:000227149600006 PM 15723166 ER PT J AU Siffledeen, JS Fedorak, RN Siminoski, K Jen, H Vaudan, E Abraham, N Steinhart, H Greenberg, G AF Siffledeen, JS Fedorak, RN Siminoski, K Jen, H Vaudan, E Abraham, N Steinhart, H Greenberg, G TI Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; INTERMITTENT CYCLICAL ETIDRONATE; CORTICOSTEROID-INDUCED OSTEOPOROSIS; POPULATION-BASED COHORT; POSTMENOPAUSAL OSTEOPOROSIS; ULCERATIVE-COLITIS; FRACTURE RISK; DOUBLE-BLIND; THERAPY; PREVENTION AB Background & Aims: Crohn's disease causes an increase in osteopenia and osteoporosis. This study assessed the efficacy of adding etidronate to calcium and vitamin D supplementation for treatment of low bone mineral density in Crohn's disease. Methods: One hundred fifty-four patients with Crohn's disease with decreased bone mineral density, determined by using dual-energy x-ray absorptiometry, were randomly assigned to receive etidronate (400 mg orally) or not for :14 days; both groups were then given daily calcium (500 mg) and vitamin D (400 IU) supplementation for 76 days. This cycle was repeated 8 times during a period of 24 months. Biochemical characteristics and bone mineral densities were assessed at 6, 12, and 24 months. Results: After 24 months bone mineral density significantly increased from baseline in both the etidronate- and the non-etidronate-treated groups (both groups receiving calcium and vitamin D supplementation) at the lumbar spine (P <.001), ultradistal radius (P <.001), and trochanter (P =.004) sites, but not at the total hip. The increase in bone mineral density was similar in each treatment group. No bone mineral density differences were found when groups were analyzed according to gender, corticosteroid use, bone mineral density at baseline, or age. Conclusions. Low bone mineral density is frequently associated with Crohn's disease. Supplementation with daily calcium and vitamin D is associated with increases in bone mineral density. The addition of oral etidronate does not further enhance bone mineral density. C1 Univ Alberta, Div Gastroenterol, Edmonton, AB T6G 2C8, Canada. Univ Alberta, Dept Radiol & Diagnost Imaging, Edmonton, AB T6G 2C8, Canada. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX 77030 USA. Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Div Gastroenterol, Houston, TX 77030 USA. Univ Toronto, Div Gastroenterol, Toronto, ON, Canada. RP Fedorak, RN (reprint author), Univ Alberta, Div Gastroenterol, Suite 205 Coll Plaza,8215,112 St, Edmonton, AB T6G 2C8, Canada. EM richard.fedorak@ualberta.ca RI Greenberg, Gordon/C-4620-2015 OI Fedorak, Richard/0000-0002-7382-0080 NR 59 TC 51 Z9 52 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD FEB PY 2005 VL 3 IS 2 BP 122 EP 132 DI 10.1053/S1542-3565(04)00663-9 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 993UI UT WOS:000233980200006 PM 15704046 ER PT J AU Goldstein, JL Eisen, GM Lewis, B Gralnek, IM Zlotnick, S Fort, JG AF Goldstein, JL Eisen, GM Lewis, B Gralnek, IM Zlotnick, S Fort, JG TI Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CONTROLLED-TRIAL; SUSPECTED CROHNS-DISEASE; RHEUMATOID-ARTHRITIS; CYCLOOXYGENASE-2 INHIBITOR; GASTROINTESTINAL TOXICITY; GASTRODUODENAL ULCERS; PLATELET-FUNCTION; COX-2 INHIBITOR; BLOOD-LOSS AB Background & Aims: Data indicate that cyclooxygenase2-specific inhibitors cause less gastroduodenal mucosal damage than nonspecific NSAIDS, but their effects on the small bowel mucosa are less well recognized. In a multicenter, double-blind, placebo-control led trial with video capsule endoscopy (VCE) we prospectively evaluated the incidence of small bowel injury in healthy subjects treated with celecoxib compared to naproxen plus omeprazole. Methods: We randomly assigned subjects with normal baseline VCEs to celecoxib 200 mg twice daily (n = 120), naproxen 500 mg twice daily plus omeprazole 20 mg once daily (n = 1:18), or placebo (n = 118) for 2 weeks. The primary end point was the mean number of small bowel mucosal breaks per subject. Results: Baseline VCE found small bowel lesions in :13.8% (57/4:13) of screened subjects, who became ineligible for randomization. The mean number of small bowel mucosal breaks per subject and the percentage of subjects with these mucosal breaks were 2.99 +/- 0.51, 55% for naproxen/omeprazole compared to 0.32 +/- 0.10, 16% for celecoxib and 0.11 +/- 0.04, 7% for placebo (P <.001, both comparisons). The magnitude of the difference between celecoxib and placebo was small but statistically significant (P =.04). Conclusions: Among healthy subjects with lesion-free baseline VCEs, celecoxib was associated with significantly fewer small bowel mucosal breaks than naproxen plus omeprazole. This study also showed that the background incidence of small bowel lesions in healthy adults is not insignificant and should be considered in future trials with VCE. C1 Univ Illinois, Dept Med, Chicago, IL 60612 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Mt Sinai Med Ctr, New York, NY 10029 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Pfizer Inc, Peapack, NJ USA. RP Goldstein, JL (reprint author), Univ Illinois, Dept Med, Room 1020,840 S Wood St,M-C 787, Chicago, IL 60612 USA. EM jlgoldst@uic.edu NR 39 TC 384 Z9 397 U1 2 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD FEB PY 2005 VL 3 IS 2 BP 133 EP 141 DI 10.1053/S1542-3565(04)00619-6 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 993UI UT WOS:000233980200007 PM 15704047 ER PT J AU El-Serag, HB Giordano, TP Kramer, J Richardson, P Souchek, J AF El-Serag, HB Giordano, TP Kramer, J Richardson, P Souchek, J TI Survival in hepatitis C and HIV co-infection: A cohort study of hospitalized veterans SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID GB-VIRUS-C; SEVERITY CLASSIFICATION-SYSTEM; NATIONAL DEATH INDEX; INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; NATURAL-HISTORY; LIVER-DISEASE; VITAL STATUS; MORTALITY; PROGRESSION AB Background & Aims: Previous studies reported increased morbidity and mortality related to liver disease among human immunodeficiency virus (HIV)-infected patients with hepatitis C co-infection. However, the longterm effect of hepatitis C virus (HCV) co-infection on the mortality of HIV-infected patients remains unclear. Methods: By using national Veterans Affairs (VA) databases, we performed a retrospective cohort study of HIV patients hospitalized between October :1991 and September 2000. Mortality rates and hazard rate ratios (HRRs) for mortality were calculated for the entire cohort as well as after excluding patients with pre-existing liver disease, with follow-up through September 2001 after discharge. Multivariable adjustment for differences in demographics, comorbidities, and HIV disease severity was performed. Separate analyses were performed for patients identified during the highly active antiretroviral therapy (HAART) era. Results: We identified 18,08:1 patients, of whom 5320 patients had dual HCV/HIV infection and 1.2,761 patients had HIV monoinfection. The number of deaths per 100 patient-years was 7.33 in the dual infection group and 14.13 in the HIV monoinfection group during 22,054 and 40,655 person-years of follow-up, respectively. The mortality rate ratio between HCV/HIV dual infection and HIV monoinfection was .53. In Cox multiple regression, the dual HCV/HIV infection group had an adjusted HRR for mortality of.55 compared with the HIV monoinfection group (95% Cl, .51.58, P < .0001), after controlling for age, race, sex, year of diagnosis, and HIV disease severity. These findings persisted in several sensitivity analyses. However, in the HAART era, if patients with liver disease at baseline were excluded, the HRR for mortality was .83 (95% Cl, .73-.94, P =.003). Conclusions: Co-infection with hepatitis C is associated with a significant decrease in the mortality of HIV-infected patients. However, this effect was less pronounced during the HAART era. C1 Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Houston Vet Affairs Med Ctr, Houston, TX 77030 USA. Baylor Coll Med, Gastroenterol Sect, Houston, TX 77030 USA. Baylor Coll Med, Infect Dis Sect, Houston, TX 77030 USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu FU NIMH NIH HHS [K23MH67505-01] NR 30 TC 22 Z9 22 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD FEB PY 2005 VL 3 IS 2 BP 175 EP 183 DI 10.1053/S1542-3565(04)00620-2 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 993UI UT WOS:000233980200012 PM 15704052 ER PT J AU Aspinall, SL Berlin, JA Zhang, YW Metlay, JP AF Aspinall, SL Berlin, JA Zhang, YW Metlay, JP TI Facility-level variation in antibiotic prescriptions for veterans with upper respiratory infections SO CLINICAL THERAPEUTICS LA English DT Article DE antibacterial agents; drug utilization; physician's practice patterns ID TRACT INFECTIONS; CARE PHYSICIANS; ADULTS; BRONCHITIS; TRENDS AB Background: Programs have targeted individual patient and physician behaviors to reduce the use of antibiotics for upper respiratory infections (URIs), but such efforts have had limited success to date. Objective: The aim of this study was to measure the extent of variation in antibiotic prescribing patterns at the hospital-facility level to determine whether organizational factors may be associated with patterns of antibiotic prescribing. Methods: This was a cross-sectional study using linked pharmacy and encounter data to measure hospital-level variation in patterns of antibiotic prescribing at US Department of Veterans Affairs (VA) medical centers between October 1, 2000, and September 30, 2001. The main outcome measure was the proportion of visits for URIs or acute bronchitis with an antibiotic dispensed within 1 day before to 3 days after the encounter, restricted to primary-care and emergency/urgent care clinics at VA medical centers with >= 100 annual visits for URIs. Results: A median of 523 visits for URIs occurred across 1.08 medical centers. The median proportion of visits with an antibiotic dispensed was 52% (range, 14%-88%). Hospitals in the South had increased odds of prescribing antibiotics for veterans with URIs compared with hospitals in the Northeast (odds ratio, 1.8 [95% CI, 1.2-2.5]). Among facilities with < 200,000 visits per year, an increase in the percentage of unscheduled outpatient visits increased the odds of prescribing antibiotics for veterans with URIs (odds ratio per 10% increase, 1.3 [95% CI, 1.1-1.5]). Conclusions: Our results suggest variation in antibiotic prescribing for URIs at the hospital-facility level within the VA health care system. Organizational factors, such as time pressure, may be important targets for future interventions designed to reduce inappropriate antibiotic use in ambulatory care settings. Copyright (c) 2005 Excerpta Medica, Inc. C1 Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. Vet Affairs Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Metlay, JP (reprint author), Univ Penn, Ctr Clin Epidemiol & Biostat, 712 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM metlay@cceb.med.upenn.edu NR 14 TC 5 Z9 5 U1 0 U2 0 PU EXCERPTA MEDICA INC PI NEW YORK PA 650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA SN 0149-2918 J9 CLIN THER JI Clin. Ther. PD FEB PY 2005 VL 27 IS 2 BP 258 EP 262 DI 10.1016/j.clinthera.2005.02.002 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 907BZ UT WOS:000227691400015 PM 15811491 ER PT J AU Dula, A Williams, S AF Dula, A Williams, S TI When race matters SO CLINICS IN GERIATRIC MEDICINE LA English DT Article ID CORONARY-REVASCULARIZATION PROCEDURES; SERIOUSLY ILL PATIENTS; OF-LIFE DECISIONS; HEALTH-CARE; RENAL-TRANSPLANTATION; RACIAL DISPARITIES; COMMUNICATION; ETHNICITY; PREFERENCES; ATTITUDES AB Several widely held assumptions shape end-of-life discussion in the United States. They are embedded in mainstream bioethics and biomedical discourse, debate, and discussion, as well as in the popular media. We have come to regard them as the conventional wisdom. Despite their apparent reasonableness, the assumptions are not held universally by all United States citizens, particularly, by those of color. They hold contradictions that partially explain why fewer African Americans than whites complete advance directives, and why African Americans tend to desire aggressive care at the end of life. This article considers some of these assumptions. It then considers a case and an approach to care that seeks to resolve potential conflicts proactively. C1 Univ Pittsburgh, Ctr Bioeth & Hlth Law, Pittsburgh, PA 15232 USA. Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco Vet Adm Med Ctr, San Francisco, CA USA. RP Dula, A (reprint author), Univ Pittsburgh, Ctr Bioeth & Hlth Law, 5923 Kentucky Ave, Pittsburgh, PA 15232 USA. EM dula@colorado.edu NR 46 TC 10 Z9 10 U1 3 U2 6 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD FEB PY 2005 VL 21 IS 1 BP 239 EP + DI 10.1016/j.cger.2004.10.003 PG 16 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 894UG UT WOS:000226816500018 PM 15639049 ER PT J AU Shugarman, LR Lorenz, K Lynn, J AF Shugarman, LR Lorenz, K Lynn, J TI End-of-life care: An agenda for policy improvement SO CLINICS IN GERIATRIC MEDICINE LA English DT Article ID HEALTH-CARE; HOSPICE USE; LAST YEAR; MEDICARE BENEFICIARIES; PALLIATIVE CARE; OLDER AMERICANS; REGIONAL-VARIATIONS; FAMILY CAREGIVERS; VULNERABLE ELDERS; NATIONAL HOSPICE AB Current arrangements for health care in the United States do not adequately address the needs of a growing population that has serious, eventually fatal chronic illness. New programs and policies are necessary to encourage coordination of care; better match services to the needs of patients; better provide education and incentives; and better support formal and informal caregivers. Models of end-of-life care, such as MediCaring, are described along with a research and policy agenda that focuses on modifying the health care system and building on new innovations. C1 RAND Corp, Santa Monica, CA 90407 USA. Vet Adm Greater Los Angeles Healthcare Syst, Vet Integrated Palliat Program, Los Angeles, CA 90064 USA. RAND Corp, Arlington, VA 22202 USA. Washington Home Ctr Palliat Care Studies, Washington, DC 20016 USA. RP Shugarman, LR (reprint author), RAND Corp, 1700 Main St,POB 2138, Santa Monica, CA 90407 USA. EM Lisa_Shugarman@rand.org NR 83 TC 9 Z9 9 U1 5 U2 7 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA SN 0749-0690 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD FEB PY 2005 VL 21 IS 1 BP 255 EP + DI 10.1016/j.cger.2004.08.008 PG 19 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 894UG UT WOS:000226816500019 PM 15639050 ER PT J AU Chen, Q He, Y Yang, KY AF Chen, Q He, Y Yang, KY TI Gene therapy for Parkinson's disease: Progress and challenges SO CURRENT GENE THERAPY LA English DT Review DE Parkinson's disease; gene therapy; glial cell line-derived neurotrophic factor; viral vectors; tyrosine hydroxylase; guanosine triphosphate cyclohydrolase I; glutamic acid decarboxylase; helper-dependent adenoviral vectors ID AMINO-ACID DECARBOXYLASE; ADENOASSOCIATED VIRUS VECTORS; NEUROTROPHIC FACTOR GDNF; GTP-CYCLOHYDROLASE-I; VESICULAR MONOAMINE TRANSPORTER-2; NIGROSTRIATAL DOPAMINERGIC SYSTEM; EXPRESSING TYROSINE-HYDROXYLASE; DEPENDENT ADENOVIRUS VECTOR; RECEPTOR-DEFICIENT MICE; VIRAL CODING SEQUENCES AB Therapy for Parkinson's disease (PD), a common neurological disorder characterized by pathological degeneration of the nigrostriatal dopaminergic system, remains unsatisfactory. Gene therapy is considered one of the most promising approaches to developing a novel effective treatment for PD. Among the numerous candidate genes that have been tested as therapeutic agents, those encoding tyrosine hydroxylase, guanosine triphosphate cyclohydrolase I and aromatic L-amino acid decarboxylase all boost dopamine production, while glial cell line-derived neurotrophic factor promotes the survival of dopaminergic neurons and is generally believed to possess the greatest potential for successful restoration of the dopaminergic system. The genes encoding vesicular monoamine transporter-2 and glutamic acid decarboxylase have also produced therapeutic effects in animal models of PD. Both viral and non-viral vectors, each with its particular advantages and disadvantages, have been used to deliver these genes into the brain. Whether or not regulatable expression systems are essential to successful gene therapy for PD remains a critical issue in the clinical application of this emerging treatment. Here we review the current status of gene therapy for PD, including the application of control systems for transgene expression in the brain. C1 Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA. Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. VA Med Ctr, PADRECC Neurol Care Line, Houston, TX 77030 USA. RP Chen, Q (reprint author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Pl, Houston, TX 77030 USA. EM qchen1@bcm.tmc.edu FU NINDS NIH HHS [R01-NS35502-05] NR 104 TC 26 Z9 28 U1 1 U2 4 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1566-5232 J9 CURR GENE THER JI Curr. Gene Ther. PD FEB PY 2005 VL 5 IS 1 BP 71 EP 80 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA 893KQ UT WOS:000226718200006 PM 15638712 ER PT J AU Trautner, BW Hull, RA Darouiche, RO AF Trautner, BW Hull, RA Darouiche, RO TI Prevention of catheter-associated urinary tract infection SO CURRENT OPINION IN INFECTIOUS DISEASES LA English DT Review DE biofilm; urinary catheter; urinary tract infection ID RNAIII-INHIBITING PEPTIDE; BACTERIAL BIOFILM; HOSPITALIZED-PATIENTS; RANDOMIZED-TRIAL; COLONIZATION; BIOMATERIALS; RATES; JUICE AB Purpose of review The underlying cause of catheter-associated urinary tract infection is biofilm formation by uropathogens on the urinary catheter. Biofilm is a relatively new concept in medicine, and current measures to prevent biofilm formation are inadequate. Considerable work is being done in this area, but little clinical progress has been made. The purpose of this review is to analyze recent publications concerning prevention of catheter-associated urinary tract infection. Recent findings Several recent studies have elucidated aspects of biofilm formation in catheter-associated urinary tract infection. Other researchers are working on methods to disrupt biofilm formation on catheter surfaces. At the same time, the magnitude of the problem of catheter-associated urinary tract infection has increased awareness of the effectiveness of basic infection control measures. A modern approach to infection control may include computerized ordering systems that minimize unnecessary days of catheterization. Finally, consumption of cranberry juice products and bacterial interference are two novel approaches to urinary tract infection prevention. Summary Biofilm-disrupting strategies offer promise for the future but have little immediate applicability. Implementation of infection control measures to improve catheter function and remove unnecessary catheters can be done at the present time. In general, prevention of catheter-associated urinary tract infection remains an elusive goal. More basic research at the level of pathogenesis is needed so that novel strategies can be designed. C1 Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Infect Dis Sect, Houston, TX USA. Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. Michael E DeBakey Vet Affairs Med Ctr, Ctr Prostheses Infect, Dept Phys Med & Rehabil, Houston, TX USA. RP Trautner, BW (reprint author), MEDVAMC, 128,2002 Holcombe Blvd, Houston, TX 77030 USA. EM trautner@bcm.tmc.edu FU NICHD NIH HHS [HD42014, K23 HD042014, K23 HD042014-01, K23 HD042014-02, K23 HD042014-03, K23 HD042014-04] NR 44 TC 43 Z9 50 U1 1 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7375 J9 CURR OPIN INFECT DIS JI Curr. Opin. Infect. Dis. PD FEB PY 2005 VL 18 IS 1 BP 37 EP 41 DI 10.1097/00001432-200502000-00007 PG 5 WC Infectious Diseases SC Infectious Diseases GA 900QC UT WOS:000227228400006 PM 15647698 ER PT J AU Carr, DB Utzschneider, KM Boyko, EJ Asberry, PJ Hull, RL Kodama, K Callahan, HS Matthys, CC Leonetti, DL Schwartz, RS Kahn, SE Fujimoto, WY AF Carr, DB Utzschneider, KM Boyko, EJ Asberry, PJ Hull, RL Kodama, K Callahan, HS Matthys, CC Leonetti, DL Schwartz, RS Kahn, SE Fujimoto, WY TI A reduced-fat diet and aerobic exercise in Japanese Americans with impaired glucose tolerance decreases intra-abdominal fat and improves insulin sensitivity but not beta-cell function SO DIABETES LA English DT Article ID TYPE-2 DIABETES-MELLITUS; RANDOMIZED CONTROLLED TRIAL; WEIGHT-LOSS; LIFE-STYLE; BODY-FAT; OLDER MEN; NATURAL-HISTORY; BASE-LINE; FOLLOW-UP; PREVENTION AB Lifestyle modification reduces the risk of developing type 2 diabetes and may have its effect through improving insulin sensitivity, P-cell function, or both. To determine whether diet and exercise improve insulin sensitivity and/or beta-cell function and to evaluate these effects over time, we quantified insulin sensitivity and the acute insulin response to glucose (AIRg) in 62 Japanese Americans (age 56.5 +/- 1.3 years; mean +/- SE) with impaired glucose tolerance (IGT) who were randomized to the American Heart Association (AHA) Step 2 diet plus endurance exercise (n = 30) versus the AHA Step 1 diet plus stretching (n = 32) for 24 months. P-Cell function (disposition index [DI]) was calculated as S-i x AIRg, where Si is the insulin sensitivity index. The incremental area under the curve for glucose (incAUCg) was calculated from a 75-g oral glucose tolerance test. Intra-abdominal fat (IAF) and subcutaneous fat (SCF) areas were measured by computed tomography. At 24 months, the Step 2/endurance group had lower weight (63.1 +/- 2.4 vs. 71.3 +/- 2.9 kg; P = 0.004) and IAF (75.0 +/- 7.9 vs. 112.7 +/- 10.4 cm(2); P = 0.03) and SCF (196.5 +/- 18.0 vs. 227.7 +/- 19.9 cm(2); p < 0.001) areas, greater Si (4.7 +/- 0.5 vs. 3.3 +/- 0.3 x 10(-5) min (.) pmol(-1) (.) 1(-1); P = 0.01), and a trend toward lower AIRg (294.9 +/- 50.0 vs. 305.4 +/- 30.0 pmol/l; P = 0.06) and incAUCg (8,217.3 +/- 350.7 vs. 8,902.0 +/- 367.2 mg (.) dl(-1 .) 2 h(-1); P = 0.08) compared with the Step 1/stretching group after adjusting for baseline values. There was no difference in the DI (P = 0.7) between the groups. Si was associated with changes in weight (r = -0.426, P = 0.001) and IAF (r = -0.395, P = 0.003) and SCF (r = -0.341, P = 0.01) areas. Thus, the lifestyle modifications decreased weight and central adiposity and improved insulin sensitivity in Japanese Americans with IGT. However, such changes did not improve P-cell function, suggesting that this degree of lifestyle modifications may be limited in preventing type 2 diabetes over the long term. C1 Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA. Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Univ Washington, Epidemiol Res & Informat Ctr, Seattle, WA 98195 USA. Gen Clin Res Ctr, Seattle, WA USA. Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. RP Carr, DB (reprint author), Univ Washington, Dept Obstet & Gynecol, Box 356460, Seattle, WA 98195 USA. EM darcarr@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X FU NCRR NIH HHS [RR-00037, RR-16066]; NIDDK NIH HHS [DK-35816, DK-02654, DK-17047, DK-48152] NR 44 TC 36 Z9 37 U1 2 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 J9 DIABETES JI Diabetes PD FEB PY 2005 VL 54 IS 2 BP 340 EP 347 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 891XD UT WOS:000226613400006 PM 15677490 ER PT J AU Cruciani, M Mengoli, C Lipsky, BA De Lalla, F AF Cruciani, M Mengoli, C Lipsky, BA De Lalla, F TI Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections? A meta-analysis SO DIABETES CARE LA English DT Article ID CONTROLLED-TRIAL; CLINICAL-TRIALS; ADJUNCTIVE THERAPY; MELLITUS; ULCERS; BIAS; NEUTROPHILS; FILGRASTIM; DISEASE AB OBJECTIVE - To assess the value of granulocyte colony-stimulating factor (G-CSF) as adjunctive therapy for diabetic foot infections. RESEARCH DESIGN AND METHODS - We systematically searched the medical literature (including Medline, Embase, LookSmart, and the Cochrane Library) for prospective randomized studies that used G-CSF as an adjunct to standard treatment for diabetic foot infections. Using a conventional meta-analysis, we pooled the relative risks (RRs) for Outcomes of interest, including, resolution of infection, wound healing, duration of antibiotic therapy, and 0 need for various surgical interventions, using a fixed-effects model. RESULTS - Five randomized trials, With a total of 167 patients, met our inclusion criteria. The Methodological quality of the Studies was satisfactory. The investigators administered various G-CSF preparations parenterally for between 3 and 21 days. The meta-analysis revealed that adding G-CSF did not significantly affect the resolution of infection or the healing of the wounds but was associated with a significantly reduced likelihood of lower extremity surgical interventions (RR 0.38 [95% CI 0.20-0.69], number of patients who needed to be treated 4.5), including amputation (0.41 [0.17-0.95], number of patients who needed to be treated: 8.6). There was no evidence of heterogeneity among the Studies or of publication bias, Suggesting that these conclusions are reasonably generalizable and robust. CONCLUSIONS - Adjunctive G-CSF treatment does not appear to hasten the clinical resolution of diabetic foot infection or ulceration but is associated with a reduced rate of amputation and other surgical procedures. The small number of patients who needed to be treated to gain these benefits suggests that using G-CSF should be considered, especially in patients with limb-threatening infections. C1 Univ Washington, Sch Med, Gen Internal Med Clin, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Ctr Prevent Med, Verona, Italy. Univ Padua, Dept Histol, Padua, Italy. Univ Padua, Dept Microbiol, Padua, Italy. Univ Padua, Dept Med Biotechnol, Padua, Italy. San Bortolo Hosp, Dept Infect Dis & Trop Med, Vicenza, Italy. RP Lipsky, BA (reprint author), Univ Washington, Sch Med, Gen Internal Med Clin, VA Puget Sound Hlth Care Syst, S-111-G1MC,1660 S Columbian Way, Seattle, WA 98108 USA. EM benjamin.lipsky@med.va.gov RI Lipsky, Benjamin/B-4645-2013 OI Lipsky, Benjamin A./0000-0001-9886-5114; Mengoli, Carlo/0000-0002-7422-0554 NR 53 TC 41 Z9 45 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2005 VL 28 IS 2 BP 454 EP 460 DI 10.2337/diacare.28.2.454 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 891WY UT WOS:000226612900045 PM 15677817 ER PT J AU Karsan, HA Morton, SC Shekelle, PG Spiegel, BMR Suttorp, MJ Edelstein, MA Gralnek, IM AF Karsan, HA Morton, SC Shekelle, PG Spiegel, BMR Suttorp, MJ Edelstein, MA Gralnek, IM TI Combination endoscopic band ligation and sclerotherapy compared with endoscopic band ligation alone for the secondary prophylaxis of esophageal variceal hemorrhage: A meta-analysis SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE meta-analysis; esophageal variceal hemorrhage; Health Services Research ID RANDOMIZED-TRIAL; CLINICAL-TRIALS; MULTICENTER; BIAS AB Endoscopic band ligation (EBL) is the community-accepted standard therapy for the secondary prophylaxis of esophageal variceal hemorrhage. Recent data indicate that combination EBL and sclerotherapy may be a more effective therapy than EBL alone. Yet existing data are conflicting. We therefore performed a meta-analysis to compare the efficacy and safety of EBL and sclerotherapy versus EBL alone for the secondary prophylaxis of esophageal variceal hemorrhage. We performed a systematic review of two computerized databases (MEDLINE and EMBASE) along with manual-searching of published abstracts to identify relevant citations without language restrictions from 1990 to 2002. Eight studies met explicit inclusion criteria. We performed meta-analysis of these studies to pool the relative risk for the following outcomes: esophageal variceal rebleeding, death, number of endoscopic sessions to achieve variceal obliteration, and therapeutic complications. There were no significant differences between EBL and sclerotherapy versus EBL alone in the risk of esophageal variceal rebleeding (RR = 1.05; 95% CI = 0.67-1.64; P = 0.83), death (RR = 0.99; 95% CI = 0.68-1.44; P = 0.96), or number of endoscopic sessions to variceal obliteration (RR = 0.23; 95% CI = 0.055-0.51; P = 0.11). However, the incidence of esophageal stricture formation was significantly higher in the EBL group than in the sclerotherapy group. There is no evidence that the addition of sclerotherapy to endoscopic band ligation changes clinically relevant outcomes (variceal rebleeding, death, time to variceal obliteration) in the secondary prophylaxis of esophageal variceal hemorrhage. Moreover, combination EBL and sclerotherapy had more esophageal stricture formation than EBL alone. C1 VA Greater Los Angeles Healthcare Syst, Div Gastroenterol & Hepatol, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med Hlth Serv Res, Los Angeles, CA USA. Univ Calif Los Angeles, Ctr Hlth Sci, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90024 USA. RAND Hlth, Los Angeles, CA USA. CURE Digest Dis Res Ctr, Los Angeles, CA USA. Ctr Study Digest Healthcare Qual & Outcomes, Los Angeles, CA USA. So Calif Evidence Based Practice Ctr, Los Angeles, CA USA. RP Gralnek, IM (reprint author), Univ Calif Los Angeles, CURE Digest Dis Res Ctr,David Geffen Sch Med, Ctr Study Digest Healthcare Qual & Outcomes, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 115,Room 215B, Los Angeles, CA 90073 USA. EM igralnek@mednet.ucla.edu FU NIDDK NIH HHS [DK-07180] NR 27 TC 37 Z9 39 U1 0 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD FEB PY 2005 VL 50 IS 2 BP 399 EP 406 DI 10.1007/s10620-005-1618-9 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 896YG UT WOS:000226969900034 PM 15745108 ER PT J AU Street, KA Xu, G Hall, KL Intano, GW McCarrey, J Herbert, DC Kilimann, MW Walter, CA AF Street, KA Xu, G Hall, KL Intano, GW McCarrey, J Herbert, DC Kilimann, MW Walter, CA TI Rat synapsin 1 promoter mediated transgene expression in testicular cell types SO DNA AND CELL BIOLOGY LA English DT Article ID NERVE GROWTH-FACTOR; SPERMATOGENIC CELLS; I GENE; MORPHOLOGICAL CHARACTERIZATION; LEYDIG-CELLS; DNA; MOUSE; MICE; ESTABLISHMENT; REGION AB Previous reports described the rat synapsin 1 promoter as primarily neuron selective. However, ectopic expression of a transgene under the rat synapsin 1 promoter was also detected in testis from some transgenic mouse lines. Here we investigate which cells within the testis express a transgene consisting of the rat synapsin 1 promoter fused with luciferase. Synapsin 1-luciferase expression vectors were introduced into HeLa cells, into TM3 cells derived from mouse testicular Leydig cells, and into one-cell embryos to make transgenic mice. Indirect immunofluorescence suggests that nontransfected TM3 cells do not express endogenous synapsin 1. TM3 stable transfectants, however, expressed luciferase under the direction of the synapsin 1 promoter, in both promoter orientations. HeLa cells displayed only low levels of activity. Transgenic mice carrying the synapsin 1-luciferase construct displayed high levels of luciferase activity in the brain, spinal cord, and testis. Enriched populations of prepuberal types A and B spermatogonia and adult Leydig cells, pachytene spermatocytes, and round spermatids prepared from transgenic mice all displayed substantial luciferase activity. Thus, the rat synapsin 1 promoter can mediate reporter gene expression in neurons and testicular cell types. C1 Univ Texas, Hlth Sci Ctr, Dept C&SB, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, Barshop Ctr Longev & Aging Studies, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr, San Antonio Canc Inst, San Antonio, TX 78229 USA. Univ Texas, Dept Biol, San Antonio, TX 78285 USA. Ruhr Univ Bochum, Inst Physiol Chem, D-4630 Bochum, Germany. Uppsala Univ, Dept Cell & Mol Biol, Uppsala, Sweden. S Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Walter, CA (reprint author), Univ Texas, Hlth Sci Ctr, Dept C&SB, Mail Code 7762,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM walter@uthscsa.edu FU NIA NIH HHS [AG14674, AG19316, AG13560, AG21163]; NIEHS NIH HHS [ES09136] NR 35 TC 6 Z9 6 U1 0 U2 0 PU MARY ANN LIEBERT INC PI LARCHMONT PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA SN 1044-5498 J9 DNA CELL BIOL JI DNA Cell Biol. PD FEB PY 2005 VL 24 IS 2 BP 133 EP 140 DI 10.1089/dna.2005.24.133 PG 8 WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity GA 895CX UT WOS:000226839600007 PM 15699633 ER PT J AU Warden, SJ Robling, AG Sanders, MS Bliziotes, MM Turner, CH AF Warden, SJ Robling, AG Sanders, MS Bliziotes, MM Turner, CH TI Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth SO ENDOCRINOLOGY LA English DT Article ID REUPTAKE INHIBITORS; MICE LACKING; TRICYCLIC ANTIDEPRESSANTS; TARGETED DISRUPTION; MAJOR DEPRESSION; MINERAL DENSITY; OLDER WOMEN; FLUOXETINE; CHILDREN; RISK AB Selective serotonin-reuptake inhibitors (SSRIs) antagonize the serotonin (5-hydroxytryptamine) transporter (5-HTT), and are frequently prescribed to children and adolescents to treat depression. However, recent findings of functional serotonergic pathways in bone cells and preliminary clinical evidence demonstrating detrimental effects of SSRIs on bone growth have raised questions regarding the effects of these drugs on the growing skeleton. The current work investigated the impact of 5-HTT inhibition on the skeleton in: 1) mice with a null mutation in the gene encoding for the 5-HTT; and 2) growing mice treated with a SSRI. In both models, 5-HTT inhibition had significant detrimental effects on bone mineral accrual. 5-HTT null mutant mice had a consistent skeletal phenotype of reduced mass, altered architecture, and inferior mechanical properties, whereas bone mineral accrual was impaired in growing mice treated with a SSRI. These phenotypes resulted from a reduction in bone formation without an increase in bone resorption and were not influenced by effects on skeletal mechanosensitivity or serum biochemistries. These findings indicate a role for the 5-HTT in the regulation of bone accrual in the growing skeleton and point to a need for further research into the prescription of SSRIs to children and adolescents. C1 Indiana Univ, Sch Hlth & Rehabil Sci, Dept Phys Therapy, Indianapolis, IN 46202 USA. Indiana Univ, Sch Med, Dept Orthopaed Surg, Indianapolis, IN USA. Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN USA. Indiana Univ, Sch Med, Biomech & Biomat Res Ctr, Indianapolis, IN USA. Portland Vet Affairs Med Ctr, Portland, OR 97201 USA. Oregon Hlth & Sci Univ, Portland, OR 97239 USA. RP Warden, SJ (reprint author), Indiana Univ, Sch Hlth & Rehabil Sci, Dept Phys Therapy, 1140 W Michigan St,CF-326, Indianapolis, IN 46202 USA. EM stwarden@iupui.edu RI Warden, Stuart/C-5287-2012 OI Warden, Stuart/0000-0002-6415-4936 FU NIAMS NIH HHS [AR-45218 (P01), AR-46530 (R01)] NR 57 TC 129 Z9 136 U1 2 U2 4 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD FEB PY 2005 VL 146 IS 2 BP 685 EP 693 DI 10.1210/en.2004-1259 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 887HA UT WOS:000226295300019 PM 15539550 ER PT J AU Liu, YY Brent, GA AF Liu, YY Brent, GA TI Thyroid hormone-dependent gene expression in differentiated embryonic stem cells and embryonal carcinoma cells: Identification of novel thyroid hormone target genes by deoxyribonucleic acid microarray analysis SO ENDOCRINOLOGY LA English DT Article ID DOMINANT-NEGATIVE MUTATION; RNA-BINDING PROTEIN; KINASE-IV GENE; BRAIN-DEVELOPMENT; RECEPTOR-BETA; POSTNATAL-DEVELOPMENT; FUNCTIONAL-PROPERTIES; RETINOIC ACID; IN-VITRO; ALPHA AB T-3 is required for normal early development, but relatively few T-3-responsive target genes have been identified. In general, in vitro stem cell differentiation techniques stimulate a wide range of developmental programs, including thyroid hormone receptor (TR) pathways. We developed several in vitro stem cell models to more specifically identify TR-mediated gene expression in early development. We found that embryonic carcinoma (EC) cells have reduced T-3 nuclear binding capacity and only modestly express the known T-3 target genes, neurogranin (RC3) and Ca2+/calmodulin-dependent protein kinase IV (CaMKIV), in response to T-3. Full T-3 induction in transient transfection of EC cells was restored with cotransfection of a TR expression vector. We, therefore, performed gene expression profiles in wild-type embryonic stem (ES) cells compared with expression in cells with deficient (EC) or mutant TR (TRalpha P398H mutant ES cells), to identify T-3 target genes. T-3 stimulation of wild-type ES cells altered mRNA expression of 610 known genes (26% of those studied), although only approximately 60 genes (1%) met criteria for direct T-3 stimulation based on the magnitude of induction and requirement for the presence of TR. We selected five candidate T-3 target genes, neurexophilin 2, spermatid perinuclear RNA-binding protein (SPNR), kallikrein-binding protein (KBP), prostate-specific membrane antigen ( PSMA), and synaptotagmin II, for more detailed study. T-3 responsiveness of these genes was evaluated in both in vitro endogenous gene expression and in vivo mouse model systems. These genes identified in a novel stem cell system, including those induced and repressed in response to T-3, may mediate thyroid hormone actions in early development. C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, David Geffen Sch Med, Mol Endocrinol Lab, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Mol Endocrinol Lab, Dept Physiol, Los Angeles, CA USA. RP Brent, GA (reprint author), VA Greater Los Angeles Healthcare Syst, Bldg 114,Room 230,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM gbrent@ucla.edu FU NIDDK NIH HHS [R01DK67233] NR 50 TC 10 Z9 12 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD FEB PY 2005 VL 146 IS 2 BP 776 EP 783 DI 10.1210/en.2004-1177 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 887HA UT WOS:000226295300029 PM 15550503 ER PT J AU Overduin, J Frayo, RS Grill, HJ Kaplan, JM Cummings, DE AF Overduin, J Frayo, RS Grill, HJ Kaplan, JM Cummings, DE TI Role of the duodenum and macronutrient type in ghrelin regulation SO ENDOCRINOLOGY LA English DT Article ID CIRCULATING GHRELIN; FOOD-INTAKE; GASTRIC BYPASS; WEIGHT-LOSS; ACYLATED PEPTIDE; ACTIVE FORM; BODY-WEIGHT; SHORT-TERM; SECRETION; HORMONE AB The orexigenic hormone ghrelin is implicated in preprandial hunger and meal initiation in part because circulating levels increase before meals and decrease after food intake. The mechanisms underlying postprandial ghrelin suppression are unknown. Although most ghrelin is produced by the stomach, we have shown that neither gastric nutrients nor gastric distension affect ghrelin levels. We hypothesized that the nutrient-sensing mechanism regulating ghrelin is in the duodenum, the second richest source of ghrelin. To test whether duodenal nutrient exposure is required for ghrelin suppression, we infused nutrients into either the proximal duodenum or proximal jejunum in rats bearing chronic intestinal cannulas. At 0, 30, 60, 90, 120, 180, 240, and 300 min after infusions, blood was sampled via jugular-vein catheters for ghrelin, insulin, and glucose measurements. To elucidate further the mechanisms governing nutrient-related ghrelin suppression, we also assessed the ghrelin responses to isocaloric (3 kcal) infusions of glucose, amino acids, or lipids delivered into the stomach or small intestine of chronically catheterized rats. Regardless of macronutrient type, the depth and duration of ghrelin suppression were equivalent after gastric, duodenal, and jejunal infusions. Glucose and amino acids suppressed ghrelin more rapidly and strongly (by similar to70%) than did lipids (by similar to50%). Because jejunal nutrient infusions suppressed ghrelin levels as well as either gastric or duodenal infusions, we conclude that the inhibitory signals mediating postprandial ghrelin suppression are not derived discretely from either the stomach or duodenum. The relatively weak suppression of ghrelin by lipids compared with glucose or amino acids could represent one mechanism promoting high-fat dietary weight gain. C1 Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA. Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA. RP Cummings, DE (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Dept Med, Div Metab Endocrinol & Nutr, 1660 S Columbian Way,S-111 Endo, Seattle, WA 98108 USA. EM davidec@u.washington.edu FU NIDDK NIH HHS [R01 DK61516] NR 46 TC 114 Z9 121 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 J9 ENDOCRINOLOGY JI Endocrinology PD FEB PY 2005 VL 146 IS 2 BP 845 EP 850 DI 10.1210/en.2004-0609 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 887HA UT WOS:000226295300037 PM 15528308 ER PT J AU Jha, SK Brennan, FX Pawlyk, AC Ross, RJ Morrison, AR AF Jha, SK Brennan, FX Pawlyk, AC Ross, RJ Morrison, AR TI REM sleep: a sensitive index of fear conditioning in rats SO EUROPEAN JOURNAL OF NEUROSCIENCE LA English DT Article DE fear conditioning; post-traumatic stress disorder; REM sleep; Sprague-Dawley rats; unpaired control ID POSTTRAUMATIC-STRESS-DISORDER; EYE-MOVEMENT SLEEP; AMYGDALA; DISTURBANCE; ANXIETY; NUCLEUS; BRAIN AB To examine the influence of conditioned fear stimuli on sleep-wake states, we recorded sleep in Sprague-Dawley rats after exposure to tones previously paired with footshock. After habituation to a recording chamber and the recording procedure, a baseline sleep recording was obtained the next day. One day later, experimental animals were exposed to shock training designed to induce conditioned fear (FC), consisting of five tone-footshock pairings. The 5-s tones (conditioned stimuli; CS) co-terminated with 1-s footshocks (unconditioned stimuli; US). The next day sleep was recorded for 4 h in the recording chamber after presentation of five CSs alone. Sleep efficiency (total sleep time/recording period) and REM sleep (REM) and non-REM (NREM) measures were determined. While sleep efficiency was not significantly changed after CS presentation, the percentage of total sleep time spent in REM (REM percentage) was reduced in the FC animals. The reduction in REM percentage in the FC animals was due to a decrease in the number of REM bouts. In a separate experiment, we repeated the procedures, except the tones and shocks were presented in an explicitly unpaired (UP) fashion. The next day, presentation of the tones increased REM percentage in the UP group. Results are discussed in terms of the decreases in REM as a response to conditioned fear, and the relevance of these findings to the sleep changes seen in post-traumatic stress disorder (PTSD). C1 Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Med Res Serv 151, Philadelphia, PA USA. Univ Penn, Sch Vet Med, Dept Anim Biol, Lab Study Brain Sleep, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Ctr Sleep & Resp Neurobiol, Philadelphia, PA 19104 USA. RP Morrison, AR (reprint author), Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. EM armsleep@vet.upenn.edu OI Jha, Sushil/0000-0001-8638-898X FU NHLBI NIH HHS [HL007953]; NIMH NIH HHS [MH42903] NR 17 TC 45 Z9 46 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0953-816X J9 EUR J NEUROSCI JI Eur. J. Neurosci. PD FEB PY 2005 VL 21 IS 4 BP 1077 EP 1080 DI 10.1111/j.1460-9568.2005.03920.x PG 4 WC Neurosciences SC Neurosciences & Neurology GA 906OX UT WOS:000227652600023 PM 15787712 ER PT J AU Cui, ZR Lockman, PR Atwood, CS Hsu, CH Gupte, A Allen, DD Mumper, RJ AF Cui, ZR Lockman, PR Atwood, CS Hsu, CH Gupte, A Allen, DD Mumper, RJ TI Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS LA English DT Article DE Wilson's disease; Alzheimer's disease; metal chelation; beta-amyloid; copper; aggregates; resolubilization ID ENHANCED IMMUNE-RESPONSES; AMYLOID-BETA; COATED NANOPARTICLES; MICROEMULSION PRECURSORS; CELL UPTAKE; IN-VITRO; COPPER; ZINC; PARAMETERS; FRAGMENTS AB Metal ions accumulate in the brain with aging and in several neurodegenerative diseases. Aside from the copper storage disease, Wilson's disease, recent attention has focused on the accumulation of zinc, copper and iron in the Alzheimer's disease (AD) brain and the accumulation of iron in Parkinson's disease. In particular, the parenchymal deposition of beta-amyloid (Abeta) and its interaction with metal ions has been postulated to play a role in the progression of AD. Thus, the strategy of lowering brain metal ions and targeting the interaction of Abeta peptide and metal ions through the administration of chelators has merit. Our recent finding that nanoparticle delivery systems can cross the blood-brain barrier has led us to investigate whether chelators delivered conjugated to nanoparticles could act to reverse metal ion induced protein precipitation. In the present studies, the Cu (I) chelator D-penicillamine was covalently conjugated to nanoparticles via a disulfide bond or a thioether bond. Nanoparticle-chelator conjugates were stable between pH 6-8 in aqueous suspension if stored at 4 degreesC, and did not aggregate when challenged with salts and serum. Release Of D-penicillamine from the nanoparicles was achieved using reducing agents such as dithiothreitol (as a model for glutathione). Nanoparticles treated only under reducing conditions that released the conjugated D-penicillamine were able to effectively resolubilize copper-Abeta (1-42) aggregates. These results indicate that nanoparticles have potential to deliver D-penicillamine to the brain for the prevention of AD (1-42) accumulation, as well as to reduce metal ion accumulation in other CNS diseases. (C) 2004 Elsevier B.V. All rights reserved. C1 Univ Kentucky, Coll Pharm, Ctr Pharmaceut Sci & Technol, Dept Pharmaceut Sci, Lexington, KY 40536 USA. Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX USA. Univ Wisconsin, Dept Med, Madison, WI USA. William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA. Edith Cowan Univ, Grad Biomed & Sports Sci, Ctr Aging & Alzheimers Dis, Joondalup, WA, Australia. RP Mumper, RJ (reprint author), Univ Kentucky, Coll Pharm, Ctr Pharmaceut Sci & Technol, Dept Pharmaceut Sci, 725 Rose St, Lexington, KY 40536 USA. EM rjmump2@email.uky.edu NR 38 TC 87 Z9 92 U1 2 U2 28 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0939-6411 J9 EUR J PHARM BIOPHARM JI Eur. J. Pharm. Biopharm. PD FEB PY 2005 VL 59 IS 2 BP 263 EP 272 DI 10.1016/j.ejpb.2004.07.009 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 895WI UT WOS:000226894300002 PM 15661498 ER PT J AU Dulai, GS Jensen, DM Cortina, G Fontana, L Ippoliti, A AF Dulai, GS Jensen, DM Cortina, G Fontana, L Ippoliti, A TI Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus SO GASTROINTESTINAL ENDOSCOPY LA English DT Article; Proceedings Paper CT Annual Scientific Meeting of the American-Society-for-Gastronintestinal-Endoscopy CY MAY 19-23, 2002 CL San Francisco, CA SP Amer Soc Gastrointestinal Endoscopy ID HIGH-GRADE DYSPLASIA; ACID SUPPRESSION; ENDOSCOPIC REVERSAL; SQUAMOUS EPITHELIUM; ANTIREFLUX SURGERY; FOLLOW-UP; THERAPY; RESTORATION; ERADICATION; RECURRENCE AB Background: Endoscopic ablation of Barrett's esophagus has been described in which various thermocoagulation modalities are used in combination with a high dose of a proton pump inhibitor. No randomized comparison of ablation strategies has been published. Methods: Referred patients were screened to identify those with Barrett's esophagus 2 to 7 cm in length, without high-grade dysplasia or cancer. Included patients received pantoprazole (40 mg twice a day), followed by randomization to treatment with argon plasma coagulation (APC) or multipolar electrocoagulation (MPEC). T e primary outcome measure was the number of treatment sessions required for endoscopic ablation. Results: Of 235 patients screened, 52 were randomized. The mean length of Barrett's esophagus was 3.1 cm in the MPEC group vs. 4.0 cm in the APC group (p = 0.03). Otherwise, the treatment groups were similar with regard to baseline characteristics. The mean number of treatment sessions required for endoscopic ablation was 2.9 for MPEC vs. 3.8 for APC (p = 0.04) in an intention-to-treat analysis (p = 0.249, after adjustment for the difference in length of Barrett's esophagus). The proportion of patients in which ablation was endoscopically achieved proximal to the gastroesophageal junction was 88% for the MPEC group vs. 81% for the APC group (p = 0.68) and histologically achieved in 81% for MPEC vs. 65% for APC (p = 0.21). The mean time required for the first treatment session was 6 minutes with MPEC vs. 10 minutes with APC (p = 0.01.) in per protocol analysis. There was no serious adverse event, but transient moderate to severe upper-GI symptoms occurred after MPEC in 8% vs. 13% after APC (p = 0.64). Conclusions: Although there were no statistically significant differences, ablation of Barrett's esophagus with pantoprazole and MPEC required numerically fewer treatment sessions, and endoscopic and histologic ablation was achieved in a greater proportion of patients compared with treatment with pantoprazole and APC. C1 Univ Calif Los Angeles, Sch Med,Ctr Study Digest Healthcare Qual & Outcom, CURE Digest Dis Res Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Dulai, GS (reprint author), Univ Calif Los Angeles, Sch Med,Ctr Study Digest Healthcare Qual & Outcom, CURE Digest Dis Res Ctr, VA Greater Los Angeles Healthcare Syst, Bldg 115,Rm 215C,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. FU NCRR NIH HHS [M01-RR0865, K23 RR 1618801]; NIDDK NIH HHS [DK 41301, K24 DK 02650] NR 29 TC 74 Z9 78 U1 0 U2 2 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD FEB PY 2005 VL 61 IS 2 BP 232 EP 240 AR PII S0016-5107904)02576-2 DI 10.1016/S0016-5107(04)02576-3 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 900SH UT WOS:000227234100008 PM 15729231 ER PT J AU Dziak, K Anderson, R Sevick, MA Weisman, CS Levine, DW Scholle, SH AF Dziak, K Anderson, R Sevick, MA Weisman, CS Levine, DW Scholle, SH TI Variations among Institutional Review Board reviews in a multisite health services research study SO HEALTH SERVICES RESEARCH LA English DT Review DE Institutional Review Boards; health services research; privacy rule ID CARE; QUALITY; PARTICIPATION; DECISIONS; TRIAL AB Objective. To document the Institutional Review Board (IRB) review process and to explore the impact of different patient notification procedures. Data Sources/Study Setting. Review of IRB application and correspondence records prospectively collected during a multisite study of health care quality involving telephone interviews of 3,000 participants across 15 primary care sites. Study Design. Records were reviewed to ascertain: (1) the type of IRB review conducted, (2) the number of days from submission to approval of the IRB application, (3) whether the IRB required patient notification and/or consent prior to the release of names, and (4) patient participation rates. Data Collection/Extraction Methods. The study coordinating center prepared a common study protocol for IRB submission and assisted sites with submission. The application, correspondence with the IRB, consent script, and patient letters were collected, reviewed, coded, and analyzed. Principal Findings. IRBs at the 15 sites and survey center varied in the type of IRB required and the number of days from submission to approval (range of 5-172 days). Four sites required patient notification in advance of the study; 2-11 percent of patients refused in opt-out sites and 37 percent in the single opt-in site. Participation among contacted patients did not appear to be related to patient notification procedures. Conclusions. Variations in IRB requirements can affect response rates and sample generalizability. C1 Natl Comm Qual Assurance, Res & Anal, Washington, DC 20036 USA. Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. Univ Pittsburgh, Sch Publ Hlth, Pittsburgh, PA 15260 USA. Wake Forest Univ, Sch Med, Publ Hlth Serv, Winston Salem, NC 27109 USA. Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15260 USA. VA Pittsburgh Hlth Care Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. Penn State Coll Med, University Pk, PA USA. Univ S Carolina, PFRC, Columbia, SC 29208 USA. RP Scholle, SH (reprint author), Natl Comm Qual Assurance, Res & Anal, 2000 L St NW,Suite 500, Washington, DC 20036 USA. NR 26 TC 64 Z9 64 U1 1 U2 5 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD FEB PY 2005 VL 40 IS 1 BP 279 EP 290 DI 10.1111/j.1475-6773.2005.00353.x PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 893UB UT WOS:000226743700016 PM 15663713 ER PT J AU Messmore, HL Jeske, WP Wehrmacher, W Coyne, E Mobarhan, S Cho, L Leya, FS Moran, JF AF Messmore, HL Jeske, WP Wehrmacher, W Coyne, E Mobarhan, S Cho, L Leya, FS Moran, JF TI Antiplatelet agents: Current drugs and future trends SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Review ID PERCUTANEOUS CORONARY INTERVENTION; GLYCOPROTEIN-IIB/IIIA BLOCKADE; RANDOMIZED CONTROLLED-TRIAL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PLATELET-SUBENDOTHELIUM INTERACTION; HEPARIN-INDUCED THROMBOCYTOPENIA; PRACTICE GUIDELINES COMMITTEE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ACUTE MYOCARDIAL-INFARCTION; ACTIVATED HUMAN PLATELETS AB Antiplatelet drugs in clinical use are discussed in terms of their mechanisms of action and the relevancy of that to the physiology of platelets and the pathophysiology of arterial thrombosis. Current clinical usage is outlined in detail for each drug. Experimental antiplatelet drugs also are discussed. C1 US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. Loyola Univ, Stritch Sch Med, Med Ctr, Ctr Canc, Maywood, IL 60153 USA. Loyola Univ, Stritch Sch Med, Cardiovasc Inst, Med Ctr, Maywood, IL 60153 USA. Loyola Univ, Stritch Sch Med, Med Ctr, Dept Physiol, Maywood, IL 60153 USA. Loyola Univ, Stritch Sch Med, Med Ctr, Dept Gastroenterol, Maywood, IL 60153 USA. Loyola Univ, Stritch Sch Med, Med Ctr, Div Cardiol, Maywood, IL 60153 USA. RP US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA. EM hlmehd64@aol.com NR 150 TC 8 Z9 11 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 EI 1558-1977 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD FEB PY 2005 VL 19 IS 1 BP 87 EP + DI 10.1016/j.hoc.2004.09.004 PG 32 WC Oncology; Hematology SC Oncology; Hematology GA 893RH UT WOS:000226736400005 PM 15639110 ER PT J AU Ko, CW Beresford, SAA Schulte, SJ Matsumoto, AM Lee, SP AF Ko, CW Beresford, SAA Schulte, SJ Matsumoto, AM Lee, SP TI Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy SO HEPATOLOGY LA English DT Article ID GESTATIONAL DIABETES-MELLITUS; GALLBLADDER-DISEASE; GALLSTONE DISEASE; CONTRACEPTIVE STEROIDS; SYMPTOMATIC GALLSTONES; WOMEN; PREVALENCE; LEPTIN; EPIDEMIOLOGY; ASSOCIATION AB Gallstones are strongly associated with higher parity in women. This study prospectively assessed the incidence, natural history, and risk factors for biliary sludge and stones during pregnancy and the postpartum in 3,254 women at an army medical center. Women with a prior cholecystectomy or with stones at their first study ultrasound were excluded. Gallbladder ultrasound and subject questionnaires were obtained in each trimester and at 4 to 6 weeks postpartum. Serum glucose, lipids, insulin, leptin, estradiol, and progesterone were measured at 26 to 28 weeks' gestation. A nested case-control study was done to examine the effects of serum leptin and insulin on incident gallbladder disease. At least two study ultrasounds were available for 3,254 women. Sludge or stones had been found on at least one study ultrasound in 5.1% by the second trimester, 7.9% by the third trimester, and 10.2% by 4 to 6 weeks postpartum. Regression of sludge and stones was common, such that overall 4.2% had new sludge or stones on the postpartum ultrasound. Twenty-eight women (0.8%) underwent cholecystectomy within the first year postpartum. Prepregnancy body mass index was a strong predictor of incident gallbladder disease (P < .001). Serum leptin was independently associated with gallbladder disease (odds ratio per 1 ng/dL increase, 1.05; 95% CI, 1.01, 1.11), even after adjusting for body mass index. In conclusion, incident gallbladder sludge and stones are common in pregnancy and the postpartum, and cholecystectomy is frequently done within the first year postpartum. Prepregnancy obesity and serum leptin are strong risk factors for pregnancy-associated gallbladder disease. C1 Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Dept Radiol, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. RP Ko, CW (reprint author), Univ Washington, Dept Med, Div Gastroenterol, Box 356424, Seattle, WA 98195 USA. EM cwko@u.washington.edu RI Lee, Sum Ping/C-4333-2009 FU NIDDK NIH HHS [DK46890] NR 31 TC 78 Z9 80 U1 0 U2 2 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD FEB PY 2005 VL 41 IS 2 BP 359 EP 365 DI 10.1002/hep.20534 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 892GK UT WOS:000226637900018 PM 15660385 ER PT J AU Curtis, MP Sales, AEB Sullivan, JH Gray, SL Hedrick, SC AF Curtis, MP Sales, AEB Sullivan, JH Gray, SL Hedrick, SC TI Satisfaction with care among community residential care residents SO JOURNAL OF AGING AND HEALTH LA English DT Article DE satisfaction; long-term care; community residential care; assisted living ID HEALTH-STATUS; OLDER-ADULTS; HOME CARE; SERVICES; DETERMINANTS; OUTCOMES; QUALITY AB Measuring satisfaction with community residential care (CRC) is growing in importance but still in its infancy. The authors conducted interviews with 176 CRC residents and their providers. Logistic regression was used to identify resident and physical characteristics, policies and services, and aggregate resident characteristics associated with satisfaction. Residents had high levels of satisfaction. demonstrating most concern with the facility being able to meet their future needs and food quality. Resident demographics and health status were associated with satisfaction. Contrary to hypotheses. facility type (adult family home and assisted living) was the only facitity characteristic strongly associated with satisfaction. Possible explanations include that the relationship between satisfaction and facility characteristics is more complex than expected. as well as significant challenges in measuring satisfaction and facility characteristics. The inconsistent results of previous satisfaction studies do not provide direction for imposition of uniform standards for facility characteristics, if the goal is improved satisfaction. C1 Calif Dept Hlth Serv, Maternal & Child Hlth Branch, Sacramento, CA 95899 USA. Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Curtis, MP (reprint author), Calif Dept Hlth Serv, Maternal & Child Hlth Branch, 1615 Captiol Ave,MS 8304,POB 997420, Sacramento, CA 95899 USA. EM mcurtis@dhs.ca.gov RI Sales, Anne/D-9678-2012 OI Sales, Anne/0000-0001-9360-3334 NR 26 TC 14 Z9 14 U1 3 U2 10 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0898-2643 J9 J AGING HEALTH JI J. Aging Health PD FEB PY 2005 VL 17 IS 1 BP 3 EP 27 DI 10.1177/0898264304268590 PG 25 WC Gerontology; Health Policy & Services SC Geriatrics & Gerontology; Health Care Sciences & Services GA 891MV UT WOS:000226586100001 PM 15601781 ER PT J AU Lipsky, BA Stoutenburgh, U AF Lipsky, BA Stoutenburgh, U TI Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE diabetic ulcers; foot infections; soft tissue infections; antibiotic resistance; Gram-positive infections ID RESISTANT STAPHYLOCOCCUS-AUREUS; QUINUPRISTIN-DALFOPRISTIN; ENDOCARDITIS; MANAGEMENT; PATHOGENS; THERAPY; SAFETY; SAMPLE; MODEL AB Objectives: The predominant pathogens causing diabetic foot infections are Gram-positive cocci, many of which are now resistant to commonly prescribed antibiotics. Daptomycin is a new agent that is active against most Gram-positive pathogens. To compare the effectiveness of daptomycin against semi-synthetic penicillins or vancomycin, we analysed the subset of diabetic patients with an infected ulcer enrolled in two randomized, controlled investigator-blind trials of patients with complicated skin and soft-tissue infections presumptively caused by Gram-positive organisms. Patients and methods: Patients with a diabetic ulcer infection were prospectively stratified to ensure they were equally represented in the treatment groups, then randomized to either daptomycin [4 mg/kg every 24 h intravenously (iv)] or a pre-selected comparator (vancomycin or a semi-synthetic penicillin) for 7-14 days. Results: Among 133 patients with a diabetic ulcer infection, 103 were clinically evaluable; 47 received daptomycin and 56 received a comparator. Most infections were monomicrobial, and Staphylococcus aureus was the predominant pathogen. Success rates for patients treated with daptomycin or the comparators were not statistically different for clinical (66% versus 70%, respectively; 95% CI, -14.4, 21.8) or microbiological (overall or by pathogen) outcomes. Both treatments were generally well tolerated, with most adverse events of mild to moderate severity. Conclusions: The clinical and microbiological efficacy and safety of daptomycin were similar to those of commonly used comparator antibiotics for treating infected diabetic foot ulcers caused by Gram-positive pathogens. Daptomycin should be considered for treating these infections, especially those caused by resistant Gram-positive pathogens. C1 Univ Washington, Sch Med, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Gen Internal Med Clin, Seattle, WA 98108 USA. Cubist Pharmaceut Inc, Lexington, MA USA. RP Lipsky, BA (reprint author), Univ Washington, Sch Med, Seattle, WA 98108 USA. EM Benjamin.Lipsky@med.va.gov OI Lipsky, Benjamin A./0000-0001-9886-5114 NR 42 TC 102 Z9 105 U1 2 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD FEB PY 2005 VL 55 IS 2 BP 240 EP 245 DI 10.1093/jac/dkh531 PG 6 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 891WR UT WOS:000226612200018 PM 15659542 ER PT J AU Kellogg, DL Zhao, JL Coey, U Green, JV AF Kellogg, DL Zhao, JL Coey, U Green, JV TI Acetylcholine-induced vasodilation is mediated by nitric oxide and prostaglandins in human skin SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE skin blood flow; endothelial function; microdialysis; laser-Doppler flowmetry ID CUTANEOUS ACTIVE VASODILATION; HEAT-STRESS; BLOOD-FLOW; IN-VIVO; MICRODIALYSIS; IONTOPHORESIS; MECHANISMS; RESPONSES AB Acetylcholine (ACh) can effect vasodilation by several mechanisms, including activation of endothelial nitric oxide ( NO) synthase and prostaglandin ( PG) production. In human skin, exogenous ACh increases both skin blood flow (SkBF) and bioavailable NO levels, but the relative increase is much greater in SkBF than NO. This led us to speculate ACh may dilate cutaneous blood vessels through PGs, as well as NO. To test this hypothesis, we performed a study in 11 healthy people. We measured SkBF by laser-Doppler flowmetry (LDF) at four skin sites instrumented for intradermal microdialysis. One site was treated with ketorolac ( Keto), a nonselective cyclooxygenase antagonist. A second site was treated with N-G-nitro-L-arginine methyl ester (L-NAME) to inhibit NO synthase. A third site was treated with a combination of Keto and L-NAME. The fourth site was an untreated control site. After the three treated sites received the different inhibiting agents, ACh was administered to all four sites by intradermal microdialysis. Finally, sodium nitroprusside ( SNP) was administered to all four sites. Mean arterial pressure ( MAP) was monitored by Finapres, and cutaneous vascular conductance (CVC) was calculated (CVC = LDF/MAP). For data analysis, CVC values for each site were normalized to their respective maxima as effected by SNP. The results showed that both Keto and L-NAME each attenuated the vasodilation induced by exogenous ACh ( ACh control = 79 +/- 4% maximal CVC, Keto = 55 +/- 7% maximal CVC, L-NAME = 46 +/- 6% maximal CVC; P < 0.05, ACh vs. Keto or L-NAME). The combination of the two agents produced an even greater attenuation of ACh-induced vasodilation (31 &PLUSMN; 5% maximal CVC; P < 0.05 vs. all other sites). We conclude that a portion of the vasodilation effected by exogenous ACh in skin is due to NO; however, a significant portion is also mediated by PGs. C1 Univ Texas, Hlth Sci Ctr, Dept Med, Div Geriatr & Gerontol, San Antonio, TX 78229 USA. Univ Texas, Hlth Sci Ctr,S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr,Dept Vet Affairs, Audie L Murphy Vet Hosp Div, San Antonio, TX 78229 USA. RP Kellogg, DL (reprint author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Geriatr & Gerontol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM kelloggd@uthscsa.edu NR 25 TC 84 Z9 85 U1 0 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD FEB PY 2005 VL 98 IS 2 BP 629 EP 632 DI 10.1152/japplphysiol.00728.2004 PG 4 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 887CZ UT WOS:000226282400029 PM 15649880 ER PT J AU Minshew, NJ Turner, CA Goldstein, G AF Minshew, NJ Turner, CA Goldstein, G TI The application of short forms of the Wechsler intelligence scales in adults and children with high functioning autism SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE intelligence; short forms; assessment ID PERVASIVE DEVELOPMENTAL DISORDERS; WAIS-R; DIAGNOSTIC INTERVIEW; DEPRESSED SAMPLE; INDIVIDUALS; POPULATION; VALIDATION; INSTRUMENT; PRESCHOOL AB We evaluated the predictive accuracy of short forms of the Wechsler intelligence scales for individuals with high functioning autism. Several short forms were derived from participants who had received the full procedure. Stepwise multiple regression analyses were performed to determine the strength of association between the subtests included in the short form and IQ scores based upon the full test. These analyses were performed for all participants, and also for autism participants with atypical subtest profiles. In all analyses the percentages of explained variance were typically in the .8-9 range. It was concluded that short forms may be used with good predictive accuracy in individuals with high functioning autism, even when the subtest profile is atypical. C1 Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. VA Pittsburgh Hlth Care Syst, Pittsburgh, PA 15206 USA. RP Goldstein, G (reprint author), VA Pittsburgh Hlth Care Syst, 151R,7180 Highland Dr, Pittsburgh, PA 15206 USA. EM ggold@nb.net FU NINDS NIH HHS [NS33355] NR 34 TC 63 Z9 63 U1 0 U2 9 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD FEB PY 2005 VL 35 IS 1 BP 45 EP 52 DI 10.1007/s10803-004-1030-x PG 8 WC Psychology, Developmental SC Psychology GA 909RD UT WOS:000227877500006 PM 15796121 ER PT J AU Singh, H Gordon, HS Deswal, A AF Singh, H Gordon, HS Deswal, A TI Variation by race in factors contributing to heart failure hospitalizations SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE ethnicity; patient nonadherence; severity of illness index; heart failure ID VENTRICULAR SYSTOLIC FUNCTION; QUALITY-OF-CARE; HEALTH-CARE; RACIAL-DIFFERENCES; BLOOD-PRESSURE; MEDICAL-CARE; MORTALITY; GENDER; ADJUSTMENT; COMMUNITY AB Background: Previous studies have shown a paradox of lower mortality in black compared with white patients after hospitalization for heart failure, in contrast to the overall hi.-her mortality reported for nonhospitalized black patients with heart failure. We examined racial differences in factors contributing to hospitalization and in severity of illness in a cohort of black and white patients with heart failure who were hospitalized within a financially "equal access" health care system. Methods and Results: We performed a retrospective cohort study on 100 black or white male veterans admitted with heart failure to a VA Medical Center (black, n = 52; white, n = 48). Severity of illness as measured by the APACHE II score, a generic severity score, was similar between black and white patients (P = .72). However, using a recently developed heart failure-specific risk score, we found that white patients had higher severity of illness (P =.03). White patients had a higher number of coexisting comorbidities than black patients (P = .01), while black patients more frequently had uncontrolled hypertension at the time of admission (P = .004). Nonclinical factors contributing to hospitalization-such as nonadherence with medications or diet, inadequate outpatient follow-up, poor social support, and substance abuse-were documented more frequently for black patients compared with white patients. Conclusions: At the time of hospitalization for heart failure, black patients may have an overall lower burden of disease and may more frequently have heart failure exacerbation precipitated by nonclinical factors. These findings may partly account for better long-term survival after hospitalization in black patients compared with white patients. C1 VA Med Ctr, Med Care Line, Houston, TX USA. Baylor Coll Med, Houston, TX 77030 USA. VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. Vet Affairs Med Ctr, Winters Ctr Heart Failure Res, Houston, TX 77030 USA. RP Deswal, A (reprint author), VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. RI Gordon, Howard/E-4420-2010 OI Gordon, Howard/0000-0002-6712-5954 NR 42 TC 13 Z9 13 U1 1 U2 3 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD FEB PY 2005 VL 11 IS 1 BP 23 EP 29 DI 10.1016/j.cardfail.2004.04.002 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 901AP UT WOS:000227255700006 PM 15704060 ER PT J AU Khan, M Sekhon, B Giri, S Jatana, M Gilg, AG Ayasolla, K Elango, C Singh, AK Singh, I AF Khan, M Sekhon, B Giri, S Jatana, M Gilg, AG Ayasolla, K Elango, C Singh, AK Singh, I TI S-nitrosoglutathione reduces inflammation and protects brain against focal cerebral ischemia in a rat model of experimental stroke SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE apoptosis; cerebral ischemia; inflammation; NF-kappa B; nitric oxide; S-nitrosoglutathione ID NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; ISCHEMIA/REPERFUSION INJURY; ARTERY OCCLUSION; FLAP SURVIVAL; BLOOD-FLOW; CELL-DEATH; L-ARGININE; INHIBITION; EXPRESSION AB Preservation of endothelial functions with low-dose nitric oxide (NO) and inhibition of excessive production of NO from inducible NO synthase (iNOS) is a potential therapeutic approach for acute stroke. Based on this hypothesis, an NO modulator, S-nitrosoglutathione (GSNO) was used, which provided neuroprotection in a rat model of focal cerebral ischemia. Administration of GSNO after the onset of ischemia reduced infarction and improved cerebral blood flow. To understand the mechanism of protection, the involvement of inflammation in ischemic brain injury was examined. Treatment with GSNO reduced the expression of tumor necrosis factor-alpha, interleukin-1beta, and iNOS; inhibited the activation of microglia/macrophage (ED1, CD11-b); and downregulated the expression of leukocyte function-associated antigen-1 and intercellular adhesion molleculle-1 in the ischemic brain. The number of apoptotic cells (including neurons) and the activity of caspase-3 were also decreased after GSNO treatment. Further, the antiinflammatory effect of GSNO on expression of iNOS and activation of NF-B-kappa machinery in rat primary astrocytes and in the murine microglial cell line BV2 was tested. Cytokine-mediated expression of iNOS and activation of NF-B-kappa were inhibited by GSNO treatment. That GSNO protects the brain against ischemia/reperfusion injury by modulating NO systems, resulting in a reduction in inflammation and neuronal cell death was documented by the results. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Khan, M (reprint author), Med Univ S Carolina, Dept Pediat, 316 GSB,96 Jonathan Lucas St, Charleston, SC 29425 USA. EM khanm@musc.edu OI Ayasolla, kameshwar/0000-0002-4265-2168 FU NINDS NIH HHS [NS-22576, NS-34741, NS-37766, NS-40144, NS-40810] NR 75 TC 91 Z9 92 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD FEB PY 2005 VL 25 IS 2 BP 177 EP 192 DI 10.1038/sj.jcbfm.9600012 PG 16 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 893SS UT WOS:000226740100004 PM 15647746 ER PT J AU Foster-Schubert, KE McTiernan, A Frayo, RS Schwartz, RS Rajan, KB Yasui, Y Tworoger, SS Cummings, DE AF Foster-Schubert, KE McTiernan, A Frayo, RS Schwartz, RS Rajan, KB Yasui, Y Tworoger, SS Cummings, DE TI Human plasma ghrelin levels increase during a one-year exercise program SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID FOOD-FREQUENCY QUESTIONNAIRE; PRADER-WILLI-SYNDROME; GROWTH-HORMONE; ENERGY-INTAKE; BODY-WEIGHT; CIRCULATING GHRELIN; LONGITUDINAL DATA; ACYLATED PEPTIDE; DISTANCE RUNNERS; HUMAN OBESITY AB Weight loss resulting from decreased caloric intake raises levels of the orexigenic hormone, ghrelin. Because ingested nutrients suppress ghrelin, increased ghrelin levels in hypophagic weight loss may result from decreased inhibitory input by ingested food, rather than from lost weight. We assessed whether ghrelin levels increase in response to exercise-induced weight loss without decreased caloric intake. We randomized 173 sedentary, overweight, postmenopausal women to an aerobic exercise intervention or stretching control group. At baseline, 3 months, and 12 months, we measured body weight and composition, food intake, cardiopulmonary fitness (maximal oxygen consumption), leptin, insulin, and ghrelin. Complete data were available for 168 women (97%) at 12 months. Exercisers lost 1.4 +/- 0.4 kg (P < 0.05 compared with baseline; P = 0.01 compared with stretchers) and manifested a significant, progressive increase in ghrelin levels, whereas neither measure changed among stretchers. Ghrelin increased 18% in exercisers who lost more than 3 kg (P < 0.001). There was no change in caloric intake in either group and no effect on ghrelin of exercise per se independent of its impact on body weight. In summary, ghrelin levels increase with weight loss achieved without reduced food intake, consistent with a role for ghrelin in the adaptive response constraining weight loss and, thus, in long-term body weight regulation. C1 Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Sch Med, Seattle, WA 98195 USA. Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Fred Hutchinson Canc Res Ctr, Canc Prevent Res Program, Seattle, WA 98109 USA. Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA. Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Med, Denver, CO 80262 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. RP Cummings, DE (reprint author), Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, 1660 Columbian Way,S-111-Endo, Seattle, WA 98108 USA. EM davidec@u.washington.edu RI Yasui, Yutaka/E-2564-2015 OI Yasui, Yutaka/0000-0002-7717-8638; Rajan, Kumar/0000-0003-1268-4617; Tworoger, Shelley/0000-0002-6986-7046 FU NCI NIH HHS [R01-CA-69334]; NCRR NIH HHS [M01-RR-00037]; NIA NIH HHS [AG-1094]; NIDDK NIH HHS [R01-DK-61516, T32-DK-007247]; PHS HHS [T32-EF-07262] NR 60 TC 85 Z9 88 U1 0 U2 2 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD FEB PY 2005 VL 90 IS 2 BP 820 EP 825 DI 10.1210/jc.2004-2081 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 895HD UT WOS:000226850700036 PM 15585547 ER PT J AU El-Serag, HB Mallat, DB Rabeneck, L AF El-Serag, HB Mallat, DB Rabeneck, L TI Management of the single liver nodule in a cirrhotic patient - A decision analysis model SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article ID PERCUTANEOUS ETHANOL INJECTION; SMALL HEPATOCELLULAR-CARCINOMA; CHRONIC HEPATITIS-C; COST-EFFECTIVENESS; TRANSPLANT PATIENTS; NATURAL-HISTORY; UNITED-STATES; HELICAL CT; SURVIVAL; BIOPSY AB The widespread use of liver imaging in patients with cirrhosis results in the discovery of small (<3 cm) nodules. Although the subsequent management of these patients is variable, it is generally focused on the diagnosis and treatment of hepatocellular carcinoma (HCC). We aimed to compare the 3-year survival associated with several competing strategies used in the management of patients with compensated liver cirrhosis in whom a single small liver lesion is detected during surveillance. We constructed a decision analysis model using a decision tree and Markov model. We assumed that all patients undergo an initial "diagnostic phase" consisting of an imaging study and serum alpha-fetoprotein (AFP). Patients with a "positive initial diagnostic phase" for HCC are referred for either imaging-guided biopsy (IGB) or surgical resection or orthotopic liver transplantation (OLT) without preceding IGB. IGB, if positive for HCC, was followed by OLT, surgical resection, or local therapy. Patients with a "negative initial diagnostic phase" undergo either repeat diagnostic testing (imaging, AFP) every 4 months or are referred for either OLT, surgical resection, or IGB followed by interventions. Probability assumptions were estimated from the published literature. The outcomes compared were 3-year overall survival and recurrence-free survival. When the initial diagnostic phase is positive for HCC, OLT it is associated with the longest survival. In the sensitivity analysis, when the 3-year overall survival for patients referred to OLT is <54%, surgical resection or IGB preceding therapy become more favorable strategies. This 3-year overall survival (<54%) associated with OLT is reached after a waiting time of 4 months on the transplant list, if a 4% monthly dropout rate is assumed. When the initial diagnostic phase is negative for HCC, then performing IGB, before proceeding to therapeutic intervention, is associated with the longest 3-year overall survival. If the IGB is positive, subsequent OLT is associated with the longest survival. The higher the predictive value of the initial diagnostic phase for HCC, the more favorable is OLT (for the "positive results" arm), and follow-up testing (for the "negative results" arm). In conclusion, given a high pretest likelihood of HCC in a single liver nodule detected during surveillance in patients with cirrhosis, IGB may not be required in the presence of a positive noninvasive diagnostic testing. The long waiting time prior to OLT limits its advantage over surgical resection in the treatment of patients with early HCC. C1 Baylor Coll Med, Vet Affairs Med Ctr 152, Houston, TX 77030 USA. Baylor Coll Med, Gastroenterol Sect, Houston, TX 77030 USA. Baylor Coll Med, Sect Hlth Serv Res, Houston, TX 77030 USA. RP El-Serag, HB (reprint author), Baylor Coll Med, Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.tmc.edu FU NIDDK NIH HHS [1 K24 DK 59318-01] NR 44 TC 13 Z9 13 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD FEB PY 2005 VL 39 IS 2 BP 152 EP 159 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 892IR UT WOS:000226644300013 PM 15681913 ER PT J AU Roodman, GD Windle, JJ AF Roodman, GD Windle, JJ TI Paget disease of bone SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Review ID TUMOR-NECROSIS-FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; COLONY-STIMULATING FACTOR; LYMPH-NODE ORGANOGENESIS; BASIC MULTICELLULAR UNIT; CANINE-DISTEMPER VIRUS; NF-KAPPA-B; MICE LACKING; OSTEOBLAST DIFFERENTIATION; 1,25-DIHYDROXYVITAMIN D-3 AB Paget disease of bone (PD) is characterized by excessive bone resorption in focal areas followed by abundant new bone formation, with eventual replacement of the normal bone marrow by vascular and fibrous tissue. The etiology of PD is not well understood, but one PD-linked gene and several other susceptibility loci have been identified, and paramyxoviral gene products have been detected in pagetic osteoclasts. In this review, the pathophysiology of PD and evidence for both a genetic and a viral etiology for PD will be discussed. C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. Univ Pittsburgh, Med Ctr, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA. Virginia Commonwealth Univ, Dept Human Genet, Richmond, VA USA. RP Roodman, GD (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr, Pittsburgh, PA 15240 USA. EM roodmangd@upmc.edu OI Windle, Jolene/0000-0001-6690-385X FU NIAMS NIH HHS [P01-AR049363, P01 AR049363] NR 111 TC 164 Z9 170 U1 0 U2 8 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD FEB PY 2005 VL 115 IS 2 BP 200 EP 208 DI 10.1172/JCI200524281 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 895ML UT WOS:000226867300001 PM 15690073 ER PT J AU Ngauy, V Lemeshev, Y Sadkowski, L Crawford, G AF Ngauy, V Lemeshev, Y Sadkowski, L Crawford, G TI Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID AUSTRALIA; EPIDEMIOLOGY; THAILAND AB Melioidosis, an infection caused by the gram-negative bacillus Burkholderia pseudomallei, is endemic to Southeast Asia and Northern Australia. Human infection is acquired through contact with contaminated water via percutaneous inoculation. Clinical manifestations range from skin and soft tissue infection to pneumonia with sepsis. We report a case of a man who was taken as a prisoner of war by the Japanese during World War II who presented with a nonhealing ulcer on his right hand 62 years after the initial exposure. C1 Wilford Hall USAF Med Ctr, Lackland AFB, TX 78236 USA. Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX USA. Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX USA. Audie L Murphy Mem Vet Adm Med Ctr, VA Mycol Reference Lab, San Antonio, TX 78284 USA. RP Ngauy, V (reprint author), SGOMI, 89MDOS, Andrews AFB, TX USA. EM viseth.ngauy@andrews.af.mil NR 11 TC 129 Z9 134 U1 3 U2 11 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD FEB PY 2005 VL 43 IS 2 BP 970 EP 972 DI 10.1128/JCM.43.2.970-972.2005 PG 3 WC Microbiology SC Microbiology GA 897ZO UT WOS:000227045600081 PM 15695721 ER PT J AU Spudick, JM Garcia, LS Graham, DM Haake, DA AF Spudick, JM Garcia, LS Graham, DM Haake, DA TI Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID RESPIRATORY-DISTRESS-SYNDROME; BENIGN TERTIAN MALARIA; RADICAL CURE; PULMONARY-EDEMA; PROPHYLAXIS; INFECTIONS; FALCIPARUM; STRAIN AB We describe a U.S. Army Ranger returning from duty in Afghanistan and Iraq with life-threatening infection due to Plasmodium vivax. Morphological variants were observed in blood films prepared using samples collected by venipuncture. The patient's multiple relapses indicate infection with primaquine-tolerant P. vivax. Strategies for relapse prevention using primaquine are reviewed. C1 VA Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, DAvid Geffen Sch Med, Dept Med, Los Angeles, CA USA. LSG & Associates, Santa Monica, CA USA. RP Haake, DA (reprint author), VA Greater Los Angeles Healthcare Syst, Div Infect Dis, 111F, Los Angeles, CA 90073 USA. EM dhaake@ucla.edu NR 28 TC 19 Z9 20 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD FEB PY 2005 VL 43 IS 2 BP 978 EP 981 DI 10.1128/JCM.43.2.978-981.2005 PG 4 WC Microbiology SC Microbiology GA 897ZO UT WOS:000227045600083 PM 15695723 ER PT J AU Sutton, DA Thompson, EH Rinaldi, MG Iwen, PC Nakasone, KK Jung, HS Rosenblatt, HM Paul, ME AF Sutton, DA Thompson, EH Rinaldi, MG Iwen, PC Nakasone, KK Jung, HS Rosenblatt, HM Paul, ME TI Identification and first report of Inonotus (Phellinus) tropicalis as an etiologic agent in a patient with chronic granulomatous disease SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID FUNGUS SCHIZOPHYLLUM-COMMUNE; PHYLOGENETIC-RELATIONSHIPS; SPOROTRICHUM-PRUINOSUM; DISSEMINATED INFECTION; PULMONARY INFECTION; MAXILLARY SINUS; GENUS PHELLINUS; RIBOSOMAL DNA; HORMOGRAPHIELLA; OSTEOMYELITIS AB Although isolates of filamentous basidiomycetes can usually be recognized in a clinical laboratory setting, identification is problematic, as they seldom exhibit diagnostic morphological features formed in nature. This paper is the first report of Inonotus (Phellinus) tropicalis inciting human disease and describes the methods used to support the identification. C1 Univ Texas, Ctr Hlth Sci, Dept Pathol, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. Baylor Coll Med, Houston, TX 77030 USA. Texas Childrens Hosp, Houston, TX 77030 USA. Univ Nebraska, Med Ctr, Omaha, NE USA. US Forest Serv, USDA, Forest Prod Lab, Madison, WI USA. Seoul Natl Univ, Sch Biol Sci, Seoul, South Korea. RP Sutton, DA (reprint author), Univ Texas, Ctr Hlth Sci, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM suttond@uthscsa.edu NR 63 TC 28 Z9 29 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD FEB PY 2005 VL 43 IS 2 BP 982 EP 987 DI 10.1128/JCM.43.2.982-987.2005 PG 6 WC Microbiology SC Microbiology GA 897ZO UT WOS:000227045600084 PM 15695724 ER PT J AU Weisbart, RH Hansen, JE Nishimura, RN Chan, G Wakelin, R Chang, SS Baresi, L Chamberlain, JS AF Weisbart, RH Hansen, JE Nishimura, RN Chan, G Wakelin, R Chang, SS Baresi, L Chamberlain, JS TI An intracellular delivery vehicle for protein transduction of micro-dystrophin SO JOURNAL OF DRUG TARGETING LA English DT Article DE antibody; transport; muscular dystrophy; dystrophin ID DUCHENNE MUSCULAR-DYSTROPHY; GENE-THERAPY; MONOCLONAL-ANTIBODY; MDX MICE; EXPRESSION; TAT; LOCALIZATION; AUTOANTIBODY; CULTIVATION; MYOSIN AB The Fv fragment of an antibody that selectively targets and penetrates skeletal muscle in vivo was produced as a fusion protein with a micro-dystrophin for use as a delivery vehicle to transport micro-dystrophin into muscle cells. Fv-micro-dystrophin was produced as a secreted protein by transient transfection of Fv-micro-dystrophin cDNA in COS-7 cells and as a non-secreted protein by permanent transfection in Pichia pastoris. Isolated Fv-micro-dystrophin was shown to be full-length by Western blot analysis. Fv-micro-dystrophin penetrated multiple cell lines in vitro, and it localized to the plasma membrane of a cell line with membrane beta-dystroglycan. In the absence of membrane beta-dystroglycan, it localized to the cytoplasm. Antibody-mediated transduction of micro-dystrophin into muscle cells is a potential therapy for dystrophin-deficient muscular dystrophies. C1 Vet Affairs Greater Los Angeles Healthcare Syst, Dept Res, Sepulveda, CA 91343 USA. Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. Calif State Univ Northridge, Dept Biol, Northridge, CA 91330 USA. Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA. RP Weisbart, RH (reprint author), Vet Adm Med Ctr, 16111 Plummer St 111S, Sepulveda, CA 91343 USA. EM rweisbar@ucla.edu NR 20 TC 6 Z9 6 U1 0 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1061-186X J9 J DRUG TARGET JI J. Drug Target. PD FEB PY 2005 VL 13 IS 2 BP 81 EP 87 DI 10.1080/10611860400029002 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 919UI UT WOS:000228642700001 PM 15823959 ER PT J AU Swenson, KE Eveland, RL Gladwin, MT Swenson, ER AF Swenson, KE Eveland, RL Gladwin, MT Swenson, ER TI Nitric oxide (NO) in normal and hypoxic vascular regulation of the spiny dogfish, Squalus acanthias SO JOURNAL OF EXPERIMENTAL ZOOLOGY PART A-COMPARATIVE EXPERIMENTAL BIOLOGY LA English DT Article ID PERIPHERAL NERVOUS-SYSTEM; MYKISS CORONARY SYSTEM; BLOOD-FLOW REGULATION; RAINBOW-TROUT; CARBONIC-ANHYDRASE; DORSAL AORTA; SYNTHASE; ACETYLCHOLINE; VESSELS; SHARK AB Nitric oxide (NO) is a potent vasodilator in terrestrial vertebrates, but whether vascular endothelial-derived NO plays a role in vascular regulation in fish remains controversial. To explore this issue, a study was made of spiny dogfish sharks (Squalus acanthias) in normoxia and acute hypoxia (60 min exposure to seawater equilibrated with 3% oxygen) with various agents known to alter NO metabolism or availability. In normoxia, nitroprusside (a NO donor) reduced blood pressure by 20%, establishing that vascular smooth muscle responds to NO. L-arginine, the substrate for NO synthase, had no hemodynamic effect. Acetylcholine, which stimulates endothelial NO and prostaglandin production in mammals, reduced blood pressure, but also caused marked bradycardia. L-NAME, an inhibitor of all NO synthases, caused a small 10% rise in blood pressure, but cell-free hemoglobin (a potent NO scavenger and hypertensive agent in mammals) had no effect. Acute hypoxia caused a 15% fall in blood pressure, which was blocked by L-NAME and cell-free hemoglobin. Serum nitrite, a marker of NO production, rose with hypoxia, but not with L-NAME. Results suggest that NO is not an endothelial-derived vasodilator in the normoxic elasmobranch. The hypertensive effect of L-NAME may represent inhibition of NO production in the CNS and nerves regulating blood pressure. In acute hypoxia, there is a rapid up-regulation of vascular NO production that appears to be responsible for hypoxic vasodilation. (C) 2005 Wiley-Liss, Inc. C1 Univ Washington, Div Pulm & Crit Care Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Mt Desert Isl Biol Lab, Salsbury Cove, ME 04672 USA. NIH, Dept Crit Care Med, Bethesda, MD 20892 USA. RP Swenson, ER (reprint author), VA Puget Sound Hlth Care Syst, Pulm Div S111 Pulm, 1660 S Columbian Way, Seattle, WA 98108 USA. EM eswenson@u.washington.edu NR 39 TC 17 Z9 18 U1 0 U2 5 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1548-8969 J9 J EXP ZOOL PART A JI J. Exp. Zool. Part A PD FEB 1 PY 2005 VL 303A IS 2 BP 154 EP 160 DI 10.1002/jez.a.145 PG 7 WC Zoology SC Zoology GA 894XV UT WOS:000226825800006 PM 15662661 ER PT J AU Liu, R Nair, D Ix, J Moore, DH Bent, S AF Liu, R Nair, D Ix, J Moore, DH Bent, S TI N-acetylcysteine for the prevention of contrast-induced nephropathy - A systematic review and meta-analysis SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Review DE N-acetylcysteine; contrast-induced nephropathy; acute renal failure; kidney disease ID ACUTE-RENAL-FAILURE; PERCUTANEOUS CORONARY INTERVENTION; AGENT-ASSOCIATED NEPHROTOXICITY; RANDOMIZED CONTROLLED-TRIAL; RADIOGRAPHIC-CONTRAST; RISK-FACTORS; CARDIAC-CATHETERIZATION; ANGIOGRAPHY; MEDIA; BIAS AB OBJECTIVE: Contrast-induced nephropathy is a common cause of acute renal failure in hospitalized patients. Although patients are often given N-acetylcysteine to prevent renal injury from contrast agents, there are no clear guidelines supporting its use. We conducted a systematic review to determine whether administering N-acetylcysteine around the time of contrast administration reduces the risk of contrast-induced nephropathy. DESIGN: We searched MEDLINE, EMBASE, the Cochrane Collaboration Database, bibliographies of retrieved articles, and abstracts of conference proceedings, and consulted with experts to identify relevant studies. Randomized controlled trials of N-acetylcysteine in hospitalized patients receiving contrast were included. Studies were excluded if they did not report change in creatinine or incidence of contrast-induced nephropathy at 48 hours. MEASUREMENTS AND MAIN RESULTS: Nine randomized controlled trials satisfied all inclusion criteria and were included in the analysis. The difference in mean change in creatinine between the N-acetylcysteinetreated group and controls was - 0.27 mg/dl (95% confidence interval [CI], - 0.43 to -0.11). The relative risk of developing contrast-induced nephropathy was 0.43 (95% CI, 0.24 to 0.75) in subjects randomized to N-acetylcysteine. Significant heterogeneity existed among studies, suggesting differences in patient populations or study methodology not identified by sensitivity analyses. The incidence of dialysis was rare (0.2%). CONCLUSIONS: Our findings suggest that N-acetylcysteine helps prevent declining renal function and contrast-induced nephropathy. While N-acetylcysteine is inexpensive and nontoxic, undeviating insistence for dosing at least 12 hours in advance of contrast exposure may delay diagnostic and therapeutic procedures. Future studies are needed to address the longer-term clinical outcomes and cost-effectiveness of this agent. C1 San Francisco VA Med Ctr, Vet Affairs PRIME Program, San Francisco, CA 94121 USA. San Francisco VA Med Ctr, Dept Med, San Francisco, CA 94121 USA. Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94115 USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA. RP Liu, R (reprint author), San Francisco VA Med Ctr, Vet Affairs PRIME Program, 111-A1,4150 Clement St, San Francisco, CA 94121 USA. EM rliu3@yahoo.com FU NCCIH NIH HHS [K08 AT001338, 1 K08 AT01338-01] NR 46 TC 68 Z9 73 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2005 VL 20 IS 2 BP 193 EP 200 DI 10.1111/j.1525-1497.2005.30323.x PG 8 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 912GC UT WOS:000228064600014 PM 15836554 ER PT J AU Janckila, AJ Parthasarathy, RN Parthasarathy, LK Seelan, RS Hsueh, YC Rissanen, J Alatalo, SL Halleen, JM Yam, LT AF Janckila, AJ Parthasarathy, RN Parthasarathy, LK Seelan, RS Hsueh, YC Rissanen, J Alatalo, SL Halleen, JM Yam, LT TI Properties and expression of human tartrate-resistant acid phosphatase isoform 5a by monocyte-derived cells SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE macrophage; dendritic cell; osteoclast; immunoassay; immunocytochemistry ID BONE-RESORPTION; MONOCLONAL-ANTIBODIES; STAPHYLOCOCCUS-AUREUS; DENDRITIC CELLS; INSECT CELLS; SERUM MARKER; OSTEOCLAST; SPLEEN; 5B; PURIFICATION AB Human serum tartrate-resistant acid phosphatase exists as two enzyme isoforms (TRACP 5a and 5b), derived by differential, post-translational processing of a common gene product. Serum TRACP 5b is from bone-resorbing osteoclasts (OC) and becomes elevated in diseases of increased bone resorption. TRACP 5a is secreted by macrophages (MPhi) and dendritic cells (DC) and is increased in many patients with rheumatoid arthritis. Our purpose was to fully characterize the properties of human TRACP isoforms and to produce an antibody specific to TRACP 5a for use as a biomarker in chronic inflammatory diseases. Partially purified, natural serum TRACP isoforms and recombinant TRACP 5a (rTRACP 5a) were compared with respect to specific activity and subunit structure and presence of sialic acid. Mice were immunized with rTRACP 5a, and resulting hybridomas were screened for monoclonal antibody to serum TRACP 5a. One antibody, 220, was tested for its epitope specificity and use in various immunological techniques. rTRACP 5a had properties identical to serum TRACP 5a. Antibody 220 was specific for the trypsin-sensitive epitope in the loop peptide, present only in TRACP 5a. Antibody 220 was effective for specific immunoprecipitation, immunoassay, and immunoblot of TRACP 5a. Intact TRACP was present in MPhi, DC, and OC. TRACP 5a was the predominant isoform secreted by MPhi and DC, whereas TRACP 5b was the predominant isoform secreted by OC. TRACP isoforms 5a and 5b may have different functions inside and outside of monocyte-derived cells. Antibody 220 is an important resource for studies of the biosynthetic relationship among TRACP isoforms and of the significance of serum TRACP 5a as a marker in diseases of bone metabolism and inflammation. C1 US Dept Vet Affairs, Med Ctr, Special Hematol Lab, Louisville, KY 40206 USA. US Dept Vet Affairs, Neurosci & Bioinformat Lab, Med Ctr, Louisville, KY 40206 USA. Univ Louisville, Dept Microbiol & Immunol, Sch Med, Louisville, KY 40292 USA. Univ Louisville, Dept Biochem & Mol Biol, Sch Med, Louisville, KY 40292 USA. Univ Louisville, Dept Psychiat, Sch Med, Louisville, KY 40292 USA. Univ Louisville, Dept Med, Sch Med, Louisville, KY 40292 USA. Pharma Test Serv Ltd, Turku, Finland. Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland. RP Janckila, AJ (reprint author), US Dept Vet Affairs, Med Ctr, Special Hematol Lab, 800 Zorn Ave, Louisville, KY 40206 USA. EM anthony.janckila@med.va.gov NR 41 TC 41 Z9 41 U1 0 U2 0 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD FEB PY 2005 VL 77 IS 2 BP 209 EP 218 DI 10.1189/jlb.0504287 PG 10 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 902XW UT WOS:000227391000010 PM 15542543 ER PT J AU Casada, JH Roache, JD AF Casada, JH Roache, JD TI Behavioral inhibition and activation in posttraumatic stress disorder SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE psychomotor performance; impulsive behavior; anxiety; motivation; reward ID RESPONSE-INHIBITION; COMBAT VETERANS; PTSD SYMPTOMS; ANXIETY; IMPULSIVITY; DEPRESSION; DISINHIBITION; INDIVIDUALS; PERSONALITY; PERFORMANCE AB Posttraumatic stress disorder (PTSD) is characterized by anxiety symptoms and impulsivity and aggression, which are thought to represent examples of excessive behavioral inhibition and activation, respectively. PTSD and traumatized control subjects performed the Stop-Signal Task to assess behavioral activation and inhibition simultaneously. PTSD subjects showed no evidence of the generally increased behavioral inhibition expected to accompany anxiety, but exhibited progressively decreased behavioral activation during acquisition of the task. However, when behavior was facilitated using monetary rewards, both PTSD and traumatized control subjects showed increases in behavioral activation, whereas PTSD subjects also showed significant disinhibition. These findings argue against PTSD patients being chronically inhibited and unresponsive to rewards, and the presence of disinhibition accompanying behavioral activation in these subjects may explain the impulsivity and aggression associated with PTSD. C1 Univ Texas, Hlth Sci Ctr, Dept Psychiat, San Antonio, TX 78229 USA. S Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp Div, Dept Vet Affairs, Psychiat Serv, San Antonio, TX 78284 USA. RP Casada, JH (reprint author), Univ Texas, Hlth Sci Ctr, Dept Psychiat, 7703 Floyd Curl Dr,Mail Code 7792, San Antonio, TX 78229 USA. FU NIDA NIH HHS [K08 DA00507] NR 44 TC 33 Z9 33 U1 3 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD FEB PY 2005 VL 193 IS 2 BP 102 EP 109 DI 10.1097/01.nmd.0000152809.20938.37 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 896FG UT WOS:000226919400004 PM 15684912 ER PT J AU Atwood, CS Meethal, SV Liu, TB Wilson, AC Gallego, M Smith, MA Bowen, RL AF Atwood, CS Meethal, SV Liu, TB Wilson, AC Gallego, M Smith, MA Bowen, RL TI Dysregulation of the hypothalamic-pituitary-gonadal axis with menopause and andropause promotes neurodegenerative senescence SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Review DE aging; Alzheimer disease; amyloid-beta; cell cycle; dyosis; hypothalamic-pituitary-gonadal axis; menopause; reproductive hormones ID ESTROGEN REPLACEMENT THERAPY; AMYLOID PRECURSOR PROTEIN; NEURONAL CELL-DEATH; ALZHEIMERS-DISEASE; LUTEINIZING-HORMONE; CHORIONIC-GONADOTROPIN; POSTMENOPAUSAL WOMEN; SERUM LEVELS; OLDER WOMEN; COGNITIVE IMPAIRMENT AB Senescence is characterized neurologically by a decline in cognitive function, which we propose is the result of degenerative processes initiated by the dysregulation of the hypothalamic-pituitary-gonadal (HPG) axis with menopause and andropause. Compelling epidemiologic evidence to support this assertion includes the increased prevalence of Alzheimer disease (AD) in women, the correlation of serum HPG hormones with disease and the decreased incidence, and delay in the onset of AD following hormone replacement therapy. Dysregulation of the axis at this time leads to alterations in the concentrations of all serum HPG hormones (decreased neuronal sex steroid signaling, but increased neuronal gonadotropin releasing hormone, luteinizing hormone, and activin signaling). Hormones of the HPG axis, receptors for which are present in the adult brain, are important regulators of cell proliferation and differentiation during growth and development. Based oil this, we propose that dysregulated HPG hormone signaling with menopause/andropause leads to the abortive reentry of differentiated neurons into the cell cycle via a process we term "dyosis." Interestingly, the major biochemical and neuropathologic changes reported for the AD brain also are intimately associated with neuron division: altered APPP metabolism, Abeta deposition, tau phosphorylation, mitochondrial alterations, chromosomal replication, synapse loss, and death of differentiated neurons. Recent evidence supports the premise that AD-related biochemical changes are likely the combined result of increased mitotic signaling by gonadotropins and GnRH decreased differentiative and neuroprotective signaling via sex steroids, and increased differentiative signaling via activins. This results in a hormonal milieu that is permissive of cell cycle reentry but does not allow completion of metaphase. Partial resetting of the axis following administration of normal endogenous sex steroids delays the onset and decreases the incidence of AD. Ideally, supplementation with HPG hormones should mimic closely the serum concentrations of all HPG hormones in reproductive men and cycling women to prevent dyotic signaling and attempted neuron division. C1 Univ Wisconsin, Dept Med, Sect Geriatr & Gerontol, Madison, WI 53705 USA. Vet Adm Hosp, Ctr Geriatr Res Educ & Clin, Madison, WI USA. Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA. Voyager Pharmaceut Corp, Raleigh, NC USA. RP Atwood, CS (reprint author), Univ Wisconsin, Sch Med, William S Middleton Mem Vet Adm Hosp, GRECC 11G,2500 Overlook Terrace, Madison, WI 53705 USA. EM csa@medicine.wisc.edu RI Smith, Mark/A-9053-2009 NR 106 TC 50 Z9 50 U1 3 U2 20 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3069 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD FEB PY 2005 VL 64 IS 2 BP 93 EP 103 PG 11 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 898WK UT WOS:000227106700001 PM 15751223 ER PT J AU Pannu, R Barbosa, E Singh, AK Singh, I AF Pannu, R Barbosa, E Singh, AK Singh, I TI Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats SO JOURNAL OF NEUROSCIENCE RESEARCH LA English DT Article DE atorvastatin; SCI; inflammation ID CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; KAPPA-B ACTIVATION; MESSENGER-RNA; LEWIS RATS; REDUCTASE INHIBITOR; MULTIPLE-SCLEROSIS AB Spinal cord injury (SCI) is a devastating and complex clinical condition involving proinflammatory cytokines and nitric oxide toxicity that produces a predictable pattern of progressive injury entailing neuronal loss, axonal destruction, and demyelination at the site of impact. The involvement of proinflammatory cytokines and inducible nitric oxide synthase (iNOS) in exacerbation of SCI pathology is well documented. We have reported previously the antiinflammatory properties and immunomodulatory activities of statins (3-hydroxy-3-methylglutaryl [HMG]-CoA reductase inhibitors) in the animal model of multiple sclerosis, experimental allergic encephalitis (EAE). The present study was undertaken to investigate the efficacy of atorvastatin (Lipitor; ILP) treatment in attenuating SCI-induced pathology. Immunohistochemical detection and real-time PCR analysis showed increased expression of iNOS, tumor necrosis factor alpha (TNFalpha) and interleukin 1beta (IL-1beta) after SCI. In addition, neuronal apoptosis was detected 24 hr after injury followed by a profound increase in ED1-positive inflammatory infiltrates, glial fibrillary acidic protein (GFAP)-positive reactive astrocytes, and oligodendrocyte apoptosis by 1 week after SCI relative to control. LP treatment attenuated the SCI-induced iNOS, TNFalpha, and IL-1beta expression. LP also provided protection against SCI-induced tissue necrosis, neuronal and oligodendrocyte apoptosis, demyelination, and reactive gliosis. Furthermore, rats treated with LP scored much higher on the locomotor rating scale after SCI (19.13 +/- 0.53) than did untreated rats (9.04 +/- 1.22). This study therefore reports the beneficial effect of atorvastatin for the treatment of SCI-related pathology and disability. (C) 2004 Wiley-Liss, Inc. C1 Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA. Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Med Univ S Carolina, Dept Pediat, 96 Jonathan Lucas St, Charleston, SC 29425 USA. EM singhi@musc.edu NR 77 TC 76 Z9 82 U1 0 U2 2 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0360-4012 EI 1097-4547 J9 J NEUROSCI RES JI J. Neurosci. Res. PD FEB 1 PY 2005 VL 79 IS 3 BP 340 EP 350 DI 10.1002/jnr.20345 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 892FG UT WOS:000226634800009 PM 15605375 ER PT J AU Weintraub, D Newberg, AB Cary, MS Siderowf, AD Moberg, PJ Kleiner-Fisman, G Duda, JE Stern, MB Mozley, D Katz, IR AF Weintraub, D Newberg, AB Cary, MS Siderowf, AD Moberg, PJ Kleiner-Fisman, G Duda, JE Stern, MB Mozley, D Katz, IR TI Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE TRODAT-1; dopamine transporter; anxiety; depression; Parkinson's disease ID MAJOR DEPRESSION; BASAL GANGLIA; PERSONALITY-TRAITS; PUTAMEN NUCLEI; FRONTAL-LOBE; COMORBIDITY; PRAMIPEXOLE; DISORDERS; BINDING; SYSTEM AB We studied the correlation of striatal dopamine transporter (DAT) imaging with anxiety and depression symptoms in Parkinson's disease (PD). Methods: Patients with idiopathic PD (n = 76) and age-matched healthy volunteers (n = 46) underwent SPECT brain scans with Tc-99m-TRODAT-1, a radiolabeled tropane that selectively binds to the DAT. TRODAT-1 distribution volume ratios, a reflection of DAT availability, were calculated from the SPECT scan data for 6 regions of interest (ROIs) in the caudate and putamen. The association between neuropsychiatric symptoms (anxiety, depression, and fatigue) and DAT availability was explored for both subject groups, and the impact of disease severity on this association was examined in the PD group. Results: PD patients showed lower DAT availability than did healthy volunteers in all examined regions (for all ROIs, P < 0.001). In PD patients, higher individual affective measures (for anxiety, r = -0.30 and P = 0.01; and for depression, r = -0.24 and P = 0.05) and total affect scores (r = -0.31; P = 0.01) were associated with diminished left anterior putamen DAT availability. The association between total affect scores and DAT availability was present only in the subset of patients with less severe PD (r = -0.35; P = 0.04), but subjects with the highest DAT availability did not show high total affect scores. No association between neuropsychiatric measures and DAT availability was found in the controls. Conclusion: These preliminary findings suggest that decreased DAT availability may be necessary for but not invariably associated with the development of affective symptoms in PD. This suggestion is consistent with previous research showing a link between depression and basal ganglia impairment, particularly involving the left hemisphere, and extends this finding to include anxiety. C1 Univ Penn, Dept Psychiat, Sect Geriatr Psychiat, Philadelphia, PA 19104 USA. Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. Univ Penn, Dept Radiol, Div Nucl Med, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA. RP Weintraub, D (reprint author), Univ Penn, Dept Psychiat, Sect Geriatr Psychiat, 3535 Market St,Room 3003, Philadelphia, PA 19104 USA. EM weintrau@mail.med.upenn.edu FU NIMH NIH HHS [1K23 MH067894 1A1] NR 39 TC 102 Z9 106 U1 0 U2 3 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD FEB PY 2005 VL 46 IS 2 BP 227 EP 232 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 896JD UT WOS:000226929500023 PM 15695780 ER PT J AU Hartman, TJ Albert, PS Snyder, K Slattery, ML Caan, B Paskett, E Iber, F Kikendall, JW Marshall, J Shike, M Weissfeld, J Brewer, B Schatzkin, A Lanza, E AF Hartman, TJ Albert, PS Snyder, K Slattery, ML Caan, B Paskett, E Iber, F Kikendall, JW Marshall, J Shike, M Weissfeld, J Brewer, B Schatzkin, A Lanza, E CA Polyp Prevention Study Grp TI The association of calcium and vitamin D with risk of colorectal adenomas SO JOURNAL OF NUTRITION LA English DT Article DE calcium; vitamin D; Polyp Prevention Trial; colorectal adenomas ID COLON-CANCER; UNITED-STATES; DAIRY-PRODUCTS; LOW-FAT; DIETARY INTERVENTION; SUPPLEMENTAL CALCIUM; HYPERPLASTIC POLYPS; OLDER WOMEN; LARGE-BOWEL; D-RECEPTOR AB The Polyp Prevention Trial (PPT) was a multicenter randomized clinical trial designed to determine the effects of a high-fiber, high-fruit and vegetable, low-fat diet on the recurrence of adenomatous polyps in the large bowel. Detailed dietary intake and supplement use data were collected at baseline and at each of 4 annual study visits. Adenoma recurrence was ascertained by complete colonoscopy at baseline and after 1 and 4 y. Recurrence was found in 754 of the 1905 trial participants. We evaluated the association between calcium and vitamin D intake and adenomatous polyp recurrence after adjusting for intervention group, age, gender, nonsteroidal anti-inflammatory drug use, total energy intake, and the interaction of gender and intervention group. Vitamin D models were also adjusted for the location of the clinic site. Dietary variables were adjusted for total energy intake via the residual method. There were no overall significant associations between adenoma recurrence and dietary calcium intake [odds ratio (OR) for the 5th compared with the lowest quintile = 0.91; 95% Cl = 0.67-1.23; P-trend = 0.68], total calcium intake (OR = 0.86; 95% Cl = 0.62-1.18; P-trend = 0.20), or dietary vitamin D intake (OR = 0.93; 95% Cl = 0.69-1.25; P-trend = 0.43) averaged over follow-up. Total vitamin D intake was weakly inversely associated with adenoma recurrence (OR = 0.84; 95% Cl = 0.62-1.13; P-trend = 0.03). Supplemental calcium and vitamin D use during follow-up also were inversely associated with adenoma recurrence (OR for any compared with no use = 0.82; 95% Cl = 0.68-0.99; and OR = 0.82; 95% Cl = 0.68-0.99; for calcium and vitamin D, respectively). Slightly stronger associations were noted for the prevention of multiple recurrences. Our analyses did not suggest a significant effect modification between total calcium and total vitamin D intake (P = 0.14) on risk for adenoma recurrence. This trial cohort provides some evidence that calcium and vitamin D may be inversely associated with adenoma recurrence. C1 Penn State Univ, Dept Nutrit Sci, University Pk, PA 16802 USA. NCI, Biometr Res Branch, Div Canc Treatment & Diag, Bethesda, MD 20892 USA. Informat Management Serv Inc, Rockville, MD USA. Univ Utah, Salt Lake City, UT 84112 USA. Kaiser Fdn Res Inst, Oakland, CA USA. Ohio State Univ, Columbus, OH 43210 USA. US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. Natl Naval Med Res Inst, Bethesda, MD USA. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Univ Pittsburgh, Pittsburgh, PA 15260 USA. WESTAT Corp, Rockville, MD 20850 USA. NCI, Nutrit Epidemiol Branch, Div Epidemiol & Genet, Bethesda, MD 20892 USA. NCI, Lab Canc Prevent, Ctr Canc Res, Bethesda, MD 20892 USA. RP Hartman, TJ (reprint author), Penn State Univ, Dept Nutrit Sci, University Pk, PA 16802 USA. EM tjhg@psu.edu NR 49 TC 63 Z9 64 U1 2 U2 8 PU AMER INST NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD FEB PY 2005 VL 135 IS 2 BP 252 EP 259 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 894GU UT WOS:000226779700018 PM 15671222 ER PT J AU Strack, S AF Strack, S TI Paradigms of personality assessment. SO JOURNAL OF PERSONALITY ASSESSMENT LA English DT Book Review C1 US Dept Vet Affairs, Los Angeles, CA USA. RP Strack, S (reprint author), VA LAACC, Psychol Serv 116B, 351 E Temple St, Los Angeles, CA 90012 USA. NR 14 TC 4 Z9 4 U1 0 U2 0 PU LAWRENCE ERLBAUM ASSOC INC PI MAHWAH PA 10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA SN 0022-3891 J9 J PERS ASSESS JI J. Pers. Assess. PD FEB PY 2005 VL 84 IS 1 BP 105 EP 107 DI 10.1207/s15327752jpa8401_17 PG 3 WC Psychology, Clinical; Psychology, Social SC Psychology GA 886PI UT WOS:000226240400016 ER PT J AU Zhou, XH Qin, GS AF Zhou, XH Qin, GS TI A new confidence interval for the difference between two binomial proportions of paired data SO JOURNAL OF STATISTICAL PLANNING AND INFERENCE LA English DT Article DE binomial proportion; diagnostic tests; sensitivity and specificity; paired data; edgeworth expansion; skewness ID CORRELATED BINARY PROPORTIONS AB Motivated by a study on comparing sensitivities and specificities of two diagnostic tests in a paired design when the sample size is small, we first derived an Edgeworth expansion for the studentized difference between two binomial proportions of paired data. The Edgeworth expansion can help us understand why the usual Wald interval for the difference has poor coverage performance in the small sample size. Based on the Edgeworth expansion, we then derived a transformation based confidence interval for the difference. The new interval removes the skewness in the Edgeworth expansion; the new interval is easy to compute, and its coverage probability converges to the nominal level at a rate of O(n(-1/2)). Numerical results indicate that the new interval has the average coverage probability that is very close to the nominal level on average even for sample sizes as small as 10. Numerical results also indicate this new interval has better average coverage accuracy than the best existing intervals in finite sample sizes. (C) 2003 Elsevier B.V. All rights reserved. C1 VA Puget Sound Hlth Care Syst, Biostat Unit, HSR & D Ctr Excellence, Seattle, WA 98108 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Georgia State Univ, Dept Math & Stat, Atlanta, GA 30303 USA. RP Zhou, XH (reprint author), VA Puget Sound Hlth Care Syst, Biostat Unit, HSR & D Ctr Excellence, 1660 S Columbian Way, Seattle, WA 98108 USA. EM azhou@u.washington.edu NR 14 TC 14 Z9 14 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-3758 J9 J STAT PLAN INFER JI J. Stat. Plan. Infer. PD FEB 1 PY 2005 VL 128 IS 2 BP 527 EP 542 DI 10.1016/j.jspi.2003.11.005 PG 16 WC Statistics & Probability SC Mathematics GA 874FH UT WOS:000225335800015 ER PT J AU Wolf, CJ Ebrahimi, R AF Wolf, CJ Ebrahimi, R TI Acetylcysteine does prevent contrast-induced nephropathy after coronary angiography in patients submitted to low-osmolar contrast media but not in patients submitted to iso-osmolar contrast media and in higher risk patients - A meta-analysis SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 54th Annual Scientific Session of the American-College-of-Cardiology CY MAR 06, 2005 CL Orlando, FL SP Amer Coll Cardiol C1 Univ Calif Los Angeles, Los Angeles, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD FEB 1 PY 2005 VL 45 IS 3 SU A BP 31A EP 31A PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 894RB UT WOS:000226808200127 ER PT J AU Zahid, M Sonel, AF Wall, L Good, CB AF Zahid, M Sonel, AF Wall, L Good, CB TI Elevated wbc count not associated with obstructing coronary lesions in patients presenting with non-st elevation acute coronary syndromes. SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 54th Annual Scientific Session of the American-College-of-Cardiology CY MAR 06, 2005 CL Orlando, FL SP Amer Coll Cardiol C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. Univ Pittsburgh, Cardiovasc Inst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD FEB 1 PY 2005 VL 45 IS 3 SU A BP 240A EP 240A PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 894RB UT WOS:000226808201049 ER PT J AU Sonel, AF Good, CB Rao, H Macioce, A Wall, LJ Niculescu, RS Sandilya, S Krishnan, S Aloni, P Rao, B AF Sonel, AF Good, CB Rao, H Macioce, A Wall, LJ Niculescu, RS Sandilya, S Krishnan, S Aloni, P Rao, B TI What is the most efficient data extraction method for quality improvement and research in cardiology? A comparison of REMIND artificial-intelligence software verus manual chart abstraction for determining ACC/AHA guideline adherence in non-ST elevation acute coronary syndromes SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 54th Annual Scientific Session of the American-College-of-Cardiology CY MAR 06, 2005 CL Orlando, FL SP Amer Coll Cardiol C1 VA Pittsburgh Healthcare Syst, Ctr Hlth Equit Res & Promot, Pittsburgh, PA USA. Siemens Med Solut, Malvern, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD FEB 1 PY 2005 VL 45 IS 3 SU A BP 348A EP 348A PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 894RB UT WOS:000226808201501 ER PT J AU Aronow, HD Samaha, FF Weiner, M Kimmel, SE Roche, D Williams, M Jacobs, P Lauer, MS AF Aronow, HD Samaha, FF Weiner, M Kimmel, SE Roche, D Williams, M Jacobs, P Lauer, MS TI Higher statin dose is associated with lower all-cause mortality: Evidence for a dose-response relationship in primary prevention SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 54th Annual Scientific Session of the American-College-of-Cardiology CY MAR 06, 2005 CL Orlando, FL SP Amer Coll Cardiol C1 Hosp Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. Cleveland Clin Fdn, Cleveland, OH 44195 USA. RI Lauer, Michael/L-9656-2013 OI Lauer, Michael/0000-0002-9217-8177 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD FEB 1 PY 2005 VL 45 IS 3 SU A BP 391A EP 391A PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 894RB UT WOS:000226808201691 ER PT J AU Casarett, D Crowley, R Stevenson, C Xie, S Teno, J AF Casarett, D Crowley, R Stevenson, C Xie, S Teno, J TI Making difficult decisions about hospice enrollment: What do patients and families want to know? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE hospice; decision making; end-of-life care; palliative care; informed consent ID OF-LIFE CARE; INFORMATION NEEDS; DISCUSS HOSPICE; ADVANCED CANCER; END; SATISFACTION; PERCEPTIONS; PREFERENCES; VALIDATION; AUTONOMY AB OBJECTIVES: To define patients' and families' priorities for information about hospice. DESIGN: Cross-sectional interview. SETTING: Urban, not-for-profit, Medicare-certified hospice. PARTICIPANTS: Patients and families recruited from consecutive hospice information visits. MEASUREMENTS: Understanding of hospice, assessment of the relative importance of eight categories of information (by direct rating and ranking tasks), and nurse observation of shared decision making between patient and family (5-point scale). RESULTS: Interviews were conducted with 237 patients and families at a hospice information visit. Forty percent (n=94) said that they knew anything about hospice. Most often, family members made the enrollment decision (n=132, 57%). Of the eight categories of information, patients and families placed the greatest importance on visit frequency (n=143, 60%), payment for hospice (n=140, 59%), and the practical help that hospice provides (n=123, 52%). Principal component factor analysis reduced the categories to three distinct factors reflecting concerns related to impending death, practical support, and changes from established patterns of care. CONCLUSION: Most patients and families who are referred for a hospice information visit know little about hospice and have substantial information needs. Referring physicians and hospice teams may be able to better support hospice enrollment decisions by anticipating common priorities for information. C1 Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA. Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA. Univ Penn, Div Geriatr, Philadelphia, PA 19104 USA. Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. San Diego Hospice, San Diego, CA USA. Brown Univ, Brown Med Sch, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA. RP Casarett, D (reprint author), Inst Aging, 3615 Chestnut St, Philadelphia, PA 19104 USA. EM casarett@mail.med.upenn.edu NR 39 TC 39 Z9 40 U1 1 U2 5 PU BLACKWELL PUBLISHING INC PI MALDEN PA 350 MAIN ST, MALDEN, MA 02148 USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2005 VL 53 IS 2 BP 249 EP 254 DI 10.1111/j.1532-5415.2005.53110.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 889VW UT WOS:000226471900010 PM 15673348 ER PT J AU Kestenbaum, B Sampson, JN Rudser, KD Patterson, DJ Seliger, SL Young, B Sherrard, DJ Andress, DL AF Kestenbaum, B Sampson, JN Rudser, KD Patterson, DJ Seliger, SL Young, B Sherrard, DJ Andress, DL TI Serum phosphate levels and mortality risk among people with chronic kidney disease SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC-RENAL-FAILURE; LEFT-VENTRICULAR HYPERTROPHY; PARATHYROID-HORMONE; HEMODIALYSIS-PATIENTS; CALCIUM; CALCIFICATION; HYPERPARATHYROIDISM; ASSOCIATION; DIALYSIS; METABOLISM AB Elevated serum phosphate levels have been linked with vascular calcification and mortality among dialysis patients. The relationship between phosphate and mortality has not been explored among patients with chronic kidney disease (CKD). A retrospective cohort study was conducted from eight Veterans Affairs' Medical Centers located in the Pacific Northwest. CKD was defined by two continuously abnormal outpatient serum creatinine measurements at least 6 mo apart between 1999 and 2002. Patients who received chronic dialysis, those with a present or previous renal transplant, and those without a recent phosphate measurement were excluded. The primary end point was all-cause mortality. Secondary end points were acute myocardial infarction and the combined end point of myocardial infarction plus death. A total of 95,619 veterans with at least one primary care or internal medicine clinic contact from a Northwest VA facility and two or more outpatient measurements of serum creatinine, at least 6 mo apart, between January 1. 1999, and December 31, 2002, were identified. From this eligible population, 7021 patients met our definition of CKD. After exclusions, 6730 CKD patients were available for analysis, and 3490 had a serum phosphate measurement during the previous 18 mo. After adjustment, serum phosphate levels >3.5 mg/dl were associated with a significantly increased risk for death. Mortality risk increased linearly with each subsequent 0.5-mg/dl increase in serum phosphate levels. Elevated serum phosphate levels were independently associated with increased mortality risk among this population of patients with CKD. C1 Univ Washington, Div Nephrol, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. Univ Washington, Dept Biostat, Seattle, WA 98195 USA. Univ Washington, Dept Comp Sci & Engn, Seattle, WA 98195 USA. Univ Washington, Div Nephrol, Seattle, WA 98195 USA. Univ Washington, Div Gen Internal Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. NW Kidney Ctr, Seattle, WA USA. RP Kestenbaum, B (reprint author), Univ Washington, Div Nephrol, Vet Affairs Puget Sound Hlth Care Syst, Mail Stop 111A,1660 S Columbian Way, Seattle, WA 98108 USA. EM brk@u.washington.edu FU NIDDK NIH HHS [K23 DK63274-01] NR 28 TC 586 Z9 623 U1 2 U2 21 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1046-6673 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD FEB PY 2005 VL 16 IS 2 BP 520 EP 528 DI 10.1681/ASN.2004070602 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 896UM UT WOS:000226959400030 PM 15615819 ER PT J AU Tareen, N Martins, D Nagami, G Levine, B Norris, KC AF Tareen, N Martins, D Nagami, G Levine, B Norris, KC TI Sodium disorders in the elderly SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION LA English DT Article DE sodium; elderly; hyponatremia; hypernatremia ID ATRIAL-NATRIURETIC-PEPTIDE; ALDOSTERONE SYSTEM; WATER-DEPRIVATION; AGE; HYPERNATREMIA; RENIN; HYPONATREMIA; EXCRETION; THIRST; MEN AB Disorders of sodium imbalance are commonly encountered in clinical practice and can have a substantial impact on the prognosis of the patient. These disorders are more common in the elderly. Sodium disorders can cause serious neurologic symptoms and even death, particularly among hospitalized patients. The identification of sodium abnormalities and appropriate clinical intervention are critical for improving patient outcomes. Early recognition of hyponatremia and hypernatremia can provide a clue to an underlying disorder. In this update, we have summarized age-related homeostatic changes that impair sodium balance, medications that alter salt and water handling, and the recognition and management of sodium disorders in elderly patients. C1 Charles R Drew Univ Med & Sci, Dept Internal Med, Los Angeles, CA 90059 USA. W Los Angeles Vet Adm Med Ctr, Dept Med, Los Angeles, CA USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. RP Norris, KC (reprint author), Charles R Drew Univ Med & Sci, Dept Internal Med, 12021 S Wilmington Blvd, Los Angeles, CA 90059 USA. FU NCRR NIH HHS [P20 RR011145, P20-RR11145, U54 RR014616, U54-RR14616]; NIA NIH HHS [P30-AG-21684] NR 31 TC 18 Z9 18 U1 2 U2 5 PU NATL MED ASSOC PI WASHINGON PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA SN 0027-9684 J9 J NATL MED ASSOC JI J. Natl. Med. Assoc. PD FEB PY 2005 VL 97 IS 2 BP 217 EP 224 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 893EH UT WOS:000226701600032 PM 15712785 ER PT J AU Moe, SM Chertow, GM Coburn, JW Quarles, LD Goodman, WG Block, GA Drueke, TB Cunningham, J Sherrard, DJ McCary, LC Olson, KA Turner, SA Martin, KJ AF Moe, SM Chertow, GM Coburn, JW Quarles, LD Goodman, WG Block, GA Drueke, TB Cunningham, J Sherrard, DJ McCary, LC Olson, KA Turner, SA Martin, KJ TI Achieving NKF-K/DOQI (TM) bone metabolism and disease treatment goals with cinacalcet HCl SO KIDNEY INTERNATIONAL LA English DT Article DE calcimimetic; cinacalcet HCl; NKF-K/DOQI guidelines; secondary hyperparathyroidism (HPT); chronic kidney disease (CKD); dialysis ID STAGE RENAL-DISEASE; INTRAVENOUS CALCITRIOL TREATMENT; INTACT PARATHYROID-HORMONE; SECONDARY HYPERPARATHYROIDISM; HEMODIALYSIS-PATIENTS; PHOSPHORUS RESTRICTION; CALCIMIMETIC AMG-073; DIALYSIS PATIENTS; PROSPECTIVE TRIAL; MORTALITY RISK AB Background. The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI(TM)) has established guidelines for treatment of secondary hyperparathyroidism (HPT). The ability of cinacalcet HCl (Sensipar(TM)) treatment to improve achievement of target levels of parathyroid hormone (PTH), calcium, phosphorus, and calcium-phosphorus product (Ca x P) was investigated in subjects on dialysis with secondary HPT. Methods. Data were combined from three placebo-controlled, double-blind, 26-week studies with similar design that randomized 1136 subjects on dialysis to receive traditional therapy plus cinacalcet or placebo. Oral cinacalcet was titrated from 30 to 180 mg/day. Achievement of K/DOQI goals was determined for each treatment group overall and for subgroups defined by baseline intact PTH (iPTH) and Ca x P levels. Results. Cinacalcet-treated subjects were more likely to achieve a mean iPTH less than or equal to300 pg/mL (31.8 pmol/L) than were control subjects on traditional therapy (56% vs. 10%, P < 0.001). Cinacalcet-treated subjects were more likely to achieve concentrations of serum calcium within 8.4 to 9.5 mg/dL (2.10-2.37 mmol/L) and serum phosphorus within 3.5 to 5.5 mg/dL (1.13-1.78 mmol/L) than were control subjects (49% vs. 24% and 46% vs. 33%, P < 0.001 for each). Cinacalcet also improved achievement of Ca x P < 55 mg(2)/dL(2) (4.44 mmol(2)/L(2)) and concurrent achievement of Ca x P < 55 mg(2)/dL(2) (4.44 mmol(2)/L(2)) and iPTH less than or equal to300 pg/mL (31.8 pmol/L) (65% vs. 36% and 41% vs. 6%, P < 0.001 for each). Conclusion. In subjects on dialysis with secondary HPT, cinacalcet facilitates achievement of the K/DOQI-recommended targets for PTH, calcium, phosphorus, and Ca x P. C1 Indiana Univ, Sch Med, Indianapolis, IN 46202 USA. Univ Calif San Francisco, Sch Med, San Francisco, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. Duke Univ, Med Ctr, Durham, NC USA. Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. Denver Nephrol, Denver, CO USA. Hop Necker Enfants Malad, Paris, France. UCL Hosp, London, England. Univ Washington, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Amgen Inc, Thousand Oaks, CA 91320 USA. St Louis Univ, St Louis, MO 63103 USA. RP Moe, SM (reprint author), Indiana Univ, Sch Med, 1001 W 10th St,OPW 526, Indianapolis, IN 46202 USA. EM smoe@iupui.edu NR 32 TC 182 Z9 196 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD FEB PY 2005 VL 67 IS 2 BP 760 EP 771 DI 10.1111/j.1523-1755.2005.67139.x PG 12 WC Urology & Nephrology SC Urology & Nephrology GA 889CH UT WOS:000226420600041 PM 15673327 ER PT J AU Saab, S Ibrahim, AB Shpaner, A Younossi, ZM Lee, C Durazo, F Han, S Esrason, K Wu, V Hiatt, J Farmer, DG Ghobrial, RM Holt, C Yersiz, H Goldstein, LI Tong, MJ Busuttil, RW AF Saab, S Ibrahim, AB Shpaner, A Younossi, ZM Lee, C Durazo, F Han, S Esrason, K Wu, V Hiatt, J Farmer, DG Ghobrial, RM Holt, C Yersiz, H Goldstein, LI Tong, MJ Busuttil, RW TI MELD fails to measure quality of life in liver transplant candidates SO LIVER TRANSPLANTATION LA English DT Article ID DISEASE MELD; MODEL; ALLOCATION; SURVIVAL; INSTRUMENTS; IMPACT AB Previous studies have demonstrated an association between Child Turcotte-Pugh (CTP) class and impaired quality of life. However, the relationship between the model for end-stage liver disease (MELD) score and quality of life (QOL) has not been well studied. In this study, quality of life questionnaires (Medical Outcomes Short Form 36 [SF-36] and the Chronic Liver Disease Questionnaire [CLDQ]) were administered to 150 adult patients awaiting liver transplantation. We also collected demographic data and laboratory results and recorded manifestations of hepatic decompensation. The study found that all domains of the SF-36 and CLDQ were significantly lower in our patient cohort than in normal controls (P < .001). There was a moderate negative correlation between CPT class and physical components of the SF-36 (r = -.30), while there was a weak negative correlation (r = -.10) between CPT class and the mental component. There was a negative moderate correlation between CPT class and overall CLDQ (r = -.39, P < .001) and a weak correlation (r = -.20) between MELD score and overall CLDQ score. Both encephalopathy (correlation coefficient = -.713, P = .004) and ascites (correlation coefficient = -.68, P = .006) were predictive of the QOL using CLDQ (adjusted R-2 = .1494 and f = 0.000). In conclusion, in liver transplant candidates, the severity of liver disease assessed by the MELD score was not predictive of QOL. The presence of ascites and/or encephalopathy was significantly associated with poor quality of life. CTP correlates better to QOL, probably because it contains ascites and encephalopathy. C1 Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Surg, David Geffen Sch Med, Los Angeles, CA 90024 USA. W Los Angeles Vet Adm Med Ctr, Los Angeles, CA USA. Inova Fairfax Hosp, Ctr Liver Dis, Los Angeles, CA USA. Kaiser Permanente, Dept Med, Los Angeles, CA USA. RP Saab, S (reprint author), Pfleger Liver Inst, 200 UCLA Med Plaza,Suite 214,Box 957302, Los Angeles, CA 90095 USA. EM SSaab@mednet.ucla.edu NR 26 TC 56 Z9 57 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1527-6465 J9 LIVER TRANSPLANT JI Liver Transplant. PD FEB PY 2005 VL 11 IS 2 BP 218 EP 223 DI 10.1002/lt.20345 PG 6 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA 891QF UT WOS:000226594900013 PM 15666392 ER PT J AU Silber, JH Rosenbaum, PR Trudeau, ME Chen, W Zhang, XM Kelz, RR Mosher, RE Even-Shoshan, O AF Silber, JH Rosenbaum, PR Trudeau, ME Chen, W Zhang, XM Kelz, RR Mosher, RE Even-Shoshan, O TI Changes in prognosis after the first postoperative complication SO MEDICAL CARE LA English DT Article DE multivariate matching; case-control study; outcomes research; quality of care; mortality; failure-to-rescue; complications; Medicare; general surgery; orthopedic surgery ID PATIENT CHARACTERISTICS; PROPENSITY SCORE; BIAS REDUCTION; SURGICAL RISK; OUTCOMES; QUALITY; CARE; ADJUSTMENT; MORTALITY; SEVERITY AB Background: Postoperative complications are common in the Medicare population, yet no study has formally quantified the change in prognosis that occurs after a broad range of first complications. Objective: We sought to estimate the relative severity of 24 first postoperative complications. Research Design: We undertook a multivariate matched, population-based, case-control study of death after surgery in a sample of 1362 Pennsylvania Medicare patients. Subjects: Cases (681 deaths) were selected randomly using claims from 1995-1996. Models were developed to scan all Pennsylvania claims, looking for similar controls that did not die. Measures: Charts were abstracted, complications identified, and models were constructed to estimate the odds of dying after any 1 of 24 first postoperative complications. Results: The odds of dying within 60 days increased 3.4-fold (95% confidence interval [CI] 2.5-4.7) in patients with complications as compared with those without complications. A first complication of respiratory compromise was associated with a 7.2-fold increase in the odds of dying (95% CI 4.5-11.6). The first complications of pneumonia or congestive heart failure were associated with, respectively, 5-fold (95% CI 2.1-12.1) and 5.1-fold (2.3-11.1) increases in odds of dying as compared with no complication. Conclusions: First complications after surgery, even seemingly mild ones, may radically alter the patient's risk of death. First complications often begin the cascade of complications that end in death. Caregivers should consider the first complication as a timely signal of a changed clinical situation demanding a reevaluation of the patient's care. Researchers may use these estimates to determine the relative severity of a broad range of first or early complications. C1 Childrens Hosp Philadelphia, Ctr Outcomes Res, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. Univ Penn, Sch Med, Dept Anesthesia, Philadelphia, PA 19104 USA. Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. Univ Penn, Wharton Sch, Dept Stat, Philadelphia, PA 19104 USA. VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA. RP Silber, JH (reprint author), Childrens Hosp Philadelphia, Ctr Outcomes Res, 3535 Market St,Suite 1029, Philadelphia, PA 19104 USA. EM silberj@wharton.upenn.edu RI Rosenbaum, Paul/H-8687-2012 FU AHRQ HHS [HS-R01-9460] NR 26 TC 53 Z9 53 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD FEB PY 2005 VL 43 IS 2 BP 122 EP 131 DI 10.1097/00005650-200502000-00005 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 892MK UT WOS:000226654500004 PM 15655425 ER PT J AU Geraci, JM Johnson, ML Gordon, HS Petersen, NJ Shroyer, AL Grover, FL Wray, NP AF Geraci, JM Johnson, ML Gordon, HS Petersen, NJ Shroyer, AL Grover, FL Wray, NP TI Mortality after cardiac bypass surgery - Prediction from administrative versus clinical data SO MEDICAL CARE LA English DT Article DE coronary artery bypass surgery; administrative data; mortality; risk adjustment; outlier ID ADJUSTED SURGICAL OUTCOMES; SHORT-TERM MORTALITY; QUALITY IMPROVEMENT; GRAFT-SURGERY; VETERANS-AFFAIRS; MEDICARE BENEFICIARIES; COMORBIDITY MEASURES; CABG SURGERY; CLAIMS DATA; CARE AB Background: Risk-adjusted outcome rates frequently are used to make inferences about hospital quality of care. We calculated risk-adjusted mortality rates in veterans undergoing isolated coronary artery bypass surgery (CABS) from administrative data and from chart-based clinical data and compared the assessment of hospital high and low outlier status for mortality that results from these 2 data sources. Study Population: We studied veterans who underwent CABS in 43 VA hospitals between October 1, 1993, and March 30, 1996 (n = 15,288). Methods: To evaluate administrative data, we entered 6 groups of International Classification of Diseases (ICD)-9-CM codes for comorbid diagnoses from the VA Patient Treatment File (PTF) into a logistic regression model predicting postoperative mortality. We also evaluated counts of comorbid ICD-9-CM codes within each group, along with 3 common principal diagnoses, weekend admission or surgery, major procedures associated with CABS, and demographic variables. Data from the VA Continuous Improvement in Cardiac Surgery Program (CICSP) were used to create a separate clinical model predicting postoperative mortality. For each hospital, an observed-to-expected (O/E) ratio of mortality was calculated from (1) the PTF model and (2) the CICSP model. We defined outlier status as an O/E ratio outside of 1.0 (based on the hospital's 90% confidence interval). To improve the statistical and predictive power of the PTF model, selected clinical variables from CICSP were added to it and outlier status reassessed. Results: Significant predictors of postoperative mortality in the PTF model included I group of comorbid ICD-9-CM codes, intraortic balloon pump insertion before CABS, angioplasty on the day of or before CABS, weekend surgery, and a principal diagnosis of other forms of ischemic heart disease. The model's c-index was 0.698. As expected, the CICSP model's predictive power was significantly greater than that of the administrative model (c = 0.761). The addition of just 2 CICSP variables to the PTF model improved its predictive power (c = 0.741). This model identified 5 of 6 high mortality outliers identified by the CICSP model. Additional CICSP variables were statistically significant predictors but did not improve the assessment of high outlier status. Conclusions: Models using administrative data to predict postoperative mortality can be improved with the addition of a very small number of clinical variables. Limited clinical improvements of administrative data may make it suitable for use in quality improvement efforts. C1 Houston Vet Affairs Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. Univ Colorado, Hlth Sci Ctr, Denver Vet Affairs Med Ctr, Dept Med, Denver, CO 80202 USA. Univ Colorado, Hlth Sci Ctr, Cardiol Sect, Dept Med, Denver, CO 80202 USA. Denver Vet Affairs Med Ctr, Denver, CO USA. Univ Colorado, Hlth Sci Ctr, Dept Surg, Denver, CO 80202 USA. RP Geraci, JM (reprint author), Univ Texas, MD Anderson Canc Ctr, Dept Gen Internal Med, Unit 437, 1515 Holcombe Blvd, Houston, TX 77030 USA. EM jmgeraci@mdanderson.org RI Gordon, Howard/E-4420-2010; Shroyer, Annie Laurie/B-8836-2016 OI Gordon, Howard/0000-0002-6712-5954; Shroyer, Annie Laurie/0000-0001-6461-0623 NR 37 TC 34 Z9 34 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD FEB PY 2005 VL 43 IS 2 BP 149 EP 158 DI 10.1097/00005650-200502000-00008 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 892MK UT WOS:000226654500007 PM 15655428 ER PT J AU Xu, JM Capezzone, M Xu, X Hershman, JM AF Xu, JM Capezzone, M Xu, X Hershman, JM TI Activation of nicotinamide N-methyltransferase gene promoter by hepatocyte nuclear factor-1 beta in human papillary thyroid cancer cells SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID HNF1 HOMEOPROTEIN FAMILY; NAD(+) SALVAGE PATHWAY; TRANSCRIPTION FACTOR; PARKINSONS-DISEASE; SACCHAROMYCES-CEREVISIAE; CDNA CLONING; HUMAN LIVER; RAT-LIVER; EXPRESSION; CARCINOMA AB We previously demonstrated that the human nicotinamide N-methytransferase ( NNMT) gene was highly expressed in many papillary thyroid cancers and cell lines. The expression in other papillary and follicular cancers or cell lines and normal thyroid cells was low or undetectable. To gain an understanding of the molecular mechanism of this cell-specific expression, the NNMT promoter was cloned and studied by luciferase reporter gene assay. The promoter construct was expressed highly in papillary cancer cell lines, including those with higher (e.g. BHP 2-7) and lower (e.g. BHP 14-9) NNMT gene expression, and expressed weakly in follicular thyroid cancer cell lines. Further study with 5'-deletion promoter construct suggested that the NNMT promoter was regulated differently in BHP 2-7 and BHP 14-9 cells. In BHP 2-7 cells, promoter activity was dependent on an upstream sequence. In BHP 14-9 cells, sequence in the basal promoter region contributed notably to the overall promoter activity. RT-PCR or Western blot analysis indicated that hepatocyte nuclear factor-1beta (HNF-1beta) was expressed in only papillary cancer cell lines with high NNMT gene expression. HNF-1beta was not expressed or expressed very weakly in other papillary, follicular, and Hurthle cancer cell lines and primary cultures of normal thyroid cells and benign thyroid conditions. A HNF-1 binding site was identified in the NNMT basal promoter region. Mutations in this site decreased NNMT promoter activity in the HNF-1beta-positive BHP 2-7 cells, but not in the HNF-1beta-negative BHP 14-9 cells. HNF-1beta bound to the HNF-1 site specifically as a homodimer as determined by gel retardation assays with HNF-1beta-specific antibody. Cotransfection of a HNF-1beta expression plasmid increased NNMT promoter activity significantly in both HNF-1beta-positive and -negative thyroid cancer cell lines and Hep G2 liver cancer cells. Furthermore, transient expression of HNF-1beta in BHP 14-9 cells increased endogenous NNMT protein levels. In summary, HNF-1beta functions as a transcription activator for NNMT gene expression in some papillary thyroid cancer cells. C1 Univ Calif Los Angeles, Sch Med, Vet Affairs Med Ctr, Endocrinol & Diabet Div, Los Angeles, CA 90073 USA. RP Hershman, JM (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Endocrinol Div 111D, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jhershmn@ucla.edu NR 47 TC 28 Z9 30 U1 0 U2 3 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD FEB PY 2005 VL 19 IS 2 BP 527 EP 539 DI 10.1210/me.2004-0215 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 890WZ UT WOS:000226543200020 PM 15486044 ER PT J AU Jing, Z Goodlett, DR Peskind, ER Quinn, JF Yong, Z Qin, W Pan, C Yi, E Eng, J Aebersold, RH Montine, TJ AF Jing, Z Goodlett, DR Peskind, ER Quinn, JF Yong, Z Qin, W Pan, C Yi, E Eng, J Aebersold, RH Montine, TJ TI Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid SO NEUROBIOLOGY OF AGING LA English DT Article DE cerebrospinal fluid; proteins; proteomics; ICAT; aging ID MASS-SPECTROMETRY; ALZHEIMERS-DISEASE; PROTEIN-ANALYSIS; IN-VIVO; BRAIN; IDENTIFICATION; EXPRESSION; DEMENTIA; CANCER; TESTS AB Identification of cerebrospinal fluid (CSF) biomarkers of the common age-related neurodegenerative diseases would be of great value to clinicians because of the difficulties in differential diagnoses of these diseases in clinical practice. Proteins are one class of potential biomarkers currently under investigation in the hope that different ensembles of proteins will aid in the diagnosis of these diseases, as well as in the assessment of progression and response to therapy. However, before undertaking a rational approach to CSF protein biomarkers of age-related neurodegeneration, we must first systematically identify CSF proteins and determine whether their levels change with normal aging. In this study, we used a powerful shotgun proteomic method, two-dimensional microcapillary liquid chromatography electrospray ionization tandem mass spectrometry, to identify proteins in human CSF. Additionally, using pooled CSF samples, we quantitatively compared the CSF proteome of younger adults with that of older adults using isotope-coded affinity tags (ICAT). From these studies we identified more than 300 proteins in CSF and found that there were 30 proteins with >20% change in concentrations between older and younger individuals. Finally, we validated changes in concentration for two of these proteins using Western blots in CSF from a separate set of individuals. These data not only expand substantially our current knowledge regarding human CSF proteins, but also supply the necessary information to appropriately interpret protein biomarkers of age-related neurodegenerative diseases. (C) 2004 Elsevier Inc. All rights reserved. C1 Univ Washington, Sch Med, Div Neuropathol, Harborview Med Ctr, Seattle, WA 98104 USA. Inst Syst Biol, Seattle, WA USA. Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Neurol, Portland, OR 97201 USA. RP Jing, Z (reprint author), Univ Washington, Sch Med, Div Neuropathol, Harborview Med Ctr, Box 359635, Seattle, WA 98104 USA. EM zhangj@u.washington.edu RI Eng, Jimmy/C-6556-2017 OI Eng, Jimmy/0000-0001-6352-6737 NR 43 TC 0 Z9 0 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD FEB PY 2005 VL 26 IS 2 BP 207 EP 227 DI 10.1016/j.neurobiolaging.2004.03.012 PG 21 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 885TC UT WOS:000226178800006 ER PT J AU Rasgon, NL Silverman, D Siddarth, P Miller, K Ercoli, LM Elman, S Lavretsky, H Huang, SC Phelps, ME Small, GW AF Rasgon, NL Silverman, D Siddarth, P Miller, K Ercoli, LM Elman, S Lavretsky, H Huang, SC Phelps, ME Small, GW TI Estrogen use and brain metabolic change in postmenopausal women SO NEUROBIOLOGY OF AGING LA English DT Article DE [F-18]fluorodeoxyglucose; positron emission tomography; FDG-PET; estrogen use; cerebral glucose metabolism ID CEREBRAL GLUCOSE-METABOLISM; RANDOMIZED CONTROLLED-TRIAL; REPLACEMENT THERAPY; ALZHEIMERS-DISEASE; OLDER WOMEN; COGNITIVE FUNCTION; PLUS PROGESTIN; BLOOD-FLOW; MEMORY; RISK AB Objective: We used positron emission tomography to evaluate cerebral glucose metabolic change in postmenopausal women in a naturalistic observational study. Method: Women estrogen users (n = 11) and non-users (n = 9) were studied at baseline and 2 years later. Analyses focused on glucose metabolism in regions previously reported to decline in older persons at risk for Alzheimer's disease (AD) (posterior cingulate and lateral temporal cortex). Results: Region of interest (ROI) analysis at baseline showed no regional differences between women estrogen users and non users. ROI follow-up analysis revealed that women non-users declined significantly in the posterior cingulate cortex (P = 0.04). Statistical parametric mapping (SPM) analysis confirmed a significant decrease in metabolism of the posterior cingulate cortex among non-users at 2-year follow-up (P = 0.004). In contrast, women estrogen users did not exhibit significant metabolic change in the posterior cingulate. Conclusions: Estrogen use may preserve regional cerebral metabolism and protect against metabolic decline in postmenopausal women, especially in posterior cingulate cortex, the region of the brain found to decline in the earliest stages of AD. (C) 2004 Elsevier Inc. All rights reserved. C1 Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Inst Neuropsychiat, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Alzheimers Dis Ctr, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Ctr Aging, Los Angeles, CA 90095 USA. Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90049 USA. RP Rasgon, NL (reprint author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, 401 Quarry Rd,Room 2360, Stanford, CA 94305 USA. EM nrasgon@stanford.edu RI Lavretsky, Helen/M-5711-2015 OI Lavretsky, Helen/0000-0001-9990-5085 FU NCRR NIH HHS [MO1 RR00856-21]; NIA NIH HHS [AG 16570, AG10123, AG13308]; NIMH NIH HHS [MH57423, MH52453] NR 39 TC 51 Z9 51 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD FEB PY 2005 VL 26 IS 2 BP 229 EP 235 DI 10.1016/j.neurobiolaging.2004.03.003 PG 7 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 885TC UT WOS:000226178800007 PM 15582750 ER PT J AU Witsell, DL Stewart, MG Monsell, EM Hadley, JA Terrell, JE Yueh, B Rosenfeld, RM Hannley, MT Holzer, SS AF Witsell, DL Stewart, MG Monsell, EM Hadley, JA Terrell, JE Yueh, B Rosenfeld, RM Hannley, MT Holzer, SS TI The Cooperative Outcomes Group for ENT: A multicenter prospective cohort study on the outcomes of tympanostomy tubes for children with otitis media SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article ID QUALITY-OF-LIFE; BINAURAL HEARING; LANGUAGE; EFFUSION; SURGERY AB OBJECTIVE. Outcomes for patients with otitis media were assessed in this prospective, multicenter study. STUDY DESIGN AND SETTING: Thirty-one otolaryngologists enrolled 272 pediatric patients with otitis media; caregivers completed surveys at 3-month intervals, and clinical and treatment data was also collected. The Otitis Media 6 (OM-6) was the primary outcome measure. RESULTS: One hundred seventy-seven patients (mean age 2.0 years) completed 3-month follow-up. One hundred thirty-seven patients underwent tympanostomy tube placement. Large improvements in disease-specific quality of life (QOL) were seen up to 9 months of follow-up. Baseline OM-6 score was the best predictor of clinical success in regression modeling. CONCLUSIONS: Patients referred to an otolaryngologist for treatment of otitis media see large improvements in disease-specific QOL regardless of treatment rendered. SIGNIFICANCE. The study demonstrates the feasibility of multicenter outcomes studies and confirms appropriate triage of patients with otitis media into surgical versus medical interventions. EBM rating: C. C1 Duke Univ, Med Ctr, Div Otolaryngol Head & Neck Surg, Durham Vet Adm Med Ctr, Durham, NC USA. Baylor Coll Med, Dept Otolaryngol, Houston, TX 77030 USA. Wayne State Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Detroit, MI USA. Univ Otolaryngol, PC, Southfield, MI USA. Univ Rochester, Rochester, NY 14627 USA. Univ Michigan, Med Ctr, Ann Arbor, MI USA. Amer Acad Otolaryngol Head & Neck Surg Fdn, Alexandria, VA USA. Univ Washington, Dept Otolaryngol Head & Neck Surg, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. Suny Downstate Med Ctr, Dept Otolaryngol, Brooklyn, NY 11203 USA. RP Witsell, DL (reprint author), Duke Univ, Med Ctr, Div Otolaryngol, Box 3805, Durham, NC 27710 USA. EM witse001@me.duke.edu OI Yueh, Bevan/0000-0003-1380-1053 NR 15 TC 16 Z9 18 U1 0 U2 0 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2005 VL 132 IS 2 BP 180 EP 188 DI 10.1016/j.otohns.2004.11.004 PG 9 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 894JU UT WOS:000226788200003 PM 15692524 ER PT J AU Davis, GE Yueh, B Walker, E Katon, W Koepsell, TD Weymuller, EA AF Davis, GE Yueh, B Walker, E Katon, W Koepsell, TD Weymuller, EA TI Psychiatric distress amplifies symptoms after surgery for chronic rhinosinusitis SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article; Proceedings Paper CT 108th Annual Meeting of the American-Academy-of-Otolaryngology-Head-and-Neck-Surgery CY SEP 19-22, 2004 CL New York, NY SP Amer Acad Otolaryngol Head & Neck Surg ID DEPRESSIVE SYMPTOMS; CHRONIC SINUSITIS; PRIMARY-CARE; OUTCOMES; VALIDATION AB BACKGROUND: Psychiatric disorders are associated with increased symptom burden when combined with chronic medical conditions. However, there are no reports of how psychiatric distress influences outcomes with surgical treatment for chronic rhinosinusitis (CRS). We hypothesized that subjects with psychiatric distress (somatization, anxiety, and depression) would report more severe long-term sinus symptoms and worse quality of life (QOL) than subjects without psychiatric distress. METHODS: This is a community-based, prospective, observational cohort study of patients diagnosed with CRS presenting for surgery. Patients were interviewed before surgery; CT scans were reviewed, and questionnaires were completed about sinusitis-related symptoms (SNOT-16), general health status and QOL (SF-36), and psychiatric distress (BSI and PHQ). Outcomes were also assessed 1, 3, 6, and 12 months postoperatively. RESULTS: Ninety-five patients had complete records for analysis. Psychiatric distress was prevalent, with 31% screening positive for somatization, 17% positive for anxiety, and 25% positive for depressive disorders. Subjects with somatization had significantly worse SNOT-16 scores at each time point compared with those without somatization (P < 0.05). Subjects with depression reported more severe symptoms at 6 and 12 months after surgery than those without depression (P < 0.05). The presence of somatization preoperatively was also independently associated with worse symptom severity 12-months after surgery, even after adjusting for prior sinus surgery, CT stage, Charlson Index, and deviated septum. In addition, subjects with psychiatric distress reported significantly worse SF-36 physical and mental component summary scores 12-months after surgery than subjects without psychiatric distress. CONCLUSIONS: Psychiatric distress is associated with worse reported sinus symptoms and lower QOL throughout surgical management of chronic rhinosinusitis. Despite this, subjects with psychiatric distress report a similar degree of improvement in sinus symptoms after surgery compared with those without distress. CLINICAL SIGNIFICANCE: Psychiatric distress should be considered in patients with persistent symptoms after surgery. Psychiatric distress should also be considered in efforts to design a chronic sinusitis staging system. C1 Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA 98195 USA. Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. Univ Washington, Dept Psychiat, Seattle, WA 98195 USA. Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. Univ Washington, Robert Wood Johnson Clin Scholars Program, Seattle, WA 98195 USA. VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. VA Puget Sound Hlth Care Syst, Dept Surg & Perioperat Serv, Seattle, WA USA. RP Davis, GE (reprint author), Univ Washington, Dept Otolaryngol Head & Neck Surg, 1959 NE Pacific St,Box 356515, Seattle, WA 98195 USA. EM gedavis@u.washington.edu OI Yueh, Bevan/0000-0003-1380-1053 FU NIDCD NIH HHS [DC-00018] NR 21 TC 36 Z9 41 U1 0 U2 1 PU MOSBY, INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA SN 0194-5998 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD FEB PY 2005 VL 132 IS 2 BP 189 EP 196 DI 10.1016/j.otohns.2004.09.135 PG 8 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 894JU UT WOS:000226788200004 PM 15692525 ER PT J AU Romero, EJ Moya, FR Tuvim, MJ Alcorn, JL AF Romero, EJ Moya, FR Tuvim, MJ Alcorn, JL TI Interaction of an artificial surfactant in human pulmonary epithelial cells SO PEDIATRIC PULMONOLOGY LA English DT Article DE RDS; type II cells; surfactant; Surfaxin((R)); SP-B; KL4 ID RESPIRATORY-DISTRESS-SYNDROME; PRETERM VENTILATED LAMBS; SYNTHETIC SURFACTANT; EXOGENOUS SURFACTANT; PROTEIN-C; LUNG; METABOLISM; PEPTIDES; TURNOVER; EFFICACY AB Surfaxin(R) (lucinactant), a peptide-based surfactant consisting of dipalmitoylphosphatidylcholine (DPPC) plus KL4 (sinapultide) (a synthetic peptide modeled after human surfactant protein-B), is effective in treating respiratory distress syndrome in preterm infants. Our goal was to determine the uptake and effects of Surfaxin(R) on human pulmonary type 11 cells isolated from fetal tissue and other lung cell types. Based on previous published reports, we hypothesized that this exogenous synthetic surfactant would have little effect on type 11 cell surfactant-related physiological features. Human type 11 cells and A549 and NCI-H441 adenocarcinoma cells incorporated H-3-KL4 and C-14-DPPC components in Surfaxin(R), but with different kinetics. Fractionation of NCI-H441 and A549 cellular components indicated that the highest specific activity of H-3-KL4 was present in the 18,000g cellular fraction (which contains vesicles and lysosomes). The number of lamellar bodies (LBs) appears to increase inhuman type 11 cells incubated in the presence of Surfaxin(R) when visualized by light microscopy, while LB structure (determined by electron microscopy) was not altered. Expression of endogenous surfactant protein (SP-A, SP-B, and SP-C) mRNA levels in human type 11 cells was not altered by the presence of Surfaxin(R). We conclude that while human type 11 cells and other lung cell types can incorporate the components of Surfaxin(R), the surfactant-related physiological functions of these cells are not altered. C1 Univ Texas, Hlth Sci Ctr Houston, Dept Pediat, Div Neonatal Perinatal Med, Houston, TX USA. Baylor Coll Med, Dept Med, Houston, TX 77030 USA. Houston VA Med Ctr, Houston, TX USA. RP Alcorn, JL (reprint author), Univ Texas, MD Anderson Canc Ctr, Dept Pulmonol, 1515 Holcombe Blvd, Houston, TX 77030 USA. EM Joseph.L.Alcorn@uth.tmc.edu NR 44 TC 9 Z9 9 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 8755-6863 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD FEB PY 2005 VL 39 IS 2 BP 167 EP 177 DI 10.1002/ppul.20166 PG 11 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA 890GN UT WOS:000226499800012 PM 15633204 ER PT J AU Kozel, FA Nahas, Z Bohning, DE George, MS AF Kozel, FA Nahas, Z Bohning, DE George, MS TI Functional magnetic resonance imaging and transcranial magnetic stimulation for major depression SO PSYCHIATRIC ANNALS LA English DT Article ID BOLD-FMRI RESPONSE; CEREBRAL-BLOOD-FLOW; HUMAN MOTOR CORTEX; SENSORIMOTOR CORTEX; BRAIN ACTIVITY; TMS; MRI; LOCALIZATION; EXCITABILITY; PHOSPHENES C1 Med Univ S Carolina, Ctr Adv Imaging Res, Dept Psychiat, Charleston, SC 29425 USA. Med Univ S Carolina, Brain Simulat Lab, Dept Psychiat, Charleston, SC USA. Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. RP Kozel, FA (reprint author), Med Univ S Carolina, Ctr Adv Imaging Res, Dept Psychiat, 67 President St,POB 250861, Charleston, SC 29425 USA. EM kozelfa@musc.edu RI Kozel, Frank/I-5366-2012 NR 55 TC 0 Z9 0 U1 0 U2 2 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0048-5713 J9 PSYCHIAT ANN JI Psychiatr. Ann. PD FEB PY 2005 VL 35 IS 2 BP 130 EP 136 PG 7 WC Psychiatry SC Psychiatry GA 897GL UT WOS:000226991900010 ER PT J AU Brau, N AF Brau, N TI Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin SO SEMINARS IN LIVER DISEASE LA English DT Review DE hepatitis C; HIV; coinfection; therapy; epidemiology ID HIV-INFECTED PATIENTS; SUSTAINED VIROLOGICAL RESPONSE; ACTIVE ANTIRETROVIRAL THERAPY; PLACEBO-CONTROLLED TRIAL; ALPHA-2A PLUS RIBAVIRIN; LIVER-TRANSPLANT RECIPIENTS; PROTEASE INHIBITOR THERAPY; TERM-FOLLOW-UP; HEPATOCELLULAR-CARCINOMA; PEGINTERFERON ALPHA-2A AB A significant percentage of human immunodeficiency virus (HIV)-infected individuals are also infected with the hepatitis C virus (HCV). With the much-improved survival of HIV-infected patients through the use of highly active antiretroviral therapy, liver disease caused by coinfection with HCV has emerged as a significant threat to the health and survival of persons with HIV disease. HIV/HCV-coinfected patients with ongoing HIV viremia have a faster rate of HCV-related liver fibrosis progression and a more rapid progression to liver failure or hepatocellular carcinoma than HCV-monoinfected persons. In contrast to the deleterious effect of HIV on HCV-related liver disease, most studies have shown that HCV does not influence progression of HIV infection to AIDS or death. HCV therapy with peginterferon alfa (2a or 2b) plus ribavirin can achieve a sustained viral response in HlV/HCV-coinfected patients of up to 38% in HCV genotype 1 and up to 73% in genotypes 2 and 3. The safety profile is largely similar to therapy in HIV-monoinfected patients, but there is a higher incidence of mitochondrial toxicity in patients taking didanosine or stavudine and of anemia in patients taking zidovudine. There is no proven anti-HCV therapy for HIV/HCV-colnfected patients with end-stage liver disease (ESLD). Liver transplantation is being investigated as a potential therapeutic option for HIV-infected individuals with ESLD, and initial reports are encouraging. Given that pegylated interferon and ribavirin have been shown to be safe and effective for HIV/HCV coinfection as well as HCV monoinfection, all HTV/HCV-coinfected patients should be evaluated for therapy. C1 CUNY Mt Sinai Sch Med, Bronx Vet Affairs Med Ctr, Infect Dis Sect, Bronx, NY 10468 USA. CUNY Mt Sinai Sch Med, Div Infect Dis, New York, NY 10029 USA. CUNY Mt Sinai Sch Med, Div Liver Dis, New York, NY 10029 USA. RP Brau, N (reprint author), CUNY Mt Sinai Sch Med, Bronx Vet Affairs Med Ctr, Infect Dis Sect, 111F,130 W Kingsbrige Rd, Bronx, NY 10468 USA. EM norbert.brau@med.va.gov NR 117 TC 24 Z9 25 U1 1 U2 1 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0272-8087 J9 SEMIN LIVER DIS JI Semin. Liver Dis. PD FEB PY 2005 VL 25 IS 1 BP 33 EP 51 DI 10.1055/s-2005-864780 PG 19 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 902KJ UT WOS:000227354400003 PM 15731996 ER PT J AU Littner, MR AF Littner, MR TI Portable monitoring in the diagnosis of the obstructive sleep apnea syndrome SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE obstructive sleep apnea; portable monitoring; polysomnography ID POSITIVE AIRWAY PRESSURE; EXCESSIVE DAYTIME SLEEPINESS; APNOEA/HYPOPNOEA SYNDROME; PRACTICE PARAMETERS; BREATHING DISORDERS; HOME SLEEP; APNEA/HYPOPNEA SYNDROME; RESPIRATORY EVENTS; HYPOPNEA SYNDROME; IDENTIFY PATIENTS AB Portable monitors are classified into three levels (Level II, III, and IV) with decreasing measurements of sleep and respiratory variables. A full overnight sleep study with respiratory measurements and sleep staging (polysomnography) unattended by a sleep technician is Level II, three or more respiratory channels and heart rate generally without sleep staging either attended or unattended is Level III, and one or two channels attended or unattended, usually including oximetry, is Level IV. To date, some Level III portable monitors appear to have sufficient specificity to diagnose the obstructive sleep apnea (OSA) syndrome but are not sufficiently sensitive to exclude OSA. Attended portable monitoring appears to provide better sensitivity and specificity than unattended portable monitoring and is an option for diagnosis of OSA. The role of portable monitoring is evolving but at this time cannot substitute for attended polysomnography as a standalone approach. The exact place of portable monitoring and the cost-benefit depends on local circumstances and cannot be generalized at this time. C1 VA Greater Los Angeles Healthcare Syst, Sepulveda, CA USA. Univ Calif Los Angeles, David Geffen Sch Med, Sepulveda, CA USA. RP Littner, MR (reprint author), Vet Adm Med Ctr, 111P,Bldg 200,Rm 3534,16111 Plummer St, Sepulveda, CA 91343 USA. EM mlittner@ucla.edu NR 63 TC 14 Z9 14 U1 0 U2 3 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 J9 SEM RESP CRIT CARE M JI Semin. Respir. Crit. Care Med. PD FEB PY 2005 VL 26 IS 1 BP 56 EP 67 DI 10.1055/s-2005-864200 PG 12 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 904KU UT WOS:000227497700007 PM 16052418 ER PT J AU Iribarren, C Jacobs, DR Kiefe, CI Lewis, CE Matthews, KA Roseman, JM Hulley, SB AF Iribarren, C Jacobs, DR Kiefe, CI Lewis, CE Matthews, KA Roseman, JM Hulley, SB TI Causes and demographic, medical, lifestyle and psychosocial predictors of premature mortality: the CARDIA study SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE mortality; young adults; risk factors; race/ethnicity; smoking; psychosocial factors; hostility; social support; USA ID CORONARY-ARTERY DISEASE; UNITED-STATES; CIGARETTE-SMOKING; YOUNG-ADULTS; POSTMENOPAUSAL WOMEN; EXCESS MORTALITY; HIV-INFECTION; WEIGHT-LOSS; IMPACT; HOSTILITY AB We examined the 16-year mortality experience among participants in the baseline examination (1985-86) of the Coronary Artery Risk Development in Young Adults (CARDIA) Study, a U.S. cohort of 5115 urban adults initially 18-30 years old and balanced by sex and race (black and whites) in the USA. We observed 127 deaths (annual mortality of 0.15%). Compared to white women, the rate ratio (95% confidence interval) of all-cause mortality was 9.3 (4.4, 19.4) among black men, 5.3 (2.5, 11.4) among white men and 2.7 (1.2, 6.1) among black women. The predominant causes of death, which also differed greatly by sex-race, were AIDS (28% of deaths), homicide (16%), unintentional injury (10%), suicide (7%), cancer (7%) and coronary disease (7%). The significant baseline predictors of all-cause mortality in multivariate analysis were male sex, black race, diabetes, self-reported liver and kidney disease, current cigarette smoking and low social support. Two other factors, self-reported thyroid disease and high hostility, were significant predictors in analyses adjusted for age, sex and race. In conclusion, we found striking differences in the rates and underlying cause of death across sex-race groups and several independent predictors of young adult mortality that have major implications for preventive medicine and social policies. (C) 2004 Elsevier Ltd. All rights reserved. C1 Kaiser Permanente, Div Res, Oakland, CA USA. Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN USA. Univ Alabama, Div Prevent Med, Birmingham, AL USA. Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Iribarren, C (reprint author), Kaiser Permanente, Div Res, Oakland, CA USA. EM cgi@dor.kaiser.org FU NHLBI NIH HHS [N01-HC-48049, N01-HC-48047, N01-HC-48050, N01-HC-48048]; NIA NIH HHS [R01-AG12264-01A1] NR 56 TC 29 Z9 31 U1 2 U2 4 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD FEB PY 2005 VL 60 IS 3 BP 471 EP 482 DI 10.1016/j.socscimed.2004.06.007 PG 12 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 888WD UT WOS:000226404000003 PM 15550296 ER PT J AU Kusumoto, A Arai, T Kinoshita, K Hodoshima, N Vaughan, N AF Kusumoto, A Arai, T Kinoshita, K Hodoshima, N Vaughan, N TI Modulation enhancement of speech by a pre-processing algorithm for improving intelligibility in reverberant environments SO SPEECH COMMUNICATION LA English DT Article DE speech enhancement; modulation spectrum; modulation transfer function; reverberation; word intelligibility ID ROOM ACOUSTICS; PERCEPTION; LISTENERS; HEARING; IDENTIFICATION; RECEPTION AB Most listeners have difficulty understanding speech in reverberant conditions. The purpose of this study is to investigate whether it is possible to reduce the degree of degradation of speech intelligibility in reverberation through the development of an algorithm. The modulation spectrum is the spectral representation of the temporal envelope of the speech signal. That of clean speech is dominated by components between 1 and 16 Hz centered at 4 Hz which is the most important range for human perception of speech. In reverberant conditions, the modulation spectrum of speech is shifted toward the lower end of the modulation frequency range. In this study, we proposed to enhance the important modulation spectral components prior to distortion of speech by reverberation. Word intelligibility in a carrier sentence was tested with the newly developed algorithm including two different filter designs in three reverberant conditions. The reverberant speech was simulated by convoluting clean speech with impulse responses measured in the actual halls. The experimental results show that modulation filtering incorporated into a pre-processing algorithm improves intelligibility for normal hearing listeners when (1) the modulation filters are optimal for a specific reverberant condition (i.e., T-60 = 1.1 s), and (2) consonants are preceded by highly powered segments. Under shorter (0.7 s) and longer (1.6 s) reverberation times, the modulation filtering in the current experiments, an Empirically-Designed (E-D) filter and a Data-Derived (D-D) filter, caused a slight performance decrement respectively. The results of this study suggest that further gains in intelligibility may be accomplished by re-design of the modulation filters suitable for other reverberant conditions. (C) 2004 Elsevier B.V. All rights reserved. C1 Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, VA RR&D, Portland, OR 97239 USA. Sophia Univ, Dept Elect & Elect Engn, Chiyoda Ku, Tokyo 1028554, Japan. RP Kusumoto, A (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, VA RR&D, NCRAR,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM akiko.kusumoto@med.va.gov; arai@sophia.ac.jp; kinoshita@cslab.kecl.ntt.co.jp; n-hodosh@sophia.ac.jp; vaughann@ohsu.edu NR 35 TC 20 Z9 20 U1 1 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-6393 EI 1872-7182 J9 SPEECH COMMUN JI Speech Commun. PD FEB PY 2005 VL 45 IS 2 BP 101 EP 113 DI 10.1016/j.specom.2004.06.003 PG 13 WC Acoustics; Computer Science, Interdisciplinary Applications SC Acoustics; Computer Science GA 903WZ UT WOS:000227457600001 ER EF